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Minutes of Evidence
TAKEN BEFORE THE SELECT COMMITTEE ON SCIENCE AND TECHNOLOGY
(SUB-COMMITTEE I)
TUESDAY 31 MARCH 2009
Present Crickhowell, L Neuberger, B
Haskel, L O’Neill of Bengarve, B
Krebs, L (Chairman) O’Neill of Clackmannan, L
Methuen, L Selborne, E
Memorandum by the Food Standards Agency
General Comments
Nanotechnologies may oVer a range of potential beneﬁts to consumers and industry in the area of food and
food contact materials, from improving the solubility and bioavailability1 of ingredients to extending the
shelf-life of food. Nanotechnology applications for the food sector have raised a number of safety,
environmental, ethical, policy and regulatory issues. The main concerns stem from the lack of knowledge
about the potential eVects and impacts of nanomaterials on human health and the environment.
Nanotechnology has been deﬁned by The British Standards Institute (BSI)2 as “the design, characterisation,
production and application of structures, devices and systems by controlling shape and size at the nanoscale”,
where the nanoscale is deﬁned as the size range from approximately 1 nm to 100 nm. For comparison, a single
human hair is about 80,000 nm wide. Similarly, a nanomaterial can be deﬁned as any material with at least
one dimension in the nanoscale.3 According to this deﬁnition, the term “nanotechnology” can encompass a
wide range of products, processes and applications whose sole unifying factor is that they are linked in some
way to the nanoscale. For example, the term would include:
— tiny water-ﬁlled fat droplets, which are being investigated as an ingredient for use in reduced fat
products such as mayonnaise
— incorporating fat-soluble vitamins into nano-sized packages (micelles) that will dissolve in water
— the understanding and modiﬁcation of the ﬁne structure of food products such as ice cream—food
technologists are looking for ways to replicate the physical properties of such foods in products with
a reduced fat content
— investigation of the structure-function relationships of enzymes, which play a central role in many
types of traditional food processing
— nano-particles of titanium dioxide, which are used in transparent sunscreen products (no known food
applications)
— nanoparticles of silver, which are used for their antibacterial properties in a range of consumer goods
and which may ﬁnd applications in food containers
— carbon nanotubes—thin cylinders made of carbon atoms—which are being used as a structural
component of consumer products such as tennis racquets and golf clubs (no known food
applications).
1 Bioavailability: the extent to which a substance can reach the systemic blood circulation and its availability at the site of action, when
taken orally.
2 BSI Publicly Available Speciﬁcation “Vocabulary – nanoparticles” (May 2005). PAS 71:2005
3 Note: The International Standards Organisation uses the term “nano-object” to refer to a discrete object with one or more external
dimensions in the nanoscale. In this usage, the term “nanomaterial” includes material which is larger than the nanoscale but which is
nanostructured—ie it is made up of smaller, nanoscale elements.
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It may therefore be misleading to discuss “nanotechnology” in relation to food as if it is a single discipline,
and the applications of nanoscience are more accurately described in the plural as “nanotechnologies”.
The principal area of interest and concern in relation to food appears to be engineered nanomaterials, which
are speciﬁcally designed and manufactured with the intention of being incorporated into food to fulﬁl a
particular function. It is nevertheless important to note that nanomaterials are widely found in the natural
world and foods will naturally contain nanoscale structures, including individual macromolecules, micelles
and crystals. For example, a molecule of haemoglobin is about 5.5 nanometres in diameter, and milk contains
micelles ranging from 50 to 500 nm in diameter.
Nanotechnologies can also be applied indirectly to food manufacture, for example through the development
of improved surfaces for food preparation and for food transport in factories, or rapid diagnostic tests for
contaminants or pathogens in food. This type of application would not directly aVect the properties of the
ﬁnal product but could lead to improved eYciency and improved quality control. The remainder of this
document focuses on the use of engineered nanomaterials in food and in food contact materials.
In order to understand better how nanotechnologies might be applied to food, the FSA recently commissioned
two research projects covering food additives and ingredients, and food contact materials. Both projects were
undertaken by a panel of experts from the Safety of Nanomaterials Interdisciplinary Research Centre
(SnIRC), led by the Central Science Laboratory (CSL). These projects collected information on current and
future applications of nanotechnologies, considered the potential implications for consumer safety and
assessed of the regulatory position. In addition, the project on food contact materials included experimental
work on the potential migration of nanoparticles from two types of food container. The project reports are
being published on the Agency’s website and are attached as Appendices 1 and 2 respectively. The ﬁndings
from this research are mentioned in the relevant sections below.
A. State of the science and its current use in the food sector
Potential applications
The FSA-funded research project on food additives and ingredients identiﬁed a number of potential
applications of nanotechnology in these areas including nano-sized carriers for nutrients and other food
supplements, nano-sized or nano-encapsulated food additives, and nanostructured food ingredients. Practical
examples included nutritional supplements, nutraceuticals and a small number of food ingredients and food
additives.
The parallel project on food contact materials identiﬁed a range of potential applications including barrier
layers to improve packaging properties, active antimicrobial or oxygen scavenging materials to extend shelf
life, intelligent nanosensors to monitor time/temperature storage conditions and biodegradable polymer-
nanomaterial composites. The researchers concluded that future applications in this area are most likely to
relate to antimicrobial activity or improved barrier properties.
Current market (UK, EU and non-EU)
At least two global inventories exist and these provide some information on some of the types and numbers of
nano-derived products thatmay be on the globalmarket across a range of areas, including food. TheWoodrow
Wilson Centre’s global inventory is published on the Internet,4 as is an inventory of nanoproducts
constructed by Friends of the Earth.5 Both registers list several dozens of “food” products that have been
identiﬁed However, it should be noted that Friends of the Earth’s register includes materials with a particle
size greater than 100 nm, which do not ﬁt the common deﬁnition of “nanomaterial”. Also, the registers are
largely based on marketing information, which may or may not accurately reﬂect what is actually on the
market.
At present, it is not possible to provide a deﬁnitive list of nanofoods and nanoscale food contact materials on
the EU market, primarily because of the absence of an EU-wide register or inventory. The Food Standards
Agency is currently considering various options for developing aUK-based register of nano-derived foods and
food contact materials. The European Commission has stated that it will begin work on an EU inventory of
nanomaterials during 2009 (see Section C).
4 Woodrow Wilson Center (online inventory)
5 Friends of the Earth (2008)
6 EFSA (2009)
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According to the European Food Safety Authority’s (EFSA) recent opinion on nanotechnologies7, most
nanotechnology applications for food and beverages in the EU are currently at the research and development
stage or near market stage and have not reached the EUmarket as yet. The only UK exceptions known to the
Agency are
— colloidal silver in the form of food supplements (an aqueous colloidal suspension of particles of silver
with an average size of 0.8 nm in puriﬁed water, also known as “silver hydrosol”). There are claims
that such products may ﬁght infections and enhance the immune system. Silver hydrosol has recently
been evaluated by EFSA in the context of establishing an EU list of authorised sources of vitamins
and minerals for use in food supplements. As there was insuYcient information to complete the
assessment, this product is unlikely to be included in the eventual list of approved mineral sources
that will come into eVect on 1 January 2010, in which case its continued use will not be permitted.
and
— food supplements comprising a nano-sized formulation of co-enzymeQ10 (micelles of approximately
30 nm diameter). It is claimed that co-enzyme Q10 is an antioxidant with the nano formulation
apparently improving bioavailability when compared with powdered co-enzyme Q10 or oil-based
formulations. The co-enzyme Q10 product was launched in 2006 and is manufactured in Germany.
The German authorities have concluded that this type of formulation does not fall within the scope
of the novel foods regulation (see Section C below), as the process for producing the micelles does not
lead to a signiﬁcant change in the properties of the active component.
The FSA-funded project on food contactmaterials revealed that little was available on theUKorEUmarkets.
Most products were found on the American and Asian markets although some could be sourced by UK
purchasers via the Internet.
B. Health and Safety
Risk assessment
Approaches to the risk assessment of nanomaterials have been reviewed by a number of national and
International advisory committees. In the UK the Committees on Toxicity,Mutagenicity and Carcinogenicity
of Chemicals in Food, Consumer Products and the Environment (COT, COM and COC) produced a joint
statement on nanomaterial toxicology in 2005. The COT produced an addendum in 2007 following a review
of healthcare nanoparticles.
The 2005 statement (attached at Appendix 3) provided a baseline review of the available toxicity data and
outlined the risk assessment approach the Committees would use for the risk assessment of nanomaterials,
including those in food and feed. They concluded that conventional toxicological assessment should be
suYcient to identify toxic hazards from nanomaterials provided studies were designed based on the properties
of the nanomaterial under investigation. Whilst the standard toxicological test batteries would detect possible
eVects from nanomaterials, there was as yet, insuYcient information to exclude the possibility of eVects not
detectable by thesemethods.Although in 2007 the COTwas not currently aware of such eVects being reported.
The 2007 addendum to this statement (Appendix 4) concluded that biodegradable and non-biodegradable
nanoparticles require a diVerent risk assessment approach, since biodegradable particles are less likely to have
toxicity intrinsic to their nanoparticulate state.
In the European Union, the Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks
(SCHENIR) has recommended strategies for the risk assessment of nanomaterials in 2006 and 2007.8
Although there are some diVerences in emphasis due to the questions being addressed and the remit of
SCHENIR, the strategy is consistent with that of the UK advisory committees.
In March 2009 the Scientiﬁc Committee of the European Food Safety Authority published its opinion on the
risk assessment of engineered nanomaterials, speciﬁcally in relation to food and in animal feed The Scientiﬁc
Committee also agreed that the general risk assessment paradigm (hazard identiﬁcation, hazard
characterization, exposure assessment and risk characterization) can also be applied to the risk assessment of
engineered nanomaterials in the food and feed area. The risk assessment of engineered nanomaterials has to
be performed on a case-by-case basis and needs to consider the speciﬁc properties of nanomaterials in addition
to those common to the equivalent non-nano forms of the same chemical substance.
There is currently limited information in several areas which leads to uncertainties in the risk assessment of
nanotechnologies and their possible applications in the food and feed area. Speciﬁcally there are diYculties in
characterising, detecting and measuring engineered nanomaterials in food, feed and biological matrices. This
7 EFSA (2009)
8 SCENHIR (2006, 2007a, 2007b)
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limits the ability to assess actual exposure from possible applications and products in the food and feed area.
There is limited data on oral exposure to speciﬁc nanomaterials and any consequent toxicity; the majority of
the available information on toxicity of nanomaterials is from, in vitro studies or from, in vivo studies using
other routes of exposure. These limitations in the database need to be reﬂected as qualitative and quantitative
uncertainties in the risk characterization step of any risk assessment.
The risk assessment of a nanomaterial in the food and feed area requires comprehensive identiﬁcation and
characterisation of the material, information on whether it is likely to be ingested in nanoform, and, if
ingested, whether it remains in nanoform at the point of absorption. If ingested in nanoform, then repeated-
dose toxicity studies on the nanomaterial are needed together with appropriate, in vitro studies (eg for
genotoxicity).
FSA Funded research
The FSA-funded projects, mentioned above, included an assessment of implications for consumer safety and
these reports are consistent with the EFSAopinion. The researchers also highlighted several gaps in knowledge
and recommended further research into the physico-chemical properties, behaviour, fate and eVects of
nanomaterials used in food applications,.
The project on food contact materials included tests on migration of nanoparticles from two typical materials
made of nanomaterial-polymer composites (nanoclay and nanosilver). The results showed no detectable
migration from the polymer composite consisting of nanoclay embedded between PET (polyethylene
terephthalate) layers and a very low level of migration of silver from food containers consisting of
polypropylene-nanosilver composite. In both cases, the presence of nanoparticles did not aVect the migration
of other (non-nano) components. The study provided some reassurance in the safety of nanotechnology-
derived food contact materials but nonetheless demonstrated that migration is likely to be dependent on the
type and composition of the polymer.
Research co-ordination
The Nanotechnology Research Coordination Group (NRCG) was set up in 2005 to coordinate publicly
funded research into the potential risks presented by the products and applications of nanotechnologies. Defra
chairs this Group and the membership includes Government Departments (including the Food Standards
Agency), Regulatory Agencies and the Research Councils. NRCG has three main aims.
— to develop and oversee the implementation of a cross-Government research programme into the
potential human health and environmental risks posed by free manufactured nanoparticles and
nanotubes to inform regulation and underpin regulatory standards.
— to establish links in Europe and internationally to promote dialogue and to draw upon and facilitate
exchange of information relevant to the Group’s research objectives.
— to consider the outputs of dialogue between stakeholders, researchers and the public (as integrated
with the NIDG’s wider plans for stakeholder and public dialogue) with a view to enhancing and
informing research decisions.
The NRCG began by identifying a programme of 19 research objectives aimed at characterising the potential
risks posed by engineered nanoscale materials.9 NRCG published progress reports in 2006 and 2007 that
provide an overview of the work that has been commissioned in pursuit of these objectives.10 Work in these
areas is primarily funded by the Research Councils under their standard procedures for commissioning
research. As noted above, the FSA has commissioned two reviews covering food additives and ingredients,
and food contact materials.
C. Regulatory Framework
The FSA has conducted a review to identify potential gaps in regulations relating to the use of
nanotechnologies in the food sector. The review was published in August 2008 (Appendix 5). The main areas
covered were food ingredients, food additives and food contact materials.
No major gaps in legislation were identiﬁed by this review and, on the basis of current information; it was
found that most potential uses of nanotechnologies that could aVect food would require some form of
approval process before being permitted for use. Manufactured nano-derived ingredients, additives and food
contact materials will be captured by the general safety requirements of the EU Food Law Regulation
(Regulation (EC) 178/2002), which requires that food placed on the market is not unsafe. Additionally, more
9 Defra (2005)
10 Defra (2006, 2007)
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speciﬁc legislation exists in three major areas that cover all the likely applications leading to engineered
nanomaterials being present in food:
(i) novel foods and food ingredients
The European regulation on novel foods (Regulation (EC) 258/97) applies to foods and food ingredients
(other than food additives) that were not consumed in the EUprior to 15May 1997. It establishes amandatory
pre-market approval system for all novel foods and processes and is legally binding across all 27 EUMember
States. Nanoparticulate forms of a food ingredient that has a history of use will also require authorisation
under the novel foods Regulation due to the diVerence in the production process employed, if the net result is
that the nanoparticles have diVerent properties to the existing ingredient.
In January 2008 the European Commission published a proposal to revise and update the 1997 regulation.
The European Parliament has proposed that any new regulation should explicitly apply to all nanomaterials,
in order to eliminate any doubt as to their status under this legislation. This proposal is still under discussion
by Member States and the European Parliament
(ii) food additives
Nano-derived additives are considered within the scope of Food additives legislation. Food additives are
controlled in the UK by the Sweeteners in Food Regulations 1995 (as amended), the Colours in Food
Regulations 1995 (as amended), and the Miscellaneous Food Additives Regulations 1995 (as amended), with
smoke ﬂavourings being speciﬁcally controlled by the Smoke Flavourings (England) Regulations 2005. A
recently agreed amendment to food additives legislation speciﬁes that where an existing food additive is
produced through nanotechnology, it should be assessed by EFSA as a new additive.
(iii) food contact materials
Migration of nanocomponents into food from, for example, packaging would be considered in the scope of
Regulation (EC) 1935/2004, which provides the overall framework for the regulation of food contact
materials. Provision exists for the Commission or Member States to request the EFSA to conduct an
independent, expert human health risk assessment of any substance or compound used in the manufacture of
a food contactmaterial/article. Speciﬁcmaterials such as plastics are subject to additionalmeasures andwithin
these measures it is possible for a nanomaterial to be treated separately from the normal scale substance from
which it is derived. It would therefore be possible for a nanocomponent to be authorised only following a risk
assessment by the EFSA. The regulation of nanoscale substances in food contact plastics is currently being
clariﬁed in preparation for an updatedEuropean regulation, and the EuropeanCommission has proposed that
any substance with a deliberately altered particle size should not be used, even behind a speciﬁc migration
barrier, without a speciﬁc authorisation.
Animal feed
EU legislation on animal feed covers the additives (vitamins, colourants, ﬂavourings, binders, and so on)
authorised for use in animal feed; the maximum levels of various contaminants (eg arsenic, lead, dioxins);
ingredients that may not be used in feed; nutritional claims that can be made for certain feeds; the names and
descriptions which must be applied to various feed materials; and the information to be provided on feed
labels.
The Agency is not aware of any speciﬁc applications in the pipeline with respect to the use of nanotechnology
directly in animal feed. However, current procedures would allow a proper risk assessment to be performed
on such products if and when they appear, including the manufacture of currently authorised additives and
bioproteins by new methods.
Imported foods
Food imported from countries outside the EU can only bemarketed if it meets food safety and food standards
requirements that are at least equivalent to those for food produced in the UK and elsewhere in the EU. Food
businesses are legally responsible for ensuring the food they import complies with these requirements, andUK
enforcement authorities have powers under food safety legislation to check all imported food for compliance.
However, food products ordered from a non-EU country by members of the public in limited quantities for
their personal use, for example over the Internet, may not be subject to the protection of UK food safety
requirements.11
11 The applicability of UK legislation will depend on issues such as where the contract between the seller and purchaser is made.
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Intergovernment cooperation
At EU level, DG SANCO12 organised a workshop in October 2008, the second Nanotechnology Safety for
Success Dialogue, which provided a platform for presentations and discussions between relevant stakeholders
in the nanotechnologies ﬁeld, including industry, academia, NGOs, Government departments and
Commission OYcials. The Director General of DG SANCO subsequently identiﬁed 10 priority actions to
address the key points raised during the workshop (listed in Appendix 6), grouped under the following
headings: dialogue and governance, market intelligence, scientiﬁc knowledge and gap ﬁlling; and risk
assessment and guidance. Several of these action points will encompass applications of nanotechnologies in
the food area and will involve collaboration between EU Member States and the Commission.
The Organisation for Economic Cooperation and Development also provides a forum for international co-
operation on nanomaterials through its Working Parties on Manufactured Nanomaterials and on
Nanotechnology, although these are not speciﬁc to food and its current risk assessment projects are focussed
on materials with no direct food connection, such as carbon nanotubes and cerium oxide.
The Swiss-based International Risk Governance Council (IRGC) recently completed a report on
nanotechnology applications in food and cosmetics,13 which included a discussion of regulatory approaches
in the USA, Europe and Japan. IGRC noted that the regulatory responses to nanotechnology have been
similar in each of these jurisdictions, in that existing regulations are thought to be adequate suYcient to cover
nanoscaled materials in general. In each case, however, questions have been raised about the adequacy of
current test methods and the ability of regulatory bodies to monitor and control measurements and risk
assessments.
D. Public Engagement and Consumer Information
Public engagement
In late 2008 the Food Standards Agency commissioned an evidence review in relation to public attitudes to
emerging food technologies, including nanotechnologies. The report of this review is expected to be published
in March 2009. The main ﬁndings in relation to previous studies on attitudes to nanotechnologies were as
follows:
— Awareness of nanotechnology is low, particularly in relation to food.
— Although general attitudes towards nanotechnologies seem fairly positive, attitudes towards its use
in food are less positive. Whilst people are concerned about the risks of nanotechnology in all its
forms, they seem less convinced about the potential beneﬁts of food applications than other uses and
are sceptical about why these are being developed.
— In general, use of nanotechnology in food packagingmay be seen more positively than its use in food.
— Concerns about nanotechnology, in general include eVectiveness, long-term side-eVects and the
ability of regulators and others to ensure safety and to ensure that developments beneﬁt the
general public.
— Other factors aVecting attitudes towards nanotechnology, which are often better predictors than
socio-demographics, include their scientiﬁc knowledge (eg experience of previous technological
innovations), their general outlook/worldview and where they have received information from
(people are more positive towards sources deemed to share a similar view point to them).
— The review uncovered no evidence of how people’s views on nanotechnology aVect their food
behaviour or choices, mainly due to lack of food products on the market.
— The review highlighted that nanotechnology is an extremely active area of research which will be
covered under FP7 (The Seventh Framework Programme (FP7) combines all research related EU
initiatives, it is a key pillar of the European Research Area) but at the time of writing, awards were
still pending. Research in the pipeline included looking at how consumers weigh up the risks and
beneﬁts of the technology and the psychological underpinning of diVering attitudes.
12 DG SANCO: the European Commission’s Directorate General for Health and Consumers
13 IRGC 2008
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Effective engagement and public information
The evidence review identiﬁed a consensus form the existing body of work that public opinion is in the process
of being formed and there was little information currently available to the public on which they can formulate
their views.
Future public engagement
As the issues arising from the breadth of nanotechnologies and nanomaterials are complex, more time and
resources need to be provided for the public to learn and understand the pros and cons in terms of any
consumer or societal beneﬁts and any potential risks. Developing a range of engagement activities to engage
the public rather than using a “one size ﬁts all” approach will ensure that a wider spectrum of the public are
provided with an opportunity to be involved.
Any materials provided for the public need to be prepared with the public in mind ie in plain English.
Lessons learned from engagement
EVective engagement needs to developed upstream of any important decision making. The public should be
involved in the framing of the discussion so that their questions are answered. As an example, the FSA
commissioned research on cloned animals in 2007–2008, which took the form of reconvened workshops with
the general public across the UK. This showed that the public were less concerned with how the technologies
and science work, and their focus was on the ‘why’ and what the consequences may be. This was closely
connected to the drivers behind the development and a perception that the motives were about increasing
proﬁt above other factors.
Good public engagement needs to be based on more than just scientiﬁc evidence and needs to take account of
wider societal issues ie environmental, ethical, moral and economic. The worldview that consumers’ hold and
the channel used to provide information is as important as the content.
Some issues, like nanotechnology, are not on everyone’s radar and are not part of their everyday life. To engage
eVectively the subject should be brought to life and the public need to see the relevance to their lives. Bringing
scientists and the public together in the same room and talking on the same level can foster good relationships
and can have a positive eVect on the outcome.
Good public engagement will have feedback built in at the planning stage. It is good practice to let people
know how their input has made a diVerence. This need not be more complicated than sending an email or
updating websites.
Consumer information
A fundamental principle of food labelling legislation is that consumers should be provided with suYcient
information to make informed choices about the foods that they eat. Information must, by law, be clear and
notmisleading. There is also a limit to the amount of information that can sensibly be provided on a food label.
Recognising these conﬂicting requirements, it is necessary when deﬁning mandatory labelling requirements to
give priority to items that are important for the safe use of the food, while ensuring that any additional
labelling requirements are balanced and proportionate. Any demands for special labelling of “nanofoods”
would have to be viewed against this background. At present we do not have information about whether UK
consumers would value information on the use of nanotechnology in food production, and what sort of
information would meet the necessary criteria of clarity and comprehension.
References
Defra, 2005. Characterising the potential risks posed by engineered nanoparticles: A ﬁrst UK Government
research report. http://www.defra.gov.uk/environment/nanotech/research/reports
Defra, 2006. Characterising the potential risks posed by engineered nanoparticles: UK Government
research—a progress report (October 2006). http://www.defra.gov.uk/environment/nanotech/research/reports
Defra, 2007. Characterising the potential risks posed by engineered nanoparticles: A second UKGovernment
research report (December 2007). http://www.defra.gov.uk/environment/nanotech/research/reports
EFSA, 2009—The Potential RisksArising fromNanoscience andNanotechnologies onFood andFeed Safety
(March 2009).
http://www.efsa.europa.eu/EFSA/efsa locale-1178620753812 1211902361968.htm
8 nanotechnologies and food: evidence
Friends of the Earth, 2008. Report—“Out of the laboratory and on to our plates: Nanotechnology in food
and agriculture” (March 2008) http://www.foeeurope.org/activities/nanotechnology/index.htm
IGRC, September 2008 (International Risk Governance Council) “Risk Governance of Nanotechnology
Applications in Food and Cosmetics”: http://www.irgc.org/Nanotechnology.html
SCENIHR, 2006 (Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks), 10 March 2006,
modiﬁed opinion on: The appropriateness of existing methodologies to assess the potential risks associated
with engineered and adventitious products of nanotechnologies http://ec.europa.eu/health/ph risk/
committees/04 scenihr/docs/scenihr o 003b.pdf
SCENIHR, 2007a (Scientiﬁc Committee on Emerging or Newly-Identiﬁed Health Risks), 21–22 June 2007,
The Appropriateness of the Risk Assessment Methodology in Accordance with the Technical Guidance
Documents forNew andExisting Substances forAssessing theRisks ofNanomaterials, at http://ec.europa.eu/
health/ph risk/committees/04 scenihr/docs/scenihr o 010.pdf
SCENIHR, 2007b (Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks), 29 November
2007, Opinion on the scientiﬁc aspects of the existing and proposed deﬁnitions relation to products of
nanoscience and nanotechnologies, at http://ec.europa.eu/health/ph risk/committees/04 scenihr/docs/
scenihr o 012.pdf
Woodrow Wilson Center, Project on Emerging Nanotechnologies: An inventory of nanotechnology-based
consumer products currently on the market. Available online at: http://www.nanotechproject.org/inventories/
consumer/
Appendices: [not printed]
1. Food Standards Agency research project A01057: Assessment of the potential use of nanomaterials as food
additives or food ingredients in relation to consumer safety and implication for regulatory controls. (July 2007)
2. Food Standards Agency research report A03063: Assessment of current and projected applications of
nanotechnology for food contact materials in relation to consumer safety and regulatory implications.
(July 2008)
3. COT, 2005. UK Committees on toxicity, mutagenicity and carcinogenicity of chemicals in food, consumer
products and the environment (COT, COM, COC). Joint statement on nanomaterial toxicology. http://
cot.food.gov.uk/pdfs/cotstatements2005nanomats.pdf
4. COT, 2007. UK Committee on toxicity, of chemicals in food, consumer products and the environment.
COT Addendum to joint statement of the Committees on toxicity, mutagenicity and carcinogenicity of
nanomaterial toxicology. COT Statement 2007/01, March 2007. http://cot.food.gov.uk/pdfs/
cotstatementnanomats200701.pdf
5. Report of FSA regulatory review of potential implications of nanotechnologies for regulations and risk
assessment in relation to food. (August 2008). http://www.food.gov.uk/multimedia/pdfs/
nanoregreviewreport.pdf
6. Letter from Robert Madelin (Director General for Health and Consumers, European Commission).
Follow-up to the secondNanotechnology Safety for SuccessDialogue—Top 10 actions to take by Easter 2009.
(December 2008)
12 March 2009
Memorandum by Department for Innovation, Universities and Skills (DIUS)14
The Department for Innovation, Universities and Skills (DIUS) is pleased to submit the following evidence
to assist the Committee in its inquiry into Nanotechnologies and Food.
Our response provides the information that the Committee requested from the Science and Innovation
Network about nanotechnologies in food in the following countries:
— Brazil (Annex 1)
— China (Annex 2)
— France (Annex 3)
— Germany (Annex 4)
— Japan (Annex 5)
— United States of America (Annex 6)
14 Now part of the Department for Business Innovation & Skills (BIS).
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DIUS notes that the Food Standards Agency, the Research Councils UK and the Department for
Environment, Food andRuralAVairs are also submitting evidence on areas for which they have responsibility.
DIUS has a wider responsibility for promoting good practice in public engagement about science and
technologies. The Sciencewise-Expert Resource Centre15 supports public dialogue projects and aims to
promote best practice inGovernment departments. It also builds capacity for public dialogue and engagement
across Government.
DIUS also provides funding for the Research Councils to support research and related post-graduate training.
TheResearchCouncils support a broad range of activities relating to nanotechnologies, which include support
for research which has or may have an application in the food sector. They have also been involved in public
engagement activities focusing on the social, ethical, legal and regulatory issues surrounding applications of
nanotechnologies. Research Council activities and inputs into the cross-Government coordination activities
are coordinated by the RCUK Nanotechnology Group. The Research Councils are submitting separate
evidence to the inquiry.
In addition, DIUS chairs the Ministerial and policy coordination groups that seek to coordinate work across
Government to ensure the responsible development of nanotechnologies. These groups consider the
implications for nanotechnologies across a wide range of policy areas and we would like to draw the
Committee’s attention to key documents that explain the widerGovernment agenda, its coordination and how
we are pursuing it in international fora.
In February 2005, the Government published its response16 to the Royal Society andAcademy of Engineering
report “Nanoscience and nanotechnologies: opportunities and uncertainties”.17 The response set out the
Government’s agenda for nanotechnologies and invited the Council for Science and Technology to review its
progress after two and ﬁve years. The Council reported on its ﬁrst review in March 2007 in Nanosciences and
nanotechnologies: a review of Government’s progress on its policy commitments.18
Following the report by the Council for Science and Technology, the Government established a Ministerial
group on nanotechnologies, chaired by the Science and Innovation Minister, to make sure that the UK
continues to play a leading role in the understanding, development and regulation of nanotechnologies. The
Ministerial group is informed by policy19 and research20 coordination groups and views expressed in the
Nanotechnologies Stakeholder Forum.21 At the request of the Ministerial group, a statement by the UK
Government22was published in February 2008 setting out the Government’s vision for nanotechnologies and
outlining the range of activities being carried out.
More recently, theMinisterial group announced23 its intention to develop a strategy for nanotechnologies that
addresses both the exploitation of technologies and the management of potential risks. This will be developed
in dialogue with the full spectrum of interested parties (academia, industry, non-governmental organisations
and the public). DIUS is currently developing the programme of dialogue which will build on lessons learned




Brazil is the world’s largest producer and exporter of agricultural goods. The sector contributes more than 20
per cent of Brazilian GDP, and as such is considered to be a key area of strategic interest for the Brazilian
economy. In this context, Brazil continues to invest heavily in research and development related to agri-
technologies, and nano-technology has been identiﬁed as a priority. Brazilian eVorts in this area are channelled
through an organisation Embrapa—The Brazilian Agricultural Research Corporation.
Embrapa is an agency of the BrazilianMinistry of Agriculture, Livestock and Food Supply (MAPA) in charge
of developing and extending knowledge and technology generation and transfer across a broad range of
programme areas to achieve sustainable agricultural development in Brazil. Embrapa is a world-leading
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Its budget increased by R$914 million (approximately £278 million) from May 2008 to December
2010 through PAC (GrowthAcceleration Programme) a Federal government initiative. This contribution was
added to Embrapa’s already existing budget (around half a billion GBP) and will be used for new research,
facilities, the modernisation of infrastructure of labs, and for hiring new staV. The strategy released by the
Brazilian government states that the investment should focus on work related to new challenges of agriculture,
which are; new areas of science (genomics, nanotech, TI), challenges of production (food security, climate
change, sustainable agriculture), public policies (including knowledge transfer) and institutional ﬂexibility
(international cooperation). According to the Brazilian Minister for Agriculture, Reinhold Stephanes,
Embrapa is responsible for 60 per cent of the increase in ﬁeld production in Brazil, which grew by 150 per cent
in the last 15 years.
Brazil is also investing heavily in nanotechnology—around £70 Million were invested between 2001 and
2006 by the Ministry for Science and Technology. Nanotech also features as a key priority in the Brazilian
Strategy for Science and Technology.
In this context Embrapa has decided to set up a dedicated National Centre for Nanotechnology Applied to
Agri-business, which is hosted in the city of SaoCarlos (Sao Paulo state). The Centre has the speciﬁc objectives
of increasing the competitiveness of Brazilian agriculture through the development of new nano-technologies.
Importantly, the Centre has formed partnerships with important companies in the private sector, such as Vale
Rio Doce, Braskem, the Brazilian Association of Agri-business, and Guaxupe (coVee).
Main Research Priorities and Applications
The Centre has set up a successful National Network for Nanotechnology Applied to Agri-business, which
includes every major player across the private and public sectors. This national network is responsible for
managing Brazil’s priorities in the sector, by designing research programmes and applications in conjunction
with Brazilian private companies and farmers. The Network is divided in three main programmes: 1)
Development of nano-structured materials and sensors, 2) Processing techniques for membranes and ﬁlms for
packaging and separation processes 3) New uses for materials based on agro-industrial processes (ﬁbres, etc.)
The following have been identiﬁed as priorities in the area of applications:
— “Ready to Eat”, edible bioplastic coating. The Network’s strategy notes that the US edible bioplastic
coating market has increased from 19 Million USD in 2001 to 103 Million in 2006.
— Edible bioplymer coating generating a functional barrier.
— Functional packaging, with functional additives, including nutri-ceuticals (vitamins), spices,
ﬂavour, aroma.
— Nanoparticles of natural polymers (chitosan, pectin, starch), for applications in packaging,
antimicrobial, strength reinforcement, controlled release.
— Palate sensors for quality control (this is an Embrapa International patent, aimed primarily at
increasing the quality of Brazilian wine).
— Hidrogel for soil conditioning.
— Hidrogel for controlled release of pesticides.
— Agro-based composites (amid, ﬁbres).
— Cellulose nanoﬁbers from cotton, new varieties (colored cotton), sisal, and nanoparticles, including
starch and chitosan.
— Improvement in mechanical properties in PVC composites.
— Recycled Polyethylene terephthalate and sugar cane bagasse ﬁbre.
Note: Sugar cane bagasse ﬁbres are largely produced in Brazil as a by-product from the sugar cane and bio-
ethanol industries. In 2006 Brazil produced 387Million tons of sugar cane, and 100Million tons of sugar cane
bagasse ﬁbres.
Brazil does not seem to have any dedicated regulatory framework for nanotechnology research.
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Annex 2
EVIDENCE FROM CHINA
There is no systematic reporting system in China about nanotechnology in the food sector and thus
information is limited.
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
Nanotechnology within the food production chain is used in agricultural cultivation, food processing and
manufacturing, animal feed, additives, supplements, and food packaging.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, in China?
The ﬁeld of food nanotechnology has experienced signiﬁcant growth over the last ﬁve years in China. There
is no statistical data available on the level of use but it is widespread.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
It is still not clear what the next generation of nanotechnologies will look like but we would expect them to
enter the market and quickly spread throughout all phases of agro-food production.
What is the current state of research and development in China regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
R&D on nanotechnologies is quite advanced and is comparable to other countries. Focus is not in the food
sector directly but other sectors such as antimicrobial nano-kitchenware, food packaging, sun screen,
cosmetics, textiles, etc.
What are the barriers to the development of new nano-products or processes in the food sector?
Safety issues and acceptance by the public are key barriers to the development of new nano-products or
processes in the food sector. A current concern is that there is too little information available on the properties
of nanoparticles and their potential impact such as how the body motabilises nanoparticles because of their
varying size and high mobility. There is also no requirement for manufacturers to label nanoparticles on their
products, and consumers are unlikely to be aware of such applications in foods.
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
The current regulatory framework for nanotechnologies and nanomaterials is inadequate in China though
recent general legislation on food safety should help plug some gaps. Many imported food products to China
are not properly inspected and domestic standards from the country of origin are not always available for
review.
How effective is voluntary self-regulation at an international level? What is the take up by companies working in the
food sector?
Food nanotechnology is an emerging ﬁeld and good regulation is a critical issue. Self-regulation in China is
diYcult to measure but is likely to be focused on food safety. If the nanoparticles are shown to be safe then
that could be the end of any self-regulation by a company. Take up by companies is unknown but probably
widespread.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
In China, the answer is no. The current regulatory system does not require manufacturers to label whether
nanoparticles are present in their product. Regulations are also not particularly extensive in relation to the
development and manufacture of nanoparticles.
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Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?




What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
There are many potential applications and beneﬁts of nanotechnology and nanomaterials in the food sector
from food production such as cultivation (eg nano-pesticides) to food processing like the packaging of foods.
In addition nanotechnologies can be used to enhance the nutritional aspects of food by means of nanoscale
additives and nutrients and nanosized delivery systems for bioactive compounds. Table 1 summarises the
potential applications of nanotechnology in the food production chain. These applications are expected to ﬁnd
their way into various products for consumer use in the coming years in France.
Table 1


























Nanospray on food commodiities
Hand-held devices


















Binds and colours micro organisms
Detection of contaminants etc.
Detection of food deterioration




Removal or catalysation of oxidation of
contaminants
Large reactive surface area
Anti-bacterial coating of storage and
food handling devices
Anti-bacterial action
Detection of food deterioration.
Monitoring storage conditions
Increasing barrier properties, strength of
materials
Oxygen scavenging, prevention of
growth of pathogens
Claimed to enhance desirable uptake
Protecting and (targeted) delivery of
content
Claimed enhanced uptake
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials in France?
The current state of the French market is estimated to be very small. According to the experts contacted, it is
likely that the nanotechnology applications will be similar to what will be found elsewhere in the Western
world as a result of globalisation.
Many international food companies (eg Nestle) have subsidiaries in France. These companies are known to
be interested in the applications of nanotechnology in this sector so there is a distinctive possibility of an issue
on nanotechnology in food in France although it will not be conﬁned only to France.
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What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
The use of nano-materials in food packaging and food additives is expected to correspond to the two main
types of applications. Use in food packaging is expected to take oV over the next few years as it is likely to be
more acceptable to the general public (ie little (supposedly) contamination of the food). Food additives will
be the next target although it is expected that there will be resistance from consumers.
What is the current state of research and development in France regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector?
The French National Research Agency (ANR) supports several programs in nanoscience and
nanotechnology, which may lead to new applications within the food sector. These include:
— Pnano, dedicated to nanoscience and nanotechnology and supporting projects of basic and applied
research in nanocomponents, micro-nanosystems, nanobiotechnology, nanomaterials,
instrumentation and metrology, modelling and simulation. A special section deals with the impact
and risks of nanotechnology on health and the environment as well as with ethical and societal
aspects.
— Materials and Processes focuses on research into new materials and industrial processes,
improvement of their technical and economic performance and stimulation of technology transfer to
industry.
— SEST (Health Environment and Health Work): the goal of this program is to reveal the impact, as
yet unknown, of environmental factors on human health by measuring the exposure to these factors
and identifying their role in the origin or the worsening of some diseases. This program deals
particularly with the potential toxicity of nanoparticles.
ANRalso recently launched a programme calledALIA (Spring 2008) on food and in particular food processes
encouraging the use of nanotechnology.
All in all, although France is currently running a large number of R&Dactivities in the area of nanotechnology
and nanomaterials, only a minority of projects is dealing with food.
What are the barriers to the development of new nano-products or processes in the food sector?
France will ﬁnd doubt and objection from consumers to be the main barriers to the development of nano-
products in the food sector. The main issue in France, at the moment, is carbon nanotube because of its
similarity to asbestos—a story that was not very well handled by the French health authorities. The CEA is
now the main organisation handling nano-issues in France because of its success in handling the very sensitive
issue of Atomic Energy. AFSSA is also heavily involved in this area and has recently published an oYcial
communique´ on nanoparticles in water.
It is important to note, as a conclusion, that the European Commission has already put calls for research on
detection and characterisation of nanoparticles in the food as part of the Framework programme and this is
the ﬁrst in a series of calls on risk assessment of nanoparticles in the food. So there is action at the European
level on this issue which will undoubtedly aVect France.
Note: This Annex was compiled with the assistance of the Institute of Medicine (IoM), Edinburgh, from
information supplied by the Commissariat a` l’ Energie Atomique (CEA) and the AFSSA (the French Food
Standards Agency).
The scientiﬁc evidence used by the French comes from (a) the reports and paper published by Dr Qasim
Chaudhry of the Central Science Laboratory (York) fromworks in collaborationwith the IOMand sponsored
by the UK FSA, (b) a report by the RIKKILT and RIVM institutes in Holland, and (c) a report compiled by
Friends of the Earth.
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Annex 4
EVIDENCE FROM GERMANY
1. Main potential applications and benefits of nanotechnologies and nanomaterials in the food sector
Potential applications and beneﬁts:
— improving the stability and durability of food;
— improving the bioavailability of important nutrients;
— better optical properties; improved ﬂavour and consistency;
— carrier material for other substances, eg liposomes, micellas and vesicles;
— functional foods (nano-ceuticals);
— food packaging (with sensors to monitor freshness);
— pesticides (carried by nanoparticles to improve the absorption by plants); and
— food safety (eg synthetic nanoparticles which irreversibly bind microorganisms).
Source: Federal Institute of Risk Assessment; presentation given to the Nanotechnology Forum, Berlin,
10 November 2008
2. Market for, and the use of, food products and food production processes involving nanotechnologies or nanomaterials
in Germany?
Current use of nanotechnology in food and dietary supplements:
— Nano green tea—use of nanotechnology to improve the bioavailability of selenium contained on
tealeaves and to enhance the antioxidant eVect.
— Frying oil “Canola Active Oil” with nano-phytosterole capsules (30 nm) to prevent the absorption
of cholesterol and reduce the risk of cardiac diseases.
— Dietary supplements, eg nano-vitamins, nano-calcium, nano-magnesium and nano silicon (eg
Neosino capsules).
— Carotenoid—nanostructured carotenoid might overcome the problems with insolubility in water and
bad absorbability, improving the beneﬁcial impact on health.
Product examples:
— NutraleaseTM—patent pending for the Nano-sized Self-assembled Liquid Structures (NSSL)
technology. This uses nano-sized carriers to targeted compounds (such as nutraceuticals and drugs).
These carriers are expanded micelles with a size of x30 nanometers, referred to as fortifying nano-
vehicles (FNVs). Further information available at http://www.nutralease.com.
— Aquanova—uses nanotechnology to produce micellas to improve the solubility of insoluble
substances and to change the water/fat solubility of nutrients (eg vitamins A, C, D, E, K, ß-carotene,
omega fatty acids). The patent protected NovaSOLE solutions is manufactured in ISO—and GMP
certiﬁed production plants and suitable for a variety of applications in the area of food, dietary
supplements, healthcare, cosmetics and pharma. They can for example easily be ﬁlled into softgels
and are ready to use components for industrial processes such as preservation. AQUANOVA in
2006 received the “Excellence in Technology Award” (Frost&Sullivan) and is located in Darmstadt
near Frankfurt (Germany). Further information at http://www.aquanova.de.
Use of inorganic compounds in food processing:
Use of synthetically amorphous silica (SiO2) as food additive (E551), as auxiliary material to support the ﬂow
of powder (eg tomato powder, salt, spices), or as dispersion medium for vitamins.
Source: Federal Institute of Risk Assessment; presentation given to the Nanotechnology Forum, Berlin,
10 November 2008
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NANO-ENHANCED DIETARY SUPPLEMENTS AVAILABLE IN GERMANY
Tabelle 4: In Deutschland erhältliche Nahrungsergänzungsmittel mit Nano-Materialien
Hersteller Produkt Nano-Inhaltsstoffe Zweck
Trace Minerals Co-Enzym  Q10 “ultrakleine Flüssigkeitspartikel” Das Q 10  gelangt direkt in Herz und 
Research nano liquid Muskulatur ohne von der Leber ver-
stoffwechselt zu werden, beworben 
zur Stärkung der Immunkraft und zur 
Überbrückung von Energiemangel
fairvital fairvital Colloidales Nano-Silberpartikel Antibakterielle Breitbandwirkung, 
Silber beworben zur Stärkung der Immun-
abwehr
Vitafosan Nano-Know-How Nano-Zeolith und weitere Verbesserte Aufnahme der Mineralien,
Stoffe (bis 400 nm) beworben als “Aktivator für den
ganzen Körper”
Vitafosan Nano Men-Power Nano-Zeolith plus Silizium-Sol Verbesserte Aufnahme der Mineralien,
(bis 400 nm) beworben “zur Stärkung der Mannes
kraft”
Vitafosan Aufbau for kids Nano-Zeolith (bis 400 nm) Verbesserte Aufnahme von Mineralien 
plus Vitamine und Vitamine, beworben “für eine 
gesunde Entwicklung”
Vitafosan Toxi-Drain Nano-Zeolith und weitere “Saugt Gifte wie ein Schwamm in
Stoffe (bis 400 nm) feinste Kanälchen und führt sie ab”
Healthy Generation Nano Life by Carlo Unspezifischer Nano-Inhalt unklar
GmbH Thraenhardt
Life Light Nanosan Silizium-Sol Beworben als “Spurenelement für 
Nanosilizium Gesundheit, Schönheit und 
Jugendlichkeit”
Medica Consulting Ltd. Energy Well Nano Nano-Silizium unklar
Mineral Silizium Pulver
Squeezy SQUEEZY Nano Nano-Mineralien Hohe Bioverfügbarkeit, fördert den
energised mineral gel Muskelaufbau und die Regeneration
des erschöpften Sportlers
Muscle tech Nano Vapor “Nanomolekulare “NaNO Vapor ist eine muskelaufbau-
gefäßerweiternde Wirkstoffe” ende psychoaktive  Erfahrung”
Muscle tech naNOX9 “Nanoskaliges Stickstoffoxid” “Durchflutet die Muskulatur sofort mit
gefäßerweiternden Wirkstoffen”
Source: BUND (German branch of Friends of the Earth), “Aus dem Labor auf den Teller—Nutzung der
Nanotechnologie im Lebensmittelsektor” (From the lab onto the plate—use of nanotechnologies in food) (see
http://www.bund.net/ﬁleadmin/bundnet/publikationen/nanotechnologie/20080311 nanotechnologie lebens
mittel studie.pdf)—See page 51–61 for overview of nano-enhanced food and beverages, food additives,
dietary supplements, food packaging and kitchen-utensils available in Germany and in international markets.
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NANO-FOOD ADDITIVES AND AUXILIARY MATERIALS AVAILABLE IN GERMANY
Manufacturer Product Nanomaterial Purpose
Evonik Industries Aerosil, Sipernat Nano-Siliziumdioxid Rieselhilfe fu¨r
(formerly Degussa) pulverfo¨rmige
Inhaltsstoffe
Rieselhilfe fu¨r AdNano Nano-Zinkoxid fu¨r Mineralzubereitungen
pulverfo¨rmige
Inhaltsstoffe





BASF Solu E 200 Vitamin E nanosolution Ermo¨glicht die Zusetzung
based on NovaSOL (see von Vitamin E zu





BASF LycoVit Synthetisches Lycopin
Antioxidationsmittel
('200 nm)
Source: BUND (German branch of Friends of the Earth), “Aus dem Labor auf den Teller—Nutzung der
Nanotechnologie im Lebensmittelsektor” (From the lab onto the plate—use of nanotechnologies in food) (see
http://www.bund.net/ﬁleadmin/bundnet/publikationen/nanotechnologie/20080311 nanotechnologie lebens
mittel studie.pdf)—See page 51–61 for overview of nano-enhanced food and beverages, food additives,
dietary supplements, food packaging and kitchen-utensils available in Germany and in international markets.
3. Research and development in Germany regarding nanotechnologies and nanomaterials which have or may have an
application within the food sector?
Overview
The Federal Government launched a number of projects in 2006 to address health and environment related
issues. A total of ƒ 7.6 million (£ 5.2 million) has been allocated to these projects for a three year period. The
table below sets out public-sector and industry allocations to research into the risk of nanotechnology on
human health and the environment.
Project Duration Public sector funding Industry’s contribution
NanoCare 2006–08 ƒ 5 m ƒ 2.6 m
Dialogue on Nanoparticles 2004–06 n/a n/a
NANOTOX/INOS 2006–08 ( ƒ 1 m n/a
NanoHealth 2006–08 n/a n/a
TRACER 2006–08 ƒ 1.5 m ƒ 1.5 m
Source: British Embassy Berlin—own research on various websites
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The table below sets out the Federal Government overall allocations to research into the ecological, ethical,
social, and military as well as consumer and health-related aspects of nanotechnology, including—the
above projects.
2002 2003 2004 2005 2006
in in in in in
ƒ m ƒ m ƒ m ƒ m ƒ m
Opportunities and risks 0.257 0.460 0.460 0.040 1.582
(eg technology assessment, INOS,
NanoCare)
Support measures 1.840 2.189 3.048 2.929 3.780
(eg Nanotechnology Networks, Horizon
Scanning)
Education, further training, social aspects 0 0.200 1.900 1.500 1.152
Total in ƒ m 2.097 2.849 5.408 4.429 6.514
(£ m) (1.436) (1.951) (3.704) (3.033) (4.461)
Source: BMBF, Response to Parliamentary Question 16/2150, 31 July 2006
NanoCare
The NanoCare project (ﬁrst phase in 2006–09; second phase to start in 2009), a collaborative project bringing
together representatives from industry, science and the wider public. Germany’s government allocated
ƒ5 million to the ﬁrst phase of the project, industry contributed a further ƒ2.6 million. The project involves
13 collaborative partners, including six companies and seven research institutes. The project involves:
— publication of data on known and unknown impact of nanomaterials on the environment and health;
— combination of industrial manufacturing and toxicity research (BASF involved as key player);
— development of standardised processes for the use of nanomaterials;
— generating knowledge into the synthesis and characterisation of nanoparticles;
— in vitro and in vivo risk assessment;
— development of standard operating procedures for the use of nanoparticles; and
— dialogue with the wider public.
While NanoCare initially focused on nanoparticles used in skin care products, the later phase of the project
now also includes a wider range of aspects, including:
— research into potential exposition routes and barriers (eg pulmonary tract, gastrointestinal tract,
broken skin, blood-brain-barrier, blood-plasma barrier;
— research into the link between materials properties and human toxicity;
— identiﬁcation of response mechanisms; and
— development of measuring strategies and testing systems.
A follow-up call for NanoCare was launched in October 2008, the deadline for submitting further project
proposals was late February 2009.
Further information: http://www.bmbf.de/pub/ﬂyer nanocare-projekte en.pdf (English); NanoCare project
website at http://www.nanopartikel.info; NanoCare call for proposals October 2008 http://www.bmbf.de/
foerderungen/13084.php (German)
NanoNature
Additionally, the BMBF funds the NanoNature programme project, which was launched in August 2008. The
projects are expected to start in the ﬁrst half of 2009. NanoNature focuses on the use and impact of
nanotechnology in environmental protection. Nanotechnologies that may be used in clean processes and to
protect the environment include:
— water reprocessing; cleaning air and water and reprocessing polluted soil;
— recycling processes including separation of diVerent types materials; and
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— catalytic processes and materials separation in order to reduce harmful emissions into the
environment.
In terms of potential impact of the use of nanotechnologies in clean processes and environmental protection,
NanoNature will investigate interaction between nanomaterials structure and impact identify impact
parameters, taking into account harmful substances occurring naturally:
— development of reference materials, processes and standardised testing;
— conduct research into the mobility and transformation of nanoparticles;
— carry out risk assessment using real matrices; and
— develop characterisation processes for nanoparticles in air, water and soil.
Source: Federal Ministry of Education and Research; presentation given to BfR Nanotechnology Forum,
10 November 2008; NanoNature call for proposals http://www.bmbf.de/foerderungen/12531.php (German)
NANOTOX
NANOTOX is a joint initiative by several research institutes and companies in Dresden and Leipzig (Saxony).
It seeks to establish a virtual laboratory specialising in the analysis of health and environment aspects of
nanotechnology. NANOTOX aim is to become a service provider for SMEs and to carry out contract research
in to the potential risk of nano-scale particles. The members of NANOTOX are:
— Fraunhofer Institute for Ceramic Technologies and Systems.
— Max Bergmann Centre for Biomaterials.
— UFZ Centre for Environmental Research.
— University Clinic Dresden.
— Namos GmbH.
The members of NANOTOX launched the INOS research project in February 2006. INOS stands for
“Identiﬁcation and Assessment of Health and Environment Risks of Nano-scale Particles”. The projects aim
to conduct a comprehensive analysis of the potential adverse impact of nanoparticles on man and the
environment. The Federal Research Ministry provides ƒ 1 million towards the cost of the project. As a result
of the project, a database will be established, which provides information about the health risks linked to
individual types of nanoparticle. This will serve as a guide to companies on developments in this area.
Links:
— Nanotox Homepage: http://www.nanotox.de/nanotox/Willkommen.html (German)—with links to
English-language websites of the Nanotox participants.
TRACER—Toxicological Assessment and Functionalisation of Carbon Nanomaterials
In March 2006 the BMBF launched TRACER, a toxicological assessment of carbon nanomaterials. The
participants in thisƒ 3million project include four companies (including BayerMaterialScience) and a public-
sector research institute. The project aims to investigate the biocompatibility and toxicity of carbon-nanotubes
and carbon nanoﬁlaments along the whole value added chain—from manufacture, processing and blanks to
prototypes. On the basis of research results, participants will make recommendations for the production and
processing of carbon-nanomaterials as well as the use of relevant products.
Links:
— Information on NanoCare and Tracer projects http://www.bmbf.de/de/5915.php (German)
— Bayer MaterialScience: http://www.bayerbms.de/(English)
Bayer News Release on the NanoCare project: http://www.presse.bayer.de/baynews/baynews.nsf/id/
A87EF8F221792B54C12571180034DE8F/$File/2006-0058E.pdf (English)
NanoHealth Project
The Helmholtz Association—the umbrella for Germany’s 15 large science institutes—stated a project on
nanotechnology-related health risks in May 2006. This aims to develop preventive strategies to minimise
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health risks linked to synthetic nanoparticles and neuronal implants. The project is carried out by the Institute
for Technology Assessment and SystemsAnalysis (ITAS) at theHelmholtz Research Centre inKarlsruhe. The
key elements of the NanoHealth project are:
— Analysis and summary of current state-of-the-art in both areas, ie nanotechnology and neuronal
implants.
— Development and test of an evidenced-based strategy to analyse and assess the risk of synthetic
nanoparticles.
— Debate on visions and ethical issues in the context of neuronal implants.
— Discussion of key issues in 2x2 focus groups involving experts and laymen; development of action
strategies.
— Presentation of the results in the form of a workshop open to the wider public.
Links:
— Homepage NanoHealth http://www.itas.fzk.de/deu/news/2006/11.htm (German)
— Homepage ITAS: http://www.itas.fzk.de/home e.htm (English)
Further Federal Government Initiatives
The Federal Ministry of Food, Agriculture and Consumer Protection (BMELV) organises conferences on
consumer protection and a foresight type study (based on the Delphi method of expert forecasts) into
nanomaterials in consumer goods. The BMELV will also conduct a survey into nanomaterials in food.
BMELV Food Safety Strategies (in English)—Reference to nanotechnology on page 35 http://www.bmelv.de/
cln 045/nn 1299748/SharedDocs/downloads/ EN/01-Brochures/FoodSafety,templateId%raw,property%p
ublicationFile.pdf/FoodSafety.pdf
The Federal EnvironmentMinistry (BMU) has been responsible for driving the NanoDialogue initiative—an
interdisciplinary dialogue involving all stakeholders including government, industry, research, NGOs,
industry associations and the wider public. The Federal Environment Agency (UBA) within the remit of the
BMU will conduct nanotechnology life cycle analysis and studies into toxicokinetic.
What lessons can be learned from public engagement activities that have taken place during the development
of other new technologies?
BMU NanoDialogue and NanoCommission English-language website: http://www.bmu.de/english/
nanotechnology/nanodialog/doc/37402.php
A number of German government agencies—including the Federal Institute of Risk Assessment (BfR), the
Federal Institute for Occupational Medicine and Health (BAuA) and the Federal Environment Agency
(UBA) with input from others—have proposed a programme of risk-related research into nanotechnology.
This has not yet led to the establishment of dedicated research funding in addition to NanoCare and other
risk-related nanotechnology research projects (eg into CNTs).
English translation of the draft research strategy into nanotechnology environment and health risks: http://
www.baua.de/nn 7554/sid 61037A3BB139D43BBCE4BA5848D183C8/en/Topics-from-A-to-Z/Hazardous-
Substances/Nanotechnology/pdf/draft-research-strategy.pdf; further information:
— Federal Environment Agency (UBA) http://www.uba.de
— Federal Institute of Risk Assessment (BfR) http://www.bfr.bund.de
— Federal Institute for Occupational Medicine and Health (BAuA) http://www.baua.de
4. Barriers to the development of new nano-products or processes in the food sector?
Poor public acceptance of nanotechnology in food
BfR study illustrates that only 20 per cent of respondents consulted would buy nanotechnology-enhanced
food products. Public acceptance is much better in the area of surface treatment/cleaning (86 per cent would
buy such nano-based products), clothes (75 per cent) and skin care (36 per cent). In terms of risk perception,
the majority of respondents consider inhalation of nanoparticles the greatest risk (78 per cent). Almost 12 per
cent consider oral intake as the biggest risk associated with nanotechnologies.
Source: Federal Institute of Risk Assessment (BfR) representative opinion poll conducted in May 2008; Full
report available at http://www.bfr.bund.de/cm/238/wahrnehmung der nanotechnologie in der bevoelker
ung.pdf
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Issues with general safety of nanoparticles
DiVerent toxicity of nutrients/bioactive substances due to enhanced bioavailability or diVerent distribution
within the human body; further research necessary on the impact on physiological substances/matabolites
transport in organisms; investigation needed into whether nano-carriers aVect epithelial tissue and intestinal
function; further research needs to be carried out into the bioavailability of nanoparticles following oral
exposition.
Source: Federal Institute of Risk Assessment; presentation given to the Nanotechnology Forum, Berlin,
10 November 2008
Potential risks associated with synthetically amorphous silica (SiO2)
There is some in-vitro evidence of impact on cell nuclei, ie accumulation of 40–70 nm nanoparticles in nuclei;
negative impact on replication and transcription (but manufacturers doubt that in nano-particles are present).
New gel-based production processes for SiO2 may require new safety assessment. This BfR assessment has
been endorsed by the Risk Assessment Working Group of Germany’s NanoCommission.
Open questions about the risk of nanoparticles in food
The physical and chemical properties of industrial nanoparticles as potential food additives need to be
investigated, especially whether the nanoparticles bind with other food components or whether they move
freely through the gastrointestinal tract. Further questions to be investigated are whether nanoparticles as
food additives aVect the gastrointestinal function or the gastrointestinal microﬂora. The risks through indirect
contamination and migration from packages need to be investigated as well as the status of nano-particle
enhanced food compared with novel food.
Methodology for risk assessment
The BfR recommends that methodologies be developed for a risk assessment of nanoparticles in food,
including deﬁnitions and distinction between synthetic vs. natural nanoparticles; free vs. matrix-bound
nanoparticles. Further generation of toxicological data, especially after oral exposition, is needed.
Sources: Federal Institute of Risk Assessment; presentation given to the Nanotechnology Forum, Berlin,
10 November 2008; Bericht und Empfehlungen der NanoKommission der deutschen Bundesregierung




State of the Science and its Current use in the Food Sector
In Japan, nanotech is applied mostly to food products, including supplements, food additives and ﬂavours,
and not much to food packaging or food production processes. The size of the Japanese market is still small—
approximately 1 billion yen (GBP14 million) as of 2005, according to the National Agriculture and Food
Research Organisation, citing statistics by the Ministry of Economy, Trade and Industry (METI). It was a
tenth or less the size of the market of cosmetics containing nano-materials.
But the nanotech-containing food market is likely to exceed the nanotech-containing cosmetics market in the
near future. It is expected to grow 20 billion yen (GBP148 million) in 2010, 150 billion yen (GBP1.1 billion)
in 2020 and 250 billion yen (GBP1.85 billion) in 2030.
According to a symposium in January 2008,25 Japan is far ahead in the development of surface chemistry of
emulsifying agents, followed by North America and the EU. Japan is also in the top position of solid
fermentation, solid culture technologies and brewing technologies. These technologies are mainly aimed at
improving the absorption of nutrition in the body, although some researchers are hoping to increase the use
of nanotechnologies to raise Japan’s self-suYciency ratio for food, which stood at 40 per cent in 2007, the
lowest among developed countries.
25 “Food Nanotechnology committee—application of nanotechnology and materials technologies to the food industry.” (Excerpts of a
symposium organised by Centre for Research and Development Strategy, the Japan Science and Technology Agency held on
30 January 2008 in Japan.)—Japanese only.
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In the symposium, a researcher at Japanese food company Kagome said that food companies are keen on
research into food structures; ie research into gel structures in such products as cheese, gelatin and puddings.
However, R&D to improve the texture and taste of food products is yet insuYcient. Therefore, many
companies expect to establish technologies to measure and evaluate ﬁne structures in foods eVectively.
Ministries have launched various research projects on nano-foods, but they are still at the early stage. For
example in 2007, the Ministry of Agriculture, Forestry and Fisheries (MAFF) launched a project called
“Development of nanoscale processing or evaluation technologies for food materials”. Researchers in the
projects set a goal to reduce the size of solid particles of 100micron in diameters (such as rice, grains, soybeans)
to 100 nanometres, and create 10 emulsion particles of 10 nanometres, in ﬁve years. They are also working to
develop technologies to create and evaluate particules and assess the safety of these products. To this end, the
project has 22 sub-projects with participation from four quasi-independent research institutions, six
universities one company and two regional governments.
Health and Safety & Regulatory Framework
The National Agriculture and Food Research Organisation said that there are few regulatory frameworks to
control the application of nanotechnologies in the food sector in Japan. They also said there are probably no
rules for imported food products containing nanotechnologies and nanomaterials. So basically Japan is
allowed to use particles of even less than 100 nanometres in diameters for food products.
The main reason of few regulations is that there are little data which can convince the risk of nano-foods
against people’s health. Still, since 2004 the government has been garnering various opinions about safety
through committees. The main ministries are METI, MAFF, the Ministry of Health, Labour and Welfare
(MHLW) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT). An MHLW
committee issued a report in late 2008, and recommended the government to work hard to collect information
to create possible regulations as well as to educate the public.
TheNational Agriculture and FoodResearch Organisation said Japanmay take a step forward this year, after
WHO and EFSA held conferences on safety issues.
Inter-governmental co-operation has been going well among these key ministries (MHLW, METI, MEXT,
MAFF) in terms of participation in committees etc. But major responsibilities are divided by each ministry:
MAFF for overall food issues, MHLW for safety issues, and METI and MEXT for overall nanotechnology.
In the future, the National Agriculture and Food Research Organisation believes that Japan should make a
rule to conduct safety tests when large particles, which are currently widely used in foods, are re-engineered
as nano-particles because these structures may change and endanger people’s health.
Public Engagement
In the autumn of 2008, Hokkaido University held a small conference to discuss nano-food and its safety with
consumers. The National Agriculture and Food Research Organisation was represented at the conference and
believed the general public had a positive impression about nano-foods. Meanwhile, in the symposium in
January 2008, a journalist of Nikkei Biotechnology Japan said that nano-foods and food nanotechnologies
have yet to be a topic among consumers, and there are few consumermovements against nano-food and safety
issues. Japanese consumers tend to show strong resistance against GM foods, so nanotech for food
applications may trigger similar safety concerns once people get to know more about it. Accurate and proper
dissemination of scientiﬁc information is therefore necessary in Japan.
GBP1% 135 yen
Annex 6
EVIDENCE FROM THE UNITED STATES OF AMERICA
State of the Science and use of Nanotechnology in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
— Use of nanotechnologies in food products or in food production is considered to fall in one of two
categories—nano-inside vs. nano-outside. Nano-inside indicates use of nanotechnology as food
additives, and nano-outside indicates the use of nanotechnology in the production of food packaging.
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— Applications and beneﬁts in food products—In food additives, improvements could be made in food
shelf life, texture, ﬂavor, or nutrient composition. Some additives can also be used to detect food
pathogens, or used as food quality indicators.
— Applications and beneﬁts in food production process—In food packaging—nanotechnologies in this
area are considered to be of use to increase product shelf life, provide indication of spoilage (though
nanosensors), or generally increase product quality (eg by inhibiting gas ﬂow across packaging
materials.)
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
— Current State of the Market—According to Lux Research, sales of products containing
nanotechnology (in general) generated $30 billion of sales in 2005. In the food industry, some experts
predict that nanotechnology will be incorporated into $20 billion worth of consumer products by
2010 (Helmut Kaiser Consultancy). Five out of the 10 world’s largest food companies are pursuing
research in exploring use of nano in their food products or packaging. According to the Woodrow
Wilson Project on emerging nanotechnologies consumer products list there are around products in
the food and beverage ﬁeld—around 10 per cent of the total products in their database.
www.nanotechproject.org/inventories/consumer/analysis draft/
— Examples of current items on the market are: Canola oil that contains nanomaterials which block
cholesterol from entering the bloodstream (Canola Active Oil by Shemen Industries). Another is a
chocolate “slim” shake which is supposedly tastier and more nutritious due to the properties of
nanoparticles designed to carry nutrition more eYciently into cells (Nanoceuticals Slim Shake
Chocolate by RBC Life Sciences). There are beer bottles on the market from Hite Brewery Beers
(Honeywell) whose bottles are created using nanoparticles which block the transmission of oxygen
into the beer, thus keeping it fresher for longer periods of time. Nanotea is another product, which
claims to use nanoparticles to increase absorption of selenium in the body from the tea, which
purportedly boosts selenium’s natural activity in the body by 10x (Shenzen Become Industry &Trade
Co, Ltd).
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
— According to Kuzma and VerHage’s Nanotechology Report (http://www.nanotechproject.org/
publications/archive/nanotechnology in agriculture food), industry observers indicate that there
are literally hundreds of new food and food packaging products under development which could be
on the market in as little as two years.
— According to the report above, there are several examples of next generation nanomaterials which
could be used in future food products. Some nanoparticles are being designed to block substances in
food (like the canola oil example), but could also include blocking food allergens. Other
nanomaterials are being developed to be given to livestock, in order to detect and neutralize animal
pathogens before they reach consumers (Clemson is designing a nanoparticle to neutralize the poultry
pathogen campylobacter). There are additional nanoparticles being developed in order to deliver
nutrients to human cells that either had previously low or no absorption. In the area of food
packaging, nanosensors would be embedded in food packages designed to alert consumers that a
product has spoiled, and is no longer safe to eat.
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
— R&D in U.S.—A project by Dr. Jennifer Kuzma and Peter VerHage (detailed in the report above)
included the creation of a database of all available food-related nanotechnology applications and
products that are likely to appear on the market in the coming years. It compiles information about
food nanotechnologies that are still in the developmental stage, but includes only those from
companies or labs that have agreed to release the information. Most of these are being made/
developed within the United States. The website for the database is: www.nanotechproject.org.
— Beyond this database, which the creators admitted only “scratches the surface” of food related
nanotechnology products, there are many products under development which are being kept secret,
mostly by industries, due to varying concerns regarding public opinion, regulation, or duplication.
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What are the barriers to the development of new nano-products or processes in the food sector?
— Currently, there are few methodologies or guidelines in the industry sector on how to asses potential
risks from certain nanomaterials/particles, which can complicate risk assessment in the food sector.
Future regulation spurred by these perceived risks could limit or inhibit use of nanotechnology in
food products, especially if all nanomaterials are required to go through the review phase (see below),
and not be eligible to be considered as a material Generally Recognized As Safe (GRAS) if the parent
material had that classiﬁcation.
Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
— The legislation regulating nanotechnology in food is currently the Food Additives Amendment of
1958, which has been subsequently renewed and added to. The regulatory agency in charge of this is
the Food and Drug Administration (FDA). This law states that any new substance added to food
must undergo formal pre-market review and approval by the FDA through a food additive petition
process which results in a regulation which speciﬁes the conditions by which the additive can be safely
used in food. http://www.fda.gov/nanotechnology/regulation.html
— However, circumventing the approval process occurs because some nanoparticles are just drastically
reduced sizes of familiar Generally Recognised as Safe (GRAS) substances. This could allow a
manufacturer to assert that the new particle has a “reasonable” certainty that a particular additive
will have no harm, if the parent material is considered safe. However, the reduced size actually
changes the particles physical properties, which could necessitate a case-by-case scientiﬁc evaluation
of all nanoparticles, which could inhibit or slow innovation of new particles if all nanoparticles/
materials must go through a new extensive regulatory process.
— A new bill that just passed in the House, which has yet to be introduced in the Senate, will attempt
to further coordinate nanotechnology information. H.R. 554 mandates that the Nanoscale Science,
Engineering, and Technology Subcommittee of the National Science and Technology Council
(NSTC) develop and maintain a publically accessible database of projects falling under the various
existing categories. This databasewill be “oYcial”, and is not related to the nanotech project database
referred to in the fourth question. This bill still needs to be approved by the Senate prior to
becoming law.
— Additional papers on this subject can be found on proposals for nanotechnology regulation on the
website for the Woodrow Wilson Center for Emerging Technology—http://www.wilsoncenter.org/
index.cfm?topic id%166192&fuseaction%topics.home
How are imported food products regulated?
— Currently, all imported food products containing nanomaterials are subject to the same levels of
regulation that U.S. products undergo. However, the House has just introduced a bill, called the
“Food and Drug Globalization Act of 2009”, sponsored by Representative John Dingell (D-MI)
which would greatly increase U.S. oversight on imported food products. This Act focuses on all food
and drug imports, but will aVect those including nanotechnology as well. This Act will require that
ALL foreign food manufacturers to be certiﬁed as meeting all U.S. food safety requirements
(including nanotechnology safety requirements) by third parties accredited by the FDA. All testing
would need to be done by facilities certiﬁed by the FDA, and the results provided to the FDA.
Uncertiﬁed facilities and their uncertiﬁed products would be banned from being imported in the U.S.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take
up by companies working in the food sector?
— The FDA could be unaware of nanomaterials used in a product if the company does not report it.
Also, some small particles can be derived from existing substances and still be above the 100nm size
range required to be considered a nanoparticle, and therefore not technically qualify as
“nanotechnology” and thus would not require reporting.
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Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
— The 1958Act which governs food additives has done a comprehensive, albeit limited, job of providing
regulation for nanomaterials so far. The current regulations are not seen as adequate for the future,
according to the testimony of Dr. Michael R. Taylor of the George Washington University of Public
Health at a public meeting discussing nanotechnology materials in FDA regulated products. http://
www.nanotechproject.org/publications/archive/statement michael taylor at fda/
— Others like him have expressed their concerns that the current regulatory system will prove to be
inadequate to deal with the predicted high number of new food and food packaging nanotechnologies
that will be forthcoming.Many experts believe that more regulations need to be put in place, and that
the FDA is also not currently adequately funded to review the potentially large number of new
products coming under review, or even to handle more in-depth checking of current nanotechnology
used in the food sector. A listing of additional papers on this subject can be found on the Woodrow
Wilson’s Project on Emerging Technologies website—http://www.nanotechproject.org/publications/
page4/
— The FDA itself claims that through coordination with other agencies, future regulation of
nanotechnology should not pose a problem. The FDA regulation policy for nanotechnology can be
found at the following link: http://www.fda.gov/nanotechnology/regulation.html
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
— Currently, there does not appear to be any inter-governmental co-operation on regulations and
standards for nanotechnology in the food and food packaging sector.Many critics of the FDA system
of regulation in the U.S. have cited the regulatory system in Europe as being equally as good, but
faster. Recent trends indicate that regulations are becoming more globalized, which could prove
useful for the development of future regulations for nanotechnology.
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Memorandum by Department for Environment, Food and Rural Affairs (DEFRA)
1. This memorandum sets out Defra’s written response to the inquiry that the Committee is undertaking into
nanotechnologies and food.
2. We understand the inquiry speciﬁcally excludes the potential impacts of nanomaterials in waste streams
and the environment, instead focussing on food products and consumers.
3. In this context Defra would like to make the Committee aware of the role of nanotechnology in pesticides
and highlight some related research on the potential environmental beneﬁts of nanotechnology use in
agriculture.
Pesticides
4. Of the authorised pesticide products currently on themarket, nearly all utilise nanotechnology in some way
if they contain a surfactant eg an emulsifying agent or dispersant.
5. However, rather than being a novel nanoscale process this is actually an established method of pesticide
production, with these surfactants (which are necessarily at the nanoscale) acting to stabilise the product.
6. There are currently 1,468 products approved for use in the UK that utilise surfactants. All agricultural
pesticides used throughout Europe are considered under an EU review programme to ensure that the safety
of all pesticides is evaluated tomodern standards. This is implemented in the UK through the Plant Protection
Products Regulations 1995 as amended.
7. We are aware of research being undertaken into developing “smart nanoscale pesticides” aimed at slower
release (so reducing the amount of pesticide needed). However, we understand this remains at the R&D phase
and we are not yet clear whether these would actually be considered as being at the nanoscale ie'100nm.
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Other Related Research—“Environmentally Beneficial Nanotechnologies”
8. Defra published a report inMay 2007 entitled “Environmentally beneﬁcial nanotechnologies: barriers and
opportunities”, which can be viewed at:
http://www.defra.gov.uk/environment/nanotech/policy/index.htm
9. In this report the possible beneﬁts of nanoscale environmental sensors in agriculture were highlighted, as
these could allowmore precise nutrient management. However, this was in the context of reducing greenhouse
gas emissions and was not explored in detail in the report.
March 2009
Examination of Witnesses
Witnesses: Dr Andrew Wadge, Chief Scientist, Food Standards Agency, Dr Stephen Axford, Head of
Science and Society, Department for Innovation Universities and Skills (now part of Department for Business
Innovation and skills) and Mr John Roberts, Head of Chemicals and Nanotechnologies, Department for
Environment, Food and Rural Affairs, examined.
Q1 Chairman: Good morning, I should like to
welcome our ﬁrst three witnesses; this is the ﬁrst
public hearing of the Select Committee’s inquiry into
nanotechnologies and food and I should like to thank
you very much for coming to join us to kick oV our
inquiry. I should inform you that the proceedings are
being webcast, so your sotto voce comments will be
picked up and broadcast to the nation. I should also
draw attention to the information note which is
available to members of the public. This sets out the
interests which have been declared bymembers of the
Select Committee, so I will not be asking members to
repeat their interests whilst they are asking questions
because you have those written down. Before we start
on our questioning I should like to invite the three
witnesses to introduce themselves and also, if they
have any opening statement they would like to make
at this stage, to make a statement please. Perhaps we
could start with Dr Axford.
Dr Axford: Stephen Axford from the Department for
Innovation, Universities and Skills where I am
responsible for Science and Society. That comes with
a speciﬁc interest relevant to today of the public
engagement, public dialogue and attitude of the
public towards the science.
Dr Wadge: I amAndrewWadge. I am the Director of
Food Safety and Chief Scientist at the Food
Standards Agency, so considerable interest obviously
in the topic today.
Mr Roberts: I am John Roberts from the Department
for Environment, Food and Rural AVairs. I head the
division which deals with chemicals and
nanotechnologies.
Q2 Chairman: Are there any general comments that
the three of you would like to make before we move
to the questions? Do you have any prepared opening
statement you would like to make or are you happy
just to go to the questions?
Dr Wadge: I am happy to go straight to the questions.
Q3 Chairman: I will kick oV with a very general
question which is to ask you how the Government
see the opportunities and challenges for
nanotechnologies in the food sector. We are
obviously just starting this inquiry but we have heard
various comments about the very large potential for
nanotechnologies in the food sector, which is of
course why we are carrying out this inquiry at this
point. I should be interested to hear your views on
both the opportunities and the challenges.
Dr Wadge: The words “potential” and “challenge”
are very much pertinent here in that a lot of the
applications are very much at a potential stage; they
are still in the laboratory. There is a lot of talk about
what might be in the future in terms of applications,
perhaps in food contact materials or in relation to
speciﬁc ingredients. Those are potential applications
whichmay bring beneﬁts for foodmanufacturers and
possibly for the consumers as well. In terms of
challenges, our number one challenge, certainly from
the Food Standards Agency perspective and
Government perspective more generally, will be to
ensure consumer safety. It is assessing the safety and
looking at whether the risk assessment paradigms are
appropriate, looking at the regulatory framework,
whether the current regulatory framework is
appropriate and also another challenge is around
consumer and public engagement and understanding
of nanotechnologies. We have obviously learned
from previous experience where technologies have
developed without some appreciation and
understanding amongst the public that whilst on one
level theymay confer certain beneﬁts, if the public are
not convinced or are mistrustful of those beneﬁts,
then they will not be interested in purchasing the
products. In general there is tremendous potential
there but it is very much at the potential stage;
uncertainties exist in terms of what that might mean
and real challenges centre around assessing safety
and public acceptance.
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Q4 Chairman: I do not know whether the other
witnesses wish to add anything at this point. You say
that the development is still at the laboratory stage
and we will come back to that later on in the session
to try to understand where we are. Are you talking
about the UKor are you talking about globally when
you refer to the product still being at the research and
development stage rather than in the market?
Dr Wadge: In general, a lot of the potential is still in
the laboratory stage. There are products on the
market globally and there are two products that we
are aware of that are currently on the market in the
UK; rather niche products, I have to say, that are
both food supplements. It is very much the case that
we are looking at potential applications in the UK
rather than products on the market but we are aware
that in other parts of the world there is perhaps a
greater range of products on the market.
Q5 Chairman: What areas do you think the
applications are likely to be in and are the
Government doing something to encourage
development of those applications?
Dr Wadge: I will leave colleagues to talk about the
extent to which we are encouraging the innovation of
new technologies. The main areas in relation to food
are food contact materials and the opportunities that
are present for nanomaterials to provide greater
impermeability. I see prevention of permeability,
antimicrobial applications, perhaps intelligent
packaging and sensors and also, in terms of food
ingredients, greater solubility of fatty materials in an
aqueous media, ingredients and contact materials as
the most likely. That is the intelligence that we have
got from our conversations and discussions with the
food industry.
Q6 Chairman:What about initiatives?MaybeDIUS
can give us a view on initiatives for encouraging
nanotechnology development.
Dr Axford: Yes. We would have to look to the
structures we have in place such as the Technology
Strategy Board, Knowledge Transfer Networks and
so forth which are ways of getting the science out of
the laboratory and into those businesses which can
ﬁnd ways of developing innovative products and
developing the commercial opportunities.
Q7 Chairman: Can you say anything more speciﬁc
about that?
Dr Axford: I do not know a huge amount of the detail
of some of those speciﬁcs around particular
technologies, certainly not speciﬁcally in relation to
food. I would have to look to colleagues who were
closer to the food sector.
Chairman: Perhaps that is something you could send
us a note on to follow that up, just to look more
speciﬁcally at what is being done to encourage R&D
and translation in relation to food.
Q8 Lord Crickhowell: We had a seminar the other
day with a wide representative group of advisers and
I asked the same question then. We are told today, as
we were told then, that there are only two known
products, supplements and so on, in this country; we
are going to cover questions about European
legislation later. However, the fact is that we live in a
global world and therefore I am rather sceptical
about the view that because products are not known
to be here, that are known to be in use in other parts
of the world, they will not be here and it seems that if
they are not now, they very soon will be, either in
large quantities or brought in in various ways. Could
you enlarge a little on this slight disregard for what is
happening globally elsewhere? We heard, for
example, of onemanufacturing company based in the
United States and what it was doing in the way of
research and so on. Clearly there is a great deal going
on in other parts of the world. How are we setting
about really seriously identifying the global impact,
which must be a UK impact as well?
Dr Wadge: I certainly would not want to give the
impression that we are complacent about what is
happening around the world. That is partly why we
have commissioned two projects and we have
provided you with reports on them in terms of what
the current state of the market is. We have not been
solely looking within the UK; we have been looking
more broadly. You are absolutely right; if products
are being developed in other parts of the world then
we have a global food supply. Obviously within
Europe we have European food legislation which
requires that any food which is imported into the UK
or any other part of the EU needs to meet at least the
level of food safety requirements within the EU. That
provides some reassurance but that is why we need to
look at speciﬁcally improving methods of assessing
the hazard characterisation and identiﬁcation,
exposure assessment, better understanding about
what happens when nanomaterials are ingested, how
they are distributed through tissues in the body and
the toxicity of these materials. Those will be
important areas for research that go along side by
side with the development of the products. It is
important as well that we tailor the research to meet
the speciﬁc nature and properties of the
nanomaterials which are being developed.
Q9 Lord Haskel: Dr Wadge spoke about the
challenges of safety and public engagement. It seems
to me that one of the challenges would be, from the
point of view of the man in the street, the fact that
these materials are so small. Are we able to detect
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them so that we know whether they are present or
not? Is the state of the science of detecting them
suYciently advanced as well?
Dr Wadge: Yes, it is a signiﬁcant challenge and it is
one which we will need to address over the years. At
the moment I do not think we can be clear about the
distribution of nanomaterials within the body,
whether we can detect them in tissues and therefore
to carry out a full and complete risk assessment you
would need that type of information.
Q10 Lord Haskel: Can we detect them in food?
Dr Wadge: It dependswhat we are talking about. Part
of the challenge here is that we are talking about
nanotechnologies, a whole range of diVerent
technologies from micelles to hard particles to
biodegradable particles. Certainly, with products
which are going to be approved and put on the
market, that is something which we will look at very
closely tomake sure that there are appropriate testing
methods andmeans of assessing the exposure and the
safety of those products.
Q11 Baroness O’Neill of Bengarve: This is a very
general question. How do the Government
coordinate their work on nanotechnologies? How do
they strategise? How do they prioritise funding
through research and innovation? I should say that in
the next question we will come to some more speciﬁc
points about the Nanotechnology Research
Coordination Group, so we know that exists.
Generally how do the Government coordinate?
Dr Axford: Taking an overview of that, you
mentioned the Research Coordination Group and
that is down a level below the strategic. There is a
ministerial group on nanotechnologies, currently
chaired by Lord Drayson, including representatives
speaking for the ministers who speak for health and
safety; I think that is Work and Pensions. Other
members of the high level ministerial group are
Huw Irranca-Davies from the Department for
Environment, Food and Rural AVairs, Dawn
Primarolo from Health, Lord McKenzie of Luton,
responsible for health and safety and Ian Pearson
from Business, Enterprise and Regulatory Reform
[now known as Business Innovation and Skills]. That
sets Government’s direction on nanotechnologies
overall; obviously not exclusively with relation to
food but across the piece. Below that there is also
eVectively a policy group called the Nanotechnology
Issues DialogueGroup. That allows the Government
to coordinate activity at a policy level, that is between
all interested parties, between Government and other
stakeholders. Then there are other bodies such as the
Nanotechnology Research Coordination Group
which looks at how the publicly funded research, say
in research councils and elsewhere, is covered and
looked after. Then there is a number of other groups
as well which inform those various bodies such as the
Stakeholder Forum which is open to the public,
which allows wider views to be input to the system.
Q12 Baroness O’Neill of Bengarve: That lists the
bodies, which is extremely helpful. When we come to
the actions which are taken, for example inDecember
2006 the DTI—of which I take it DIUS is the
successor body here—published a review of the
framework of current regulations covering
nanomaterials. How are the Government responding
to that review? Who is coordinating the response
speciﬁcally?
Dr Axford: In relation to how it responds on the
nanotechnology regulations, that is Defra.
Mr Roberts: The BRASS report reviewed the
regulations whichwere applicable to nanotechnology
and demonstrated in fact that there is a very wide
range of potential regulations. Many of them in fact
derive from European regimes; many of the
regulatory regimes are determined by European
legislation. We are currently pulling together
responses from departments because a wide range of
diVerent departments have responsibility for the
particular regimes and we are asking them to make
sure that they continue to have regard to
nanotechnology issues as they develop those regimes.
The European Commission has also published its
own review of the European regulation; that was
done towards the end of last year. They also are
monitoring and keeping an eye on how those various
regimes need to respond.
Q13 Baroness O’Neill of Bengarve: In their evidence
to us DIUS talked about the development of a
national strategy for nanotechnologies. What
progress is there at this point on that strategy and
who is responsible for coordination?
Dr Axford:Agreement to the strategy will be taken by
the ministerial group. They are next meeting towards
the end of April, when they will agree the way ahead
for the next steps of the strategy, potentially including
a consultative process through the summer into the
autumn. That is where that is at the moment.
Q14 Baroness O’Neill of Bengarve: So there is a draft
strategy at this point.
Dr Axford: I do not believe there is a draft strategy.
Q15 Baroness O’Neill of Bengarve: The workings
for one?
Dr Axford: It is certainly work in progress with, no
doubt, an awful lot of evidence and information
already collated. It has to capture the work of many
other parties who are also similarly developing what
youmight call strategies both on the research end but
also the Technology Strategy Board also has its own
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development of a strategy for nanotechnologies.
Government have to somehow capture all of these in
their overarching strategy.
Q16 Baroness O’Neill of Bengarve: It is now nearly
ﬁve years since the Royal Society and Royal
Academy of Engineering report on nanotechnologies
was published. Is this not quite a slow pace at which
to be developing a strategy?
Dr Axford: I do not know the answer to that question.
I would imagine that it is an incredibly complex area
and as others have already alluded to, there are huge
issues around knowing who should be accountable,
who should be responsible, where the regulatory
regimes reside and I imagine it is ﬁnding one’s way
through the forest which is slowing it down.
Q17 Lord O’Neill of Clackmannan: What was the
purpose of the 2006 review which followed the Royal
Society and Royal Academy study? DTI published a
review of the framework of current regulations and
nanomaterials; that was in 2006, three years ago. It
does seem an unconscionably long period. Who is
responsible? Which department was responsible for
leading on this?
Mr Roberts:May I just answer that slightly diVerently
by saying that the government approach is based on
two things? First of all we need to get the science in
place because the science has to underpin the way
that the regulatory system develops. Then we need to
keep an eye on the regulatory system. To the extent
that it needs to be changed, we need to make the
changes. The BRASS report showed that in a lot of
areas the regulation is in principle capable of dealing
with nanotechnology, provided that one understands
the risks and the hazards that nanotechnology may
present. It is a question of developing the science and
developing the regulation step by step to keep the two
together. Would it be helpful if I talked a little bit
about how the research agenda has been carried
forward since the Royal Society report, because I
think that may help?
Q18 Chairman: Yes.
Mr Roberts: Following the Royal Society report the
Nanotechnology Research Coordination Group
identiﬁed 19 research priorities which were set out.
There are ﬁve taskforces under that coordination
group which take forward particular aspects. Those
are to do with measurement and detection and
characterisation of nanomaterials, fate and
behaviour in the environment, human toxicology, co-
toxicology and social engagement. It has taken a
while to get momentum on the research, but it is true
to say that the research is now accelerating. Over the
period 2005–08 the Government spent about £10
million on research in these areas and I suspect the
pace has picking up since. I can refer to a number of
particular initiatives but not an overall ﬁgure. I just
make the point that some of the researchwe are doing
for underpinning regulation is actually also relevant
to innovation. For example, characterising and
detecting nanomaterials is important for regulation,
but it also forms the basis for the industry to take
forward, so some of the research covers more than
two areas. In terms of research, last year we
commissioned an independent review of the progress
we have made on those 19 research objectives, a very
comprehensive piece of research which was done by a
team of academics and it will be published very
shortly; it is going through peer review and ﬁnal
preparation for publication. That was encouraging in
the sense that they found a lot of evidence that
progress is being made on all the research objectives
but it also indicated that on none of the research
objectives have we yet completed the task. We do not
yet know the answer fully on any of the research
objectives. What we are going to do with that
research is to use it to revisit the 19 research objectives
to identify the gaps and the next directions so that we
can take forward the next phase of research. If I may,
the other two points I would make about research are
ﬁrst of all that we need to do this internationally. As
Lord Crickhowell was saying, the issue is global;
there is a lot of experience in other countries and we
can get much better results if we coordinate our
research programmes. That is being done through
OECD, which has a similar structure of task forces,
and we are sharing out research tasks among us to
cover the ﬁeld. The other observation is that themost
productive research tends to come from collaborative
projects involving diVerent institutions and diVerent
disciplines. We are seeing much stronger results
coming through from that, although it does take a
little bit longer to get the research proposals put
together and in place. In my own area, two quite
exciting issues are the environmental nanoscience
initiative, the second phase; the ﬁrst phase was worth
about £850,000, the second phase will be worth about
£4.5 million and almost half that money is coming
from the US because we have a partnership with the
US EPA, so we will get the beneﬁts of collaboration
there. OECD has set out an ambitious programme to
look at 14 of the most commonly produced
nanoparticles. We are taking forward analysis of two
of them; as it happens they are not food products but
cerium oxide and zinc oxide. We have just launched
a £3.5 million programme to characterise those two
nanomaterials. Other countries will be doing others
which are on the list. When that work is done we will
know about those particular substances in much
more detail but we will also have a much better
knowledge of how to do the assessment of
nanomaterials, how to do the characterisation, the
measurement and the assessment of health and safety
implications.
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Q19 Lord Methuen:We have talked quite a lot about
the national Research Coordination Group but in
2007 the Council for Science and Technology
expressed concern over the progress of funding for
health and safety research. You indicated that quite a
lot of progress has been made in addressing these
concerns. Would you comment on that?
Mr Roberts: Those were the points I have been
covering to some extent. The EMERGNANO report
has looked at something like 650 projects which have
been ﬁnanced globally over the last three or four
years. It has demonstrated that there has been
progress on all of our research objectives but there is
still progress to be made on all of them.
Q20 Lord Methuen:TheCST stated that the primary
reason for this lack of researchwas theGovernment’s
over-reliance on responsive funding to deliver the
necessary research. What has been done to overcome
that problem or would you not agree with that?
Mr Roberts: The question of funding is an important
one and the route we have chosen to go down is using
the existing mechanisms and existing programmes
and seeking to coordinate them, for example relying
on the budgets of my department to look at
environmental issues, the Medical Research Council
and theDoH to look at toxicological issues, the Food
Standards Agency to look at food issues. This has the
strength that the research is embedded in those
departments’ programmes and those are the
departments who will need to use the research for
their regulatory processes but it does not mean that
we have a single centrally directed budget to drive
forward the research.
Dr Axford: In terms of research councils, there is a
major cross-council programme on nanotechnology
and even within that, on the issues, for example, of
toxicology, the Medical Research Council has
speciﬁcally had a call to look at that area, to look at
the implications of nanotechnology on health to the
tune of about £3 million.
Q21 Lord Methuen: What is being done to look at
the long-term eVects of possible toxicity due to
nanomaterials?
Dr Axford: I would imagine that will be part of the
research undertaken.
Q22 Lord Methuen: But you are not aware of what
is going on at the moment.
Dr Axford: No, not the detail of what has actually
been funded under that programme.
Q23 Chairman:What sort of response has there been
to the MRC’s call?
Dr Axford: It is fully taken up. It is a direct
programme but it is obviously there to be
responded to.25
Q24 Chairman: Mr Roberts, in your helpful
summary of the OECD assessment of risk associated
with 14 nanomaterials, as I understood it the 14 did
not include any potential food applications. Do you
think it should?
Mr Roberts: I think it is right that it does not contain
many that are connected with food, although
possibly the nanoclays may be used in bottles and
therefore may have some link with food. They were
chosen on the basis that they are ones which are in
production now and therefore where there is
potentially exposure to the environment or to human
beings from those. It is those where we have some
evidence available in order to make the assessments.
It was a programmedesigned to capitalise onwhatwe
already have and the challenges we face today rather
than a more prospective programme looking at
potential applications in future.
Q25 Chairman:We have heard that, for example, the
nanosilver particles are used in food contact
materials like chopping boards or refrigerators. Is
nanosilver included in the list of 14?
Mr Roberts: It is. Nanosilver was identiﬁed by the
Royal Commission as one that was potentially
something we should be concerned about. Defra has
asked our Advisory Committee on Hazardous
Substances to have a look at the issues around
nanosilver and they are due to give us preliminary
advice, although it will require some further work.
Q26 Earl of Selborne: On silver, when you
mentioned earlier that there were two known food
products with nanoparticles, was silver one of them?
Dr Wadge: Yes, in relation to a supplement.
Q27 Earl of Selborne:Yet the European Food Safety
Authority has said that there is not enough evidence
to suggest that this is cumulatively safe.How is it then
that this has got through the system already?
Dr Wadge: Yes, that is one which will fall within the
system; at the moment it is outside the system, it is
quite a niche product and has been around for a long
time. Under the new controls on supplements, that
will fall out of the permitted list from January next
year, 2010, because the safety data has not been
provided to support that.
Q28 Earl of Selborne: That means that the material
which is already available will be withdrawn.
25 “To date the MRC has made ﬁve awards totalling
approximately £3 million from response (not directed) mode
funding. There is an open call and the submission of further
proposals is being encouraged. Details are included in the
additional written evidence provided by DIUS”.
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Dr Wadge: Yes.
Q29 Lord Crickhowell:May I ask a general question
and then follow up with a speciﬁc one which has
already been touched on?MrRoberts, you have been
giving very helpful and impressive evidence, if I may
say so. We were a bit surprised that Defra’s response
to our enquiries was a one-page note on pesticides.
We wondered what Defra were up to. Clearly Defra
are more heavily involved than that indicated. You
have been doing your best to cover a lot of ground in
response to speciﬁc questions. Surely what we are
going to need from you is a pretty detailed report
from Defra about all this work you are clearly
engaged in and about which we have not yet been
informed except by you this morning. May I ask that
you follow up your evidence—I hope the Chairman
agrees to my request—with a really detailed account
from Defra of what you are doing, covering all these
points you have been talking about and adding any
more that you would like to include. May I then put
my speciﬁc question which follows two which have
already been asked by LordMethuen and the Earl of
Selborne in a way and that is on long-term
toxicology? Certainly the medical evidence that we
received in an interesting seminar we had indicated
that we do not really know a great deal yet about
long-term eVects. We know a good deal about the
way the gut absorbs and the eVectiveness of the gut in
dealing with all the normal things, including some of
the natural nanoparticles which it has been dealing
with for millennia, but we do not know the long-term
eVects yet and we do not know therefore how these
nanoparticles move on into the other parts of the
body, the brain particularly and so on. Is one of these
19 research projects really homing in on the need for
this long-term assessment of nanoparticles on the
human body? If not, what is going to be done about
it?
Dr Wadge: While John is looking through the
particular 19 projects, I should like to comment on
that, if I may? One of the real challenges for us is
around the toxicological assessment and the risk
assessment. We have received advice from our
independent Committee on Toxicity and also the
independent panel which advises the European Food
Safety Authority that whilst the current risk
assessment paradigm is appropriate there are
considerable gaps in our understanding along the
way around exposure and distribution and toxicity. I
think that therewill need to be a considerable amount
of research in this area and I know that the MRC are
picking up some of that. However, it raises bigger,
wider questions about whether we have the
appropriate capacity of toxicologists within the UK
and that is something we need to look at. I am sure
that at an OECD level, consideration will be given to
develop harmonised risk assessment processes for
nanomaterials. OECD currently agree the
toxicological assessments for long-term eVects of
contaminants and other chemicals and it will be
OECD which agrees those risk assessment methods
for the very speciﬁc thing you mentioned around
long-term toxicity. You are absolutely right that this
is an area which will need a lot more research.
Q30 Chairman: Before we move on to the next
question, perhaps we could home in on the particular
issue of toxicology in the gut which LordCrickhowell
mentioned. We have gained the impression that, at
least in this country, there is rather limited expertise
in that area which is crucial of course to
understanding potential risks associated with food. I
just wondered, either from the Food Standards
Agency or from DIUS, how many grants have been
issued for research in relation to toxicology of
nanoparticles in the gut which would be a central
issue in understanding and ﬁlling the gaps.
Dr Wadge: We have just put a call out for our ﬁrst
project on the toxicokinetics of nanoparticles and
that will be a collaborative project. We are very much
at the early stages here. The research we have
commissioned so far has been to carry out reviews:
reviews of what products are available; reviews of the
regulatory framework; reviews of public engagement
and public attitudes to nanotechnology. We are very
much at the early stages and a lot more needs to be
done. I am not familiar with what MRC are doing.
Dr Axford: I am not familiar with the absolute detail
of what the speciﬁc projects are. We could come back
to you with information on that.
Chairman: Please do.
Q31 Lord O’Neill of Clackmannan: Much play has
been made of the OECD and EU. Where are our
partners in these organisations in relation to research
and in relation to the seemingly endless process of
reviews that you have been telling us about this
morning? Are we missing out on other people’s
research or are we further ahead? At the moment we
do not really know howwe are comparing against, let
us say, the French or the Germans or the Italians or
the Swiss. I am not asking for a league table but we
need to know how you are behaving or how you are
performing by comparison with people alongside
whom you are supposed to be working in these
international organisations.
Mr Roberts: If I may say on nanotechnology
generally rather than on food, my impression is that
the amount being spent on EHS, environment, health
and safety issues is broadly similar in three markets,
Japan, Europe and the US? They are broadly of
similar orders of magnitude both in terms of
investment in innovation and investment in health
and safety research. We can see whether there are
more detailed ﬁgures and if the information I have
31nanotechnologies and food: evidence
31 March 2009 Dr Andrew Wadge, Dr Stephen Axford and Mr John Roberts
given is not absolutely right, I will try to provide
something in more detail.
Chairman: It would be helpful if we could have some
ﬁgures on that.
Q32 Lord Haskel: Like other members of the
Committee I am quite impressed with all the work
that you are doing on getting the science in place and
getting the research done. Meanwhile this industry
has to be regulated. It seems to me that the ﬁrst thing
you do when you regulate is to deﬁne what it is that
you are regulating. I wonder whether you could tell
us how you are going to deﬁne nanotechnologies and
nanomaterials in this context of regulation.
Dr Wadge: There are very many deﬁnitions out there
at the moment and we provide the BSI deﬁnition in
our evidence to you. I know that the European
Commission is also looking at deﬁnitions currently in
relation to cosmetics but what they have agreed there
will also no doubt be broadened out at some point in
relation to food. From our perspective it is not so
much the exact precise cut-oV point in terms of size,
it is far more around the properties which will have a
bearing on the risk assessment; whether it is
biodegradable or not, whether it is persistent and so
forth, those are the key points. It is important that
there is some agreed deﬁnition and that is something
which is being worked up at a European level because
that is where European food law is agreed.
Q33 Lord Haskel: Is this work on agreeing a
deﬁnition within Europe proceeding through the
European Parliament Committee on the
Environment?
Mr Roberts: May I make two observations? First of
all, I am not sure it is clear that we have to have a
common deﬁnition of nanotechnology across all
regulatory regimes. Clearly we need consistency; we
also need to deal with the circumstances of each
regime. A lot of regimes will say that products have
to be safe and they have to be safe irrespective of
whether they contain nanotechnology or not. If they
contain nanotechnology then of course there has to
be an assessment of the nanotechnology component
but you do not have to deﬁne nanotechnology in
legislative terms in order to achieve that. In terms of
chemicals and nanotechnologies generally, the EU
Scientiﬁc Committee on Emerging and Newly
Identiﬁed Health Risks has proposed some
deﬁnitions. I can provide a copy of these but for
nanomaterials it simply says any form of material
that is composed of discrete functional parts, many of
which have one or more dimensions of the order of
100 nanometres or less.
Q34 Lord Haskel: So it is size.
Mr Roberts: It is size as the starting point for
consideration of risk.
Q35 Chairman: Does that make sense
toxicologically?
Dr Wadge: I think it does as a useful starting point.
If I may broaden out to the regulatory framework in
relation to food, we have looked at that and asked the
very speciﬁc question as to whether nanomaterials,
nanotechnology, nanoparticles will fall under the
current regulation or could somehow squeeze
through the current regulatory framework. We
received some reassurance on that point from that
review. Under general food law there is a requirement
on food businesses to make sure that any food which
is put on the market is not unsafe. That provides a
general level of safety. Then there are some speciﬁc
pieces of legislation relating to novel foods, food
additives and food contact materials. The food
additives regulations have recently been amended so
that where an existing food additive is produced
through nanotechnology it would have to be assessed
by EFSA for its safety, so it would have to go through
some independent assessment. Similar proposals are
currently underway and we are supporting those for
the novel foods and food ingredients regulations, also
for food contact materials. There is a sense that the
existing regulation, once it has been strengthened to
capture the speciﬁc requirements around altered
particle sizes and changed composition and
properties of nanomaterials, that they would be
captured under the regulations.
Q36 Lord Haskel: What deﬁnitive view then are you
giving to the food industry if they come to ask you
whether to label something as a nanomaterial or not?
Dr Wadge: Labelling is a separate issue. The ﬁrst
point is whether it would be permitted and we would
provide advice, as we do generally and we are in
discussion regularly with the food industry about
products, about whether they fall within certain
requirements of novel food legislation and so forth. If
we felt that it was a novel property or a new size that
was being produced, then our advice would be that it
would need to be submitted for pre-market approval
under the novel food regulations or food additive
regulations.
Q37 Lord Crickhowell: What measures are currently
in place to allow the Government to monitor the use
of nanotechnologies in the food sector?
Dr Wadge:That is something that is being considered
at the moment. Obviously if we are starting from a
point where there is not very much on the market in
the UK we need to look at what our role might and
should be in relation to monitoring the use of that
technology. There are proposals for the European
Commission to produce a European register of
nanotechnologies in relation to food and we also
have the option of producing something within the
UK. Our current thinking is that it would make sense
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to work alongside the Commission to make sure we
are familiar with what they are doing and to see
whether we then need to add a further register within
the UK. In terms of really understanding what is
happening in the market, a register clearly could be
very useful. However, our experience has been that as
useful for us certainly is the regular dialogue that we
have with all parts of the food industry about the
technologies that they are developing, the products
they are developing and how they ﬁt within the
regulatory framework. I have to say that a register
might have some beneﬁt in terms of actually
dispelling some of the myths which are currently
around that somehow nanotechnologies are being
widely used in food currently on the market in the
UK because those are some of the suggestions I have
read in some articles. So a register might be helpful in
terms of dispelling myths in that way and setting
straight what products really are being used and not
being used.
Q38 Lord Crickhowell: At one point in your answer
I thought I was going to sum up as “There are no
measures currently proposed” but you actually then
said “We have our usual ongoing discussions with the
food industry and they are really the existing
measures”. However, in your evidence you did say
that you were seriously considering a register. If you
did have it, how do you think it would work?
Dr Wadge: It is still very early stages and we are still
thinking that through and we want to see what the
proposals are from the Commission. I have to say
that it is not something we have done in any other
ﬁeld and we need to think through the beneﬁts of
that. We do not, for example, have a register of GM
technologies that are used, a register of other diVerent
types of technologies which are used in food. We
would need to think carefully about what the beneﬁt
of putting that eVort in to a speciﬁc area such as
nanotechnology might be and that is something we
are considering.
Q39 Lord Crickhowell: Defra has a voluntary
reporting scheme. How successful do think that has
been?
Mr Roberts: It has not been terribly successful. It has
only generated a dozen or so responses in the ﬁrst two
years. We are examining how we can make that more
successful. There is a challenge here between
industry’s desire for conﬁdentiality of new
developments and our interest in knowing what they
are doing.
Q40 Lord Crickhowell: Youmade exactly the point I
was going to put to you. Is there not a real problem
here because with the best will in the world I am sure
many of the best companies are doing some very
serious research and very responsible research and we
have had an account of one company doing just that.
But one is extremely sceptical about their willingness
to reveal what they are doing, if it is going to make a
diVerence to them in the competitive market if they
suddenly have a smoother ice cream or dressing using
much less fat or whatever they are seeking to achieve
and want to show that it is of beneﬁt to the customer
and not just for themselves, which is the big lesson
learned from the GM disaster. So you have quite a
problem, have you not, in getting real material out of
companies about the research they are doing?
Dr Wadge: There is a genuine tension there is there
not? However, we do have regular dialogue, for
example we talk with beverage manufacturers
around possible use of micelles to put colours in and
so forth so there are technical developments which
they are happy to discuss with us but they would not
necessarily want to discuss more widely because of
commercial pressures. The fundamental safeguard
here is that these companies know and are very
familiar with the need to make sure that their
products fall within the requirements of general food
safety and even wider than that the general
requirements of the public acceptability. There will be
a real caution amongst these companies about
learning the lessons from theGM experience in terms
of simply thinking that because they have some new
bit of technical kit, somehow this will be broadly
welcomed by the public at large. They are very, very
cautious on that point.
Q41 Chairman: In the evidence that DIUS
submitted it mentions that in Germany it appears
from the table that there are 17 products on the
market which use nanotechnologies. Presumably de
facto those are also on the market in Britain because
Europe operates as a single market? What kind of
approval process have they been through?
Dr Wadge: I am not sure. They would be permitted
under EU law but I am not sure whether they would
be on sale in the UK. I am not sure what 17 products
are being referred to there. I can refer to one speciﬁc
product, which is the co-enzyme Q10, where we had
quite detailed conversations with our counterparts in
Germany around whether that particular product
should fall within the novel food requirements and
they were quite clear that the micelles which were
being used were not changing the nature of the
properties of the coenzyme Q10 so it did not need to
go through that additional safety assessment. In a
way that shows the ability of regulatory bodies such
as ourselves to communicate, as we do regularly with
counterparts across Europe, so that where there are
products on sale in one Member State we will talk
and discuss as to why those products are on sale and
whether they should or should not need to go through
further assessments.
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Q42 Lord O’Neill of Clackmannan: In the case of the
Federal Republic there are two quite substantial
supermarket chains, German owned and German
directed. Has nobody thought of looking at their
range of products and sending anybody to do that?
This is quite a sizeable part of the supermarket
market share in the UK. I would have thought that
major players like that might well have been taking
advantage of nanotechnology on some of their
products.
Dr Wadge: You referred earlier on to the reviews that
we are doing and two of the reviews were looking at
the use of nanomaterials, food contact materials and
food ingredients more generally and that showed
very little is currently in use in theUKmarket, but we
fully expect that to change and that is why we are so
concerned about getting the regulatory framework
and the risk assessment frameworks right in
anticipation of that change.
Q43 Baroness O’Neill of Bengarve: Do you have a
sense of the timeframe? How urgent is it? It is rather
a diVerent story, requiring the withdrawal of a large
number of products which have been on the shelves
and would have had bad eVects on public conﬁdence
in the technology and preventing them getting on the
shelves until the assessment has been done. How
much time do you think you have to get this
regulatory framework in place?
Dr Wadge: The particular silver product that we
talked about earlier is an anomaly in the sense that it
is a product which has been around for some time, it
is a rather niche product, as a food supplement it will
fall from the permitted list and no longer be
permitted. What I was trying to explain earlier is that
the regulatory framework is such that any
nanoparticle that is either changing the size or the
nature of the property of the material will need to go
through additional safety checks so that we will not
be in a situation where we have lots and lots of
products out there on the market which then have to
be withdrawn.
Q44 Baroness O’Neill of Bengarve: The “we” there is
European, is it?
Dr Wadge: Yes.
Q45 Baroness O’Neill of Bengarve: So there is an
expectation that a number of these products on the
market in Germany will quietly be withdrawn
because they will need to go through additional
checks before they come back on the shelves.
Dr Wadge: I would be very happy to look into that
and provide some additional information because I
am not familiar with the particular products that you
are talking about. I would rather not comment
without being familiar with what they are.
Q46 Chairman: Perhaps you could follow that up.
They were listed in an annex to the DIUS submission
in a table produced by the German Federal Risk
Assessment Institute.
Dr Wadge: Yes; okay.
Q47 Earl of Selborne: I should like to take us back to
the European regulatory framework and in answer to
Lord Haskel’s question Dr Wadge helpfully referred
to the review which the FSA had conducted on the
European regulatory framework. I think you referred
to the general safety requirements of the EU food law
regulation whichwould be the same whether the food
was nano-engineered or not. You referred to novel
food and food ingredients and noted that this is in
course of revision. The regulation for food additives
has already been added. Then there is provision
under packaging regulations which presumably are
relevant, animal feed and the like. Would you like to
comment on whether you are satisﬁed that the
amendments either in progress or already in place put
the regulatory framework in a ﬁt-for-purpose state?
Dr Wadge: I think that they do. I think that they do
provide the necessary regulatory framework. Where
the challenges and diYculties will lie will be far more
around the precise nature of the risk assessment and
the toxicological testing rather than the regulatory
framework. It is there thatmore work is needed. I feel
reasonably conﬁdent around the regulatory
framework that products would need to go through
additional safety testing. Once a product has been
developed then the nature of that safety testingwill be
adapted on a case by case basis according to the
properties of the particular material that is being
looked at and that is one of the very speciﬁc bits of
advice that we have received from the independent
toxicological experts.
Q48 Earl of Selborne: You refer to the problem
about the adequacy of current test methods. In your
evidence you refer to the International Risk
Governance Council’s report which says that
whether you are looking at Japan, America,
European Union, all seem to be approaching this in
roughly the same way but you point out that
questions have been raised about the adequacy of
current test methods and the ability of regulatory
bodies tomonitor and controlmeasurements and risk
assessments. In other words, the technology does not
appear to be there to give the sort of assessments
which are clearly going to be needed. You have
identiﬁed the problem. How do you see this being
resolved?
Dr Wadge: It is an area where we clearly have a part
to play and we have just put the call out for our ﬁrst
particular project looking at toxicokinetics whichwill
really address one speciﬁc part of that. The MRC is
starting to fund projects and there is an international
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programme which is being coordinated through
OECD of risk assessment work. If I were a budding
young toxicologist then that is an area I would be
getting into because I think there will be considerable
research funding in that area over the next ten to 15
years and that is what is required.
Q49 Earl of Selborne: We have already talked about
colloidal silver which has been around for a long
time. We are now realising that the EFSA is not
likely to list it as an approved supplement. At what
moment does the precautionary principle rear its
head? Do we just wait until the ﬁnal review is listed
and presumably there will be other such products
coming forward which eventually will be withdrawn
but meanwhile they could or could not be
cumulatively toxic. Why do we not take the
precautionary principle seriously?
Dr Wadge: The precautionary principle is what is
going to lead to the colloidal silver being withdrawn
because the company has not produced the safety
data to support the sale of that particular product.
The regulatory framework that is set out requires a
pre-market assessment of safety that would be
approved by independent experts on scientiﬁc
committees. That is a precautionary basis; it is one
where the onus is on the manufacturer, the food
business, to demonstrate safety before it is put on
the market.
Q50 Earl of Selborne: It just seems surprising, as
you can already anticipate that in a year or so this
will be withdrawn, that you do not enact the
principle sooner rather than later. Precaution
usually means you take it sooner rather than later,
rather than just allow the process to continue.
Dr Wadge: The area of food supplements is quite a
speciﬁc area apart and the UK in particular
compared to other Member States has a long history
of quite large consumption of a range of food
supplements which are perhaps not consumed in
other parts of Europe and there are current
measures under way to bring the sale of those
products under greater control and assessment of
safety. This particular product and a number of
other supplements have been on the market for a
while and manufacturers now have to provide the
safety data to support their continued use. These are
not nanotechnology supplements in general but it is
just the nature of that area of legislation in relation
to supplements. In relation to food more generally,
we have been able to demonstrate that there is not
currently a range of nanotechnology materials on
the UK market and that food businesses would need
to go through a pre-market assessment of safety that
would be considered by independent experts.
Q51 Earl of Selborne: On the revision of the novel
foods regulation, a 1997 regulation which is to be
updated, the European Parliament has proposed
that any new regulation should explicitly apply to
all nanomaterials. I gather that is under discussion
by Member States and the European Parliament.
What is our position on this?
Dr Wadge: We support the additional controls and
requirements to assess safety of nanomaterials
which would have a diVerent size or a diVerent
property compared with the existing foods that are
on the market. The whole way the novel foods
regulation works is that it makes a comparison and
sets a date back in 1997 where, if a food has been
in continued use for a period of time within Europe
then it is not considered to be novel. What this
change in the legislation is ensuring is that a change
in the size or the properties due to nanotechnology
would make that a novel product and would require
further assessment before it is used.
Q52 Chairman: Presumably that is going to involve
a deﬁnition of nanotechnology. You said earlier on
that the deﬁnition is a bit woolly. So when we talk
about a new product being deﬁned as a novel
product, I assume there will have to be a precise
deﬁnition.
Dr Wadge: Yes.
Q53 Chairman: As a related question, you talked
about this product involving a co-enzyme which was
deemed not to be a novel product even though it
had nanotechnology in it. How does that square? Is
that the current situation which will change in future
and will not be able to slip under the radar screen
in future?
Dr Wadge: In the end the debate was around the
properties of that particular material and although
it was produced by nanotechnology, under the
current novel food regulations the properties were
not considered diVerent, therefore it was not
considered novel. If the regulations are changed to
include anything produced by nanotechnology
methods, then perhaps it may come under that
requirement in future.
Q54 Baroness O’Neill of Bengarve: You have been
telling us about the likely shape that the European
regulation will have. Will that put the European
regulation on a diVerent track from the Japanese or
US regulation? We have been there before in other
areas and it does create diYculties.
Dr Wadge: There are very speciﬁc diVerences of
approach and we have seen that clearly in relation
to GM between North America and Europe. In a
sense that reﬂects the diVerent political and social
environments that the regulations are derived from.
Probably what is most important from a scientiﬁc
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point of view is that we have international
agreement on the risk assessment procedures and
that is where the OECD work has a really important
part to play. There will always be an opportunity for
a much wider socio-political layer which is then put
on top of the science in terms of the types of controls
which are required in one part of the world
compared with another part of the world. That is
just the nature of the diVerences between diVerent
parts of the world.
Q55 Lord O’Neill of Clackmannan: In your
evidence in relation to project A03063 you give a
helpful description of the proposed changes to the
food packaging regulations. What is the attitude of
the Government to this? You are rather coy. I realise
this is just a re´sume´ of the regulations but what is
the Government’s attitude to that? How do you
envisage implementing this on labels which are small
enough to be acceptable to the packaging
requirements?
Dr Wadge: There are two questions there. One is:
what are the changes required to make sure that
nanomaterials are properly assessed and need to be
assessed before they are permitted for use such as
nanoclays for example. Then the second question is
the question of labelling. At the moment labelling
is something which in broad terms is required where
consumers need information that is meaningful to
them. The priority has always been around
information on safety and nutritional composition.
For genetically modiﬁed materials there is a
requirement for safety assessment and also labelling.
Given that we are at such an early stage in
nanotechnology we have not had that debate yet
around what the nature of the labelling might be
and how useful it would be for consumers to have
the word “nano” put on one part of the label. That
is certainly something where we would be engaging
with consumers to ﬁnd what type of information
they would ﬁnd useful. Once we get to a position
where there are very speciﬁc products which are
much closer to coming onto the market, of course
we are in a position there where there are competing
demands of clarity and useful information and a
very small space on particular products to provide
information around safety and use-by dates and
nutritional composition, some environmental
factors and possibly also information about the
nanotechnology as well. It is something we are going
to need to engage in and that is something we have
done in the past. We will engage with consumers
quite broadly with deliberative research to ﬁnd out
what sort of information they need and what is
actually useful. There is no point putting “nano” on
a label if it does not actually mean anything to
anybody.
Q56 Lord O’Neill of Clackmannan: One of the
problems we have had so far is the debate about
nutritional information and whether it should be
something which is imposed or be the right of the
manufacturer or provider of the food to put down
with their own particular spin. I ﬁnd I am an avid
reader of breakfast cereal nutritional values and if
there are more than two cereals on the table I get
totally bewildered. I understand the problem and I
wish you well in your endeavours.
Dr Wadge: Thank you.
Q57 Lord Haskel: We have had a fair bit of
discussion about the draft report on Regulatory
Aspects of Nanomaterials by the European
Parliament and indeed I think you told us you are
conducting a review about this. Can you tell us
whether you think that this is going to be a basis
for having the same risk assessment procedures
throughout Europe? Are you working with your
counterparts in Europe on this? What is your
general view about this draft report?
Mr Roberts: On many products we have European-
wide systems. If you look at chemicals generally, for
example, we have just introduced a major new
regulation, which is European-wide, to identify the
risks around chemicals generally. If I may, I will
explain how I think that relates to nano which is
why I think some of the comments the European
Parliament rapporteur has been making are perhaps
misfounded. REACH regulates substances other
than those which are regulated by other regimes
such as the food regime, the pesticide regime or the
pharmaceuticals regime. Nanoparticles are
substances so they therefore fall within the scope of
the general European regulation. The question that
we need to work through is how we should apply
that regime in the circumstances of nanomaterials.
The ﬁrst question you have to ask is whether a
nanomaterial is the same substance as a larger
material or not. We are quite clear across Europe,
both the Commission and the Member States, that
if someone is producing a nanomaterial then the risk
assessments they have to do under REACH would
have to deal with the risks which might be
associated with the nanomaterial. There are still big
issues which we have to deal with because the testing
regime associated with chemicals was designed for
chemicals rather than nanotechnology. It may pick
up many of the risks but it may not pick up all of
the risks and therefore we do need to review how
the tests are done to see whether there are new risks
or new tests which need to be added to the suite to
make sure we do capture the risks. We may also
need to deal with some of the issues such as the fact
that for registration under REACH there is a
threshold of one tonne before a manufacturer has to
go to Europe. For most chemicals that is ﬁne; for
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nanomaterials a tonne may be rather a lot. It does
not necessarily mean that nanomaterials are exempt,
because if a manufacturer produces, for example,
bulk titanium oxide and nano titanium dioxide, then
they have to register the whole of their production,
so the nanomaterial would be included. The
principles which underlie general regulation of
chemicals, similarly pharmaceuticals or pesticides,
that you have to provide information, that you have
to provide information through the supply chain so
they can be used safely and the regulator has the
opportunity to restrict the manufacturing use if
there are proven risks, apply to both bulk materials
and nanomaterials in the same way. The way I
would see the regulatory regime going forward is
amendment of some of the detail to make sure the
tests are suYciently comprehensive and any criteria
in terms of thresholds and so on may need to be
adapted to reﬂect nano. However, the principles that
we use for regulation of chemicals, of foods, of
pesticides should apply to nano in the same way
they apply to the products generally.
Q58 Lord Haskel: That is very helpful. Do you
think that will be adopted throughout Europe?
REACH is a European system so we are working
on this together and whatever rules we come up with
will apply throughout the market; it will be part of
REACH.
Mr Roberts: It will be part of the REACH system.
Q59 Chairman: Just to be clear, in this report to
which Lord Haskel is referring from the Committee
on the Environment, Public Health and Food
Safety, the European Parliament says in paragraph
E “ . . . in the context of REACH, it has so far not
even been possible to agree on guidance on the
identiﬁcation of nanomaterials, leaving important
decisions in the context of registration to economic
operators”. I am assuming translated into English
that means that nanomaterials could slip through
the net under REACH. Are you saying that is
wrong, that this committee are wrong?
Mr Roberts: It is more subtle than that. Some
guidance was published by the European
Commission after agreement with Member States a
couple of weeks ago about how far we have got in
terms of the application of REACH to
nanomaterial. I can happily provide a copy of that,
if that would be helpful; that analyses the issue in
rather more detail. What it says is that if the
nanomaterial is a new substance, if, for example, it
is a fullerene, then it is clearly a substance on its own
and REACH would apply to that substance. If it is
the same as a bulk form, then it is probably the same
substance as the bulk form but the chemical
assessments and the safety data sheets would have
to reﬂect any particular risks that arise in the
nanomaterial and in terms of classiﬁcation and
labelling, the hazard symbols which are put on
products, if the nanoform has diVerent risks, then it
might merit a diVerent hazard symbol to the same
chemical in bulk form. The draft report from the
rapporteur is an over-simpliﬁcation of a rather more
complex situation.
Q60 Chairman: This report is pretty hard hitting in
general and I wondered whether you think that the
European Parliament committee is kind of over-
egging it when they say, for example, the committee
“Considers it highly misleading for the Commission
to state, in the absence of any nanospeciﬁc
provisions in Community law, that current
legislation covers in principle the relevant risks
relating to nanomaterials”. That seems almost
directly contradictory to what Dr Wadge has said
a few moments ago and I could quote from other
paragraphs. This is much more critical of the
European regime than you appear to have been.
Could you enlighten us as to whether the committee
has got it wrong or whether you have got it wrong?
Mr Roberts: If I may make one procedural point,
this is a proposal from the rapporteur; it has not yet
been endorsed by the committee. My understanding
is that the committee is considering it today and
then the European Parliament will vote on it in the
next week or so. My view is that some of the
statements in the report are absolutely right and
some of the statements in the draft are wrong. The
one you have just indicated is one I would not
agree with.
Dr Wadge: John put that extremely well. I have
nothing further to add to that.
Q61 Lord Crickhowell: I happen to chair another
committee’s examination of REACH’s report on
food so I pricked up my ears when you started
talking about REACH. I think it is probable that if
there need to be changes they will take quite a time.
My experience of these things is that they take a
long time to change right across Europe because
everyone wants a say and the industries want a say.
How long do you think it will take to sort out the
regulatory changes to make them sensible?
Mr Roberts: I have a lot of sympathy with that
point. It is going to take four or ﬁve years for the
European system to work through the issues and
then for the legislative process to be completed.
From the UK Government’s point of view we have
been urging the Commission to make fast progress
on these issues. My Secretary of State did write to
the Commissioner last year stressing the importance
of addressing nano issues comprehensively and
urgently.
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Q62 Lord Methuen: Can we go back to pesticides?
Often these pesticides use surfactants at the
nanoscale but they do not currently use engineered
nanoparticles although there are products, “smart
nanoscale pesticides” in development. Does Defra
have a policy in place to deal with such products
once they leave the research and development phase
and enter the marketplace? I also include in this
things like fertilisers which presumably will use the
same things and things which are used by animal
feedstuVs.
Mr Roberts: I can answer that question in respect of
pesticides although I am afraid I do not have the
information with me today on fertilisers and
feedstuVs so I would need to respond to that
separately if I may. There is a European regime in
place which deals with the authorisation of pesticides
which operates at two levels. The active ingredient
has to be agreed at the European level as having
passed the tests included in the relevant annex.
Secondly, individual products are approved for use in
theUKand the Pesticide SafetyDirectorate does that
on behalf of my department. The advice I have had
from them is that they would regard a pesticide
containing a nanomaterial as a new product
requiring a speciﬁc authorisation. So if a company
changed the formulation of a pesticide to include, for
example, an encapsulated active ingredient instead of
one in solution, then that would require a new
approval and a safety case would have to be made for
the use of that product before it was authorised.
Q63 Lord Methuen: You will obviously risk assess
these products. Is there suYcient information to
understand fully their impact on the food chain and
the environment? This goes for the other products
which I mentioned.
Mr Roberts: That question is hypothetical to an
extent until we get a case because it would depend on
the nature of the case. We would do the normal test
that we would do and we would look at all the
scientiﬁc evidence that is available. It is a system of
positive approval, so they have to make the case that
it is safe rather than that it can be used in the absence
of any evidence to the contrary. They would have to
make a case and the Advisory Committee on
Pesticides would give us the scientiﬁc view about the
case that had been made.
Q64 Lord Methuen: You would get the equivalent
for fertilisers presumably.
Mr Roberts: I am afraid I am not familiar with the
authorisation procedure for fertilisers so I would
need to take advice.
Q65 Lord Methuen: There must be something
similar in place.
Mr Roberts: The regime on pesticides is clearly
tougher because pesticides are necessarily toxic to
something. There is therefore a system of positive
approval. Fertilisers generally are more benign
substances so I amnot sure they are tested to quite the
same rigorous extent as pesticides but I will need to
take advice on that and come back to you.
Q66 Chairman: May I follow up a little bit on Lord
Methuen’s question? You said that the risk
assessment would be done by the Advisory
Committee on Pesticides.
Mr Roberts: They would review the evidence
submitted by industry.
Q67 Chairman: Does that Committee have on it
anybody who is an expert in nanotechnology?
Mr Roberts: I will need to look at the list. To be
honest, I doubt it, but it is clearly an issue we would
need to look at. The issues we would need to
understand would be environment and fate, how the
nanomaterial moves through the environment,
followed by toxicology and eco-toxicology from
exposure of humans or animals or plants or eco-
systems as a result of that application. If we did not
have that expertise, then we would need to look
elsewhere for it. We have it, for example, on the
Advisory Committee on Hazardous Substances and
if necessary we would make a link between the
Advisory Committee on Pesticides and the Advisory
Committee on Hazardous Substances.
Dr Wadge: There are eco-toxicologist and
toxicologists on the Advisory Committee on
Pesticides but as I understand it the point you are
making is whether they have speciﬁc expertise in the
toxicology of nanoparticles, I doubt that. It would
not preclude the opportunity to bring that expertise
in to those particular committees.
Q68 Chairman: May I also ask the same question,
whilst we are engaged in conversation, about the
Advisory Committee onNovel Foods and Processes?
If a nanofood product were to come through for
approval with the UK competent authority, is there
expertise in this area on that Committee?
Dr Wadge: No is the answer. Is there access to
toxicological advice? The answer is yes. There is quite
a lot of history of seeking advice from the Committee
on Toxicity and I have included in the evidence some
of the reviews which the committees have done on
nanotechnology so far and the recommendations
that they are making around the risk assessments. If
there were very speciﬁc points on nanotechnology
that required additional expertise, we would refer
that to the Committee on Toxicity and they would
take advice as necessary.
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Q69 Baroness Neuberger: You have already
mentioned the issue of public engagement and this
being a key area. What future plans do the
Government have to engage with the public, or
conduct research on public perceptions on the use of
nanotechnologies in the food sector? We would like
to know who is going to carry it out and how it is
going to be coordinated across Government.
Dr Axford: I could give a general view. Recently, in
January of this year, there was a renewed ministerial
commitment on nanotechnology overall. They gave
seven key commitments overall but one of those was
to develop the programme of dialogue around
nanotechnology involving all key players. That
includes, for example, academia, industry, non-
governmental organisations and of course, critically,
the public. That is part and parcel of the strategy to
which I alluded earlier being put forward by the
ministerial committee. We therefore, through a
number of mechanisms, for example DIUS are
responsible for a programme of activity called the
Sciencewise Programme, which is all about getting
better evidence of what the public thinks or ﬁnding a
way of engaging the public in a constructive way on
key issues. That is a process which can be applied on
nanotechnology. There have already been two major
goes at talking to the public about nanotechnology
within the last two or three years. When it comes to
the speciﬁcs of what is actually done on food that
would have to be somethingAndrewwould be able to
talk about and what would be done in relation to
food. I do not know what level of detail you would
like to know about the general way that Government
go about some of their work in other areas.
Q70 Baroness Neuberger: It is not particularly so
much about how the Government work. We know a
little bit about the general public understanding of
science-type work. It is really perhaps some of the
methodologies you are going to use for this actual
engagement. For instance, there is very good
evidence that with quite complex areas of
nanotechnology, in the food sector would be a good
example, things like citizens’ juries may be very
useful. It would be very interesting to know, given
that this is part of the strategy, what Government are
intending to do.
Dr Axford: Certainly on nanotechnology as a whole
and even more so on food in particular it is a little bit
early to say exactly which techniques we would use.
Given what we have heard this morning about the
problems almost of deﬁnition, we need to know what
we need to achieve through any engagement process.
Are we worried about the toxicological impacts? Are
we looking at the commercial beneﬁts? Until we
know where nanotechnology is exploited in the
commercial sector, it is very hard to know what to
talk to the public about. It is very hard to engage
them at the fundamental science level where a lot of
it still is. We heard earlier that a number of these
technologies are still often in the lab.
Dr Wadge: The Food Standards Agency absolutely
stands ready to engage in public debate and, taking
the lead fromLordKrebs whowas our ﬁrst chairman
who really set a very high standard of public
engagement on science, that is something we are very
keen to follow. We do have a number of mechanisms
in place. Perhaps I can talk about what we did on
cloned animals a couple of years ago as an example
of the type of engagement that we might do in
relation to emerging technologies more generally. We
commissioned work in 2007–08 which took the form
of reconvened workshops. We brought members of
the general public together, we had a range of experts
from all diVerent parts of the debate, talking about
their work and we reconvened the group after they
had gone away to think about it and they had an
opportunity to ask questions.26 It worked very well in
terms of eliciting a rather broad consensus as to what
the general public’s concerns were. They were less
concerned, interestingly, with how the technology
and the science worked and their focus was much
more on the why and the consequences and the
beneﬁts from the technology. That is perhaps not
surprising, given what we learned from the GM
debate which got very polarised. What we would
want to do through citizens’ juries, and we have a
number of citizens’ forums available which we
regularly use and debate a range of issues that are
topical for us, is to make sure that we are not simply
ﬁnding out what the people on the extremes of public
opinion think but actually what the general public
feel once they have had a chance to be really informed
about a technology. We do have the methodology
available and we stand ready to engage in that
debate.
Q71 Baroness Neuberger: You have already raised
the GM issue and obviously some of that was
extremely uncomfortable in many ways. Presumably
one of the things you are saying therefore is that the
engagement with the public will happen relatively
early in order to avoid that kind of extreme view. I am
not sure whether you are saying that.
Dr Wadge: If we do not, then it seems to me then that
we have failed to learn one of the key lessons. It is
important that there is an engagement and
recognition of the role of everybody, not just
Government but food businesses a well, to engage
and talk about the types of technology andmake sure
that there is a general understanding and acceptance
of technology.
26 “This answer is not entirely correct. The Participants were in
fact presented with information about the technology by the
research company and not by a range of outside experts”.
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Q72 Baroness O’Neill of Bengarve:This is a question
which also bears on public engagement but it really
arises out of the DIUS submission which very
usefully brought together evidence from a number of
diVerent countries. Brazil is quite startling and of
course lies outwith the three big groups that we have
discussed and one meets ready-to-eat edible
bioplastic coating and pallet sensors for quality
control apparently aimed at increasing the quality of
Brazilian wine. Then there is a statement that Brazil
does not seem to have any dedicated regulatory
framework for nanotechnology research. There is a
big player with a lot of research and there is free trade
and it is quite complex to keep out products which do
not meet certain standards. Do either DIUS or Defra
or the Food Standards Agency have a reaction to the
Brazilian evidence?
Mr Roberts: I am not familiar with the Brazilian
situation but I can talk about the attempts at
regulation of nanotechnology on the global level, if
that would be helpful.
Q73 Baroness O’Neill of Bengarve: That would be.
Mr Roberts: If I may take one step back and look at
chemicals, broadly speaking there are very few global
rules restricting chemicals. The only ones which are
restricted at the global level are 12 persistent organic
pollutants which include substances like DDT and
PCBs. Attempts for a broader regulatory framework
for chemicals generally have not been possible to
agree politically until recently. A big attempt to have
a strategic approach to international chemicals
management in order to deliver theWSSD, theWorld
Summit on Sustainable Development objectives on
chemicals had to be on a voluntary approach because
some countries, not least the United States, opposed
global regulation. The global community has
attempted to regulate chemicals such as mercury for
the last decade and in fact we had a breakthrough last
month and there is now agreement to have
international regulation of mercury emissions and
that reﬂected a change in the approach of the United
States and countries such as China and India were
quite reluctant but in the end came along. In terms of
nanotechnologies, we will be discussing that at the
SAICM, the Strategic Approach for International
ChemicalManagement meeting, which takes place in
Geneva in May, where it has been identiﬁed as an
emerging issue. We will be raising awareness there. It
would be wrong to say there is scope for international
global regulation of nanotechnology in the
immediate term. We are trying to raise awareness of
the issues in countries, not only those producing
nanotechnologies but those which may also import
products containing nanotechnologies and therefore
have to deal with waste streams that may require
specialist handling; at least raise awareness, spread
the science and begin to get cooperative action going.
Q74 Baroness Neuberger: May I move on to the
question of labelling and consumer information?
Again this is mainly for the FSA. You said in one of
your additional reports that there is a need for
consultation on declaring the use of nanoparticle
ingredients or additives in food products but in your
main evidence you say that you do not have
information on whether UK consumers would value
information on the use of nanotechnologies in food
and what sort of information would meet the
necessary criteria. What are the Government doing
to obtain the information about what the public feels
about that?
Dr Wadge: We need to address that through the
deliberative research with consumer forums, once we
are a bit closer to products being on the market. At
the moment it is a little bit diYcult to do it in a
vacuum in a way. Consumers need to know what
speciﬁc products we are talking about that are now
about to come onto the market and how that might
beneﬁt them or beneﬁt others. Certainly that is how
we would carry out that research, through our
citizens’ forums, to really gauge a sense of what
information they would ﬁnd useful and whether
particular types of labelling would actually be helpful
to them. At this stage, it is still a little bit too early
to say.
Q75 Baroness Neuberger: I completely take the
argument about it being early and therefore very
hypothetical, but I just wonder whether there is not
an argument for at least beginning that discussion,
simply tomake it clear that there will be transparency
in this area.
Dr Wadge:Certainly we will be starting the process of
talking about nanotechnologies with our citizens’
forums in the autumn this year. I can ensure, given
this conversation, that the question of labelling and
information is included in those sorts of discussions.
Q76 Lord Methuen: Mine is an unrelated question.
Mr Roberts mentioned these 19 tasks of priority
research projects and ﬁve taskforces and he also
mentioned 14 nanomaterials which were under
investigation. It would be useful if we had details of
what those were.
Mr Roberts: Certainly.
Q77 Earl of Selborne: I want to go back to the
process of public dialogue, public engagement. I
think everyone recognises and admits that the GM
debate was a bit of a disaster quite frankly, because of
the polarisation to which you referred. What are the
lessons learned from the GM debate, even if they are
only negative ones, as to how this debate should be
structured?
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Dr Wadge: That is a very big question, is it not? I am
not sure that necessarily everything from the GM
debate translates and transfers to this particular
issue. Having said that, there clearly are some very
important lessons and the ﬁrst is to engage with the
public at an early stage to ensure that a range of
debate and dialogue takes place around the types of
technologies which are being used ormight be used in
producing food and what the implications are for
consumers of those diVerent types of technology.
Early engagement and bringing together scientists
and the general public and groups such as the Food
Standards Agency can play a facilitative role in
encouraging that sort of debate to raise awareness to
begin with of the sorts of issues and then speciﬁcally
to tease out some of the very speciﬁc questions
around acceptability and requirements for
information and labelling and so forth.
Q78 Lord O’Neill of Clackmannan: Perhaps I should
declare an interest as Chairman of the Nuclear
Industries Association. A consultation was
conducted by DTI which subsequently fell in the
courts and they had to undergo the same process in a
rather modiﬁed fashion to secure acceptability.
Really what I just want to say is that the GM
consultation was not the classic example we would
want to follow but there are other failures as well.
There is the potential pitfall of the litigious
opponents and some of the peoplewho are already on
the fringes of the debate, having a higher bar of
standards, wanting to pull more things into
nanotechnology than perhaps the current deﬁnitions
will allow. These are the kinds of people who might
well be standing in the wings with lawyers ready to
require judicial review. I merely make this additional
cautionary point that the unfortunate experience of
GM is as nothing compared to some of the
subsequent failures of theGovernment’s consultative
processes which were expensive both in time and
money to correct.
Dr Wadge: Yes.
Q79 Lord Crickhowell: As we approach the end of
the session, I am extremely grateful that I have a very
much clearer idea of what the Food Standards
Agency and Defra are about and what is going on.
The big gap I have at the end of this session is in
understanding what the Government are really doing
to close the big gaps we have in scientiﬁc knowledge.
I have a big gap in my impression of what drive is
being put, what money is being put behind the
research programmes, behind what the universities
are doing. I just do not have an impression that there
is as much eVort going in to really stimulating the
research that is needed as I think there should be.
Dr Axford: We can respond to that in a broad sense.
Looking at nanotechnology overall, setting aside the
food speciﬁc for the moment, across the research
councils there is something like £50 million across all
programmes generally in the area of nanotechnology
and a further £50 million in the speciﬁc cross-council
programme on nanotechnology projects. There is
actually a lot of investment going on in the broad area
of nanotechnology.
Lord Crickhowell: May I ask then—I really do have a
black hole here—what is actually going on here? I am
afraid you have not given me any clear picture at all
in your answers to questions; even that last answer
does not. We really do need a pretty detailed report
from your department as to what they are doing,
what the programmes are, what money is being spent
where and what you hope to achieve by it.
Chairman: Particularly in the area of risk assessment
which is what concerns us rather than, say,
development of new TV screens or something like
that. If you could help us with a bit more detailed
information on that area.
Q80 Baroness Neuberger: I have just been left with a
sense of unease on the public engagement side. It is
partly in your response to the Earl of Selborne when
talking about the lessons learned from GM. One of
the things you have been saying is that it is a bit too
early. At the same time your response on GM is that
we should have got in there earlier. I do not feel very
comfortable that thinking has been developed very
carefully. I have always taken the view personally that
it is better to get in earlier. All the evidence about
public engagement in other areas, say in the health
services, shows that to be the case. I know you say
this is starting in the autumn. Is there not some
argument, given that we are doing this inquiry now,
for ratcheting up at least the advance warnings of
what you are going to be doing in the autumn?
Mr Roberts:Of course, we did do somework on social
engagement in the period 2004 to 2006–07, whichwas
the ﬁrst wave, which included citizens’ juries and a
number of engagement exercises. A number of other
people have also done them, such asWhichwho ran a
jury last year and we have access to those results. The
second phase of work which has been described will
build on the ﬁrst phase of work which was done three
years ago.
Q81 Baroness Neuberger: I understand that. I still
think there is a time issue.
Dr Wadge: It is useful to clarify what I meant around
that in the sense that I do not think it is too early to
start the engagement; far from it.We need to learn the
lessons and start the engagement. I meant in relation
to speciﬁc products and the types of information that
people might require in relation to that.
Baroness Neuberger: I accept that.
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Q82 Lord Haskel: On this question of research and
all the work you are doing, does that fall in at all with
the money which the Government are putting into
resuscitating the economy? Is that part of that?
Dr Axford: The money we have talked about so far is
money which was allocated in the last spending
review, to the research councils for example. Not any
new money, no new stimulus potentially.
Q83 Lord Haskel: It is not going to be part of
stimulating the economy.
Dr Axford: We do not have any idea about that.
Q84 Chairman: We shall learn after the Budget. Do
you have any other comments you wish to add? I
should like to thank you very much for giving us
nearly two hours of very interesting conversation but
there may be things that you would like to add at
this point.
Dr Wadge: No, nothing. Thank you for the
opportunity.
Supplementary memorandum by the Food Standards Agency
At the evidence session on 31 March, the Food Standards Agency was invited to provide additional
information in relation to a list of products reported to be available on themarket inGermany. Our comments
on this list are given below.
In addition, we would like to provide supplementary information in relation to products from non-EU
countries (exempliﬁed by Brazil, as raised during the meeting on 31 March), and on the FSA-funded review
of public attitudes that was published after our earlier evidence was submitted.
(a) Products on the German market
On investigation, it seems that not all of these products are currently on sale and in many cases the presence
of nanoparticles has not been conﬁrmed.
The information provided from the UK contact in Germany (Annex 4 to the written evidence from DIUS)
referred to two sources, a presentation by a member of the Federal Institute for Risk Assessment (BfR) and
a list of products reported by BUND, the German equivalent of Friends of the Earth, to be available on the
German market.
The ﬁrst presentation was given at a forum “Consumer Protection—Nanotechnology” that was held at the
BfR inNovember 2008.We have conﬁrmed with theGerman authorities that the examples in this presentation
were given as illustrations of potential future applications, rather than examples of “nano-products” that were
already available on the German market. In the case of the nanoscale micelles manufactured by the company
Aquanova, this technology has been investigated by the German authorities, who concluded that the
coenzyme Q10 product did not fall within the deﬁnition of “novel food” as since the metabolism of the
coenzyme Q10 in this formulation was not diVerent from common products already on the market.
The BUND lists were based on a global inventory published earlier in 2008 by Friends of the Earth (FoE) in
Australia. In addition to the products in the original FoE inventory, BUND reported that a number of
additional products available in Germany, largely via internet sites, were being marketed as containing
nanoparticles. In drawing up these lists, a size threshold 300nm was applied (where particle size information
was available). The lists include products which are poorly described in the marketing information, and which
may or may not contain nanoparticles.
Dr Axford: No thank you.
Q85 Chairman: There will be a transcript of these
proceedings which will be sent to you for corrections
so you will have a chance to make sure the written
record accurately represents what you have said. We
have asked you for some written material and the
Committee Clerk, Antony Willott, will follow that
up. Equally, if you have any points you think of that
you would like to submit to us in writing, we should
very much welcome that. Finally, I should like to ask,
if you were advising us on recommendations we
should produce at the end of our deliberations,
whether you have any particular thoughts.
Dr Wadge: Other than a large increase in the budget
of the Food Standards Agency . . . I think you have
touched on an area of concern in relation to risk
assessment and the capacity we have in relation to
toxicological expertise and that is a concern that I
have more broadly than simply around
nanotechnology and I am involved in discussions
with other chief scientists around that particular
point. It is something that this very speciﬁc issue of
nanotechnology does raise from my perspective.
Chairman: Thank you. Would others like to add
anything? Thank you very much indeed.
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The list also includes a number of brands of food supplements containing nanoparticles of silver, also known
as colloidal silver. This is a long-established substance and, as explained in our original evidence (page 4), it
is found also on the UK market.
In the case of food additive silicon dioxide (silica, E551), the German industry has conﬁrmed that this
substance has a long history of use and the speciﬁcation currently used is the same that has already been
assessed and authorised for many years. Although nanoparticles occur during the manufacturing process,
these immediately aggregate and agglomerate into much larger units and the dimensions of the silica particles
used in foodstuVs are typically in the range 2-12µm.
The presence of nanoparticles in other products on the list, whether below 300nm or 100nm, has not been
conﬁrmed.
We would certainly agree with the point made in the FoE and BUND reports, that the extent to which
substances are absorbed into the body is likely to diVer when they are presented in small particles compared
with larger particles. This is truewhether the particles are in the nanoscale or of some larger dimension. Indeed,
the eVect of diVerent formulations, including diVerent particles sizes, on the bioavailability of active
substances has been a major area of investigation in the pharmaceutical industry for many years. Similar
investigations are also carried out by the supplements industry. We would reiterate that it is the responsibility
of food businesses to ensure that the products they market are safe, and this includes considering the eVect of
changes to manufacturing processes and reformulation of existing ingredients, even where such changes do
not trigger a formal regulatory review.
(b) Products on the Brazilian market
At the evidence session on 31 March, the Committee was concerned about the implications of product
development in countries like Brazil and whether such products could automatically gain entry to the EU
market.
We would like to emphasise that UK and EU regulations apply equally to imported products as to domestic
production. World Trade Organisation rules are designed to prevent unfair barriers to international trade but
it is not the case that a product that is legally marketed in one WTO member state must be accepted in other
WTOmember states. Countries are free to establish their own safety requirements, provided that these do not
discriminate against imports.
The UK contact in Brazil has conﬁrmed that their report (Annex 1 to the evidence submitted by DIUS) refers
to the absence of regulatory controls in relation to research and not to the marketing of food. In other words,
there are no laws or directives preventing Brazilian scientists from conducting research in nanotechnology
applied to food. The same situation applies in the UK. Brazil does however have a solid regulatory framework
that applies to the commercialisation of new products, especially in the area of food, and there are standard
food safety! health and safety laws which are applicable for all new products, including products obtained
using nanotechnologies.
(c) Evidence review of public attitudes to emerging food technologies
In September 2008 the Food Standards Agency commissioned a review of existing studies on public attitudes
to a range of new technologies in relation to food, including nanotechnologies. This report was published on
26 March 2009 and a copy is attached [not printed] for the Committee’s information. The main ﬁndings in
relation to nanotechnologies and food were summarised on page 7 of our earlier evidence.
21 April 2009
Supplementary memorandum by Department for Innovation, Universities and Skills (DIUS)
This response provides the further information that the Committee asked BIS to provide at the evidence
session on 31 March 2009.
Nanotechnologies cut across traditional scientiﬁc disciplines and could lead to a very diverse range of potential
applications and potential risks, therefore research usually involves inter-disciplinary working and
responsibility for risk management is shared across a number of Government departments and agencies.
In February 2008, theGovernment published a detailed statement that described the range of activities carried
out by Government departments and agencies and the Research Councils, and the reasons for those activities.
It also described the mechanisms that are in place to coordinate those activities. We have provided copies of
the statement to the Committee.While it does not speciﬁcally address nanotechnologies in speciﬁc sectors such
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as food, we hope that it will give the Committee an overview of how the various activities and responsibilities
are linked.
The direction of the Government agenda for nanotechnologies was set out in 2005 in response to the report
by the Royal Society and Royal Academy of Engineering “Nanoscience and nanotechnologies: opportunities
and uncertainties”. The Council for Science and Technology review in 2007 found that good progress was
beingmade in certain areas, although therewas scope for improvement in others. Subsequently, theMinisterial
group on nanotechnologies was established to give a greater proﬁle to the Government’s work in this area.
The statement was the result of the ﬁrst meeting of the group. At its most recent meeting the group agreed on
the need for an informed debate about the future direction of the development of nanotechnologies, and
agreed that a strategy should be developed in dialogue with stakeholders.
On the speciﬁc information that DIUS oVered to provide to the Committee–
Work taking place to encourage research and development and translation in relation to nanotechnologies in the food
sector. (This would include projects such as knowledge transfer networks which are not aimed specifically at the food
sector but would impact upon it.)
The Government funds a number of activities to translate the knowledge and ideas generated by fundamental
research into new products and services in areas where there are market opportunities through the Technology
Strategy Board. It does this in a number of ways, for example Innovation Platforms, Knowledge Transfer
Networks, Knowledge Transfer Partnerships and initiatives such as the Small Business Research Initiative.
The joint evidence submitted to the Committee by the Nanotechnology Knowledge Transfer Network and
Leatherhead Food International noted that they have formed a Food Focus Group to promote awareness of
the potential for nanotechnologies for the food industry.
One of the 24 Micro and Nanotechnology open access centres funded by the Technology Strategy Board,
Eminate, focuses its work on state of the art solutions to the food and pharmaceutical industries with the aim
of applying in-house process technologies to develop customer products in the areas of advanced coatings,
materials and powders, food technology, drug delivery, measurement and scale up through to pilot
productions. This is a ﬁve year project and the total grant is £3.5 million of which £3 million has been drawn
down to date.
Although not speciﬁcally addressing food, the Technology Strategy Board is currently preparing strategies for
nanoscale technologies and biosciences. For nanoscale technologies there is a focus on linking the pervasive
nature of nanoscale technologies to societal challenges of living with environmental change, living with a
growing/ageing population, and living in an intelligent connected world. For Biosciences, the focus will be on
food technology and food safety.
The Research Councils are not speciﬁcally encouraging research in relation to nanotechnologies in the food
sector although, as described in their evidence to the Committee, they are funding a large amount of
fundamental research in areas that may be of relevance to the development of new technologies and products
and to the improved understanding of potential risks.
Details of projects being funded by the Government into the toxicology of nanoparticles in the gut.
The Medical Research Council issued a “highlight notice” in March 2007 to encourage applications in
nanotoxicology with the aim to inform policy development. The notice has proved successful in stimulating
a signiﬁcant increase of applications to the Research Boards. Since launch ﬁve awards were made at a total
level of approximately £3 million. This research aims to better understand the uptake of nanoparticles into
cells and the functional consequences including oxidative stress, inﬂammatory response, cell death and
genotoxicity. By linking this information to the physical and chemical characteristics of nanoparticles,
predictive models for nanoparticle toxicity can be developed that will help risk assessment. There is currently
no agreement on which characteristics should be studied to evaluate the toxicity of nanoparticles and many
of the funded studies aim to address this issue. A lot of this work is currently focused on the lung, although
some of the principles may be transferable to other organs systems. Building on the current funding and the
recommendations in the recent report from the Royal Commission on Environmental Pollution, the Medical
Research Council has further reﬁned the highlight notice to encourage in particular studies which investigate
the eVects of engineered nanoparticles in vivo.
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More detail on the awarded studies is below:
1) Mechanisms of bioreactivity of engineered nanoparticles with pulmonary gas exchange barrier (Imperial
College)—£600k/3yrs
Investigates the toxicity of common nano-particles, such as carbon nanotubes, silver and titanium oxide, when
taken up by lung cells. The toxic eVects will be related to the physical and chemical properties of the
nanoparticles to establish patterns that will allow to predict the health eVects engineered nanoparticles.
2) Understanding the genotoxic potential of ultra-ﬁne superparamagnetic iron oxide nanoparticles (University
of Wales, Swansea)—£450/3yrs
Studies the genotoxic properties of iron oxide nanoparticles with the aim to develop high-trough-put screening
tests for genotoxic eVects; Aims to understand dose-response relationships, to inform future in vivo studies
and predictive approaches.
3) Deﬁning the biologically eVective dose for pro-inﬂammatory eVects of nanoparticles in lung target cells
(University of Edinburgh)—£500k/3yrs
Investigates the inﬂammatory response in lungs following the exposure to commonly used industrial
nanoparticles. The potential of these nanoparticles to cause oxidative stress and inﬂammation will be
examined at the cellular level and in animal models to establish and validate better models for predictive
testing.
4) Biological consequences of exposure to prosthetic nanoparticles (University of Leeds)—£500k/3yrs
Hip replacements generate nano-sized metal wear particles that are released into the body. The project studies
the genotoxic and immunotoxic consequences in animal models over a period of 10 months.
5) Pathway analysis in characterising toxicological properties of nanoparticles (Imperial College)—£550k/3yrs
Uses novel technologies (proteomics, functional genomics) to identify key pathways that are responsible for
toxic eVects. The aim is to apply these for routine screening purposes in the future.
In addition to these projects theMedical ResearchCouncil supports research exploring the potential of dietary
nanoparticles for therapeutic use at the MRC Collaborative Centre for Human Nutrition Research in
Cambridge. This programme investigates the uptake of dietary nanoparticles in the gut, the toxicity of these
particles and their eVect on diseases of the digestive tract. Dr Jonathan Powell, the Principal Investigator, has
given evidence to the Committee.
The toxicity of wear particles released from hip replacements and the dietary nanoparticles for therapeutic use
are studied in the medium to longer term.
Although the focus of research at the National Nanotoxicology Inhalation Research Centre (funded by the
Health Protection Agency) is on inhalation, research into the absorption of nanoparticles across the skin is
planned and the possibility of studies into gut absorption is being considered. In addition, the Food Standards
Agency has recently published a research requirement in the area of the toxicokinetics of nanoparticles, which
includes their behaviour in the gut.
Details of how the Government is trying to close the gaps in scientific knowledge required for risk assessment: what
programmes are being supported, what money is being spent, and how the Government is measuring progress.
Through the Nanotechnologies Research Coordination Group (NRCG), Defra coordinates the activities of
Government departments, their agencies and the Research Councils. The NRCG has published two research
reports that provide much of this information and copies of the reports can be found at http://
www.defra.gov.uk/environment/nanotech/research/index.htm. A Defra-commissioned report “Emergnano”
was published on 15 April 2009 and details how much progress has been made between 2004 and 2008 on
NRCG’s health, safety and environmental research objectives (http://www.defra.gov.uk/environment/
nanotech/research/reports/index.htm<emergano). On the basis of the report, the NRCG will update its
research requirements and publish the new requirements.
The Emergnano report looks at global research in this area and identiﬁes gaps that still remain. Globally there
is insuYcient evidence to be able to say that any of the health, safety and environmental research objectives
have been completed. Thus full risk assessments for any nanomaterial are not possible at present.
The OECD and EU are also very active in the area of risk assessment. Defra leads an OECD steering group
that is dedicated to identifying best risk assessment methods in the absence of complete data.
DIUS does not retain funds centrally (these are managed by delivery partners) and hence does not directly
fund work on risk assessment. However, DIUS does provide support in the following areas
— Progress in the ability to measure and characterise nanoscale materials is essential for both the
development and the risk assessment of nanotechnologies. DIUS supports the National
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Measurement Programmes across a number of diVerent areas, with a signiﬁcant sum being spent on
nanometrology.
— DIUS provides funding for the fundamental research supported by the Research Councils, who have
provided a separate submission to the Committee.
— DIUS funds the Technology Strategy Board. In addition to its support for innovation, the Board
part-funds SAFENANO, a free information service run by the Institute of Occupational Medicine
to provide companies with a multi-disciplinary range of solutions to ensure that they can oVer
employees a safe and healthy working environment and products that are safe for consumers.
March 2009
Supplementary memorandum by Department for Environment, Food and Rural Affairs
1. This memorandum sets out Defra’s additional written evidence to the inquiry being undertaken by the
Committee into nanotechnologies and food, as requested in the letter from the Clerk to the Science and
Technology Sub-Committee I of 15 April.
2. Defra oYcials have spoken with the Clerk of the Committee to clarify the information requested and
understand the information below reﬂects those discussions.
3. The Communication from the European Commission to the European Parliament, the Council and the
European Economic and Social Committee on the “Regulatory Aspects of Nanomaterials” accompanies this
Memorandum, but as a separate document. [not printed]
I) Details of Recent and Current EHS Research Projects Funded by Defra
Project Title Description
Environmental Nanoscience ENI-2 aims to develop an interdisciplinary research programme
Initiative programme (Phase 2) between the UK and USA to develop models that will support our
understanding of environmental exposure, bioavailability, fate and risks
of nanomaterials. It is intended that the research will cover a wide range
of disciplines including detection and risk analysis. This second phase
builds successfully on the ﬁrst which concentrated on developing UK
capacity in nanotechnology research. ENI-2 will utilise synergies and a
wider skills base to enhance the value and impact of the programme
outputs and ensure a truly multi-disciplinary approach to
nanotechnology research. Work is ongoing to ﬁnalise the contract with
a planned letting date later this year.
An outline scoping study by Concerns about the potential health effects of high aspect ratio
the Institute of Occupational nanoparticles (HARN) are based primarily on toxicology studies of
Medicine to determine whether industrial ﬁbres including asbestos. The objectives of this study are: i) to
high aspect ratio nanoparticles undertake a scoping study to review the existing literature on industrial
(HARN) should raise the same ﬁbres and HARN to determine whether they should raise the same
concerns as do asbestos ﬁbres concerns as do asbestos ﬁbres and ii) to set out a research strategy to
determine whether health concerns about HARN are well–founded.
A study by the Institute of The Cell Pen project investigated the mechanisms of particle movement
Occupational Medicine to across the respiratory epithelium to try to establish the resulting possible
identify physicochemical factors toxic effects in and beyond the lung. The project advised on i)
controlling the capacity of Identifying which features of nano-particles/tubes/ﬁbres are important
nanoparticles to penetrate cells in particle-cell interactions, considering the potential role of
of the respiratory epithelium, nanoparticle (NP) chemistry, structure, mass, numbers, shape, surface
especially those of ﬁrst contact area, surface charge and surface functionalisation; ii) Suggested how they
on inhalation of the particles. may be modiﬁed to enhance or reduce their capacity to enter cells; and
iii) Suggested how interactions between NPs and cultured human cells
might be studied.
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Project Title Description
EMERGNANO: a review by This report was commissioned by Defra as a way of taking stock of the
the Institute of Occupational research work on nanotechnologies since the 2004 Royal Society and
Medicine of completed and Royal Academy of Engineering report.27 The EMERGNANO report
near-completed environment, has assessed global research undertaken since then and mapped the
health & safety research on knowledge gained against the UK NRCG’s 19 research objectives. The
nanomaterials & nanotechnology report identiﬁes where research gaps remain.
Identiﬁcation of physiochemical For some susceptible individuals inhaling high levels of air pollution
factors controlling the capacity containing nano-sized particles,may lead them to develop heart and lung
of nano-particles to penetrate problems. This suggests that breathing in very small, nanosized
cells of the respiratory engineered particles might also cause heart and lung problems. This
epithelium—A study by work aims to discover how inhaled engineered nanoparticles reach the
Imperial College Consultants delicate air sacs of the lung, and how they interact with the cell barriers
Ltd that protect us. The research uses human epithelial cells to look at
whether the nanoparticles interact with and/or are internalised by the
cells, what properties of the particles might make them reactive and
what cellular processes are involved.
Research into the likelihood and This study follows recent research ﬁndings from the University of
possible pathways of human Edinburgh which demonstrated that some types of carbon nanotubes
exposure via inhalation arising (CNTs) may present health hazards similar to those of asbestos. This
throughout the lifecycle of a further study will collate all available information in regard to potential
selection of commercially hazards of CNTs, possible route(s) of exposure, andwill use the available
available articles containing data and modelling approaches to estimate the extent of human
carbon nanotubes—Central inhalation exposure to CNTs throughout the lifecycle of some selected
Science Laboratory CNT products. The information generated will help identify the critical
stages within the lifecycle of selected CNT products that may pose risk
to human health or the environment.
An evaluation of the UK skills There are concerns about the capacity of the scientiﬁc community to
base for toxicologists and respond to current and emerging demands for toxicological and
ecotoxicologists—Plymouth ecotoxicological assessments and whether there are enough scientists
University working at the bench (toxicologists, chemists, biologists) and experts
involved in regulation and policy to support this activity. The aim of this
project is to identify the current status of the scientiﬁc community, areas
of expertise, and identify the gaps in skills, knowledge or recruitment.
The analysis will identify whether there are gaps in provision, and areas
where investment may be needed in future training and/or recruitment.
Imperial College study to An important area of research is to evaluate the mechanisms of action of
indentify physiochemical factors engineered nanomaterials and one key aspect of the reactivity of
controlling the capacity of nanosubstances is their interaction with cells andmembranes. This work
nanoparticles to penetrate cells aims to determine (a) which combination of factors inﬂuence
of the respiratory epithelium, nanoparticle uptake and/or translocation by human alveolar epithelium;
especially those of ﬁrst contact (b) the fate/cellular location of internalized nanoparticles and whether
on inhalation of the particles particle uptake is active or passive; and (c) whether nanoparticles
inﬂuence the functional integrity of the alveolar epithelial barrier.
PROSPEcT: UK contribution The PROSPEcT LINK project is the UK’s contribution to the OECD
to the OECD Nanomaterials sponsorship programme and aims to undertake a detailed
sponsorship programme characterisation of two nanomaterials of commercial relevance to the
UK—cerium oxide and zinc oxide. The data generated, and test
methodologies employed will go a long way towards the ecotoxicological
hazard assessment for these nanomaterials. In addition the data
generated will be used to help establish QSARs (Quantitative Structure
Activity Relationships) for predictive safety evaluations of novel
nanomaterials.
27 2004Royal Society andRoyalAcademyof EngineeringReport “Nanoscience and nanotechnologies: opportunities and uncertainties”
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Project Title Description
An examination of the nature This research project will attempt to ascertain how much dependence is
and application among the currently being placed on corporate social responsibility and how
nanotechnologies industries of effective CSR, as currently employed by the UK nanotechnologies
corporate social responsibility in industries and researchers, is in limiting the exposure to public health
the context of safeguarding the and environmental risks. The project will also attempt to identify
environment and human exemplar models of CSR and ascertain where failure by industry
health—Cardiff University stakeholders to adopt a responsible approach is resulting in potential
(BRASS) risks to public health and the environment.
II) Comparison Figures on Amounts Spent by the UK, European Union and United States of
America, on Nanotechnologies Environmental Health and Safety Research
The recent Defra commissioned EMERGNANO project identiﬁed the following levels of expenditure by the
UK, EU and USA over the period 2004–08:





* includes the UK ﬁgure, plus work from Switzerland.
III) Note on Regulations and Authorisation Procedures Governing Fertilisers
There are three tiers of regulatory controls which ensure that all fertilisers for sale in the UK are safe for use.
These are set out in two areas of primary fertiliser legislation, namely fertilisers which may be freely sold
anywhere in the European Union (EC Fertiliser Regulation 2003/2003), and other fertilisers (The Fertilisers
Regulations 1991). The third tier covers Health & Safety regulations which apply to all products
manufactured or used in the UK. All manufactured fertilisers (including those containing nanomaterials) are
required to comply with all of these regulations and legislation. We are not aware of any current plans for
manufactured nanomaterials to be included in fertilisers by manufacturers.
The EC Fertiliser Regulation 2003/2003 deﬁnes the composition and deﬁnition of all fertilisers, which have
been approved as EC Designated fertilisers. All EC Designated fertilisers can be traded freely within the EU.
Every importer and manufacturer must ensure any fertiliser intended for sale in the EU complies with this
Regulation.
The Fertilisers Regulations 1991 (as amended) specify the labelling and packaging of the product and place
a responsibility on the manufacturer to declare the nutrient content of the product. The Regulations include
a series of Schedules listing type designations of fertilisers.
Additional controls exist for AmmoniumNitrate (AN) fertilisers and these are set out under the “Ammonium
NitrateMaterials (HighNitrogenContent) SafetyRegulations 2003”. They require that all imports intoGreat
Britain of relevant Ammonium Nitrate material from outside the EU are to be notiﬁed to Defra.
Details of the Task Forces and Research Objectives under the Nanotechnology Research Co-
Ordination Group (NRCG)
Task Force Research Objectives (by most relevant Task Force)
1. Metrology, characterisation RO 2 To identify the most suitable metrics and associated methods for
and standardisation the measurement and characterisation of nanoparticles.
RO 3 To develop standardised, well-characterised reference
nanoparticles.
RO 4 To understand the properties of nanoparticles in the context of
their ignition and explosion potential, and assess/develop methods for
evaluating this.
RO 9 Optimisation, development and application of technologies that
enable the measurement of exposure to nanoparticles in soil and water.
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Task Force Research Objectives (by most relevant Task Force)
2. Exposure, sources, pathways RO 5 Further identification of sources of nanoparticles.
and technologies RO 6 Optimisation and development of technologies that enable the
measurement of occupational and environmental exposure to
nanoparticles via air.
RO 7 Understanding the fate and behaviour of nanoparticles in air.
RO 8 Development of exposure control devices.
RO 10 Research to understand the environmental fate, behaviour and
interaction of nanoparticles in soils and water.
3. Human health hazard and risk RO 11 Research to establish a clear understanding of the adsorption
assessment of nanoparticles via the lung, skin and gut and their distribution in the
body (ie toxicokinetics), identifying potential target organs/tissues for
toxicity assessment.
RO 12 Research to establish a clear understanding of inter and intra-
cellular transport and localisation of nanoparticles and their cellular
toxicity.
RO 13 To establish a clear understanding of whether oxidative stress,
inflammatory effects and genotoxicity apply to nanoparticles.
RO 14 Research to establish a clear understanding of the deposition,
distribution, toxicity, pathogenicity and translocation potential and
pathways for nanoparticles in the airways and lung and their
potential impacts on the cardiovascular system and brain.
RO 15 Given the current use of nanoparticles in consumer products
there is a need to further our understanding of dermal uptake,
penetration and toxicity in the skin.
RO 16 To develop testing strategies for human health hazard
assessment and assess how fit for purpose current test methods are as
applied to nanoparticles.
4. Environmental hazard and risk RO 17 Research to establish the uptake, toxicity and effects of
assessment nanoparticles on groundwater and soil microorganisms, animals and
plants, especially in the context of remediation.
RO 18 Research to establish the mechanisms of toxicity, toxicokinetics
and in vivo effects of nanoparticles to key ecological groups (including
invertebrates, vertebrates (eg fish) and plants). A key aspect of such
work should be the facilitating of knowledge transfer from human
toxicological studies to inform ecotoxicology.
RO 19 Define endpoints to be measured in ecotoxicological studies and
assess how fit for purpose current standard tests for persistence,
bioaccumulation and toxicity are when considering nanoparticles. This
should lead to the defining of a suite of standard PBT protocols for use
in environmental hazard assessment.
5. Social and ethical dimensions of RO 1 To understand the social and ethical implications of
nanotechnologies nanotechnologies through a programme of public dialogue and social
research.
IV) Details of the Fourteen OECD Sponsorship Nanomaterials
The materials for the sponsorship programme were selected as a representative set of either commercially
available, or soon to be available nano materials.
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The table28 below shows the materials and which countries have agreed to work on them.
Sponsorship material Lead sponsor1 Co-sponsor2 Contributors3
Cerium oxide UK, USA, BIAC Australia, Netherlands Germany,
Switzerland, EC
Zinc oxide UK, BIAC USA, BIAC Australia, Canada
Fullerenes (C60) Japan, USA Denmark, China
SWCNTs Japan, USA Canada, France,
Germany, EC, China,
BIAC
MWCNTs Japan, USA Korea, BIAC Canada, Germany,
France, EC, China,
BIAC
Silver nanoparticles Korea, USA Australia, Canada, France, EC, China
Germany, Nordic
Council of Ministers
Iron nanoparticles China, BIAC Canada, USA, Nordic
Council of Ministers
Carbon black Denmark, Germany,
USA
Titanium dioxide France, Germany Austria, Canada, Korea, Denmark, China
Spain, USA, BIAC
Aluminium oxide Germany, USA





1% Lead sponsor assumes responsibility for conducting or co-ordinating all of the testing determined to be
appropriate and feasible to address the endpoints for Phase 1 of a listed nanomaterial. A Joint lead may be
developed depending on the degree of participation committed toward addressing endpoints.
2 % Co-sponsor conducts some of the testing determined to be appropriate and feasible to address the
endpoints of Phase 1 for a speciﬁc listed nanomaterial.
3%A contributor provides test data, reference or testing materials or other relevant information to the lead
and co-sponsors.
March 2009
28 The most recent table as provided by the OECD Working Party on Nanomaterials, December 2008.
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Memorandum by Leatherhead Food International
Background
Leatherhead Food International (LFI) is proudly independent and has been providing solutions and services
to the food and drink industry since 1919.
LFI is renowned for its comprehensive Global Food Regulation services, applied Food Safety Research,
Nutrition and Food Innovation expertise. These technical areas are complemented by a wide range of
Knowledge services including publications, training, consultancy, market research, conferences, and online
databases.
LFI clients use our services and solutions to ensure their businesses, from dynamic start-ups and SMEs
through to the largest multinationals, can meet the challenges of today’s ever changing market place. The
client list includes the major global companies in the food industry as well as ingredient suppliers,
manufacturers, retailers and foodservice businesses.
As part of the need to provide cutting edge information and research, LFI has started a working group called
NanoWatch. This group is composed of food and drink companies who wish to understand the potential
beneﬁts and concerns of new technologies. In addition, in collaboration with the nanotechnology Knowledge
Transfer Network (NanoKTN) LFI has formed a food focus group. This group will enable the industry to
have a voice on research funding, regulation and other developments that could impact on the industry.
State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
Currently the main applications and beneﬁts for nanotechnologies and nanomaterials in the food sector are
in packaging and in the addition of nutraceuticals or vitamins to foods. Examples for the packaging sector
include the addition of antimicrobial coatings to packaging matrices to reduce bacterial contamination/
growth and the addition of speciﬁc additives to the packaging matrices to improve resistance to oxygen
permeability and preserve freshness of the product. With respect to the addition of nutraceuticals to foods,
examples include nano-/microencapsulation (the formation of very small capsules around the nutraceutical)
to preserve them from oxidation. Furthermore, research is published indicating that nanoscale nutraceuticals
have increased eVectiveness because of their small sizes and increased surface areas.
Nanomaterials are being used to coat surfaces of buildings, windows, electronics, appliances (such as washing
machines and refrigerators), personal clothing etc, In the main, the use of these has not transferred to the food
industry, however the potential beneﬁts are great. For example, it is likely that as well as preventing bacterial
contamination on food surfaces in food preparation areas, the use of inert non-sticky nano-materials on
machinery could also be used to prevent fouling of food processing machinery. This would reduce the
frequency of cleaning the machinery and not only result in greater eYciency of the process and energy usage
but also reduce the amount of detergent needed for cleaning.
The potential applications are extensive. Some examples are:
— Development of smart sensors. These could be used in packaging to alert the retailer or customer
when the contents are not safe to eat.
— Development of smart sensors for food analysis. Very rapid detection of the presence of food
poisoning bacteria or viruses would be extremely beneﬁcial. Additionallymany products are analysed
for nutritional content, and these are done by traditional laboratory analyses. Smart lab-on-a-chip
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or lab-on-a-foil sets are being developed which could increase the speed and accuracy of analysis and
cut the cost.
— Development of smart ﬁlters that could selectively remove allergenic ingredients from foods while
they are being manufactured. This would be very beneﬁcial for removing trace amounts of peanut or
similar allergenic material.
— Development of technologies that allow the formation of nanoscale emulsions. The properties of
these are not known but could include higher stability of the emulsions, reducing or eliminating the
need for the addition of emulsiﬁers. This would contribute greatly to “cleaner-label” foods by
reducing additives. In addition, complex multiple emulsions could be made which would allow a fat
reduction in foods whilst keeping the popular creamy sensory mouthfeel that consumers like.
— Manipulation of the size and structure of ingredients to increase their functional properties. Examples
of this include making smaller crystals of salt that would have a higher salty taste allowing a salt
reduction in foods which would be a healthy beneﬁt for the consumer. Other examples could include
an increase in thickening or gelling ability of the hydrocolloids/thickening agents, or in emulsifying
ability of hydrocolloids/emulsiﬁers, reducing the need for several chemical additives to stabilise a
food product
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
Cientiﬁca predicted that the value of the nanotechnology applications in the food industry would rise from
$410 million in 2006 to £5.8 billion in 2012. Currently, the technology and applications are mainly in the
packaging and food contact materials sectors, but potentially the whole of the food & drink industry and
market would beneﬁt from the very diverse materials and technologies being developed.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
In the area of nanotechnologies, ultra high mixing technologies are likely to be implemented in the next few
years. In food products these are likely to be applied to emulsions in the ﬁrst instance and then to other
ingredients and products. In the area of nanomaterials, coatings such as the glass-like nano coatings will be
applied to food preparation surfaces to minimise bacterial contamination, to interior surfaces of fridges,
microwaves, cookers and also to food contact machinery in manufacturing processes. They will probably
reduce the amount of “downtime” due to cleaning needed and therefore reduce water wastage, energy costs
and level of detergents used. It is likely that application of these will grow rapidly in the next ﬁve years. In
addition, self-assembly technology to create functional nanomaterials will be of signiﬁcant interest for the food
and drink industry.
Beyond this there will be developments in the chemical andmicrobiological analyses based on nanotechnology
and nano materials that will make for faster and better detection of contaminants. There will also be
applications in structuring of food products to make healthier ingredients and products.
As the pharmaceutical industry is very active in nanotechnology applications; an overview and transfer of the
technologies adopted for the production of pharmaceutical products across to the food industry would be
essential.
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
There is very little research and development in the UK regarding nanotechnology within the food and drink
industry. In spite of enormous interest from the food & drink industry in the potential, very little is known
about what is out there, what is feasible, what is safe and how it might be applied. The industry needs
independently-reviewed knowledge and expertise that can be transferred to food product development, along
with a scientiﬁc approach to be able to see the potentials. To achieve this, Leatherhead Food International has
formed aNanoWatchWorkingGroup to informmembers of the group on new developments and also to carry
out small proof-of-principle trials. In addition, Leatherhead is in collaboration with the Nanotechnology
Knowledge Transfer Network (nanoKTN), having formed a Food Focus Group to promote awareness of the
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potential for these emerging technologies and materials for the food industry and to encourage the industry
to make their voice heard.
The main developments are being carried out outside the UK in countries (such as USA, Japan, India) that
see the potential beneﬁts to the industry and are being actively encouraged to develop further.
What are the barriers to the development of new nano-products or processes in the food sector?
— Possible confusion over nanotechnologies and nanomaterials.
— Legislation on safety/novel foods that would impose unviable costs and delays to development.
— Lack of knowledge on developments in the non-food areas and in transference of such knowledge to
the food & drink industry.
— Lack of funding for research into the potential beneﬁts for the food & drink industry and Consumer.
— Lack of funding for research into the safety/toxicology of nanomaterials in food & drink industry
— Fear of consumer backlash driven by the media spotlight on “Franckenfoods”—this in turn is driven
by a lack of consumer understanding on how foods are manufactured, why they are made the way
they are, and what the industry is trying to achieve.
— Lack of funds for education of the public in relation to nanotechnology in foods
Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials in the food sector? In which areas does our understanding need to be developed?
The scientiﬁc understanding is very limited and confused by various experiments that do not apply to foods;
an example is the direct treatment of cells or animals with selected nano particles especially those unlikely to
be used in the food industry applications. Speciﬁc research within the speciﬁc food & drink model systems is
essential.
Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the food sector
sufficient? Are current funding mechanisms fit for purpose?
There needs to be a clear distinction between nano particles naturally and currently present in foods (this will
include ones made during manufacture), and those that are not normally expected such as the persistent
materials. The development and use of nanotechnologies that restructure accepted current ingredients also is
unlikely to need safety or toxicology testing.
There needs to be more funding in certain areas but this should go hand in hand with the development of the
technology in foods.
Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to nanotechnologies
and nanomaterials for consumers? If not, what amendments are necessary?
In some cases current frameworks are thought to be suYcient. However further research within speciﬁc food
&drinkmodel systems is required for assessment of the risk of exposure tomaterials not normally used in food
and drinks.
Are the risks associated with the presence of naturally occurring nanomaterials in food products any different to those
relating to manufactured nanomaterials? Should both types of nanomaterials be treated the same for regulatory
purposes?
It is unnecessary to treat naturally present nanomaterials or particles in the sameway as certainmanufactured
materials. It is important to recognise that natural ingredients in foods are already subjected to processes that
create nanoparticles. These have been eaten and considered as safe for a long time. A common sense approach
is needed and the realisation that elimination of total risk is not possible.
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Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
It has been acknowledged by the Food Standards Agency in its regulatory review report on potential
implications of nanotechnologies for regulations and risk assessment in relation to food1 (August 2008) that
the existing European/UK legislative framework is broadly adequate to cover potential risks of
nanotechnology-based products.
Under general food law, “unsafe food” (as deﬁned in Article 14, Regulation (EC) 178/2002 on general food
law) cannot be placed on the market.
Additionally, new food ingredients and agents used in food and feed manufacture and processing marketed in
the European Union (EU) must be subject to a pre-market safety assessment. These include:
— novel foods and novel food processes,
— food additives,
— ﬂavourings, and
— food packaging materials.
It is anticipated that the engineered nanomaterials in food will fall into one of these categories and would
therefore require a pre-market approval before being placed on the European/UK market.
These procedures involve the submission of dossier to the Commission or an EU Member States by the
company asking for approval of the placing on the EU market of its new food ingredient or agent.
Compositional, production and safety data must be provided in this dossier, as required by the Commission.
Any imported nanomaterials engineered using nanotechnologies will have to comply wit EU law and be
subject to the EU approval procedures mentioned above.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
According to EU/UK food law, it is the responsibility of a food manufacturer to ensure that its food products
are safe for human consumption and have been submitted to the relevant EU approval procedures, when
these apply.
In terms of voluntary reporting on the use of nanotechnologies, in the UK, Defra has set up a voluntary
reporting scheme. After a two year trial, they have received a very low response from the Industry and this
may reﬂect the very limited use of nanotechnologies by the UK/EU food industry.
According to UK government oYcials from the Food Standards Agency, the food industry claims not to use
nanomaterials.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
Yes, as aforementioned, the current European/UK legislative framework is adequate to cover potential risks
of nanotechnology-based products. Moreover, although nanotechnologies is not speciﬁcally mentioned in
current food-related legislative texts, the new regulation on food additives published in December 2008 and
the proposal for a new novel food regulation which may be adopted by 2010 both refer to nanotechnologies
for their pre-market approval requirements.
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
The European Commission has set up an international co-operation program in order to develop a common
strategy on nanotechnologies with speciﬁc countries or regions around the world.2 The Commission intends
to develop with Member States, international organisations, European agencies, industry and other
stakeholders, terminology, guidelines, models and standards for risk assessment throughout the whole life-
cycle of nanosciences and nanotechnologies products. It also aims at looking at current risk assessment and
management procedures to verify if they are adapted for ensuring a high level of consumer/environment
protection.
1 See at: http://www.food.gov.uk/multimedia/pdfs/nanoregreviewreport.pdf
2 See at: http://cordis.europa.eu/nanotechnology/home.html
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In terms of regulatory systems in other parts of the world, the EU regulatory framework can be compared to
the ones in the USA and Japan.
In the USA, like in the EU, there are currently no special regulations for the application or utilisation of
nanotechnology in foods. The US Food and Drug Administration (FDA) states that it regulates “products,
not technologies,” and anticipates that many products of nanotechnology will fall under the jurisdiction of
multiple centers within FDA and will therefore be regulated by the OYce of Combination Products. As in the
EU, any new materials sold in the USA, regardless of the technology used to create them, must be subject to
the standard battery of safety tests. Therefore, like in the EU, any new nanomaterials will undergo a pre-
market safety assessment. The diVerence with the EU is that some US States have decided to enact laws on
nanotechnologies that are more stringent than federal laws. For example, Bekerley, CA adopted a municipal
ordinance on nanotechnology in December 2006 to impose reporting obligation on facilities that manufacture
or use manufactured nanoparticles. Cambridge MA, city council recently declined to adopt an ordinance
regulating nanomaterials, but agreed to take numerous steps, including developing an inventory of
commercial, industrial and research facilities in the city that manufacturer, process, handle or store engineered
nanoscale materials.
In Japan, no provisions are laid down speciﬁcally on nanotechnology in their current legislation. They have
like in the EC, legislative requirements on ensuring that that food sold on their market in safe for human
consumption and this would apply to nanomaterials. The Japanese government is not currently intending to
set up committees or workshops to discuss nanotechnologies and food safety. Although a network is being
developed for European researchers in Japan (ERA-Link/Japan), via the Commission international co-
operation program on naotechnologies. In 2002, the Japanese government emphasised in its Biotechnology
Strategy guidelines that nanotechnology along with biotechnology and IT can be used as a tool to achieve
developments in medical science, food safety, agriculture and the environment.
Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
From studies on consumer acceptance, there appears to be a lack of knowledge of nanotechnology generally,
but those who do know something about it are more prepared to accept it if they see a beneﬁt to themselves
or society.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
It is not known how eVective they have been. A survey is currently being undertaken by BRASS at CardiV
University on the importance of company responsibility in considering safety issue in research. It is unlikely
that the food industry will engage with this to any extent. A series of educational days would be useful for
the public
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
The lack of any obvious beneﬁt to the consumer leads to a refusal to accept GM foods. The beneﬁts from
nanotechnology need to be understood and clearly communicated to the public
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
The information could involve lengthy technical data in order to avoid over simpliﬁcation. Yes the consumer
should know but not necessarily on the label. Regulations on the information need to be considered together
with education on the technology
Additional Comments
It is of concern that any speciﬁc legislation will increase consumer concerns on nanotechnology and demonise
it. The food industry is careful to ensure that foods are safely produced and current legislation requires
ingredients, foods and food packaging to be safe for the public. In the main, nanotechnology is a new tool for
the industry to produce safe foods but with added beneﬁts.
March 2009
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Memorandum by the Institute of Food Research
Summary
The UK has played a leading role in the understanding of the functionality of foods at the molecular level.
The major barrier to the use of knowledge to rationally manipulate natural nanostructures in foods to design
novel “functional” foods is the technological challenges of producing acceptable commercial products,
clearing them as novel foods and substantiating health claims for such products. For manufactured
nanoparticles based on materials that are metabolised within the body, there is a need to establish whether the
nanostructures adversely aVect metabolism and to demonstrate beneﬁts from improved bioavailability. In the
case of products that could lead to deliberate or incidental ingestion of non-metabolisable nanoparticles there
are major barriers concerned with lack of knowledge on release, uptake, retention within the body and
potential toxicity, which make assessment of risk and safety diYcult at present. It is important that the initial
products that emerge have tangible beneﬁts.
If food-approved materials are to be adequately labelled then there may need to be a basis for discriminating
between the native material and the nanoform. Current regulations within theUK and EUwould be adequate
for controlling future nanoproducts related to food or food contact materials produced or sold within the UK
or EU. However, without agreed standards worldwide, regulation of imported products, either at a national
or personal level may become increasingly diYcult.
Nanotechnology will impact the whole food chain and there needs to be coordination between government
bodies and funding agencies on research.
State of the Science and its Current Use in the Food Sector
1. Nanotechnology oVers potential solutions to excessive food waste through improved protection against
food spoilage and improved shelf-life on storage; improved microbial safety of food products through anti-
microbial packaging and food contact materials; improved authenticity and security through smart packaging
and radio frequency identiﬁcation technology; the development of novel functional foods with enhanced
nutritional value; the design of foods to combat problems such as obesity and associated long-term chronic
disease, to promote good health and protect against disease—with the potential to tailor such systems to
personal needs (genetic pre-dispositions) and lifestyle.
2. If nanoscience of foods is understood to mean an understanding of the functionality of foods at the
molecular level then the UK has played a leading role in this area particularly through work at the Unilever
Research Laboratories, the University of Leeds, the University of Nottingham and IFR. The use of
nanoscience tools such as probe microscopy has enhanced this understanding. The current need to design
foods to combat obesity and associated diseases is building on this knowledge to rationally manipulate
naturally occurring nanomaterials and nanostructures in foods to tackle these problems. To our knowledge
there are no food-approved food products in the UK which contain added nanoparticles. Such products are
available world-wide and appear to be mainly targeted to additives that improve the nutritional properties of
foods (nanoceuticals) or applications designed to enhance food safety through use of anti-microbial coatings
(usually nanosilver) on packaging, containers, surfaces or devices such as refrigerators, utensils etc. Some of
the anti-microbial products may be available within the UK.
3. We believe that functional foods designed to improve the bioavailability of nutrients could be on themarket
almost immediately, subject to regulatory approval and public acceptance. The “next generation”, foods
designed to combat problems such as obesity could be available within ﬁve years and in the longer term there
are opportunities to design foods to provide targeted protection against chronic disease and to promote good
health through into old age.
4. The UK has played a leading role world-wide in developing a nanoscience understanding of food structure
andmaterials which can underpin the development and design of novel foods. There are relevant studies on the
uptake and toxicology of nanoparticles that can be of relevance to the food sector. However, there is restricted
research on the ingestion of nanoparticles within a food matrix which will inﬂuence uptake and retention
within the body. Although there is funding for research on the release of nanoparticles from surfaces into the
environment and the consequences of their anti-microbial action, there is less opportunity to fund research on
the consequences of release and uptake within foods and eVects on natural human microbial ﬂora.
5. The major barrier to the use of knowledge to rationally manipulate natural nanostructures in foods to
design novel “functional” foods is the technological challenges of producing acceptable commercial products,
clearing them as novel foods and substantiating health claims for such products. Additional barriers to the
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use of foods or food contact materials containing manufactured nanoparticles would depend on the nature of
the nanoparticles concerned. For nanoparticles based onmaterials that are metabolised within the body there
would be a need to establish whether the nanostructures adversely aVects metabolism and to demonstrate
beneﬁts from improved bioavailability. In the case of products that could lead to deliberate or incidental
ingestion of non-metabolisable nanoparticles there are major barriers concerned with lack of knowledge on
release, uptake, retention within the body and potential toxicity, which make assessment of risk and safety
diYcult at present. Such products would be perceived as “nanofoods” and public perception with respect to
beneﬁts and risks could be a barrier to their use and development.
Health and Safety
6. Scientiﬁc knowledge related to the rational manipulation of naturally occurring nanostructures, or the use
of metabolisable nanocarriers for encapsulation, is suYciently advanced to assess the risks and safety of novel
foods based on such technology. There is a gap in knowledge on the ingestion of non-metabolisable
nanoparticles from complex food matrices and the consequences of such ingestion on uptake, storage and the
long-term potential risks due to such accumulation within the body. There is a need for specialised, directed
research on the interplay between food matrices and nanoparticles, both in terms of the release and uptake of
the nanoparticles themselves, and also of the consequences of the adsorption of biologically-active materials
released from food, such as peptides, oligosaccharides, etc, and their subsequent uptake and transport within
the body. Generic information on the role and mechanisms of the action of nanoparticles as anti-microbials
for aerobic microorganisms may not be of relevance to the behaviour of the anaerobic populations of
microorganisms within the gut.
7. We believe that the distinction between environmental and food-related issues mean that there is a
disproportionate level of funding in the environmental area. Nanotechnologywill impact the whole food chain
and there needs to be coordination between government bodies and funding agencies on research. For example
the use of nanotechnology in the delivery of pesticides, insecticides, fertilisers and nutrients requires
information on both their inhalation, and on ingestion through contamination of foods, in order to evaluate
their safety and application. It is a food as well as an environmental issue and the research should be
coordinated, although funded through diVerent sources. Similarly the release of nanoparticles from packages
or containers is a food issue related to uptake and acceptable daily intake values, particularly for edible
coatings, but also an environmental issue related to disposal of coated raw materials and packaging,
particularly for biodisposable packaging. Such research needs to be coordinated and may be very important
in ultimately inﬂuencing consumer reactions to nanotechnology and food.
8. We believe that current risk assessment frameworks within the food sector are adequate: it is a lack of
knowledge in some areas rather than a lack of adequate procedures.
9. We believe that the naturally occurring nanoparticles in foods such as proteins, carbohydrates or fats are
safe because they have undergone stringent testing and assessment appropriate to the materials. Some plant
proteins are NOT inherently safe—materials such as ricin and certain allergens are potentially very dangerous,
but adequate procedures are in place for risk assessment and clearance of novel foods. For nanoceuticals based
on metabolisable materials there may be additional risks associated with enhanced bioavailability and
overconsumption, rather than optimum consumption of nutrients or additives, and also potential
consequences of changes in the sites of metabolism and nature of the metabolic products. For non-
metabolisable nanoparticles the risks are currently indeterminate because of the lack of adequate information
on uptake, storage and long-term potential toxicity.
Regulatory Framework
10. The current regulatory framework is basically ﬁt for purpose, certainly with regard to the safety of foods,
based on the onus within European law on producers to ensure that food and food contact materials are safe.
Hence they are liable to ensure adequate clearance of foods or food contact materials based on
nanotechnology through the appropriate regulatory bodies. However, there are concerns which may inﬂuence
public perception regarding regulations on the labelling of foods and food contactmaterials. If food-approved
materials are to be adequately labelled then there may need to be a basis for discriminating between the native
material and the nanoform, possibly throughmodiﬁed E numbers, where there are diVerences in safety aspects
and ADIs for the two materials. Currently there would appear to be no requirement to label food contact
materials as containing nanoparticles. This may have an adverse aVect on consumers who may feel that they
are being denied information and choice even where the concerns are largely with disposal rather than the
safety of the product in a food context. A major problem with imported materials is that “NanoE” is used as
brand name and has no meaning in terms of the health and safety claims for the product. In addition the use
of the term Nano is voluntary and products containing nanomaterials may not be labelled. This makes
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assessment of products at a personal and national level diYcult particularly because the countries of origin
for the products may have very diVerent criteria for assessment. It would be better if there was universal
agreement on standards and a branding that signiﬁed quality and safety.
11. Although there are published codes of practice it is diYcult to assess howwell they are followed. A general
observation might be that voluntary self-regulation is often open to abuse. In this case one bad product could
easily lead to a strong public backlash against nanotechnology in food, particularly if consumers felt they were
being misled, deceived or exploited.
12. Current regulations within theUKandEUwould be adequate for controlling future nanoproducts related
to food or food contact materials produced or sold within the UK or EU. However, without agreed standards
worldwide it is possible that regulation of imported products, either at a national or personal level may become
increasingly diYcult. For example, in terms of imports there could be potential problems with novel
applications such as edible coatings on fruits and vegetables: if such coatings containing nanoparticles were
made and used on imported materials to reduce microbial spoilage then it is diYcult to see how this could be
detected or regulated.
13. IFR’s understanding is that there is inter-Government co-operation within the EU and exchange of
information between certain Governments. The lack of agreed standards is a major problem with potential
imports and for individual consumers purchasingmaterials through the internet. Themain lesson to be learned
from the diVerent regulatory systems world-wide is the need for such systems to be timely and correct, thus
not stiﬂing commercial development of products, but equally not inﬂaming public disquiet or mistrust about
nanotechnology.
Public Engagement and Consumer Information
14. Purely from involvement with workshops and meetings concerned with nanotechnology and food, IFR’s
impression is that there is a general awareness of nanotechnology and an awareness of its potential use in food.
A general question asked seems to be “are nanotechnology applications in food safe?” The diYculty is that
such a generic question is diYcult to answer because the risks and safety aspects depend on the product or
application and need to be assessed for individual cases. The answer that there are procedures in place to
ensure the safety of the use of nanotechnology in the food area in the UK is not entirely convincing because
there does appear to be an underlying mistrust of the Government and industry in issues of this type.
15. Having taken part in public engagement activity we believe that Government, certain industries and
stakeholders have made good eVorts to engage and inform the public about nanotechnology and food.
However, the coverage in the media, with notable exceptions, is often negative, less balanced or informative,
but probably reaches a wider audience. Wider publicity could be given to the general problems that face the
food and agricultural industries which could be tackled using nanotechnology.
16. The most interesting lessons that can be learned from other technologies are from what happened in the
initial debate on the use ofGM technology. The public wishes to have the right to choose based on information
on beneﬁts and risks. It is important that the initial products that emerge have tangible beneﬁts, and are not
trivial or seen to have shallow commercial beneﬁts for a restricted group of multinationals.
17. The ability to exercise choice is very important to the public and raises the issue of labelling. Many
applications of nanoscience or nanotechnology in food need not be labelled or called nanofoods. However,
there are some areas where labelling could be important. Where approved food ingredients or additives have
been reduced in size to alter and improve their function, and there are diVerences in the safety data and
recommended intake levels, then there is a need to discriminate between the two forms in the use of labelling.
Use of conventional E numbers or named materials may not be suYcient on labels if safety data and ADIs
are diVerent for the two forms. The use of nanoparticles in foods or food contact materials which are not
metabolised in the body should require labelling to allow consumers to exercise choice in the purchase and use
of these materials. Even if the food contact products are shown not to contaminate foods and the foods to be
safe on ingestion then consumers may have concerns relating to the disposal of waste material such as
packaging and the consequent environmental eVects.
Other Aspects
18. Although touched upon in some of the answers to some of the above questions we believe that there are
wider issues that aVect the use of nanotechnology related to food and that these issues are also important to
the public perception of the use of nanotechnology in the food sector.
19. Nanotechnology will impact across the whole food chain. “Smart” farms and “smart” delivery systems
oVer routes to improving agricultural yields, responding to local climatic variations and reducing the use of
pesticides, insecticides and fertilisers. Selective and targeted use of chemicals, through sensing environmental
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variations locally, or sensing chemical signals related to pests, or plant wound responses, oVer routes to
reduced use of chemicals in farming. Some of the advantages of nanoencapsulation and delivery could be oVset
by problems related to contamination of crops, soils and streams, or problems associated with the detection
of contaminants on food materials, possible new routes of uptake, distribution and bioaccumulation within
the body, and the subsequent long-term eVects of such accumulation Thus it is not just the advantages to
agricultural production weighed against environmental factors that need to be considered but also the
downstream eVects in the food sector. Given that funding is these areas is often through diVerent agencies there
is a need to ensure adequate and co-ordinated funding covering all aspects.
20. Another aspect that will impact on the food sector, but not directly related to food or food contact
materials, is the use of GPS and RFI technologies in the tracking of food and food materials from source
through transport and storage to shops and distribution centres. Coupled with smart packaging this could
improve authentication of foods, inhibit or allow more rapid identiﬁcation of food contamination or
adulteration, and reduce waste.
21. At the far end of the chain there is the ultimate disposal of waste material. This raises questions about
the fate of packaging and food contact material containing manufactured nanoparticles, particularly if such
technology is used in conjunction with biodisposable packaging. The containment of anti-microbial
nanoparticles within matrices may answer the questions raised about accidental release of these particles into
foods. However, the question remains as to the fate of these nanoparticles on disposal of these food contact
materials and the consequences for the environment. The contamination of rivers or streams could ultimately
lead to the re-introduction of these materials back into the food chain but in a diVerent, perhaps more easily
ingested form. Again, diVerent agencies deal with the funding of research and with the regulation of food and
environmental issues. DiVerent agencies can be reactive or proactive in their approaches and this can lead to
disproportionate levels of funding, gaps in knowledge and diVerent approaches to regulation. There needs to
be a way of co-ordinating activities to ensure that regulation and decisions on the use of nanotechnologies in
food and agriculture are based on knowledge of the long-term eVects of these products. IFR hopes that the
Ministerial Group onNanotechnologies (led by theMinister of State, DIUS) will provide a catalyst for action.
22. In terms of public opinion, portrayal of the wider beneﬁts of nanotechnology in both food and agriculture,
and the demonstration of a co-ordinated approach to assessing risks across the whole food chain, would
counter some of the negative media rhetoric directed to applications directly related to food.
11 March 2009
Examination of Witnesses
Witnesses: Ms Kathy Groves, Leatherhead Food International, Dr Vic Morris, Institute of Food Research,
Dr Paul Butler, Packaging Materials and Technologies Limited, and Dr Frans Kampers, Wageningen,
BioNT, examined.
Q86 Chairman: I would like to welcome our four
witnesses. Thank you very much for coming to join
us for this second public hearing in our inquiry into
nanotechnologies and food. We are very grateful to
you for sparing the time to come and answer some
questions and hopefully enlighten us on this
important and interesting topic. I should inform you
that proceedings of this hearing are webcast, so are
available to the public. I should also draw attention
to the information note which is available to those
members of the public who are here in the audience
and that note sets out the declared interests of
members of this Select Committee so we do not need
to repeat those during the questioning.Whenwe start
in just a second I would like to invite the four
witnesses to introduce themselves for the record, but
also if you wish to make any form of opening
statement describing your views about the issues then
you are very welcome to do so, otherwise we will
move straight on to the questions. Perhaps I could
ask Kathy Groves to kick oV and introduce herself
and then move along the row.
Ms Groves: Goodmorning. I amKathy Groves. I am
the principal microscopist at Leatherhead Food
International.
Professor Morris: I am Vic Morris. I work at the
Institute of Food Research in Norwich, which is a
BBSRC institute, and I am interested in nanoscience
techniques to look at food structure.
Dr Butler: I am Paul Butler. I run a consultancy
company advising packaging converters and retailers
on the latest advances in packaging materials and
technologies, including nanotechnology.
Dr Kampers: My name is Frans Kampers. First of all
I would like to thank you for inviting me to this
prestigious committee. I am from the Netherlands,
fromWageningen UR. One half is the university and
the other half is a contract research organisation. I
co-ordinate the bionanotechnology research at
Wageningen, so I head a virtual institute called
BioNT within Wageningen UR, and our main focus
is on the applications of nanotechnology in food.
Various groups within Wageningen UR work on
food, applications in food, sensors, processing
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improvement and things like that. That is my interest
in this.
Q87 Chairman:Thank you verymuch.Would any of
you like to make any further statement before we
start? Let us move straight on to the questioning. I
would like to kick oV with a very general question to
all of you. We are obviously interested both in the
potential of nanotechnology in the food industry in
the future and also on the regulatory side of that
whether there is any need for additional regulations
and what the uncertainties are in risk assessment. I
wonder if we could start oV by seeking your views on
what you think the potential beneﬁts of
nanotechnologies and nanomaterials are to the food
industry and, of course, to consumers of food?
Professor Morris: There are four areas I would think
of. One is the reduction of waste in the food chain;
safer foods, particularly anti-microbial eVects;
healthier foods, you can design food structures to try
and prevent and slow the progression of diseases and
you can also design foods to combat things like
obesity and build eVects into foods that would
control hormonal responses that control the amount
people eat; and there are new commercial
opportunities, particularly with small ﬁrms, in the
nano area.
Ms Groves:That sums up a lot of them. An added one
is the advantages of nanomaterials in the food
processing and manufacturing side, either anti-
microbial surfaces or anti-stick surfaces that would
stopmachinery clogging up and reduce the downtime
for cleaning.
Dr Butler: My background is packaging so I will just
address the food packaging side of things. In food
packaging, one of the major problems we have in all
the developing countries is food waste. This is
consumer food waste from the home. I think
nanotechnology could help in terms of producing
packaging that is more communicative and
informative to the consumer. For example, a
consumer would have a much better idea of whether
the food was safe to eat or had to be discarded. At the
moment we have some very ineVectual date coding
systems on food and a lot of food is thrown away that
is perfectly healthy and still suitable to eat.
Nanotechnology as an enabling technology could
help with what is known as smarter packaging or
intelligent packaging.
Dr Kampers: I would like to place the question into
the larger perspective of challenges for mankind
basically. We have a growing world population and
increasingly people want to have more protein in
their diet but we know at the moment that is
impossible to produce in the way that we produce it
now. Sincemeat is a nanostructuredmaterial that has
a structural hierarchy from the nano level up, you can
understand that if you want to have replacements for
meat in a more sustainable production way then we
will need to look at how we recreate the structural
hierarchy from the nano level up, so you start with
nanotechnology in these areas. Another big challenge
for mankind is keeping the health system
economically viable. The curative healthcare system
that we have nowadays will not be sustainable in the
long run because it is too costly. We believe that with
a paradigm shift towards preventive healthcare we
can both help individuals remain healthy and also
keep the systemwithin economic boundaries. Food is
a very important component of that preventive
healthcare system paradigm. We believe that
nanotechnology can add to that system.Mind you, if
everybody ate 200 grams of vegetables a day and two
pieces of fruit a day in a varied diet nobody would
need any technology to stay healthy. We very rarely
do that, so the food industry is looking at
technologies to help individuals get the nutrients that
they need to stay healthy and in that way we hope to
reduce some of the costs of the healthcare system.
These are basically large challenges to mankind in
which we believe nanotechnology can play a role as
an enabling technology.
Q88 Chairman: Thank you for those helpful
responses. In the work we have done so far and the
literature we have read we understand that
nanotechnology may mean diVerent things to
diVerent people, so we deliberately entitled our
inquiry “nanotechnologies” rather than
“nanotechnology”. I wonder whether any of you
would like to comment on distinctions that youmight
see amongst diVerent nanotechnologies that could be
usefully drawn in terms of the food sector and what
the functional indications of those diVerences might
be.
Professor Morris: I think an area where there is a big
diVerence is in talking about nanotechnology we are
talking about natural structures and materials which
are manufactured which are not broken down in the
body and that is an area where possibly the risk
beneﬁt analysis is harder to assess because of a lack
of knowledge in those areas.
Q89 Chairman: So natural versus persistence?
Professor Morris: Particularly in manufactured
materials that are not broken down in the body and so
are likely to persist in the body and we do not know
the consequences of that. I think that is an area that
attracts toomuch public concern, particularly because
there seems to be a reluctance to label materials or you
have labelling over the Internet which is not regulated
and there seems to be a reluctance in the UK to want
to label packaging or these non-metabolisable
materials put into food and people might feel,
therefore, they have not got a choice in assessing the
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risks themselves either in what they buy on the
Internet or what they might buy in the UK.
Dr Butler: My own view on nanotechnology is that
obviously it is everyone’s favourite preﬁx—we have
got the Nano iPod and everything like that—so it has
become a bit of marketing hype. My own view is that
nanotechnology only gets really interesting—and I
know you do not want to get sucked into what size is
nanotechnology and what size is not—when you have
property changes which you do not normally have. I
grew up with my Periodic Table of 92 elements and I
was quite happy with all their physical properties.
Nanotechnology gets very interesting when you get
down to the 20–50 nanometre size and all kinds of
unusual properties are now generated by these so-
called bulk materials. It is like a material scientist who
is given a whole new palette of materials, strange
elements with unusual properties. I did metallurgy at
university and with something like silver, silver melts
at 960)C and it does until it gets tiny, tiny, tiny and
then you can melt it with a hairdryer. These are
dramatic changes in properties that could have huge
effects in terms of aerospace and medicine. Packaging
and agri-food just happens to be one of the many
applications of nanotechnology, but to me true nano is
when the quantum effects kick in and you get these
dramatic changes and the material just does not
behave like it ought to behave and then you can do
some really, really interesting things with it.
Dr Kampers: It is really from what perspective you
look at nanotechnology. If you look from the
opportunities perspective then you look at the
quantum effects that allow you to create new
functionality that we have not been able to create
before. The various applications in all sorts of
application areas beneﬁt from these new properties
and arise from quantummechanics basically and from
the fact that you have a lot of surface versus volume
ratio. If you look at it from the beneﬁt side, we have
all sorts of different applications for nanotechnology
in food which ranges from sensors that have very little
to do with the food itself and packaging materials that
come into contact with food, but also applications that
go into the food that are intended to be eaten. There
are very many sorts of nanotechnology in the
application area of food. If you look from the
perspective of risk and risk assessment then you have
to look at what classes of nanotechnology could pose
risks and toxicologists agree that the persistent
nanoparticles, especially those that are non-
biologically degradable, in-organic, the inorganic
metal oxides and metals, are the particles that pose
most risk. There we start to look at what sorts of
properties determine that risk and that is an area we
know very little of yet, especially if you ingest the
particles. This is an area that still needs to be assessed,
but it is only a very, very small part of all the
applications of nanotechnology in food. For me, it is a
pity that everybody focuses on that speciﬁc area. I
know risk is something that concerns us all but, on the
other hand, the beneﬁts may be tremendous and
outweigh the risks to a very large extent.
Q90 Lord Cunningham of Felling: I just wondered
whether very brieﬂy each of you could say what you
think the public reaction would be to manufactured
nanoparticles in food, given that, for example, there
is still something of a debate going on about putting
ﬂuoride ions in the drinking water even though the
evidence in terms of dental health is pretty
overwhelming. What do you think would be the
prospect of persuading people that it is in all our
interests to have nanoparticles in the food chain?
Dr Kampers: Are you referring to inorganic
nanoparticles, the persistent nanoparticles?
Q91 Lord Cunningham of Felling: Any kind. I said
manufactured nanoparticles.
Dr Kampers: The most important area of application
in food probably is not nanoparticles but in delivery
systems. These are larger systems so they usually are
not seen as nanoparticles. They are nanotechnology
because the nanotechnology is in the wall of the
particle, but it is not a nanoparticle per se since it is
much larger than 100 nanometres, although you
would like to include that as well. I think you have to
explain to the general public what the beneﬁt for the
individual consumer is, like there is a product that
delivers oil to the small intestine and it makes sure
that the oil does not come free in the stomach, in the
mouth or anything, it is delivered to the small
intestine, and the idea is it triggers the small intestine
to give a signal to your brain that you are saturated
basically and is a way of convincing your body that
you have eaten enough. This is a product that when
you use it is supposed to make sure that you stop
eating sooner than you would have done if you had
not had this product. Obviously the product falls
apart in your gastrointestinal tract so there is nothing
left of the nanotechnology except molecules, of
course, but these are all harmless molecules, they are
food grade molecules. If you have story like that—
Q92 Lord Cunningham of Felling:Excuse me, I think
ﬂuoride ions are pretty harmless too myself but that
has not persuaded the public to universally accept it.
The question is not really about the eYcacy or
otherwise of the technology in scientiﬁc or nutritional
terms, it is the public acceptance.
Ms Groves: Your answer would be in how you asked
the question. It depends on how you ask the question.
If you say, “How do you feel about the food industry
putting nanoparticles in your food” then I think you
would probably get a big response saying, “I’m not
keen on that at all”, but if you say, “The food industry
are structuring food on a nano scale” then you might
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get a diVerent answer. If you put choice of beneﬁt
from healthier food against less healthier food then
that would weight their response. The public do not
really know how food is manufactured and then put
on the shelves in the shops. There is a lack of
information on actually how it is currently
manufactured.
Q93 Lord Cunningham of Felling: I am struck by
what you have just said on what was happening with
the genetically modiﬁed tomato sauce, which was a
best seller until people discovered that it was
genetically modiﬁed and then they stopped buying it.
Professor Morris: I think the most important thing is
people aim to exercise choice. We might think it is
unreasonable they do not want to eat those sorts of
foods but they ought to have the choice as to whether
they do or not, and they ought to be able to access the
beneﬁts and risks in an understandable form so they
can make their own assessment. I think if they have
that choice, whether it means labelling or
information in some way, their perception would be
much better and they would not feel it is something
that is being forced on to them.
Q94 Lord May of Oxford: If I understood your
example right, and I may not have, it was an example
where you put in something that is completely
harmless and safe which, however, in eVect modiﬁed
behaviour in a way that was advantageous, and all I
can say, like Lord Cunningham having had
experience of the genetically modiﬁed fuss and so on,
is just wait until Greenpeace hears that you are going
to put nanoparticles in food that modify behaviour,
there will be some term like “Frankenstein food” that
comes with that.
Dr Kampers: It is inevitable that some of the NGOs
will come on to this area. However, I believe that
communication about the application, beneﬁts and
potential risks of these technologies is essential and it
is also important, as my colleague said, that the
consumer has the choice so they can choose whether
or not they would like to have the beneﬁts versus the
risks or perceived risks of such a product. It is
important not to do that in obscurity.
Chairman: I think the choice point has an echo in the
response of the public to ﬂuoride because although
people object to ﬂuoridation of water almost
everybody buys toothpaste with ﬂuoride.
Q95 Lord Haskel: I wonder if we could move on to
another aspect, which is the politics of
nanotechnology in food. You have told us about the
way in which nanoparticles enhance food safety,
reduce waste, is healthier and more sustainable. In
view of the fact that there are so many beneﬁts, are
there any Government initiatives in place to
encourage nanotechnology development that
contributes to these objectives and towards achieving
these objectives? Are governments doing anything to
help you?
Professor Morris: Certainly the Research Councils
are. There are research programmes on
nanotechnology in most of the Research Councils
and there are programmes on things like health into
old age in the BBSRC which ﬁts that agenda.
Certainly in terms of basic research there are
programmes available to fund that. I am not sure
about the other Government agencies, such as the
FSA or environmental agencies.
Q96 Lord Haskel: Is there any co-ordination
between the Government and the industry? I notice
that there is a technology transfer network.
Ms Groves: There is, and there are nanotechnology
centres dotted about the country. There is one we
have been working with that has been set up with
Government funding through the Technology
Strategy Board and the Knowledge Transfer
Network for Nanotechnology is obviously set in
place to enable technologies from diVerence research
areas to be translated into food or other areas.
Q97 Lord Haskel: Obviously your company
supports that. Do you ﬁnd it eVective? Does it work?
Ms Groves: It is very limited in resources, I would say.
There are not enough resources for that sort of
knowledge transfer.
Q98 Lord Haskel: Where do the resources come
from?
Ms Groves: They come from the funding for research
and development and that has short pockets.
Q99 Lord Haskel: It is not the commercial
companies?
Ms Groves: The commercial companies will put
money into research and they do collaborate together
on pre-competitive research funding. In fact, they are
doing that on a small scale.
Q100 Chairman: I wonder if Dr Kampers would like
to add any comment about the situation in the
Netherlands or other European countries.
Dr Kampers: Obviously I cannot say very much
about the situation here in the UK, but in the
Netherlands we have just completed a proposal for
the next generation of nanotechnology
programming, science programming and one of the
ten themes that we have identiﬁed is food. The
proposal is to spend aboutƒ40million over ﬁve years
on applications of nanotechnology in food in the
Netherlands. In the Seventh Framework
Programme, both in the nanotechnology theme and
in the food theme, there are calls that address
nanotechnology applications in food.
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Dr Butler: The Institute for Nanotechnology in the
UK is one of the partners for this European project
which is funded for four years fromApril 2008. There
are 16 partners from ten European countries. Part of
that is to share information about health and safety,
about regulatory aspects of nanotechnology. Again,
they are looking at all the major sectors, which
includes agri-food.
Dr Kampers: Can I add one point. You also asked
about the involvement of the industry. In the
proposal in the Netherlands, 50 per cent3 of all the
money comes from industry. It is aimed at
collaboration between government institutes, science
institutes and the industry.
Q101 Lord O’Neill of Clackmannan: On this point
about funding, to what extent could you draw an
analogy, say, with the biotech industries? Admittedly,
there it is linked with pharmaceuticals and speciﬁc
research programmes for the development of
particular drugs, but that has been very successful in
attracting venture capital and that kind of money.
Would it be right to say that the state of
nanotechnology at the moment is that it is
insuYciently advanced to attract the attention of
speciﬁc investors rather than people who have, as it
were, food industry interests, the like of which you
were alluding to both in your introduction and your
example?
Dr Butler: It is quite early. Nanotechnology is such a
broad platform that at this stage where you are
discovering what it is and what it can do you are
probably not going to get the VCs involved until you
have got a speciﬁc application in a speciﬁc sector, and
that is beginning to happen, but at themomentwe are
still exploring the many, many potential applications
of nanotechnology. That would be my take on it.
Ms Groves: Yes, it is very broad and that complicates
it to some extent. Also, it is at a very early stage in
terms of the food industry and I think it is fair to say
there is a nervousness in the food industry about how
the consumer views what they are doing if they
launch into nanotechnology, yet they want to see
what is available and what could be beneﬁcial so they
are courting it.
Dr Kampers: In the Netherlands we see two ways in
which the results of the research get to market. The
ﬁrst is existing companies adopting results from the
research and putting them into products or processes
and improving them. The second way, that is
probably the most important and eVective, is spin-
outs, small companies, new companies, start-ups
generated by the knowledge institutes and the
knowledge infrastructure. So PhD students start up
their own business, they attract a little venture capital
3 This ﬁgure is actually 25 per cent. 50 per cent of the total funding
comes from the participants (including universities, industry and
research institutes) and of this, half is contributed by industrial
participants.
but basically rely on funding from the market side.
There is a little bit of venture capital involved there
but most of the funding is through other funding
programmes that are available and things like that,
subsidies.
Q102 Lord May of Oxford: You have already given
us some examples of potential applications of
nanotechnologies and nanomaterials, but I wonder if
you could say a bit more about the applications of
these technologies that UK companies or, more
generally, companies in other countries are currently
working on and what applications we are likely to see
on the market maybe next year, in ﬁve years or ten
years?
Dr Kampers: You have got everything about sensing
and diagnostics. These are low-hanging fruits, as we
call them, where small companies are working to
improve sensing devices, sensors basically that can
detect volatiles or bacteria, fungi, things like that, to
improve food quality. Another application area is
improving processes like the emulsiﬁcation processes,
sieves and things like that, these kinds of areas. In the
application area where you add technology,
nanostructured materials to foods, nanoparticles,
there are very few applications of persistent
nanoparticles in food at the moment, but these
delivery systems are something that attract a lot of
attention and are not very far from the market as we
speak. Then you have got packaging materials that
improve the shelf life especially of fresh products but
also inform the consumer about the quality of the
food inside the packagewith sensors and also systems
that change colour when the quality of the product
deteriorates or the ripeness changes. These are
applications that are already available in the US.
There are systems that you can buy at themoment for
these applications. They are fairly close to market.
Dr Butler: From a food packaging point of view, to
give one speciﬁc application which will involve using
nanotechnology to create a self-adjusting use-by
date. We need to move away from date coding to
more visual displays on a package to inform the
consumer whether the food is still good enough to eat
or not. That will involve a display, a printed battery,
some very, very simple electronics which will be
printed on ﬂexible trace paper or plastic and the
enabling technology to do that will be
nanotechnology, for example inkjet printing using
nanoparticles to lay down circuits on ﬂexible ﬁlms to
then put on top of food packaging, but of course the
nanoparticles that you inkjet print will be part of the
manufacturing process and once they are
consolidated and have been cured they will no longer
be nanoparticles, they have done their job, they have
created a structure so will present no problems at all
to the consumer. I think it is important we
understand that sometimes in nanotechnology you
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might start oV in the manufacturing process with a
nanoparticle with perhaps some concerns over its
health and safety and what it might do, but at the end
of the day you might produce a product where, yes,
you would use nanotechnology but that product is
now completely benign.
Professor Morris: There is another example of that.
Frans mentioned the idea of marketing nano-
encapsulating oils and delivering them further down
the small intestine to generate a hormonal response.
Using nanoscience you can actually look at how you
design the structures in the emulsion and you can
manipulate those structures to have the same eVect so
you can slow down the rate of hydrolysis of the fats
so they are hydrolysed further down the small
intestine and you can visualise how to do that and
then you can use normal processing techniques to
generate those structures by using nanoscience to
understand how to use conventional processing to
generate a new product that has got new properties.
I think they are the sorts of products that could come
on the market in perhaps ﬁve to ten years.
Q103 Lord May of Oxford: Let me put it another
way.We had a study from something called Cientiﬁca
and it seems concordant with other studies. First of
all it makes the projection that by 2015 it is going to
be a trillion dollar industry, and then it looks at 2007
and it says excluding semiconductor applications it is
nearly all the applications in chemistry, less than one
per cent in the food sector, and its projection for 2012
is that maybe the share of the food sector by 2012 of
all nanotechnological research might be as much as
two per cent. My question is what are the main
drivers of R&D in the food sector? Are there research
drivers that are driven by the food industry or does
the food industry, insofar as it is a player, primarily
rely on adopting and applying new technologies that
have been developed in other sectors? I ﬁnd it a little
bit disconcerting to think that the main driver of
applications for nanotechnology in food is going to
be chemicals. I do realise food is chemistry but, again,
it plays into the hands of the NGOs who are worried.
Ms Groves: Those are really probing questions and
the others will have a view on them. There is no doubt
that one of the main drivers, and there are drivers for
the food industry and their R&D, is in healthier
foods. Consumers are very keen, and I am keen to
carry on eating fatty, nice tasting foods but I want to
be healthy as well, so people do want that. Healthier
foods is a big driver. Cleaner labels or removal of E
numbers and trying to simplify manufactured
products is a big driver. In order to do that you have
to understand what those ingredients do and then
you have to understand how maybe changing the
process of the food will allow you to remove some of
those ingredients by using nanostructures of those
natural ingredients in food. Those are just two drivers
but I am sure there are many others.
Dr Butler: No. I think there are many, many ways to
skin a cat and there are many ways to get lighter
packaging andmore recyclable packaging. I think we
have got the nanoclays, which have been ﬂoated as a
way of getting better barrier properties on transferred
plastics, which has been hyped up a little bit. I know
of no commercial examples. They have certainly tried
PT plastic beer bottles, for example
Q104 Lord May of Oxford: Are there any
applications?
Dr Butler: I do not know of any at all, in packaging.
I know lots of people working on it.
Dr Kampers:Apparently, in the US, you can buy beer
in PT bottles, thanks to the nanoclay and
nanocomposite applications. I know that one of the
brewers in the Netherlands is looking at that
application but it is not on themarket. Can I also add
one more application area or driver for the industry?
The industry, also, apart from the health aspects of
food, looks very much at the safety of foods. Food
has never been as safe as it is now in industrialised
countries and it is a tremendous eVort for the food
industry to enhance that even more, and that is why
they are very anxious to look at all sorts of measuring
devices, diagnostic devices, that can maintain that or
improve even on that aspect, and they are looking for
devices that can give theman answer quickerwith less
qualiﬁed personnel and closer to the production line.
Basically, that is what they are looking for, also, in
nanotechnology—if nanotechnology can deliver on
devices like that.
Professor Morris: I think there is an example of
sectoral use of nanotechnology, in terms of future
chips, and so on, in GPS and radio frequency
identiﬁcation of food, and tracking them from source
right through to the shop or the consumer, so you can
actually check the conditions under which they are
stored and transported, and you can check whether
that route has been interrupted. So if the food was
adulterated you could very quickly ﬁnd out where it
happened and track it down. So there is that aspect of
nanotechnology which applies to the agri-food sector
which is readily acceptable at the moment by the
public.
Q105 Lord Crickhowell: The question I want to
address is: what are the main challenges to the use of
nanotechnologies and nanomaterials in the food
sector? We have in front of us, as it happens today, a
submission from the Leatherhead Food
International & Nanotechnology Knowledge
Transfer Network. Basically, what this submission
says is that they see enormous potential and
considerable scope for growth but that we know
almost nothing about the whole subject. They say:
64 nanotechnologies and food: evidence
21 April 2009 Ms Kathy Groves, Dr Vic Morris, Dr Paul Butler and Dr Frans Kampers
“There is very little research and development in the
UK regarding nanotechnology within the food and
drink industry . . . very little is known about what is
out there, what is feasible, what is safe and how it
might be applied”, and they refer to the lack of
research or the forthcoming research. We have heard
in earlier evidence that we really do not know yet very
much about the long-term eVects on the gut of certain
manufactured nanoproducts. So over the millennia,
nature has been absorbing nanoparticles into the gut
and modifying it but we do not know very much
about it. So I suppose my question is: is the lack of
knowledge and the lack of much research yet the
biggest obstacle? What are the obstacles? What is the
main challenge, if it is not that?
Ms Groves: In looking at that question that was sent
tome, I put “scientiﬁc challenges”. As a scientist that,
perhaps, would be a natural answer for me to give.
There are some huge scientiﬁc problems in both
structuring at that nano-level in complex foods (and
nearly all manufactured foods are pretty complex)
but, also, measuring them. It is a challenge just to
know where fat, sugar and protein are in a lot of
foods, let alone what size and scale they are.
Obviously, there are challenges in terms of consumer
acceptance of the food industry manufacturing foods
at a nano-scale with nanoparticles. I think it is
important to, again, stress the distinction between
nanoparticles which are not normally consumed in
large quantities, like titanium dioxide or silica or
silver or any of the metals, and the foods which are
usually consumed—fats, proteins and
carbohydrates. I think it is important to distinguish
between those.
Q106 Lord Crickhowell: As I understood it, you
referred, I think, to really changing the process of
manufacturing but not really using nanoparticles in
the gut, except you have learnt how to change the
process. We did have a description, I think, at one of
our seminars, of the way in which you might reduce
the fat content in food by, basically, attaching the
food from much smaller—I am not sure what the
word is—segments, but it did seem to me that we are
into an area of confusion, which I am not sure I
understand, about what is a manufactured
nanoparticle and what is simply a change in the
manufacturing process. Is this an area that we really
know enough about and understand enough about?
Ms Groves:No. I think it is very diYcult because early
on, I think, one of the ﬁrst questions was a distinction
between manufactured and natural. Actually, a lot of
manufactured particles are natural particles; they are
natural foods which have been manufactured into
structures within a food product. So, yes, there will be
changes to food processing which may well need to
involve nanotechnologies in order to change the
structure of the ingredients in the food that we put in.
That is one aspect of the nanotechnology of foods,
and it is the distinction as to whether they are
manufactured nanoparticles of water being boiled,
which I think, in the seminar is one of the low-fat
examples. So if you have water in oil and water,
emulsion, in a salad dressing, are those water droplets
manufactured nanoparticles or are they natural but
they have been processed to be very small? That is
going to be something that needs to be decided in
order for legislation purposes and regulation.
Q107 Lord Crickhowell: If there is a need for more
research, again we heard in evidence at our last
session the diYculty about manufacturers’
intellectual property rights; even if they are not
worried so much about intellectual property rights
they are, perhaps, reluctant to exchange too much
information about technological developments
which may have huge commercial advantages. Is that
an obstacle that you see as a real one to real
progress—the very natural lack of willingness to
communicate too much between companies about
their research programmes?
Professor Morris: I think it comes down to a matter of
choice. If those products are introduced without any
way that the consumer can tell that it involves
nanotechnology, they might be concerned. I think
then there could be a problem.However, if those were
labelled in some way, so that people can choose
whether they use them or not, I think it would not be
so much of a problem.
Q108 Lord Crickhowell: You keep coming back to
labelling as a solution.
Professor Morris: It is a possible solution.
Q109 Lord Crickhowell: One of the problems is that
we have got far too much labelling, in many ways,
and people now ﬁnd almost all labelling confusing.
Surely it is a step too soon to talk about labelling if
we cannot actually know quite what the threats are,
what is right and what is wrong and we have not got
the basis of scientiﬁc research on which to label. Are
you not jumping a bit far ahead?
Professor Morris: I am not saying labelling has to be
the way to do it; I am saying that the consumer needs
to have some choice as to whether they opt to buy a
particular food or not, and they need some way of
knowing whether the processing of that food is
something that might concern them. We might think
it is unreasonable they should be concerned, but they
still feel they have a choice as to whether they buy it
or not
Q110 Lord Crickhowell: My ﬁnal question on
research, if this is an obstacle, is that we found it
rather diYcult in our last session to get really reliable
and complete information about the amount of
65nanotechnologies and food: evidence
21 April 2009 Ms Kathy Groves, Dr Vic Morris, Dr Paul Butler and Dr Frans Kampers
government research and ﬁnance for the research in
this ﬁeld, and we hope we are going to get a rather
more complete paper from the department concerned
in the future. Would any of you like to comment on
the adequacy of the government’s research
programmes in this ﬁeld in this country, in Europe or
elsewhere?
Dr Kampers: “In the ﬁeld”—you mean?
Q111 Lord Crickhowell: If it is so important that we
know more about the science of nanotechnology, if it
is going to be possible to assess the safety of these
products, ought there not be a more concerted
scientiﬁc programme, and what are governments
doing, or should governments be doing, to see that
that happens?
Dr Kampers: In my personal view, building trust with
the consumer is very basic; it is a pre-requisite for the
acceptance of the technology. “Building trust” means
that we understand the risks, so risk assessment is
important. We know that the risk is predominantly
located at the inorganic nanoparticles, but still we
feel that we have to do more research into the risk
assessment, both hazard assessment and the exposure
assessment of nanoparticles. There it is tremendously
complex because if we talk REACH, basically, that is
governed by the chemistry; for bulk or small particles
it is the same. Nanotechnology has added a whole
new dimension to that problem because size matters
now. There is another dimension that
nanotechnology has added because we also can
control the geometry of the particles, so we can make
rod-like particles and we can link spherical particles.
So there is another dimension added to the
complexity. There are even other dimensions because
we can functionalise particles so that they behave
totally diVerent from the particles that we started oV
with. So the complexity to look at these kinds of
issues is tremendous, and we lack the data to get to a
level where we have generic knowledge of where the
risks really are in this multidimensional space. That
is something that, in my view, needs to be addressed
internationally; it is too complex for one country to
do. We have to co-operate to ﬁnd out where the hot
spots are and where the relative safe zones are in this
area, and that is something that we have not
succeeded yet. But it predominantly focuses on
nanoparticles. So the application of nanotechnology
in sensors and surfaces is totally diVerent; it is
something that focuses on these particles.
Professor Morris: I think there is an emphasis on
manufactured nanoparticles, and I think it really
should be on materials that are not broken down in
the body. I think that is the distinction that alters the
risk involved in these technologies.
Q112 Lord Haskel: Of course, the research that you
are speaking about is very, very important, but is
there any research going on to look at what are the
concerns of the public? What are the concerns of the
consumer? Obviously, the two go together.
Dr Butler: Yes. If any of us buy a packet of crisps, or
potato chips, inside is a metallised plastic ﬁlm. That
ﬁlm is nanodimensional4, but it is not declared
anywhere on the label and it has been around for
donkeys years. It depends how you deﬁne
“nanotechnology” but actually if you wanted to
deﬁne it that way, as aluminium metallised ﬁlm,
which is used extensively, people are totally relaxed
about it, are they not?
Professor Morris: Certainly Which? have carried out
workshops to look at public concern on
nanotechnology, and the nanotechnology institutes,
particularly Cambridge, have actually hired social
scientists to try and answer public questions and have
public forums where people can ask the sorts of
questions they are concerned about and get scientiﬁc
answers.
Q113 Lord Haskel: So you think the public will just
be quite passive—
Professor Morris: I do not expect them to be quite
passive about it.
Dr Kampers: As a matter of fact, Wageningen UR is
doing research on the mechanisms that govern the
processes within groups in society to accept this kind
of technology in food. So we are doing research to get
some generic knowledge on how these processes are
conducted and what inﬂuences these processes and
how communications, for instance labelling, could
help make society accept these kinds of new
technologies in application areas of food. We are
doing research ourselves in that area.
Professor Morris: The worst thing that can happen is
that people are told: “This is a product that involved
nanotechnology; it is perfectly safe, you should
accept it”, and not be allowed to assess the risk
themselves. I think people feel that whatever the risk
they may choose not to accept it, even if it is a very,
very small risk. They want that choice, and as long as
they have that choice I think they are more likely to
accept it.
Q114 Lord May of Oxford: At the risk of seeming
unduly obsessed with risk and public attitude, I
would remind you that, at least in the UK, when
nanotechnology ﬁrst appeared on the scene there was
concern voiced in various quarters, not least by
Prince Charles, and Michael Crichton’s book, and I
think we managed to handle that pretty well, by
putting together a committee that consulted and met
with many of the concerned people and sketched
some of the credible worries, and so on, and possible
4 It is nanosized in one direction only, as are nanoclays.
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regulatory things to do. So that we have not had any
fuss about it because we have learnt, at least, some of
the lessons of GM foods. However, I am not myself
at all convinced that that will persist once you have
the particularly sensitive issue of putting what some
people would feel are worrying things into food. I am
a little surprised that none of you share this worry.
Professor Morris: I think the worry is about what is
available on the internet which is not regulated. One
of the things that would be useful is if the ﬁrst
products that come from large, multinationals have
really demonstrable good health beneﬁts, or good
beneﬁts to people. With GM, the beneﬁts did not
seem to outweigh the risks that people were
concerned about. At the moment, some of the
products you can buy over the internet seem fairly
trivial and the beneﬁts in using those seem almost
non-existent.
Q115 Lord May of Oxford:Myown personal view is
that the answer to this is to have products that people
want to buy, so that they can see a beneﬁt and they
can weigh that against the risk. What happened with
GM is that the ﬁrst wave of products was not oVering
beneﬁts of a manifest kind to the consumer. I would
hope that in the food industry the ﬁrst wave of
products would be for things that oVer clear beneﬁts
to the consumer rather than to the food business. I
wonder whether you share that. Do you have any
thoughts about what to do about that?
Professor Morris: I agree with that. Certainly in terms
of healthier foods and foods that provide protection,
I think those are things that people can see a real
beneﬁt for. The trouble is that to do that science, it is
not concerned about risk it is simply about doing the
science to understand how tomanipulate these things
using conventional processes. I think that is just
taking time and while that is happening lots of trivial
products are appearing on the internet, and I think
that is the problem.
Dr Kampers: One of the problems, as was addressed
earlier, also, is that the industry is very, very reluctant
to communicate that they are using nanotechnology
in food. It is not that they are not willing to share the
knowledge with their competitors; it is because they
are very much afraid of the reaction of the consumer
to the product.
Q116 Lord May of Oxford: That is surely a mistake?
Dr Kampers: Yes, sure, but I cannot help it. We try to
communicate—
Ms Groves: Who is going to put their head above the
barrier ﬁrst?Which company is going to risk going to
the wall?
Dr Kampers: The eVect is that nobody tells anybody
that nanotechnology is used, so the beneﬁts of the
product are not associated with the nanotechnology
used; the beneﬁts are claimed to the product. So the
wider public cannot distinguish between beneﬁts that
are generated by this new technology and will not
learn to appreciate the technology in this way. So that
is one of the reasons why labelling might have a
beneﬁcial eVect on this.
Ms Groves: Coming back to your question on
research funding, generally, in the years that I have
been in science, research funding has gone from quite
generous funding in the food industry to being very
speciﬁc, and anything which was near-market or was
in any way commercial would not be funded by
government. Maybe there is now a point for
discussion where you could actually say there should
be some government funding, linked with food
industry funding, to make open research into the
sorts of nanotechnologies in food product
development.
Q117 Baroness O’Neill of Bengarve: Is there any
research going on into this question of identifying
those nanoparticles (inorganic nanoparticles, I
understand) which might be the area of risk, and,
also, conversely, identifying where the areas of
relatively low-risk are? Is that research something
that is being done behind closed doors and in a non-
co-ordinated way?
Dr Kampers: There is a project by the OECD at the
moment going on where they look at diVerent kinds
of nanoparticles, and this is the ﬁrst initiative to co-
ordinate this kind of research. What I am always
saying is very many people, research institutes, are
doing research on the toxicology of more sexy
particles, like carbon nanotubes and things like that,
and there are few people looking at the toxicity of
particles that are less applicable or less sexy. There is
really a need for more co-ordination in this area.
There is research going on looking at what kind of
properties will inﬂuence the risk of particles. For
instance, I know of research in the US where they
look at particles that are used in the bloodstream for
medical purposes and where there are four
parameters that are seen as crucial in determining
whether the particle is in a hot zone or in a relatively
safe zone. So there is research going on and we are
making progress but, as I said, it is a very complicated
issue and then there are many aspects to that. So we
really need to do more in this area.
Q118 Earl of Selborne: I would like to follow up the
line of thought that you have been developing as to
what extent UK public funding of research in this
area might contribute to this international need. I
thinkDrKampers reminded us that this is too big for
one country, that we lack data and that there is an
urgent need to get this data on risk assessment and
hazard assessment, particularly to head oV any
public concern which may well be coming at us. First
of all, my question is: are we pulling our weight
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already? Leatherhead say, in their evidence, that we
are under-funded in this area, and we have heard
from Holland that you have, in Holland, a ƒ40
million programme with 50 per cent funded by—
Dr Kampers: It is only the food part of the
programme. There is also a risk theme, so there is also
ƒ20 million going into risk research.
Q119 Earl of Selborne: That is over and above the
ƒ40 million?
Dr Kampers:That is on top of that. Food is one of the
10 themes and risk is also one of the 10 themes in that
programme.
Q120 Earl of Selborne: Perhaps I could ask our
witnesses from the UK as to where we ﬁt into the
scheme of things at the European level. Arewe able to
pull our weight? Are we contributing to these, clearly,
European level programmes that you have identiﬁed
as needing to be undertaken?
Ms Groves: In terms of gut health, there is
considerable funding. In terms of real products and
foods there is very little.
Q121 Earl of Selborne: So are youmaking a plea that
the government funding (research council funding in
the main, we are talking about and departmental
funding) should be directed to this area of hazard
assessment, risk assessment and determination of
what happens to these nanoproducts in the human
body?
Ms Groves: I think you have to, again, make the
distinction between persistent, non-digestible
products, particles, and other normal foods—normal
manufactured foods—which may well be enclosed or
packaged ormadewith nanotechnologies, in terms of
research into toxicity.
Professor Morris: I think the diYculty is that those
particles are very unlikely to be added directly into
food. So it is a big problem in understanding what
would happen to those particles if they got into the
body, particularly in the food matrix, and how they
would interact with things like gut bacteria. There is
a lot of information in the environmental ﬁeld on
how they aVect bacteria, but when you are talking
about aerobic and anaerobic conditions they are very
diVerent. You need a lot of understanding of the risk
associatedwith those particles, and their applications
in the food industry are going to be very small. They
are very expensive and there is very little reason why
you would want to introduce them.
Dr Butler: I think it is going to be in health and
medicine that there is going to be a major application
of nanoparticles, and that is, of course, going to bring
this whole issue about interaction with the body into
sharp focus. I agree with colleagues that the food side
is going to be relatively small, and I still go back to
what I originally said, that in many instances
nanotechnology is an enabling technology, and
nanoparticles are used to create something—to
devise a system—and that something that you have
created is totally benign because the properties of the
nanoparticles are now no longer what they were at
the beginning. That is what we do not really
understand: when you have got this brand new
functionality and brand new properties, what does it
mean to various sectors? It is security, it is
information technology, it is energy and it is
construction, including food, but there are many,
many sectors and application areas where using
nanotechnology to make things is going to be
terriﬁcally important.
Q122 Earl of Selborne: Would you give your
thoughts as to what role the United Kingdom’s
research communities should be playing in
addressing these issues?
Dr Butler: I think printed electronics, to me, which
underpins many of these industrial sectors, is
terriﬁcally important. In other words, the ability to
print a two-dimensional, ﬂexible, electronic display,
or battery-powered sensor, whatever it might be—it
could be an e-book, or an e-newspaper that
constantly updates, for example, when you are on the
tube or it could be a smart package on a food—that
uses nanotechnology as an enabling technology for
printed electronic displays, sensors or batteries, all
printed at high speed, roll-to-roll printing. That is an
area that the UK is a little active in but, in my view,
needs to bemore active. So it is using nanotechnology
but the result is printed electronics, and then the
applications are in a number of ﬁelds, which include
things like alternative energy, for example—solar. If
you can print solar cells then you will get much more
dramatic properties using nanoparticles. Having
printed the solar cell it is now completely safe and
benign.
Q123 Earl of Selborne: Where within the European
Union would you expect the most progress in this
area to be made?
Dr Kampers: May I comment on your ﬁrst question
ﬁrst? Obviously, we made a diVerent choice. We are
doing research and we would like to know about the
kinetics and the dynamics of nanoparticles in the
gastrointestinal tract, because we see that worldwide
there is very little attention to these persistent
nanoparticles in the gastrointestinal tract and the
oral route. There is a lot on inhalation toxicology,
also the skin is researched for certain particles, but
there is very little known about the oral route. We
have decided, within the Netherlands, that since we
are looking at applications of nanotechnologies in
food it is also our obligation to know what might be
the risks of these applications. Also, we do not want
to wait until somebody, somewhere in the world,
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starts with an application of some kind of
nanoparticles in a food product and it comes on
somewhere in the market or it can be bought on the
internet; we would like to knowwhat kind of risks are
associated with these kinds of applications of
nanotechnology. Although, at the moment, there is
very little of these applications known, there are very
few persistent nanoparticles in food products at the
moment. But we cannot rule out that there might be,
in the future, somebody who wants to put
nanoparticles in food. In the Far East we already
know that there are companies that, for instance, add
nanoplatinum to food products because they think it
is beneﬁcial. As I said, in the Netherlands we would
like to know what kind of risks are associated with
these kinds of applications, from a generic point of
view, so that we can distinguish between things that
have low risk and things that have high risk, so that
we can focus in the ﬁrst instance on these high risk
applications.
Q124 Chairman: Can I come back and seek a bit of
clariﬁcation, because we have had two written
submissions? On the one hand, the Institute of Food
Research, from which Professor Morris hails says:
“The UK has played a leading role world-wide in
developing a nanoscience understanding of food
structure and materials . . . ”, and the Leatherhead,
from which Kathy Groves hails, says: “There is very
little research and development within the UK
regarding nanotechnology within the food and drink
industry.” Those two statements seem to me to be, at
one level, almost contradictory. I wondered which
one is correct, or are they diVerent slants on the same
position?
Professor Morris: I assume they are, possibly, diVerent
slants. When we are talking about what has been
done in the UK we are talking about the
understanding of actual food structure itself, the food
matrix, its functionality and how to process it.We are
one of the world leaders in that respect.
Q125 Chairman: Are you saying that, as so often
happens in the UK, the basic research is being done
but the translation of research into products and
beneﬁts is being done elsewhere?
Professor Morris: I think that probably needs
qualifying. I think it is being done in major
companies like ICI andUnilever, but they do not talk
about it, at the moment. It is a fear of public
perception of nanotechnology.Who is going to be the
ﬁrst person to bring these products on to the market?
Q126 Chairman: As Lord May has said, it does not
make any sense to do it and keep it a secret because
eventually you are going to have to divulge that it is
going on.
Professor Morris: I think there is a real concern within
companies that people ﬁnd out they are using what
somebody might call nanotechnology when, in fact,
they are using nanoscience; they are trying to
understand the foods and through that
understanding they will produce products using
conventional technologies, and then they can talk
about those products and sell the beneﬁts without the
associated risk. They are not really nanoproducts;
they are conventionally processed products but they
are done in a rational way.
Q127 Lord Methuen: What mechanisms are in place
for companies, academia and the Government to
share information on new developments in this ﬁeld?
Is this limited by IPR considerations?
Ms Groves: Well, there is the NanoKTN centre set up
by the Government and the Technology Strategy
Board, and Leatherhead does play a role in linking
universities to industry. I do not think there are many
structures in place designed to do that.
Q128 Lord Methuen: How much involvement is
there with academia?
Ms Groves:A limited amount, but only limited by the
amount of time you have in your life and the number
of resources or people that can liaise between
industry and academia. Sometimes industry will go
to universities directly, but there is a need, I think, for
an interpreter between universities and industry, to be
honest, because fundamental research on food is a
long way oV what will happen in the manufacturing
process. So there are companies like Leatherhead
which are good at being able tomake that connection
between the two.
Professor Morris: I think there is an eVort to try and
correlate all the safety data and the toxicity data; the
FSA and the Central Science Laboratory are trying
to build up databases, and that sort of information is
freely available.
Q129 Lord Methuen:Would it be true to say that this
is not a subject which tends to interest universities—
it is not sexy enough?
Professor Morris: Which—the food or complexity?
Q130 Lord Methuen:This type of research into food.
It seems to be more into industry rather than
academia.
Dr Kampers: Not in the Netherlands.
Ms Groves: I think in the UK it is.
Professor Morris: There have been very good
universities in the past—the University of Leeds, the
University of Nottingham, and Unilever Research,
Colworth where there was almost a university kind of
atmosphere, which were doing very fundamental
research and published it, on food structure and how
to manipulate it, at that sort of scale. There has been
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academic research on manipulating the
nanostructures in food, and it is published and is
available.
Q131 Chairman: You talk about it in the past tense.
Professor Morris: It is still being done. I think, in the
past, it was simply trying to understand the food
structure in terms of understanding the functionality
of foods—how you can make foods last longer or
more attractive to eat. Now it is more about what
happens to that food when you digest it, how it is
broken down by the body and how you can
manipulate those structures to control that
breakdown. It comes back to this idea about
controlling fat; if you canmake a full-fat product but
you can slow down the breakdown of the fat, then
you can actually make people think that they have
eaten enough, so the next time they eat the food they
will eat less of it. You can try in a rational way now,
from past understanding, to try and do those sorts of
processes. Certainly, in the lab, on an in-vitro scale it
works. You can change food structure and control
lipolysis and you can do it at a suYcient rate to
actually expect to create hormonal change.
Q132 Chairman: Is any research done in-vivo or is it
all in-vitro?
Professor Morris: It is starting to be done. We have
contacts across Europe, particularly in countries like
Finland, where we are starting to do human trials on
those types of food. Thatwork is starting to occur but
it is quite diYcult because translating the science on
interfaces on to emulsions—what happens to
emulsions when you process it on a large scale and
then eat it—is quite diYcult. That is why it takes a
long time to translate it into practice.
Q133 Baroness O’Neill of Bengarve: You have
spoken about the universities doing research that is
published and open, and you have also spoken about
the companies doing research that is, I take it, not
published and not open. That is a pretty unstable
situation, in some ways, if it is to end up as consumer
products. What would you see as a useful thing that
this Committee could recommend that would move
things forward in terms of co-ordination? An
alternative thought: if you were making a pitch to the
Technology Strategy Board to put more resource into
the development of research on the use of
nanotechnologies in food, what would you say to
them?
Ms Groves: I think there is a need for a pre-
competitive area of research which is publicly funded
with full, open information to the public that the
industry are willing to participate in. It has got to be
close enough to their drivers and to their products for
them to realise the beneﬁt and the need for doing it.
Also, it has got to be far enough away, if you like, so
they can take their IP, their whole ownership of the
ﬁnal development. Ultimately, I am not sure if you
are asking should we control the food industry far
more in terms of what they produce.
Baroness O’Neill of Bengarve: I was thinking of
empowering rather than controlling.
Lord O’Neill of Clackmannan: Commercial research
is done not for philanthropic or blue skies reasons, it
is done for proﬁt, and it is trying to reconcile these
two, what appear to be, conﬂicting objectives. If the
Unilevers of this world can get an edge over their
competitors they are not going to share it in the
interests of humanity, in general, because they have
shareholders who have a higher priority.
Q134 Baroness Neuberger: Are we not hearing, also,
that there is a rather diVerent attitude in Holland,
from what we are seeing in the UK? Clearly, the
companies keep their secrets, as it were, close to their
chest, but there is a greater emphasis on doing more
general research, if I understood you rightly, Dr
Kampers.
Dr Kampers: Yes. Also, in the Netherlands, it is true
that, for economic reasons, of course, you keep
results conﬁdential, at a certain point in time. It is a
continuum from pre-competitive research towards
application-driven research, and somewhere we meet
each other and we are trying to ﬁnd ways of
exchanging the results in such a way that we are
bridging the knowledge gap—which is not typical to
the UK; it is there everywhere. So methods of
bridging the knowledge gap are very important, so
results are applied in the industry and the economics
start to work and we start making money with these
results. Because if we do not make money we do not
earn the money to do the research for the next
generation of applications, of course. We are looking
at things like, as I explained, these other research
initiatives in Holland where we participate with the
industry to make sure that results in academia are
used by the industry, because they also have invested
in these research projects. Also, we look at things like
setting up joint research centres where academia use
the infrastructure but, also, industry can use the
infrastructure, so that people meet up and start
discussing the possibilities of results while the
research is being done. These are ways of trying to
bridge this knowledge gap, but it is also there in the
Netherlands, I have to admit.
Ms Groves: In the Netherlands, my feeling is, there is
a better set up for linking universities to industry.
Going back to your point, yes, the industry is there to
make a proﬁt but it is then part of the economy, so it
is important that we have successful industries. The
universities are there to conduct fundamental
research but, also, to teach, and there is a need for
industry to link up with the universities far more
closely, but I do not think you can do that easily
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directly because they are operating to completely
diVerent goals and at completely diVerent levels.
Maybe one recommendation will be to have some
sort of set-up where you have an intermediary which
can understand how the industry works but, also, can
understand the fundamental science that the
universities produce, and merge the two together.
Q135 Lord Haskel: There is, of course, a third
element to this, and that is the regulator.
Ms Groves: I thought you were going to say “the
consumer” then.
Q136 Lord Haskel: Presumably, with so much
uncertainty around, and you have been telling us
about the uncertainty, what do you say to the
regulator? Howmuch information do you give to the
regulator about the work that companies are doing?
Dr Kampers: As much as possible. I think the role of
the regulator is very crucial in building trust with the
consumer. Regulatory bodies represent an objective
body to the consumer and they are generally regarded
as looking after the interests of the consumer. Having
regulation in place implies that somebody,
objectively, has assessed the risks of such products,
and that means that the consumer is more likely to
trust the claims and, also, the low risk of such
products. I would say having good regulation is
crucial to the acceptance of these technologies in
food, and therefore it is my vision that both academia
and industry should give as much information as
possible to these regulatory bodies in order to have
the right regulation in place at the right time.
Professor Morris: I think, also, when they are
regulated it should not just be on the risks and: “Is
this a safe product?” but what are the actual beneﬁts
of a product, what are the health claims and are they
viable claims?
Q137 Chairman: One of the points we have heard in
a previous session is the question of whether or not
foods incorporating nanotechnologies would require
regulation under the Novel Food regulations or
whether they would pass into public consumption
under more general, food safety regulations. I think
that we were not quite clear about the situation with
regard to diVerent nanotechnologies. I do not know
whether any of you have a view about that.
Ms Groves: I think part of the diYculty with
regulation is that you get into semantic arguments
about deﬁnitions rather than trying to look and see
whether something is actually safe or how you might
label it. So maybe there needs to be a change to the
nature of regulation, certainly for something as
complicated as nanotechnologies where you have to
look at a far wider spectrum of technologies and
applications.
Q138 Chairman: That is not the view of the
regulators themselves; the Food Standards Agency
told us that the current framework is adequate.
Ms Groves: I think it is adequate in terms of health
and of safety, but if you want to move on to regulate
nanotechnologies, it needs to be more than just
deﬁnitions.
Professor Morris: I think it may also need to co-
ordinate the diVerent parts of the regulation. If you
are talking about food packaging, there may be
concerns about whether a material can leak into a
food and perhaps be certain that that will not happen,
so it is safe in terms of its use in the food aspects, but
what happens to that material when it is thrown
away? That is an environmental issue, but it may be
a factor that is very important in whether people
want to use that sort of packaging. I think you need
to tie that use up over the lifetime of the product. It
could happen that with use of nanotechnology across
the agri-food chain, if you are thinking about
nanotechnology applications in spraying pesticides,
you may see the beneﬁts to the agricultural industry
but there is also the possibility of contamination or
detection of the material in food.
Q139 Baroness Neuberger:Moving on, and the large
question ﬁrst: is there a diVerence between using
manufactured nanoparticles and using natural
ingredients that have beenmodiﬁed at the nano scale?
Professor Morris: I think it comes down to the
question of material that is not broken down in the
body.
Q140 Baroness Neuberger: So with the persistent
ones there is a diVerence?
Professor Morris: I think so.
Q141 Baroness Neuberger: The diVerence being
mainly a diVerence in risk or a potential diVerence in
risk? Or a potential diVerence in hazard, maybe.
Professor Morris: I think it is a potential problem in
risk because you simply do not know how these
materials will be accumulated, where they will be
accumulated and what the consequences will be. I do
not think you can extrapolate that knowledge from
the size of particle.
Q142 Baroness Neuberger: Should we be making a
distinction for regulatory purposes between these
two types of nanoparticle?
Professor Morris: I think so, yes.
Ms Groves: I think so.
Professor Morris: If you are talking about labelling,
the only concern is I think the label ought to be for
materials that persist in the body and are not
broken down.
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Q143 Baroness Neuberger: Yes, this yoghurt with
nanoplatinum, which is not on the market in the EU,
I understand—has that been through any trials and is
that labelled?
Professor Morris: I have no idea.
Q144 Baroness Neuberger: Could we import it? Do
you think that the manufactured nanoparticles will
turn out to have a lot of applications in foods or will
their usefulness be quite limited?
Dr Kampers: The usefulness will be limited. In my
view there is very little sense in putting expensive
nanomaterials in a food that the body does not do
anything with. So its use is very limited, but there are
examples where there is improvement on the ﬂowing
characteristics of certain food products, and, also, as
a carrier for vitamins.
Q145 Baroness Neuberger: So there would be
applications in the food sector, and particularly the
packaging applications or the clean surface
applications, but much less in foods themselves?
Professor Morris: I think for the persistent ones, I
would imagine, there would be very little use at all,
but you can make nanoparticles that are broken
down in the body which act as carriers.
Q146 Baroness Neuberger: Do you think that a
single regulatory system should be used for health
and safety purposes, or is that asking too much?
Professor Morris: I would like to see any regulation of
particles emphasising the health beneﬁts as well as
considering the risk. At the moment, the trouble is
you have a brand name, on the internet and it says:
“Nanosilver—wonderful, marvellous”, but if you
actually had some sort of brandwhere you used those
particles which said: “This does give you health
beneﬁts but there is no perceptible risk that you can
detect”, I think that would be an advantage. If there
was some sort of voluntary labelling of where people
use nanotechnology, that might be an advantage, but
I can see the objections to its use.
Q147 Chairman: Can I ask a bit more about your
view on the regulatory process? You drew this
distinction between persistent nanoparticles and
things that are not persistent in the body. Earlier on,
we heard from Dr Butler that the key point was
whether or not the properties of a material change as
it approaches the nano scale (he gave a graphic
example of the properties of silver, which is a nice
example). I just wondered, within the regulatory
system, do you think that the regulation should look
at the total exposure to all kinds of nanoparticles over
a period of time? The temptation would be to look at
each food type or each application independently and
give approval to something on an independent risk
assessment for that particular product, but as far as
the consumer is concerned, he or she may be eating
10, 20 or 50 diVerent products as we roll forward in
time, each of which has been separately approved but
their exposure is as a result of an interaction and
accumulation of all these diVerent products. What is
your view about how that should be tackled in the
regulatory system?
Professor Morris: I think there are two aspects. One is,
again, particles that are not broken down, but, again,
I would have thought that is something that is going
to be fairly rare in the food industry. Certainly if you
are using nanocarriers then what you are trying to do
is to enhance the delivery of something, and ideally
what you would want to do is optimise it and, hence,
you have lots of products that are enhancing the
delivery of something and you could end up having
too much of it, and that would be as bad as having
too little. So by having lots and lots of products that,
say, enhance the delivery of vitamins, you could
actually have a problem due to an over-consumption
of those materials. Again, it may come back to not so
much labelling but a recommendation that this gives
you a certain percentage of your daily intake of that
product, and at least then people are aware that if
they take more of that there could be problems.
Q148 Chairman: That is placing quite a lot of
expectation on the consumer to keep track of how
much they are getting from diVerent products.
Professor Morris: I think the problem is that if you do
enhance delivery then you have to think about the
consequences. Particularly if it is an orange juice, say,
and you are enhancing the delivery of a vitamin,
people might want to drink the same amount of the
orange juice when they probably ought to drink a
tenth. They have no way of knowing what their
delivery is or what the optimum level of intake is.
People do accept now labelling that says: “This
product will give you one-tenth of your expected
amount of that compound in a day”. I think that
would be acceptable.
Dr Kampers: In my view it is a product development
issue. It is not typical to nanotechnology because
nanotechnology is used as a technology to enhance
the delivery. But I think when you develop a product
that delivers more of a speciﬁc nutrient then you have
to realise that this accumulation of diVerent products
can take place. So, in my view, it is the responsibility
of the company that developed this product, to make
sure that there are safeguards that people do not get
too much of a nutrient in some way. So it is a product
development issue more than a nanotechnology
issue, in my view.
Q149 Baroness Neuberger:You have already said, to
some extent, that we get into terrible deﬁnitional
problems with this, but would you be able to have a
go at deﬁning nanotechnologies and nanomaterials
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in the context of the food sector speciﬁcally? I realise
that Ms Groves, particularly, has already raised your
eyebrows about this. I know it is hard.
Ms Groves: It is very diYcult. My instinctive reply is
to say that nanotechnologies are technologies which
allow you to manufacture or structure particles at a
nano scale—so less than 100 nanometres.
Nanoparticles and nanomaterials could very well be
large structures made up of nanoparticles. It is very,
very diYcult (and a lot of nanotechnologies are still
very much emerging; they are still at the developing
stage) to deﬁne them, other than by saying they
produce nanoparticles. Then I do know that there are
products, not in the food area, which use
nanotechnology to create nano-sized particles less
than 100 nanometres which then become larger
particles (in a sense, that is what you have in the
packaging) and, therefore, are not a risk in terms of
their size. So you do get into: do you label those as a
nanotechnology when, in fact, they are completely
locked into a much larger structure? I am sorry, that
is a scientist’s answer.
Q150 Baroness Neuberger: I think that is one of our
diYculties in looking at some of that. You have all
made it very clear that you think we should, in a
sense, worry more about things that remain in some
sense in the body and are not broken down rather
than whether something is a manufactured
nanoparticle or something that is a natural
ingredient. Going back to the regulatory theme, how
would you distinguish that? How would you state
that in terms of a regulatory environment?
Professor Morris: You mean: how do you deﬁne—
Q151 Baroness Neuberger: Yes.
Professor Morris: I think with persistent particles it is
fairly easy to deﬁne what are nanoparticles; it is when
its properties change—for example, when titanium
changes its transparency. So there I think you can say
these are particles where they have been reduced in
size and their properties have changed; they are being
put into food packaging or they could be put into
food because they give new properties.
Q152 Baroness Neuberger: You think there it is
really easy?
Professor Morris: Yes. I think when you are talking
about manipulating structures in food that are
naturally there it is nanoscience, but the actual
technology may be a conventional technology, which
you understand.
Dr Kampers: If you boil an egg you will change the
nanostructure of the egg. How much change can you
allow to call it nanotechnology? It is a very diYcult
issue. On the other hand, it is not diYcult because the
ISO deﬁnition of nanotechnology and the OECD
deﬁnition of nanotechnology are fairly good
deﬁnitions; it is just that they are virtually useless
from a regulatory point of view, and that is the issue.
So the diYculty is in ﬁnding a deﬁnition that can
stand up in a court of law, that provides you with
sound criteria to classify whether something is
nanotechnology or not. In my view, one of the
solutions could be that you look not at the size but at
the new functionality which has been created by
exploiting nanoproperties. Then you could say that
“this is a nanomaterial”. If there is new functionality
created by man, by using nanotechnology or
nanostructured materials, then you have a
nanomaterial.
Q153 Baroness Neuberger: Would you argue that
that should be applied across all sectors or was that
purely, would you say, in the food industry?
Dr Kampers: No, it should be applied to all sectors.
Professor Morris: I think there is an example of a
natural nanoparticle where people have taken
enzymes, which you can think of as natural particles,
and modiﬁed their functionality. Then they would
have to go to conventional trials if they were used in
food. The diVerence there is themethodology and the
procedures are well established to test whether those
materials are safe, whereas with an engineered
persistent material the methods are not there to
assess it.
Q154 Chairman: Before we draw to a close (and I
would like to give you a chance to make any other
points you would like to make), I want to go back to
an earlier question which Lord May asked about the
timeline, because we are hearing, at the moment,
some fairly mixed messages about what is available
now, what is likely to be available in two to ﬁve years’
time, and beyond. Recognising that it is always
diYcult to predict what is going to happen,
particularly when it is in the future, what I have
understood is that at the moment, as we speak, there
are applications of nanotechnology in the broad
sense in the food industry. We have heard about the
nanoclay ﬁlms that are used in beer bottles, for
example, andwe have heard about themetallised ﬁlm
in potato crisp packets that involve nanotechnology,
and we were told in a seminar about fridges that are
on the market with nanosilver linings, and I know
from one of the submissions we had from a
government department that there are 17 products on
the market in Germany in which nanotechnology is
used to encapsulate food products. These are mainly
in the food supplements industry. So there are things
going on now, and obviously with the internet there
are things that you could buy in this country whether
or not they are manufactured in this country. So that
is my understanding of where we are now, and I
would like to ask whether that is your understanding
of where we are now. Perhaps you could be a bit more
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explicit about where you think wewill be, say, in three
to ﬁve years’ time. Will we be in about the same place
or will things have changed dramatically, in your
judgment?
Professor Morris: I think in ﬁve to ten years’ time there
is a real prospect that nanoscience understanding of
foods will have generated a range of new foods that
have health beneﬁts or protection against disease,
improving lifestyle into old age. I think that is a real
possibility. They will be prepared by conventional
technology through an understanding of how to do
it.
Dr Kampers: I sometimes compare nanotechnology
in general—not in food—to electricity; we are at the
stage now that we know how to make a light bulb, a
resistor and a coil, but we are in no way at the level
that we can build a radio or a computer. The
technology is very generic and thatmakes it very, very
diYcult to extrapolate into the future. However, if we
look atwhat is happening now in food, I agree, within
ﬁve to ten years’ time we will see improvements in
food safety, monitoring, we will see improvements in
the sustainability of certain processes that are
important to the food industry, we will see better
packaging materials and increased shelf life,
especially for fresh products, and wewill see products
that deliver speciﬁc nutrients to individuals. What we
see in the further future is that we have to link up to
the needs of the body—basically, the biochemistry of
the body—and then deliver the right nutrients, and
that is something that is much further on and is a very
complex issue but, also, will require nanotechnology
to deliver that part of the delivery end.
Dr Butler: In packaging, as Dr Kampers has just
mentioned, I think we will have much more
communicative packaging that will allow consumers
to manage their food inventory better so that there
will be less food waste, for example; there should be
less examples of sicknesses from food-borne bacteria
because there will be things like freshness indicators
on packaging, ripeness indicators on packaging—
ripeness indicators on fruit, for example, because we
all know sometimes it is extremely diYcult to tell
whether a pear or a melon is ripe or an avocado is
ripe. So I think there will be advances of that kind,
and convenience and functionality, that will be
underpinned by nanotechnology.
Ms Groves: I think your assessment of the state of it
at the moment is right. Packaging was the ﬁrst area
that really developed nanotechnology for foods, and
I think that will carry on. What Paul says is correct,
too; I think we will be able to accurately judge
whether packaged food really has gone past its safe
use-by date or whether you can actually use it, or say:
“That date has gone” and it goes into the tip. In the
short term I think there will be developments and
understanding of what happens in the gut which will
lead to healthier foods, and there will probably be
more food supplements out there on the internet
available for people. I think, probably, the next step-
change will be taking the properties of packaging
surfaces into the manufacturing and food
preparation area, to make eYciencies and waste
savings there and, also, make safer areas. Long term,
I think, the idea of looking at manufacturing
processes and how you structure foods to make them
healthier or safer, because we are looking at
nanotechnology, will develop better, more stable
products.
Chairman: Thank you very much. Are there any
additional comments that any of you would like to
make before we close the session?
Lord May of Oxford: I cannot resist remarking that
there was an obese character called HermanKahn 50
years ago who coined the word “futurology”, and I
think, also, the phrase “mutually assured
destruction”. He prepared a list of the 50 great
challenges confronting humanity, and in the top ten
was a pill to control appetite; somewhere around 28
was worries about population growth, and I am
reassured to see that maybe we are, at least, in that
direction and moving.
Chairman: On that cheerful note, I draw the session
to a close and thank our four witnesses for their help
in exploring the issues that we have put to you today.
Thank you very much for answering our questions.
Copies of the transcript will be sent to you for
correction before it is ﬁnalised, and of course if there
are any points which you would like to follow up by
writing to us we always very much welcome any
additional comments in writing which will help us in
our deliberations later on. Written material is
published alongside the transcript, so you can add to
our work in that way. Thank you all very much
indeed.
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Memorandum by the Food and Drink Federation
1. General Introduction and FDF Position
1.1 The Food andDrink Federation (FDF) is the leading representative of the food and drink manufacturing
industry in the UK. A brief summary of the industry and organisations we represent is attached as an Annex.
1.2 FDF has been studying nanotechnology and the implications for our industry sector for several years. We
support the use of nanotechnology as a general enabling technology with widespread industrial applications.
We believe there is a need for adequate safety assessment in all applications of nanotechnologies, where their
application gives rise to changes in existing products or processes, such that a new assessment of any risks to
human health or the environment may be required. We believe that it is possible to adapt the existing
regulatory system to deal with new scientiﬁc evidence on engineered nanoparticles as necessary.
1.3 According to our knowledge to date, FDF is of the view that direct applications of nanotechnologies in
food appear limited, though there is interest at ingredient level, particularly in delivery systems, and interest
in potential indirect applications in, for example, packaging, processing applications and food safety.We know
of no food products or processes currently on the market in the UK which use nanotechnologies within the
working deﬁnition which is generally applied.1 To the best of our knowledge, interest in nanotechnologies
within our membership is still at the research stage, though we understand that some applications are near
market and beginning to enter the European market, such as packaging materials containing silver
nanoparticles.
1.4 The food and drink manufacturing industry is very sensitive to the need for consumer acceptability of its
products and is innately conservative in the application of new technologies to food. That said, our industry
strives to innovate and improve products to meet consumer demand and expectations and is under pressure
to reformulate to meet the needs of a changing population in a rapidly changing global environment. It is
therefore important that we are able to make the best use of all the tools available to meet the challenges of
innovation and competitiveness against a background of limited resources and the pressures of a global
economy.
1.5 FDF has sought involvement in dialogue at all levels to enhance our knowledge and understanding of
nanotechnologies and to inform our membership, where they are not directly or actively engaged in R & D in
this area, and act on their behalf in national and European fora. As such we are represented on a task force
established by our European Confederation, CIAA; on the BSI NTI/1 Committee; Leatherhead Food
International’s Nanotechnology Forum; we are aYliate members of the Nanotechnology Industries
Association; and are involved in public dialogue through CIAA and the Responsible Nano Forum.
1 In the absence of international agreement on a deﬁnition, we use the generally adopted measure of 1-100nm in any one dimension to
describe nanoparticles. The recently published SCENIHR report ((Scientiﬁc Committee on Emerging and Newly Identiﬁed Health
Risks), Risk assessment of products of nanotechnologies, 19 January 2009) describes and characterises nanomaterials, and the Czech
Presidency has suggested a deﬁnition for inclusion in the proposal to amend the novel foods Regulation as follows: “‘nanomaterial’
means any intentionally engineered material that has one or more dimensions of the order of 100 nm or less or is composed of discrete
functional parts, either internally or at the surface, many of which have one or more dimensions of the order of 100 nm or less, including
structures, agglomerates or aggregates, which may have a size above the order of 100 nm but retain properties that are characteristic to
the nanoscale. Properties that are characteristic to the nanoscale include: (i) those related to the large speciﬁc surface area of the materials
considered and/or (ii) speciﬁc physico-chemical properties”
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2. State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
2.1 Areas of interest include direct application in food, eg nano-encapsulation of ﬂavourings and other
ingredients; packaging applications, eg nano-coatings and barriers, “intelligent” packagingwhichwill indicate
the safety status of the enclosed food, improved printing inks; cleaning applications and equipment in
processing facilities; diagnostics and process technologies, such as novel ﬁltration and other separation
technologies such as nano-sieves. The ability to understand and manipulate particles at the nanoscale is also
opening up potential applications to improve foods in a conventional way through enhanced application of
food technology. Such applications oVer a number of beneﬁts. For example, nano-encapsulation oVers the
ability to deliver smaller quantities of ingredients in a way that maintains ﬂavour and texture properties of the
food whilst reducing the content of ingredients that consumers are encouraged to eat less, such as salt and fats.
Ingredients such as ﬂavourings andmicronutrients could also be protected until ready for release into the food,
thus maintaining the quality of the ingredient for longer shelf life. Packaging could provide a quick and easy
indication of whether or not the food inside is still microbiologically safe, for example by changing colour, or
extend shelf-life through better oxygen barriers. The application of special coatings could enhance the use of
modiﬁed atmosphere packaging through better control of the gases and moisture which aVect the product,
reducing spoilage and waste. Silver is a natural antimicrobial, and at the nanoscale is already in use in
refrigerators and food containers in some countries, and has applications in food packaging.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
2.2 We know of no food products currently on the market produced by companies within our membership
that either contain, are packaged in, or have used nanotechnologies in their production. We are aware of a
small number of products on the market in the UK and elsewhere in the EUwhich are, or claim to be, “nano”,
such as a beer bottle which uses clay nanoparticles as a gas barrier; a food supplement using a nano-
encapsulated ingredient; various food ingredients such as theminerals calcium,magnesium and silicon dioxide
which claim to be of the nanoscale for improved absorption. These are understood to be in use mainly in the
sports, health food and supplements sectors. There are also developments in oil-in-water and water-in-oil
emulsions through the use of micelles, which can encapsulate ingredients such as omega-3 ﬁsh oils and deliver
them in products without the ﬁshy taste to provide a health beneﬁt. Such applications are already understood
to be in use in some parts of the world. EFSA has recently undertaken risk assessments on certain
nanomaterials, for example Titanium nitride, in nanoparticle form, for use as a nano-coating in PET bottles,
was recently assessed by EFSA as being of no toxicological concern.2 We assume from such applications to
EFSA for safety opinions that there are proposals to market the products in Europe.
2.3 We do not consider as nanotechnology applications the natural occurrence of nanoparticles such as in
protein, fat or sugar molecules, or their presence through conventional processing techniques, such as milling,
homogenising and emulsifying. Nor would we consider the ability to understand and manipulate particles at
the nanoscale to fall within the deﬁnition of nanotechnology applications, unless particle size has been
deliberately engineered to behave diVerently to its conventional counterpart. There are, however, grey areas
in interpretation in the absence of an agreed deﬁnition and characterisation of nanomaterials.
2.4 At processing stage, nanosensors could lead to improved quality control and testing along the production
and supply chain, indicating any breaks in optimum refrigeration, for example. Higher up the chain, sensors
could be used at agricultural stages to monitor pest control and regulate the use of fertilisers and pesticides,
minimising inputs according to conditions.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
2.5 FDF is not aware of applications beyond the general areas mentioned above, though we would not rule
out the possibility of exciting developments which we cannot yet foresee. There may be developments at
research level which could be of potential future interest to the food industry. As with any new technology,
developments are proceeding apace and many research applications are subject to commercial conﬁdentiality.
2 EFSA Scientiﬁc opinion of the Panel on food contact materials, enzymes, ﬂavourings and processing aids (CEF) on 21st list of
substances for food contact materials. The EFSA Journal (2008) 888–890, 1–14.
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What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
2.6 FDFand itsmembers are closely connected to the research community and academia but as amembership
organisation, we are not directly involved in research activities. Some of our members are linked to science-
based organisations involved in research. We believe the UK to be at the cutting edge of R & D in
nanotechnologies in general, though applications in food, food production and food packaging are currently
limited by comparison with applications in other industry sectors.
What are the barriers to the development of new nano-products or processes in the food sector?
2.7 Consumer acceptability is clearly a pre-requisite for any application of nanotechnology in or around food.
Consumers tend to be distrustful of new technologies applied to food and drinkmanufacture, especially if they
ﬁnd the technology diYcult to understand or react to alarmist media coverage. What might be considered of
beneﬁt in other consumer goods such as electronic equipment or mobile telephones, or in pharmaceuticals and
medical applications, may not be appreciated in food.Whilst FDF andmany of its members and counterparts
elsewhere in Europe are actively engaging in stakeholder dialogues, there is a clear distrust of the industry and
in some quarters what appears to be deliberate scaremongering. There is also a degree of “hype” that makes
it diYcult to distinguish between genuine and new applications of nanotechnologies and marketing eVorts to
make a product more interesting by advertising it as “nano”. For this reason we are advocating transparency
throughout the supply chain so that food and drink manufacturers are adequately informed by their upstream
ingredients and packaging suppliers about any applications of nanotechnologies in the products they
purchase.
2.8 The other major hurdles are regulatory procedures and the immense costs of bringing new products to
market, which might be regarded as prohibitive to all but the largest producers. In addition to R & D costs,
the time and resource needed to develop a submission for regulatory approval are signiﬁcant. Timings are also
lengthy in the EU and can add signiﬁcantly to the timescale of bringing a new product to market by
comparison with other areas of the world such as the USA or Australia. Recently adopted legislation on food
additives and ﬂavouringsmay improve timescales, and current negotiations on a recast novel foodsRegulation
may centralise and accelerate approval procedures, but we have yet to see this in practice.
3. Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials in the food sector? In which areas does our understanding need to be developed?
3.1 The recently published SCENIHR Report3 and EFSA opinion4 set out the areas of uncertainty
regarding toxicology and potential new risks associated with articles at the nanoscale. EFSA’s opinion, the
draft on which we commented via CIAA, our European Confederation, considers current toxicity-testing
approaches used for conventional materials to be suitable as a starting point for risk assessment for engineered
nanomaterials (ENMs). This provides helpful guidance to industry. With new regulatory texts already setting
out requirements for assessment of new particle sizes, industry needs clear terms of reference and guidance on
the expectations from approval packages if innovative products are to be brought to the European market.
EFSA also notes the absence of reliable and cost-eVective methods of measurement and detection of ENMs
in food and feed and recommends action to develop such methods to assess exposure in both humans and
animals, and to generate information on the toxicity of diVerent ENMs.We would add that such methods are
essential to industry to verify products and to comply with regulatory requirements.
3.2 FDF is also conscious of health and safety aspects of handling nanoparticles by our own workforce and
we are actively monitoring developments in risk assessment in this area, thus acting as responsible employers.
We applaud the work being undertaken by the Institute of Occupational Medicine, which we believe to be a
leader in the ﬁeld.
3 SCENIHR (Scientiﬁc Committee on Emerging andNewly Identiﬁed Health Risks), Risk assessment of products of nanotechnologies,
19 January 2009.
4 EFSA Scientiﬁc Opinion on a request from the European Commission on the Potential Risks Arising from Nanoscience and
nanotechnologies on Food and Feed Safety. The EFSA journal (2009) 958 , 1–39.
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Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the food sector
sufficient? Are current funding mechanisms fit for purpose?
3.3 We believe the research associations, Campden BRI and Leatherhead Food International, are best placed
to comment, though please see also our comments in paragraph 3.2 above. The EU has made a considerable
research investment, someƒ3.5 billion, into nanotechnologies, including the health and safety aspects of their
use, under the FP7 programme. The nanotechnology Knowledge Transfer Network (KTN) and International
Life Sciences Institute (ILSI) are active in this area. We would also refer the Committee to the response of the
BSI’s nanotechnology NTI/1 Committee concerning the need for funding of work on international standards
and metrology, which are basic tools for the practical application of nanotechnologies, as is an internationally
agreed deﬁnition.
Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to nanotechnologies
and nanomaterials for consumers? If not, what amendments are necessary?
3.4 FDF believes the SCENIHR and EFSA reports cited above have clearly set out the requirements in this
area. We acknowledge that there remain some unknowns and further research is needed.
Are the risks associated with the presence of naturally occurring nanomaterials in food products any different to those
relating to manufactured nanomaterials? Should both types of nanomaterials be treated the same for regulatory
purposes?
3.5 FDFdraws a clear distinction between naturally occurring nanoparticles and the presence of nanoparticles
in food from certain conventional processes, and nanoparticles or nanomaterials that have been deliberately
engineered to confer diVerent properties. The latter should be treated diVerently for regulatory purposes where
they confer novel properties and therefore might pose diVerent risks. FDF’s view is that food processing
technologies like emulsifying and homogenisation as well as processes based on colloidal properties with
particle sizes in the nanoscale range should be diVerentiated from the term nanotechnology unless deliberately
engineered nanoparticles are involved.
4. Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
4.1 EU food regulation is already very comprehensive. We consider the existing legislative framework to be
adequate or adaptable in all areas where nanotechnologies may be applied in food or food processing.
Regulatory gaps are being ﬁlled as speciﬁc regulatory texts come up for review (eg food additives, enzymes
and ﬂavourings, novel foods, food contact materials). FDF responded to this eVect to the Food Standards
Agency’s (FSA) regulatory review in 2006. The European Commission noted in its Communication on
Regulatory Aspects of Nanomaterials5 that “Overall, it can be concluded that current legislation covers to
a large extent risks in relation to nanomaterials and that risks can be dealt with under the current legislative
framework. However, current legislation may have to be modiﬁed in the light of new information becoming
available, for example as regards thresholds used in some legislation.” (Section 2, paragraph 4.) We concur
with this position.
4.2 Imports to the EU are subject to the same legislation as products produced within the EU. We cannot,
however, comment on the eVectiveness or otherwise of implementation and enforcement of the law on
imported products, particularly those traded via the internet.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
4.3 We believe the food and drink manufacturing industry behaves responsibly and would seek regulatory
approval for any product or process which was signiﬁcantly changed through the application of
nanotechnologies such that it diVered from the conventional product or process. We would question whether
self-regulation is even applicable: the European General Food Law, Regulation 178/2002, in any case places
an obligation on food business operators to ensure that any food product placed on the market is safe.
5 Communication from the commission to the European Parliament, the Council and the European Economic and Social Committee,
COM(2008) 366 ﬁnal, Brussels, 17.6.2008
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Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
4.4 We believe the regulatory framework will be able to adapt to meet any new requirements in view of the
general way in which the Regulations are cast. Any change in material speciﬁcation, eg for food additives,
would require a re-evaluation of the substance. The EU regulatory structure relies strongly on positive
approval, therefore newproducts and processes would not come tomarket unless the controlmechanismswere
in place. We believe that the products of nanotechnologies, used directly in food, already fall within the scope
of the existing EUNovel FoodsRegulation, and that recast regulation of food contactmaterials will also cover
packaging applications.
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
4.5 Dialogue is ongoing at several levels: EU institutions, EU and international standards bodies, trans-
Atlantic co-operation, OECD. There is also a project on EU/US regulatory convergence.
5. Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
5.1 We assume awareness in the general population to be low, except where interest is taken in developments
that have already come to market, such as in the area of sunscreens. The term “nano” has taken on a general
meaning of “very small” and is widely used in themarketing of many newer and smaller consumer goods, such
as mobile telephones and electronic devices. We have engaged with Which? in their public dialogue and are
actively involved with the Responsible Nano Forum, which is promoting public engagement. Through our
European Confederation, CIAA, we are involved in a stakeholder dialogue at EU level.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
5.2 Industry is involved in initiatives as above. This is a relatively new area of public engagement, as
developments are largely still at research phase. Previous experience with new technologies is that consumers
tend not to take an interest until products are on or near themarket, or awareness is raised through high proﬁle
campaigns or media coverage, often in a negative way. We are not aware of any speciﬁc Government initiative
to engage the public in dialogue. Which? and other NGOs such as Friends of the Earth have been at the
forefront.
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
5.3 Whatever attempts are made to engage the public, interest tends to be limited to those either with speciﬁc
issues or concerns or a strong opinion or viewpoint, whether or not based on factual information, or those
with a high level of interest in new technologies. Only when products actually come to market or media
headlines raise awareness in either a positive or negative way have we seen mass interest in the application of
new technologies in food. Our experience is that most consumers do not care, as long as the product looks and
tastes good and the price is right.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
5.4 Yes, provided this is done in a factual, objective and balanced way. In view of the many potential
applications of nanotechnologies in ﬁelds other than food and feed, information should be application-
speciﬁc. General references to “nanofoods” would be uninformative and unhelpful in terms of informing
consumers about the use of nanotechnologies in food, food packaging and food production.
The Committee would also be interested to hear about any other issues not already covered by this call for
evidence that are relevant to the scope of the inquiry.
5.5 FDF sees nanotechnologies as useful enabling technologies that could enhance food production to
provide processing and consumer beneﬁts. It would be regrettable if such scientiﬁc advances were closed oV
because of irrational fears about the use of new technologies or a failure to provide convincing evidence of
their safety in use. FDF would like to see rapid developments in addressing the uncertainties outlined in
EFSA’s report so that industry can progress research into innovative products and processes with conﬁdence
in assessment procedures and regulatory outcomes. For our part, we are engaging in co-operative dialogue
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and, through CIAA, engaging with the Commission’s Safety for Success initiative. Through stakeholder
dialogues we are seeking to ensure transparency and exchange of information with interested parties. We
welcome the Committee’s very timely Inquiry and look forward to constructive outcomes.
Annex
THE UK FOOD AND DRINK MANUFACTURING INDUSTRY
The Food and Drink Federation (FDF) represents the food and drink manufacturing industry, the largest
manufacturing sector in the UK, employing over 500,000 people. The industry has an annual turnover of
£70 billion accounting for 15 per cent of the total manufacturing sector. Exports amount to almost £10 billion
of which 64 per cent goes to EU members. The Industry buys two-thirds of all UK’s agricultural produce.
The following Associations are members of the Food and Drink Federation:
ABIM Association of Bakery Ingredient Manufacturers
ACFM Association of Cereal Food Manufacturers
BCA British CoVee Association
BOBMA British Oats and Barley Millers Association
BSIA British Starch Industry Association
CIMA Cereal Ingredient Manufacturers’ Association
EMMA European Malt Product Manufacturers’ Association
FA Food Association
FOB Federation of Bakers
FPA Food Processors’ Association
GPA General Products Association
MSA Margarine and Spreads Association
SB Sugar Bureau
SMA Salt Manufacturers’ Association
SNACMA Snack, Nut and Crisp Manufacturers’ Association
SPA Soya Protein Association
SSA Seasoning and Spice Association
UKAMBY UK Association of Manufacturers of Bakers’ Yeast
UKHIA UK Herbal Infusions Association
UKTC UK Tea Council
Within FDF there are the following sectoral organisations:
BCCC Biscuit, Cake, Chocolate and Confectionery Group
FF Frozen Food Group
MG Meat Group
ORG Organic Food and Drink Manufacturers’ Group
SG Seafood Group
VEG Vegetarian and Meat Free Industry Group
YOG Yoghurt and Chilled Dessert Group
13 March 2009
Memorandum by British Retail Consortium
1.0 Introduction
1.1 The British Retail Consortium (BRC) is the main trade association for retailers, and our members are
responsible for approximately 80 per cent of all grocery sales in the UK
1.2 Retailers take a keen interest in all issues aVecting food production and packaging. Whilst retailers sell a
large number of own brand products in their stores, they are not manufacturers in their own right. For this
reason our submission focuses on issues of retail and consumer acceptance, rather than the detailed science
around nanotechnology.
1.3 Retailers have strict policies in place to ensure the products they sell are safe and legal. We believe there
could be beneﬁts in nanotechnology for consumers; however, as the application of the science is new we
support a robust regulatory and safety assessment framework. We want to work with stakeholders to ensure
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there is a good understanding of the beneﬁts, risks and regulatory gaps around nanotechnology to avoid it
being rejected due to lack of understanding.
1.4 We have responded to those questions in the request most relevant to our sector.
2.0 State of the Science and its Current use in the Food Sector
2.1 What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector,
either in products or in the food production process?
2.2 We believe the beneﬁts could be in improving the composition and packaging of existing foods. In terms
of food, the main application we foresee is the ability to improve the eYciency of an ingredient in terms of
reducing its usage but retaining its quality. For example, manipulating salt crystals at a nano level could have
a huge impact in reducing salt consumption but retaining the taste customers expect. Re-formulation on this
basis, to improve the nutritional composition of a product without compromising the taste could play its part
in improving the nutritional value of processed foods. In terms of packaging, there could be beneﬁts through
lengthening the shelf life of food, reducing the amount of packaging and improving its potential for recycling.
2.3 What is the current state of the market for, and the use of, food products, and food production processes involving
nanotechnologies, either abroad or in the UK?
2.4 This depends to a certain extent as to the deﬁnition of a nano food process as we understand this could
extend to products such as traditional cheeses. In our opinion the deﬁnition of nano food should take account
of whether it is engineered or naturally occurring, whether it is soluble, its size and change in properties. This
raises the issue ofwhethermanipulating existing ingredients such as salt at a nano level is something that would
be counted as new technology or simply the better application of a known product. There could be a market
for these types of products as consumersmay see it as re-formulation but retaining the taste theywant. In terms
of more innovative, new products developed from scratch, our market is conservative and consumers will
weigh up the beneﬁt to them.
2.5 What are the barriers to the development of new nano-products or processes in the food sector?
2.6 All retailers are led by consumer demand, which means consumers need to see tangible beneﬁts, which
could cover a number of factors including nutrition, sustainable development or innovation. As consumer
knowledge is currently low they would need to recognise such beneﬁts over existing products and for this to
be suYcient to overcome concerns they might have. We know, from the GM debate that consumers could not
see a beneﬁt in GM food for them and became concerned about the perceived health and environmental risks
due to the messages they received at the time. This demonstrates the need for Government to explain to
consumers the beneﬁts, give clear direction on risk and also the key role the media have in reporting new and
emerging science in a factual and balanced way.
3.0 Health and Safety
3.1 Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to
nanotechnologies and nanomaterials for consumers? If not, what amendments are necessary?
3.2 We believe there does need to be a distinction in terms of food safety between completely new food
ingredients which are produced from scratch and existing ingredients which are engineered at a nano size that
retains their properties but enables them to be used more eYciently. We also believe risk assessment needs to
account for where nanotechnology is used, drawing a distinction between packaging and food. We responded
to the FSA consultation in 2008 on novel foods to suggest more detail was required on the deﬁnition of novel
foods and if that covered nanotechnology. We are clear, however, that we support a robust and transparent
regulatory framework.
4.0 Regulatory Framework
4.1 Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
4.2 We believe this would be improved by clarifying the deﬁnitions in the novel food regulations to make it
clearer if it applied to nanotechnology.
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4.3 How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take
up by companies working in the food sector?
4.4 In general terms self-regulationworkswell in theUK food sector, for example, the industry hasmade good
progress on nutrition, removing artiﬁcial transfats and colours, reformulating products to reduce the amount
of salt and saturated fat, and supporting public health campaigns to encourage customers to eat healthily.
5.0 Public Engagement and Consumer Information
5.1 What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of
nanotechnologies and nanomaterials in the food sector? What is the public perception of the use of such technologies and
materials?
5.2 Our belief is there is a very low awareness of nanotechnology generally amongst consumers. In some non-
food products there is an understanding that nanotechnology is used positively, improving quality, for example
miniaturising components in electronic equipment. Our members have conﬁrmed from that their customer
care lines do not receive queries about nanotechnology and our belief is that customers do not believe it is
currently used in food. In terms of the public perception, there is a positive approach to some of the non food
applications butwe are cautious about their perception of its use in food. Consumer demand forGMhas never
recovered from the damagingmedia reaction in the late 1990’s andwe believe they remain cautious about other
products that use new technology.
5.3 How effective have the Government, industry and other stakeholders been in engaging and informing the public on
these issues? How can the public best be engaged in future?
5.4 To date engagement with the public has been limited. We would be happy to contribute to a Government
led engagement which aims to raise awareness and discuss the issues in a pragmatic fashion. The Government
needs to be at the heart of discussions to ensure these are based on science and fact and not dominated by
speculation and individual opinions.
5.5 What lessons can be learned from public engagement activities that have taken place during the development of
other new technologies?
5.6 We need to bear in mind the lessons that should be learnt when GM food was trialled in the 1990’s. We
must ensure that an authority, FSA in our opinion, is available to provide the facts from a consumer
perspective. FSA action should include proactive engagement with stakeholder groups, including consumers
and the media, to ensure current issues are understood and uncertainties answered. Ultimately the
introduction of nanotechnology to food products will only succeed if consumers can see a beneﬁt for
themselves, something that was never clearly demonstrated with GM food.
5.7 Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
5.8 The key issue is whether consumers understand the use of nanotechnology and the issues around them,
which will rely on education. Information is only eVective where it helps consumers make an informed choice.
Without the knowledge to make informed decisions there is a danger that labelling will mislead consumers.
12 March 2009
Memorandum by Dr George Kellie, KellieSolutions Ltd
HOUSE OF LORDS PRESENTATION
Background
Dr George Kellie is chairman of KellieSolutionsTM, a leading UK marketing and technology company. Dr
Kellie’s businesses have been in existence for nearly 20 years and have a strong reputation and expertise in
plastics, packaging, and sustainability strategies. KellieSolutionsTM has been focused on the detailed analysis
and evaluation of advanced new technologies in packaging, paper and plastics ﬁlms on a world-wide basis.
This has included shelf life extension solutions.
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In the ﬁeld of sustainable materials, KellieSolutionsTM has also been particularly active, working on advanced
materials in packaging, ﬁlm, sheet and ﬁbre form. Dr Kellie is actively involved in generating new sustainable
solutions across a broad range of applications for major international clients.
In recent months George Kellie has published a series of articles on practical business actions in the recession
and as a contribution to the recovery is oVering a free consultancy service to struggling UK businesses.
Nanotechnology and its Place in the Packaging Market
From a KellieSolutions perspective, nanotechnology ﬁts in to a group of processes and techniques designed
to meet a complex range of requirements. These range from extended shelf life through to easy to recycle, etc.
In general, we view nanotechnology in a much broader category of micromaterial addition.Whether these are
actually in nanometres or just in very low addition levels largely does not matter. What does matter is the
ability to create products which can meet a complex series of challenges.
Trends and Opportunities in Advanced Packaging Materials
Summary. Packaging developments in the coming years need to focus on an interlocking series of objectives.
These include aspirations such as lightweight, easy to recycle, low CO2/greenhouse gas impact and, of course,
low cost. Overriding all of this is product safety.
At the heart of this work is the need to extend packed food shelf life and dramatically reduce food waste. These
are beneﬁcial outcomes that apply to society in general and not just to the commercial enterprises involved in
the industry. However in order to gain mass market acceptance these new packaging formats have to be cost
eVective and safe. Three of the major trends are in techniques for extending shelf life, time/temperature
Indicators, and nanotechnology. These threads are interdependent.
Shelf Life Extenders. In the area of advanced technology for extending shelf life, we can already see the
development of materials which oVer shelf life improvement through atmospheric modiﬁcation. These can be
modiﬁed atmosphere (MAP) packs (these are very well known) andmore recently the use of moisture, oxygen,
ethylene, and CO2 sachet-type absorbers. All of those play a part in extending shelf life depending on the food
degradation/barrier requirements.
Time Temperature Indicators (TTIs) and related devices are also interesting. KellieSolutions have done a
considerable amount of work with a number of these products. While they attract consumer interest, at this
time their costs are often prohibitively high and at times it is diYcult to easily verify whether they really provide
more information than the simple “use-by” date. A much more important area where TTIs can have impact
is to look at monitoring and management of the Chill Chain. The Chill Chain process is one of the key
controllers of the quality of food that arrives in the store. The more we know about the Chill Chain, the more
we know the history of how packs have been stored and distributed. By measuring and monitoring pack
history we reduce food degradation risks and improve process eYciency. This is the area where we believe there
are greatest gains to be made. In addition, the cost of TTIs becomes insigniﬁcant when they are monitoring a
transit pack or pallet with multiple packs compared to the cost when they are applied to individual packs.
Nanotechnology
Nanotechnology involves advanced materials dimensioned at or near atomic scale. A nanometer is one
billionth of a meter. At this nano level the characteristics and performance of materials can radically change
often providing unique properties and beneﬁts previously impossible to achieve. In our work we talk more
about “micro” and “miniature” rather than nano. These micro additives are still materials used at low levels
but not strictly nano. For example this allows us to create new generation vacuum micro-deposited materials
for clear barrier ﬁlms. The opportunities are exciting. In the future nanocomposites may be able to modify
packaging ﬁlms to increase gas barrier, enhance strength, and improve temperature resistance. Not
surprisingly nanotechnology has not yet achieved its much-hyped potential which has runwell ahead of reality.
Also before nanotechnology can be fully adapted to direct food-contact packaging applications, the
technology must be evaluated in safety regulatory systems.
Some examples of nanopackaging materials include:
— Nano composites. These can create high barrier layer in ﬁlms and bottles with minimal extra weight.
These can help to create barrier packs with long shelf life under ambient storage conditions.
— Electrically conductive inks. Potentially these can be used to print radio-frequency identiﬁcation
(RFID) tags and other on-pack electronics.
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— Nanoclays. These are being incorporated into plastic nanocomposites. Once again gas/moisture
barrier is the main focus.
— Zinc oxide nanoparticles. Such materials are aimed at providing antimicrobial performance.
By using a nano level or just micro level deposition, we can open up a whole new set of markets and
opportunities.
Ultra Clean Materials. A related area is the micro evaluation of surface properties. This is not about
deposition, rather the reverse. The aim of these techniques is to produce ultra pure and ultra clean ﬁlms.
Measuring “clean” and “pure” is diYcult and requires using diVerent techniques including liquid particle
scanning and Time-of-Flight Secondary Ion Mass Spectrometry (TOF-SIMS). This work opens up new
opportunities by focussing on packs that have a minimal impact on the products contained within them. In
simple terms.. “less is more”.
One of the most promising innovations in smart packaging is the use of nanotechnology to develop
antimicrobial packaging. KellieSolutions has recently patented advanced processes to micro-deposit anti-
bacterial additives.
Safety
This is a live issue which is being followed by several bodies. The Food and Agriculture Organisation of the
United Nations (FAO) and the World Health Organization (WHO) are starting to look at the issues. In June




Witnesses: Dr Mike Knowles, The Coca-Cola Company, Mr Andrew Opie, British Retail Consortium, and
Dr George Kellie, Microﬂex Technologies Limited, examined.
Q155 Chairman: I would like to welcome our three
witnesses this morning, as well as the members of the
public who are sitting behind them, to this third
public hearing in the inquiry into nanotechnologies
and food. I should inform witnesses and members of
the audience that the proceedings are being webcast
as usual and that an information note is available for
members of the public which sets out the declared
interests of the members of this Select Committee.
Before we start on our questions I would like to invite
the three witnesses to introduces themselves and if
you have any comments that you would like to make
as a prelude please feel free to do so, and youwill have
another opportunity at the end to make any
additional comments if you wish. Dr Kellie, would
you like to go ﬁrst?
Dr Kellie: Thank you, my Lord Chairman.My name
is George Kellie. I am Chairman of a very small
specialist company called Kellie Solutions. You will
see the name Microﬂex Technologies, that is one of
our businesses. We have been around for about 20
years. Our core work is technology-based with a
certain marketing involvement. By sector, packaging
is about half of what we do in terms of technology.
Other related areas are in things like hygiene. Our
customer base is very varied. It goes from, at one end,
the supermarkets and food companies to, at the other
end, basic packaging material companies. Finally,
just to say we invest in our own technology as well as
work we do with customers and we have developed a
signiﬁcant number of patents and other
developments.
Q156 Chairman: Thank you. Dr Knowles?
Dr Knowles: My Lord Chairman, I am Mike
Knowles. I am here representing the UK Food and
Drink Federation and also the European
Confederation of Food Industries. I also work as
Vice-President for Global Scientiﬁc and Regulatory
AVairs for The Coca-Cola Company. I would like to
make a short statement if I may. We are very pleased
to be here to give evidence to this Committee. I am
sure you have already heard there is a shared
enthusiasm within the food industry to explore the
potential beneﬁts and applications of
nanotechnologies in food production, processing and
packaging. The publicity given to the application of
nanotechnologies in food suggests there are many
current applications on the market, but this is
contrary to our understanding and knowledge of the
situation. We believe there is a need for a full safety
evaluation before any product from a
nanotechnology should be commercialised. We are
bound by the current legal frameworks within the
European Union and, of course, we exercise due
diligence to ensure our members comply with that
European framework. We are working actively to
prepare the ground for potential applications
through transparency and engagement with
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appropriate organisations, including the Food
Standards Agency and European institutions. We
believe it is extremely important to build trust
throughout the supply chain and, of course, with the
ﬁnal consumer. Thank you.
Q157 Chairman: Thank you. Mr Opie?
Mr Opie: My name is Andrew Opie. I am the Food
Policy Director at the British Retail Consortium. We
are the trade association that represents retailers who
account for approximately 80 per cent of grocery
sales in the UK. We welcome the chance to give oral
evidence today. The timing of the Committee’s
inquiry is very apt because we are just starting to get
to the stage where customers are getting curious
about nano in food, but what we would welcome is
more discussion around the demystifying of some of
the terms that have been bandied around nano so
consumers can understand more both about the
beneﬁts and potential issues around nanotechnology
as well.
Q158 Chairman: Thank you all very much. Perhaps
I could kick oV with a general question. Dr Knowles,
we have heard that the food manufacturers as
represented by the FDF are enthusiastic to explore
the potential beneﬁts of nanotechnologies and
nanomaterials. I also note in Dr Kellie’s written
evidence he says: “Not surprisingly, nanotechnology
has not yet achieved its much hyped potential which
has run well ahead of reality”. I wonder if, between
you, you could give us a feeling for where you think
that these potential beneﬁts lie that you are keen to
explore.
Dr Knowles: My Lord Chairman, I think the
advances in packaging are the ones which are most
advanced in terms of real applications and, in fact,
the European Food Safety Authority has reviewed
two of these recently and given its endorsement to
their use but that, of course, is subject to the
Commission and the Council giving their ﬁnal
approval. There are the potential beneﬁts for barriers
to protect against oxygen ingress or gas escaping
through the walls of plastic materials, antibacterials,
which you know are on the market already in the UK
in plastic containers, nanosilver, and also, looking a
little further forward, sensors in the packaging which
may detect deterioration in quality or even the
presence of pathogenic micro organisms. In terms of
the direct addition to food there are many, and I
know you have received a host of examples of the
potential direct applications, for example the nano-
encapsulation of vitamins, nutrients, some additives
and what we call functional ingredients to protect
them during manufacturing and storage of the food,
but also to enhance their functionality in the body. It
is somewhat analogous to the medical application
where you can improve targeted delivery of some
ingredients through protection by the application of
certain nano-encapsulation processes. In addition,
the carriage, if you like, of certain functional
ingredients to their target organs within the body, as
inmedicines, we believe can be enhanced in the future
by appropriate nano-coatings or nano-carriers. I
know there are already examples on the market of
certain supplements which are nano-encapsulated to
enhance their properties in this way. There are
beneﬁts in cleaning operations; surfaces can be
coated with various nano-coatings. Some call it the
Lotus eVect as in the Lotus leaf where the water falls
oV in discrete droplets rather than getting into the
leaf. This would reduce the use of water for cleaning
and has beneﬁts in terms of protecting against
contamination by ﬁlms being built up on food
processing machinery surfaces. Of course, in
ﬁltration, nano-sieves, there are applications that are
quite advanced in the puriﬁcation of water through
nanoﬁltration. We have ultra-ﬁltration now and we
have nanoﬁltration coming along which we have
been looking at as a company, as a member of the
International Water Association, for developing
countries. It is a very eVective way of cleaning water.
Those are just a few of them, my Lord.
Q159 Chairman: Thank you very much indeed. I do
not know whether Dr Kellie or Mr Opie would like
to add anything to that.
Dr Kellie: First of all to say that what we have just
heard ﬁts in very much with some of what I have put
inmy own paper.When I look at the work that we are
engaged in, which is very much packaging, we do not
get involved in food directly, we see the opportunities
that nano oVers as being very exciting because they
also interlock with another major theme that we are
involved in which is in terms of sustainability and
packaging waste. I do not want to divert the
Committee into another whole subject, but
packaging waste is an equally critical area. The
ability to take, for example, plastic ﬁlmsmuch used in
packaging andmake them thinner, make them lighter
and yet retain their strength, and therefore by doing
that signiﬁcantly reduce the weight of material that
we use in packaging, and almost all the UK’s major
retailers are signed up to packaging weight reduction,
is of great beneﬁt because ultimately as wemake these
materials thinner, and you can recognise it from your
own experience, it becomes harder to deal with the
strength properties. The second thing is barrier. We
have talked a bit about barrier. Barrier is the critical
element in terms of shelf-life, and I am sure you are
all very well aware of that.We look at barrier in terms
of moisture, in terms of oxygen, and in terms of CO2.
It depends what you are packaging in terms of what
you want to exclude from the pack. This is incredibly
important for two reasons. One, it goes without
saying that every step that we can take that reduces
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food waste in a global sense is a positive move for us
to make. The second thing is it oVers us the potential
to pack products and retain their shelf-life under
ambient conditions. In other words, we do not have
to expend energy to retain the product under frozen
or chilled conditions. There are some terriﬁc gains if
nano can deliver but there is a lot of work to be done.
There are great gains that we think are enormously
beneﬁcial.
Mr Opie: The only thing I would add to that is we do
see there is quite a big role for nanotechnology
potentially to answer some of the public policy issues
we are facing. We have already spoken quite a lot
about food waste packaging and those sorts of issues
at the moment where retailers and manufacturers are
under pressure, quite rightly, from Government and
from their consumers to deliver on these issues. The
other area that we are quite interested in is some of
the areas around reformulation of food. Can we
deliver the same beneﬁts to consumers in terms of
taste and texture, for example, but cutting out some
of the issues such as some saturated fats in products.
What we have found in some areas of reformulation
is that it is diYcult always to take consumers with you
if they do not get the same taste or texture from the
food that they would usually expect to see in the food
they are routinely buying and, therefore, some of the
measures to cut some of theworst nutrients out of our
diet would be improved if we could deliver the same
taste, texture and product to consumers but help
them by taking some of the saturated fat out of the
product, for example.We see there could be potential
in this in terms of taking customers with us in an
easier way to meet some of the targets in nutrition
and health.
Q160 Lord Haskel: I wonderwhether you could help
us on the matter of deﬁnition. I think at the very
beginning we ought to decide what it is that we are
talking about. We wondered how you would deﬁne
“nanotechnologies” and “nanomaterials” in the
context of the food sector.
Dr Knowles: My Lord Chairman, if I can start. This
is a diYcult question that we have been discussing for
many months. I am going to refer to greater
authorities than I in terms of developing deﬁnitions.
The International Standards Organisation—ISO—
has a deﬁnition of “nanotechnologies” and I will read
this: “Understanding and control of matter and
processes at the nanoscale typically, but not
exclusively, below 100 nanometres in one or more
dimensions where the onset of size dependent
phenomena usually enables novel applications”.
Then it deﬁnes a “nanometre” where one nanometre
is 1,000 millionth of a metre. For “nanomaterials”,
we in the food industry are looking at the emerging
deﬁnitions from the Scientiﬁc Committee on
Emerging and Newly-Identiﬁed Health Risks—
SCENIHR—in Europe who have discussed this
themselves and the deﬁnition that they propose, that
we think is reasonable, is as follows: “Nanomaterial
means any intentionally engineered material that has
one or more dimensions of the order of 100
nanometres or less or is composed of discrete
functional parts either internally or at the surface,
many of which have one or more dimensions of the
order of 100 nanometres or less, including structures,
agglomerates or aggregates which may have a size
above the order of 100 nanometres but retain the
properties that are characteristic to the nanoscale.
Properties that are characteristic to the nanoscale
include those related to the large speciﬁc surface areas
of the materials considered and special physico-
chemical properties.” The importance for us is to link
both the size and the novel properties that the
materials have. It is not size alone which determines
whether a material is nano. That is how we currently
think of nanomaterials and nanotechnologies.
Dr Kellie: I would like to endorse that and say that
we, being practical people, are about producing
practical solutions, we are not theoreticians, we are
not writing academic papers, we are trying to
produce real results. For us, the deﬁnition matters far
less than the important issue which is we are dealing
with materials which at a very small level or micro
level or, ultimately, nano level have got exceptional
properties. That is the key. The key for us is that these
materials in extremely small quantities turn out to
have properties which are amazing. For example, we
could put a nanoclay into a plastic nanocomposite
and suddenly obtain signiﬁcantly greater strength
properties. It is the exceptional properties rather than
the pure deﬁnition of nanotechnologies that matters
i.e. the materials do not have to be 100 nanometres or
less. It is the exceptional properties that we are
concerned with because we want results, quite
frankly.
Mr Opie: I am not going to disagree with the
deﬁnitions here. The one thing I would say is the
thing we discussed at the start; deﬁnitions is one issue
in terms of the regulatory framework, which I am
sure is one issue we will look at later, but there is also
the general consumer’s understanding about what is
meant by nano. I talk about that for both potential
beneﬁts and risks. For example, on the non-food side
we have seen a lot of interest in the use of nano—
iPods, sunscreens, those sorts of issues—where
consumers have embraced nano. Whether they have
an understanding of what is meant by “nano”, there
is a risk in some ways that products could be sold as
nano on the basis that they give something extra
when they might not and whether they understand
what is going on. Do they understand, for example,
that there are already nanomaterials out there in food
at the moment, for example in cheeses and various
other products? For us, the deﬁnition is obviously
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important in terms of the regulatory framework but
a bigger issue for us is a consumer’s understanding of
what is meant by nano so when they go into a store
they know what to expect.
Q161 Lord Haskel: I think you are right. I assume
the public would be concerned about the
nanoparticles that persist in the body. I wonder
whether you think that diVerent types of
nanomaterials should be treated diVerently for
regulatory purposes? What you have given us is a
deﬁnition of particles which are intentionally
manufactured, but do you think we need a deﬁnition
for regulatory purposes of nanoparticles which are
speciﬁcally for the food industry which persist in
the body?
Dr Knowles: That is a diYcult question to answer
because at the moment we do not have any
information about nanoparticles that persist in the
body or persist anywhere. What we are doing to
address part of your question is we are deﬁning
engineered nanomaterials and separating them from
naturally occurring nanomaterials, such as Mr Opie
just alluded to. Of course, we are exposed to
nanomaterials all the time through the food supply.
When we metabolise proteins, carbohydrates, lipids,
they are metabolised at a nanoscale in-vivo, so the
body is well-used to handling, if you like, natural
nanomaterials. Ricotta cheese is the example that is
frequently quoted as having been around an awfully
long time and has micelles and nanoparticles in it,
nano-emulsions, if you like, it is not nanoparticles. I
am sure your concerns are related to the nanosilvers,
nanogold and nanozinc oxides, the inorganic
nanoparticles, and personally at the moment I do not
see any direct applications of those in food. In
supplements that is a diVerent matter, and I do not
represent the supplements industry. I am not ducking
the question. I do feel there are toxicological
questions being asked about those materials. I know
that the Public Health Institute in Bilthoven in the
Netherlands is looking at the pharmacokinetics of
nanogold and nanosilvers as part of their study into
the toxicology and fate of those materials. I do not
see the persistent, if they are persistent, materials as
being something that applies to the food industry per
se but may apply to some of the supplements that are
currently on the market in other countries. I should
add, they are not being manufactured in Europe to
my knowledge. I hope that helps.
Q162 Lord Mitchell: Continuing on the subject of
practicalities, Dr Kellie, you mentioned it ﬁrst of all
but I want to talk in terms of applications and what
applications of nanotechnologies and nanomaterials
in the food sector are UK companies and overseas
companies currently working on. When you have
answered that I want to ask about what is going to be
happening in the future, so you can think about
that too.
Dr Kellie: First of all, I think clearly there are a
number of signiﬁcant development programmes
going on in nano at the moment in diVerent areas. I
have alluded to a number of the ones I am
particularly familiar with in terms of lightweight
barrier materials, but there are others which interact
with those which are nano in the packaging sense but
maybe not in the direct sense. For example, one of the
areas we see as having a sizeable impact in time is the
ability to produce printed electronics. You might say
what has that got to do with packaging, but it has got
a lot to do with packaging. The most direct
application is printing so-called RFIDs, that is the
tags, so-called smart tag idea, so that we can print the
electronics on to the pack. That is (a) cost-eVective
and (b) by printing electronics we can carry a vast
amount of interrogatable date about the content of
the pack. Much more than a bar-code, an RFID
allows us to carry data ﬁrst of all about the life of the
pack and, secondly, if necessary, about the
application of the pack. We see that as particularly
important. A secondary stage beyond that that
people are looking at is something we talked about
earlier, which is being able to actually monitor the
status of the pack. If we print electronics, for
example, that would measure the temperature the
pack has been under through the Chill Chain, which
we regard as a very important piece of data to be able
to manage, it tells us more about the lifecycle that the
pack has endured. The range of nano-derived
applications is wide. The number that is coming to
market is still relatively small at the moment. The
amount of work and eVort that is going on to develop
these concepts is pretty substantial.
Q163 Lord Mitchell: This tagging you are talking in
terms of, I can understand how it is beneﬁcial to the
manufacturers but how does it help the consumer?
Dr Kellie: It beneﬁts the consumer in a number of
ways. First of all, the more data that we know about
the pack, and the products we contain in the pack, the
better. It is more than just when to replenish the stock
in the warehouse, which I accept is one piece of
information, or to tell the retailer how many he has
sold in any oneweek, which is commercially valuable,
it can carry a lot more data than that. As I explained,
for example, it can carry data about the lifecycle of
the product. As these electronics become more
complex, just to take the example of its progress
through the Chill Chain, printing electronics allows
us to know how long it has been in the Chill Chain
and what the temperature conditions are.
Temperature conditions are absolutely critical. It is
critical for chilled products that they remain in this
magic temperature band of 2–4) which is the typical
temperature range. If for any reason it goes outside
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that, potentially food can go oV. That beneﬁts the
consumer absolutely directly because the more we
know about the pack and the more we reduce the risk
of exposure to food that has gone oV for any reason
the better for the consumer. That data will deﬁnitely
beneﬁt the consumer if we can apply it in that way.
Q164 Lord Mitchell: I know in your marketplace at
the moment forecasting what is going to happen in a
month’s time is probably diYcult, but how do you see
developments in the next ﬁve or ten years? Where do
you expect them to come from?
Dr Kellie: First of all, over the next ﬁve years I expect
it to be an explosive period of development. If I look
at the amount of research that is going on, the
number of speciﬁc applications that you can see that
are in early stage development at this point, that is
signiﬁcant. The amount of ﬁnance that is going
behind that is also signiﬁcant. The $64 million
question is what is going to come ﬁrst and fastest. I
have outlined some of the areas that we think are
going to come ﬁrst and fastest, in other words lighter/
thinner materials is one that is going to come
relatively quickly. Barrier is going to come at some
pace as well. The controlling factor probably will be
more about the regulatory issue, which is what you as
a Committee are addressing, and that is critically
important because if we do not put safety ﬁrst it does
not matter how wonderful our technology is, safety
has to be paramount throughout the process. In my
opinion, that will be the controlling factor. The
developments that are going to come most rapidly
will be those that ensure the nanomaterial is buried
within the layers of the product and the pack rather
than directly in food contact. Once we get into direct
food contact the regulatory demands and the safety
demands, rightly, are higher. My anticipation is over
the next three years, far less the next ﬁve years, you
are going to see a signiﬁcant number of developments
coming to market and coming forward as well for
regulatory testing.
Q165 Chairman: Thank you. Would you like to add
anything to that?
Dr Knowles: If I move to the direct applications, of
which there are very few at the moment in terms of
development, and what individual companies are
doing then I guess you would have to ask them. It is
a very competitivemarket in the food industry, as you
know, and if the major companies are working this
area, and some are of course, in the direct
applications, as Mr Opie mentioned one of the
technologies which is quite near to market now is the
changing of the texture of the foods, the new mixers,
special types of food machinery. I am not a food
technologist but they are capable of producing nano-
emulsions to change the texture, reduce the use of
certain macro-ingredients, such as saturated fats or
other fats, and retain the organoleptic properties. In
addition, there are extensions of that application to
change the way in which the materials are
metabolised. It may increase satiety by using some
nano-emulsiﬁed materials. More along the lines I
mentioned earlier is the nano-encapsulation of
certain nutrients to improve the bioavailability as
well as protect them against oxidation or other
degradation processes, and that is quite an exciting
area. It is paralleling the developments in medicine
where, knowing what the target organs are, one can
improve the speciﬁcity by appropriate manipulation
with nano-encapsulation. Again, there are
opportunities there for maybe delaying digestion and
improving satiety, which we are all looking for. We
are all competing for the same diet. Certainly
nowadays we are told to reduce the amount that we
are consuming, so we are all competing for a smaller
market, so to speak, and we are looking for ways in
which we can improve the health properties of foods.
Nanotechnology does oVer opportunities there. I
only know of onemajor project that is going on in the
US with the Food and Drug Administration, the
Institute of Food Technology and the International
Life Sciences Institute, of which I happen to be the
President globally, and the Grocery Manufacturers
Association. The European food industry is involved
peripherally in that. They are looking at all of the
potential applications, doing a major review of the
literature, which is the ﬁrst phase, and then looking
at potential applications at diVerent periods of time.
Then they will look at all of the toxicological data,
which is the next phase, and draw from that the
published papers which will put in context what they
think will be the sequence of applications of
nanotechnology following appropriate safety
evaluation. I am sure we are going to discuss safety
evaluation later. It is all predicated on appropriate
safety evaluation before we can use any direct
applications.
Q166 Chairman: When is that review due to be
completed?
Dr Knowles:The ﬁrst phase certainly by the end of the
summer, maybe September/October, and then we will
move on to the later phases. We are also looking at
the development of what is called the Woodrow
Wilson project on nanopackaging last year, as an
example for an exercise on hypothetical additions to
hypothetical foods. There will be a series of case
studies looking at how they would be evaluated by
the regulators both in terms of the chemistry and the
technology as well as the toxicology. It is not a good
time to go asking for a lot of money from our bosses
in the food industry—it is never a good time to do
that but this is a particularly bad time, as you are well
aware—but we are asking for funds to try to get this
series of case studies up and running to give, as the
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packaging study did, some real examples that we can
use not only in terms of educating the public as to the
beneﬁts of nanotechnology, which is extremely
important, but identifying any gaps that we need to
identify for a safety evaluation.
Q167 Lord Methuen: I think we all know that trace
elements, such as beryllium, copper and selenium,
are also necessary in our diet. Does nanotechnology
oVer the capability of controlling the levels of this
or is this already handled by current technology?
Dr Knowles: My Lord Chairman, the addition of
selenium and other trace minerals is handled by
current technology. We do not usually add selenium
to food as such, it has a very small safety threshold
between what is required nutritionally and what is
unsafe only by a factor of three, so certainly in the
major companies it is not an element that we add.
There are issues around diVerent parts of the world
where local selenium levels are high so we do not
want to exacerbate those issues. I am not sure if
there are nanoparticulate selenium compounds or
nano-encapsulated compounds in the supplements
industry which are being marketed. Nano zinc
oxide, nanosilver, nanogold, nano selenium, nano
copper, many minerals are being looked at from a
supplements point of view. I do not know anything
about the beneﬁcial properties of those materials but
they are available.
Q168 Lord Methuen: With regard to research and
development, where does the UK stand? Are we at
the cutting edge or are other countries ahead of us?
Dr Kellie: My Lord Chairman, ﬁrst of all I am
aware of one or two developments in the UK. For
example, Hallam University is doing a programme
under the SustainPack Development Programme
which is about adding or using nanotechnologies in
packaging. I talk most of the time as if all the
packaging developments were plastic, and, while it
is easier to add nano to plastic materials, paper and
paperboard are a very signiﬁcant part of the
packaging regime and, indeed, attractive materials
to the public. The problem normally with paper and
board-based packaging is that it does not carry very
good barrier properties, you have to coat it or do
something to it, so the potential to use
nanotechnology there is being explored and, as I say,
I am aware Hallam has an active programme in that
area. Outside that I am not so well aware. I suspect,
but I do not know for deﬁnite, that there is more
taking place outside the UK than inside the UK at
the moment.
Q169 Lord Methuen: We have information that
Japan and Brazil, for instance, are doing quite a lot
in this area.
Dr Kellie: Again, my Lord Chairman, this is exactly
the type of technology which Japanese packaging
companies are exceptionally good at. If you look at
their history they have been extremely good at
developing lightweight advanced barrier packaging
and this is a natural ﬁt to what they have done, so
what you tell me would not be a surprise.
Dr Knowles: May I add something which may be
helpful. The European Union claims to be the
biggest supporter of nanotechnology research in the
world, certainly it has allocated several hundred
million this year in the Framework 7 programmes
for nanotechnology and last year it committed, I
think, ƒ1.4 billion to this and overall ƒ3 billion has
been committed to nanotech research. The UK is
part of that. I must say, I see far more activity in
Holland as a single country in nanotechnology than
anywhere else. I live in Brussels so I am not too far
from the centres around Wageningen University, the
TNO, NIZO, which is another research association
there, doing a huge amount of work. At a meeting
I was at in the States last year the Dutch
Government had a stand itself rather paralleling
Silicon Valley for electronics to their 50 kilometre
valley—not quite a valley in Holland—their stretch
of the countryside where all these organisations are
situated. They are very well supported both
nationally by their own research funds as well as
being very good at obtaining the EU funds for this
work. There is a project on safety in nanomaterials
being formulated, again led by the Dutch, but it
does include universities in the UK and ILSI,
International Life Sciences Institute. There are
projects which the EU has funded, I believe, in the
UK on the applications of nanotechnologies. In
terms of the health research, and maybe we will
come to this later, in Ken Donaldson’s laboratory
at the University of Edinburgh, the UK has one of
the leading laboratories in the health-related eVects
of inhalation of nanoparticulate matter, particularly
from diesels and also the rigid engineered
nanomaterials, such as carbon nano-tubes. That is
a world class organisation. The Institute of
Occupational Medicine, also in Edinburgh, is doing
a great job in now pulling together all of the research
that is ongoing on health-related aspects of
nanotechnology. That is a world class centre. In
terms of the health side we are doing very well; on
the application side, perhaps not as well as some of
the others.
Q170 Lord Crickhowell: On that last point, we have
got a paper in front of us from the Department for
Innovation, Universities and Skills trying to set out
what is going on. What seems to be clear is that
there is much more going on about the lung and
inhalation than there is about the gut at the present
time. All the evidence we have received so far
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suggests that there is very little yet about the long-
term eVects on the gut and there is quite a lot going
on about inhalation. There are quite a lot of
suggestions, of course, that nature has been coping
very well with nanoparticles for a very long time,
but clearly if there is going to be a regulatory
framework there does need to be substantial
research into the toxic eVects, if any, of the long-
term consequences of absorption. Would it not be
rather important for the industry, even if the
Government has not yet directed its funding much
in this direction, to ensure that it takes place and
surely it is in the interests of the industry to develop
research work in this ﬁeld. We have heard all about
the beneﬁts. We do not want to discover rather too
late in the day that there are rather nasty
consequences because nothing could be more
disastrous for the industry than for the thing to blow
up in its face.
Dr Knowles: My Lord Chairman, on your last point
we cannot put them on the market until there has
been a safety evaluation under the legal regimes for
the food industry in Europe. You are absolutely
right, most research has been, and continues to be,
on inhalation, partly because there are concerns
about the impact of particulate matter in the
environment and partly because of worker safety.
The chemical industry, who is the primary supplier
of nanomaterials, and the food industry does not
make nanomaterials, it works with its suppliers and
they are the chemical industry, the big chemical
companies, they are concerned about the
manufacture of these materials for whatever
purposes, food or primarily for other applications.
Their major exposure is through inhalation and that
is why I think most of the work is there. Plus, it is
easier from an analytical point of view to work with
particles which are airborne. There is a dearth of
analytical methods which would allow us to measure
those same particles in a food matrix or any
biological matrix. Until we have that methodology
development and, again, the Central Science
Laboratory and the University of York have
produced an extremely good overview of the
diYculties of the analytical challenges in
nanoparticulate analyses in biological matrices, it is
very diYcult to put the toxicology in place because
you do not know how to measure what you are
giving to animals, if you are using animals. That is
one of the reasons why there is so little research in
the area of ingestion. I do agree 100 per cent with
you that it has to be funded by both the industry
and the Government, and the industry is funding
that. I mentioned the International Life Sciences
Institute and that is an organisation that is global,
supported by the food industry, the chemical
industry and the pharma industry, through over 400
companies. We are paying collectively for the
research they are doing, but they are not doing the
basic research, they are trying to develop through
consensus meetings the areas of research others
should have been funding. The member companies
in the chemical or pharma area would then be
expected to do the appropriate toxicological
research on their materials. Where we are lacking
guidance, and the European Food Safety Authority
has issued its opinion on what types of tests should
be undertaken to identify hazards, is the type of test
that one would carry out to identify hazards from
a material which is derived from a nanotechnology
in a food because once it is in the food, then because
they are reactive materials the food itself, I am sure,
is going to coat the surface of these materials and
then how do you measure what is being absorbed.
In the classical drug context, the absorption,
distribution, metabolism and excretion of materials
needs to be measured and until we have the tools to
measure them it is very diYcult to do that
toxicology, which is why I believe it will be some
years before the food industry will be looking at
direct applications. I am sure we do make less than
we ought to be making in terms of contributions to
the basic science from the toxicological point of view
from the industry in total, but I do not know,
because I am not in the chemical industry, what
work they are actually funding themselves or doing
themselves in fact.
Q171 Lord Crickhowell: You have talked about the
desirability and necessity for proper hazard
assessment but the departmental paper I was
quoting from says: “Globally there is insuYcient
evidence to be able to say that any of the health,
safety and environmental research objectives have
been completed, thus full risk assessments of any
nanomaterial are not possible at present”. In a
sense, I think that summarises what you have just
been saying, that it is going to take a very long time,
which suggests that probably it will not be possible
for a number of the areas that may be desirable to
be really entered into the market until that research
has been done. Is that right?
Dr Knowles: As a generalisation I think that is right.
There are potential applications where one is using,
for example, natural materials to nano-encapsulate
some materials and there it is rather easier to do the
appropriate toxicology and look at the normal
digestion processes to see whether, in fact, they are
completely digested within the gut and absorbed in
the normal way or, if they are absorbed in a
nanoparticulate form, are they metabolised rapidly
once they are in the systemic system via the
conventional processes. There are areas where there
has been more progress in safety evaluation than
others, but it is a diYcult, challenging and
exciting area.
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Q172 Lord May of Oxford: That is all very
interesting, but going back to the essence of this
question, which was is the UK in the lead, in the
middle of the pack or a laggard in applications, I
understood the answer to be broadly it is a laggard.
That was what I heard you say. I would ask why do
you think this is? Is it simply the familiar
phenomenon which is a rather peculiar thing
whereby the current Government is very keen to get
people from the world of business to tell universities
which are among the best in Europe how to run
themselves, whereas business itself is notable for
being rather poor in picking up things that are done
here or elsewhere?What would you say in response to
that? Did I not hear the reason to the original
question correctly? If I did, why is it so?
Dr Knowles: I would not use the term “laggard”. I
think it is investing perhaps less than other countries
because the basic industries which are generating
those materials are not in the UK. The heavy
chemicals, which is the BASFs, et cetera, of this
world are not in the UK and they are the major
producers of thematerials and are close to the centres
where the research is being undertaken in Holland
and Germany and so on. The Commission is also
seen as the primary source of funding in this area and
what we really need because of the enormity of the
challenges is a co-ordinated research approach. The
European Union has a system called CORDIS which
is trying to do that, trying to fund work across the
appropriate centres in the European Union to
address all of the questions, which are many, related
to nanotechnologies. I think the UK on the health
side and inhalation, as we have mentioned, is
certainly in the vanguard. In the applications, I am
not sure how much work is being funded by industry
here. As I have said, it is far greater in the
manufacturing companies. It is related to where the
actual development work is taking place rather than
where the centres of expertise may be, and I am sure
there are opportunities in theUKwhich are not being
exploited in that area. I should say, my Lord
Chairman, that I have lived outside the UK for
almost 18 years now, I have lived in Brussels all that
time, so I tend to be more familiar with what is going
on in continental Europe rather than now in the UK
research establishments.
Dr Kellie: Maybe I can add to this without turning it
into a table-thumping exercise. First of all, the
comment that we are a laggard might be too harsh,
but we are certainly not in the vanguard, that is
absolutely clear. Why are we not in the vanguard,
because we have allowed our manufacturing
industries to decline and you are seeing simply the
basic decline of UK manufacturing as a proportion
of GDP. I have given that lecture for the last ten years
and every time I do the proportion of GDP that is
manufacturing goes down. I am an absolute advocate
that the future of this country, particularly coming
out of the recession, will be led by manufacturing
companies. Let me add a more positive spin to that.
There are some super small and medium-sized
companies in this country that are picking up that
challenge. I do not just talk about my own company,
I am aware of a number of small to medium-sized
businesses that recognise by picking up these
technologies they can gain new markets and
signiﬁcant opportunities, there just are not enough of
them about. There are some great relatively small,
relatively young companies which are on the way, we
just need a lot more of them quite frankly.
Q173 Lord Cunningham of Felling: Is it the case that
you think the regulatory, research or other obstacles
and challenges that you face are going to be overcome
quickly or do you see some real obstacles which will
slow down the eventual implementation of the use
and sale of food or packaging with nanomaterial
content?
Dr Knowles: The European regulatory system is very
comprehensive, as it should be, in terms of the control
of the use of these materials. As we have discussed,
until the safety evaluation procedures are developed,
agreed and accepted by all interested parties, all
stakeholders, that is going to be a barrier to the
introduction of nanomaterials in food. In packaging
it is a little easier because if you have barrier
properties between the nanomaterial and the food
and can demonstrate by analysis there is no
migration into the food, from the public health point
of view that application is easier and is already taking
place. There is, of course, the environmental impact
which is being looked at; what the eVect is of these
materials in the environment when the packaging is
discarded. That is another series of research topics
which are being undertaken right now. As far as the
regulatory barriers in other countries, the US’s is
similar to ours, and by “ours” I mean the European
Union’s. It requires case-by-case evaluation of the
introduction of any nanotechnology derivedmaterial
into the food supply, but it has a process for doing it
rather quicker and has stated publicly that it operates
on a case-by-case basis. In Japan, again, it is a much
quicker process for getting materials onto the
market. These are single country regulatory entities,
of course, and as you will know it is easier with a
single country regulatory entity than trying to discuss
with 27. There is an opportunity for industries in
those countries to get their materials evaluated and
onto the market quicker than in Europe, which is not
to say that there is not a great deal of activity within
the European Union regulatory system to improve
the speed—there is. What we are seeing now is the
introduction of what is called the comitology
procedure to expedite approvals, through the
Member States voting within standing committee
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rather than going to the European Parliament for a
number of co-decision procedures which extend the
debates. To summarise, as soon as we have an
appropriate safety evaluation system the current
regulatory process will allow a more rapid
introduction of materials than we have in the current
discussions, but it will never be as rapid as theUS and
Japan simply because of the process.
Q174 Lord Cunningham of Felling: I think what you
are really saying is the speed or the momentumwhich
develops for packaging, wrapping, bottling, will be
signiﬁcantly diVerent from the momentum for
nanomaterials being added to the food chain?
Dr Knowles: Yes.
Q175 Lord Cunningham of Felling: Can I ask you
one other question in this regard. Where do you put
public opinion in your ranking of barriers and
obstacles to be overcome?
Dr Knowles: This is a question that has been asked
many times before and what we in the European
Food Industries Confederation, and of course the
FDF is a major participant in that, are doing with
regard to public opinion is holding public meetings
with all of the interested stakeholders. We started
these inmid-September last year where we invited the
NGOs, Friends of the Earth, Greenpeace and any
other NGO that had an interest in this area, the
suppliers, the Commission oYcials, the Consumers’
Association of Europe, about 50 people to a meeting
whichwas chaired by the European food industries to
discuss their issues. We had a series of presentations
from oYcials and from industry. We repeated that at
the end of March this year and we have made a
commitment to continue to have these public
meetings for as long as is necessary to gain the
conﬁdence of the consumer and other stakeholders as
well. The NGOs are an important factor in whether
these are a success. We have learned our lesson from
GM and we are committed to hold these meetings
alongside similar meetings, in which we participate,
that the Commission holds. They have had two what
they call Safety for Success meetings with all public
stakeholders, academics and industry on the
application of nanotechnology. The very name—
Safety for Success—tells you what are the real
barriers to the implementation of nanomaterials. We
are 100 per cent committed. I do not know if you have
seen this, but this is from the Food Safety Authority
of Ireland and is an extremely good little booklet
derived from a large report they produced for the
public on the beneﬁts and explains the functionality
of nanomaterials in food. We support that and we
support any type of leaﬂet or other form of education
for the public about nanotechnology. We are not in a
position to have direct public contact, but through
the consumer associations we expect this to cascade
out and we will continue to do this as long as is
necessary.
Q176 Baroness O’Neill of Bengarve: Are you
concerned that a mishap in those jurisdictions which
you have described as having more rapid approval
systems might boomerang on the pace at which
public conﬁdence could be built in the European
jurisdictions?
Dr Knowles:As far as theUS is concerned, and we are
working very closely and the Commissionworks very
closely with the FDA, they are implementing the
same rigid safety procedures that Europe implements
as well. Japan, whilst it talks a lot about the use of
nanotechnology there, I do not think actually has
anything on the market so it will also undertake
appropriate safety evaluations in the same way.
Globally, through our various international
organisations that we belong to as the food industry,
and the pharma industry though less so because they
have their own organisation, likewise the chemical
industry, we are ensuring that all the risks associated
with production of nanomaterials, worker safety, as
well as the public health risks from the application of
those materials are understood and discussed in
public fora globally, so wewant to bring in the others.
China is also interested in nanotechnology andwe are
operating through the International Life Sciences
Institute with China as well. We have 14 branches
outside theUS. Europe is the biggest one actually.We
are working together to ensure that does not happen.
It would certainly have dire consequences for the
technologies if it did.
Mr Opie: Can I just answer the previous question
about public opinion that Lord Cunningham raised?
Q177 Chairman: Yes, please do.
Mr Opie: Obviously for us that is the key issue.
Consumer acceptance of any product is going to be
the key thing.We are not scientists ourselves, you will
note I am the only one who is not a doctor on the
panel, we are retailers, andwe need to take consumers
with us with any products we put on the shelves
otherwise we would not stay in business. For us, it is
very important that consumers ﬁrst of all understand
the beneﬁts for them, and that was one of the issues
with GM, I do not think consumers ever really
understood what the beneﬁts were for them in GM.
There may be some clearly deﬁned beneﬁts here. For
example, we know people are looking at maybe being
able to take salt down a nanosize so we use less salt in
the product but give people the same taste. We know
when we have reformulated previously with salts and
sauces, crisps and things like that, it is a diYcult thing
to achieve to take consumers with you but it is
something they would see a beneﬁt in for themselves
in reducing their salt consumption. The beneﬁts need
to be explained to consumers. We also need to
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demystify some of the issues around nano as well so
they understand both the beneﬁts and risks to them
and all of those beneﬁts and risks are put in
proportion in a way that they can understand. I think
of an example the Food Standards Agency did. A
couple of years ago it did a survey on the levels of
benzene in ﬁzzy drinks, for example, but in the press
release they put out they put it in proportion by
talking to consumers about the exposure to benzene
from walking down a busy street, for example. That
resonated with consumers because that was
something they understood. We talk about nano and
lots of the safety issues and things like that, but I
think consumers are a long way from that and we
need to ﬁnd a way where we can explain to them the
beneﬁts, the risks, the safety assessments and the
regulatory frameworks in a way that they can
understand so where there are beneﬁts for them, and
beneﬁts maybe in their diet or lifestyle, they can
accept that and canmake a clear choice when coming
into our stores about whether they buy that product
or not.
Q178 Earl of Selborne: I would like to go back to the
comparison of the regulatory framework between the
European Union and other members of the OECD,
particularly Japan and the United States. As I
understand it, and perhaps Dr Knowles will correct
me if I have him wrong, he said that fundamentally
Japan and the United States are working to the same
rigid safety procedures as the European Union. Here
in the European Union we are waiting for resolution
as to what would be appropriate safety evaluation
systems. Japan and the United States seem to be
getting on with it. There seems to be less barrier to
innovation than here in the European Union. How
do I reconcile these two observations that we are both
working to the same standards and yet Japan and the
United States are getting on with it?
Dr Knowles: They are. We are getting on with it too.
They do not have products on themarket either. They
have systems which are inherently quicker because
they are single country regulatory systems, but,
because they are still waiting for the appropriate
safety evaluation procedures as far as direct
application to food is concerned, they do not have
any products on the market in those countries either.
They are still applying whatever science they have
and, if anyone has made any submissions to them,
they are being refused. I am not aware in those
countries of any nanomaterial directly added to food.
Packaging is a diVerent matter and we have already
had two applications approved through the EFSA
system in Europe, so we are at the same level, if you
like, as the current state of science, the current
knowledge level which is equivalent globally. We are
trying to ensure that it remains equivalent globally.
As we increase our knowledge, we can apply that
through the regulatory system for approvals of
nanomaterials. They will be quicker because they are
single country approval systems and in Europe it is
just an inherently slower process.
Q179 Earl of Selborne: That is the nature of the
problem, is it, that the timescale of the European
Union is more bureaucratic or takes longer, or is it
more thorough because it is adopting harsher
scientiﬁc criteria?
Dr Knowles: I do not think it is adopting harsher
scientiﬁc criteria than the others. I think it is just
slower bureaucratically.
Q180 Chairman: Could I just clarify one thing, Dr
Knowles. You say there are no man-modiﬁed
nanoparticles used in food. I am just looking at a
submission we have had from theMRC, which refers
to silicates, luminosilicates and titanium dioxide. It
says that exposure has been for decades as food
additives mainly. Is there some disagreement between
the MRC and yourselves?
Dr Knowles: I hope not. I think what they are
referring to is that those materials have a distribution
curve of particle sizes, as you will know. At the
bottom end of the distribution curve, there will be
some particles which fall within the nano size.
Certainly titanium dioxide and silicates are being
made now more towards the nano scale than they
used to be, but they are not being used directly in
food. Titanium dioxide is being used in sunscreens.
There have been discussions in Brussels about those
from the German Bureau of Risk Assessment as to
whether they should be re-evaluated. Where they are
being speciﬁcally engineered to have a much higher
proportion of nanomaterials present, it needs to be
evaluated as to whether that means they have
diVerent properties to the macro and micro scale.
Q181 Chairman: Are the silicates in use at the
moment?
Dr Knowles:The silicates are used as free-ﬂow agents.
They help ﬂow. I do not know in respect of food as to
whether they are being used in increased nano
proportions. As far as I understand—and we
discussed this at the end of last year in the Safety for
Success meeting—there is very little, if any, of this
material used in Europe, the silicates material, for
direct food addition. Silicates are produced in situ for
packaging for a barrier material, but again I do not
think that has ﬁnal approval from the European
Union, although the European Food Safety
Authority has approved that. It is coated inside
bottles in situ for improved barrier properties.
Q182 Baroness O’Neill of Bengarve: The Food
Standards Agency is currently considering
developing a register of nano-derived foods and food
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contact materials. Do you think this would be useful?
How would it work and, if it could work, should it be
voluntary or mandatory?
Dr Kellie: It must be right that in a development area
like this, where we all admit that it is an exciting
product area, we also clearly realise that we do not
know all the answers for the direct food contact
applications, nor indeed the long-term eVect. The
more data that is collected and managed the better. I
come back to a previous question on the public
opinion issue. For me, nanotechnology opens some
great opportunities, but we have to carry the public
conﬁdence to get all the beneﬁts we are going to get.
If we do not do that now, we will regret it and end up
with a situation which will act ultimately against the
public interest. The more we can monitor and
manage what is coming onto the market, it seems to
me a better system.Whether it should be voluntary or
regulatory, I will leave to others, but I think it is
important to do this.
Q183 Baroness O’Neill of Bengarve: Do you think it
should be done by the Food Standards Agency or by
another body?
Dr Kellie:Theyare thenatural party here in theUKto
do that.
Dr Knowles: I believe Defra tried to operate, and still
does operate, a voluntary register which was not
whollysuccessful.Giventhediscussionwehavehad, it
is not surprising that many materials were not
submitted as being nanomaterials because they are
still very much in development. Assuming that those
involved knowwhat they are supposed to do in terms
of making an application or a notiﬁcation to the
register for averyearlydevelopment,whichmaycome
to nothing, at which point do you have to notify
whichever agency is responsible? The French also, by
the way, are thinking along the same lines. Therefore,
it is diYcult to sayat thismoment in timehow itwould
be developed and indeed how it would be policed.We
cannot put products on the market until they have
been through a full safety evaluation. As soon as they
have been through that, they are public knowledge
anyway, so I amwonderingwhat thevalueof a register
would be. I am not opposed to it, I am just still at the
stage of contemplating howonewould develop such a
register andwhat its value would be to the public. If it
does have public beneﬁts when products are
approved, I think that is ﬁne.
Q184 Baroness O’Neill of Bengarve: You think it is
either premature or redundant really?
Dr Knowles: I think at this moment in time it is
premature. It may be of course that the Commission
itself will develop such a register after these materials
are approved.
Mr Opie: We would query what the purpose of the
register is if all the products have been through the
regulatory framework, the products are safe for the
market and they are on the market. Why would we
then need a subsequent register on top of that? Any
retailer will give information to any consumer who
wants to know about the products it sells, so that is
openly available. They can approach the retailer
directly and lots of people do. We are not sure, if the
food that is being put on the market satisﬁes all the
regulations and is safe for the market, what the
purpose of this would be. The second point raised is
what are we deﬁning as nanoproducts here. Are we
talking about ricotta cheese or the traditional
materials, some of the milled products, for example,
which would be down to a nano size? Until we see the
further deﬁnitions of what we are describing as nano-
engineered food, I think it is diYcult for us to say
exactly what would be on there, but we remain to be
convinced that there is a purpose in having something
above and beyond what is already available through
the regulatory framework.
Q185 Chairman: What we have understood, both
from this conversation today and from previous
witnesses, is that there are a number of products
which, for one reason or another, do not go through
any speciﬁc regulation beyond the general
requirement set for food. You picked up the cheese
example. One beneﬁt of having a register would be to
explain to people that they are already eating a lot of
food that contains nanoparticles. They may be
natural, theymay beman-made as to the silicates that
we referred to a few minutes ago, but they are out
there. It does notmean to say that they are unsafe, but
they have not been through a speciﬁc novel food
regulatoryor foodadditive regulatoryprocess.Would
there not be beneﬁt in explaining to the public more
transparently what was happening?
Mr Opie: I would absolutely support the issue around
communication and education of consumers and
using things like cheeses and various traditional
products, milled products, to explain the process. The
problem with registers is that they can quickly turn
into blacklists, in eVect. There is another way to
communicate that to the public without necessarily
needing touse a register.Wewould absolutely support
the FSA using things like traditional cheeses in a way
to demonstrate to the public that the products they
have been consuming already they may well see as
nanoproducts, but we are yet to be convinced about
the value of a register of itself, not that it could not be
used in communication and education.
Dr Knowles: The very same point was made to me by
the Director General of the Health and Consumer
ProtectionDirectorate in the Commission.We talked
about production not of a register but of this kind of
material to explain from traditional cheese
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manufacturing, as an example, through to the more
modern developments in terms of making
nanoemulsions and nano-encapsulated materials
which are natural, if I can use that word, to help
educate the public as to what these materials actually
are.A list is notgoing tohelp educate thepublic.There
should be some continuum from the very traditional
food-processing which has produced nanomaterials,
such as someof the cheese-making processes, through
to the more modern food-processing techniques
which are stillmanipulating conventional, traditional
food materials. Then we move on to what we call the
engineered nanomaterials.
Q186 Lord Cunningham of Felling: If the industry or
maybe the Food StandardsAgencywere to produce a
list of traditional food production processes and
techniqueswhich resulted in saying to the public all of
these things which have gone on for centuries—wine-
making, brewing and cheese-making—all result in
products which contain nanoparticles, is this part of
the education process?
Dr Knowles:Yes, that is what I was alluding to. I think
it may be helpful. I cannot speak for the Food
Standards Agency of course, but I think that is
certainly one tool in the education of the public which
should not be overlooked.
Dr Kellie: I heartily endorse this. This is an areawhere
education done early is going to be very valuable.
What we do not want, in my opinion, is to see a new
technology which has in a broad sense great
advantages suddenly derailed because we have run
into a period of, let us say, misdirected publicity. We
should put what we are doing in context. We should
explain what we are doing. That is the right thing to
do, inmyopinion, and putting it in context is the right
way to do it.
Q187 LordMayofOxford:Myquestionbuildsonthe
discussion we have been having and the remarks Mr
Opie andDrKellie havemade about the need to bring
people with you as you do this, which involves, on the
one hand, having products that are clear and, on the
other hand, being upfront about what is going on.We
had evidence earlier from somebodywho,whenasked
the question, ”What are you doing to inform people
about nanoparticles in products?” said, ”We hope
theydonotnotice.”Thatoccasionedacertainnumber
of raised eyebrows. The FDF have said that they are
advocating transparency throughout their supply
chain. Are they doing this? Howdo they do it? Do the
current regulations facilitate this sort of transparency
in what is coming into the food you then process?
Dr Knowles: It is being done by the FDF and by every
Member State’s equivalent of the FDF from an
initiative in the Confederation of European Food
Industries in Brussels.We have drafted and sent it out
to all members—and there are over a quarter of a
million food producers in the European union, a
dozen rather large companies cascading down to the
single, familyorganisations—toensureallunderstand
what the regulatory regime is that controls the use of
nanomaterials shouldtheygetapproached,as theyare
of course, by salesmen from the various producer
companies. They are aware of what questions to ask,
either verbally or in writing. They are given this
template of questions including the law, such as the
novel food regulations, additives, ﬂavours and
packaging regulations that control the use of these
materials in food, given as an annex to this document.
We are making sure that the whole supply chain is
aware. We are working with the Chemical Industries
Association of Europe. They have just set up a new
nano forum of their own which the food industry will
be a member of to ensure we have continuity of
information from the producer through to the user
and then hence to the public. As far as we are
concerned, it does not stopwith us, it carries on to the
public, but we have to have the information from our
suppliers.
Q188 Lord May of Oxford: I take it that was a yes
from you?
Dr Knowles:Yes.
Q189 LordMayofOxford: If somebodystartedusing
nanomaterials in their products in a novel and
deliberate way, either in food or in packaging, you are
conﬁdent that youwould know about it?
Mr Opie: Speaking for our members as major
retailers, they would all have approved lists of both
suppliers and ingredient suppliers that theywould use
in their speciﬁcations for their own-brand products.
They would pick this up deﬁnitely and will have an
ongoing dialogue as well with suppliers. It is not as if
either a major or a minor supplier is going to come
with a product directly to a retailer without them
doing due diligence on that product before they then
specify for something that they ultimately sell under
their own brand in their stores.
Q190 Lord May of Oxford: Looking back up the
supply chain, suppose fertilisers or pesticides using
nanotechnologies came onto the market. Would you
be aware if your suppliers were using them? Insofar as
you want to be reassured, would you have any
concerns about things like that if the products
themselves, the pesticides or the fertilisers, had been
approved by government?
Dr Knowles: If the products had been approved, we
would be aware because our suppliers would be
required to divulge to us and the bigger companies the
speciﬁcations of their materials. That would apply to
any supplier. We are making every eVort we can to
make sure that these smaller companies are aware of
their responsibilities, hence we have given them this
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template for questions that they should be asking of
their suppliers.
Q191 Lord May of Oxford: You are at peace about
this. Are your colleagues also?
Dr Kellie: In packaging terms, I am conﬁdent that
there is pretty open declaration. There has to be open
declaration of developments. In almost all the
developments I work on, the composition of the
materials is openly declared and we would not have it
otherwise.
Q192 Chairman: How about from the retail sector?
Mr Opie: Yes.
Q193 Chairman: Can I challenge that? From my
experience of the Food Standards Agency, I have
some questions about the reliability of knowledge
about the supply chain. If the system were as robust
as you indicate, how do you end up with these major
issues of contamination that spread throughout the
food chain—for example the famous case of Sudan 1?
As I understand it, the way you check is that you ask
your immediate supplier one up in the supply chain,
”Can you authenticate this product and that it is
what it says on the tin?” If they say yes, that is your
validation. They do exactly the same, but of course it
is like Chinese whispers. If you are only asking the
one person next to you, themessage can get degraded
as it goes through the supply chain. In the case of
Sudan 1, it ended up that there was a producer
somewhere in the Far East who was contaminating
the chilli pepper. The importer accepted the
certiﬁcation that it was not contaminated and all of
the users accepted the certiﬁcation from the importer.
I am not at all conﬁdent that the system is as robust
as you suggest. How do you respond to that?
Dr Knowles:You are quite right. No system is 100 per
cent perfect. You picked out Sudan 1, an example
that went through without being caught. This
happens. There is no such thing as a 100 per cent
guarantee that we will not miss something. In terms
of nanotechnologies, these are highly sophisticated,
way beyond the competence of the kind of suppliers
that are dealing with those materials. They will be
very expensive materials as well, so the likelihood of
that happening in this situation is remote.
Q194 Lord May of Oxford: I do not see that as an
answer to the question about pesticides or
fertilisers, frankly.
Dr Knowles: If we are buying materials, we ask all the
way through as a company, right through to buying a
ﬂavour from a ﬂavour house; we ask for the full
composition of individual ﬂavour chemicals which
are in there. Not every company does that, but we do.
Most major companies do the same. The concerns
are the small companies, which is why we are
spending time educating them, but again on
nanotechnology they are very expensive techniques.
The packaging is extremely expensive compared to
conventional and the use of these materials is not
going to be such that the small companies are likely
to pick it up, at least for some considerable time. It
requires a lot of expertise which only the major
companies will have.
Mr Opie: Sudan 1 has certainly improved vigilance
along the chain, if nothing else since then. That
situation has deﬁnitely improved since then. There
will always be a problem with adulteration of
product, for example, whether that is deliberate or
inadvertent, as we sawwithGMrice a couple of years
ago when we had problems with imports of GM rice,
but what it does show is that, once the chain knows
there is a problem, it can act incredibly quickly by
taking the products out of the chain. Irish pork
dioxins, for example, were a problem before
Christmas. The chain right up to the retailer, as soon
as it knew it had a problem, reacted extremely quickly
to that and took all potential problem products out
of the chain. Whilst there may be a problem with
adulteration on odd occasions, when that is
identiﬁed, action is quickly taken to prevent that
reaching the consumer.
Q195 Lord Haskel: If we can continue this
discussion about engaging the public, you told us
that you spend a lot of time on presentations to the
public, demystifying the regulations, communication
and education. Presumably, this is done because of
the experience with GM food. You want to avoid the
experience of that. Have you done any work to try
and ﬁnd out what it is that the public is concerned
about, or are you assuming that the public’s concerns
are similar to those about GM food? Because, if you
want to reassure them just informing them is not
enough, you need to deal with their concerns. Do you
know what their concerns are?
Dr Knowles: The UK Consumers’ Association
Which? has conducted that type of study. They have
asked consumer focus groups about
nanotechnologies and diVerent applications and
presented that last February at a meeting that we
attended. It is clear that they have diVerent concerns
depending on diVerent applications and, when it
comes to food of course, they have the greatest
concerns. Studies have been done also by academic
organisations between European countries and the
US, published inThe Public Understanding of Science
last year. There is an interesting diVerence where the
majority in the US think that nanotechnology is a
positive contribution to the economy and something
to be welcomed, whereas it is the reverse in Europe
where more people do not want to have something
which they perceive as potentially risky and where
they cannot see any beneﬁt. It comes back to
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explaining the relative beneﬁts of the diVerent
applications to the consumer. We are working with
consumers in Europe and we leave it to the European
Consumers’ Association to invite whoever they like
from their organisations, from whichever country.
The discussions have been very interesting to date. In
the UK, we have the Responsible Nano Forum and
the FDF is amember of that organisation. It includes
the consumer groupWhich? too and we discuss their
concerns and listen to what their concerns are. You
are absolutely right, that, until one knows what their
speciﬁc concerns are, one cannot address them. We
are operating this dialogue at every level where we
think it is needed and at every level they tell us it is
needed. We are responding to their requests and we
want to ensure we do not lose what we see as this
potentially very valuable technology in the way that
we ”lost” GM in Europe.
Mr Opie: I guess for retailers they have all of that and
also that they have the beneﬁt of direct contact daily
with their customers, so they know exactly what
customers think about products and a whole range of
issues which they can capture through their own
surveys and through enquiries to their customer care
line. Interestingly in GM, they do not tend to get
many enquiries until there is a potential issue either in
terms of contamination or in the media. Then they
get a spike of enquiries and it will drop away again
because most consumers assume that British retailers
do not sell GM and, therefore, when they go into a
store, they are quite happy with what is on the
shelves. In a similar way, we have spoken to some of
our members who sell non-food nanoproducts like
sunscreen, for example, and it has been very
interesting to hear from them that they have had very
few enquiries from consumers about the use of those
products. In fact, the enquiries have been all around
the beneﬁcial properties of things like sunscreen, the
fact that you do not have to put quite so much of the
product on your face, as much as queries about the
product itself. I guess retailers are lucky in a way.
They can draw on the research done by people like
the FSA,Which? and others but also they have direct
feedback from their own consumers and they will
take that into account before they put any product on
the shelves.
Q196 Lord Haskel: Do you think the Government
has any role in this?
Mr Opie: I spoke earlier about the role of the FSA,
for example, as the independent authority on food, of
the beneﬁts as well as the risks in proportion to other
foods and other issues that we encounter from the
public. Going back to the early days when we used to
have problems with avian ﬂu, for example, the FSA
did an excellent Q and A on the issues about avian ﬂu
and what it means for you in terms of possible
transmission and all these issues. All the retailers
referred their customers to the FSA line and found it
incredibly helpful. It was very well written, very clear
and it satisﬁed what customers needed to know
because it was written in a language they could
understand and allayed their fears. What we saw
quite quickly after that was a real drop-oV in terms of
problems with poultry sales.
Q197 Lord Haskel: You see the FSA as the
Government?
Mr Opie: Yes, for this purpose because the
Government has had problems sometimes around
the presentation of food safety, the creation of Defra
from MAFF, those sorts of issues, therefore, we do
support the FSA and what it does. We feel it has a lot
of trust amongst consumers. By being able to refer
consumers to an independent authority, that helps to
reinforce the messages that retailers can give.
Lord Cunningham of Felling:The whole point of the
FSA was that it was not the Government.
Q198 Lord Mitchell: Clearly, the whole GM saga
was a public relations and communications disaster.
If there were another GM equivalent which
developed today and was about to be launched, do
you feel that your industry ismuch better placed to be
able to handle the potential objections of the public?
Dr Kellie: What you have seen from all the
conversations to date is the fact that we are proactive.
I speak of my end of the technical chain. We believe
that the whole issue of consumer conﬁdence has to
stand right towards the top of the agenda.We have to
be proactive.What theGM issue taught us, if nothing
else, was that in bringing new technologies to the
market, if we do not bring the consumer with us, it is
all a waste of time. There is amassive amount ofmore
advanced thinking. These subjects are discussed very
early on.
Dr Knowles: I think we are much better equipped. I
worked through the GM saga as an industry member
of a group that really did not understand
communication with the public. The food industry
did, but it was not the food industry that was running
that; it was the producers. Now that lesson has been
learnt by all the supply chain and I think, as an
example with nanotechnology, we are engaging with
the public even before these materials are starting to
get oV the laboratory benches.
Q199 LordO’NeillofClackmannan:Yousaythatyou
have learnt the lesson of GM food.What you did was
to pack your bag and run away. That was the lesson
that you learned. If you cannot win an argument the
ﬁrst time, youdonot try andwin it the second. Iwould
askof the retailers: is your role to leador is it to follow?
If it is to follow, it sometimes can be inconvenient. If I
go into a supermarket wanting to buy vegetables, my
choice is heavily skewed towards organic food, about
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the value of which I remain to be convinced. As a
Scotsman, Idonotﬁndmuchattraction intermsof the
pricediVerential. I amencouragedbyoneaspectof the
recession, and that is that the sales of organic food are
declining.Youdonothaveagoodrecord in thisareaof
standingup for science andhaving a go.You say, ”It is
not our problem. It is the producers’,” but you screw
theproducers in somanyotherwayswhenyouwant to
get the prices down from wholesale organisations. I
am not convinced of the intellectual strength of the
retailers’ case.
Mr Opie: We are led by consumers. If consumers do
not want it and do not want to pay for it, there is no
point in a retailer putting it on the shelves. It is
interesting that you raise organics. Organics are still a
very small proportion of the products that a retailer
sells, but they have grown over the years because
consumer demand has driven them and, therefore,
retailers have kept pace with demand and put more
organics on the shelves. The problemwithGM is that
consumers could not see a beneﬁt for them so they
rejected theproduct.Theone thingwehavenot talked
about today, when we talk about public opinion, for
example, is where consumers are getting all of their
food messages from. We have talked a lot about
industry and government but we have not talked
about the roleof themedia, for example,wherea lotof
consumers will get their messages from. It is not
always about science, sometimes it is about
perception. Therefore, if we come back to the role the
FSAor theGovernment canplay, it is in brieﬁng some
of the key informers and also journalists as well as
ourselves, consumer groups, to get the messages
through all the avenues to people. The basic point is
retailers are good if theymeet consumer demand. The
ones that do not meet consumer demand go out of
business because we are a very competitive industry
and, therefore,wehave tomeetwhat consumerswant.
That is why we are very careful about any products
that we put on the shelves.
Dr Kellie: There are some still ﬁghting GM in
packagingbecauseGMhasanenormousopportunity
in packaging. We are actively involved in bioplastics
made frompotentiallyGM-derivedmaterials because
they oVer enormous, real, positive beneﬁts in, for
example, compostable packaging which is a great
opportunity and indeed possible alternatives to your
plastic cups here on this table. Those are still being
actively pursued.
Lord May of Oxford: Resonating with what Lord
O’Neill just said,LordCunninghamandIwerebothat
the centre of the storm of GM. That was not a
spontaneous event that arose from the general public,
it was a carefully orchestrated campaign by a very
eVective NGO. The ﬁrst time they tried it did not
work.The second time itwas spectacularly successful,
and of course the lack of conspicuous beneﬁcial
products to motivate people to engage is the key. The
reason they disappeared is that the retailers just
decided they did notwant to bother.Nanotechnology
has had an attempt to do this, if you remember, which
was indeed headed oV at the pass by an inquiry that
involved the NGOs. I would not be too complacent,
even with perfect oversight, information and good
products, ifoneof theNGOsdecides that this isagood
campaign that shouldbewaged,maybe really ﬁghting
an anti-globalisation campaign under this banner.
Thatwasmore a statement than a question. The air of
feeling that it is all okayandweareon topof it, I think,
is well steered clear of.
Q200 Baroness O’Neill of Bengarve: It sounds, I
suppose, very appropriate for the retail sector to say
that we are following what our customers want, but
every time you put out a new product—not a new
product involving high-tech but just a new and
diVerent biscuit—you are leading your customers.
Advertising is used to lead customers. People are
eating things theyhadnot even seenorheard thename
of tenor20yearsago, so, frankly, you lead. If you lead,
do you not have to confront both GM and nano in a
slightly diVerent way than following what the
consumer says?
Mr Opie: I would deﬁnitely agree that we probably
need to think about the way we would even approach
GM, but our statement on GM is quite clear. If
consumer demand changes and consumers demand
GM,wewouldreviewthepositiononGM.Thereason
we do not stock GM is because no consumers want it
on the shelves.
Q201 Baroness O’Neill of Bengarve: It is deﬁnitely a
follower position?
Mr Opie:Yes.
Q202 Baroness O’Neill of Bengarve: You do not
attempt to lead on this?
Mr Opie:No.
Q203 Chairman: Could I pick up the point about
consumer information? All of you have emphasised
the need to be transparent and explain what is
happening. Do you include in that support for the
notion of labelling food products that have
nanomaterials or use nanotechnologies in their
manufacture?Would you be in favour of labelling?
Mr Opie: We always see labelling as just part of
consumer information and the ability of someone to
make a choice. We would think about that if we
thought that consumers were in a position where they
would be able to use that information to make a
choice. It comes back to my very original point about
maybe demystifying what “nano” means for
consumers, both beneﬁts and potential issues for
them.
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Q204 Chairman:You are not against labelling as one
of the routes to consumer information and consumer
conﬁdence?
Mr Opie:Wedonot see it as a deﬁnitive thing, that we
must have labelling of nanoproducts beforewewould
put them on the shelves.Wewould do it if we thought
it was necessary or needed for consumers to make a
choice. For any product that is sold in a retail
establishment,a consumercanalwaysask thedetails if
they need to know. We put things on labels. The
legislative stuV aside,wedonot put informationonby
accident, we put it on to help consumers make a
choice. We would need to know that consumers
wanted to be able to make that choice for whatever
reason, either to buy the product or to sell it, in which
case you are into appropriate claims that might be
made around nano and whether they can be justiﬁed,
or if it is something that people just want on there so
that they can avoid it, like an allergen mark or
something.
Q205 Chairman: What about the manufacturers?
Would you be in favour of labelling?
Dr Knowles: I agreewithMrOpie. It is something that
we are discussing. It needs to be considered in the
context of the discussions we have been talking about
on the beneﬁts of nanotechnology, explaining what
nanotechnology and nanomaterials are so that
consumers canunderstandwhatever goeson the label.
As farasmanyof theseapplicationsareconcerned, the
manufacturer is going to bemaking a claim.These are
expensive technological developments and they are
going to be used for a purpose. That purpose is going
to be put onto the label in some form or another, so
there will be claims related to the use of these
materials, I am sure. How do we label them and what
form does the label take? There is an awful lot of
material on a label already. We know 95 per cent of
consumers never look at it. In some cases, it is just the
colour of the can that is suYcient for them to make a
choice. It is something that we are not discarding.We
are approaching this in the sameway that the retailers
are, from the basis that consumers must be aware of
what thematerials mean.
Q206 Chairman: I take it that you are both hedging
yourbetsabit onwhetheryou think labelling isagood
idea? Is that a fair summary, in a sentence? Yes or no?
Mr Opie:Yes.
Q207 Lord Crickhowell: We have talked a good deal
about research and there has been some collaboration
between the industry and government and academia.
What about collaboration on safety testing and risk
assessment between the various parties? There is an
obvious diYculty here. Your companies are spending
very large sums of money on producing and
researching competitive products. There must be a
reluctance to immediately exchange information
which may give you a competitive advantage. Does
that interfere with collaboration on risk assessment
and testing or is there any way round? Speciﬁcally, on
intellectual property rights,whichare part of the same
story, I would like a comment on how industry
eVectively is going to collaborate or is collaborating
with both the researchers in academia and with the
national and international regulatory bodies in
providing the information that is needed.
Dr Knowles: It would fall under what we call ‘pre-
competitive research’.The research is going tobedone
on the materials themselves or examples of the
materials, a nano-encapsulated material or a nano-
particulatematerial, rather than the application in the
food. It is at a stage where we are collaborating with
the EuropeanFood SafetyAuthority in the sense that
they are party to an organisation that we have in
Brussels with all the companies there. The suppliers
and the major food companies are members. We are
looking at how one should organise the research that
you are talking about in terms of in vivo ingestion of
these materials as opposed to inhalation. At the same
time, we are working with academia, for example, the
Bilthoven laboratories of the Dutch Public Health
Service, on how to measure these materials in food
matrices as part of that research. It is ongoing. It is a
joint activity which we hope will be translated into a
major, multicentre project with the Commission
funding that project, or at least funding half of it. The
other half will come from the industry, as for all
commissioned researchof this nature. It is not diYcult
for us to collaborate. In fact, we are actively
collaborating with each other and with our suppliers
at this stage of the research.
Q208 Lord Crickhowell: All right, there is general
research of that kind, but here you are, you are
researching to produce this material that is going to
consume less fat or whatever it is. You are clearly
doingyourownsafety testingbecauseyoudonotwant
to ﬁnd yourself launching a product you have wasted
all your money and time on and it is rejected. How
inhibited are you at that point in providing
information which is going to be of huge importance
across the industry indealingwith this sortofproduct,
when there may be some other competitor who is at
about the samepoint in their development, also doing
their testing? Is there an inhibitiononyour sharing the
information that enables eVective testing and risk
assessment to take place?
Dr Knowles: Yes. We would not share that with a
competitor, but both would be submitted to the
European Food Safety Authority for the risk
assessment. We would do our own risk assessment
before we submitted it. If we felt it was safe, we would
submit it andtheywouldsubmit it. It isnotunusual for
EFSA to have similar submissions.
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Q209 Lord Crickhowell: That means that, if a
particular lesson has been learnt about safety, you
may get the thing passed, but the lesson cannot easily
be passed back to other people so that they beneﬁt
from it.
Dr Knowles:Once it goes to EFSA, it becomes public,
so they beneﬁt from that research immediately. The
work that we carry out is published. If it is us and
most other companies, we would be doing it through
an academic organisation and they would publish the
ﬁndings. The reports are available for the
Commission. All the toxicology and details are
submitted to the European Food SafetyAuthority, so
they would be fully cognisant of all of the issues that
have been addressed.
Q210 Lord Crickhowell: Your simple answer is that
you believe commercial conﬁdentiality is not an
inhibition on eVective sharing of safety information?
Dr Knowles: At the time when it is commercialised,
no, the safety information is circulated.
Q211 Lord Mitchell: What guidance does industry
need from the Government on health and safety risks
for nanotechnology?
Dr Knowles: I suppose it needs the kind of guidance
in more detail that has been given by the European
Food Safety Authority on how to undertake
appropriate hazard identiﬁcation testing, how to do
exposure assessments and the analysis of these
materials. It is nothing that the Government in itself
can do alone. It needs to work with all of the
stakeholders to provide that guidance. All of the
regulators and the academics need to work together
with the Government to provide that information to
allow the suppliers and manufacturers of
nanomaterials to carry out appropriate safety testing.
That is the major problem that we have at the
moment.
Q212 Chairman: Is it alwaysmade clear to you or do
you understand automatically which set of
regulations nanotechnologies might come under? We
have already heard that there is a debate about
whether things would come under the novel food
regulations or other food regulations.
Dr Knowles: The novel food regulations certainly of
course catch probably the majority of
nanotechnology applications, but the food additive
regulations will also catch them and there is an
amendment to those to make it so, the ﬂavouring
regulations catch them, the speciﬁcations on purity
catch them and the packaging regulations catch
them. All regulations that control the manufacture
and sale of food are drafted in a way to pick up
advances in technology, whatever those may be; they
are designed to do that.
Q213 Lord Methuen: To put things in perspective,
you have said that we have used nanofoods
essentially for years or ingredients. If you take ﬁnely
ground ﬂour, what size would the particles be?
Dr Knowles: Signiﬁcantly larger than nano, I suspect.
They look small, but nano is extremely small.
Chairman: In drawing the session to a close, I would
like to thank all three of our witnesses for their
answers to our questions. It has been very
illuminating and interesting for us. If you have any
further points that you would like to make that you
have not been able to express during this session,
please write them down and send them in to the
Committee Clerk. We would very much like to hear
fromyou if you have additional points youwould like
to make. In due course, you will receive a draft of this
evidence session and of course you will have an
opportunity to make any amendments you wish to
make to the evidence.With that, I would like to thank
you all very much and end this session.
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Supplementary letter from the Food and Drink Federation
Thank you for your letter of 1 June addressed to Dr Mike Knowles, with whom I have discussed and agreed
this response, which is sent on his behalf.
To clarify Mike’s statement to the Committee about the use of titanium dioxide (El71) in food, I can conﬁrm
that it is an authorised food colour permitted for use in all foods, except unprocessed foodstuVs and those
foods in which the use of colours is speciﬁcally restricted, according to Directive 94/36/EC,6 implemented in
the UK by the Colours in Food Regulations 1995 (as amended).
Titanium dioxide is extracted from natural ores and milled to the desired particle size relative to its intended
use, which is traditionally, as is the case in food, to provide optimum opacity and whiteness. As with anymilled
product, particle sizes will vary, and some preparations may include some particles in the nanoscale range, by
which we mean below 100nm. We understand that the MRC are referring to materials of about 200nm as the
average particle size, and with no novel nanoscale properties. The nano-engineered titanium dioxide used in
sunscreens is, as we understand it, deliberately engineered at the low nanoscale, ie below 100nm, to be
transparent. As titanium dioxide no longer imparts opacity and whiteness at the nanoscale, it self-evidently
has no application in food as a white colour.
The recently adopted European Regulation on food additives,7 which will eventually supersede Directive 94/
36/EC, includes a clause requiring that any food additive already approved which is prepared by production
methods or using starting materials signiﬁcantly diVerent from those covered by the existing speciﬁcations,
laid down for all approved additives, should be submitted for evaluation by the European Food Safety
Authority (EFSA). The Regulation speciﬁes that: “‘Signiﬁcantly diVerent’ could mean, inter alia, a change of
the production method from extraction from a plant to production by fermentation using a micro-organism
or a genetic modiﬁcation of the original micro-organism, a change in starting materials, or a change in particle
size, including the use of nanotechnology.” (Recital 14.) These provisions can be seen as clarifying the
meaning, as far as nanotechnology is concerned, of the current provision in the EC legislation on additives
that requires prior evaluation by EFSA before application of a new production method of food additives.
We are in regular discussionwith the associations that are broadly representative of suppliers of food additives,
both in theUK and at EU level. They assure us that their membership is very well aware of the ongoing debate
on nanotechnology, and fully cognisant of their legal obligations, as described above, and committed to abide
by them.
I hope this clariﬁes the position, but should you have any further questions, please do not hesitate to
contact me.
1 July 2009
6 European Parliament and Council directive 94/36/EC of 30 June 1994 on colours for use in foodstuVs, OYcial Journal L 237/13,
10.9.94, 13–29.
7 Regulation (EC)No 1333/2008 of the European Parliament and of the Council of 16December 2008 on food additives,OYcial Journal
L 354, 31.12.2008, 16–33.
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Memorandum by Professor Ken Donaldson, University of Edinburgh
I am a lung particle toxicologists and so I will start of there. Nanoparticles are ubiquitous in the environment
from natural and anthropogenic sources and have been throughout evolutionary time. Combustion-derived
nanoparticles (CDNP; soots) are present in air, and to a greater extent in the last few hundred years than in
previous times, and they are considered to drive a number of adverse eVects in the lungs and cardiovascular
system that are well-documented These arise, in the opinion of many experts, primarily from inﬂammatory
eVects in the lungs. There is a hypothesis that there is also translocation of such NP to the blood and the brain
and there is restricted evidence that there is limited translocation, using animal and experimentally-generated
NP. There is no evidence currently that translocation of NP out of the lungs occurs in humans or leads to any
adverse eVects, although it is possible, even likley. I personally have come to believe that there is minor
redistribution of very small particles from the lungs. The question is whether this translocation is important
in any adverse eVects, compared to the systemic eVects caused of the inﬂammation at the primary site of
deposition in the lungs, acting on other sites like atherosclerotic plaques or even the brain. This remains
unanswered at the moment.
FormanufacturedNP, eVects will depend on exposure and on the intrinsic hazard (eg surface reactivity, ﬁbrous
shape). The majority of bulk-produced NP (silica, alumina, TiO2, carbon black) presently are low toxicity but
there is concern over carbon nanotubes and other high aspect ratio nanoparticles (HARN) because of their
superﬁcial similarity to asbestos. There may be higher hazard NP to which there will be exposure and so there
must be vigilance but this can be foreseen with adequate testing. All-in-all it seems unlikely that there will be
any large-scale pandemic of lung disease from bulk-manufacture NP if sensible hygiene standards are used but
we must be watchful for increasing production of unusual NP like HARN and some metals (Copper, silver,
possibly).
The gut can be considered to have undergone similar evolutionary forces to allow it to deal with nanoparticles
over evolutionary time. The gut will certainly be evolved to deal with natural particles which has always been
present on food and probably only in the last few hundred years will these have been thoroughly removed by
washing prior to preparation/eating. So nanoparticles in soils will be able to be dealt with by the gut. A key
question is whether the gut has evolved to deal with the traYc of CDNP from the lungs that it encounters from
the normal process of mucociliary clearance. This delivers 99.9 per cent of all particles that deposit in the
airspaces to the gut. Its true that the stomach and its acid environment stands a key gatekeeper and that all
particles will be acid-treated prior to entering the gut, but many particle will not be dissolved by the acid in
the stomach and will continue, albeit with surface modiﬁcation due to acid treatment, to the intestine. One of
these modiﬁcations could be to the aggregation status (I don’t know if it would causemore or less aggregation)
and that could be important in subsequent eVects on the intestine. The PM10 epidemiology literature, which
documents in large part the adverse eVects of CDNP, since the CDNP is probably themost pathogenic fraction
of the PM cloud, does not pick up an adverse eVect on the gut. This may be a result of some quirk of reporting/
death certiﬁcates etc but, taken at face value, it does suggest that the delivery of CDNP to the gut from the
lung does not have an adverse eVect on the gut.
The question is whether any manufactured NP might have such an eVect. The ante is greatly increased when
the NP are added to food purposely. All toxicity is dose-related and so the likelihood of an adverse eVect
increases with dose and so adding NP to food deﬁnitely increases the likelihood of adverse eVects. It is to be
hoped that the companies that make the food have testing procedures in animals that demonstrate no ill-
eVects—such data should be made available to the Committee. The likely eVects might include pro-
inﬂammatory eVects and immunological abnormalities.
Another problem lies with the normal ﬂora of the gut, which could well be unbalanced if there was selective
toxicity toward commensals—silver NP seem a particular threat in this area.
There is a suggestion that asbestos exposure is linked to cancer of the stomach and colon although this is
disputed, and would arise from the delivery of ﬁbres to the gut via mucociliary clearance. It is just possible
that a HARN might be especially active in this regard.
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Use of NP in food will greatly increase the likelihood for release of NP into the environment during
manufacture and disposal and in human waste, where there might be ecotoxicological eVects that are not in
my area of expertise.
20 March 2009
Memorandum by Central Science Laboratory
Nanotechnologies in Food
This submission is meant to provide a brief summary of ﬁndings of the studies carried out at Central Science
Laboratory (CSL) into the potential applications and implications of nanotechnologies in food.More detailed
ﬁndings are submitted as two separate reports on the studies that the CSL team has recently carried out for
the Food Standards Agency.
A number of recent reports and reviews have identiﬁed the current and short-term projected applications of
nanotechnologies for food and beverages (Bouwmeester et al., 2007; Chaudhry et al., 2008; EFSA, 2008; Food
Safety Authority of Ireland, 2008). Like other sectors, nanotechnologies are promising to revolutionise the
food sector—from production to processing, storage, and development of innovative materials, products and
applications. Currently, such applications in the food sector are new emergent, but their number and range is
expected to increase in the coming years. Virtually all current applications of nanotechnologies in food are
outside Europe, although some supplements and food packaging materials are available in the EU. Also, the
global nature of food business means that more products and applications are likely to be available in the EU
in the coming years. This also means that there will be a need for regulation of the risks, and establishment of
liabilities at the global level.
The current and short-term projected applications of nanotechnologies include nano-sized or
nanoencapsulated ingredients and additives for food, beverage, and health-food applications. A current niche
for such applications is in the areas where there is an overlap between the food, medicines, and cosmetics
sectors. For example, some food products are marketed as ameans to enhance nutrition for diVerent lifestyles,
or as an aid to beauty, health and wellbeing. These hybrid sectors have been the ﬁrst focus of nanotechnology
applications, which have only recently started to appear in the mainstream food sector. Thus the vast majority
of the currently available nanotechnology products is in the areas of supplements, healthfoods and
nutraceuticals, with only a few products in the food and beverage areas. The main tenet behind the
development of nano-sized food ingredients and additives appears to be the enhanced uptake and
bioavailability of nano-sized substances in the body, although other beneﬁts such as improvement in taste,
consistency, stability and texture etc have also been claimed (Chaudhry et al., 2008).
A major application area for engineered nanoparticles (ENPs) is for food packaging. Whilst most
nanotechnology applications for food and beverages are currently at R&D or near-market stages, the
applications for food packaging are rapidly becoming a commercial reality. A contributing factor to such
developments seems to be the expectation that, due to the ﬁxed or embedded nature of ENPs in plastic
polymers, they are not likely to pose any signiﬁcant risk to the consumer. Indeed, nanotechnology applications
for food contact materials (FCMs) already make up the largest share of the current and short-term predicted
nanofood market (Ciehtiﬁca, 2006).
Nanomaterials Relevant to Food Applications
The currently available information suggests that nanomaterials used in (health)food applications include
both inorganic (metal, metal oxides) and organic materials. In addition to the ENPs, there is a possibility that
certain microscale materials used in the food and feed area may contain a nanoscale fraction due to natural
size range variation (EFSA, 2008).
Based on the available information, the ENP likely to be found in food fall into three categories: metal and
metal oxide (including alkaline earth metal and silicate), surface functionalised, and organic ENPs. Examples
of these include:
1. Metal/Metal-oxides
A number of meal/metal-oxide ENPs are known to used in (health)food products and food packaging
applications. These include ENPs of transition metals such as silver and iron; alkaline earth metals such as
calcium and magnesium; and non metals such as selenium and silicates. Others ENPs that can potentially be
used in food applications include titanium dioxide. Food packaging is the major area of application of
metal(oxide) ENPs. Example applications include plastic polymers with nano-clay as gas barrier, nano-silver
and nano-zinc oxide for antimicrobial action, nano-titanium dioxide forUVprotection, nano-titanium nitride
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for mechanical strength and as a processing aid, nano-silica for surface coating etc. The use of insoluble
metal(oxide) ENPs in food applications, especially those that are unlikely to be assimilated in the Gl tract,
raises a number of concerns. The likelihood of translocation of such ENPs with potentially large reactive
surfaces to various cells and tissues in the body may lead to certain risks to consumer health; for example,
potential cellular damage and inﬂammatory reactions due to generation of reactive oxygen radical species
(Oberdo¨rster, 2000; Li et al., 2003; Donaldson et al., 2004). ENPs can also adsorb or bind diVerent substances
on their surfaces (S˘imon and Joner 2008), and thus may carry potentially harmful chemicals and foreign
substances into the blood and to various tissues and organs in the body.
Certain metal(oxide) ENPs, such as that of silver, magnesium oxide and zinc oxide, are known to have strong
antimicrobial activity. Especially, there is an increasing use of nanosilver in a number of consumer products,
including (health)food and food packaging applications. Indeed, the use of nano-silver as an antimicrobial,
antiodorant, and a (proclaimed) health supplement, has already surpassed all other ENPs currently in use in
diVerent sectors (WoodrowWilson, 2008). This has also led to concerns over its safety to human health when
ingested orally. Despite this, there is no published research at present on how the intake of nanosilver via food
and drinks might aVect the cellular function or the gut natural microﬂora.
Nano-silica is known to be used in food contact surfaces and food packaging applications, and some reports
suggest its use in clearing of beers and wines, and as a free ﬂowing agent in powdered soups. The conventional
bulk form of silica is a permitted food additive (Si02, E551), but concerns have been raised over the safety of
nano-silica because it is likely to remain undigested in the Gl tract and thus may pose a risk due to greater
uptake and translocation in the body. In this regard, a commercial product “Slim Shake Chocolate”, available
in the USA, is understood to incorporate nano-sized silica particles (between 4 to 6 nm in diameter) that are
coated with coco to enhance the chocolate ﬂavour through the increase in surface area that hits the taste buds.
Titanium dioxide, in conventional bulk form, is an already approved additive for food use (Ti02 E171), but
there is a concern that the conventional form may also contain a nano-sized fraction. Nano-titanium dioxide
is used in a number of consumer products (eg paints, coatings) and its use may extend to foodstuVs. For
example, a patent by Mars Inc. (US Patent US5741505) describes nano-scale inorganic coatings applied
directly on food surface to provide moisture or oxygen barrier and thus improve shelf life and/or the ﬂavour
impact of foods. The materials used for the nano-coatings, applied in a continuous process as a thin
amorphous ﬁlm of 50 nm or less, include titanium dioxide. The main intended applications described in the
patent include confectionary products.
2. Surface Functionalised Nanomaterials
Surface functionalised nanoparticles are the second generation nanoparticles that add certain functionality to
the matrix, such as antimicrobial activity, or a preservative action through absorption of oxygen. For food
packaging materials, functionalised ENPs are used to bind with the polymer matrix to oVer mechanical
strength or a barrier against movement of gases, volatile components (such as ﬂavours) or moisture.
Compared to inert materials, the use of this category of ENPs in food applications is likely to grow in the
future. They are also more likely to be react with diVerent food components, or become bound to food
matrices. Examples include organically-modiﬁed nano-clays that are currently used in food packaging to
enhance gas-barrier properties. The nanoclay mineral is mainly montmorillonite (also termed as bentonite),
which is a natural clay obtained from volcanic ash/rocks, and has a natural nano-scaled layer structure.
3. Organic Nanomaterials
A number of organic nano-sized materials are used (or have been developed for use) in food products. These
include vitamins, antioxidants, colours, ﬂavours, and preservatives. The main principle behind the
development of nano-sized organic substances is the greater uptake, absorption and bioavailability in the
body, compared to conventional bulk equivalents. However, a greater uptake and bioavailability of certain
compounds, such as certain preservatives, can also be detrimental to consumer health. Also developed for use
in food products are nano-sized carrier systems for nutrients and supplements. These are based on
nanoencapsulation of the substances both in liposomes and micelles as well as protein based carriers. Such
nano-carrier systems are used for taste masking of ingredients and additives, and their protection from
degradation during processing. They are also claimed for enhanced bioavailability of nutrients/supplements,
antimicrobial activity and other health beneﬁts. There is a wide range of materials available in this category,
for example, food additives (eg benzoic acid, citric acid, ascorbic acid), and supplements (eg vitamins A and
E, isoﬂavones, ß-carotene, lutein, omega-3 fatty acids, coenzyme-Q10). The concept of nano-delivery systems
has essentially originated from research into targeted delivery of drugs and therapeutics. The use of similar
technology in foodstuVs is interesting in the sense that whilst it can oVer increased absorption, uptake and
bioavailability, it also has the potential to alter tissue distribution of the substances in the body. For example,
104 nanotechnologies and food: evidence
certain water-soluble compounds (such as vitamin-C) have been rendered fat dispersible through nano-carrier
technology. Vice versa, certain fat-dispersible compounds (eg vitamin-A) have been rendered water
dispersible. It is hoped that these nano-carriers are completely broken down and their contents are released in
the GIT. As such, the encapsulated compounds will not be any diVerent from their conventional equivalents.
However, if a nano-carrier system is capable of delivering the encapsulated substance to the bloodstream, its
absorption, tissue distribution and bioavailabiiity may be drastically diVerent from the conventional forms.
This raises the concern that some nano-carriers may act as a “Trojan Horse” and facilitate translocation of
the encapsulated substances or other foreign materials to unintended parts of the body.
It is also worth mentioning that there are many other nanomaterials that are used for other applications but
their use in food/food packaging is uncertain or unlikely. Examples include certain carbon-based materials
(such as fullerenes, carbon nanotubes). Although, recent studies have linked carbon nanotubes with potential
harmful eVects in biological system, they are not likely to be used in food applications. This is because
functionalities that carbon nanotubes oVer mainly derive from their enhanced tensile strength and electrical
conductivity, which are of little relevance to potential use in food, although there may be some applications
in the packaging area.
Consumer Safety Concerns
It is known that the conventional physicochemical rules are not fully applicable at the nanometer scale, and
that there can be some fundamental shifts in physicochemical properties, behaviour, and interactions of ENPs
compared to their bulk equivalents. For example, quantum eVects may have a much greater inﬂuence on the
properties of ENPs, especially of those in the lower nanometer size range, compared to their bulk equivalents.
In some cases, such changes in physicochemical properties may also lead to a change in the eVects and impacts
on biological systems. Some studies have suggested a deviating toxicity proﬁle for some ENPs compared to
their conventional equivalents (Donaldson et al. 2001; Nel et al. 2006. An important aspect to consider in
relation to potential harmful eVects of ENP is their increased ability to penetrate cellular barriers (Geiser et
al., 2005; Oberdo¨rster et al., 2004). This adds a new dimension to particulate toxicology, as ENPs can
potentially reach new targets in the body where entry of larger particulates is restricted (Jani et al. 1990; Carr
et al. 1996; Hillyer and Albrecht 2001; Hoet et al. 2004; Florence 2005; des Rieux et al. 2006; De Jong et al.
2008). ENPs are also known to adsorb or bind diVerent compounds andmoieties on their surfaces (S˘imon and
Joner 2008), and may act as a carrier of potentially harmful chemicals and foreign substances into the blood
and diVerent tissues and organs in the body.
Depending on the surface chemistry, systemically introduced ENPs have been found to interact with various
biological entities, such as eg plasma proteins, platelets and cells (Nemmar et al. 2002; S˘imon and Joner 2008).
Such interactions may have a substantial eVect on the distribution and excretion of an ENP (Dobrovolskaia
2007). In this regard, there is emerging evidence to suggest that ENPs become coated with certain
biomolecules, especially proteins, and these coatings can direct them to speciﬁc locations in the body (Lynch
and Dawson 2008). For example, coating with apolipoprotein E has been associated with their transport to
the brain (Michaelis et al. 2006). The protein “corona” is, however, also reported to be changeable in diVerent
surroundings (Cedervall et al. 2007). This suggests that ENPs can undergo complex and dynamic interactions
in biological environments, and studies carried out on “neat” ENPs under artiﬁcial conditions may not
represent their true behaviour and eVects in real-life situations.
Nanomaterials that are likely to dissolve/solubilise either in the food matrix or in the Gl tract are not likely
to raise health concerns as, once digested or dissolved, they are not likely to behave any diVerently from the
conventional bulk equivalents. One example is that of nano-selenium, which is being marketed as an additive
to a tea product in China for a number of (proclaimed) health beneﬁts. However, nano-selenium is likely to
solubilise in food or in the Gl tract. Another example is that of a mayonnaise (currently under development)
which is composed of nano-micelles that contain nano-droplets of water inside. The mayonnaise is being
developed to oVer taste and texture attributes similar to the full fat equivalent, but with a signiﬁcant reduction
in the amount of fat intake by the consumer.
It is also worth highlighting that currently there are a number of major knowledge gaps in regard to the
behaviour, interactions, fate and toxicological eVects of most ENPs in theGl tract. It is possible that the ENPs
added (or migrated) to food will not remain in a free form (and hence not available for translocation) because
of agglomeration, binding with food components, reaction with stomach acid or digestive enzymes.
Furthermore, much of the available toxicological information relates to in vitro studies, or to exposure
through inhalation of ENPs, and full extent of hazard, exposure, and risk from the ingestion of ENPs via food
and drinks are therefore largely unknown.
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Memorandum by the Medical Research Council Human Nutrition Research Unit
MRC Collaborative Centre for Human Nutrition Research (hereafter HNR) was established in 1998 to
advance knowledge of the relationships between human nutrition and health by providing a national centre
of excellence for the measurement and interpretation of biochemical, functional and dietary indicators of
nutritional status and health. HNR conducts basic research in relevant areas, focusing on optimal nutritional
status and nutritional vulnerability in relation to health, including the development of innovative
methodologies. HNR responds to the strategic priorities of the wider scientiﬁc community by conducting
research projects, within the scope of HNR’s activities, in collaboration with, and on behalf of: other MRC
establishments and groups, Government departments, industry, national and international agencies,
universities, research foundations and charitable organisations. HNR also acts as an independent,
authoritative source of scientiﬁc advice and information on nutrition and health in order to foster evidence-
based nutrition policy and practice. In light of the work carried out at HNR and the expertise of our staV, our
comments are conﬁned primarily to the role of nutrition in securing good health for the whole population.
The Micronutrient Status Research section at MRC Human Nutrition Research, Cambridge, led by Dr
Jonathan Powell, has a long history of research interests in mineral based nano—and micro-particles in the
gastrointestinal tract in terms of exposure, uptake and potential cellular eVects. We study both endogenously-
formed mineral particles (mineralised calcium) and exogenous mineral particles (eg dietary ferritin or food
additives such as silicates and titanium dioxide) and we use a range of approaches from synthetic chemistry
and basic cellular thought to whole-animal studies (human and murine).
Introductory Concepts
We consider a nanoparticle to be a non-living nano-scaled entity. Traditionally such particles would be
considered ultra-ﬁne, ﬁne or coarse, depending upon size, and there is an increasing consensus that the ultra-
ﬁne fraction is equivalent in meaning to nanoparticulate, which would be of' 100 nm diameter. Biologically
this makes sense because, as a rule of thumb, particles below 100 nm diameter tend not to trigger active uptake
mechanisms (ie macro-pinocytosis and phagocytosis) but instead tend to be taken up through more
constitutive endocytic mechanisms. Nonetheless we wish to point out that the gut is heavily exposed to ﬁne
particles (ie particles ( 100 nm diameter) and that these should be considered in the overall picture.
Additionally, the diVerent mechanisms of uptake, determined by particle size, will aVect intracellular exposure
and outcomes.
The gastrointestinal tract is a unique environment. Unlike any other tissue the gut has speciﬁcmechanisms for
the purposeful uptake of nanoparticles as well as the inevitable inadvertent pathways that nanoparticles are
able to access. The major pathways are as follows:
1. Epithelial cell endocytosis. This is for true ultra-ﬁne particles and, for example, is the route of uptake
of dietary ferritin.
2. Paracellular uptake of small ultra-ﬁnes, which may be enhanced through disease processes or drugs,
or dietary agents that enhance this pathway.
3. Persorption, which will allow the uptake of ﬁne and ultra-ﬁne particles. This is a mechanism of
inadvertent permeation where an enterocyte leaving the villous tip leaves a hole through which
particles can permeate.
4. M-cell uptake overlying intestinal lymphoid aggregates. This is the classical route for the uptake of
ﬁne particles and is eYcient but it is likely that ultra-ﬁnes also access this route.
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A further aspect of the unique gut environment is that it contains many luminal toxins and antigens and, due
to entropic forces, particles will bind these in the lumen with relatively high aYnity. This will change the overall
properties of the particle surface and the cellular eVects of the antigen or toxin. It should be noted that there
are recent data showing that prion infectivity is greatly increased when prions are ingested with particulates.
Immune cells from the gut will migrate to other organs and, therefore, there is a systemic route for distribution
of particles from the gut as well as the obvious routing through venous and lymphatic channels.
Gut diseases may potentially increase permeability of nanoparticle uptake.
State of the Science and its Current use in the Food Sector
— What are the main potential applications and beneﬁts of nanotechnologies and nanomaterials in the food
sector, either in products or in the food production process?
— What is the current state of the market for, and the use of, food products and food production processes
involving nanotechnologies or nanomaterials, either abroad or in the UK?
— What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they
be applied in the food sector, and when might they enter the market?
— What is the current state of research and development in the UK regarding nanotechnologies and
nanomaterials which have or may have an application within the food sector? How does it compare to
research and development in other countries?
— What are the barriers to the development of new nano-products or processes in the food sector?
We wish to make clear to the Committee that nanoparticles are not a new phenomenon, they occur naturally
and that the gut has been exposed to them presumably throughout evolution. However, due to marked
technological advances over the last ﬁve to 10 years, we are able to characterise nanoparticles so much better
than before, which is at least one reason for their recent appearance on the scientiﬁc horizon. The main areas
pertinent to the G.I tract are as follows:
1. Enhanced delivery of nutrients: nano-encapsulation or micellar protection of micronutrients and
antioxidants to prevent them from degradation during manufacture and storage or under
gastrointestinal conditions. These products are already in the marketplace, for example, Novasol is
a product range of supplements from Aquasol which consists of pH-resistant micelles that deliver
vitamins and antioxidants. Another example is Canola Active oil, produced by Shemen Industries,
that delivers phytosterols to inhibit the transportation of cholesterol from the digestive system into
the bloodstream.
2. Safety: nanosensors for pathogen and contaminant detection. Raﬂatac have recently released,
commercially, a hydrogen sulphide indicator label for fresh poultry products, where the generation
of hydrogen sulphide indicates spoilage. This label contains a nano-layer of silver that changes colour
once it reacts with hydrogen sulphide
3. Smart packaging: Packaging that reacts to stimuli such as materials with self-healing properties when
perforated or an intelligent ripeness indicator that responds to aroma as fruit ripens.
4. Reducing spoilage: nanoclays in food packaging prevent the permeation of oxygen to slow the ageing
process of food or slow the ripening of fruits and vegetables. Honeywell are marketing an oxygen
barrier based on nanoclays and a nylon resin that scavenges oxygen to extend the shelf-life of beer
(AegisE OX barrier).
5. Interactive food: foods and beverage products that can be personalized to ﬁt the tastes, nutritional
needs, or allergies of individual consumers. Kraft are one of the leaders in this ﬁeld of research.
6. Taste or texture improvement: reduce consumption of fat, sugar and salt through the enhancement
of taste characteristics. Slim Shake Chocolate is a product already in the market, which the
manufacturer (RBC), claims to contain 4–6 nm silica nanoparticles that are coated with cocoa
components (“cocoa clusters”) and due to their high surface area provide a satisfactory sensory
experience in a low fat and low sugar product. Another example comes fromUnilever which aims to
reduce the fat content in ice-cream from 16 per cent to about 1 per cent by decreasing the size of
emulsion particles that give ice-cream its texture.
7. Equipment coating: application of nano-coating in food processing equipment to prevent the growth
of bioﬁlms that can lead to food spoilage and contamination. Many commercially available food
containers are already coated with nano-silver, or anti-sticking nano-composites, and some
refrigerators are coated with nano-silver. Zinc oxide is also being studied as a cheaper anti-microbial
agent to replace nano-silver, and applications are expected in the near future.
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8. Removal of unwanted chemicals or pathogens from food.
9. Food processing: nanosensors that can withstand extreme conditions (eg temperature, pressure,
viscosity) and provide real-time data on processing conditions.
Further examples can be found in the presentation given by Dr Dora Pereira of the MSR section at MRC-
HNR (Appendix, page 3) [not printed] to an audience of the Cambridge Science festival on 13 March. We
would like to add that although the range of nanotechnologies that can be applied to food, or food production,
is vast, and many diVerent strategies are being developed or are already in the market, the perception of safety
will determine public acceptance and may limit the growth in several areas.
Health and Safety
— What is the current state of scientiﬁc knowledge about the risks posed to consumers by the use of
nanotechnologies and nanomaterials in the food sector? In which areas does our understanding need to
be developed?
— Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the
food sector suYcient? Are current funding mechanisms ﬁt for purpose?
— Can current risk assessment frameworks within the food sector adequately assess the risks of exposure
to nanotechnologies and nanomaterials for consumers? If not, what amendments are necessary?
— Are the risks associated with the presence of naturally occurring nanomaterials in food products any
diVerent to those relating tomanufactured nanomaterials? Should both types of nanomaterials be treated
the same for regulatory purposes?
Gastrointestinal exposure to nanoparticles may be natural, due to inadvertent environmental exposure or due
to purposeful environmental exposure. Examples of naturally occurring nanoparticles are dietary ferritin,
which is about 13 nm in diameter but when digested releases iron oxide particles of around 2 to 3 nm and the
endogenous calcium phosphate particles that are formed within the gut lumen and appear to have diameters
of 20 to 200 nm. It is likely themajority of natural nanoparticles to which the gut is exposed are mineral based.
Inadvertent environmental exposure comes through soil, dust, exhaust fumes etc. In contrast, purposeful,
man-made exposure is mainly through food additives and excipients or congeners that are used in supplements
and medicines etc.
We believe that traditional toxicology models are not likely to capture much information when it comes to
nanoparticle adverse eVects. This is because any eVects are likely to be mediated immunologically and,
therefore, identiﬁed through chronic exposure and by interaction with individual genotypes. It may ﬁrst be
useful to categorise particles as ﬁne or ultra-ﬁne to identify their likely route of cellular uptake and thereafter
to establish their chemical stability to predict cellular processing. It may thus become possible to develop
assays that will predict nanoparticle toxicity.
Several companies are developing nano-delivery systems that enhance the absorption of antioxidants known
to provide health beneﬁts. However, many of these antioxidants are normally poorly absorbed and may not
be well tolerated at higher levels, which may result in “too much of a good thing” scenarios. Therefore, prior
knowledge based on normal delivery of nutrients should be ignored and these nano-delivered nutrients should
be treated as novel chemical entities. However, the use of naturally occurring nanomaterials (eg ferritin) may
be fast-tracked in future regulatory processes providing that there is evidence of their consumption over
periods of time long enough to guarantee their safety, and that their administration is not substantially above
what would be found in an average diet. MRC-HNR is working on the synthesis and commercialisation of
ferritin-core mimetics as novel iron supplements.
Regulatory Framework
— Is the regulatory framework for nanotechnologies and nanomaterials ﬁt for purpose? How well are
imported food products containing nanotechnologies and nanomaterials regulated?
— How eVective is voluntary self-regulation either in the UK or EU or at an international level? What is
the take up by companies working in the food sector?
— Will current regulations be able adequately to control the next generation of nanotechnologies and
nanomaterials?
— Is there any inter-governmental co-operation on regulations and standards?What lessons can be learned
from regulatory systems in other countries?
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Currently, legislation does not account for the nano-scaling of current approved excipients and additives. An
example of this is noted above, namely that amorphous silica is an approved particulate which recently has
been nano-sized by RBC in their Slim Shake Chocolate product and thus has “inherent” FDA approval
although the original toxicity testing is likely to have been carried out on particles of tens of micrometres in
diameter. We, therefore, believe that the regulatory process should be based on a case-by-case approach.
Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
We have not carried out any surveys to consider the level of public awareness or perception of
nanotechnologies in the food sector.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
EVorts to inform the public have not kept pace with the growth of this new technology area. This increases
the risk that a false alarm over safety or health consequences could undermine public conﬁdence, engender
consumer mistrust, and, as a result, damage the future of nanotechnology, before the most exciting
applications are realised.
In the latest nationalMORI Survey for theOYce of Science and Technology (2005) a large proportion of those
surveyed said that they wanted to hear about new developments in science and technology before they happen,
not afterwards; and 49 per cent said that they receive too little information about science (more than twice the
proportion than in 1999–2000). TheWellcome Trust document “Engaging Science: Thoughts, deeds, analysis
and action report” (2006) recognises the value of a well informed public debate “to enable a wide range of
opinions to feed into policy-making discussions.”
If the public is to trust, debate and value scientiﬁc progress, we need a society engaged with contemporary
science. Scientists themselves need to be encouraged, trained and supported in communicating their work.
Stimulating public interest in science, its potential applications, misapplications and impacts, as well as the
nature of science itself can be achieved through the development of a clear public engagement strategy with
speciﬁc audiences identiﬁed, measurable objectives and outputs.
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
The value of public engagement within the ﬁelds of science and nutrition is increasingly recognised but, to date,
under-utilised. A report prepared for the Research Councils UK and the Department for Innovation,
Universities and Skills highlights that “direct dialogue with the public should move from being an optional
add-on to science-based policy making and to the activities of research organisations and learned institutions,
and should become a normal and integral part of the process” (People Science and Policy Ltd/TNS 2008).
Moreover it notes that the public increasing want more information; 8 out of 10 people agreed that “science
is such a big part of our lives we should all take an interest.”
The Nutrition and Health Communications team at MRC HNR has a strong track record in engaging with
a variety of diVerent audiences to drive improvements in public health. Our aim is to build bridges between
our scientists and people of all ages and from all walks of life to consider, question and debate the key issues
in relation to diet and health and to stimulate their awareness and enthusiasm for science in society.
Public engagement has many diVerent levels and mechanics and is a key part of the MRC Corporate
Communications Strategy. At HNR our activities tend to focus on issues directly relevant to our own research
or broad nutrition and health messages about a healthier diet. Our key learnings are:
— Develop a communications plan with agreed key messages appropriate to the audiences.
— Provide an in depth brieﬁng to journalists at an early stage and keep them regularly informed.
— Encourage and train scientists to engage with the public.
— Make scientists accessible to the media throughout the communication process.
— Engage leading medical research and scientiﬁc bodies to make a positive and proactive contribution
to the debate, not just defensive responses.
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Given our particular research interest in the area of nanoparticles we are at the start of a scoping exercise to
identify how we might contribute to the debate across a variety of audiences, including the public. We shall
observe the progress of this Inquiry in some detail and would welcome the opportunity to discuss public
engagement opportunities in more detail.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
Public attitudes towards new technologies play an increasingly crucial role in supporting their development
and application. The public should be provided with information on the use of nanotechnologies and
nanomaterials in food productions because public opinion has the potential to inﬂuence the public policy and
regulatory environment in either positive or negative directions, with recent examples including biotechnology
and genetically modiﬁed crops. It also impacts on the investment environment, with investors inﬂuenced by
actual and potential community and shareholder concerns.
12 March 2009
Further memorandum by the Medical Research Council Human Nutrition Research Unit
Introduction
When cells fail to recognise surface molecules or molecular structure of small particles, the fate of these
particles may be determined by their physical size and no longer by their chemical composition.
Nanoparticulate, nanosized and nanostructured are then descriptors that relate to a dominant characteristic.
Natural Exposure
The human gut has been exposed to non-biological particles of varying sizes for millennia. For example,
dietary ferritin is a small nanoparticle (-) of 13 nm diameter when whole and 2.5 nm as the smallest core sub-
unit, while dust and soil nanoparticles tend to be hundreds of nm in diameter/length (-). Four uptake
(absorption) mechanisms have been proposed in the gastrointestinal tract (Figure 1):
1. Through “regular” epithelial cells (gut-lining cells) via a route termed endocytosis (“engulﬁng” the
particle). Very small particles—tentatively generally'20nm in diameter.
2. M cell uptake (transcytosis) at the surface of intestinal lymphoid aggregates. This is the quintessential
pathway for gut particle uptake and is very well described, especially for large nanoparticles (
100 nm), although smaller particles are also likely to be able to access this route. M cells have a
“surveillance” role in the gut and are specialised in particle uptake.
3. Persorption. Volkhemer’s concept of passage through “gaps” at the villous tip following loss of
enterocyte(s) to the gut lumen. Small and large nanoparticles potentially access this route but its
quantitative validity is unclear.
4. Putative paracellular (between cell) uptake.Generally junctional complexes are unlikely to allow even
the smallest of nanoparticles to permeate but certain drugs and/or dietary situations, and especially
diseases, may alter this situation allowing inﬂux of very small nanoparticles. Theoretical pathway as
it stands.
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Figure 1: Schematic representation of diVerent routes for particle uptake in the small intestine. The numbers
refer to those pathways described in the text. Uptake via (1) regular epithelial cells (2) M cells of the lymphoid
aggregate (3) persorption and (4) the theoretical paracellular pathway.
Regardless of mechanisms, it is clear that ingested particles across the nano-range (0-1000 nm) will be
absorbed to some extent into both the circulation and the gut tissue itself. Percentage absorption will depend
on many factors (eg size, surface charge, host gut permeability, etc). But even if only 0.1 per cent of a total 1013
ingested particles is absorbed, that corresponds to 109 particles absorbed/day.
From the circulation, particles will be retained by cells in the liver and other vascular organs. From the gut
tissue, cells can migrate systemically with their cargo (eg particles), especially to mesenteric lymph nodes. The
persistence or degradation of particles at any site depends upon the physico-chemical characteristics of the
particles but even undegradable particles have some clearance through cellular-shedding in the gut and lung.
Man-made Particle Exposure—Currently
Silicates, aluminosilicates, titanium dioxide and carrageenan are among the typical man-made, or at least
man-modiﬁed, particles that the human gut is now exposed to, especially in theWestern world, on a daily basis.
Exposure has been for decades-as food additives mainly. Except at MRC-HNR there is little research on the
gut-associated eVects of these although some appear to accumulate in gut tissue. Nonetheless, studies to-date
suggest that, overall, these particles are safe and even if they can be shown to have any adverse eVects it will
almost certainly be in a small minority with a diVerent genetic make-up. However there is no evidence for this
currently.
The above particles are almost all in the larger nano-range (being( 100 nm diameter/length). There is, in the
UK, no evidence currently for the signiﬁcant intake of new/man-made small nano-sized particles, although,
increasingly at the global level, proposals for this are made in industry and in research studies.
Man-made Particle Exposure—Future
“Nanosizing” can have a variety of commercial advantages for certain foods, supplements (especially),
medicines, food packaging and othermaterials thatmay be ingested. However, inmany cases, the “nanosized”
foods will undergo simple gastrointestinal digestion prior even to meeting any cells (Figure 2). Examples
include “nano-salt” (1) and probably some “nano-micelles” (2). However, even with nano-micelles that are
absorbed whole, they will undergo fairly rapid cellular degradation and are likely to be recognised for their
molecular structure rather than their nanosize. Indeed it should be noted that yoghurt and milk are foods
containing nano-micelles (40–300 nm) of casein that occur in large abundance in the intestinal lumen upon
ingestion. For competitive commercial reasons, as well as the potential to lose scientiﬁc/toxicological focus, it
would seem sensible that such foods are considered separately with regards to further “nano-legislation”.
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Figure 2: 1, Some nanoformulated materials, eg nanosalts, are likely to be digested in the gut before any
cellular exposure. 2, Micellar nanoformulations may partially degrade in the gut or be absorbed whole, but
are likely to be rapidly broken down in cells. 3, In contrast, truly or transiently persistent nanoparticles are
likely to lose any surface adsorbed material in the stomach, but may themselves remain intact, and then, later
in the gut, could (depending on size, surface charge etc.) adsorb other soluble luminal molecules before
cellular uptake.
Thus, in the case of micellar nanoparticles it is highly likely that the constituent molecules would dictate
toxicity, rather than their aggregated nature to form a nano-micelle, although this latter property could
inﬂuence bio-distribution.
In the ﬁnal scenario in Figure 2, novel nanoparticlesmay be bio-persistent, either transiently as there is gradual
cellular breakdown, or truly persistent as they can only be cleared with the sloughed cells, as noted above. If
the latter process is slower than the rate of uptake then particlesmay accumulate. Examples could speculatively
include, nano-silver, nano-clays and nano-silica. Depending upon their size, surface charge etc., ingested
particles may adsorb (to their surface) other soluble molecules, including bacterial toxins, from the gut lumen,
and carry these across into cells (Figure 2:3). Probably the larger nanoparticles are better at this.
Particle Toxicity: Factors and Why Nanoparticles?
A number of poorly predictable properties dictate particle toxicity—eg crystalline structure, surface reactivity,
dissolution characteristics, adsorptive properties etc. So, for example the α-quartz form of silicon dioxide is
a toxic particle while the amorphous form of silicon dioxide is not. A second example, mediated by a similar
process to that of quartz, is that nano-particulate hydroxyapatite may be toxic to cells while some other forms
of nano-particulate calcium phosphate are considered less so.
Particle shape can also aVect particle toxicity. Thus asbestos, erionite and some man-made nanotubes appear
toxic due to their high aspect-ratio or “needle-like” shapes.
Finally, size. This is often poorly understood. The large majority of particles are fairly inert/non toxic unless
they have some speciﬁc property, as noted above. In the absence of any “special property”, particle toxicity
can be considered in two simple forms:
(1) Direct toxicity. Normally mediated through “free radical” activity and, in this case, smaller particles
are considerably more active than the same mass of larger particles. This appears to be a surface area
phenomenon.However, just because this can happen, wemust ask does it happen?Many experiments
use such unrealistic particle doses that extrapolation to lower doses, that represent real exposures,
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may be artefactual. The result of drinking a bottle of whisky one evening tells us little about the result
of one drink per evening over a fewmonths. Secondly, most tissues, including the gut and circulation,
are armed with complex and replenishable antioxidant defences to combat such acute (short-term)
exposures. In doing so, however, there may be downstream costs (long-term).
Accumulating evidence suggests that lung exposure to nanoparticles is linked with an increased risk
of chronic cardiovascular disease. A second potential lesson from the lung is that certain individuals
(eg those with asthma) can experience an exacerbation of disease upon acute exposure to an
abnormally high environmental dose of particles (eg at peaks of urban pollution). However it is the
view of these authors (but not the wider community) that this latter phenomenon, as opposed to the
chronic systemic eVects, could be more related to the large nanoparticle fraction (-) than it is to the
small fraction (-), leading onto the second potential mechanism of general particle toxicity.
(2) Large nanoparticles (or aggregated small ones) can make good cellular “adjuvants” such that an
immune response to a protein/allergen/antigen is enhanced or “polarised” when exposure is in the
presence of a particle. Contact between the allergen/antigen and the particle (eg adsorption) appears
important.
What is Special about Nanoparticles?
Three things. First, as detailed above, in the absence of a “special property” for particle toxicity, all particles
will be more directly toxic to cells as small nanoparticles than as larger ones. The pros and cons of this
observation are noted above. Secondly, as a rough guide, particles'100 nm diameter will be taken up by cells
through a diVerent pathway to that of larger particles (Figure 3), meaning that theywill access diVerent cellular
compartments and have diVerent cellular eVects. Again, “induction of free radicals” versus “adjuvant activity”
are the basic diVering outcomes. Thirdly, very small nanoparticles are especially mobile and motile and may
access all areas of the body including even the brain and all areas of the cell including even the nucleus (being
smaller than nuclear pores). It is this latter property that probably makes very small nanoparticles most
worrisome to scientists and hence the translation of this concern (but not the knowledge of why) to the public.
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Figure 3: Schematic representation of cellular particle uptake for large particles via 1. active phagocytosis or
engulﬁng of large particles and 2. macropinocytosis which is a diVerent type of active particle capture. These
events are triggered by the size of the particle. 3. small particles are taken up by constitutive pinocytosis and
are processed by the cell in a diVerent fashion.
Finally, it should be noted that in the absence of speciﬁc particle toxicity there is no logical reason to assume
that, in the gut, smaller nanoparticles will always have worse adverse health eVects than larger ones or that
either will have any adverse health eVects at all. It will depend on many other variables including host
genotype, persistence, dose, and ability to adsorb gut luminal molecules. And thus there is no logical reason
to use 100 nm as a cut-oV for adverse eVects, even though, as discussed, this size discrimination may help
determine the type of cellular eVect.
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Other Important Factors
(1) Particles may aggregate so that their behaviour during at least part of the exposure process is more typical
of large particles (-) even though their single unit is as a small particle (-). This is especially true for small
nanoparticles.
(2) Particles are rarely seen by cells in their “native form”. Most particles readily adsorb to their surface
molecules and ions from their environment. In the gut, particle surfaces may be “cleared” in the acid and
enzyme-active area of the stomach but re-adsorb material further down the G.I. tract. In this environment,
bacterial proteins and carbohydrates are especially common.
(3) Classical toxicity or toxicology studies may be poor or even misleading at deciphering particle toxicity
following oral exposure. In particular, long-term (decades) eVects and host genotypes cannot be mimicked in
animal studies. Instead a “logic algorithm” and some targeted in vitro tests may be more useful.
(4) Nanotechnology may actually serve to make some materials less toxic. For example, MRC-HNR is
developing a transiently stable nano-formulation of supplemental iron which should exhibit much less toxicity
to the intestinal mucosa, and therefore side-eVects, than the current common therapeutic supplements, namely
ferrous sulphate and other ferrous salts.
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Witnesses: Professor Ken Donaldson, (University of Edinburgh), Dr Qasim Chaudhry, (The Food and
Environment Research Agency), Dr Jonathan Powell, (MRC Centre for Human Nutrition Research) and
Professor Michael Depledge, (Peninsula College of Medicine and Dentistry), gave evidence.
Q214 Chairman: Good morning. I would like to
start by welcoming our four witnesses today, as well
as themembers of the public sitting behind; to remind
you that the proceedings today are being webcast so
the public can observe what is going on; and also to
draw the attention of members of the public to the
information note which sets out members’ declared
interests; so we will not be declaring interests as we go
through the questioning. I would like to kick oV by
asking each of our four witnesses to introduce
themselves for the record. If there are any points you
would like to make in a brief opening statement
please feel free to do so. Perhaps I could start with Dr
Powell and then go along the row?
Dr Powell: I am Jonathan Powell from the Medical
Research Council Human Nutrition Research Unit
based in Cambridge.My area of expertise is minerals,
particularly nanominerals in the gut.
Dr Chaudhry: I am Qasim Chaudhry. I work for the
Food and Environment Research Agency of Defra. I
am a research scientist and we have been working on
the safety of nanoparticles through human health
and the environment.
Professor Donaldson: My name is Ken Donaldson. I
am Professor of Respiratory Toxicology in the
University of Edinburgh, and I specialise in the
harmful eVects of inhaled particles on the lungs and
the cardiovascular system.
Professor Depledge: I am Michael Depledge. I am
Professor of Environment and Human Health at the
PeninsulaMedical School in south-west Britain. I am
a member of the Royal Commission on
Environmental Pollution. As you may be aware, the
Royal Commission conducted a study on novel
materials, and in particular nanomaterials, over the
last two years and I have been deeply involved in that
particular study. I am an ecotoxicologist and have
worked on nanomaterials in lower animals.
Q215 Chairman: Thank you very much indeed.
Perhaps I could kick oV with an opening question of
a fairly general nature and any of you might wish to
respond to this. As you will understand, part of the
focus of our inquiry is about possible or potential
health and safety concerns relating to the use of
nanomaterials and nanotechnologies in the food
sector. You are all experts in this area and I wonder if
you would like to express to us what you think are the
potential health and safety concerns, and what
evidence is available to address those?
Dr Powell: I think we know quite a lot about the
uptake of particles in the gut, in terms of the route of
entry; and we know a reasonable amount about the
likely cellular targets. We know very, very little about
what happens once those particles meet those cells.
We would certainly consider persistence to be
important, so that were you to ingest a particle that
was broken down in the gut lumen prior to meeting
its cellular target, it would in our eyes have a
toxicology related to its chemistry, i.e. the
components, rather than to its nanoparticulate
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sizing.We do believe thatmore work needs to be done
in terms of both nanoparticles and the larger
nanoparticles or microparticles, i.e. those larger than
100 nm in diameter, in terms of what happens inside
the gut.
Dr Chaudhry: In our view there are two fundamental
concerns about the health and safety of
nanomaterials, and both relate to oral intake of food
products that contain free nanoparticles that are
insoluble, indigestible and that can translocate from
the gut in particulate form to other parts of the body.
Essentially that category of particles is of most
concern. The ﬁrst concern is the ability to cross
cellular barriers, and there is scientiﬁc evidence for
that. Cellular barriers prevent entry of larger
insoluble particulate material; but nanoparticles,
because of their very small size, can override that
principle and potentially reach new targets in the
body, for example the brain. The second concern is
the potential eVects of nanoparticles, and that will
depend on the chemical nature of nanoparticles, as
Dr Powell mentioned. If the chemicals that constitute
nanoparticles are toxic then it can be perceived that
they deliver toxic chemicals to new targets in the body
where those chemicals would otherwise have not
gone, had they not been in nanoparticle form. The
other concern is that many nanoparticles have a
reactive surface and they can interfere with cellular
processes, for example oxygen metabolism, and this
can lead to the emission of oxyradicals. This has been
shown in a number of studies. This can lead to
inﬂammatory reactions and oxidative damage. There
are other concerns: for example, some nanoparticles
or nanodelivery systems can carry harmful
substances out of the gut into the blood circulation
from where they can lead to other parts of the body.
Another concern is about antimicrobial eVects of
some metallic nanoparticles; when ingested they can
have a harmful eVect on gut natural microﬂora,
which can ultimately harm consumers’ health.
Professor Donaldson: As a non-specialist in terms of
the gut, my main concern is that there is so little
research on what is happening with nanoparticles in
the gut; whereas there are fairly huge amounts of
research funding pouring into Europe and the USA
into the lungs, the inhalation hazard, and to some
extent the skin, although less so. The research into the
gut is much, much less. I do not think you can
generalise from the eVects of particles in the lungs or
on the skin to the eVects on the gut. The gut is a
wholly diVerent environment to me to these other
situations in terms of the extremity of the conditions,
for instances of acidity in the stomach. My main
concern would be the lack of research in the non-
generalisability of existing research to the gut.
Professor Depledge: Just to add I think it is worth
emphasising the diversity of nanotechnologies and
the diverse nature of nanomaterials. It is very
diYcult, I think, to make general statements about
nanomaterials: some are very reactive; some are not;
some are very persistent; some are not. I think we
need to focus on that. The second point concerns
nanomaterials in food, some of them are put there
intentionally, and some are unintentional occupants
of food, as it were. I certainly agree with the idea that
the amount of evidence available with regard to the
eVects of nanomaterials, delivered through food or in
food, is very, very small indeed and there is an urgent
need to conduct many more studies. I also think that
we ought to consider plausibility.We know that some
of these nanomaterials are designed to be highly
reactive. We know that some of them have very
highly reactive surface properties; and there are little
bits of evidence which show that they can convert
chemicals from one form into another: so it may not
be the nanomaterial itself that is toxic but the role it
plays in converting substances that are non-toxic to
be toxic. There is a lot of plausibility that needs
investigating.
Q216 Chairman: When you look at the current
developments in the use of nanotechnologies and
nanomaterials in food in the evidence that both
MRC and CSL submitted, you referred to various
examples. Do those examples themselves trigger
concerns about the lack of knowledge of
toxicological eVects and risk?
Dr Powell: The examples I think you are referring to
are those such as nano-silver, nano-silica and nano-
clays. I believe those do trigger concerns, in
particular that, as has already been mentioned, when
a substance is nanosized, in doing so its major cellular
interaction and biochemistry may be driven by its
nanoparticulate nature. If that becomes the major
characteristic that drives its reactivity, then there is no
doubt that some of those materials will have diVerent
properties compared with bulk materials—and I
think of nano-silica in particular. The other point to
make is that, as a nanoparticle in the gut, there is
always the possibility of picking up local soluble
molecules onto the surface, such as bacterial toxins,
and that those then become delivered with almost a
Trojan horse eVect into cells of the gut; and of course,
as has been explained by Dr Chaudhry, with the
possibility of dissemination to other organs as well.
Dr Chaudhry: I think the main point is that if
nanomaterials are solubalised, digested or degraded
within the gut then they are of least concern, because
then their properties or eVects will be dependent on
what sort of chemical composition they had, i.e. what
chemical constituted the nanoparticle. The main
concern is on insoluble, indigestible, non-degradable
nanoparticles than can survivemechanisms in the gut
and can come out of the gut.
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Q217 Chairman: From the point of view of a
toxicologist, I wonder if you might think that
particular groups of consumers would bemore at risk
than others? If there were a risk would you think, for
example, young children or elderly people would be
more at risk? I think one of the points theMRCmade
in its evidence is that theway thebody responds to free
nanoparticles is an immunological response. I think
that iswhat you said. Bearing that inmind,would you
expect particular population subgroups to bemore or
less susceptible?
Professor Depledge: I have certainly read one study—I
say one because it emphasises the scarcity of
information—which involved rats and looking at the
uptake of iodine labelled polystyrenemicrospheres of
more than 50 nm. They have demonstrated uptake of
thesemicrospheres. Itwas suggested in that particular
study that people, or animals with inﬂammatory
bowel disease of one form or another, would be at
greater risk. I am not aware of any other evidence.
Professor Donaldson: I think there is maybe one case
where the lung data might come to hand here.
Certainly in the human lung the adverse susceptibility
to particles is greatly enhanced in those people who
have inﬂammatoryconditionsof the lung,asthmaand
COPDespecially. If youhave inﬂammationalready in
your airways then the eVect of the particles are worse.
That is very strong data to support that. One would
imagine that the gut would be exactly the same. The
eVect of particles in the gut may be much worse in
someonewho has got some inﬂammation in their gut.
Dr Powell: I can add to that in two forms: ﬁrstly, that
gut permeability is enhanced in thepresence of certain
disease, includingchronicdiarrhoea;and there isgood
evidence that small particles or large molecules will
have enhanced permeability under these conditions.
The second point to make is to pick up on Professor
Donaldson’s point, which is that we have looked in
inﬂamed cells from patients with inﬂammatory bowel
disease; we have challenged them with particles and
we have shown that they will have enhanced pro-
inﬂammatory eVects; again, I stress this is ex vivo, and
there is little or no data as far as I know in vivo.
Dr Chaudhry: There is no evidence in scientiﬁc terms
but nanoparticles may act as seeds for crystallisation
of certain chemicals, but this has been shown in test
tube experiments. Concerns have been raised that if
nanoparticlesget into, forexample, thekidneyandthe
kidney is inﬂamed, they might act as seeds for
calciﬁcation there; but there is no scientiﬁc evidence
for that.
Q218 Lord Haskel: Could I just put the layman’s
question: if you do get some nanoparticles in your gut
and they have the reaction youdescribe,what can you
do about it? Is there an antidote, or something like
that?
Dr Chaudhry: I think, depending on the chemical
nature of nanoparticles, they may not cause toxicity
there and then. If they are excreted from the body,
metabolised, broken down, that is another story
because they will be eliminated from the body. The
concern is if they become lodged into the cells and
tissues and remain there and get accumulated over
timeandwhat sortof eVects theymayhave.Wearenot
talking about immediate eVects; we are talking about
medium to long-term eVects.
Professor Donaldson: Jonathan would know better
than me, but if we go back to the situation where
someonehasan inﬂammatorybowel conditionandhe
already takes somemedication, theywould takemore
of it more often, I would imagine; which is the case
withasthmaandairpollution;peopleuse theirasthma
medication more when the air pollution is high. You
wouldmake the same argument, one would imagine.
Professor Depledge:The point I would like tomake is I
think this demonstrates what I was saying earlier
about plausibility. You can imagine scenarios of what
might happen, but we are operating in an area of
profound ignorance. Certainly we do not have a
comprehensive understanding; I am not sure we have
any realunderstandingofwhatwouldhappen in those
circumstances and whether you could pull
nanomaterials out. It is actually extremely diYcult to
ﬁnd the nanomaterials in the ﬁrst place
Q219 Earl of Selborne: I would like to ask our
toxicologists today how they would deﬁne
nanotechnologies and nanomaterials from a
toxicological point of view?
Professor Donaldson: There is an immediate problem
there because the standard deﬁnition (which has been
considered and thought about extensively by various
nomenclature committees which Qasim has sat on)
that a nanoparticle is a particle with one dimension at
least less than 100 nm or 0.1 of a micron, there is no
toxicological basis whatsoever for that. The idea that
a 102 nm particle is safe and a 99 nm particle is not is
just plain daft, it does notwork that way. It is a sliding
scale: we may talk later on about surface area, but as
particles get smaller their surface area per unit mass
increases; and it is surface area that interacts with
biological systems. You can talk about smallness as
well, but surface area matters a lot in terms of
delivering harm.
Q220 Earl of Selborne: In order to determine
potential toxicity, is it sensible to look not just at size,
which you say could be relevant, but reactivity, shape,
any other factors?
Professor Donaldson: Reactivity per unit surface area
and shape.
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Professor Depledge: Could I just add to that, when we
were gathering evidence for the Royal Commission
report some of the evidence we received suggested
that the term “nanotechnology” was really not a very
useful term and might disappear within ten to 15
years. I think the conclusion you will ﬁnd in the
Royal Commission’s report is that it is really the
functionality—the functions of the particles—that is
more important when it comes to classifying them in
toxicological terms.
Q221 Earl of Selborne: Eventually one would hope
in Europe there would have to be detailed risk
assessment and legislation; and there needs to be
some assessment as to how this can be best
determined in legislation. I understand that the
European Food Safety Authority has recommended
that an additional metric, taking your point of
speciﬁc surface area, should be included in the
deﬁnition of nanoscale materials, which is currently
based solely on size. Is this measure of surface area
going to be adequate to catch the high-risk
nanoparticles?
Professor Donaldson:With surface area alone there are
a large amount of nanoparticle types currently in use,
like aluminosilica and titanium dioxide, and there are
already many materials handled in workplaces,
which are classiﬁed as low toxicity materials. The
toxicity per unit surface of these is very low; as far as
a particle toxicologist can ascertain, it is about as low
as it gets; they have virtually no activity; but enough
of them in the lung, for instance, does stir up
problems in the lung. Certainly the idea that then you
move up into a particle which has lots of surface area
but that surface area is already active then you would
start to multiply the harm.
Dr Powell: There are two answers I would like to give
in response to that. Firstly, that nanosize per se does
not to my mind make a particle a nanoparticle. I say
that because there are plenty of naturally occurring
substances that are nanosized but they behave
chemically, biologically in many diVerent ways. They
may behave as solublemolecules or—at the other end
of the scale they may be a virus, for example; these
will be recognised in diVerent ways. The term
“nanotechnology” or “nanoparticulate” to our mind
means that that characteristic, that nanosize, has
become the dominant characteristic that drives the
behaviour of the material. It does not mean that
everything that is nanosized should be considered a
nanoparticle. The second point I would like to make
is that surface area may well be important in terms of
the acute eVect, these radical-inducing eVects of
particles within cells, or their potential ability to
produce these radicals; it will not, however, give us a
lot of information about the more long-term chronic
eVects. I think, therefore, there is a challenge ahead in
terms of testing these particles for their chronicity; ie
their long-term adverse eVects rather than their acute
pro-inﬂammatory eVects.
Q222 Lord Methuen: What types of nanoparticles
are likely to be used in food or packaging?Would you
class any of these particles as a high potential risk?
Dr Powell: I have mentioned earlier that from what
we have seen there are two types of nanoparticles that
are either being used or planning to be used. The ﬁrst
type are the larger nanoparticles, and within the
deﬁnition that people tend to think of nanoparticles,
i.e. less than 100 nm in diameter; these would fall
either on the edge or outside that deﬁnition; but those
are already used in food in large amounts and we
ingest large amounts. We have been studying these
for many years and we still know very little about
them. They include aluminosilicates, titanium
dioxide and silicate particles; and these are used as
food additives. The second type are the smaller
particles. These are either being used in other
countries, not in the UK, or are on the horizon and
include nano-silver, the nano-clays, as well as nano-
silica; and we are concerned mostly about those that
show either partial persistence—ie they get through
the gut lumen and into the gut cells where they may
be broken down but that does not stop them being
toxic—or they show whole persistence, and that
means that they cannot be broken down at the
cellular level either. I suspect, of those particles,
nano-silver, nano-clays and nano-silica in particular
will all fall into the latter categories.
Q223 Lord Methuen: Those are mainly used for
packaging at the moment?
Dr Powell: Yes, the nano-silica has been introduced
into at least one drink that we know of in the USA;
as far as I know, it is not available in the UK, except
were someone to bring it in or via the internet. That
is used in one food; but the others, you are absolutely
correct, are much more in packaging.
Q224 Lord Methuen: What was meant to be the
beneﬁt in this drink?
Dr Powell: The idea is that you can promote the
interaction between a substance adsorbed onto the
nanoparticle surface, in this case cocoa, and the
tastebud; so that this provides a longer lasting
interaction between the two, which then gives you a
stronger ﬂavour burst and, the idea of that being, you
can use less sugar, you can use less fat and you will
still get the same delivery eVect but in a “more
healthy” drink.
Q225 Chairman: Can I just pick up on a couple of
points. One is that you mentioned that titanium
dioxide is used as an additive in food. If my memory
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serves me correctly, when we took evidence from the
Food and Drink Federation they seemed to be
unaware of the fact that titanium dioxide was used in
food. They thought it was used in cosmetics but not
in food. Can you be more speciﬁc and deﬁnite that it
is used as a food additive?
Dr Powell: I can be very deﬁnite about that. It is a
piece of work that we have done. We have done it
both by direct analysis of the foods, and also by
looking at people’s diets. We have shown that the
average intake is around 5mg/day; that is not large in
terms of weight but in terms of number of particles
that is about 1012, one million million particles; so it
is a large number of particles that are ingested per
day. It is used as a brightening or whitening agent, so
it is an artiﬁcial additive that makes foods whiter or
brighter. It is also added to a number of medications
as an excipient; also to some toothpastes, few but
some toothpastes; and also particularly to food
supplements where it might be involved again in
giving a slightly diVerent colour eVect to that
supplement.
Q226 Chairman: I think it might be worth just
checking that the Food and Drink Federation still
stand by the statement they made last week, which I
believe was that it is used in cosmetics and sunscreens
but not in food.
Professor Donaldson: I think you have to be careful,
because the word “nano” has become such a bogey
term that, if you are not careful, they take the
question to be, “Is there nano TiO2 in food”, and you
say, “No”; but there is lots of bigger titanium dioxide
in food. White cream—the cream that comes out of a
can—that is white because it is titanium dioxide.
Q227 Chairman: Coming back to Dr Powell,
whether particles you referred to—1012 that are
ingested every day—were those within the deﬁnition
that we have been talking about? Were those
nanoparticles, or were they particles?
Dr Powell: These are within the deﬁnition that we
have been talking about. They have an average
diameter of 200 nm. You will ﬁnd a small proportion
that are smaller ie below 100 nm; but themajority will
have greater than 100 nm diameter.
Q228 Chairman: May I just ask one other question
before moving on. In the MRC’s evidence—again
this is picking up on the question of risks in current
use—you refer to nanodelivery systems that enhance
the absorption of antioxidants. However, many of
these antioxidants are normally poorly observed and
may not be well tolerated at a high level and may
result in too much of a good thing. These are
components of a diet that may be valuable to you in
very small doses but toxic in larger doses. Is that
something from the health and safety point of view
one should be really concerned about; or were you
simply speculating in a more general way that this is
a possibility?
Dr Powell: It wasmore general speculation. There are
a number of nutraceuticals or antioxidant-type
substances that occur in diets in very, very small
amounts and they are absorbed often in very, very
small amounts.We were simply speculating that were
you to create a scenario where you could get much
greater absorption, such as through nano-
encapsulation, it might not just be the nanoparticle
you have to be concerned about but the substance
within.
Q229 Lord Haskel: Dr Powell said that titanium
dioxide was used in toothpaste as brightener. Is that
correct?
Dr Powell: I believe it is used in a few now. There is a
particle that is used in much greater amounts in
toothpaste and that is the aluminosilicate; but I
believe titanium dioxide is still used in a few
toothpastes, yes.
Q230 Lord Haskel: If you go into a pharmacy there
are lots of toothpastes that say they will brighten
your teeth but we have been led to understand that
these things are hardly used at all. Because everybody
uses toothpaste, quite a number of people must be
brushing their teeth with titanium dioxide?
Dr Powell: If I could just clarify. I am not an expert in
this area but I think I am right in saying that titanium
dioxide is used to make the food, or in this case the
toothpaste, brighter. I do not think it itself is
responsible for the brightening action on the teeth.
Q231 Lord May of Oxford: We have been talking
about nanoparticles in the gut, but I am curious what
actually are the risks associated with ingesting
nanoparticles in the gastrointestinal tract? What are
the risks that we know about?What are the things we
suspect we know about? What are the unknown
unknowns?
Dr Chaudhry: There are more unknowns than
knowns in this case. Very little is known in fact.
Q232 Lord May of Oxford: I was not meaning to
knock Rumsfeld, I should say. I thought it was one of
few intelligent things he said!
Dr Chaudhry: This is a very, very topical question.
What is not known is whether nanoparticles added to
food will remain free; whether they agglomerate;
aggregate; bind to food; whether they will be
digested; whether they will be broken down by
stomach acids or enzymes; or will be excreted. These
aspects are completely normal for the majority of
nanoparticles. Because these interactions of
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behaviour and fate aspects are very important in
determining what sort of risks they may pose—risk is
not only hazard, it is also exposure—if they never
leave the gut and are excreted from the body then
obviously there is no risk; but these aspects are largely
not known.
Dr Powell: I would like to point out the gut is a rather
unusual organ, in that it is naturally tolerant, unlike
many tissues; and that is because of course we are
throwing food at it every day.
Q233 Lord May of Oxford: It has got to be!
Dr Powell: Bacteria live in there, and so it has
developed in a rather tolerant fashion. That, in the
main, of course is a good thing and it protects us. Just
occasionally that tolerance can be broken, and
broken in the most unusual ways. Unfortunately we
know so little about either that process or, indeed,
about particles and nanoparticles, that trying to tie
those two aspects together would be nothing better
than speculation, which probably would not be very
useful to the Committee. SuYce to say, in my view,
there really is nothing known.
Professor Depledge: If you think about the
developments that are underway with
nanomedicines, they are designing many, many
diVerent kinds of medicines using nanomaterials that
may gain greater use in the future. Of course, some of
those are designed for uptake through the gut so there
are possibilities. It is plausible that particles can pass
through the gut and be taken up in that way. The
other thing is that it seems that many of the
engineered or manufactured nanoparticles have not
been fully characterised in terms of their properties
and what they can do; so there are surprises with
some nanomaterials that are being used, that they do
other things that we do not discover until later down
the line. I think, again, theremay be surprises in store.
Q234 Lord May of Oxford: Speciﬁcally we have
already mentioned silver. I know nano-silver is used
as an antimicrobial in packaging and in foods and,
for that matter, in clothing; most of the hiking kit
these days tells you it has got nano-silver particles in
the shirts and pants so you will not pong at the end of
the day. What do we know about the negative
consequences, either because they are in food or
because you have accidentally got them from the
packaging or something, for nano-silver on gut ﬂora?
Dr Powell: We have not worked on that, I am afraid.
Dr Chaudhry: I know IFR has worked on that but
very, very preliminary work. Yes, it has been reported
and that is why companies are selling them because of
their antimicrobial action. So antimicrobial action is
known; but the eVect on gut microﬂora, very few
studies and not yet published.
Professor Donaldson: My understanding is it is not the
particles so much as the silver ion, which is the
chemical soluble form, that is released that is toxic.
That is why in wound dressings and so on
nanoparticles of silver do not generally leave the
dressing; the ions ﬂow from the particles. It is a
chemical toxicity as much as particle toxicity.
Q235 Lord May of Oxford: Are we similarly not in
a state of full understanding about the proportion of
ingested nanoparticles that are able to be absorbed
into the body, whereabouts and so on? Do any of you
actually worry—or particularly if you are more in the
food industry and the research industry, would you
worry—about a second attempt to demonise this
technology, as it was successful in the second attempt
to demonise GM foods? Given that, the answer at
least tomany of the putative objections toGM foods,
there were experiments and understanding, for
example, that would answer the worry about super
weeds—if people were to come again at this in a
campaign, should we not be worrying about the fact
that wewould say, unlike whatwe could saywithGM
foods, “We don’t know this; we don’t know that; we
don’t know the other thing. We don’t know if the
particles that are aggregated together can be broken
down in the gastrointestinal tract. We don’t know
where they are absorbed. We don’t know how, for
example, absorption of nanoparticles in the
gastrointestinal tract might aVect diseases like
inﬂammatory bowel syndrome and things like that”.
Would that be a fair statement of the current
position? How disturbing do you ﬁnd it?
Professor Donaldson: I am concerned about
demonisation because I think we already have had
massive exposure to nanoparticles of all sorts, in the
air for instance in traYc particles.We know that there
is not no impact of that, but there is not a huge impact
and we have evolved to deal with that. Not all
nanoparticles are the same; and there is a whole
generation or type of nanoparticles, these low
toxicity ones, that are low toxicity. I do not think we
should consider all nanoparticles to be the same.
That is the ﬁrst mistake people would make, to think
the one word “nanoparticles” embraces all particles.
It does not tell you anything about the widespread of
toxicity of nanoparticles.
Q236 Lord May of Oxford: I would turn that
argument around and say there are of course lots of
nanoparticles we have been familiar with for a couple
of hundred thousand years and they do not seem to
be doing us much harm; but now we are doing
speciﬁcally diVerent things. Nanosilver has not been
part of our ingestion process; and should we not, in
view of some of the other unintended consequences
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of well intentioned actions, be trying to know more
about it?
Professor Donaldson: Yes, we should. The whole issue
ofdemonisation—itsoundsas ifnanoparticlesareone
thing. Nobody would call big particles “a particle”;
because it couldbetraYcdustand it couldbeasbestos.
Nobodyuses theword“particle” in generic terms.Yet
people use the term “nanoparticles” in a generic way,
and I think that can lead to demonisation. Scientists
are human; they do not like to study things that are
bland; we tend to study the toxic things; so the kind of
message that goes out is thatnanoparticles canbevery
harmful. There are a whole slew of nanoparticles that
arenotveryharmfulatall.That is really importantbut
thatmessage does not come out.
Q237 LordMayofOxford: I just feel, if Iwant to runa
campaign against this, to build themembership ofmy
organisation, or some other reason, I have got the
material to do a pretty good job.
Professor Depledge: I made the point at the beginning,
and Professor Donaldson has just made it again,
about the diversity of nanomaterials. I also made the
point, when asked about deﬁning nanotechnologies,
that it is not a very helpful thing to do. In terms of risk
assessment, I think it is hugely important that we do
look at functionality, and what particular things a
particular kind of nanomaterial is designed to do; and
thatwould help inmaking risk assessments. Titanium
dioxide, for example, hasbeenusedaswehave said for
many years, and there is not much evidence that it is
doing anyharmatall. I do agreewith you thatweneed
to emphasise the beneﬁts of some kinds of
nanomaterials. I think it is about opening up this
whole debate andmaking it much clearer.
Chairman:The answers are quite technical answers to
a very broad bush campaign in Lord May’s terms. If
the simple question is: “Are there substantial areas of
uncertainty and lack of knowledge about the risks?”,
to come back and say, “Well, you’ve got to look at
diVerent deﬁnitions; you’ve got to look at this and
that” is not going to be very helpful if people are
looking for a yes or no answer.
Lord May of Oxford: I, in particular, have the belief
nanosilver has beenput into foods as anantimicrobial
preservative;but ifwedonotknowtheeVectonthegut
ﬂora, which in a somewhat broad sense resembles two
microbes, that is a legitimate thing that you really
ought to knowmore about before you do it.
Q238 Chairman: Is that fair?
Dr Powell: Yes, I think it is very fair. As I have
mentioned earlier, we have been exposed to
nanoparticles throughout evolution; I think the
diVerence there is that they tend to be nanoparticles
thatwehave establishedmechanisms todealwith; and
that there is genuinely now the concern that new
nanoparticles are coming along that we have no
mechanism to deal with; ie persistent nanoparticles. I
cannot think of a natural example of a persistent
nanoparticle. I can think ofmanynatural examples of
persistent larger particles but not persistent
nanoparticles. So were you running your campaign, I
think this would be a very good starting point. I
believe therefore genuinely these are areas we need to
understand more about. That is not to say that it is a
problem; but simply to say that the unknown exists;
and where the unknown exists we should perhaps try
and change that.
Q239 Chairman: I thinkoneor twoothermembers of
the witness panel would like to come in? Professor
Donaldson?
Professor Donaldson: I think the nano particle that we
aremost exposed to and is persistent is soot. It ismade
of graphene and it is highly persistent. It is like sheets
of graphite—pencil lead. It is the nanoparticle we are
mostusedto.Theaveragesootparticleout in thestreet
here—and there is lots of it aroundhere—is60nmand
there is lots of it in here. We are breathing billions of
them a day if you work in here. Billions of them are
depositing in your lungs every day; so we are
experienced through the lungs; and 99.9 per cent of all
particles deposited in the lung get cleared up by the
mucus escalator and we swallow them. The gut gets
delivered to it large amounts of soot. I do not know
what happens to soot in the stomach, but soot
particles are extremely tough. I would be surprised if
they are not persistent.
Q240 Chairman: Just to be clear about the last point
you made—many things that we inhale end up being
swallowed in the end?
Professor Donaldson:Absolutely, almost all of whatwe
inhale, otherwise our lungs would be bunged up by
now—after 60 years or so in my case—so it is cleared
upwards all the time; and you swallow mucus
containing particles all the time.
Q241 Chairman: Regardless of what we ingest in
food, we are ingesting a lot of material that is just
ﬂoating around in the air around us, including soot?
Professor Donaldson:Yes.
Professor Depledge: I just wanted to return to the issue.
Youwere saying about the intricacy of the debate that
we were getting into, but I think if you want to think
about reallybigproblems thatwe face,ultimately ifwe
want to devise toxicity tests for nanomaterials in
foods, then I think we should think about the
practicality of doing that because there are likely to be
amyriad of diVerent forms of nanomaterials in foods;
some ofwhichweput in deliberately; otherswhich get
there for reasonsof environmentalcontaminationand
access to food. If you think about evaluating the
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toxicity of these various forms of nanomaterial and
nanotubes, it would take years and years and years to
get through the list. In terms of protecting the public,
what happens in themeantime?
Dr Chaudhry: I justwant toadd, in thiswhole scenario
an independent industry body is missing which can
look at the whole scenario of publications. Not every
application of science here is going to give us any
major concerns or any hazards or any risks. The body
needs to separate those applications that have no or
low risk, and those applications can go ahead: but
becauseof thenanotechnology label everything seems
to be static. For example, we know from our own
experiments thatnanoparticleshardlyevermovefrom
packaging material into food; so that application, as
far as tests show, may not cause any risk to the
consumer and can go ahead: but because of the
nanotechnology label, companies are afraid of
declaring that it is nanotechnology-derived. Even if
we do not know about hazards or exposure or many
other uncertainties, we can divide applications on the
basis of whether nanoparticles are free, whether they
are soluble, digestible or insoluble; and we can form
those categories very quickly on a hypothetical basis,
whether an area of application is going to be in the
high risk category or in the low risk category.We have
attempted that and I have a handout if youwould like
to look at that.
Chairman: Perhaps you could leave that with the
Committee clerk afterwards. I would like to move on
now to BaronessNeuberger.
Q242 Baroness Neuberger: We have been talking
about persistence. I would really like to ask you what
the state of knowledge is regarding the actual
accumulation of nanoparticles in the body once we
know we have been ingesting them? How do they
accumulate? How many of them do we not get rid of
which you have been talking about earlier?
Dr Powell: The work we have done is purely around
the gut and, again, around these larger nanoparticles,
sogenerallyupwardsof100nmbutnotsolely.Wehave
shown that certain areas of the gut, the lymphoid
tissue, does with increasing age accumulate these
particles. Presumably they only represent a very small
percentage of what has been taken up, so there
probably is a clearance mechanism; but quite clearly
accumulation does occur. As I also mentioned, we
havebeenunable inanyway to link that accumulation
to any typeof disease, disorder or impactuponhealth.
We have not in our work looked beyond the gut in
terms of accumulation, but I know others have and it
may be some other members of the panel are better to
answer that.
Professor Donaldson: There is a body of work that has
been done on model nanoparticles starting from
various portals of entry: inhalation and injection into
the blood predominantly; not much through the skin
because they do not seem to pass very readily through
the skin; and virtually nothing through the gut at the
moment has been published at least. If you inhale
nanoparticles they ﬁnd their way to the blood.
Something like a per cent or so of all the material that
deposits in the lung will get into the blood—let us say
a per cent—and that circulates round the body and
accumulates in various organs at low levels. The liver
is a good place for particles to stop in. The liver
monitors the blood and it has cells that grab things in
thebloodand it grabs particles, so they are focussed in
the liver. Nobody really knows what happens to them
in the liver. Do they just remain there? If someonewas
to get a chronic exposure through food or a particle
that did get into the blood, what would be the
consequence of a lifetime’s accumulation of such
particles in the liver? Nobody knows that. There have
been no long-term studies done to know the outcome
of that. There is also evidence that they get into the
brain at a low level fromthebloodaswell, and into the
bonemarrow and someother organs.Again, it is hard
to imagine what the clearance system would be from
the brain but it is not like the lungs which have a
clearance system; so it comes back to this issue that
ProfessorDepledgehasmentioned about the fact that
there are unintended consequences when particles get
to places where particles should not get because there
is no system there to clear them.
Q243 Baroness Neuberger:That actually comes back
to Lord May’s point, does it not? If you started
explaining that and said what was not known, people
mighthavequitegoodreason togetconcerned;andwe
do not, from what you are saying, have a very
adequate answer for them; we just do not know?
Professor Donaldson:No, we do not know.
Q244 Baroness Neuberger: Can I just add one other
thing: we know that nanotechnology is used to
encapsulate substances to make them more easily
absorbed to target speciﬁc cells, organs or whatever.
Do we think there may be some particular risks
associated with that, so that you get exposure to
certain substances fromthat kindof technology to too
great an extent; or that they get through to some part
of the body they would not normally go to; so either
your liver or your brain?
Professor Donaldson:Throughmedical uses.
Q245 Baroness Neuberger: Yes, medical uses, with
drugs, for instance.
Professor Donaldson: That is very interesting and
concerning to a particle toxicologist. For example,
one of the widest uses of nanoparticles is to image the
plaques, the coronary artery plaques that cause most
people’s deaths—most deaths are from
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cardiovasculardiseaseswhenthisplaque, this lesion in
the blood vessels near the heart, ruptures. To know
when a plaque would rupture—it is called a
“vulnerable plaque”—cardiologists would really like
toknowwhatavulnerableplaque is. If you inject these
iron nanoparticles into the blood, which are now
licensed to be used and are used by cardiologists, they
seem to localise to these plaques and you ﬁnd them in
the plaques if you section the plaques. The
cardiologists can image these plaques using that
methodology, and that is one reason they are used.
That seems to me to be a really risky thing to do. One
of the most powerful signals in the air pollution
literature is that exposure to particles in the
environment causes these plaques to rupture. It seems
to me you are inviting disaster. It seems to be being
used, and maybe it is a baseless concern, but to me it
seems a considerable worry.
Q246 Baroness Neuberger: It is only being used
diagnostically. It is not being used for any form of
treatment, is it?
Professor Donaldson: No, it is not.
Q247 Baroness Neuberger: Purely diagnostic?
Professor Donaldson: There is also an idea that such
particles can be used to deliver drugs to the plaques
and to other places in the body. There seems to be
considerable potential for the accumulation over
time if the therapy went on and on. Clearly imaging
only happens maybe once or twice; but for therapy
youwould give protracted treatment so youmight get
a long-term accumulation of nanoparticles in places
and, as we have already said, you do not know what
these places are, or the extent.
Q248 Baroness Neuberger: The last thing I would
really like to ask you, maybe you have already given
us some of the answer: is there research being done
into any of this, about what the short or the long-
term eVects will be?
Professor Donaldson: The long-term I do not know. In
Edinburgh we are doing some studies and the
Department of Health has funded a student in our
department to look at these superﬁne paramagnetic
iron particles—to look at the eVect that these might
have. We have a mouse model that develops plaques
and we are going to put these into the mouse model
and see if they go to the plaques and if they cause the
plaques to grow and become more likely to rupture
andmore vulnerable. I imagine there is other research
as well but I do not know what that is.
Dr Powell: We are undertaking research at MRC
Human Nutrition Research both in terms of short-
term eVects of very small mineral nanoparticles; these
are iron oxide and other oxide nanoparticles in gut
cells; and we are also, however—and have been for a
long time—undertaking long-term studies in terms of
the eVects of larger nanoparticles on the human gut
tissue. That research is time-consuming. It takes a
very long time to get the data but we have made good
progress and I hope that within a year or so we will
start to see the fruits of that labour. There is work
going on but it is quite tricky work.
Q249 Baroness Neuberger: Do you know of other
institutions that are doing it?
Dr Powell: Yes, we have now hooked up with two
institutions inGermanywho have both just started to
work on the gut; but prior to that we knewof no other
group, certainly within Europe, who was working on
large or small nanoparticles and the gut; but we have
just started to work with two in Germany, as I have
mentioned.
Q250 Lord Methuen: Do nanotubes feature at all in
this discussion? I understand they are being used for
some purposes; but are they relevant and might they
come into this argument?
Professor Donaldson: I do not think they are used in
food.
Dr Chaudhry: Their properties are such that they are
no use in food. Their features are that they give huge
tensile strength to whatever material they are put in;
and also they are electrically conductive. These two
features have nothing to do with food. They may ﬁnd
some use in food packaging but not in food per se.
Q251 Lord Methuen: Do they form a risk if they are
in packaging?
Dr Chaudhry: If they are in the environment and they
get into food as a contaminant or into the
environment as a contaminant, yes, certainly. I think
Professor Donaldson is best placed to answer that.
Professor Donaldson: Even when you burn gas rings
you make nanotubes—not very many, but it is
surprising what has been found in the air when you
burn gas rings. Most forms of combustion—even
probably coal burning and wood burning—produces
some degree of nanotubes, so it is not a new exposure.
The workplace exposure to mg and µg/m3 of the stuV
is probably fairly new. The concern has been that it
has a particle hazard; it could be a harmful particle;
but also they are long and thin like asbestos so they
could behave like asbestos. There are two kinds of
hazard associated with these materials. The question
is: are people generally exposed to the particles, or to
the long thin ones; because the dangers are diVerent
and the hazards are diVerent for the two. Really it is
a case where we need more exposure data. We really
do not know what people are being exposed to in
workplaces with this material. Certainly it has now
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increased to be one of the major products of the
nanotechnology industry so it is being handled in tens
of hundreds of tonnes in workplaces.
Q252 Lord Haskel: Is there anything that we could
learn from ecotoxicology about the dangers or the
potential risks to humans of ingesting nanoparticles?
Professor Depledge: I think we can look at this in a
number of ways. First of all, I think the potential use
of animal models is very valuable. There has been
work done with lower organisms, which are easier to
deal with in experimental situations. Of course some
of the conditions in the guts of lower organisms are
somewhat similar to those that are in humans, so
there is a model organism kind of approach. There is
a great deal to be learnt there. I think it is very
important to understand what routes of
contamination are possible for our food items. For
example, if you like eating snails or if you like eating
shellﬁsh, some of which are ﬁlter feeding organisms,
they are exactly the kind of organisms which are
likely to take up nanomaterials from sediment or
from water bodies, and they ﬁlter vast amounts of
water and so may accumulate nanoparticles.
Looking at contamination of food by nanomaterials
involves ecotoxicological approaches to see which
organisms are mostly likely to do that. Then there is
the issue of food chain transfer. If you happen to be
a top predator that eats lots and lots of shellﬁsh, do
the nanomaterials accumulate in ﬁsh and so on? I
think those are very important points. The other
thing I would mention is that, earlier this year, I
attended a meeting in the USA at Rice University
where they have a major centre for nanotechnology.
The discussion there turned to the use of
nanomaterials in agriculture. This was voiced by the
experts attending thatmeeting as one of their greatest
concerns. There may be ways of delivering pesticides
attached to nanoparticles, or phosphates and nitrates
and other fertilisers and so on, and also maybe
agriceuticals and pharmaceuticals that are given to
domesticated animals, cows, sheep and so on; and we
have no idea, to my knowledge at least, of how these
materials might get into the food products that we
eat. I think there is some evidence from the literature
that if you expose fungi to nanomaterials, they will
take up certain kinds of nanomaterials. You can see
the uptake of nanomaterials in the roots of plants.
You can actually get nanomaterials into plants by
spraying them on the leaves. Then of course the
organisms eating those plants and fungi are likely to
be subjected to those nanomaterials as contaminants.
There is plausibility of uptake by those routes but
actual evidence of uptake into humans and where it
ends up in humans I think is absent at the moment,
or I am not aware of it anyway.
Q253 Lord Haskel: People have been eating snails
for years, they have been eating shellﬁsh for years,
they have been using agricultural chemicals for years.
If we have been ingesting nanoparticles from that
source, we have been doing for hundreds or
thousands of years. Can we take any comfort from
that?
Professor Depledge: I do not think so and the reason I
do not think so is because you are quite right, we have
been taking up nanoparticles by that route but we
have not been taking up engineered nanoparticles by
that route for long. Particular types of nanomaterials
are engineered to do speciﬁc things. If something like
nanomedicines were to become widely used in the
future—and we have heard about nanoimaging
materials and so on—one should be aware that these
materials do end up in the environment, just as the
pharmaceuticals that we use in our daily lives:
antibiotics, analgesics and even cancer chemotherapy
agents can be detected in British rivers having passed
through sewage works and so on. If we ended up with
that kind of issue with nanomedicines being delivered
into rivers or being deposited in sewage sludge on
ﬁelds, with the potential uptake into plants, again the
plausibility of getting our nanomaterials excreted
back again should be investigated, in my view.
Q254 Lord Haskel: Is there any work going on to
investigate this?
Professor Depledge: Not to my knowledge at the
moment, other than studies in the laboratory where
a variety of fungi, plants, animals, bacteria are being
exposed in laboratory tests in a very limited range of
nanomaterials.
Q255 Chairman:Could I just clarify inmy ownmind
your comment about a possible accumulation in the
food chain, rather like the story with DDT where it
was concentrated in the top predators and that, in a
sense, was the danger signal—the canary in the coal
mine that warned us of the risk. Have there been
studies of accumulation in higher predators in the
food chain that perhaps consume molluscs or other
invertebrates that may be the primary ﬁlter and
absorbers?
Professor Depledge: Not to my knowledge and at the
meeting that I attended in the US where many of the
experts were gathered together nobody mentioned
that as an issue.
Q256 Lord Methuen: What research has taken place
into the health and safety risks associated with
nanomaterials, and how much in the UK and how
much worldwide?
Professor Donaldson: There is a lot now. It is safe to
say, though, that that is focused fairly much on the
lungs and inhalation exposure. As I said, perhaps 10
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or 20:1 against the skin and hardly at all for the gut.
So in the UK there is funding from all the major
research councils now,MRC,NERCand the EPSRC
I think as well. The European Union FP7 has funded
large studies, several of which I have been involved
in. In the USA the Nanotechnology Programme is
huge in NIOSH and in EPA. In Japan and Korea
again they all have big programmes. There is a huge
amount of ongoing research but it is focused very
much on environmental exposures to the lung and I
think increasingly in ecotoxicology.
Q257 Lord Methuen:Are youworried about the lack
of attention to what happens with food in the gut?
Dr Chaudhry: There is one project call that has come
out from the Food Standards Agency recently, which
is very topical, which aims to study toxicokinetics; i.e.
how these nanoparticles move out of the gut, where
they go and what sort of toxic eVects they have, but
that project is still to be started and done. The
funding call has just been announced.
Q258 Lord Methuen: We have already talked about
the range of these particles and how you know which
ones to concentrate on. Is that not the real problem?
Professor Depledge: I agree with you; I think it is a real
problem. Currently there are in a broad sense
something like 600 or 700 products on the market
that contain nanomaterials, according to the
Woodrow Wilson Center in the US, and they have
been through standard toxicity testing, and we have
some doubts about how well it works. I think there is
a general consensus that conventional toxicity testing
is not very useful, and so the OECD has set up a
programme to develop new toxicity tests speciﬁcally
designed to evaluate nanomaterials. They have
chosen 14 model substances that are being
investigated, two per country, and I think some of
these model materials have not actually been taken
up by anybody yet, but they are trying to develop full
characterisation of these particles and also develop
toxicity tests. To mymind, that will be of value but of
limited value in the sense that we do not know that we
are looking at the right kinds of nanomaterials and
whether you can actually use 14 diVerent
representative nanomaterials from the myriad of
diVerent forms that have been produced I have
some doubt.
Lord Methuen: I ﬁnd it quite frightening.
Q259 Lord May of Oxford: I wanted to ask: is this
general area of research one at which the UK is as
well represented among the leaders as it is in many
things? I have in mind the fact that if you look, for
example, at some of the eastern European or the EU
accession countries, they are very good at the
physical sciences but not quite so at the cutting edge
in life science because the mechanisms are less agile
than those that have characterised the Scandinavian,
Anglo and other countries? Some of the things that
have happened in some of the research councils that
are deliberately trying to identify applications and so
on, I just wonder whether you feel these things are
helping or hindering and just more generally what is
the state of British facility in this area on the world
stage?
Professor Donaldson: If you take human toxicology,
theUK has always punched above its weight in terms
of particle toxicology historically because there was
such a focus in the UK in the dusty industries and
dusty trades. For instance, the Coal Board is the seat
of particle toxicology in the UK and it was in Wales
and it was in Edinburgh. That is why I am in
Edinburgh because Iwent to work for theCoal Board
ﬁrst of all. I think the Coal Board was very important
in driving forward in the UK particle toxicology and
it took over the Asbestosis Research Council. That is
not to say that there was not also a recognition of a
particle toxicology problem in the US or in other
places; there certainly was in Germany for instance a
very famous history of particle toxicology. We have
punched above our weight but there was not very
much funding in the UK until relatively recently. We
have kind of caught up but we were slow to get oV the
mark compared to America, deﬁnitely.
Q260 Lord May of Oxford: There does seem to me,
and I may be wrong, that it is a subject which is
inherently at the interface between the physical and
the life sciences, so that it does require a certain
amount of willingness to cross boundaries that not
everyone is good at.
Professor Donaldson: That is absolutely right. It is an
interdisciplinary undertaking. To study the
environmental and human health consequences of
particles, you have to understand the particle and
you have to understand the toxicology and the
toxicity, so you deﬁnitely have to have a
multidisciplinary team.
Professor Depledge: I think that is right; it has to be a
multidisciplinary activity. I think in the UK the
ecotoxicological investigations of nanomaterials are
again punching above their weight. There are a
number of groups around the country, but I would
point out that I think the amount of resource
available for undertaking research on the eVects of
nanomaterials on the environment and human health
is extremely small compared with the amount of
money that is being invested in the development of
new nanotechnologies, in new materials. It is tiny in
comparison with the investment. It is also to me very
interesting that we have some of the research councils
in the UK providing resources to look at the impacts
on the environment and human health, whereas other
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research councils are actually promoting the
development of new nanotechnologies and new
applications, so you have one chasing the other. This
is happening at a grand scale in Europe where in the
Framework 7 programme, the environment and
climate part, there is relatively limited resource
available for looking at the impacts of nanomaterials
on the environment and human health, but in other
programmes within the EU there are vast amounts of
money available for stimulating European industries
to adopt nanotechnology methodologies, and indeed
there is a suggestion that one-third of all industrial
manufacture in Europe will involve
nanotechnologies within 10 to 15 years.
Dr Powell: Just to add very quickly concerning your
speciﬁc remit here, I think there is little or no work,
either in the UK, Europe or even on the world scale,
in terms of the gut, foods and nanoparticles. Most of
what we know about comes from the work, as Ken
Donaldson said, from the lung, a little bit from the
skin and the tiny amount that has been done in the
gut. In terms ofwhat is going to happen, I believe that
there is now access to certain research grants. What
needs perhaps to be done is to try and enhance the
interest so that more work around the gut is
undertaken around foods and I think, again as Ken
has said, in the UK we should be fairly well placed at
the global level to be leaders in this area.
Q261 Chairman: If we focus that question very
speciﬁcally on the regulatory requirements for risk
assessments, if you had to summarise in a few
sentences what would be the top research priorities
for risk assessment of nanotechnologies,
nanomaterials in food and packaging in relation to
regulation, what would you pick out?
Dr Powell: I would argue that because of wherewe are
currently at, that is to say we have nanoparticulates
coming through already, if not in this country I am
sure soon to come and certainly in other countries,
and yet we do not have regulations and knowing how
slow the latter are compared to the former, we need
to do something fairly quickly. For me therefore the
priority would be a logic model, and that logic model
would unfold in a fairly simple way, starting with the
question of: are these particles degraded in the
lumen—ie do they reach the cells? If they do not, then
we consider them one way. If they do reach the cells,
are they degraded in the cell? Do they bind
constituents of the gut lumen? Then, if they do not get
degraded within the cells, where do they go thereafter
and what are the basic cellular aspects; are there
concerns for toxicity. I would like to see a fairly rapid
logic model develop because I think it will address
the gap.
Q262 Chairman:Once the model is developed, can it
be populated or do you need new research to
populate those diVerent stages?
Dr Powell: I think the model I would try to run with
would use current techniques and current
technologies that are fairly easily available. That is
not to say it is foolproof because it will not be but I
do believe it will address to a large extent our
concerns and it will at least get us to a point where we
can say that there is no logical reason to worry about
this particle or, yes, there is a logical reason to worry
this particle. The second very quick point to make is
that we need to consider how necessary are these
particles. Sowe have titanium dioxide, we have heard
about earlier, which is completely unnecessary—it
makes food whiter or brighter, which is not
necessary—versus particles which might contribute
to food safety in this country, which clearly is very
necessary. So I think that would be an important part
of this model.
Professor Donaldson: You could do a lifetime feeding
studying rats of some selected nanoparticles. All
right, there is a problem to choose which ones but you
might choose some of the ones that are most
commonly used in foods. You could start with
titanium dioxide, I would suggest. A lifetime feeding
study in rats, including toxicokinetics, to their full life
span, could be undertaken, just to see if you ﬁnd any
adverse eVects in these animals. Also, there are a
number of genetic models you get nowadays, and is
there a mouse model for an inﬂammatory bowel
condition that could be used, Professor Powell?
Dr Powell: There are a number of mouse models, yes.
Professor Donaldson: That could perhaps be coupled
with some studies in these mouse models where they
have an inﬂammatory gut condition. Looking at
toxicokinetics in these I think would go a long way to
allay people’s fears, if a couple of these studies came
up showing nothing very much, and, if they did come
up with something, then that should raise some
warning ﬂags.
Professor Depledge: I wholeheartedly agree with those
two comments. The other thing that I think that is
important is to build into the design of some of these
materials ways of getting them to biodegrade, for
example in the pH of the gut into harmless forms. A
great deal more could be donewith the design of these
materials to ensure that they do not have a
protracted lifetime.
Dr Chaudhry: I agree with the comments made by Dr
Powell and Professor Donaldson that long-term
studies are needed but also they need to be linked
with histopathology. We do not know which new
targets in the model might arise because of
nanoparticles, so not only long-term studies but also
linked with histopathology to ﬁnd if there are any
novel targets for these particles.
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Q263 Lord Haskel: We are learning that
nanotechnology is a huge ﬁeld. Are there any other
areas of research in nanotechnology which can help
research into nanotoxicology? Do we learn from any
other areas?
Dr Powell: I think certainly in terms of imaging and
analysis there is a very good cross-over between the
two areas and really our success in detecting these
particles in tissue, the histopathology that Dr
Chaudhry has referred to, has on many occasions
reliedonphysics and such technicological advances to
allow us to look at them. Tomymind, and we do a lot
ofwork in the imagingandanalysis area, thathasbeen
wholeheartedly down to advances technologically on
the physics and the engineering.
Dr Chaudhry: Another area which has a cross-over is
nanomedicines and nanomedicines are being
developed for oral intake and they are supposed to
leave the gut and take the medicines and deliver them
to speciﬁc tissues and organs. A lot can be learnt from
that mechanism about how particles can translocate
out of the gut and where they go and where they end
up.
Q264 Lord Haskel: What about nanomedicines?
Professor Depledge has mentioned nanomedicines a
couple of times. Is there anything we can learn from
that?
Professor Depledge:Yes, I think there is a great deal we
can learn from that becausewe can study the design of
nanomedicines where we are trying speciﬁcally to
deliver nanomaterials or drugs or coatings or
whatever to particular parts of the body. So I do think
that that is important. Clearly in nanomedicine
imagining techniques are being driven forward in that
area too. It is also interesting—and whether it is
possible todo it Iamnot sure—that themilitaryhavea
widevarietyof applications fornanomaterials andare
also developing techniques for measuring
nanoparticles in the environment. Theremay be some
cross-over there in appropriate circumstances.
Q265 Lord Haskel: There are more and more
nanomaterials being used in our clothing. Is there
anything that we can gather from that about the
toxicology?
Professor Depledge: I think there is a great deal that can
be gained from that but again it spills over into where
do these materials end up. We are talking about
measurement techniques. It is hard enough to
visualise nanomaterials in tissues and in organs in
humans, but imagine the problem of detecting
nanomaterials actually in the environment because
there is a background of nanomaterials around that
are just naturally produced and to actually identify
engineered nanomaterials against that background is
a terriﬁc problem. Nanomaterials are one of the few
kinds of materials that we put into the environment
about which we do not know howmuch is there, how
longtheypersist,what theytransforminto,where they
go.We do not know the answers to those questions.
Professor Donaldson: I think there is an informative
example also from nanomedicine. The nanomedical
people have designed a nanoparticle that crosses from
the blood into the brain. The blood-brain barrier is
usuallyavery tightbarrierandmost thingsdonotpass
over. The brain is very privileged and protected. The
nanomedical peoplehavedesignedparticles that cross
the blood-brain barrier, so there should be something
that tells us if somebody came up with a particle
having a similar surface as that one, then it should not
be used for any other purpose. You do not want these
things locating to the brain unless you want them to
locate to thebrain. I think there are lessons tobe learnt
generically about a big picture of what it is about
particles generally that makes them do anything. Just
a big structure activity relationship for particles is
whatweneed. If youhad that, youwouldbehomeand
dry really, but that is not going to happen tomorrow.
Q266 Chairman: I know that at least two of you are
authors on this large report that we have recently
received called EMERGNANO produced by the
Institute of Occupational Medicine in Edinburgh. I
have to confess to not having read it pageby page, line
by line—I am sure you have all read it—but the
bottom line seems to be that there are still major gaps
in theknowledgebasewith regard to characterisation,
exposure of toxicology of nanoparticles and
nanomaterials. In terms of us drafting our report,
wouldyourecommendus to take this asanassessment
of the current state of knowledge on health risks and
risk assessment?
Professor Donaldson: Not really; it is not a review of
literaturebut a reviewofongoing, research fundingby
government atEuropean level. It is not a reviewof the
literature. It is quite important to appreciate that it is
research that is going on and us saying that the
research is not looking in this and that place. It is quite
well focused (for instance nanotubes get quite a lot of
attention) but it does show the kind of ﬂightiness of
research that is very dependent on fashion.When you
look across the research, you can see that nobody
seems to be interested in the gut but everybody wants
to look at nanotubes for example. It is a problem.
Q267 Chairman: Would you say, as a follow-up to
that, and one of the issues we have been talking about
is gaps in knowledge as far as risk assessment is
concerned, that one of the issues is the capacity in the
UK or elsewhere in terms of toxicological experts
working on absorption through the gut? Is that one of
the limiting factors? I think we have heard previously
from Dr Powell that he collaborates with others in
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Germany but not with others in the UK, presumably
because there are not other groups doing gut
absorptive nanoparticles?
Dr Powell: I think the joined-up-ness between the two
groups is going to be very important. I have seen a
number of early studies, either started or proposed,
not in this countrybut elsewhere,which in termsof the
gut and in terms of the dietary aspects have schoolboy
errors in them. They have been undertaken by
toxicologists. I am sure the toxicology downstream
would be fantastic. I am surewere we to try to address
toxicologyalone,we similarlywouldmakeerrors, and
therefore it is important that the twosidesget together,
people such as ourselves who have expertise in
particles and the gut and diet and those who have
expertise with the toxicological outcomes. I do not
think that has happened and that probably needs to
happen.
Professor Donaldson: I think we are reaping what we
sowed. If we look at the Royal Academy/Royal
Society report, therewasa really importantparagraph
that there should be a central core-funded chunk of
research and expertise brought together to design a
programme that would look systematically at
nanoparticle toxicology,andthatwas ignored.Wehad
responsemode fundingwhere people just put forward
what they wanted to do, so what you get is piecemeal.
There is no cohesive approach to trying to understand
particles as a whole. Until we have a proper structure
functionviewofallparticles, then therewillwewill not
be home and dry. The only way you can do that is to
have a central core-funded programme that looks at
all the diVerent aspects and target organs and brings
people together to try and drive forward such a
programme. You do not get it from response mode
funding; you get the kind of expertise that is already
out there multiplied up. People who do work on the
lung, all putmoney in forworkon the lungand there is
nobody doing work on the gut, so nobody puts
forward research on the gut. If you had a programme
that recognised the gaps and saw the big picture, then
youwouldgodownall thesepathways.Weare reaping
what we sowed.
Q268 Chairman: The view is that that
recommendation has not been eVectively taken up?
Professor Donaldson:No, it was not taken up.
Q269 Chairman: Is it being taken up in any other
country?
Professor Donaldson:The best is America probably.
Professor Depledge: The US is taking it up and they
have set up a number of centres. They started oVwith
just one or two centres. One of the biggest was at Rice
University, but now they have set up some other
centres as well and they are trying to bring together
diversegroupsof scientists. Justgoingback towhatwe
were saying, I think the point that there is a lack of
toxicologists and ecotoxicologists in the UK and also
across Europe is being widely recognised now.
Q270 Baroness Neuberger: We have been talking
about the need for, if you like, a strategic programme
of research. If you were looking at what industry
should do, and you have already said that there is a
need for an independent industry-wide body, Dr
Chaudhry,what health and safety researchwould you
expect industry to be doing now and what
methodologies would you expect them to be looking
for when they are looking at a new food product
containingnanoparticles tomakesure that it is safe for
the consumer?
Dr Chaudhry: First of all, I think detection
technologies aremissing in thewhole scenario. People
can detect nanoparticles in neat solutions and in
isolated cells and all that. When it comes to very
complexmatrices like foodandvarietiesof foods, then
it suddenly becomes very diYcult. This is being taken
up at the European Commission level and at the
Seventh Framework Programme they are going to
fund some of the projects speciﬁcally designed to
develop and validatemethodologies for that purpose.
That will be done or it is being addressed. The other
issues are in terms of safety; what are the long-term
eVects. We are not talking about short-term or acute
typesofeVectbecausemaybeyouneedveryhighdoses
for that, which may not be present in food products
which contain nanoparticles. We are talking about
long-term eVects and again long-term studies coupled
with histopathology to ﬁndoutwhat is goingon in the
body—animal models, in vitro tests. Some of the in
vitro tests can show, for example, initial indications of
mutagenicity. Particle exposure may lead to
mutagenicity.This iswhat industry needs todo so that
if they are going to use nanomaterials for a speciﬁc
purpose or a composition, they can ensure that all the
safety aspects are being addressed.
Q271 Baroness Neuberger: Do you expect them to
have done that for a new product?
Dr Chaudhry:This has been debated for some time by
industry and by some other quarters. Industry’s view
was that these are not new materials. Because the
regulations did not at that time recognise themas new
materials, then they thought: We are already using
titanium, why should we worry about nanotitanium;
if we are using iron, why should we be worried about
iron and things like that. But now there is a realisation
and there are proposals to change some of the
legislation so that it is clear in the word of the law that
if someone is going to use food additives, even if they
are already approved but someone starts making a
nano form of them, then they will be recognised as
having been made by a diVerent process; i.e. a new
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material. That means that the company is going to
have to produce safety data to show that these are safe
to be put in food. Also, if someone is developing a
normal foodwith nanotechnology, thewording of the
lawwasabit unclear and it didnot clarifywhether any
food produced using nanotechnology would
automatically be qualiﬁed to be considered as novel
food, but now there is a proposal which will go into
European legislation to make it clear. In the next few
years hopefully we will see lots of clariﬁcation at a
legalistic level. That will then trigger companies to
ensure that they do not put anything into the food
which they assume is already approved.
Q272 Baroness Neuberger: There is a real issue, is
there not, coming back to Lord May’s point, that if
this is something that was widely known—andwe are
waiting for the law to clarify before people have to be
seen to do be doing those kinds of health and safety
studies—it is not very satisfactory for the consumer,
is it?
Dr Chaudhry: Our food laws come under national
legislation. They aremade inEurope and then ﬁltered
through down to national level. This is now being
takenup atEuropean level and then itwill comedown
to national level.
Q273 Baroness Neuberger:Comingdown tonational
level, do you think the FSAor someother body ought
to be responsible for holding a whole register
somehow of health and safety research by industry to
ensure that thework that is done is ﬁt for purpose and
that the lessons learnt and the methodologies can be
shared, which I think was your point about having an
industry-wide body?
Dr Chaudhry:Tobe fair, government has done quite a
lot.Theyhave founded theNanotechnologyResearch
Co-ordination Group (NRCG) which is headed by
Defra; the FSA and other agencies are part of that. It
deals with across-the-board issues and then every
agency is responsible for its own remit. In that sense,
the FSA are responsible for the food area. Usually
what happens is that a new technology emerges and
regulation and technology feed each other and that is
how the system goes, but this technology has taken
everyone by surprise. It emerged out of lab benches
and suddenly people thought: let us put these
materials into products—cosmetics, food, paints and
coatings, and variety of other things. The production
volume certainly started to increase from milligrams
to grams to kilograms to multi-tonne and nowwe are
talking about thousands of tonnes of somematerials.
Ithas takeneveryonebysurprise.Tobefair, regulators
are doing what is needed. They may have been a bit
slow but everything is being done, inmy view asmuch
as possible.
Dr Powell: I just want to make a couple of very quick
points. We do of course have at least one example
which has beenmentioned a couple of times here from
theUSAwhereoneparticular particle thatwaspassed
as safe to use by the FDA was never in any way
intended to be in nanoparticulate form and never was
but, as legislation did not prevent that, it suddenly
came intobeing inananoparticulate form. Idobelieve
that there are fairly simple procedures and tests that
could be undertaken and, if not within the industry
itself, certainly they could be outsourced reasonably
cheaply.Thatwould in the short tomid term,whilstwe
are getting our act together in terms of understanding
and legislation, provide I think a fairly rational
approach todeterminingnanoparticulate safety in the
foods I talked about.
Q274 Baroness Neuberger: Do you think that would
be a relatively easy thing to do?
Dr Powell: Yes. As I said earlier, I do not think it is
going to provide 100 per cent proof but, in terms of
eVectiveness for 80 to 90 per cent, this would really be
a pretty quick, cheap and easy way to proceed. These
are not complicated assays that I am talking about.
Q275 Chairman:Could you just clarify what you are
talking about?
Dr Powell: Yes. I am thinking ﬁrstly about simply in
vitro assays, test tube assays that will allow us to ask
thequestion: under simulated conditions of digestion,
is this nanoparticle persistent or does it get broken
down? Secondly, if we take two simple cell types, the
one that lines the gut (the epithelial cell) and the
underlying immune cells and we challenge those with
the nanoparticles in the presence and absence of some
bacterial toxins that are found in the gut, do we then
see eVectson those cells in termsofmaybe three simple
outcomes that are quite well established—reactive
oxygen species, cytokines and cell surface markers—
and look at degradation of the particle. If we see no
eVects there and we see degradation of the particle, I
would be fairly well reassured that that is likely to be
safe. If howeverwe see eVects on the cells, orwedonot
see degradation of the particles, I might then suggest
that we look into just how necessary is that particle to
bring into the food environment at themoment.
Q276 Chairman: Are there any other points that any
of you as witnesses would like to make? We have
reached the end of our questioning but there may be a
point that you feel we have not covered or issues you
would like to raise at this stage. No. Of course, if at a
later stage you feel that there are points youwould like
to write in about again, and already a number of you
have submittedwritten evidence, please feel free to do
so to the committee clerk sitting on my left. Also, I
should remindyouthat therewillbea transcriptof this
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session and you will have a chance to comment on it
before it is ﬁnalised. Just in closing and in thanking
you for coming to give evidence to us, I would like to
revert back to an earlier question to be absolutely
clear. In the early part of this morning’s discussion,
you all in diVerent ways emphasised the heterogeneity
of what might be considered to be nanoparticles and
considered issues like whether they were persistent or
not, their reactivity or lack of reactivity on the
nanoscale. I just wanted to go back to cases that we
have heard about of potential application which are
really of nanoengineering of items that are already in
the diet. For example we have heard about the notion
of nanosized salt particles to increase the surface area
and therefore the saltiness so you can have less salt in
food. Another example was a mayonnaise with a
nanoemulsion with I think fat droplets enclosed in
water droplets, or maybe the other way round, I
cannot remember how it was. I want to ask you
whether the concerns that you expressed in relation to
unknownsabout riskassessmentwouldapply to those
engineered, naturally occurring, already existing
components of food or whether it was more to the
components that are not already existing or naturally
occurring.
Professor Donaldson: Obviously with something
soluble like sodium chloride, like salt, all that would
happen in a nano form is that it would be much more
rapidly soluble. I cannot see that changing the toxicity
or lack of toxicity in general that salt has at all.
Likewise, changing the size of micelles, lipid micelles,
I do not think would have a big eVect. Our concern
here is, for want of a better word, about hard particles
or things that are added in. That is my feeling.
Dr Powell: I completely agree with that. I would also
just addhowever one small caveat. It is still possible to
take naturally occurring soluble molecules and make
them nanoparticulate but not make them rapidly
biodegradable. Just because they have naturally
occurring components does not immediately transfer
to safety.
Dr Chaudhry: This is the area, going on from Dr
Powell’s comment on nanoparticles naturally
occurring but made into less degradable ones, that is
Further supplementary memorandum by Medical Research Council
Thank you for the opportunity to present theMRC’s work relevant to nanotechnology and food to the Select
Committee. This response addresses issues raised during the evidence session and provides an update on
several matters.
Transfer of Nanoparticles Across the Placenta
This question was raised during the evidence session, and has been addressed in a separate response from
BBSRC, to which theMRC contributed. To summarise, cross-placental transfer of nanoparticles is the subject
of debate in the research community. There is limited data on this matter, but an unpublished (and therefore
not peer-reviewed) study showing that transfer may occur in rats. There are probably a variety of routes of
access, as with gut absorption, and diVerent particles may behave in diVerent ways. On balance, it is possible
that some nanoparticles can cross from mother to foetus, but this has yet to be formally shown.
the basis of a nano delivery system, so that they take
materials out of the gut. Although they may be
composed of naturally occurringmolecules, theymay
take things out of the gut into other cells and tissues.
Professor Depledge:Myconcerns are thematerials that
are added to food that are designed to be toxic in one
way or another, perhaps to bacteria or those kinds of
things. I also emphasise again that contaminant
nanoparticles in food are important, things that are
designed to be toxic but somehow or other end up
contaminating food. With later generations of
nanomaterials, in the thirdor fourthgenerationwhere
they combine with other systems, synthetic biology
systemsand soon, for the future thereneeds tobe even
greater care taken.
Professor Donaldson: If I can I say one word in closing,
it isnot tobe toohunguponthe100nanometre cut-oV
and to be concerned at things of 200. I do not know
where the cut-oV is to say that things are fairly close to
the size that naturemakes,maybe 500 permicron, but
certainly we should not be too struck on the idea that
100 nanometres means harmfulness beneath it and
harmlessness above it.
Q277 Chairman:That is a very helpful comment and
onewe have heard before.
Dr Powell: I am sorry but there is just one brief point,
which is that I would like to re-emphasise something
we probably have not said enough about today and
that is that the gut lumen is a very unusual
environment; it is full of bacterial toxins and ingested
particles really have the ability to bind to their surface
these kinds of toxins and other molecules and can, at
least in theory, and we now have evidence for this,
carry themacross intothegutmucosa.Youaredealing
with quite a complex situation.
Chairman:Youdidmention that earlier but it is useful
that you remind us of it. I would like to draw the
session to a close and thank all of our witnesses for an
excellent session. You have answered our questions
patiently and very clearly and been very helpful to us.
Thank you all verymuch indeed.
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Activity in the UK: Worldwide Comparisons
The select committee asked how the United Kingdom’s research eVort rated compared to other countries,
and at the time we could not give an assessment. The EMERGIMANO report which we referred to in
the evidence session, has now been released at http://randd.defra.qov.uk/Document.aspx?Document%
CB0409 7911 FRP.pdf provides information on the relative activity in environment, health and safety
research on nanomaterials and nanotechnology in countries worldwide. The United Kingdom was found to
conduct l5 per cent of studies, placing it second behind the USA. Additionally, a high number of studies had
been completed (third, behind the USA and Canada), suggesting a leading position in the ﬁeld.
While these ﬁndings are encouraging for United Kingdom nanotechnology/nanotoxicology research, there is
no doubt that there remain signiﬁcant gaps in our knowledge, and the report highlights these well. The report
covers all research funded by Research Councils (or their equivalents) and by agencies closer to policy making
needs and regulation. We expect that combined eVorts of several funders will continue to be needed, to cover
the gaps across basic and applied, ideas-led and needs-led. TheMRC, in combination with the other Research
Councils, will play an important role in generating the scientiﬁc knowledge required to ﬁll these gaps.
Regulators, particularly the Food StandardsAgency,DEFRAand theMHRA,will have an equally important
function, using basic research ﬁndings to create an appropriate and balanced legislative environment for
nanotechnology and food.
MRC Highlight Notice: Nanotoxicology
The highlight notice in nanotoxicology, whichwas ﬁrst released inMarch 2007, is at Annex 1, and on theMRC
website at:
http://www.mrc.ac.uk/Fundingopportunities/Highlightnotices/Nanotoxicology
This is currently the second version of the notice, with further revisions currently under consideration.
Revisions will include a focus on “oral route” nanotoxicology, as discussed in the evidence session.
Highlight notices are one of several mechanisms available to the MRC to increase funding in a particular
scientiﬁc area. Although there is no speciﬁc funding associated exclusively with an area, highlight notices
should not be considered inferior to other mechanisms; since they are not time-limited, it is often possible to
do more through a highlight notice than other options. They also oVer the potential for gradual revision as
the scientiﬁc landscape changes, and as such oVer an adaptable long-term commitment to an area. Our past
experience has shown them to be highly eVective in increasing the funding associated with the area in question.
Nanotoxicology at the MRC Collaborative Centre for Human Nutrition Research
Since the evidence session, this programme of research (led by Dr Jonathan Powell) has been scientiﬁcally
reviewed by the MRC. It was found to be of high quality, and the reporting subcommittee recommended its
continued support.
Annexes
Annex 1—MRC Highlight Notice in Nanotoxicology.
Annex 1
MRC HIGHLIGHT NOTICE IN NANOTOXICOLOGY
Nanotoxicology Highlight Notice
The 2004 the Royal Society and Royal Academy of Engineering report on nanotechnologies and subsequent
United Kingdom Government reports raised concerns that the investment in research to develop new
nanotechnologies is not accompanied by research addressing the health impact of these newmaterials in order
to underpin their safe use. In the light of the recommendations in these reports the Molecular and Cellular
Medicine Boardwishes to encourage innovative, high quality research applications in nanotoxicology relevant
to human health with the aim to help inform policy development in this important area.
Background
Nanotechnology involves the production and application of substances and structures at the nanoscale; within
this size range substances can have very diVerent properties when compared tomaterial in bulk form, reﬂecting
surface area, surface properties and quantum eVects.
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While engineered nanoparticles oVer signiﬁcant potential beneﬁts, there are also uncertainties with regards to
potential risks to human health. This was a key ﬁnding of the Royal Society and Royal Academy of
Engineering report Nanoscience and Nanotechnoloaies: opportunities and uncertainties, commissioned by the
United KingdomGovernment and published in July 2004. The report concluded that many nanotechnologies
pose no new health and safety risks. However, there were concerns over the potential impacts of engineered
nanoparticles and nanotubes (in a free rather than embedded form) and these materials were identiﬁed as a
priority area for research.
Highlight notice
In accordancewith theGovernment response to the report, a cross-GovernmentNanotechnologyResearchCo-
ordination Group (NRCG) has been set up to coordinate research eVorts relating to the potential human
health and environmental exposure, hazards and risks posed by the products of nanotechnologies. This work
is aimed at leading to the development of an appropriate framework and measures for controlling any
unacceptable risks. TheNRCG’s ﬁrst report, published in November 2005 sets out a programme of 19 research
objectives to characterise the potential risks posed by engineered nanoscale materials; Objectives 11–16 are
relevant to the remit of MCMB and include research to establish: a clear understanding of the absorption of
nanoparticles via lung, skin and gut, their distribution in the body and potential target tissues; inter and
intracellular transport and localisation of nanoparticles and their cellular toxicity; whether oxidative stress,
inﬂammatory eVects and genotoxicity apply to nanoparticles; and the deposition, distribution, toxicity,
pathogenicity and translocation potential and pathways for nanoparticles in the airways and lung and their
potential impacts on the cardiovascular system and brain; A subsequent progress report was published in
October 2006.
In the light of working in partnership with the Department of Health and other stakeholders MCMB
encourages innovative, high quality applications relating to the potential human health hazard of
nanoparticles, focussing on areas highlighted in the above Government reports. Since launch of the
nanotoxicology highlight notice four awards were made (Nanotoxicology Awards). In the light of these recent
awards, MCMB now wishes to encourage in particular proposals which investigate the health impact of
nanoparticles in vivo or aim to validate in vitro tests against in vivo models with a particular emphasis on
studies addressing the mechanisms of toxicity. This is in accordance with the recommendations of the recent
Royal Commission on Environmental Pollution report (2008) on Novel Materials in the Environment: The
case of Nanotechnology.
Application Process and Schedule
Applications are invited through the normal MRC funding schemes and will be considered at the regular
MCMB Board meetings. These will be in competition with other applications received, but the Board will be
mindful of the policy importance of this area to Government.
17 July 2009
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1. Which? considers that nanotechnologies have the potential to oVer consumers many beneﬁts, including in
the food area. However, we consider that there needs to be a more co-ordinated and strategic approach to
ensure that nanotechnologies are developed safely and responsibly and are used to tackle some of the major
challenges facing the food supply chain.
2. We are concerned that fundamental knowledge gaps and uncertainties are not being addressed with
suYcient urgency. These include gaps in knowledge about what is on the market, being supplied to the food
industry and what is being developed for the future; basic research to underpin meaningful risk assessment;
regulatory requirements for pre-market authorisation and understanding of consumer attitudes to potential
developments.
3. Our consumer research has highlighted a lack of public awareness of nanotechnologies, but suggests that
people are interested in nanotechnology developments, including in the food sector, provided that they see real
beneﬁts and are assured of their safety and can make an informed choice. We have made a series of
recommendations in relation to the areas highlighted in the call for evidence which are summarised below and
explained in full in our evidence:
State of the Science and Current use in the Food Sector:
— The lack of agreed deﬁnitions needs to be urgently resolved so that there is clarity over how to classify
nanomaterials.
— A mandatory reporting scheme should be introduced for manufactured nanomaterials to enable a
more accurate assessment of developments.
— The food industry needs to be more transparent about the status of developments.
— The government, particularly the Food Standards Agency (FSA), needs to more pro-actively engage
with this issue in order to understand likely applications.
— There needs to be more eVective engagement between regulators, the research councils and broader
research community and the food industry in order to understand what is going on.
— This needs to be done in collaboration with other stakeholders, including consumer organisations,
leading to a more deﬁned and strategic “roadmap” for nanotechnologies and food.
— International regulatory co-operation is also essential in order to understand what is happening in
other parts of the world, particularly as many developments are taking place in Asia and the
United States.
Health and Safety
— EVorts to ensure that research is undertaken to address key uncertainties need to be dramatically
accelerated in order to enable eVective risk assessment.
— Current knowledge should be drawn upon in order to make some general conclusions about which
materials are likely to pose most risk and which may be of little concern in order to identify priority
areas for action, restrictions and to direct future developments.
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Regulatory Framework
— There must be clarity across all food legislation (eg. through clear guidance or updating of relevant
legislation) that materials produced using nanotechnology are subject to mandatory independent
pre-market assessment and approval (ie by the European Food Safety Authority (EFSA)) and that
materials that have already been approved in their conventional formneed a separate assessment and
approval if in nano form. This needs to be addressed as part of the current review of the EU novel
foods regulation.
— Theremust be eVective enforcement so that any products that are on themarket which have not been
approved are removed. This requires clear guidance to be given to local authorities by the FSA.
— There should be greater clarity about how broader consumer and other social issues are to be taken
into account as part of the approval process.
— There needs to be eVective monitoring by the FSA of the extent to which other non-food
nanomaterials may be contaminating the food chain and any associated risks.
Public Engagement and Effective Communication
— More eVective consumer engagement at the earliest opportunity is needed speciﬁcally focused
around potential food developments so that it can be ensured that research priorities and regulatory
approaches are in line with consumer expectations and address their concerns.
— Once there is a fuller understanding of the potential of nanotechnologies for food, greater
consideration needs to be given to any social and ethical issues that may be raised and how these can
be addressed.
— There should be a requirement that manufactured nanomaterials used in food products have to be
labelled in the list of ingredients. The current EU discussions around the new food information
regulations provide an opportunity to address this.
— Greater eVort is needed across government to increase public awareness of nanotechnologies and the
issues that they raise in a balanced way.
Introduction
4. Which? welcomes this opportunity to submit evidence to the House of Lords Science and Technology
Committee’s Inquiry into Nanotechnologies and Food.
5. Nanotechnologies have the potential to oVer consumers a wide range of beneﬁts, including in the food
sector, but we are concerned about the way that developments are being handled. There has been a failure to
take a suYciently strategic approach to the issue and ensure that advantage is taken of nanotechnologies so
that they help to tackle the many challenges currently facing the food supply chain—from the need to
encourage healthier eating and produce safe food to reducing the environmental impact of food production
and consumption. Concerns have repeatedly been raised by leading expert bodies at national and EU level
about the many uncertainties that hinder eVective risk assessment of nanomaterials and about gaps in the
current regulatory framework. However, we are concerned that these are not being addressed with suYcient
urgency, to discriminate those applications that are likely to be beneﬁcial and should be given greater priority,
from those that could potentially put consumers at risk.
6. It is therefore very timely for the Committee to be reviewing this whole area and we hope that the Inquiry
will lead to a more pro-active and joined up approach by government so that it can be ensured that consumers
genuinely can take advantage of the beneﬁts oVered by nanotechnologies, while being able to make informed
choices and be conﬁdent that they are not being put at unnecessary risk.
State of the Science and its Current Use in the Food Sector
7. There is the potential for nanotechnologies to beneﬁt food production in a variety of ways. Traditionally,
many foods have relied on manipulation at the nanoscale in order to give them particular characteristics,
although this was not explicitly seen as “nanotechnology”, for example, the manufacture of custard or
mayonnaise. Advances in microscopic techniques have made it possible to deliberately manipulate materials
at the nanoscale, enabling them to take on new properties that would not otherwise be possible.
8. It is, however, very diYcult to gain a clear picture of the extent to which nanomaterials and
nanotechnologies more generally are being used in food production—or the extent to which research is taking
place into future applications that will come to market and could be impacting on consumers in the next ﬁve,
10 or 20 years. This information is essential if we are to have an informed and transparent debate about the
134 nanotechnologies and food: evidence
role of nanotechnologies, ensure the adequacy of risk assessment, management and communication
approaches and if it is to be ensured that nanotechnology applications take place in line with consumer
expectations. The situation is also further complicated by the lack of any agreed international deﬁnitions as
to what falls under nanotechnologies or should be considered a nanomaterial.
9. A few years ago, leading food companies were quoted in the trade press as taking an active interest in using
nanotechnologies.1Kraft was, for example, quoted as looking at the potential of “smart nano-ﬁlters” to limit
allergic reactions and investigating “smart packaging”, while Nestle was also reported to be looking at the
possibility of using nanotechnologies to customise and personalise food with precisely targeted delivery of
nutritional and health beneﬁts. However, the main food manufacturers now state that they currently are not
using nanotechnologies, although some chemical companies are supplying nanomaterials and there are several
“nano” food supplement products available to buy over the internet. It is, therefore, essential that there is
transparency across the entire supply chain.
10. Based on a recent overview produced by the Food Safety Authority of Ireland, the main areas of interest
appear to be:2
— sensory improvements (ﬂavour or colour enhancement, texture modiﬁcation);
— increased absorption and targeted delivery of nutrients and bioactive compounds;
— stabilisation of active ingredients such as nutraceuticals in food matrices;
— packaging and product innovation to extend shelf-life;
— sensors to improve food safety; and
— antimicrobials to kill pathogenic bacteria in food.
11. The types of nanomaterials likely to be used include:
— nanoparticles, such as silver and iron used in food supplements;
— nanoﬁbres, such as globular proteins used as thickening agents;
— nanoemulsions and dispersions, such as oil in water to produce low fat products; and
— nanoclays, such as clay composites used in packaging materials to extend shelf-life.
12. A recent review of nano food developments by Chaudhry et al3 concluded that virtually all known
applications are currently outside the UK and Europe, mainly in the USA, Australia, New Zealand, South
Korea, Taiwan, China and Israel. Two exceptions were highlighted: a synthetic form of lycopene, found in
tomatoes, produced by BASF in Germany; and a nano-micelle-based carrier system NovaSOL produced by
Aquanova, also based in Germany.
13. The online Woodrow Wilson Center’s Inventory of nano products4 and the “Nanoshop” web-site5
include a range of nano products that are available to buy, including food supplements, food packaging
materials and food containers. The lack of agreement over deﬁnitions makes it diYcult to be clear what is
deﬁnitely a nano product, but examples of products claiming to be “nano” include:
— Solgar’s Nutri-nano CoQ10 and Nutri-nano CoQ10 with Alpha Lipoic Acid6 (from the UK) food
supplements, part of “the ﬁrst-line of nutritional supplement to use nanotechnology to deliver
unprecedented bioavailability”.
— Canola Active oil by Shemen7 (from Israel) “an oil enriched with free phytosterols”.
— Nano selenium rich tea8 (from China).
— Nano calcium and magnesium food supplement9 (from the USA) “a potent 100% available and
absorbable ionic solution when dissolved in water”.
1 A mini revolution, Food Manufacture, 1 September 2004
2 The relevance for food safety of applications of nanotechnology in the food and feed industries, Food Safety Authority of Ireland,
2008.
3 Applications and implications of nanotechnologies for the food sector, Quasim Chaudhry et al, Food Additives and Contaminants,
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— ASAP solution food supplement10 (from the USA) “an engineered silver nano particle mineral
supplement” which is “an immune system support”.
— Nanoceuticals Slim Shake Chocolate by RBC Lifesciences11 (from the USA) “with a blend of high
quality protein, ﬁber (sic), complex carbohydrate and the proprietary Cocoaclusters or
Vanillaclusters [this formula] provides a nutritious and low calorie meal that will help you lose those
unwanted pounds once and for all”.
— Skybright Natural Health Colloidal Silver Liquid12 (from New Zealand) “support the body’s
immune system and natural defences, for natural healing”.
14. EFSA recently approved the use of Titanium nitride as a food contact material for use in PET bottles.13
It also issued an opinion on a silver hydrosol food supplement that it was unable to assess because the data
was inadequate.14
15. Overall, it is therefore very diYcult to gain a clear indication of what developments are already taking
place and what we could see in the future. Defra has trialled a voluntary reporting scheme for manufactured
nanomaterials, but this has had a very limited response with just 11 submissions since it was launched in
September 2006.
16. We therefore consider that the following actions are needed:
— The deﬁnitional issue needs to be urgently resolved so that there is clarity over how to classify
nanomaterials.
— A mandatory reporting scheme should be introduced for manufactured nanomaterials to enable a
more accurate assessment of what developments are taking place.
— The food industry needs to bemore transparent about the status of developments, including the food
supplement industry and suppliers across the food chain, such as ingredients and packagingmaterial
manufacturers.
— The government, particularly the Food Standards Agency, needs to more pro-actively engage with
this issue in order to understand what applications are likely.
— In line with this, there needs to be better and more formalised engagement between regulators (eg
FSA, Department of Health and Defra), the research councils and broader research community and
the food industry in order to understand what is going on.
— This needs to be done in collaboration with other stakeholders, including consumer organisations,
leading to a more deﬁned and strategic “roadmap” of where food-related nanotechnology
developments are currently going and where they should be going in order to meet the key food
policy priorities around food safety, quality, nutrition and sustainability.
— International regulatory co-operation is also essential in order to understand what is happening in
other parts of the world, particularly as many developments are taking place in Asia and the
United States.
Health and Safety
17. We are also concerned that there remains too limited an understanding of the risks that could be posed
by some manufactured nanomaterials. Despite relatively early warnings from the Royal Society and Royal
Academy and Engineering back in 200415 that some nanomaterials may pose diVerent risks to materials in
their bulk form, many uncertainties still remain.
18. While some nanomaterials may be of little concern, recent opinions by the EU’s Scientiﬁc Committee on
Emerging and Newly Identiﬁed Health Risks (SCENIHR)16 and the European Food Safety Authority’s




13 21st list of substances for food contact materials—Scientiﬁc Opinion of the Panel on food contact materials, enzymes, ﬂavourings and
processing aids (CEF) Question number: EFSA-Q-2005-151, EFSA-Q-2006-324, EFSA-Q-2006-323, European Food Safety
Authority, 27 November 2008.
14 Inability to assess the safety of a silver hydrosol added for nutritional purposes as a source of silver in food supplements and the
bioavailability of silver from this source based on the supporting dossier—Scientiﬁc Statement of the Panel on Food Additives and
Nutrient Sources added to Food (ANS), European Food Safety Authority, Question number: EFSA-Q-2005-169, 26 November 2008.
15 Nanoscience andnanotechnologies: opportunities and uncertainties, TheRoyal Society andTheRoyalAcademy ofEngineering, 2004.
16 Risk assessment of products of nanotechnologies, Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks, 19
January 2009.
17 The potential risks arising from nanoscience and nanotechnologies on food and feed safety, Scientiﬁc Opinion of the Scientiﬁc
Committee, European Food Safety Authority (Question No EFSA%Q-2007-124), 10 February 2009.
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As well as highlighting the lack of information available to enable the potential exposure to engineered
nanomaterials (ENMs) to be assessed, EFSA highlighted some fundamental gaps in knowledge around
toxicokinetics (the absorption, distribution, metabolism and excretion of substances in the body) and
toxicology.
19. The breadth of the uncertainties were summarised in EFSA’s overall conclusions: “Current uncertainties
for risk assessment of nanotechnologies and their possible applications in the food and feed area arise due to
presently limited information in several areas. Speciﬁc uncertainties apply to the diYculty to characterize,
detect and measure engineered nanomaterials (ENMs) in food/feed and biological matrices and the limited
information available in relation to aspects of toxicokinetics and toxicology, including optimal methods for
testing ENMs. There is limited knowledge of (likely) exposure from possible applications and products in the
food and feed area and of environmental impacts of such applications and products. The current usage levels
of ENMs in the food and feed area is unknown”.
20. The lack of knowledge is fundamental. For example, the understanding of the potential toxicity after
consuming manufactured (or engineered) nanomaterials has only been studied for a very limited number of
materials and only a few studies have compared the toxicity of the nano and conventional form of the same
chemical species. EFSA, therefore, concluded that the data are insuYcient to draw general conclusions. It
stressed the importance of a case by case approach to risk assessment, but emphasised that under the current
circumstances any individual risk assessment is likely to be subject to a high degree of uncertainty—and that
this would remain the case until there was more data on, and more experience with, testing of engineered
nanomaterials.
21. Defra over-sees the UK’s Research Co-ordination Group on nanotechnologies and has published and set
out a series of research priorities,18 but we are concerned that these gaps in understanding are not being
addressed with suYcient urgency. This is compounded by the failure by government to get to grips with what
is actually on the market, either in terms of speciﬁc food and applications or other non-food developments
that could have implications for the food supply chain.
22. We therefore consider that the following action is needed:
— EVorts to ensure that research is undertaken to address key uncertainties needs to be dramatically
accelerated in order to enable eVective risk assessment. Leading scientiﬁc bodies are repeatedly
producing lists of key knowledge gaps and uncertainties—the most recent coming from research the
SCENIHR and EFSA committees.
— As part of this, current knowledge should be drawn upon in order to make some general conclusions
about which materials are likely to pose most risk and which may be of little concern in order to
identify priority areas for action and to direct future developments, including identifying where any
restrictions need to be placed.
Regulatory Framework
23. Under the Food Safety Act 1990 and the EU’s regulation on food law,19 there is a general requirement
that food should be safe. The issue in relation to nanomaterials used in food production is how this can be
ensured in practice given the uncertainties highlighted above.
24. Many food applications that are relevant to the use of nanotechnology are subject to speciﬁc EU
legislation that requires a pre-market authorisation, including a risk assessment by EFSA (eg food additives,
food contact materials and food supplements). The recent review of the food improvement agents package of
legislation which included food additives, ﬂavourings and enzymes, for example, was used to clarify that an
additive produced in nano form was considered a new material compared to its bulk form and therefore
required speciﬁc approval.20
25. It is essential that there is clarity over how nanomaterials are to be dealt with. This is diYcult without
agreed deﬁnitions as to what is classed as a nanomaterial. However, it is essential that consumers are not
exposed to risks from nanomaterials while the debate over deﬁnitions is resolved.
26. One speciﬁc gap has been in relation to novel foods. The novel foods regulation is currently being reviewed
and considered by the European Parliament and Council. The European Commission proposed that products
produced using nanotechnologies (as well as any other “new production process”) should fall under the
deﬁnition of a “novel food” and therefore require pre-market approval, but only if it gives rise to “signiﬁcant
18 Characterising the Potential Risks posed by Engineered Nanoparticles: A Second UK Government Research Report, HM
Government 2007.
19 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles
and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety.
20 http://ec.europa.eu/food/food/chemicalsafety/additives/prop leg en.htm
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changes in the composition or structure of the food which aVect its nutritional value, metabolism or level of
undesirable substances.”21 We are concerned that this is too limited as it relies on a company making an
assessment as to the relevance of any changes before a product would be subject to an independent risk
assessment. The Regulation should therefore be clear that if a product is produced using nanotechnology—
and does not fall under any speciﬁc food regulations as outlined above—it should be considered a novel food
and require a pre-market assessment by EFSA and EU authorisation before it can go on the market.
27. The general food law regulation (EC 178/2002) acknowledges in Article 6 that as well as risk assessment,
risk analysis should also take account of “other factors legitimate to the matter under consideration and the
precautionary principle”. Nanotechnologies are likely to raise a wide range of issues some of which will go
beyond safety aspects. It is essential that these broader social and ethical issues are understood and are taken
into account as part of authorisation processes. This is also consistent with the FSA’s role of protecting public
health and “other consumer interests in relation to food”.22
28. The call for evidence seeks views on the role that voluntary self-regulation may play in this area. Given
that food is generally a highly regulated area compared to other products in view of the potential widespread
health consequences if it is unsafe, we consider that it would be a backward step to rely on a voluntary
approach to control the issues raised by manufactured nanomaterials. This is a highly competitive area and
is also an area where there is a great deal of uncertainty. Our experience from working with a range of other
stakeholders as part of an initiative to develop aResponsible NanoCode23 is that it is only likely to be possible
to reach agreement on broad principles, rather than on the speciﬁc measures that are needed in order to ensure
the safe and responsible development of nanomaterials. This has also been reinforced by the poor response to
Defra’s voluntary reporting scheme.
29. In relation to inter-governmental co-operation, the Organisation for Economic Co-operation and
Development (OECD) has established a Working Party on Nanotechnology and a Working Party on
ManufacturedNanomaterials looking at health and safety aspects. The International Standards Organisation
(ISO) is also undertaking several pieces of work and has been leading on eVorts towards standardisation of
deﬁnitions. The relevant international standards body for food regulation is the Food and Agriculture
Organisation (FAO) and World Health Organisation (WHO) Codex Alimentarius Commission. While it is
essential that there is international co-operation on this issue, experience from the development of standards
for other emerging technologies has been that these bodies can take many years to reach agreement on
standards—and often come after products have been on sale for many years. It is therefore important that the
UK and EU actively participate and take a leadership role in these discussions, but waiting for international
consensus could put consumers at risk.
30. There is a more speciﬁc initiative to ensure regulatory co-operation between the US and EU as part of the
Trans-atlantic Economic Council established by the previous US administration and the German Presidency
of the EU.24 This work is important to ensure that there is a common approach to the regulation of this
technology, avoiding any potential trade disputes and ensuring that consumer protection is not undermined.
31. As well as addressing the concerns raised above speciﬁcally in relation to the review of the novel foods
regulation, we consider that the following issues need to be addressed:
— It should be ensured that there is clarity across all food legislation (eg through clear guidance or
updating of relevant legislation), that materials produced using nanotechnology are subject to
mandatory independent pre-market assessment and approval (ie by EFSA) and that materials that
have already been approved in their conventional form need a separate assessment and approval if
in nano form.
— EVective enforcement should be ensured so that any products that are on the market which have not
been approved are removed. This requires clear guidance to be given to local authorities by the FSA,
including over how to deal with products available over the internet.
— There is a need for clarity over how broader consumer and other social issues are to be taken into
account as part of the approval process, in line with the recognition that “other legitimate factors”
play a role and need to be taken into account by risk managers in the EU’s general food law
regulation.
— There should be eVective monitoring by the FSA of the extent to which other non-food
nanomaterials may be contaminating the food chain and any associated risks.
21 Proposal for a Regulation of the European parliament and of the Council on novel foods, COM (2007) 872 ﬁnal, 14.1.2008—proposed
Article 3.
22 Food Standards Act 1999.
23 http://www.responsiblenanocode.org/
24 Framework for advancing transatlantic economic integration between the European Union and the United States of America,
April 2007.
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32. In addition, as highlighted above, in relation to current uses and health and safety aspects:
— Regulation needs to ensure that there are robust deﬁnitions in place that cover all potential food
applications that may be considered to exhibit diVerent properties because they are manufactured
using nanotechnology.
— Regulation is needed to ensure that manufactured nanomaterials have to be reported to the
regulatory authority (ie Defra or FSA).
Public Engagement and Consumer Information
33. Which? conducted a survey in October 2008 which found that only 45 per cent of people had heard of
nanotechnology.25 This was a slight increase from our last survey in November 2007 when 37 per cent were
aware,26 but even those who had heard about it were unclear what it is. Respondents were asked what ﬁrst
thing they think of when they hear the term “nanotechnology” and around half (52 per cent) couldn’t come
up with anything at all. Around one in ﬁve (22 per cent) made mentions relating to size and slightly fewer (18
per cent) mentioned electronics, science or technology. Awareness was higher among men than women (53 per
cent compared to 37 per cent) and those over 65 were likely to be less aware (37 per cent). When asked where
they thought nanotechnology is currently being used to produce consumer products, just 3 per cent mentioned
food—and only 6 per cent when prompted with a list of possible applications.
34. In November 2007, we commissioned a citizens’ panel in order to understand consumer attitudes towards
nanotechnologies.27 This looked at food applications as well as medicines, cosmetics and other consumer
products. A summary of the ﬁndings and the full report conducted by Opinion Leader are enclosed.
35. The Panel was made up of 14 people, broadly representative of the population. They met over three days
and heard evidence from a range of experts. Although 14 people is a small number, we felt that it was
appropriate to use this type of deliberative technique over other research methods given the complexity of the
issue and lack of consumer awareness.
36. The Panel indicated that people are unlikely to have blanket opposition to the use of nanotechnologies
for food products. Some people were positive about possible developments, such as intelligent packaging,
although others were slightly more wary of getting into areas they considered to be unnatural. Overall, people
expect there to be eVective regulation in place. They also wanted to know where manufactured nanomaterials
are being used and called for labelling. However, the panellists recognised that this would only be useful if
backed up by broader information about nanotechnologies that would make the information on the label
meaningful.
37. It is also likely that many food companies will want to make claims about the beneﬁts the use of
nanomaterials oVer. This is already the case in relation to the nano products that can be found on the internet.
It is, therefore, essential that these claims can be independently substantiated and that enforcement action is
taken over misleading claims.
38. Lessons from the introduction of other new technologies, most notably the introduction of genetically
modiﬁed (GM) foods, has been that it is essential to engage the public at the outset and ensure that there is a
two way exchange, leading to the development and use of the technology in a socially acceptable way that
brings genuine consumer beneﬁts. Although this has been widely acknowledged as necessary in relation to
nanotechnologies by the government and various engagement activities have been organised and overseen by
aNanotechnology EngagementGroup, we are concerned that these have been too limited. Part of the problem
is that until the government has a better understanding of what the use of nanotechnologies in the food area
is really going to mean for consumers, it is diYcult to have a meaningful debate. Most of the engagement
exercises to date have been quite general and while giving a general insight into how consumers expect new
technologies to be regulated, they have not explored likely reactions to diVerent developments so that the
public’s views can help to shape the research and regulatory agendas.
39. We therefore consider that the following actions are needed:
— More eVective consumer engagement at the earliest opportunity speciﬁcally focused around
potential food developments by the FSA so that it can be ensured that research priorities and
regulatory approaches are in line with consumer expectations and address their concerns.
25 October 2008 face to face survey of 977 adults aged 16! representative of adults in the UK.
26 November 2007 face to face survey of 2,091 adults aged 16! representative of adults in the UK.
27 Opinion Leader Research conducted a Citizens’ Panel on behalf of Which? with 14 members of the public. Panellists were selected
broadly to reﬂect the general public and sat for three days from29November–1December 2007. The venuewasBirminghamUniversity
and panellists were recruited from Birmingham and the wider West Midlands area. Expert witnesses were called upon to explain
nanotechnologies, the overall beneﬁts and issues, applications in particular areas (including beneﬁts and issues) and the policies and
controls in place. The Panel was overseen by a steering group, with a range of expertise and interests, who advised on the approach,
agenda and selection of witnesses.
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— Once there is a fuller understanding of the potential of nanotechnologies for food, greater
consideration needs to be given to any social and ethical issues that may be raised and whether these
can be addressed or whether some applications are inappropriate as a result.
— There should be a requirement that manufactured nanomaterials used in food products have to be
labelled in the list of ingredients. The current EU discussions around the new food information
regulations provide an opportunity to address this.28
— Greater eVort is needed across government to increase awareness of nanotechnologies and the issues
that they raise in a balanced way.
March 2009
Memorandum by the Soil Association
Introduction to the Soil Association
The Soil Association was founded in 1946 to achieve sustainable and healthy agriculture. It is now the main
organisation of the organic movement in the UK and certiﬁes about 56 per cent of organic farmers and 70 per
cent of the organic food sold in the UK. Organic farming is a management-based system which harnesses
natural ecological and biological processes, rather than using synthetic chemical inputs. Organic farming now
accounts for about 4 per cent of UK farmland. Sales of organic food are worth almost £2 billion per year.
The Sustainable Development Commission has called organic farming the “gold standard” for agricultural
sustainability. Research shows that it has signiﬁcant environmental advantages over non-organic farming. It
supports higher levels of wildlife, whilst reducing agrochemical pollution, waste, and halving the amount of
fossil fuels needed to produce food. Because of these beneﬁts the Government wishes to expand organic
farming. Defra adopted an action plan for organic food and farming in 2002, with a target of 70 per cent of
the UK organic food market to be supplied by UK farmers by 2010, and public procurement to include
organic food.
Soil Association Standard on Nanotechnology
As of January 2008, the Soil Association banned the use ofman-made namomaterials fromall Soil Association
certiﬁed organic products. We were the ﬁrst organisation in the world to take a practical stance on the use of
nano particles to protect the public, ahead of any governments. Our lead has since been followed in Australia,
where the Biological Farmers of Australia (BFA), the country’s largest organic body, have now banned
manufactured nanoparticles in certiﬁed organic products.
Under the Soil Association standard, organic producers and processors must not use ingredients containing
manufactured nanoparticles, where:
— the mean particle size is 200nm or smaller; and
— the minimum particle size is 125nm or smaller.
We recognise that this standard will have implications for some established manufacturing processes that
produce nanoparticles incidentally, such asmilk homogenization.However, we are not in a position to prohibit
these now for many reasons: these processes are currently well established, there is relatively little awareness
of this issue among the general majority of organic consumers and licencees, we currently do not know which
processes produce nano-particles and to what extent. Until we research these more fully, we will not apply this
standard to them.
There are many cases of naturally occurring nanoparticles, for example from volcanic eruptions or in wood
smoke; these fall outside the scope of this standard.
The standard does apply to engineered nanoparticles.
Summary of Reasons for the Ban
The following section outlines the key issues and documentary evidence that led the Soil Association to
develop the nanotechnology standard.
28 Proposal for a Regulation of the European Parliament and of the Council on the provision of food information to consumers,
COM(2008) 40 ﬁnal, 30.1.2008.
140 nanotechnologies and food: evidence
Organic farming methods are based on the use of natural biological and ecological processes. The use of
synthetic nano-particles which would not exist in nature and whose basic physical structure has been modiﬁed
at a very fundamental level is incompatible with this important organic principle as well as unnecessary.
Speciﬁc concerns are based on information from:
(1) the The Action Group on Erosion, Technology and Concentration (ETC Group),
(2) reviews of nanoparticle safety undertaken by the European Commission and European Parliament
and Swiss Reinsurance,
(3) the nanotechnology report by the Royal Society (RS) and the Royal Academy of Engineering
(RAE), and
(4) the UK government response to the RS and RAE report.
The RS and RAE state in the recommendations section of their report that “The lack of evidence about the
risk posed by manufactured nanoparticles and nanotubes is resulting in considerable uncertainty . . . We
recommend that the UK research councils set up an interdisciplinary centre to research the toxicity,
epidimiology, persistence and bio-accumulation of manufactured nanoparticles and nanotubes as well as their
exposure pathways.” The report also recommends a prohibition on environmental releases of nanoparticles
and strict regulation of new nanomaterials. For details of the full report see http://www.nanotec.org.uk/report/
chapter10.pdf
The UK Government Response to the RS & RAE Report
(see http://www.ost.gov.uk/policy/issues/nanotech ﬁnal.pdf)
The UK government acknowledges the need for regulation of and the lack of scientiﬁc knowledge about
nanotechnology. It places amoratorium on use of nanoparticles for environmental remediation and states that
“As a precautionarymeasure, in the interim, exposure in the workplace and releases to the environment should
be minimised until the possible risks posed by nanoparticles and nanotubes are better understood”.
In a report commissioned by the European Parliament’s committee on Industry, External Trade, Research and
Energy (ITRE) it is noted that “The release of nano-particles in the environment should be avoided. The state
of research concerning [sic] . . . the behaviour of nano-particles is actually rather limited, preliminary as well
as contradictory. Nevertheless, the advice to avoid the release of nano-particles to the environment might be
appropriate and would be in accordance with the Precautionary Principle.”
(Haum, Petschow, Steinfeldt, Nanotechnology and Regulation within the framework of the Precautionary
Principle. Final Report. Institut fu¨r o¨kologische Wirstschaftforschung (IO¨W) gGmbH. Berlin).
A subsequent preliminary risk analysis of nanotechnologies carried out by the Health and Consumer
Protection Directorate of the European Community:
— highlighted that some engineered nanoparticles may have the potential to pose serious concerns,the
most signiﬁcant ones relating to nanoscale technologies within the next 3–5 years and require further
studies (Subsection 1.1.1.2);
— revealed that panel experts were of the unanimous opinion that the adverse eVects of nanoparticles
cannot be predicted (or derived) from the known toxicity of normal bulk material; and
— exposed the limits that preclude a complete risk assessment today, in particular the present scarcity
of dose-response and exposure data (Subsection 1.1.1.3) http://europa.eu.int/comm/health/ph risk/
events risk en.htm
Swiss Reinsurance, in a 2004 review of risks associated with nanomaterials (and nanoparticles in particular)
noted that:
“Nanomaterials are already contained in numerous products worldwide and occur in various
applications. There are indications that certain nanomaterials are potential health hazards. The danger
is most probably not of an acute but chronic nature and it could be some time before it manifests itself.
This is where the real risk for insurers lies, and the comparison with asbestos should be seen in this light.”
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They recommended that:
“In view of the dangers to society that could arise out of the establishment of nanotechnology, and given
the uncertainty currently prevailing in scientiﬁc circles, the precautionary principle should be applied
whatever the diYculties”
(Nanotechnology, Small Matter, Many Unknowns, May 2004)
ETC Group articulate further concerns that:
— there are biosafety risks of using DNA, viruses, prions and bacteria in novel ways through
nanobiotechnology;
— nanotechnology will impact on labour, including farmers, especially when related to self-assembly,
crop surveillance and the replacement of agricultural commodities with new artiﬁcial nanomaterials;
— nanotechnology increases the scope for patents on nature and wide matter monopolies;
— there is strong potential for new “nano bioweapons” through nanotechnology;
— there are signiﬁcant cultural and ethical concerns that ﬂow from altering nature at this fundamental
level; and
— nanotechnology is currently an example of where there is little democratic governance over
technologies that determine our future.
HRH The Prince of Wales (Soil Association Patron): “My ﬁnal point concerns the apportionment of beneﬁts
and risks. The beneﬁts will largely accrue to those who invest successfully in these technologies and to those
who can utilise them. But these new applications will inevitably displace existing technologies. Who will lose
from that process, and will it widen the existing disparities between rich and poor nations? What exactly are
the risks attached to each of the techniques under discussion, who will bear them, and who will be liable if an
when real life fails to follow the rose tinted script.” (Independent on Sunday, 11 July 2004).
ETC has published a report listing 10 areas where research has uncovered signiﬁcant cause for concern over
the safety of engineered nanoparticles. (see document link http://www.etcgroup.org/documents/
GT TroubledWater April1.pdf)
Fit with organic principles
Nanotechnology does not ﬁt with organic principles which state that:
— organic is a whole system approach to farming and food production and recognises the close
interrelationships between all parts of the production system from the soil to the consumer; and
— new or novel technologies, ingredients and processes are not automatically applied to organic food
manufacturing.
The lack of accountability of nanotechnology does not ﬁt with organic principles in which there is:
— respect for natural systems;
— ecological responsibility in food production; and
— consideration of the social impact of agricultural systems.
Impact on the environment
Nature, in 2003 reported “. . . nanoparticles could easily be absorbed by earthworms, possibly allowing them
to move up the food chain and reach humans”, see document link http://www.etcgroup.org/documents/
GT TroubledWater April1.pdf).
The European commission has noted that “In the environment, natural enzymes can change the surface
properties of nanoparticles such as fullerenes⁄the C60 molecule consisting of 60 carbon atoms bonded in a
nearly spherical conﬁguration also nicknamed “buckyballs”. Fullerenes can form aqueous suspended
colloids . . . termed nC60 and become re-suspended after evaporation. In their native form, the small size,
colloidal characteristics, and reactive surfaces of colloidal fullerenes make them ideally suited to carry toxic
material over long distances. Thus, potentially, colloidal fullerenes could pollute aquifers.” See
“Nanotechnologies: A preliminary risk analysis” subsection 1.1.1.1.1 Toxicology and ecotoxicology - http://
europa.eu.int/comm/health/ph risk/events risk en.htm
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Impact on human health
Titanium dioxide/zinc oxide nanoparticles used in some sunscreens have been found to cause free radicals in
skin cells, (see document link http://www.etcgroup.org/documents/GT TroubledWater April1.pdf). The
toxicity of particles is increased the smaller they are and they can cross the blood brain barrier. Gold
nanoparticles have been found to cross the placenta from mother to foetus. Cadmium selenide nanoparticles
can break down in the human body potentially causing cadmium poisoning (see document link http://
www.etcgroup.org/documents/GT TroubledWater April1.pdf). Both the TradesUnionCongress and theUK
Health and Safety Executive have raised concerns about the impact of nanomaterials on worker health during
manufacturing and use. The TUC believes that the production and use of nanoparticles should be carried out
in a contained process so that employees are not exposed to the potential health risks. Presently there are no
agreed safe handling guidelines. See www.tuc.org.uk/h and s/tuc-8350-f0.cfm
Impact on animal health/welfare
All the concerns of impacts on human health (above) should also be of concern in relation to animal health. In
addition, research in 2004 found thatbuckyballs [carbonnanoparticles] causebraindamage in juvenileﬁsh alongwith
changes in gene function (see document link http://www.etcgroup.org/documents/GT TroubledWater April1.pdf).
Consumer acceptability and benefits
Some concern has been reported in the national media as a result of the work by Jim Thomas/ETC and the
speech on this issue by HRH The Prince of Wales. However, it appears that other than a small, informed
minority, there is little awareness of the technology amongst consumers. The use of nanoparticles does not
currently have to be declared on labelling although this was a recommendation of the RS & RAE report and
the UKGovernment accepts this may be necessary. The report entitled:Market research on public attitudes to
Nanotechnology carried out by the BMRB (BritishMarket Research Board) and published on 15March 2004,
can be found at http://www.nanotec.org.uk/PressMediaMar042.htm. The report mentions that the
overwhelming majority of people have not heard of nanotechnology. Participants drew a parallel with GM
when considering the ethical implications of nanotechnology because of the perception that both involve
changes at the most fundamental level to form something that does not occur in nature. Both GM and
nanotechnology could be seen as “messing with nature” in a speciﬁc way by “manipulating the building blocks
of nature”. They expressed concerns about whether scientists are trying to “play God”.
Soil Association Concerns on Regulatory Process
Case-by-case approval
We do not agree with controls based on case-by-case assessment of the scientiﬁc evidence as the principal
regulatory response for the forseeable future for free nano-scale products, at least for products to which people
are exposed to regularly and directly via food and health and beauty products. Such controls cannot in practice
be reliable, evidence-based, cost-eVective, or proportional. This is because of the lack of both a history of
experience and a robust body of scientiﬁc understanding of the impacts of such materials on the biology of
organisms, and on ecological interactions, and because it is completely unrealistic to imagine that the full range
of required safety data could and would be generated for each and every product (and it would normally be
completely disproportional to do this even if it were possible). Inevitably, with such an approach, decisions
will be strongly based on personal judgements, and thus open to the bias of expert advisers, politicians and
inﬂuence by commercial lobbyists, whilst being presented and defended as “evidence-based”.
A supposedly “evidence-based” approach is how GMOs are being dealt with now by the Food Standards
Agency. We and very many others see this as totally unsatisfactory because of the poor level of scientiﬁc
knowledge and shortage of relevant, independent evidence, and we consider that the risks to the public are
signiﬁcant. With every GMO submitted for approval, despite the long list of scientiﬁc uncertainties about the
health impacts in each case and the emerging evidence of general health risks with the genetic engineering
process, the beneﬁt of the doubt is always given to the GM company (not a single product has been rejected
despite scientiﬁc concerns always being raised). This deeply ﬂawed approach is, in our view, the basis of the
high controversy and public and market rejection of GMOs. We believe the same will occur with nano-scale
materials, if they are regulated in the same way. We and others would certainly raise these concerns in public,
in the way we have GMOs.
We instead propose that the principal regulatory approach must be a generic assessment of the safety of
engineered nano-scale materials, at least for products to which there is direct and regular public exposure. This
should comprise (i) a review of whether there is an adequate and reasonably robust body of scientiﬁc
understanding to enable case-by-case assessment and approval; (ii) an assessment of whether the current
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understanding and evidence suggests there could be health or environmental risks in at least some cases
(though which cases would not be known); (ii) and an assessment of the viability and cost-eVectiveness of
generating the required range of data to enable comprehensive reliable case-by-case assessment.
There should lead to a general decision on the use of free engineered nano-scale materials, at least for nano-
scale materials in food and health and beauty products. Because of the inevitable negative outcome of this
generic review, we believe there should be a general prohibition against the use of free engineered nano-scale
particles in agriculture and the food chain and in health and beauty products. Only where there is a clear and
speciﬁc societal beneﬁt (excluding economic beneﬁts which can always be delivered in many other ways),
should the necessary data be generated and case-by-case assessment considered
This should not be considered a lost opportunity. Unnatural products introduce new chemical and biological
interactions and therefore have a comparatively high likelihood of disrupting natural processes with negative
eVects, compared to natural processes. They also have a high likelihood of displacing as yet unidentiﬁed
beneﬁts of existing natural substances. Artiﬁcial products also generally involve a high level of embodied
energy in their production, compared to management approaches and natural processes. Moreover and
importantly, there is no signiﬁcant general societal need for nano-scale materials in food, agriculture, or health
and beauty products.
Voluntary reporting
It is not reasonable for the public or other stakeholders that the reporting scheme is voluntary. This will mean
that the results will not be reliable as a basis for developing appropriate controls as the results will under-
represent any negative eVects. It is very likely (and must be assumed) that evidence showing negative impacts
from products already on the market will sometimes be withheld or not clearly communicated (as is the case
with GM research). A voluntary approach would there go against the aim of the scheme to gather evidence of
the risks and produce a reliable basis for controls to allow “responsible development”.
A voluntary approach would also not be reasonable with respect to the companies involved, as it would create
an unlevel playing ﬁeld. It would eVectively reward companies that withhold evidence of negative eVects—and
facilitate those applications, and penalise companies who release evidence of negative eVects—and discourage
those applications.
Commitment to research
There is a major need to build up a robust and comprehensive general body of scientiﬁc understanding of the
impacts of nano-scale materials on the biology of organisms and on ecological interactions, aside from
whether there are any identiﬁed toxic eVects. (The lack of a basic body of understanding of the biological
impacts of GMOs has been the major weakness of the GMO regulatory regime, as the scientists have little
general information on which to decide on the implications of the inevitable numerous gaps in knowledge for
individual products. Commercial and political pressures means they have therefore always decided in favour
of the products, with no scientiﬁc basis).
Good practice must include product labelling, product registers, the quality of safety studies (eg. sample sizes
and time-scales that are adequate for protecting public health) and complete transparency with regard to the
results for any commercialised products and products being submitted for approval. However, at the moment,
only moratorium is acceptable for products to which the public would have regular direct exposure, ie in food,
health and beauty products.
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Memorandum by Friends of the Earth, Australia
Executive Summary
Friends of the Earth Australia (FoEA) has serious concerns about the use of nanotechnology in agriculture,
food and food packaging because:
— Nanoparticles ingested via food or food packaging, to which workers are exposed during product
manufacture, and which are released to the environment via waste streams or agricultural use have
the potential to cause long term pathological eVects or short-term toxicity.
— Decreased particle size may increase the production of free radicals leading to increased toxicity.
— A number of properties apart from size determine the toxicity of a nanoparticle.
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— There are serious knowledge gaps in our understanding of the behaviour and toxicity of nanoparticles
that present obstacles to designing appropriate new risk assessment.
— In vitro and preliminary in vivo studies of some nanoparticles used in agriculture, food, food
packaging or food contact materials have shown that these materials pose serious new toxicity risks.
— The ecotoxicity of nanoparticles remains poorly understood, however early studies suggest that they
may cause serious environmental harm.
— Nanotechnology’s widespread use in food and agriculture, resulting in greater consumption of more
highly processed foods may have serious social and cultural implications and deleterious impacts on
public health that go far beyond the toxicity risks of nanoparticle ingredients.
— Nanotechnology’s use in food and agriculture may undermine eVorts to support ecologically
sustainable, locally controlled, relocalised agriculture and food production that delivers economic,
social and environmental beneﬁts to rural communities and that help redress the global food crisis.
— There are ethical, social and cultural reasons that the public may not wish to support
nanotechnology’s use in food and agriculture. Non-science based concerns about nanofoods must be
recognised explicitly by governments as legitimate and the public given the opportunity to reject
nanotechnology development in this sensitive area.
The regulation of nanotechnology in food and food packagingwarrants a precautionary approach. To address
our concerns, we recommend that the following steps are taken:
— Deﬁne manufactured nanoparticles and nanoscale food components as all ingredients and additives
that are added to food or packaging, including as processing aids, which:
— measure '0.3 -300nm in one or more dimension, or that have a structure that exists at this
scale, or
— in which particle size is important to achieving the technological function or may relate to a
diVerence in toxicity
— Soluble manufactured nanoparticles and nanoscale food components to be included in nanoparticle
deﬁnitions, disclosure and safety testing requirements.
— Deﬁne as nanoparticles agglomerates and aggregates whose primary particles are nanoscale or which
possess nano-structures and subject them to nanoparticle-appropriate risk assessment and
exposure metrics.
— Deﬁne manufactured nanoparticles and nanoscale food components as a new class of chemicals.
Each nanoparticle or nanoscale food component, irrespective of its solubility, must be subject to case
by case safety testing that is tailored to the unique risks of nanoparticles, with pharmacological
endpoint testing. Testing requirements must be clearly stated rather than being left to the discretion
of regulators or the applicant.
— Identify foods to which manufactured nanoparticles or nanoscale food components have been added
or which are wrapped in packaging to which manufactured nanoparticles have been added as novel
foods and require them to face pharmacological endpoint safety testing. Testing requirements must
be clearly speciﬁed rather than being left to the discretion of regulators or the applicant.
— Apply amoratorium to the sale of all nanofoods until new nanoparticle risk assessment and detection
methodologies are developed and validated, as recommended by the Austrian Ministry of Health.
— Label all nano ingredients, and foods produced using nanotechnology, to give people the capacity to
make an informed choice, as well as for public health reasons (to trace adverse eVects).
— Apply social and public interest assessment to all applications for use of nanotechnology in
agriculture or food production and packaging.
— Assess speciﬁcally the potential for nanotechnology to further globalise agriculture and food
production and trade and to erode eVorts to relocalise food production to address food sovereignty.
— Assess speciﬁcally the potential for nanotechnology to promote greater consumption of highly
processed foods in preference to minimally processed fruit and vegetables and its implications for
public health.
— Recognise explicitly the right of the public to reject nanotechnology’s use in food and agriculture
— Develop mechanisms for meaningful involvement of the public in nanotechnology policy and
decision making.
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Friends of the Earth Australia (FoEA) has serious concerns about the use of Nanotechnology in
Food and Food Packaging
Ingested nanoparticles have the potential to cause long term pathological effects or short-term toxicity
The potential for nanoparticles ingested via food or food packaging to cause long term pathological eVects or
short-term toxicity is poorly understood and of grave concern. A small number of clinical studies suggest that
nanoparticles and small microparticles that are not metabolised can over time result in granulomas, lesions
(areas of damaged cells or tissue), cancer or blood clots1. Scientists have also suggested that nanoparticles and
particles up to a few hundred nanometres in size in foods may already be associated with rising levels of
irritable bowel and Crohn’s disease2. There have so far been no long-term nanoparticle feeding studies and so
the potential for pathological eVects remains very poorly understood. Such studies are clearly required to
inform the safety assessment necessary before nanoparticles are approved for use in foods.
In vitro and preliminary in vivo studies of some nanoparticles used in food, food packaging or food contact materials
have shown that these materials pose serious new toxicity risks.
As particle size decreases, in many nanoparticles the production of free radicals increases3, with increasing
potential for toxicity. In vitro studies have shown that nanoparticles which are now used commercially in food,
food packaging or food contact materials, including zinc, zinc oxide, silver, and titanium dioxide, pose serious
new toxicity risks4. In a test tube experiment 20nm nanoparticles of titanium dioxide caused complete
destruction of supercoiled DNA5. Also in the absence of UV, in another test tube experiment titanium dioxide
produced reactive oxygen species in brain immune cells6. Pilot data from test tube experiments show
nanoparticle titanium dioxide exposure negatively aVected cellular function7 and caused death of brain
immune cells after 24 hours exposure8. In vitro studies also demonstrate that silver nanoparticles are highly
toxic to rat brain cells9, mouse stem cells10 and rat liver cells11. An in vitro study found that for some cultured
cells, zinc oxide nanoparticles were more cytotoxic than asbestos12. Preliminary feeding studies have
demonstrated that high oral doses of nanoparticle zinc oxide and titanium can cause toxicity or changes in
physiological function13.
A number of properties apart from size determine the toxicity of a nanoparticle
Size is a key factor in determining the potential toxicity of a particle. However it is not the only important
factor. Other properties of nanoparticles that inﬂuence toxicity include: chemical composition, shape, surface
structure, surface charge, solubility, aggregation/ agglomeration14, catalytic properties15 and the presence or
absence of “functional groups” of other chemicals16. The large number of variables inﬂuencing toxicity means
that it is impossible to generalise about health risks associated with exposure to nanoparticles of a given
chemical composition. Each new nanoparticle must be assessed individually and all material properties must
be taken into account, including the presence or absence of coatings or functional groups and all physico-
chemical characteristics.
The ecotoxicity of nanoparticles remains poorly understood, however early studies suggest that they may cause serious
environmental harm
The ecotoxicity of nanoparticles remains poorly understood. However, there is early evidence that
nanoparticles of titanium dioxide can cause mortality17 or behavioural18 or physiological19 changes in species
such as water ﬂeas, ﬁsh or algae that are used as environmental indicator species. Byproducts associated with
the manufacture of single-walled carbon nanotubes, mooted for future use in food packaging, caused
increased mortality and delayed development of a small estuarine crustacean Amphiascus tenuiremis20.
Earthworms exposed to double-walled carbon nanotubes produced signiﬁcantly fewer cocoons in a dose-
dependent response21. If such exposure resulted in reduced numbers of earthworms, this would have a serious
negative impact on soil health. Exposure to high levels of nanoscale aluminium has been found to stunt root
growth in ﬁve commercial crop species22.
The antimicrobial properties of many nanoparticles now used in food packaging and food contact materials
have led to concerns that they may shift into microbial populations and disrupt signalling between nitrogen-
ﬁxing bacteria and their plant hosts23. Any signiﬁcant disruption of nitrogen ﬁxing could halt plant growth
and have serious negative impacts for the functioning of entire ecosystems. This would have signiﬁcant
ecologic and economic impacts.
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To Address our Concerns, we Recommend the Following:
Define manufactured nanoparticles and nanoscale food components as those ingredients that are added to food or
packaging which:
— measure'0.3 -300nm in one or more dimension, or that have a structure that exists at this scale, or
— in which particle size is important to achieving the technological function or may relate to a diVerence
in toxicity
Particle size can be important to achieving the technological function or result in diVerent toxicity of a food
additive, nutritive substance or novel food ingredient. However this alone is not suYcient to ensure that all
manufactured nanoparticles and nanoscale food components added to foods and packaging are subject to
appropriate new risk assessment. The eVect of a nanoparticle ingredient on technological function or toxicity
may be unknown to the food manufacturer, even in instances where the nano ingredient does pose novel risks
that would be detected were an appropriate risk assessment to be performed. A universal size-based deﬁnition
of nanoparticles is therefore essential to ensure that all manufactured nanoparticles and nanoscale food
components are subject to appropriate risk assessment.
Friends of the Earth Australia recommends deﬁning nanoparticles as “particles having one or more
dimensions measuring between 0.3nm and 300 nanometres (nm)”. That is, we recommend that 300nm be the
particle size at which nanoparticles are considered to be new chemicals and requirements for new health and
safety assessments are triggered. This deﬁnition of nanoparticles must include soluble particles, and also
aggregates and agglomerates composed of nanoscale particles or which have nanostructures. Particles that are
larger than this size but that also exhibit novel, nano-speciﬁc behaviour should also be permitted to be assessed
by regulators as nano-ingredients.
Particles up to a few hundred nm in size share many of the novel biological behaviours of nanoparticles than
'100nm in size, including very high reactivity, bioactivity and bioavailability, increased inﬂuence of particle
surface eVects, strong particle surface adhesion and strong ability to bind proteins24. As with even smaller
particles, particles'300nm in size have the capacity to be taken up into individual cells25. Particles up to a
few hundred nm in size may also pose similar health and environment risks to particles'100nm.
Recent studies ﬁnding that carbon nanotubes can cause the same disease as asbestos ﬁbres received world wide
attention26. Yet many of the nanotubes in the studies measured(100nm and so would not be considered to
be “nanoparticles” using a '100nm size-based deﬁnition. Poland et al.27 found that two samples of long,
tangledmulti-walled carbon nanotubes caused asbestos-like pathogenicity when introduced into the stomachs
of mice. One of their two samples had a diameter of 165nm and a length of greater than 10µm. Similarly,
Takagi et al.28 found that in a long term study,moremice died frommesothelioma following exposure tomulti-
walled carbon nanotubes than died following exposure to crocidolite (blue) asbestos. In this study(40 per
cent of sample nanotubes had a diameter(110nm.
Several studies have also reported nanoparticle-like biological behaviour in particles 200nm in size—
suggesting strongly that even 200nm is not an appropriate upper limit for deﬁning nanoparticles. In an in vitro
study Ashwood et al.29 found that 200nm particles of titanium dioxide adsorb bacterial fragments to their
surface and “smuggle” these into human intestinal tissue where they mimic invasive pathogens and can
provoke inﬂammation. Linse et al.30 found that in an in vitro study, along with smaller nanoparticles, the large
surface area and surface charge of 200nm nanoparticles catalysed protein ﬁbrillation (mis-folding). Protein
ﬁbrillation is involved in many human diseases, including Alzheimer’s, Creutzfeld-Jacob disease, and Type
2 diabetes. Cedervall et al.31 also found strong interactions between proteins and 200nm particles.
Require disclosure and safety testing for all manufactured nanoparticles and nanoscale food components that are used
as food processing aids
We emphasise that given the uncertainties surrounding the physiological and biological behaviour of
nanoparticles, including in relation to agglomeration, aggregation, de-agglomeration and de-aggregation
processes, risk assessmentmust be performed on themanufactured nanoparticle or nanoscale food component
that is added to the food or packaging, including as a processing aid. This is especially important given the
huge deﬁciencies in existing nanoparticle detection capacity.
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Soluble manufactured nanoparticles and nanoscale food components to be included in nanoparticle definitions, disclosure
and safety testing requirements
The European Food Safety Authority’s “Draft Scientiﬁc Opinion of the Scientiﬁc Committee on the Potential
Risks Arising from Nanoscience and Nanotechnologies on Food and Feed Safety” recognises the signiﬁcant
knowledge gaps regarding the behaviour of nanoparticles, including with respect to solubility. EFSA
recognises that even where nanoparticles are of soluble substances, given uncertainty regarding their
behaviour, the substance should be treated as a nanoparticle, unless it can be proved that it dissolves with no
change to its risk proﬁle. This is particularly important given early results showing that partially soluble
substances such as zinc oxide can pose extremely serious cytotoxic risks32.
Soluble nanoparticles (eg micelles, nano-liposomes and nano-encapsulated active ingredients) must be
included within the deﬁnition of “nanoparticles”. Soluble nanoparticles must be subject to new
nanotechnology-speciﬁc safety assessments and exposure metrics given the large gaps in our understanding
of how their potentially far greater bioavailability, solubility and potency will inﬂuence their biological and
toxicological behaviour33.
Nano-sizing or nano-encapsulating food additives including vitamins, enzymes or preservatives results in
greater bioavailability, improved solubility and increased potency of these substances compared to larger or
micro-encapsulated form34. These novel nanoparticles are already being exploited commercially. For example
AquaNova markets its nanoscale micelles for use in foods and cosmetics because they deliver “signiﬁcantly
higher bioavailability” of enclosed active ingredients once ingested or applied to the skin35. Omega 3 food
additives have in the past been added to food in 140-180,000 nm micro-capsules, for example micro-
encapsulated tuna ﬁsh oils used by Nu-Mega Driphorm@ to fortify Australia’s Tip Top bread line (Personal
communication with Nu-Mega representative 2007). However to increase the Omega 3 potency and
bioavailability, companies such asAquanova andZymes are now selling 30-40nmnano-forms or nanomicelles
of Omega 3 – an incredible 4,000 times smaller than the Nu-Mega range36.
If nano-nutritional additives and supplements provide an excessive dose of some vitamins or nutrients these
may have a toxic eVect or interfere with the absorption of other nutrients. Dr Qasim Chaudhry who leads the
nanotechnology research team at the United Kingdom’s Central Science Laboratory told the Times Online
that nanoparticle and nano-encapsulated food ingredients may have unanticipated eVects, far greater
absorption than intended or altered uptake of other nutrients, but warned that little, if anything, is known
currently37.
Define as nanoparticles agglomerates and aggregates whose primary particles are nanoscale or which possess nano-
structures and subject them to nanoparticle-appropriate risk assessment and exposure metrics
If nanoparticles fuse together, they form aggregates which are hard to separate. These nano-structured
aggregates may be larger than 100nm—or even larger than 300nm. However in many instances aggregates will
have close to the same surface area as the nanoparticles they aremade from andwill have “nooks and crannies”
on their surface structure that are nano-sized. Where toxicity is driven by surface characteristics, the toxic
properties of aggregated nanoparticles may be very similar to that of the primary nanoparticles that compose
them. In fact some early studies exposing animals to large nanoparticle aggregates showed eVects that
appeared to be associated with these primary particles, although the primary particles were more potent in
many respects (see reviews in Maynard and Kuempel38 and Oberdo¨rster et al.39). In other instances, nano-
structured aggregates may result in greater damage than that associated with the primary nanoparticles. In an
inhalation study using mice Shvedova et al.40 found that aggregates of single walled carbon nanotubes were
the focal point of granulomatous inﬂammation.
Nanoparticles that form clusters but do not adhere so strongly together are called agglomerates. Agglomerates
have similar structures and surface properties to aggregates and so may also share the toxicity risks associated
with the primary nanoparticles that compose them. Additionally, in principle agglomerates can also change
shape or come apart41. If particles do not de-agglomerate, their size could reduce their bioavailability relative
to that of their primary nanoparticles42. However this may not necessarily reduce their toxicity. For example
Muller et al.43 found that twomonths after intratracheal installation of multi-walled carbon nanotubes in rats,
pulmonary lesions were caused by the accumulation of large carbon nanotube agglomerates in the airways.
It is still unknown to what extent aggregates and agglomerates will break down into smaller particles in our
bodies, eg after ingestion. Researchers routinely use surfactants to “debundle” single andmulti-walled carbon
nanotube samples for physicochemical investigation44. Biological ﬂuids that contain surfactants or proteins
may similarly promote de-agglomeration45 or even break up of aggregates46 into smaller particles or even the
primary nanoparticles.
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The poor understanding we have of disaggregation and de-agglomeration processes and the early evidence
that aggregates and agglomerates may share both surface characteristics and toxic properties with the primary
nanoparticles that compose them demand that regulators take a precautionary approach and treat these
particles as nanoparticles.
Define manufactured nanoparticles and nanoscale food components as a new class of chemicals. Each nanoparticle or
nanoscale food component, irrespective of its solubility, must be subject to case by case safety testing that is tailored to
the unique risks of nanoparticles, with pharmacological endpoint testing.
The United Kingdom’s Royal Society and Royal Academy of Engineering have recommended that given the
emerging evidence of serious nanotoxicity risks, nanoparticles should be treated as new chemicals47 and be
subject to new safety assessments prior to their inclusion in consumer products48. They further recommended
that factories and research laboratories should treat nanoparticles as if they were hazardous49, and until the
environmental impacts of nanoparticles are better known, their release into the environment should be
avoided as far as possible50.
To date food regulators world wide have not treated nanoparticles as new chemicals nor required food and
food packaging manufacturers to conduct new safety testing of nano ingredients. The risk assessment process
used by regulators for nanoparticle ingredients, additives, nutritive substances, processing aids and
contaminants of food or food packaging should be speciﬁc to their new risks (eg by requiring full physico-
chemical characterisation of particles and nanoscale food components including size, shape, charge, surface
properties, solubility, catalytic properties, coatings, presence or absence of functional groups etc). A
nanoparticle-appropriate metric must be used for dose (eg particle surface area or number of particles rather
than mass). The process used for risk assessment must be explicitly stated rather than left to the discretion of
regulators or the applicant.
Identify foods to which manufactured nanoparticles or nanoscale food components have been added or which are wrapped
in packaging to which manufactured nanoparticles have been added as novel foods and require them to face
pharmacological endpoint safety testing.
The Austrian Health Ministry has called for the European novel food regulations to speciﬁcally apply to all
foods produced using nanotechnology or nanoscience51. Friends of the Earth Australia recommends that the
novel foods standard also speciﬁcally apply to all foods produced using nanotechnology or to which
manufactured nanoparticles or nanoscale food components have been added as ingredients, nutritive
additives, processing aids or contaminants, or to foods which have been wrapped in packaging to which
manufactured nanoparticles have been added.
In the recently released “Draft Opinion of the Scientiﬁc Committee on the Potential Risks Arising from
Nanoscience and Nanotechnologies on Food and Feed Safety”, the European Food Safety Authority
emphasised the serious nature of the knowledge gaps regarding the toxicity of nanoparticles used in food and
feed. EFSA suggested that pharmacological endpoints may be needed to ensure that risk assessment of nano
ingredients in food and feed did not pose unacceptable health risks:
“The available data on oral exposure to speciﬁc ENM [engineered nanoparticles/ manufactured nanoparticles]
and any consequent toxicity is extremely limited; themajority of the available information on toxicity of ENM
is from in vitro studies or in vivo studies using other routes of exposure… There may also be additional toxic
eVects caused by ENM that are not readily detectable by current standard protocols. Additional endpoints not
routinely addressed and pharmacological endpoints may need to be considered in addition to traditional
endpoints” 52 [emphasis added].
The call for nanofoods to be identiﬁed as novel foods and subject to a rigorous standard of safety testing using
pharmacological endpoints appears eminently sensible. This is especially appropriate given the use of
nanotechnology to increasingly blur the lines between foods and nutritional additives (“nutraceuticals”) and
to promote further use of functional foods that are marketed as having an enhanced health beneﬁt. It is
important that packaging is included in this high level of safety testing, given that increasingly nano packaging
is being designed to interact with the food it contains. However it should be noted that the Deputy Head of
Sector, Safety and EYcacy of Medicines at the European Medicines Agency has suggested that even existing
pharmacological endpoints may need strengthening to manage the new risks and challenges of nano-
medicines53. It is likely that such new standards will also be required for the assessment of nanofood and food
packaging ingredients.
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Until new nanoparticle risk assessment and detection methodologies are developed and validated, a moratorium should
apply to all nanofoods, as recommended by the Austrian Ministry of Health
Given the huge uncertainties surrounding the physiological behaviour and toxicological risks of nanoparticles
and the lack of reliable nanoparticle detection methodologies, the Austrian Health Ministry has called for a
European-widemoratorium on nanofoods until validated methods for identiﬁcation and risk assessment have
been developed54.
Friends of the Earth Australia supports this call. As we have said previously, a moratorium on the commercial
sale of all nano-products should apply until the safety of nano-products can be demonstrated, all nano-
products are clearly labelled, and the public is given the opportunity to be involved in nanotechnology
decision making.
All nano ingredients, and foods produced using nanotechnology, should be clearly labelled to give people the right to make
an informed choice, as well as for public health reasons (to trace adverse effects)
Manufacturers of products that contain added nanoparticles are not required to acknowledge the presence of
nano-ingredients on product labels. This denies consumers the right to make an informed choice about
whether or not they wish to eat nanofoods, or foods wrapped in nano-packaging. Failing to label nanofoods
precludes tracing any future adverse eVects back to their source and also precludes carrying out post-release
monitoring.
A recent poll of 1010 Australians carried out by Essential Research and commissioned by Friends of the Earth
found that 92 per cent support mandatory labelling of all nano ingredients in foods and food packaging55. The
poll found that only 15 per cent of people would be prepared to purchase nanofoods, whereas 40 per cent said
that theywould not purchase nanofoods at all. That is,more than nine in 10 peoplewant the capacity to choose
whether or not to eat nanofoods or food wrapped in nano-packaging, and given the choice, more than twice
as many people would not purchase nanofoods. Mandatory labelling of nanoproducts has also been a key
recommendation of the United Kingdom’s Royal Society56 and the Austrian Ministry of Health57.
Foods produced using nanotechnology or nanoscience should also be labelled. Consumers are now looking
for labelling not only for ingredients, but also for preparation instruction, storage information, nutrition
information panel and processes used in the manufacture of foods. We currently label other foods according
to the processes used, for example organic or kosher foods, and this is also important with respect to
nanotechnology.
Apply social and public interest assessment to all applications for use of nanotechnology in agriculture or food production
and packaging.
Beyond the need for new regulation to manage the serious new toxicity risks associated with nanofood and
nano agricultural products, Friends of the Earth Australia is calling for “fourth hurdle regulation” to require
manufacturers to demonstrate the social beneﬁt of products they wish to sell. There is very rarely a requirement
for productmanufacturers to “justify” risk exposures in terms of social beneﬁts58. Too often, it is an entrenched
and unchallenged assumption that the market release of a new functional food or antibacterial product will
necessarily deliver public health beneﬁts. In many instances, putative beneﬁts are argued by product
proponents to justify or counterbalance the potential for new risks, despite potential beneﬁts rarely being
subject to the same kind of scrutiny and scepticism to which claims of potential risks are subject. Friends of
the Earth Australia therefore supports the recommendations of Wynne and Felt59 for the inclusion of a social
beneﬁt test, supplementing the more usual investigations into eYcacy, safety and environmental risk, as part
of the regulation of nanotechnology in food and agriculture.
Assess specifically the potential for nanotechnology to further globalise agriculture and food production and trade and
to erode efforts to relocalise food production to address food sovereignty.
Nanotechnology in food and agriculture is emerging at a time when global food systems are under
unprecedented stress. Friends of the Earth suggests that by entrenching our dependence on the industrialised,
export-oriented agricultural system and the chemical and technology “treadmills” that underpin it,
nanotechnology is likely to exacerbate the problems that caused the current global food crisis.
Recognition by governments, industry and inter-governmental forums of the right of small scale farmers to
control food production tomeet local food needs,—“food sovereignty”—has been a key demand from farming
and peasant communities60. Around 75 percent of the world’s hungry people live in rural areas in poor
countries. If rural communities can meet more of their own food needs via local production, they will clearly
be less vulnerable to global price and supply ﬂuctuations. La Via Campesina’s has argued that: “Small-scale
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family farming is a protection against hunger!”61 This view was supported by the four year International
Assessment of Agricultural Science and Technology for Development which emphasised that to redress rural
poverty and hunger, a key focus of agricultural policy must be empowering small scale farmers to meet their
own food needs62.
The potential role of new technologies in responding to the global food crisis is controversial. As with
genetically engineered (GE) crops, proponents have argued that nanotechnology will redress food shortages
by promoting greater agricultural productivity. However the recent IAASTD report notes that whereas GE
crops have had highly variable yields, they have also had negative broader economic consequences for farmers
by concentrating ownership in agricultural resources and introducing new liabilities for farmers63. Similarly,
Friends of the Earth suggests that nano-agriculture is not required to achieve strong yields, but will add to the
capital costs faced by small farmers and increase their reliance on technology, seed and chemicals sold by a
small number of global agri-business companies.
By underpinning the next wave of technological transformation of the global agriculture and food industry,
nanotechnology appears likely to further expand themarket share ofmajor agrochemical and seed companies,
food processors and food retailers to the detriment of small operators64. Nano-encapsulated pesticides,
fertilisers and plant growth treatments designed to release their active ingredients in response to environmental
triggers, used in conjunction with nano-enabled remote farm surveillance systems, could enable even larger
areas of cropland to be farmed by even fewer people65. By dramatically increasing eYciency and uniformity
of farming, it appears likely that nano-farming technologies could accelerate expansion of industrial-scale,
export oriented agricultural production which employs even fewer workers but relies on increasingly
sophisticated technological support systems that have increasing capital costs. Such systems could commodify
the knowledge and skills associated with food production gained over thousands of years and embed it into
proprietary nanotechnologies. It could also result in the further loss of small scale farmers and further
disconnection of rural communities from food production, undermining eVorts to achieve sustainable,
relocalised food production.
Defending and reinvigorating sustainable small-scale farming requires action by governments to support
agriculture that prioritises food production for local populations. This requires land reform, including control
over and access to water, seed, credits and appropriate technology. It also requires the removal of trade policies
and ﬁnancial subsidies that preference industrial-scale farming for export or that promote the adoption of
technologies or farming practices that will undermine the viability of small-scale farming.
Assess specifically the potential for nanotechnology to promote greater consumption of highly processed foods in
preference to minimally processed fruit and vegetables and its implications for public health.
Nanotechnology is likely to inﬂuence the eating habits of urban consumers, with associated public health and
cultural implications. By enabling manufacturers to promote nano-reconstituted, nano-fortiﬁed or nano-
packaged foods as delivering superior health beneﬁts, hygiene or convenience, it is likely that nanotechnology
will encourage even greater consumption of highly processed foods at the expense of minimally processed
fruits and vegetables. Beyond the need to ensure the safety of nanofood additives, it is also useful to question
whether or not fortifying food with nano nutrients is actually desirable from a public health perspective. There
is a growing number of manufacturers prepared to claim that their nano-fortiﬁed beverages or foods will meet
a large part, or even the entirety, of an individual’s dietary needs. For example Toddler Health’s range of
fortiﬁed chocolate and vanilla “nutritional drinks”, which include 300nm particles of SunActive@ iron, is
marketed as “an all-natural balanced nutritional drink for children from 13 months to ﬁve years. One serving
of Toddler Health helps little ones meet their daily requirements for vitamins, minerals and protein”66. Yet no
matter how fortiﬁed, nanofoods cannot substitute for the nutritional value of a diet based on a variety of fresh,
minimally processed foods. There is a real possibility that the promotion of nano-fortiﬁed foods could be one
factor in people eating less fruit and vegetables, with associated negative public health outcomes.
By extending the shelf life of “fresh” and processed foods, it is also likely that nanotechnology will further
promote the eating of foods out of season and far from the place of their production. In this way,
nanotechnology may further erode the relationship that exists (or once existed) between consumers and
producers of foods, as well as peoples’ cultural connection to traditional andminimally processedwhole foods.
The development of a cola drink that could be marketed as having the nutritional properties of milk is a case
in point67. With the increasing use of nanotechnology to alter the nutritional properties of processed foods, we
could soon be left with no capacity to understand the health values of foods, other than their marketing claims.
151nanotechnologies and food: evidence
Recognise explicitly the right of the public to reject nanotechnology’s use in food and agriculture
There is an urgent need for regulatory systems capable of managing the many new risks associated with
nanofoods and the use of nanotechnology in agriculture. Alongside managing nanotoxicity risks,
governments must also respond to nanotechnology’s broader social, economic, civil liberties and ethical
challenges. To ensure democratic control of these new technologies in the important area of food and
agriculture, public involvement in nanotechnology decision making is essential.
Mandatory labelling of all nanofoods is required to enable people to make an informed choice about whether
or not to eat them. However beyond the need for labelling to enable informed purchasing choices, the public
must be given the opportunity to be involved in decision making about the use of nanotechnology in the food
and agriculture sector. Given the signiﬁcant implications of nanotechnology for our relationship with food
and agriculture, and for food producing communities worldwide, we call for public involvement in all aspects
of decision making, including the right to say no to nanofoods.
Develop mechanisms for meaningful involvement of the public in nanotechnology policy and decision making.
Public awareness about nanotechnology remains very low. However, early surveys show that once given
information about nanotechnology, people do not want to eat nanofoods or foods wrapped in packaging that
contains manufactured nanomaterials. Public engagement initiatives and experimental studies suggest that
once provided with information about nanotechnology, the public is concerned about many of the same issues
identiﬁed in relation to GE food: a lack of transparency, a lack of choice about exposure, risks to health and
the environment, unfair distribution of risks and beneﬁts, a lack of socially useful applications and a lack of
public participation in decision making68. The signiﬁcant challenges of a powerful, transformative and
controversial technology demand a reciprocal signiﬁcant government investment in the establishment of new
mechanisms for meaningful involvement of the public in nanotechnology policy and development, the
allocation of research priorities for public funding and the establishment of governance measures. We
commend wholeheartedly the establishment of this consultation process, but it must be recognised explicitly
that the public interest issues associatedwith nanotechnology’s use in food and agriculture go far beyond those
associated with risk assessment, and a far greater involvement of the public in decision making in this area are
required.
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Examination of Witnesses
Witnesses: Ms Sue Davies, Which?, Professor Vyvyan Howard, Soil Association and Ms Georgia Miller,
Friends of the Earth Australia (via video link), examined.
Q278 Chairman: Good morning, I would like to
welcome the two witnesses we have in the room, Sue
Davies fromWhich? and Professor Vyvyan Howard,
representing the Soil Association but also to welcome
Georgia Miller who is joining us by video link from
Australia and she represents Friends of the Earth
Australia. I would also like to remind the witnesses
and members of the Committee that the proceedings
are being webcast and also that the information note
available for members of the public—who are also
very welcome in this session—sets out the declared
interests of members of the Committee so they will
not be repeated whilst asking questions. In
welcoming our witnesses to this ﬁfth public hearing
of our inquiry into nanotechnologies and food I
would like to invite each of you in turn to introduce
yourselves for the record and at that same time if
there is anything youwould like to say byway of brief
introduction before we move to the questioning then
this is your opportunity. I would also like to
emphasise that given that we are working with a
video link the sound quality is very good but there is
a slight delay between what we say and what Georgia
hears and likewise in the other direction, so please
remember to speak slowly and to pause if necessary
for Georgia’s response to come through. May I now
invite the witnesses, starting with Sue Davies, to
introduce yourselves?
Ms Davies: Thank you very much and thank you for
the opportunity to come and give evidence to you
today. I amSueDavies and I amChief PolicyAdvisor
at Which?, the consumer organisation, where I work
mainly on food issues. Which?—in case you are not
aware—is an independent not-for-proﬁt consumer
organisation that campaigns on a range of issues on
behalf of all consumers and we are funded through
the sale of our consumer information, so Which?
magazine, Good Food Guide, Which? Online. This is
an issue that we have been looking at in quite a bit of
detail over the last couple of years because we
recognise that nanotechnologies oVer a lot of beneﬁts
for consumers but they also raise potential risks, and
so we want to make sure that they are developed in a
responsible way so that consumers can take
advantage of them but not unnecessarily be put at
risk.
Q279 Chairman: Thank you. Professor Howard?
Professor Howard: Thank you very much for the
opportunity to come here today. My name is Vyvyan
Howard; I am a medical doctor, pathologist and I
specialise in toxicology, I amProfessor of Bioimaging
at the University of Ulster. I have just ﬁnished six
years serving on the Advisory Committee for
Pesticides. I have sat on two European expert panels
concerning nanotoxicology; I am in receipt of two
EU grants to investigate the toxicology of
nanoparticles. I also gave scientiﬁc evidence to the
Soil Association for their consideration in the
preparation of their report. I think we will be talking
about the speciﬁcs of it later, but those are the main
things.
Q280 Chairman: Thank you very much. Georgia,
would you like to introduce yourself?
Ms Miller: Thank you. My name is Georgia Miller. I
have coordinated Friends of the Earth Australia’s
nanotechnology project since 2005 and the
application of nanotechnology in food and
agriculture is something we are very much interested
in. Last year I was one of the two primary authors of
an international Friends of the Earth report in
relation to nanotechnology in food and agriculture. I
guess that there are four key things that I am hoping
we can talk about in this session. The ﬁrst is really the
scope and I want to suggest that we are looking at
more than a question of food safety, we are actually
looking at quite a broad issue of food policy. The
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second is the need for precautionary management
given how little we know both about risks and also
how to assess those risks. The third is the need to
really critically assess claimed beneﬁts because I want
to suggest that many of these beneﬁts actually come
with signiﬁcant costs. The fourth is the need for
public involvement in decision making which I
understand will be addressed in some of the
questions later.
Q281 Chairman: Thank you very much. That is a
very helpful introduction from all of our witnesses.
I would now like to kick oV with opening the
questioning myself and I would like to ask each of
the witnesses what you feel are the potential beneﬁts
as well as the risks related to nanotechnologies and
nanomaterials in food, either in food itself or in
relation to packaging. You have all expressed views
about this in your evidence but I would like to hear
now a summary of your position.
Ms Davies: I think one of the diYcult issues in this
area is that it is hard to get a sense of exactly what
is happening now and what could be happening in
the future in order to determine whether or not there
are products that are going to oVer real consumer
beneﬁts. From looking at some of the discussions in
the scientiﬁc press and some of the food technology
literature it seems that there is a lot of potential for
things like improved nutritional characteristics,
improved sensory qualities, potentially less waste in
terms of improved packaging, better food safety;
there are a whole range of potential beneﬁts that
could be oVered by nanotechnologies. However, our
concern is that it is quite diYcult to work out exactly
what we are going to be seeing and over what
timescale. It would be nice to have a clear idea of
what is on the market now and have a sense of what
is going to be here in ﬁve years, ten years, 20 years
and what kind of issues are those going to raise. We
do think that it seems there are going to be some
genuine beneﬁts but we also think there needs to be
a more proactive approach to actually make sure
that the investment is really going into tackling the
problems we are facing in terms of food policy. How
can nanotechnology be used to help tackle obesity
and diet-related disease, improve food safety, reduce
the environmental impact of food production?
There is not really enough transparency or enough
open discussion at the moment about what is being
done and what could come along. If you look at the
Nanoshop website or you look at the Woodrow
Wilson website, which seems to be the main source
of information about nanofoods, most of the
developments to start with are in the food
supplement area which are making claims about
improved bioavailability or absorption of nutrients,
or packaging materials (EFSA has already approved
one type of packaging material, for example). That
seems to be where the main interest is at the moment
and it seems that there could be beneﬁts, certainly
in the case of packaging materials, but we are
concerned that we want to make sure that these are
genuine beneﬁts and that consumers, as Georgia
said, are not being duped into buying things at the
moment that are not really oVering any beneﬁts
beyond conventional products and paying more for
it. Of course this all needs to be balanced against
the risks. Do you want to come on to the discussion
about the risks now?
Q282 Chairman: If you could brieﬂy way what you
think the main issues are about risk then we will
cover it in a bit more detail later.
Ms Davies: The interesting thing in this area is that
the people who are really excited about this
technology are also really open about the fact that
there is an awful lot that we do not know about it
at the moment; precisely the reason why
nanotechnologies are going to oVer lots of new
beneﬁts because of the change in properties of
materials could also bring new risks that we do not
fully understand. The recent EFSA opinion on this,
for example, highlights that there are some really
key knowledge gaps in diVerent areas that need to
be addressed urgently. We think that we need to
have a clearer sense of what products are coming
along so that we can get a sense of what are the
beneﬁts and what will be really useful for
consumers, but also we need to get a sense of what
is being developed now so that we can properly
understand what kind of risks they could be posing
and make sure that we have adequate regulation in
place as well.
Q283 Chairman: Thank you. Professor Howard?
Professor Howard: I want to highlight some of the
knowledge gaps and areas of potential hazard.
Under Framework Seven of the EU Programme
there are 1.4 billion euros earmarked for
nanotechnology but every project must have a safety
aspect to it. The two grants that we have so far total
5.7 million euros. There are also targeted funds from
research councils in the UK so there is certainly an
awareness that we need to know more. Indeed I and
other colleagues around the world are trying to do
that. There are two basic questions. One is, if you
have a nano-product—a particle in a food
substance—where does it get to and how long does
it stay there? That is question number one and in a
way that is one of the easier questions to address.
The second question is, does it matter if it does get
there and stay there that long? That is actually much
more diYcult to appraise. I think we have to think
about the nature of food. If you consider how much
we spend on doing toxicological testing of
pharmaceuticals and agro-chemicals, where we
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might expect to be exposed over a lifetime to
micrograms or milligrams, our consumption of food
is measured in tons over a lifetime. So the potential
dosage is extremely high and I think that does mean
that we have to take a precautionary stand. The
main area that I am worried about is that if you
nanonise materials into mobile nanoparticles they
become more mobile within the body. The reason
for that is that there are processes going on in the
cell walls which are continuous and it is the way that
viruses get round it, it is a process called
endocytosis. There are quite a few studies on this—
Wolfgang Kreyling has done a lot of work in this
ﬁeld—which show that if you do expose animals or
humans to nanoparticles they will travel and they
will get across places like the blood-brain barrier
where we have evolved methods of keeping out
molecules that we do not want. So they can act as
a sort of “Trojan horse”. Which particular spectrum
of disease do we need to think about most? Well,
there are a series of diseases called protein
misfolding diseases. Most of them occur in the
central nervous system; there are 42 known in
humans currently (including Alzheimer’s,
Parkinson’s disease, spongiform encephalopathy).
Nerve cells cannot reproduce themselves; they have
to internalise any misfolded protein that is insoluble
and some of these fragments can be toxic. The
worry would be that if we are exposing ourselves to
large doses of nanomaterials and they are able to get
into areas like the brain, they might be able to
increase the rate of protein misfolding and that is
what our second grant is all about. We are actually
studying that now.
Q284 Chairman: I wonder, because we are short of
time, if you could keep it pretty succinct. We can
always follow up with more detailed supplementary
evidence.
Professor Howard: I think that is the main point I
want to make, that it is chronic long-term pathology
which may be rather more worrying than short-
term toxicity.
Q285 Chairman: What about potential beneﬁts? Do
you see any beneﬁts?
Professor Howard: I think Sue has already mentioned
those: a cut in waste, a cut in bacterial
contamination; those sorts of things.
Q286 Chairman: Georgia, would you like to
comment on the potential beneﬁts and risks?
Ms Miller: Vyvyan has just talked in some detail
about potential risks and I saw the excellent
presentation that the nanotoxicologists made to you
a month ago, so I do not want to talk in great detail
about the risks. I do want to observe that the
uncertainties around nanocharacterisation and risk
assessment are so great that experts anticipate that
it will take us years before we can actually do a
validated risk assessment, that is until we know the
right questions to ask, the right tests to do. I ﬁnd
this very concerning so that is one thing I do want
to draw to your attention. I guess the other thing
that I am concerned about is the size deﬁnition.
Again I heard a recurring theme when the
nanotoxicologists gave evidence to you a month ago
that 100 nanometers really does not capture
biologically relevant nanoparticles that may be 200
or 300 nanometers in size, so I think that is
something we are also concerned about. In relation
to the so-called beneﬁts, I really want to challenge
the notion that widespread use of antibacterials, for
example in packaging, will deliver socially useful
outcomes. This is for a couple of reasons. We are
very concerned that widespread use of potent
antibacterials in the form of nanomaterials could
actually cause a lot of unanticipated problems. We
are already suVering massive problems with
bacterial resistance to antibiotics in a medical
setting. There is some emerging evidence that use of
silver in a medical setting is also being met with
resistance. What are the implications of the
widespread use of nano-antibacterials in food
packaging, in refrigerators, in storage containers, as
well as in socks and computer keyboards and
dishwashers et cetera? I think there are some very
real challenges here that we need to deal with. While
we do not think any illness as a result of food
contamination is ever acceptable, I emphasise that
in the UK there is 50 times greater illness as a result
of poor diet than as a result of safety problems. I
think we need to ask: will nanotechnology as a
whole result, for example, in greater consumption of
highly processed food and less consumption of fruit
and vegetables? Will the addition of nano-additives
to junk foods enable them to be marketed for health
values, for example increased nano-encapsulated
omega-3 or iron fortiﬁcation? Will this perhaps
further confuse people and lead to a further loss in
terms of people’s diet choices? If the answers to
those things are “Yes” then it is possible that nano
will actually result in poorer health outcomes. I do
think we need to query a lot of these claimed
beneﬁts, really interrogate them, rather than just
accepting them at face value.
Q287 Chairman: Thank you very much. I just want
to ask one supplementary question here. I think that
Friends of the Earth Australia as well as the Soil
Association are calling for a moratorium on the sale
of nano-foods whereas I think Which? has not called
for a moratorium. I wonder if Sue could indicate
from the point of view of Which? why you do not
think a moratorium is necessary, and then I will ask
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Vyvyan and Georgia brieﬂy to say why they think
a moratorium is necessary.
Ms Davies: I suppose our focus has been much more
on understanding what developments are taking
place and could be taking place, making sure that
we have an eVective regulatory framework in place,
making sure that nanomaterials have to be
approved before they come to market and that we
have enough research to enable eVective risk
assessment to be able to carry that out. We do not
really think that a moratorium is very meaningful.
We have issues around deﬁnition, it is very diYcult
to ﬁnd out what is actually happening, so even if
we thought that a moratorium was useful we do not
understand how it would practically be enforced
and applied.
Q288 Chairman: Professor Howard, could you
brieﬂy indicate why you think a moratorium is
necessary?
Professor Howard: Data gaps have already been
mentioned and we ﬁnd it very diYcult to construct
a meaningful risk assessment given the level of data
gaps that we have in most areas of nanoparticle fate
and toxicity. Given the potential dose that people
would be receiving in food, the Soil Association has
come to the conclusion that they would prefer to see
a hold on development while some form of risk
assessment can be developed.
Q289 Chairman: Would that apply to naturally
occurring as well as engineered nanoparticles?
Professor Howard: I think that applies mainly to
engineered nanoparticles, things that we have not
encountered hitherto during our evolutionary
history.
Q290 Chairman: Georgia, very brieﬂy, reading the
evidence from Friends of the Earth Australia, you
wish to broaden the deﬁnition of nanotechnologies
in food to include both engineered and naturally
occurring nanoparticles. That is as I understand it;
is that correct or not?
Ms Miller: No, that is not correct. What we have
suggested in terms of broadening the deﬁnition is
that we consider, for the purposes of health and
safety assessment, particles up to 300 nanometers in
size as nanoparticles and I believe there is good
reason given the evidence that a number of particles
that are around 200 nanometers or so in size are still,
for example, showing protein binding characteristics
that Vyvyan referred to earlier as a cause for
concern. We have focused speciﬁcally on the issue
of manufactured nanoparticles and manufactured
nano-additives to food. We do highlight the issue of
nanoparticles which are in a sense a by-product of
contemporary high intensity processing technologies
as an area which does warrant further investigation,
but we have not called for a moratorium to extend
to those sorts of nanoparticles.
Q291 Lord Haskel: Of course our relationship with
the European Union is very important and central
to this. The European Parliament has proposed that
when the Novel Foods regulation is revised it should
explicitly apply to all nanomaterials; it does not
diVerentiate. Do you think the government should
accept this advice?
Ms Davies: We think that a distinction does need to
be made between manufactured nanomaterials and
the types of nanomaterials that have been
traditionally used and may use nanotechnology, so
things like custard or mayonnaise for example that
have been around, not to say that these are
inevitably risk free. We think that manufactured
nanomaterials should be the focus of the Novel
Foods regulation. We think that the deﬁnition that
was proposed by the European Parliament which
talks about in the order of one to 100 nanometers
is probably quite useful but you need to be careful
about being too strict about deﬁnitions because
there is still an awful lot that we do not understand
and some people are asking whether we should be
talking of up to 300 nanometers for example and the
surface area is obviously a crucial aspect and how
do you take that into account. The proposal from
the Commission takes into account the advice from
the European Food Safety Authority. We think it
should be focused on the manufactured
nanomaterials but it is also important to look at
other pieces of regulation as well as the Novel Foods
regulation to make sure that they are ﬁt for purpose
as well. The European Commission has said that it
feels that under the food additives legislation, for
example, if something was in nano form it would
have to be reassessed and, even if its conventional
form had already been approved, it would have to
be resubmitted and approved again. Similarly with
food supplements, if you are using vitamins and
minerals in a nano form they would have to be
submitted. There is a lack of clarity in the
regulations and with the associated guidance that all
needs sorting out at the moment and we are
concerned, about how you can you be sure that
people who are potentially looking at producing
these types of products actually understand what
applies to them and what route they need to go
through, and whether the enforcement people on the
ground, the trading standards oYcers understand. It
is hard to believe that looking at whether people are
using nanomaterials is a particular priority at the
moment given all the things that trading standards
or environment health oYcers are looking at. We
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think the Novel Foods regulation needs to be
focused but it needs to be broad enough to take
account of all manufactured nanomaterials. But we
also need to focus on the other pieces of legislation
that may be relevant to make sure that they take
account of the unique properties of nanomaterials.
It is no good just having it in the legislation; you
need to make sure that the people on the ground
actually understand what the implications are as
well.
Professor Howard: I approach these problems by
saying that if we have been exposed to something
throughout our evolutionary history it is quite likely
that we are going to be adapted to it and be able to
cope with it. When something is brand new—you
only have to look at some of the chemicals that we
have created that bio-accumulate and persist and
have hormone-disrupting capabilities—you have to
take a precautionary stance and then look at where
it might have unforeseen eVects and do a proper risk
assessment.
Lord Crickhowell: I have one question which I think
does arise from regulation and the re-examining of
regulation. I would be interested to hear Georgia’s
comments. We have been talking entirely about food
but she referred to agro-chemicals and I do wonder
whether included in her concerns are fertilizers and
agro-chemicals. I would like to know whether this
is part of the package or not.
Q292 Chairman: Georgia, would you like to
comment both on the European regulation but also
particularly whether you think we should be
concerned about the use of nanotechnologies in
fertilizers and pesticides, agro-chemicals?
Ms Miller: It was not my understanding that the
new European Parliament’s suggested amendments
were to encompass naturally occurring
nanoparticles so I do not want to comment
speciﬁcally on that because that was not my
understanding. I do agree with both Sue and Vyvyan
that we need to focus our attention on intentionally
manufactured nanomaterials which are novel
materials to which we have no history of exposure.
I do want to emphasise though that where
manufacturers are intentionally producing nano-
scale micelles or using nano delivery systems for
active ingredients this may introduce new issues and
so we should consider those as intentionally
manufactured nanomaterials where there are
intentionally putting active ingredients, for example,
into 30 nanometer micelles; there may be a
biological implication there. On the issue of whether
we should also be looking at nano formulated
agricultural pesticides and fertilizers, yes I believe
we should. I think we need to engage with some of
the broader framing which is going on. When we
read some of the predicted uses to which
nanotechnology will be put in agriculture the vision
is really quite broad and encompassing, whether it
is nano-automated farm systems or whether it is the
use of smart interactive nano-encapsulated
pesticides and fertilizers, or whether it is the use of
nanoparticles to extend the reach of genetic
engineering in seed manipulation. There is a broad
range of proposed uses for nanotechnology in the
agricultural context and I think these are very
relevant to a discussion of nanotechnology in food.
Q293 Lord Haskel: How practical is it to engage in
this diVerentiation? For instance, we modify existing
natural products into nanoparticles; are those
manufactured and engineered or are those natural
products? It seems to me that we are approaching a
regulatory mineﬁeld here.
Ms Miller: I think it is confusing so the approach we
have taken is to focus very squarely on intentionally
manufactured nano ingredients and additives, not so
much to look at how nano science is informing our
historical use of emulsions and production of
emulsions but rather to look at things like nanoscale
zinc which is being intentionally put in as a food
additive or nanoscale silver which is being added to
food packaging or whatever it is; to look very
clearly at those intentionally manufactured
nanomaterials. Having made that distinction and
focusing very squarely on that range, people are
going to a lot of trouble and expense to actually
produce these things in nano form and then to put
them into food or food packaging. We then
recognise that there is a need to actually look at the
things which are, for example, by-products of
modern food processing technologies. We are not
including these in our call for a moratorium and we
are not suggesting even that they be addressed by
the regulatory system, but we are recognising that
contemporary food processing technologies do
generate a lot of foods which have nano fragments,
nanoscale emulsions within them. I think it behoves
us to ask: is there any public health implication
there? I do think that if we all focus very clearly on
the intentionally manufactured nanomaterials both
for regulatory purposes and for the purposes of this
inquiry I think we will be better oV.
Professor Howard: I think that if you take a natural
product and you treat it in some way by, say,
encapsulating it, and you change its dynamics from
the way it normally behaves, that is the time you
have to look. Just harping back for a second to
pesticides, as I said before I have just ﬁnished six
years on the Advisory Committee for Pesticides
which is where risk assessment for pesticides is done,
and they can see this nano revolution coming. I did
ﬂag it up a couple of years ago and I think they are
considering maybe getting someone on that
Committee who has expertise in the ﬁeld to maybe
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be able to put some input; they are certainly going
to need it.
Q294 Chairman: Before moving on to ask Lord
O’Neill to introduce the next question, could I just
try to nail this question of deﬁnition and what your
concern is. We have heard from the expert
toxicologists in previous sessions that their concern
is particles that are persistent or have particular
functionality or reactivity in the body on a
nanoscale, not whether they are manufactured or
natural. You seem to be focusing on manufactured
versus natural as opposed to persistence and
reactivity or functionality. Could I just be absolutely
clear where you think the critical issue lies?
Professor Howard: Persistence for how long is a good
question. Clearly if they are metal nanomaterials
they may persist for years but if you look at what
the pharmaceutical companies are doing they are
using microsomes to encapsulate drugs to increase
penetration to the brain. There is a lot of research
going on; it is a diYcult place to get drugs but they
ﬁnd that if they use micro-encapsulation techniques
they can increase penetration of the blood-brain
barrier. That has to tell us something about what
will happen in food products and if there are things
that do not normally go there they may only have
a half life in the body of somewhere around half an
hour to an hour, but if you are taking in a very large
dose of those there may be signiﬁcant penetration.
It really depends on what you mean by persistence
and what it means for that particular set of particles.
I do agree in general that long-lived metallic
nanoparticles are things that we have to be very
careful about.
Q295 Chairman: Georgia, did you want to add
anything on that because you have quite a broad
ranging deﬁnition in your evidence?
Ms Miller: I did not actually see that distinction in
the evidence that the nanotoxicologists gave you; I
did not see them suggesting that we encompass
naturally occurring nanomaterials in the sort of
dialogue that we are having right now. In fact it
seemed to me that they were talking about their
concern about nanomaterials to which we do not
actually have a long history of exposure. However,
I do agree that persistence and functionality are
obviously going to have biological implications for
the impacts that nanomaterials may have when
introduced to our bodies. The thing that concerns
me is that when we talk about persistence that
presupposes a level of knowledge about the
biological behaviour of nanomaterials that we just
do not have. I think that is one of the reasons that
we have made this strong emphasis on focusing on
intentionally manufactured nanomaterials because
these are things which we are producing in this very
tiny form and, as Vyvyan says, sometimes in this
very tiny form there are unique biological
availability and behavioural characteristics of these
materials. I do think it is useful to focus on
manufactured nanomaterials and I would include in
manufactured nanomaterials things which have
been nano-encapsulated for the purposes of altering
their bioavailability or their behaviour in the body.
I do think there is a danger in deﬁning
nanomaterials by biopersistence when we have so
little understanding of their biological behaviours.
Q296 Lord O’Neill of Clackmannan: Perhaps I
could come back to Vyvyan Howard. We have been
talking about problems of deﬁnition and we have
been saying that there are categories in which there
is a reasonable degree of consensus, but then when
it comes to issues of control you would apparently
favour, as it were, a one size catches all approach;
you would favour the generic approach rather than
a case by case element of control. Could you
perhaps say how that sits alongside the
categorisations which you have been groping
towards in the previous questions?
Professor Howard: I feel there are many generic
aspects to this. Clearly size is something which is
associated with mobility, whatever the material. If
you consider the amount of money that is being
pumped into grants for labs like Ken Donaldson’s
(who was here) and my own to actually look into
these generic problems where we have vast areas of
ignorance and are trying to ﬁnd out the way they
perform and what the consequences are likely to be,
I think to ask individual manufacturers to go and
do that level of research is going to be impossible
for them really, it is much too expensive and they
would not have the expertise. My feeling is that we
need to ﬁll in some of these boxes in the hazard
assessment of these materials so that we can start to
categorise them and know that this size range looks
as if it is relatively safe or this size range is to be
avoided because it gets to certain places. I think
there is a lot more spade work to be done before we
start to put the onus on manufacturers.
Q297 Lord O’Neill of Clackmannan: Are there
diYculties or dangers implied in a box ticking
exercise which does not get behind the questions in
quite the way that the safety considerations that we
all have would seem to require addressing?
Professor Howard: In 2004 I sat on a committee
which met in DG SANCO and as part of that
exercise we tried to construct a comparative hazard
assessment with hazard triggers (which can be done
with pesticides where there is a lot of toxicological
information; you can actually make a sensible stab
at it) and all the boxes that we made for hazard
triggers we realised very rapidly were unknown; we
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did not know the answers. That is the main thrust
of the research that is going on now, to try to
actually get that knowledge so that we can attempt
a meaningful risk assessment, but we are not there
at the minute. It is a very expensive avenue of
research; it requires extremely expensive instruments
(electron microscopes and things like that). My
feeling is that we are at the stage still where we want
to learn more before we potentially expose a
population to high dose.
Q298 Lord Cunningham of Felling: I address my
question to all three witnesses, if I may. What would
be the merits of a register of nano-derived foods and
food contact materials as part of a comprehensive
regulatory framework?
Ms Davies: We think it is something that is essential
because at the moment—I think for the last few
years—we seem to have been going around in circles
where it is very diYcult to get a sense of exactly what
is happening in this area. A few years ago there was
a lot of talk, as we put in our written evidence, in
some of the food technology press about all the
potential applications and research that was going
on, that leading food companies were conducting,
but now the food industry says that in general it is
not using nanomaterials in its products. If you look
on the internet you will ﬁnd various products: you
will ﬁnd cooking oil, you will ﬁnd food supplements
that are on sale coming from diVerent countries
claiming to be using nanomaterials. It also seems
that some of the kind of intermediaries like the
chemical manufacturers are also producing some
food additives that are produced in nano form. It is
very diYcult to get a sense of exactly what is on the
market. We think the regulators—mainly the Food
Standards Agency—need to be much more
proactive in actually going out and seeking the
information and ﬁnding out what is happening in
this area, including talking to the chemical
companies who are producing food additives or
food pesticides and understanding exactly how
much they are producing and who they are
supplying to. We also think there needs to be a
requirement that you should register if you are going
to use manufactured nanomaterials in your products
and that should apply to food but should also apply
across the board in relation to nanotechnologies and
nanomaterials.
Q299 Lord Cunningham of Felling: Do you think
the FSA is the appropriate regulatory body?
Ms Davies: For food deﬁnitely and we think it
should be mandatory because, as I am sure you
know, Defra has had this voluntary reporting
scheme that was launched over two years ago and
has only had 11 submissions on a voluntary basis.
I think it has to be mandatory but you also need to
think carefully about what the information
requirements are so that companies are not put oV
by something that is incredibly onerous and
complicated to ﬁll in but gives the regulator the key
information that they can then follow up if they
need to.
Q300 Lord Cunningham of Felling: What about
consumers being put oV if it became a sort of
black list?
Ms Davies: We do not think that would be the case.
The danger is more in not being open about what
is happening in relation to nanotechnologies. We
conducted a citizens’ panel at the end of 2007 where
we wanted to get a sense of what consumers thought
about the use of nanotechnologies, not just in the
food area but also in relation to medicines and
cosmetics and other consumer products. People
were not against it, if anything they were surprised
it was happening because nobody had heard about
nanotechnologies at all before they came along to
the citizens’ panel. Some people were obviously
more excited than others but people were interested
in it and felt that you should be open about it. I
think the danger is that if you are not open about
it at this early stage people will wonder why we have
been hiding something and then think there is
something suspicious going on.
Q301 Lord Cunningham of Felling: Professor
Howard?
Professor Howard: I agree.
Q302 Lord Cunningham of Felling: What about
Georgia?
Ms Miller: We also support a mandatory register. I
do agree with Sue that the information required for
something like that should not be too burdensome
but at the same time we need to make sure that we
have information that actually enables us to
compare apples with apples. For example, it is not
much good if someone just says that they are using
nano-titanium dioxide and we do not know what
shape, what size, what surface coating. We need to
make sure that it is suYciently detailed and enables
rapid comparison of diVerent known materials in
use. However, I would just say this, if you are
concerned about the public concern about the use
of certain nanomaterials in food to be such that it
did serve as a black list, I do not think that is a
reason not to pursue this initiative. I think one of
the things that comes through really clearly in the
early public engagement around nanotechnology is
that this is the most sensitive area of
nanotechnology application. People feel strongly
about food and should people, particularly given the
early warning signs of risk and the huge safety gaps,
choose not to buy food that contains manufactured
162 nanotechnologies and food: evidence
2 June 2009 Ms Sue Davies, Professor Vyvyan Howard and Ms Georgia Miller
nanomaterials then I would say that is their right
and that is something that the government should
reassure them on. That it will enable them to
exercise that right because, as Sue said, I think the
worse thing that could happen at the moment is that
people feel they do not have access to relevant
information and that is a cause for future concern.
Q303 Lord Cunningham of Felling: What are the
implications then of having such a mandatory
register in one country but not in others?
Ms Miller: I would suggest that countries
everywhere at the moment are actually looking at
these issues. For example, Canada has already
announced a mandatory register of all companies
who used a kilo or more of nanomaterials last year;
they will have to provide information on the
nanomaterials but also on the safety data they have.
France has announced its intention to do something
similar. There are calls in Australia from the unions
for mandatory notiﬁcation to workers. This is
something that countries around the world are
having to deal with right now. I do note in the recent
proposals from the European Parliament they are
suggesting that nanomaterials should not be
permitted in foods without mandatory labelling on
the product. That is something that we would
support too.
Q304 Chairman: Can I just ask a mini-
supplementary to that to you, Georgia, since you
have a good knowledge of the international
situation. What is going on in China?
Ms Miller: That is a good question because of
course people have very limited information about
what is going on in China and I would suggest that
we have very limited information about what is
going on in many parts of the world. I think there
are serious language gaps and I also think there are
serious deﬁciencies in governments relying so
heavily on the OECD as the primary vehicle for
communication about risk research and policy
responses because a lot of the world is not
represented in OECD and a lot of the OECD’s
communication is happening exclusively in English.
I think we are faced with some very serious
challenges.
Q305 Lord Methuen: You have all mentioned in
your evidence the need to take into account the
public and society’s interests and views when
considering the future of nanotechnologies in the
food sector. I think we all want to avoid a situation
like the GM food ﬁasco. Could you expand on what
you think these views and interests might be, and
what government mechanisms should be considered
as part of any approval process?
Ms Davies: I think that the interests are quite broad
ranging and it is really going to depend on the
particular applications, so it kind of comes back
again to the point about getting a clearer
understanding of what is happening now and what
we could be seeing over the next few years as well
in order to have a proper understanding of what the
issues are that could be raised. The obvious concern
is about safety and making sure that products are
not coming onto the market that could raise
unacceptable levels of risk. There are issues around
the sorts of claims that products are making and
making sure that consumers can have conﬁdence in
them and that they are not mislead. For some
products it may be that they will raise broader
ethical concerns that people may have concerns
about and may want to avoid for those reasons, but
it is very diYcult at the moment in these early stages
to understand exactly what the breadth of concerns
could be. We think it is important to engage with
the public at this early stage but to try to actually
talk about the potential applications that could be
coming along to get a sense of how people would
react to them. Ultimately I think you need to have
much clearer information in order to actually look
at it on a more speciﬁc basis in order to understand
what kind of issues are going to be raised for
consumers.
Professor Howard: Certainly from discussions with
people who are in the industry, they deﬁnitely want
to avoid a GMO type scenario so they want to
engage stakeholders. I would say that transparency
at all levels is the best way forward and I think that
is why I and the Soil Association would support
mandatory labelling of products as well as this
register so that everybody knows what is going on
and awareness will be raised through that.
Ms Miller: I think that the report from the UK
Nanotechnology Engagement Group is worth a
look; it is quite extensive but well indexed. It was
published in 2007 after a couple of years of public
engagement on nanotechnologies in the UK. Their
key ﬁndings were that people were concerned about
three key areas which were uncertainty and
regulation and, in particular, whether or not
regulation could deal with uncertainty and keep
pace with risk management; the distribution of
beneﬁts and risks; and the question of public
involvement. They made the point that these are
issues that were also of concern during the GM
controversy and I would suggest in relation to food
a key question is: do we need nano in food? Why
should the public accept any new risk at all when a
lot of the applications are to improve the aesthetic
properties of food or the ﬂow properties of ketchup
or to extend the shelf life of food which might be
very useful for the food distributor or the food
retailer but perhaps be of little use for the consumer?
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Why should the public accept new risks? I think
these are three key areas that will be of concern to
the public and I think perhaps the most challenging
is the question of involving the public in decision
making about nanotechnology in this very sensitive
area. I think that is quite essential.
Q306 Lord Haskel: Could I just ask Professor
Howard, obviously an important part of public
engagement is the way all these trials and tests that
you have been urging us to carry out are carried out.
For instance, are they going to be done on humans
or are they going to be done on animals? How is it
going to be done? Do you think this is an important
part of public engagement? How do you think we
tackle that?
Professor Howard: We are not allowed to experiment
on humans. The work we are going to do on
Alzheimer’s, for example, is in a mouse which has
got a human Alzheimer gene in it—it is a well-
characterised progress of that disease—and we are
going to see if we can perturbate the progress of that
disease by challenging it with various nanoparticles.
That is the basis of the Neuro Nano EU project.
When we have ﬁnished these studies they will be
published in peer review journals and then after that
hopefully, if they show anything, will become
adopted in policy. That is a problem, in that policy
obviously has to lag behind scientiﬁc knowledge.
The most diYcult step in a risk assessment is hazard
identiﬁcation. I can remember a number of us
saying four or ﬁve years ago, “Well, with nanotubes
they might have an asbestos-like activity” and other
people said that that was just a theoretical thing,
there was no evidence of that. Now we have two
papers which give an indication that there might be
a grain of truth in that. With these long term
degenerative diseases—the protein misfolding
diseases—we have the knowledge to say that that
could be biologically plausible. We need to
investigate it and assess it I think before we start
dosing people. That is my feeling. I think all these
things will feed into that risk assessment eventually.
Q307 Earl of Selborne: I would like to continue this
theme about public engagement. I would like to ask
you all how you structure this public engagement
dialogue. Clearly in the absence of concrete
examples of nano food products the debate has to
be at a fairly fundamental level. How do you engage
the public in what many of us would see as a rather
hypothetical exercise? Does the government have a
role? Does industry lead? What role should
consumer associations play? Perhaps Georgia could
give us her views ﬁrst on how you structure such a
public engagement dialogue.
Ms Miller: The ﬁrst thing I would say is that before
talking about how one does eVective public dialogue
(which is usually the focus of discussions in the
social science literature and elsewhere), I think the
primary question to ask is why. Unless the
government is in a situation where it is prepared to
really commit to taking on board ﬁndings, not to
being led by them but certainly being informed by
them and really committing to integrate the
outcomes of public dialogue in its own process of
policy development, then I would suggest that
public engagement is actually of little value. I think
that key question must be answered ﬁrst: why? What
are the objectives and what are the constraints and
to be really clear about that. Secondly I would
suggest there is an eVective role for stakeholders
such as consumers’ advocacy organisations and
other groups. I would suggest that there should be
a broad range of community as well as industry,
research and government stakeholders involved in
dialogue together, but I do think that ultimately you
need to hear what the general public think. There
are a number of diVerent ways that you can use
deliberative models to actually resource random
groups representing members of the public to
consider various issues and I am sure you have all
encountered diVerent forms of consensus
conferences or citizens’ juries or what have you, but
I would suggest that what you actually need is an
oversight group which comprises stakeholders and
government members and public participation
practitioners to sit down once you have worked out
what the goal of the objective is and to develop a
programme that contains a variety of activities that
has a discrete start and end point and it gives you
some basis on which to start. I think that would be
quite useful.
Q308 Baroness Neuberger: Can I just follow that up
with Georgia because I thought that was really
interesting. You are saying that if government is not
prepared to take what comes out of such public
engagement seriously there probably is not a lot of
point in doing it. If I were to suggest to you that
even if government were not that interested maybe
manufacturers and consumer groups would be, then
would it not be worth doing even if government
were not going to incorporate it into policy but
maybe consumer groups and manufacturers would
and maybe that has a value in itself?
Ms Miller: I think it is certainly true to observe that
of the many public dialogue activities which have
been carried out to date and which have not resulted
in any observable change to government policy, they
have nonetheless had a value. I think that is
certainly true and it is important to say that they
have helped add to our understanding of what
members of the public think about these issues, they
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have certainly been valuable for the groups who
participated. However, I guess my point is really
that for the government to back a public dialogue
programme on this issue it would be of limited use
if it is not seen to be genuine, so to have a genuine
commitment to a two-way dialogue not just to, in
a sense, engage for the sake of engaging without
actually wanting to hear.
Q309 Chairman: Sue, would you like to add
anything?
Ms Davies: I would agree with a lot of what Georgia
has said and I think there has been a tendency with
some of the public engagement that has been done in
this area to do it in a very general sense so far and
then kind of question the value of it saying, “Well, the
public said what they always say about new
technologies and it has not really taken us any further
forward”. I think it is important that you use
deliberative techniques and it is as grounded in the
potential applications as much as possible, and that
there is a commitment to enabling it to feed into
policy. It is also important to think about at what
stage it actually happens as well and I think a crucial
stage is looking at the type of research that is
underway at the moment and what the focus of that
should be, and understand what the public’s views
are. There are some interesting examples from the
nano-medicine area, for example, where there was a
citizens’ panel that was held by the EPSRC (the
Engineering andPhysical SciencesResearchCouncil)
which directly fed into their decisions about what
research to fund in this area. I think there is a role for
public engagement at that kind of stage, but then
there also needs to be government-funded research to
understand what the public think more speciﬁcally in
relation to nano-foods. When we did our citizens’
panel—obviously there are limitations on what you
can do—we found it very helpful to have people
coming in and talking from diVerent research
associations. We had Vic Morris (who I think has
given evidence) and Qasim Chaudhry come and talk
about the potential applications and the regulations.
It is very interesting how, over three days, the people
who had no knowledge and potentially no interest in
nanotechnologies at the start of the process became
really, really engaged in it and by the end had
developed quite sophisticated views on what they
thought should be happening and what kind of
regulations should be in place.
Q310 Chairman:Could I just come back to you, Sue,
on the point that Georgia made as to why one would
want to start a public engagement exercise. Georgia
made the point that if government is not going to take
any notice of it there is no point in them initiating it,
which then Baroness Neuberger put a slightly
diVerent slant on. If the government were going to
take notice of public engagement, what would that
notice consist of? Would it be to ban foods that the
public were suspicious of? Or would it be to place
public opinion ahead of science? What would the
role be?
Ms Davies: I think at this early stage where the debate
is about what type of regulation we should have in
place, it is tomake sure that there is scope to deal with
those concerns within the regulation. We talked
about the Novel Foods regulation and one of the
amendments that was adopted by the European
Parliament was that you should have to take into
account other legitimate factors, which is obviously a
very vague term. As well as the scientiﬁc risk
assessment there should be this scope within the
regulation. If something appears to present very little
risk but maybe raises some fundamental ethical
concerns, then you have the scope within the
regulations to say in certain cases that it is not
appropriate to put that onto the market. It is partly
about the regulation and it is partly about
understanding how far that needs to go in terms of
the type of information consumers want about
nanotechnology development, but also in terms of
shaping the research agenda that government is
funding as well as just generally setting out a broader
strategy for the way that nanotechnologies should
evolve. There are obviously a lot of risks that need to
be tackled but there are potential beneﬁts and you
need to make sure that it is taken forward in a way
that ensures society in general beneﬁts. That is also
the purpose of public engagement. I would also agree
with the points that were made about industry’s role
in this. Lord Selborne will know from the
development of the Responsible NanoCode that one
of the things that was proposed in that context was
that industry should have some responsibility for
doing some kind of public engagement as it develops
products as well. I think one of the lessons from
GM—you always have to be careful about
comparing this to GM because it is obviously so very
diVerent—is that there was a real failure by the people
who were developing the technology at the start of
the food chain to properly appreciate the issues that
were going to be raised at the end of the supply chain
when products went on sale and what supermarkets’
approaches would be to it as well. I think it is
important to try to make sure that the people right at
the very start of the food chain are actually
understanding what kind of implications and what
kind of expectations consumers may have, whether
that is about product labelling or whether it is about
the types of claims that are made as well.
Q311 Lord Mitchell: Several organisations, in
particular Which?, have suggested that there is a lack
of awareness by the general public with respect to
nanotechnologies, I think not surprisingly. I think all
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of you in your evidence have said in your evidence
that products should have labels which talk about the
inclusion of nanoparticles in food. I ask the question,
given the plethora of information that is already on
many food products, whether this is such a good idea.
Ms Davies: I think it is a very diYcult issue and it is
very diYcult while people know very little about the
technology. We did a survey in November last year
and 45 per cent of people said that they had heard of
nanotechnologies—this was a representative sample
of the UK—but when we actually asked them about
what itmeant very few people really understoodwhat
it was. I think there is the issue that any labelling has
to be provided in the broader context of the need to
provide more information to the public about what
nanotechnologies are. It is something we asked when
we did our citizens’ panel just to try to get a sense of
what people thought about it and the people who had
been exposed to all this information about
nanotechnologies for three days said that they
deﬁnitely thought that they should know whether
something was produced using nanotechnology, not
for safety reasons (because they thought safety
should be a given and you should sort out the
regulatory processes and make sure you could do
proper risk assessments) but because they thought it
was a new development and it was something they
would want to know about. They recognised that if
we had asked them that on the Thursday before they
had come for the weekend and had all this
information it would not really have meant very
much to them at all. On balance it is important in
terms of transparency and it is also important in
terms of having traceability not just for the end
consumer but also throughout the whole supply
chain, but it does need to be done and backed up with
much broader information so that consumers
understand what it means. I think at the moment we
have a bizarre situation—I have brought a product
with me—where you do have products on the market
that say they are nano but there are other products
that are produced using nanotechnology and they are
not telling you that they are produced using
nanotechnology so you are going to have an
incredibly complicated situation. The other thing is
that, as you probably know, the cosmetics regulation
has recently been reviewed by the EU and within that
there is a requirement that ingredients in cosmetics
will have to say whether they are produced using
nanotechnology or not. If consumers start to become
familiar with cosmetic products stating whether or
not the ingredients are nano then it would seem very
bizarre not to give them that kind of information in
relation to food.
Q312 Lord Mitchell: Do you not think that there is
so much information that appears on things that we
buy, then to have that on is a degree of overkill?
Maybe the solution would be to have an internet site
that people could go to to get this information.
Ms Davies:That is often put forward as a solution for
labelling problems. I appreciate there is a lot of
information on the labels and there is a real move to
reduce packing size as well at the moment. However,
I think it still excludes an awful lot of people who are
not going to actively go to a website and a lot of
people want the information at the point when they
are making decisions about buying products so I
think that means that it should be on the label. If it is
put in the ingredients list it is not too onerous. At the
end of the day people are choosing to buy a particular
product and people are genuinely interested in
knowing what the ingredients are and if there are any
new types of production processes that have been
used in that product. I think it comes back again to
getting a clearer picture of exactly what kind of
developments are taking place and maybe further
down the line there will be some applications that
people are not particularly so interested in as others,
but I think as a general principle it is important that
consumers can have this kind of information.
Q313 Chairman: I wonder if Georgia would like to
add anything to what has been said about labelling.
Ms Miller: I think actually that Sue’s point is a really
good one, that people may not care so much about
labelling when they have not heard very much about
nanotechnology but once they become familiar with
nanotechnology and its applications, then labelling
becomes something that they support quite strongly.
This to me suggests that over the next few years, as
public awareness about nanotechnology grows, so
too will support for labelling and clear mandatory
labelling at the point of sale so that people can make
informed purchasing choices. If that is something
that is not supported now, particularly in relation to
food, I think we can expect a backlash from the
community later on as public awareness about
nanotechnology grows. I also just wanted to add
something to the previous conversation about the
ways in which public participation can inform
decision making around nano because I actually
think there are perhaps four or ﬁve key areas. One is
around innovation policy and in a sense we need to
think about both nanotechnology policy and how it
relates to other innovation objectives, and
technology and non-technology options to meet key
areas of social and environmental need. The other is
around food and agriculture, what sort of food and
agriculture policy we want to support and whether or
not nanotechnology actually complements or
undermines other objectives we might set ourselves,
for example improving the ecological sustainability
of agriculture or reducing food miles or helping
improve local food security and issues like this. The
other is around government strategy and I think that
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the public should have some opportunity to be
involved in setting the strategy as far as
nanotechnology oversight in the UK and elsewhere.
The third area is in research priorities which is
something that we have talked a bit about already
and where the researchmoney should be invested.We
must recognise that, like any technology
development, nanotechnology is mutable and what
we get at the end will be partly inﬂuenced by what we
put in at the beginning in terms of research focus. The
fourth area is in commercialisation. I am not so
familiar with the situation in the UK but I know
certainly in Australia our Government supports
commercialisation of nanotechnology products; it
gives grants to companies to bring to market certain
products. This is quite an inﬂuential area of
innovation policy but again all of these areas that I
have talked about so far are outside regulation; they
are outside the area that we typically focus all our
attention on. I guess that the point I wanted to make
is that we really need to open up innovation strategy,
research priorities and some of the upstream parts of
technology development to public dialogue and not
just focus on regulation because if we do that then in
a sense we have already committed ourselves to a
certain path.
Q314 Lord Crickhowell:Georgia has takenme to the
question that I wanted to ask and I was going to
address it probably to Professor Howard. In all our
sessions we come up with three things: do not know,
lack of research (particularly in critical areas like the
gut), diYculty of validation and risk assessment.
How do we get the research focus better? This is a
Supplementary memorandum by Friends of the Earth Australia
Friends of the Earth Australia (FoEA) suggests that a moratorium on commercial use of manufactured
nanomaterials in foods is essential until:
— validated, nano-speciﬁc risk assessments and detection methodologies are designed and
implemented, and regulatory gaps are closed;
— nanotechnology’s broader implications for food and agriculture are assessed, in particular its
implications for public health, and for food security and food sovereignty;
— the public is given the opportunity to participate in nanotechnology decision making, including the
right to reject the development and sales of nanofood; and
— all nanofoods face mandatory labelling on products at point of sale.
FoEA suggests that there are six key reasons to support a moratorium:
— the science demands a precautionary approach to risk management;
— the public expects governments to ensure food safety—which is not currently possible in relation to
nanofoods;
— the public has not been given an opportunity to be involved in nanotechnology decision making, but
early ﬁndings suggest that people do not support the use of nanotechnology in food;
worldwide thing, but clearly the research focus is not
ideally where it should be at the moment.
Professor Howard: I think that the EU and some of the
research councils here in the UK are giving very
focused research grants to look at speciﬁc problems.
They are to do with uptake studies, distribution
studies and toxicology. That is what we need. There
is quite a large amount of money being devoted to
that. If I could harp back for one second to what was
being said before, I think the very term
“nanotechnology” is a problem for the industry
because it does encompass a large number of
enabling technologies going from microscopes to
nano-structured surfaces on self-cleaning glasses,
many of which are not in the slightest bit threatening,
but they all come under that heading. What we are
addressing here with food is a speciﬁc problem of
increased and inappropriate mobility of substances
through the body. I think that because it is that subset
it might be rather easier than we think to
communicate that. That is certainly where the
research is focused at the minute, mobility and
toxicology.
Chairman: Thank you very much. I would like thank
all of our witnesses for helping us to explore some of
the issues that we put before you. I would like to
conﬁrm that copies of the transcript will be available
for you to comment on before it is ﬁnally published.
Also, if there are any points that you have not been
able to elaborate on suYciently that you would like
to write into us about, please feel free to do so and
those points would also be published along with the
rest of our written evidence and with the transcript.
With that I would like to thank you all very much
indeed for joining us, including Georgia from
Australia. Thank you very much, Georgia.
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— there is no social beneﬁt in permitting the sale of nanofoods before they have undergone rigorous,
validated nano-speciﬁc safety assessment, broader socio-economic challenges have been assessed,
and the public given the opportunity to take part in decision making;
— at a time of global food crisis, nanotechnology’s broader implications for food security and food
sovereignty must be assessed critically; and
— a failure to support a precautionary, transparent and inclusive approach to decision making in this
sensitive area of nanotechnology development is likely to result in a further erosion of public
conﬁdence in science and technology governance.
The science demands a precautionary approach to risk management
The scientiﬁc justiﬁcation for requiring proponents to demonstrate the safety of nano-products before they
can be sold was accepted in 2004 by theUnitedKingdom’s Royal Society andRoyal Academy of Engineering.
In their report they recommended that: nanomaterials be treated as new chemicals; nano-ingredients in
products be required to pass rigorous safety assessment before commercial use is permitted; nano-ingredients
in products be labelled; nanomaterials in factories and workplaces be treated as if they were hazardous; and
the environmental release of nanomaterials be avoided as far as possible (RS&RAE2004).Global reinsurance
agent Swiss Re called even more explicitly for precautionary management of nanotechnology risks: “In view
of the dangers to society that could arise out of the establishment of nanotechnology, and given the uncertainty
currently prevailing in scientiﬁc circles, the precautionary principle should be applied whatever the diYculties”
(Swiss Re 2004, p 47).
The 1992RioDeclaration onEnvironment andDevelopment describes the precautionary principle as follows:
“Where there are threats of serious or irreversible damage, lack of full scientiﬁc certainty shall not be used as
a reason for postponing cost eVectivemeasures to prevent environmental degradation” (UnitedNations 1992).
There is preliminary evidence of serious nanomaterial health and environment risks (UK RCEP 2008;
SCENIHR 2009), acknowledgement by leading researchers that the extent of uncertainty is such that even
design of reliable risk assessment systems for nanomaterials is impossible (EFSA 2009; Hansen 2009;
Oberdo¨rster, Stone, and Donaldson 2007) and predictions that validated nano-speciﬁc risk assessment
methodologies may take up to 15 years to develop (Maynard et al 2006). It is for circumstances such as these
that the precautionary principle was intended.
The public expects governments to ensure food safety—which is not currently possible in relation to nanofoods
It is perhaps self-evident, but useful to highlight nonetheless, that the public expects that the government will
implement rigorous safety assessments for all food ingredients, but especially those produced by uncertain new
technologies, prior to products being permitted for commercial sale. Early public engagement exercises show
that key public concerns relate to the new health and environmental risks associated with nanomaterials, and
the ability of governments to ensure their appropriate regulation (Macoubrie 2006; Gavelin et al 2007;
German FIRA 2006; Halliday 2007). It would be a major breach of the public’s trust to permit the sale of
nanofoods, containing manufactured nanomaterials that may introduce serious new risks to human health
and the environment, when experts including the European Food Safety Authority agree that it is as yet
impossible to design nano-speciﬁc risk assessment procedures in which we can have conﬁdence (EFSA 2009;
Hansen 2009; Oberdo¨rster, Stone, and Donaldson 2007).
The public has not been given an opportunity to be involved in nanotechnology decision making, but early findings suggest
that people do not support the use of nanotechnology in food
Public awareness about nanotechnology remains very low. However, early surveys show that once given
information about nanotechnology, people do not want to eat nanofoods or foods wrapped in packaging that
contains manufactured nanomaterials. Public engagement initiatives and experimental studies conducted in
the UK suggest that once provided with information about nanotechnology, the public is concerned about
many of the same issues identiﬁed in relation to GE food: a lack of transparency, a lack of choice about
exposure, risks to health and the environment, unfair distribution of risks and beneﬁts, a lack of socially useful
applications and a lack of public participation in decision making (Gavelin et al 2007).
Public concerns about nanotechnology are greatest when nanotechnology is applied to food. Participants in a
2006 consumer conference inGermany, organised by theGermanFederal Institute forRiskAssessment (BfR),
expressed the most serious reservations about nanotechnology when it was applied to foods (German FIRA
2006). A year later the BfR conducted a survey of 1,000 people and found that a majority of people not only
do not personally want to eat nanofoods, but also think that nanotechnology should not be used in food
applications at all. 60 per cent of survey respondents were against the use of nano-additives to prevent spices
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from becoming lumpy; 84 per cent rejected the idea of using nanomaterials to make foods look appealing for
longer (Halliday 2007).
A study conducted in the German speaking part of Switzerland also found that people did not want to eat
nanofoods or foods wrapped in nano packaging (Siegrist et al 2007). Similarly, a United States survey of 1,014
adults found that only 7 per cent of respondents were currently prepared to purchase foods produced using
nanotechnology. 29 per cent would not purchase food produced using nanotechnology, while 62 per cent
wanted more information about health risks and beneﬁts before they would consider buying nanofoods (Peter
D Hart Research Associates 2007). Polling of 1,010 Australians commission by FoEA and carried out by
Essential Research found that 92 per cent of Australians supported mandatory labelling of nanofoods, 96 per
cent supported mandatory nano-speciﬁc safety testing of nano-ingredients in food and packaging, and only
15 per cent were currently prepared to purchase nanofoods (Essential Research 2008).
Mandatory labelling of all nanofoods is required to enable people to make an informed choice about whether
or not to eat them. However beyond the need for labelling to enable informed purchasing choices, the public
must be given the opportunity to be involved in decision making about the use of nanotechnology in the food
and agriculture sector. Given the signiﬁcant implications of nanotechnology for our relationship with food
and agriculture, and for food producing communities worldwide, we call for public involvement in all aspects
of decision making, including the right to say no to nanofoods.
There is no social benefit in allowing the sale of nanofoods before they have undergone rigorous, validated nano-specific
safety assessment, broader socio-economic challenges have been assessed, and the public given the opportunity to take
part in decision making
There have been claims by some proponents that nanofoods will deliver a social beneﬁt that should be weighed
against new toxicity risks. FoEA rejects this framing of weighing “beneﬁts” against “risks” for three key
reasons. Firstly, we recognise that such framing ignores social concerns related to nanotechnology ownership,
access, controllability, equity, sustainability and other issues. These issues, which have nothing to do with risk,
were all important to the UK public in relation to genetically engineered foods, and early studies suggest that
they are similarly important to the UK public in relation to nanotechnology (Gavelin et al 2007). Secondly,
we recognise that many of the claimed beneﬁts are either trivial, accrue to manufacturers rather than
consumers, or come with their own health and social costs. Thirdly, we think it is entirely inappropriate to
use claimed beneﬁts to counter-balance risks, particularly given that the qualitatively new types of hazards
associated with nanotechnology demand a greater use of precaution than ever before (Dupuy and Grinbaum
2006; Ravetz 2005).
Beyond the need for new regulation to manage the serious new toxicity risks associated with nanofood and
nano agricultural products, Friends of the Earth Australia is calling for “fourth hurdle regulation” to require
manufacturers to demonstrate the social beneﬁt of products they wish to sell. Too often, it is an entrenched
and unchallenged assumption that the market release of a new functional food or antibacterial product will
necessarily deliver public health beneﬁts. In many instances, putative beneﬁts are argued by product
proponents to justify or counterbalance the potential for new risks, despite potential beneﬁts rarely being
subject to the same kind of scrutiny and scepticism to which claims of potential risks are subject. Friends of
the Earth Australia therefore supports the recommendations of Wynne and Felt (2007) for the inclusion of a
social beneﬁt test, supplementing the more usual investigations into eYcacy, safety and environmental risk, as
part of the regulation of nanotechnology in food and agriculture.
We would like to comment brieﬂy on three areas of nanofood development where we believe that the potential
for social beneﬁts has been misrepresented:
(i) Food safety
A key claim by nanotechnology proponents is that nanotechnology will improve food safety, including by the
incorporation of antibacterial nanomaterials in food contact materials and edible food coatings. There has
been rapid growth in the use of antibacterial nanomaterials such as silver, zinc and titanium dioxide in food
packaging, food storage containers, crockery, cutlery, refrigerators and dishwashers. We are concerned that
such widespread use of antibacterial nanomaterials (additional to their use in non-food items such as clothing,
cosmetics, children’s toys, personal care products, household cleaners, industrial disinfectants, computer
keyboards, vacuum cleaners, clothes washing machines and many other products) will actually promote
dangerous antibacterial resistance. This could render ineVective the use of nano-silver and other potent
antibacterial nanomaterials in a medical context (for burns victims, in wound dressings etc) where they are of
most use. This is particularly concerning given that silver is experiencing a revival in hospitals across Europe,
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partly because of the growing bacterial resistance to commonly used antibiotics (Chopra 2007). Bacterial
infections already contribute to 110,000 deaths a year in Europe.
Biocidal nanomaterials could also interfere with beneﬁcial bacteria in sewage and waste water treatment
plants, and could contaminate water intended for re-use. There are also serious concerns that nano-
antibacterials will pose unacceptable toxicity risks to human health and to environmental systems in to which
waste products are released. A recent study by imminent UK nanotoxicologists advised that there is suYcient
evidence to suggest that silver and titanium dioxide nanomaterials may be harmful to the environment and
therefore the use of the precautionary principle should be considered (IOM 2009).
While any illness as a result of food contamination is unacceptable, it is important to remember that for every
person in the UK who suVers illness as a result of food poisoning, there are 50 who suVer ill health as a result
of poor diets and inadequate consumption of fruit and vegetables (Lang andRayner 2001). If processed, nano-
packaged food is marketed successfully as safer than eating fresh, unpackaged foods, and consumption of
fresh foods declines further, it is possible that the net outcome will actually be poorer health.
(ii) Nutrition and obesity
We are concerned that nanotechnology will enable manufacturers to promote nano-reconstituted, nano-
fortiﬁed or nano-packaged foods as delivering superior health beneﬁts, hygiene or convenience thanminimally
processed “fresh foods”. If this proves true, it is likely that nanotechnology will encourage even greater
consumption of highly processed foods at the expense of fruits and vegetables. Beyond the need to ensure the
safety of nanofood additives, it is also useful to question whether or not fortifying food with nano nutrients,
or using nanotechnology to reduce the fat or sugar content of junk foods, is actually desirable from a public
health perspective.
There is a growing number of manufacturers prepared to claim that their nano-fortiﬁed beverages or foods
willmeet a large part, or even the entirety, of an individual’s dietary needs. For example ToddlerHealth’s range
of fortiﬁed chocolate and vanilla milkshakes (“nutritional drinks”), which include 300nm particles of
SunActive@ iron, is marketed as “an all-natural balanced nutritional drink for children from 13 months to
ﬁve years. One serving of Toddler Health helps little ones meet their daily requirements for vitamins, minerals
and protein” (Toddler Health undated). Yet we challenge the claim that fortiﬁcation of highly processed foods
using nano-encapsulated or nano-scale vitamins or health supplements can deliver the same health beneﬁts as
improving peoples’ diets. Rather than settling for the risky techno-ﬁx of nano-fortiﬁcation, the nutrition
challenge requires government intervention to encourage better eating habits and more aVordable healthy
foods. This should involve action at the level of pricing policies and subsidies, school lunch programs, junk
food advertising and other social policies.
We are similarly concerned that the use of nanotechnology to reduce the fat or sugar content of junk foods
may simply entrench and expand poor eating habits. Even a fat-reduced chocolate bar or donut will have
inferior health and nutritional habits compared to fresh fruit or a “real” meal. The most straightforward to
reduce the growing problem of obesity in our community is to promote healthier eating habits andmore active
lifestyles. Using nanotechnology to reduce the fat content of chips, donuts and chocolate will not address the
root causes of obesity in our community, nor will it deliver the public health beneﬁts associated with reduced
consumption of highly processed junk foods, greater consumption of fruit and vegetables, and a more
active lifestyle.
We suggest that the food industry’s key motivation in using nanotechnology to fortify or reconstitute highly
processed foods has less to do with a public health concern and more to do with the signiﬁcantly greater proﬁt
margins on processed foods compared to fruit and vegetables.
(iii) Reducing the environmental footprint of food production
We challenge the assertion that nanotechnology will necessarily reduce the environmental footprint of food
production. Even if, because of their greater potency, the quantities of nanomaterials used in agrochemicals,
food ingredients and production inputs are far smaller than the usual quantities of their bulk counterparts,
the environmental impact could be far greater. The Project on Emerging Nanotechnologies at the Woodrow
Wilson International Center for Scholars has suggested that the toxicological impact of 58,000 tonnes of
manufactured nanomaterials might be the equivalent of 5 million or even 50 billion tonnes of conventional
materials (Maynard 2006).
We also note that the manufacture of nanomaterials has a very high environmental footprint (S¸engu¨l et al
2008). This is related to the highly specialised production environments, high energy and water demands of
processing, low yields, high waste generation, the production and use of greenhouse gases such as methane
and the use of toxic chemicals and solvents such as benzene. In a life-cycle assessment of carbon nano-ﬁbres,
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Khanna et al (2008) found that producing carbon nano-ﬁbres may have the potential to contribute to global
warming and ozone layer depletion, and cause environmental or human toxicity that is as much as 100 times
greater per unit of weight than those of conventional materials like aluminium, steel and polypropylene. Early
nanomaterial life cycle assessments led the scientists to conclude that any environmental gains of
nanomaterials (for example through greater potency enabling smaller quantities of materials to be used) may
be outweighed by the environmental costs of their production.
Furthermore, many applications of nanotechnology in food packaging and edible food coatings are
speciﬁcally intended to increase the shelf life of foods. It appears inevitable that one result of this will be the
transport of foods over longer distances, increasing the “foodmiles” travelled, and increasing the climate costs
of food transport.
In short, we recognise that there are many potential social “costs” and new health and social challenges
associatedwith nanotechnology’s use in food and agriculture that require careful assessment. There is certainly
no reason that the public should accept exposure to poorly understood risks posed by nanofoods, on the basis
that there is a social beneﬁt to be obtained from their sale prior to validated, nano-speciﬁc risk assessments
being developed and implemented, full product labelling introduced, social assessment carried out, and the
public given an opportunity to be involved in decision making.
At a time of global food crisis, nanotechnology’s broader implications for food security and food sovereignty must be
assessed critically
Nanotechnology in food and agriculture is emerging at a time when global food systems are under
unprecedented stress. Recent decades have revealed the high environmental costs associated with industrial
scale chemical-intensive agriculture, including biodiversity loss, toxic pollution of soils and waterways,
salinity, erosion, desertiﬁcation and declining soil fertility (FAO 2007). The escalation of the global food crisis
has also underscored the fundamental failure of global food and agriculture systems to meet the food needs
of nearly a billion people. Price rises have had the worst impact on poor people reliant on buying food. Food
riots occurred in over 30 countries where the world’s poorest people could no longer aVord basic food.
Around 75 per cent of the world’s hungry people live in rural areas in poor countries (FAO 2006). If rural
communities can meet more of their own food needs via local production, they will clearly be less vulnerable
to global price and supply ﬂuctuations. Global small farmers’ advocacy organisation La Via Campesina has
argued that: “Small-scale family farming is a protection against hunger” (La Via Campesina 2008). This view
was supported by the four year International Assessment of Agricultural Science and Technology for
Development which emphasised that to redress rural poverty and hunger, a key focus of agricultural policy
must be empowering small scale farmers to meet their own food needs (IAASTD 2008).
The potential role of new technologies in responding to the food crisis is controversial. As with genetically
engineered (GE) crops, proponents have argued that nanotechnologywill redress food shortages by promoting
greater agricultural productivity (IFRI 2008). However the IAASTD (2008) report notes that whereas GE
crops have had highly variable yields, they have also had negative broader economic consequences for farmers
by concentrating ownership in agricultural resources and introducing new liabilities for farmers (IAASTD
2008). Similarly, FoEA suggests that nano-agriculture is not required to achieve strong yields, but will add to
the capital costs faced by small farmers and increase their reliance on technology, seed and chemicals sold by
a small number of global agri-business companies.
By underpinning the next wave of technological transformation of the global agriculture and food industry,
nanotechnology appears likely to further expand themarket share ofmajor agrochemical and seed companies,
food processors and food retailers to the detriment of small operators (Scrinis & Lyons 2007). By dramatically
increasing eYciency and uniformity of farming, it appears likely that nano-farming technologies could
accelerate expansion of industrial-scale, export oriented agricultural production which employs even fewer
workers but relies on increasingly sophisticated technological support systems that have increasing capital
costs (Scrinis & Lyons 2007; ETC Group 2004). Such systems could commodify the knowledge and skills
associated with food production gained over thousands of years and embed it into proprietary
nanotechnologies (Scrinis & Lyons 2007). It could also result in the further loss of small scale farmers and
further disconnection of rural communities from food production, undermining eVorts to achieve sustainable,
relocalised food production.
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A failure to support a precautionary, transparent and inclusive approach to decision making in this sensitive area of
nanotechnology development is likely to result in a further erosion of public confidence in science and technology
governance
The House of Lords Select Committee on Science and Technology is already very familiar with the crisis of
public conﬁdence in science and technology governance that emerged in the late 1990s in theUK.We note that
in the Committee’s 2000 report you recommended that: “direct dialogue with the public should move from
being an optional add-on to science-based policy making . . . and should become a normal and integral part
of the process”. We are grateful for the opportunity to present evidence to you as part of the current Inquiry
and recognise the Committee’s eVorts to actualise its recommendation. Nonetheless, we observe that despite
initial eVorts to engage theUKpublic in a dialogue on nanotechnology development, this has to date not been
speciﬁcally undertaken in relation to food and agriculture, nor has it been attached to a policy or governance
decision making process.
We suggest that as the public awareness about nanotechnology grows, and speciﬁcally in relation to its use in
food and agriculture, it will be essential for the government to demonstrate that it has taken a strongly
precautionary approach to risk management, that it has considered broader social challenges alongside
scientiﬁcally measurable risk issues, and that the public has had a genuine opportunity to be involved in
decision making. A perceived or actual failure in relation to any of these issues risks further eroding public
conﬁdence in science and technology governance, and taking us back to the BSE and GM controversies.
APPENDIX
CIVIL SOCIETY GROUPS WHICH HAVE CALLED FOR A MORATORIUM ON
NANOTECHNOLOGY’S USE IN FOOD AND AGRICULTURE
Growing numbers of civil society groups have called for amoratorium on the commercial release of food, food
packaging, food contact materials and agrochemicals that contain manufactured nanomaterials until
nanotechnology-speciﬁc regulation is introduced to protect the public, workers and the environment from
their risks. Some of these groups are also insisting that the public be involved in decision making. Groups
calling for a moratorium include: Corporate Watch (UK); the ETC Group; Friends of the Earth (Australia,
Europe and the United States); GeneEthics (Australia); Greenpeace International; International Centre for
Technology Assessment (US); International Federation of Journalists; the Loka Institute; Practical Action;
and The Soil Association UK. The International Union of Food, Agricultural, Hotel, Restaurant, Catering,
Tobacco andAlliedWorkers’ Associations, representing 12millionworkers from120 countries, has also called
for a moratorium.
TheNye´le´ni Forum for Food Sovereigntywas a civil societymeeting of peasants, family farmers, ﬁsher people,
nomads, indigenous and forest peoples, rural and migrant workers, consumers and environmentalists from
across the world. Delegates were concerned that the expansion of nanotechnology into agriculture will present
new threats to the health and environment of peasant and ﬁshing communities and further erode food
sovereignty. The forum also resolved to work towards an immediate moratorium on nanotechnology (Nye´le´ni
2007—Forum for Food Sovereignty 2007).
The organic sector is also beginning to move to exclude nanomaterials from organic food and agriculture. The
United Kingdom’s largest organic certiﬁcation body announced in late 2007 that it will ban nanomaterials
from all products which it certiﬁes. All organic foods, health products, sunscreens and cosmetics that the Soil
Association certiﬁes will now be guaranteed to be free frommanufactured nanomaterial additives (British Soil
Association 2008). The Biological Farmers of Australia, Australia’s largest organic representative body, have
also moved to ban nanomaterials from products it certiﬁes.
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Memorandum by Professor Derek Burke
1. My submission to this inquiry is focused on regulatory aspects of the introduction of nanotechnology into
the food industry. It draws onmyown experience as the ﬁrst Chair of theAdvisory Committee onNovel Foods
and Processes (ACNFP) from 1989 to 1997. I consider that this issue is of considerable current importance.
2. The ACNFP ﬁrst considered the issue in 2005 with a brief report on “Nanoparticles in food1”. The
Committee agreed “that the use of nanoparticles in food was an issue of increasing public interest that would
require further consideration… Members also indicated that the committee might require input from
additional experts if it is to examine this area in depth.” This report was based on a committee paper (ACNFP/
70/4)2 which deﬁned nanotechnology, referred brieﬂy to the Royal Society/RAE Report3 and highlighted the
following conclusions:
— That the toxicity of chemicals in the form of free nanoparticles and nanotubules cannot be predicted
from their toxicity in larger form and that in some cases they will be more toxic than the same mass
of the same chemical in larger form.
— That regulatory bodies and their respective advisory committees include future applications of
nanotechnology in their horizon scanning programmes to ensure any regulatory gaps are identiﬁed
at an appropriate stage.
3. In November, 2004, the environmental group ETC published a report “Down on the Farm: The Impact of
Nano-scale Technologies on Food and Agriculture”4 which identiﬁed a number of current and projected uses
of nanoparticles in food manufacture. These included:
— The current practice of using nano-scale carotenoids as colourings in lemonades, fruit juices and
margarines. The small particle size improves dispersion and stability of the ingredient.
— The current practice of micro-encapsulating nano-scale active ingredients in functional foods, for
example when adding ﬁsh oils to bread. The oils are released from the micro-capsules in the stomach
and so do not impair the taste of the product.
— The projected practice of using oxygen impermeable coatings on confectionery, made from nano-
scale silicon dioxide, to improve shelf life.
4. The conclusions in this ETC report included, inter alia:
— That national governments must establish a sui generis regulatory regime speciﬁcally designed to
address the unique health issues associated with nano-scale materials used in food.
— That in keeping with the Precautionary Principle, all food, feed and beverage products (including
nutritional supplements) incorporating manufactured nanoparticles should be removed from the
shelves until such time as regulatory regimes are in place that take into account the special
characteristics of these materials, and until the products have been shown as safe.
5. The Food Standards Agency has recently (August 2008) published “A review5 of the potential implications
of nanotechnologies for regulations and risk assessment in relation to food”. They concluded:
— On the basis of current information, most potential uses of nanotechnologies that could aVect the
food area would come under some form of approval process before being permitted for use.
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— This review has not identiﬁed any major gaps in regulations but there is uncertainty in some areas
whether applications of nanotechnologies would be picked up consistently. In these cases there are
relatively straightforward options to address this uncertainty. As food regulations are harmonised at
EU level, the Agency will seek to address them at EU level through the European Commission and
other Member States. The Commission’s Nanotechnology Action Plan commits it to coordinating
an approach to such issues.
— The view of the independent advisory Committees on Toxicity, on Carcinogenicity and on
Mutagenicity of Chemicals in Food, Consumer Products and the Environment, is that the existing
model for risk assessment is applicable to nanomaterials although there are major gaps in information
for hazard identiﬁcation. (My italics) Risk assessment relies on provision of suYcient reliable
information to inform an assessment in each case. Risk assessment procedures will need to include
procedures for provision of information to inform risk assessments, for example in relation to an
application for approval for a new product or process. The Agency will support the development of
risk assessment in this area in close partnershipwith otherDepartments and the independent advisory
bodies in the UK and the EU.
6. Myown view is that this is a somewhat complacent conclusion. For example in Paragraph 35 headed “Gaps
in regulation”, the review points out that “The legislation as it stands does not diVerentiate between chemicals
produced routinely by current methods and those that may be developed by nanotechnology.” I suggest that
this misses the whole point of nanotechnology which is that properties of substances change when they are
very small, in particular as the surface area to volume ratio changes.
7. The Food Standards Agency also consulted a number of relevant stakeholders on a draft of this report.
Only six responses (42 individual comments) were received6 but the responses are helpful and important. For
example, Friends of the Earth commented “A regulatory framework must be established that is speciﬁcally
designed to address the unique health and environmental issues associated with nanomaterials used in food
and agriculture. Thismust be part of an integratedGovernment approach to nanotechnology, which takes into
account the wider issues beyond food applications.” Similar comments were received from Professor Vic
Morris and the Institute of Food Science and Technology (IFST) which made a number of pertinent and
thoughtful comments, in particular comments about the way in which EU regulatory directives and
regulations bore on this issue. I considered that the FSA response was rather cool and I suggest that there are
a number of these issues that the committee might wish to follow up. Too often the FSA response was “The
Agency has noted these comments.”My own experience in Brussels suggests to me that the faith placed by the
Food Standards Agency places in a speedy regulatory response from Brussels is over optimistic.
8. I have not been able to ﬁnd any more recent material, in particular any record of activity by the ACNFP
since the publication of the FSA review last August. My overall impression is that the FSA are being too
complacent. The history of regulation of new technology arising from discoveries in the biosciences is that
regulatory issues are often only spotted after they have arisen (my own personal experience of genetically
modiﬁed foods and crops bears this out), and one of the lessons of the last 10 years is that regulatory issue
should be anticipated, and responses framed in advance if at all possible.
9. There are therefore a number of areas which I suggest that the Lords Science Committee might consider,
including:
— I have not found any record of horizon scanning on nanotechnology by the FSA or the ACNFP, but
maybe this is in train. But such horizon scanning, which is an important part of FSA strategy, would
be very important in this area. So the questions are: what has been done, what is planned, and if
nothing has been done, when is it going to be started?
— The next obvious question one is whether the current regulatory framework will be able to cope with
the likely developments in nanotechnology. The Research Councils recently hosted a one day
workshop with members from the Research Councils, FSA, ACNSP, Royal Society etc on possible
new regulatory issues arising from the development of synthetic biology, which I attended. In this
particular instance, it concluded that the current regulatory regime is capable of handing all
foreseeable developments. Maybe such a workshop has taken place or is planned for
nanotechnology?
— From the current list of ACNFP members7,8 I cannot see anyone with expertise in nanotechnology,
although this might be present, since the list of members’ interests9 has not been updated since April
2005. If not, it would seem an important skill to add to that committee.
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Memorandum by Dr Robert Falkner, London School of Economics
1. The evidence provided below focuses on the regulatory framework for nanotechnologies in food. It is based
on research currently being carried out as part of an international project on “Regulating Nanotechnologies
in the EU and US: Towards EVectiveness and Convergence”, which is funded by a grant from the European
Commission and involves four institutions: the London School of Economics and ChathamHouse in theUK,
and the Environmental Law Institute and the Project on Emerging Nanotechnologies in the US.1 Research
assistance by Nico Jaspers and Carmen Gayoso is gratefully acknowledged. Please note that the evidence
below is given in a personal capacity and does not represent the views of the project consortium or the
European Commission.
Q: Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
2. A clear-cut answer to this question is not possible. The regulatory framework may be ﬁt for purpose, but
given existing knowledge gaps about the presence of nanoscale materials in commercial use, their
environmental and health risks, and methodologies for assessing such risks, changes to the regulatory
framework are likely to be needed. In any case, greater eVorts need to be undertaken to gain better knowledge
about the potential risks involved in the use of nanotechnologies in food and other areas, as a ﬁrst step towards
a more robust regulatory environment.
3. Emerging nanotechnologies and nanomaterials are being regulated through existing laws and regulations
at UK and EU level, in the ﬁelds of chemicals, food, cosmetics, pharmaceuticals, among others.2 Given that
nanotechnologies are best conceived as enabling technologies for a wide range of industrial applications,
nanotechnology risks are likely to be dealt with by sector-speciﬁc and product-based, rather than
comprehensive and process-based regulation. Current regulatory eVorts in the UK, the European Union and
other industrialised countries are focused on applying existing regulations to nanotechnologies and amending
these in order to ﬁll any potential gaps in the coverage of nanotechnology risks. Given existing knowledge
gaps—about health and environmental risks, appropriate methodologies for risk assessment and the state of
commercialisation of nanomaterials—it is not possible to establish with suYcient certainty whether the
regulatory framework is ﬁt for purpose.
4. A central problem in nanotechnology regulation concerns the very deﬁnition of what constitutes the
“nanoscale”. EVorts are underway to establish common scientiﬁc and technical standards in this area, through
the International Organization for Standarization (ISO) and the OECD (see below, paragraphs 15–17).
However, the absence of reliable deﬁnitions has made it diYcult so far to establish precisely what types of
nanomaterials are in use in the food sector and whether these are adequately covered by existing regulations.
The food industry has failed to provide comprehensive information about the size or properties of
nanomaterials it currently uses as food ingredients, in food processing and in food packaging. Part of the
1 For further information, see the project website: http://www.lse.ac.uk/nanoregulation.
2 For a review of existing EU regulation and how it applies to nanotechnologies, see Communication from the Commission to the
European Parliament, the Council and the European Economic and Social Committee on Regulatory Aspects of Nanomaterials
COM(2008) 366 ﬁnal, available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri%COM:2008:0366:FIN:EN:PDF.
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problem is that, in the absence of clear deﬁntions, the use of the term “nano” or “nanoscale” remains at the
discretion of companies. EVorts are underway to address the uncertainty and incoherence surrounding
company reporting, including by the European food and drinks industry association CIAA, which has set up
a Nanotechnology Task Force. But governments will need to take the lead in removing uncertainty about
deﬁnitions and establish unambiguous disclosure requirements about the presence of nanomaterials in food
production and products.
5. In principle, imported food products should be covered by existing regulations in the same way as
domestically produced food products. As with domestic producers, the main problem at the moment is the
absence of reliablemarket data. Governments should therefore consider, as an immediate priority, the creation
of a comprehensive reporting system for nanomaterials in the food industry, covering domestic and imported
products. Given the limitations of voluntary reporting initiatives in this area (see below, paragraphs 7–13),
disclosure and reporting of nanomaterials in food should be mandatory.
6. The need to update and revise existing food safety regulations in light of newly emerging nanotechnology
applications has recently been conﬁrmed by the European Food Safety Authority (EFSA). According to the
agency’s draft strategic plan for the next ﬁve years, nanotechnology is seen as one of the key “new challenges”
that will require regulators to “upgrade existing and design new risk assessment practices to keep up with the
pace of science and innovation”.3 More recently, EFSA emphasised that available data on risks relating to
exposure to speciﬁc nanomaterials in food is “extremely limited”. Given the limited knowledge of current
usage levels and likely exposure products in the food area, the agency warned that lack of validated test
methodologies couldmake risk assessment of speciﬁc nanoproducts “very diYcult and subject to a high degree
of uncertainty”.4
Q: How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take
up by companies working in the food sector?
7. The short answer is “not very eVective”. Industry has introduced a number of voluntary initiatives that
address issues relating to nanotechnologies risk, and some governments have provided frameworks for
reporting and codes of conduct for research that are of a voluntary nature. Many of these schemes have only
recently been initiated, and little systematic evidence exists on industry self-regulation, but ﬁrst assessments
of governmental programmes for voluntary reporting suggest that such initiatives are not suYciently eVective.
8. Preliminary ﬁndings of a study currently being conducted at the LSE suggest that themajority of companies
that have initiated voluntary initiatives on nanotechnology risk are to be found in the chemicals and
pharmaceuticals sectors. These companies have a long tradition of engaging in corporate social responsibility
initiatives and have been at the forefront of developing commercial applications of nanotechnology. SuchCSR
initiatives involve, for example, codes of conduct for nanotechnology applications (eg BASF, Evonik),
participation in international research on environmental and health risks of nanotechnologies (eg American
Chemistry Council Nanotechnology Panel; Occupational Safety & Health Consortium), nanotechnology-
related statements in CSR reporting (eg Novartis, HoVman-LaRoche) and public and stakeholder
engagement activities. DuPont has recently developed a Nano Risk Framework in partnership with the US
environmental organization Environmental Defense, which provides a guidance document for
nanotechnology users for identifying and reducing potential risks as part of product stewardship programmes.
9. The food industry has been comparatively slow to develop voluntary initiatives for dealing with
nanotechnology risk, but is faced with growing demands for greater transparency about its use of
nanomaterials. So far, no industry-wide system of self-regulation has been created that could provide reliable
information on the use of nanomaterials in food production and promote safety standards. Momentum is
growing, however, for disclosure initiatives as a ﬁrst step towards industry self-regulation. Investor activist
groups in the US, for example, have ﬁled resolutions for the 2009 annual meetings of Avon Products, Kellogg
Company, Kraft Foods, and McDonald’s Corporation and are requesting that companies publish a report
detailing their use of nanomaterials in products and their overall nanomaterials policy.5 In Europe, the food
and drinks industry association CIAA is currently developing an industry-wide Code of Conduct for
Nanotechnologies, which is expected to provide a ﬁrst steps towards a self-regulatory framework.6
3 http://www.euractiv.com/en/sustainability/eu-food-safety-watchdog-outlines-future-challenges/article-176074.
4 http://www.efsa.europa.eu/cs/BlobServer/Scientiﬁc Opinion/sc op ej958 nano en,0.pdf?ssbinary%true.
5 http://www.merid.org/NDN/more.php?id%1654.
6 http://www.ciaa.be/e-newsletter/nsl2.asp?nsl id%21&nsldet id%134.
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10. Governments have also sought to promote voluntary initiatives. The UK has been at the forefront of
developing voluntary reporting schemes to improve the informational basis for risk assessment and
management of nanotechnologies. DEFRA launched the UK Voluntary Reporting Scheme (VRS) for
Engineered Nanoscale Materials, the world’s ﬁrst such governmental reporting scheme, in September 2006.
Its two-year pilot phase of the project came to an end in September 2008, andDEFRA is currently considering
how to develop a future reporting scheme. The record of the pilot phase has raised concerns about the
eVectiveness of voluntary reporting. Since its launch in 2006, DEFRA received only 12 submissions, which
represent about a third of the companies currently manufacturing nanomaterials.7
11. The UK’s experience with voluntary reporting is mirrored by the limited response to the US EPA’s
Nanoscale Materials Stewardship Program (NMSP), which was launched in January 2008 and is also meant
to run for two years. NMSP invites voluntary reports on engineered nanoscale materials that are being
manufactured, imported, processed or used in the US. A separate in-depth program invites producers to
develop and submit data, including testing, over a longer time frame.8 In its interim report of January 2009,
EPA states that 29 companies or associations had submitted information to EPA covering 123 nanoscale
materials and a further seven companies have outstanding commitments to do so. Four companies have so
far agreed to participate in the in-depth program.
12. Although EPA concludes that “the NMSP can be considered successful”, it notes that “a number of the
environmental health and safety data gaps the Agency hoped to ﬁll through the NMSP still exist”. Few of the
reports received by NMSP contain information on health and environmental aspects of nanomaterials and,
as EPA states in its review, “approximately 90 per cent of the diVerent nanoscale materials that are likely to
be commercially available were not reported”. Furthermore, commenting on the low take up of the more
ambitious in-depth program of NMSP, EPA notes that “most companies are not inclined to voluntarily test
their nanoscale materials”. It is therefore not surprising that the agency is now considering how to use existing
authorities under US chemicals legislation to ﬁll those gaps, which signals a move to strengthen mandatory
requirements in the coming years.
13. Other governments have already concluded that mandatory reporting is now needed to deal with the
existing and emerging information gaps. France proposed in January 2009 to introduce amandatory reporting
requirement of manufactured and imported nanomaterials, including environmental and health data.9
Canada announced in February 2009 that will introduce a mandatory reporting requirement for information
relating to nanoscale materials.10 In the absence of eVective voluntary schemes, I would expect more
governments to follow the lead of France and Canada in creating mandatory reporting requirements.
Q: Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
14. We cannot establish with any degree of certainty that current regulations will be able adequately to control
the next generation of nanotechnologies and nanomaterials. The nanosciences is a ﬁeld of rapid innovation,
and current indications suggest that the convergence of nanotechnology with biotechnology, information
technology and the cognitive sciences will create new challenges and risks that will require more fundamental
changes to existing regulatory frameworks. The project on “Regulating Nanotechnologies in the EU and US:
Towards EVectiveness and Convergence”, together with the Project on Emerging Nanotechnologies,
commissioned two new reports on next generation nanotechnology and synthetic biology that shed further
light on the regulatory challenges that industrialised countries are likely to face in coming years.11
Q: Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
15. The main forum for international cooperation on nanotechnologies regulations and standards is the
Organization for Economic Cooperation and Development (OECD). Two OECD working groups have been
established with an explicit focus on nanotechnologies: the Working Party on Manufactured Nanomaterials






11 Michael Rodemeyer, “New Life, Old Bottles: Regulating First-Generation Products of Synthetic Biology”, Project on Emerging
Nanotechnologies,WoodrowWilson International Center for Scholars,March 2009, forthcoming; and J. ClarenceDavies, “Oversight
of Next Generation Nanotechnology”, Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars,
2009, forthcoming.
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the European Commission, ﬁve non-OECD countries and a small number of observers from international
organizations, industry and civil society. It focuses almost exclusively on co-operation in safety assessments
and on testing a representative set of nanomaterials.12 The OECD’s second group is the Working Party on
Nanotechnology (WPN), which was set up in 2007 in the OECD’s Directorate for Science, Technology, and
Industry. Its remit is focused more broadly on emerging policy-relevant issues in science, technology and
innovation, including nanotechnology research and development, outreach and public dialogue.13
16. TheOECDworking groups are widely seen to be themost important forum for international coordination
in the ﬁeld of nanotechnologies regulation. They are likely to produce greater convergence in the development
of the basic building blocks for nanotechnology risk assessment. What is less clear, however, is whether the
OECD can serve as the basis for developing a broader international framework for coordinated and
convergent riskmanagement practices. Some observers have expressed concerns about the OECD’s suitability
in this context, particularly with regard to its limited membership basis as an industrialised countries
organization, its perceived lack of transparency and the limited nature of stakeholder involvement particularly
by civil society groups.
17. The other main forum for developing internationally harmonised standards is the International
Organization for Standardisation (ISO). Its technical committee on nanotechnologies (TC 229) promotes the
standardisation of terminology, deﬁnitions, toxicity testing and environmental studies protocols,
measurement techniques, calibration procedures, and reference materials. Much of this work will feed directly
into regulatory developments at national and international level, as ISO standards are likely to be adopted in
deﬁnitions of nanoscale materials and their properties.
18. Other international organizations have also begun to address policy issues arising from the rapid
development and commercialisation of nanotechnologies, but none has so far provided a forum for inter-
governmental cooperation on regulation and standards. The WHO’s Intergovernmental Forum on Chemical
Safety (IFCS)14 has issued the “Dakar Statement on Manufactured Nanomaterials”, which notes the “lack
of an inclusive global policy framework” and recommends increased eVorts to ﬁll gaps in scientiﬁc
understanding, promote information sharing, international cooperation on the development of national codes
of conduct, among others.15 The United Nations Environmental Programme (UNEP) has called for “swift
action” by policy makers to properly evaluate the new science of nanotechnology. UNEP’s 2007 Geo
Yearbook identiﬁes nanotechnology and the environment as a key emerging challenge for international
policy-making but stops short of outlining an alternative vision for international nanotechnologies
regulation.16
13 March 2009
12 http://www.oecd.org/department/0,3355,en 2649 37015404 1 1 1 1 1,00.html.
13 www.oecd.org/sti/nano
14 http://www.who.int/ifcs/documents/forums/forum6/meet docs/en/
15 http://www.who.int/ifcs/documents/forums/forum6/f6 execsumm en.doc.
16 http://www.unep.org/geo/yearbook/yb2007/PDF/7 Emerging Challenges72dpi.pdf.
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Examination of Witnesses
Witnesses: Professor Derek Burke and Dr Robert Falkner, London School of Economics, examined.
Q315 Chairman: I would like to start by welcoming
our two witnesses, Professor Derek Burke and Dr
Robert Falkner, to this the sixth public session of our
inquiry into nanotechnologies and food. I should
inform our witnesses that the proceedings are being
webcast as usual. For the large number of people in
the audience behind, I would like to draw your
attention to the information note which is available
setting out the declared interests of the Members of
the Committee, and so we will not be declaring our
interests whilst are asking questions. Perhaps I could
start by inviting the witnesses just to introduce
themselves for the record, Professor Burke ﬁrst and
then Dr Falkner. Equally, if you wish to make any
brief opening statements, please feel free to do so.
Professor Burke: I am Derek Burke. I am initially an
organic chemist by ﬁrst degree and PhD. I then had
an academic career: a couple of years at Yale; nine
years in Aberdeen; then I started biological sciences
at Warwick. I then spent four years in a
biotechnology company in North America as
Scientiﬁc Director. I was Vice-Chancellor at the
University of East Anglia. I retired in 1995 and I have
kept myself busy ever since. I was persuaded to chair
the new committee on novel foods and processes in
1989, which was almost a new committee, and I was
Chairman for nine years. That is really my
background for this particular discussion, since we
had to, for example, decide what a novel food was
and so there were lots of questions about deﬁnition
and scope which are not diVerent, in kind anyway,
from what is being faced here. I have been on the
EPSRC Societal Issues Panel, where nanotechnology
is discussed, and I am still on the BBSRC Bioscience
for Society Panel.
Q316 Chairman: Thank you.
Dr Falkner: Thank you, ﬁrst of all, for inviting me to
this Committee. I am Senior Lecturer in
International Relations at the London School of
Economics, so I should point out that I am a political
scientist not a natural scientist, and I am not a lawyer
either. I do, however, work on questions of
international risk regulation and have been
researching and writing about the international GM
food controversy for the last ten years. I followed the
international negotiations on the Cartagena
Protocol, which is a model international treaty on
international risk in the food and novel technology
area, and for the last two years I have been leading an
international research project involving the London
School of Economics and Chatham House here in
London, and, on the US side, the Woodrow Wilson
Center and the Environmental Law Institute. That
research project is looking into the comparative
dimensions of nanotech regulation in the US and the
EU. We will be producing a major report in
September and we will be holding an international
conference here in London on 10 and 11 September.
Imention this nowbecause I am thereby extending an
invitation to you all to that conference—which I will
do in writing, of course, when we get closer to the
date. That report will produce an overview analysis
of how the EU and the US are dealing with emerging
nanotechnology risks in chemicals, cosmetics and
food, and so my main focus has been and is on the
international and comparative dimensions of
nanotechnology.
Q317 Chairman: Thank you both very much. I
would like to start the questioning with a really very
general question about the adequacy of the current
regulatory framework with the use of
nanotechnologies and nanomaterials in food and
food packaging. I think both of you in your evidence
you have submitted have raised questions about the
adequacy of the framework and, indeed, of the risk
assessment that might populate that framework. I
know that Professor Burke said in his written
evidence that the Food Standard Agency in its review
was somewhat complacent. I wonder whether you
could comment on your concerns about the current
regime, both in relation to products and in relation to
packaging and where you think we should go from
here.
Professor Burke: I started from scratch and tried to
ﬁnd out from the web what the current regimes were
and had some diYculty. What I found most
straightforward was on the Food Standards Agency
web page. They say there that the Food Standards
Agency “will not assess the safety of using
nanotechnology in the food chain unless it is asked to
do so.” That struck me as a rather defensive position.
“If a company wants authorisation to market food
products using nanotechnology, then the Agency is
obliged to assess the food safety implications.” It is
the voluntary end of a voluntary process at the
moment, and I am unclear whether any submissions
have been made. I simply do not think that is
adequate. I am not in favour of heavy legalese, by all
means, but I am in favour of getting started on a case-
by-case basis, looking at issues coming through of
nanotechnology additions or processing of foods
because we really do not have any case law to go on.
The situation is a bit similar to the way novel foods
started in 1989, where we did not know what a novel
food was. We had to deﬁne a novel food and we
ﬁnally decided that a novel food was that food which
was novel to the UK population. It included all the
foods that came in from the waves of immigrants
coming in to London in the late 1980s and early 1990s
which were freely purchased on market stalls, for
example, as well as all the fancy foods that were being
sold that would reduce your blood cholesterol, and,
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of course, it included genetic modiﬁcation which
became ultimately the sort of motif of the
Committee. I am really quite concerned that
although we have known about this issue for a long
time, seven eight years, so little has been achieved. I
went back and looked at the web and I found a paper
in 1982 from Chemical & Engineering News which
could have been written last week. Nothing very
much seems to have been done since then.
Dr Falkner: Perhaps I could add to that a dimension
that touches more on the European Union side of the
equation, which is, of course, what I am concerned
with inmywork. I would distinguish two aspects: one
is regulatory coverage and the question of whether
emerging nanomaterials in food are covered by
existing laws, and the second question would be
whether the existing regulatory coverage then
provides for an eVective treatment of the risks
associated with nanomaterials. On the ﬁrst question
I would say that we do have a range of laws and
regulations in place from the Novel Foods Directive,
as we mentioned, to food additives, food
supplements, food labelling, food contact materials
regulations and directives, et cetera, so we have a
broad range of instruments available to us that we
can use to cover emerging risks from nanomaterials.
I think, on that front, fromwhat we know—and there
is a great deal of uncertainty about that, of course—
it is fair to say that we can work with that framework
and we should work with that framework. I think
there is not an immediate need to start from scratch.
There are some questions about regulatory coverage
in certain grey areas, and we can come back to that
perhaps later, but I want to focus on the second
question, whether the existing regulatory framework
has been providing eVective regulation, and I think
there are much greater concerns in that area. This is
to do with the uncertainty regarding deﬁnitions and
characterisation of nanomaterials. If you have no
means to distinguish clearly between a nanomaterial
and a non-nanomaterial and if you are therefore
uncertain whether existing laws apply, that restricts
the application of the framework that you have
identiﬁed. The European Commission, in its own
review of regulations whichwas published last year in
May, has admitted that, while they think regulatory
coverage is provided, the application of existing laws
is questionable. A ﬁrst point would therefore be to
look at the very question of deﬁnitions. This then
continues into the question of testing methods, the
ability to detect nanomaterials in food and to
establish potential impacts on human health. Again,
this is a question of how to implement existing
regulations and whether those regulations pick up
certain risks, and this then continues into other areas,
such as the very knowledge of what is in the market-
place and whether companies themselves that have a
duty to carry out risk assessment are able to pick this
up. I think that is where a number of grave
questions exist.
Q318 Chairman: I am sure we will come back and
elaborate on some of those points very shortly. I
wonder whether you think, in addition to the
regulations you havementioned,REACHmight play
a role in the regulation of nanomaterials. Is that an
important contribution to the regulatory regime in
your view?
Dr Falkner: I think so very much. REACH is
probably the most important regulatory instrument
to catch the wide range of nanomaterials. In a sense
most nanomaterials enter the regulatory framework
at the level where they are produced by chemical
companies for use by other industries and that is
where REACH kicks in. I think any consideration of
the food cycle would need to look at the chemical side
as well. The EU itself is making that point very
clearly. However, there are concerns about whether
REACH is ﬁt for purpose itself.
Professor Burke: The very point of nanotechnology is
that substances change their properties at the nano
level, because otherwise it would not be a new
technology and there would be no point in using
them. The extrapolation of toxicology, for example,
from the macro history of toxicology, where we know
a great deal through nanomaterials, is an
extrapolation that seems to me to be not on secure
ground. The FSA review says quite openly that the
precedents they have from testing chemicals at the
macro level, which is what REACH will do, is not
adequate to deal with chemicals when they are in the
nano form.
Q319 Chairman: Do you think these uncertainties
are suYciently important in your view to justify what
some of the pressure groups have been calling for;
namely amoratorium on the use of nanotechnologies
in food until further research is done and a more
robust regulatory framework has been established?
Professor Burke: I am not in favour of moratoria
because they tend to be situations where nobody does
anything . I am hoping we can be more positive than
that. What I do think is needed is the direction of a
procedure which oVers European governments a
defence position against accusations of the ones you
have just been making. The whole point of a
regulatory procedure is that it looks at nanomaterials
in food, so it is not only the chemistry that is going
to be important or the switches in physical properties,
but the presence of other components: oils,
emulsions. It is also going to be moving to the route
through the body, the excretion and so on. There are
a lot of things we can do which do not seem to have
been started. In the burgeoning ﬁeld of synthetic
biology there was a meeting at which I was present
where we looked at the extent to which the current
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regulations picked up the issues. It was a
brainstorming group, put together by Defra I think.
That was extremely useful. Nobody seems to have
looked at nanotechnology with a variety of
backgrounds and skills there, asking the question you
just asked us and then asking what should be done
about it.
Dr Falkner:On the question of amoratorium, I think
it is a diYcult instrument because it is a broad-brush
instrument and so it covers a wide range of
nanomaterials that perhaps do not deserve to be
covered under amoratorium.A selectivemoratorium
may be required when there are no risk assessment
methods available to test the long-term impacts on
health. I would just like to bring to your attention one
provision in the EuropeanUnion’s Code of Conduct,
a voluntary code of conduct that has been issued to
all governments with a view to implementing it for
researchers and everybody engaged in this. In 4.1.17,
that Code of Conduct states: “As long as risk
assessment studies on long-term safety is not
available, research involving deliberate intrusion of
nano-objects into the human body, their inclusion in
food (especially in food for babies), feed, toys,
cosmetics and other products that may lead to
exposure to humans and the environment, should be
avoided.” That clearly states the precautionary
approach to the use of nanomaterials in food and
other consumer products where there is no risk
assessment method available. I think that speaks
volumes.
Chairman: We will make sure we have a copy of that.
There are three Members who would like to ask
follow-up questions. I will try to keep the questions
and the responses brief, so that we can move on to
others.
Q320 Lord Crickhowell: Some of us were on this
Committee when we looked at REACH when it was
being introduced. Of course nanotechnology really
was not on the table at that time and so it was not
considered when REACH was prepared. The
Government comments on REACH that this is the
way to proceed, but functionality rather than size,
and, of course, there is a quite large, one-tonne
threshold for import and so on before REACH
comes into eVect. It is what you do with the chemicals
in the manufacturing process afterwards that may be
the more signiﬁcant element. Clearly REACH is
going to have to be revised very considerably and
reviewed. Is the European community approaching
in an urgent enough way the revision of REACH so
that it really does apply to nanotechnology?
Dr Falkner: I understand, having talked to
Commission oYcials about this issue, that the
Commission is well aware of the potential gaps to do
with the one-tonne threshold above which the
registration requirement kicks in.Most people within
DG Environment (the responsible DG within the
Commission) believe this can be addressed through
implementation guidelines. However, they are also
open to the idea that this will need to be renegotiated
through legal change. The problem there seems to be
that all the energies in Europe are vested in getting
REACH oV the ground and implementing it and the
task there is tremendous. There does not seem to be
much political energy in reopening REACH at this
stage to deal with the small problem, namely
nanotechnology and its coverage. I suspect that if we
want urgent treatment of that problem, the question
aboutREACH’s ability to pick up nanomaterials, we
should look at the implementation guidelines and get
some more sense of urgency into the Commission on
that front. But I would not rule out the need for
regulatory reform.
Q321 Earl of Selborne: If we want to proceed with
the urgent review of REACH, recognising how long
REACH took to put in place in the ﬁrst place, I know
the Royal Commission did indeed urge for the
Government to proceed with the European
Commission to urgently review REACH to facilitate
the eVective application to nanomaterials. Are we
being realistic? It took ten years to get REACH going
in the ﬁrst place.
Dr Falkner: I think there is a greater chance to
achieve any reforms in the nanotechnology area,
partly because all the concerned parties seem to be in
agreement that REACH needs to work on
nanotechnology. Nobody is keen within the chemical
sector to start discussion of a separate
nanotechnology instrument. Most parties, including
industry, including the European Union oYcials, are
keen to make REACH work. I think you have the
potential there for a broad consensus on targeted
reform. I agree with you entirely that it is going to
take a long time and the European processes are
systematic and comprehensive. I would suggest that
this will not be a quick solution, but I think there is
political momentum growing. The European
Parliament is very keen to close the loophole. In fact,
in all the current reforms going on in the cosmetics
and food areas, it is the European Parliament that is
putting in provisions, on deﬁnition on
nanotechnology, on labelling provisions, and I think
it is possible to move on that front. I think your
Committee could very well make strong
recommendations in that area.
Q322 Lord Cunningham: Dr Falkner referred to a
selective moratorium. How could that be
implemented and made practical in eVect?
Dr Falkner: I suspect I am the wrong person to
answer that question. Having proposed it, though, I
feel in a bind to say something about it. I would love
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to ask Professor Burke to comment on his own
experience.
Professor Burke: If you are going to segment a ﬁeld, I
think I would segment out pregnant mothers and
very young children ﬁrst of all. I am not a
toxicologist, and Professor Holgate is, but my
knowledge is that they are particularly sensitive and
diYcult to predict.We are back in the situation where
we have no evidence. Politically, it seems to me so sad
that neither the UK nor any other advanced nation
has tried to seize the high ground and move this
debate on, because we are going to lose the ground.
Q323 Lord Methuen: We have heard about the
problems of deﬁning nanotechnologies and
nanomaterials. We started oV with a nominal 100
nanomaterials, which is just a magic number. It could
be 250 or anything really. What role do you think the
Government should play in this debate of deﬁning
nanotechnology? Do you think any deﬁnition has to
be adopted both internationally and by the EU to be
eVective?
Dr Falkner: I think the Government should play an
active role. It does already play a role. It is diYcult for
me to establish just how active the UK Government
is in that area because much of that debate is led by
representatives of the European Union at the level of
the OECD and then by experts from industry and
regulatory institutions at the International
StandardisationOrganisation. There are a number of
processes under way. Some of these processes, such as
the ISO process, are led by private actors. My
concern there would be that governments need to
ensure that they get the deﬁnitions that serve
regulatory purposes and not only purposes of
relevant industry communities. I think that is where
the Government needs to step in to make sure that
deﬁnitions work for all parties concerned and
particularly for regulatory purposes. It seems to me
this process is underway and has been underway for
some years and there could be a greater sense of
urgency about this process. Again, that could be an
area where the Government can step in and invest
more energies. We have had the ﬁrst set of deﬁnitions
come out of the ISO technical committee recently and
theOECD itself is looking into deﬁnitions as well. All
parties that we have spoken to in our project have
voiced concern that this process is not going fast
enough, because industry depends on deﬁnitions in
order to establish where safety assessment is needed
and regulation is needed to apply existing laws.
Professor Burke: I am in favour of a pragmatic
approach. It is what happened with novel foods. All
sorts of things came upwhichwe had not anticipated.
I remember a yoghourt was fermented with micro-
organisms isolated from a Caucasian gentleman 110
years old—which might be of interest to Your
Lordships’ House. We had some really curious
applications. Sometimes we could say nothing and
sometimes it was clear that we hadmissed something.
I am not in favour of lawyers trying to decide what is
a nanomaterial. I am in favour of looking at what is
coming up the line and seeing if we can deal with it,
and if we cannot, then thinking of a way of dealing
with it. I am a principled pragmatist, really.
Q324 Lord Methuen: The BRASS Centre, whose
representatives cannot be here today, have raised
concerns about the use of a technology-based
approach to novel foods rather than a product-based
approach in the European Commission’s proposals
for the new Novel Foods Regulation. Could you
please explain your concerns? How you would view
that?
Professor Burke: I do not think I am well-equipped to
deal with that question. It was on a product basis?
Q325 Lord Methuen:Yes, whether you should deﬁne
novel foods on a product-based or technology-based
approach.
Professor Burke: I can see arguments both ways on
that. I do not think I am competent to say. Novel is
by deﬁnition product based, because it is something
that you have not eaten before. On the other hand,
articles produced by genetic modiﬁcation tend to be
treated as a group. I think that is a distinctionwithout
meaning personally.
Dr Falkner: The Novel Foods Regulation as it exists
has a process-based trigger mechanism in article
1(2)(f). It says very clearly that “food and food
ingredients to which has been applied a production
process not currently used” require regulatory action,
so that is already settled. I am not sure what the
background to that concern is but, if anything, I
would imagine it is to continue into a revised health
foods regulation that then applies to nanomaterials.
Indeed, in the draft that currently exists in the
revision process, nanotechnology would then be
mentioned as an example for a technology that would
trigger regulatory action.
Q326 Chairman: What BRASS says in their written
evidence is, “Some caution, however, should be
expressed in respect of its technology-based approach
to regulation”—this is the Commission’s approach—
“rather than a product-based approach in which the
novelty of nanotechnology is determined on a case-
by-case basis according to their individual properties,
functions and hazards remains preferable.” That is
where BRASS is coming from. I wonder whether you
agree with that.
Dr Falkner: I am not sure whether I can see the
diVerence between that approach that is advocated
here and the current technology-based approach,
because as I understand it nanomaterials are
categorically novel because they exhibit new
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characteristics and behave diVerently. That is the
whole point of creating nanomaterials. Even a
product-based approach would probably yield very
broad coverage of all nanomaterials. If they behaved
similarly to bulk materials, there would be no need to
look at them.
Professor Burke: I think it is much easier for a
regulatory committee to look at a particular product
and say what are its properties: Is it going to be taken
in by the mouth? What is going to happen in the gut?
How long does it stay in the body? Otherwise, if you
go back to the technology-based approach, you ﬁnish
up with the “all genetic modiﬁcation is wicked” sort
of approach, which helps a lot of groups but it does
not help the politicians or governments and it does
not help the regulators.
Q327 Lord Mitchell: Professor Burke, I have one
point of clariﬁcation. I think you said with respect to
regulation that you feel this should not be deﬁned by
lawyers. I am just asking how that occurs?
Professor Burke: I am not against lawyers—far be it.
Q328 Lord May of Oxford: Why not?
Professor Burke:We learned in novel foods by looking
at cases, and then we had to generalise. I suppose my
position is that we ﬁrst of all look at the problems that
the ﬁeld is throwing up to us, and then we try to
generalise. If you legislate, you almost inevitably
have to try to deﬁne, and you then get a very poor
deﬁnition which includes many things that are not
necessary. The approach that is going on in synthetic
biology is to say: “Are there any instances coming up
the line which our current regulations will not look
after?” That seems to me a more open and robust
way.
Q329 Lord Haskel: Professor Burke, you have just
said that regulation should be based on looking at
each product on its own merits. But the European
Parliament has proposed that when the Novel Foods
Regulation is revised, it should apply explicitly to all
nanomaterials. Presumably they are saying that
regulation should cover nanomaterials as a whole
and that we should not diVerentiate between food
and other uses such as cosmetics. Would you agree
with that? Do you think that is an approach that the
Government should support?
Professor Burke: I am not personally in favour of that
because I can see situations in which the toxicological
implications would be diVerent. I think that is too
broad a brush. But I am sure that Dr Falkner has a
position on that.
Dr Falkner: As I understand it there are two
movements going on in Europe, one to reform the
Novel Foods Regulation and one to turn the
Cosmetics Directive into a regulation. In both these
regulatory re-drafts, the European Parliament has
inserted provisions of the kind that you have
described, references to nanotechnology. As I
understand it, they would merely clarify an existing
assumption among European regulators that this is
already the case. European regulators argue that all
nanomaterials in foods fall under the Novel Foods
Regulation, although there is no separate explicit
reference to it, so the European Parliament would
like this to be clariﬁed and strengthened. I think the
diVerence is one between legal text and regulatory
practices and the two are very close. I do not think
this will produce a dramatic change. However, it
would, politically speaking, change the terms of the
debate, as you have just suggested, Professor Burke,
that we would begin to think much more in terms of
regulating technology rather than materials. One
could look at the precise wording here. If it were a
case of regulating nanomaterials rather than
technologies, if it was a case of novel products in
foods rather than across diVerent uses, then I think
that would be a preferable solution.
Q330 Lord Haskel: If we try to regulate the
technology rather than the use, do you think this
would lead to things being condemned as a whole, as
happened in other novel materials?
Dr Falkner: I think that is what the GM debate has
taught us. However, I note with interest that it is
scientists who themselves have created a buzz around
the word “nanotechnology” and who have perhaps
falsely argued for many years that every bit of
research that goes on at the molecular level is now
part of a big nanotechnology eVort. In fact, I
understand some would like to move away from that
because what works well in terms of getting research
funding does not work well when you then sell the
outcome of that research to the consumer. We may
well end up with a more nuanced debate as we move
away from technology.
Professor Burke: But there are situations where you
have to protect laboratory workers: the radioisotope
regulations; the regulations over genetically modiﬁed
organisms that I worked with back in the 1980s,
wherewe had extreme regulatory controls of category
3 organisms, for example. Those were necessary in
the nascent ﬁeld to protect the operatives. That is
appropriate to apply to a whole technology. Then
you break down the instances case by case, as was
ultimately done, and so on. But that is not quite what
we are talking about.We are talking about protection
of the consumers of the European Union by its
national governments.
Q331 Lord O’Neill of Clackmannan: We have been
talking about prospective regulation but we have
been told that there is in fact a general food safety law
which prohibits, across the EU, the placing of unsafe
foods or products on the market. Do we need to
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reinvent the wheel? How eVective is this existing
provision?
Dr Falkner: I think it provides a sort of ﬁrst coverage
of emerging nanomaterials. It puts the burden on
industry to carry out safety risk assessment.
Therefore, it is an important element, but on its own
I do not think it would suYce. One of the reasons for
that is that industry itself is uncertain about what new
materials it needs to test and with what
methodologies with regard to what kind of risks. The
uncertainty that exists with regard to deﬁnitions,
methodologies, exposure and hazard types is
preventing that general safety provision from
working properly. I think that is why you need a
second regulatory layer on top of it to make sure
there are clear guidelines.
Professor Burke: I can remember examples where
what you suggest was necessary. It is often
retrospective. The food inspectors found that there
was selenium being sold as an additive to pills
available in drugstores and selenium is toxic. But this
was picked up by the scrutiny process that works
under the Food Act. It is retrospective; it is not really
protecting the population ab initio. I do not think it is
adequate politically on its own.
Q332 Lord Crickhowell: The FSA is apparently
considering a register of nano-derived foods and food
contactmaterials.Would you support such a register?
Do you think it should be voluntary or mandatory?
Professor Burke: I am certainly in favour of a register.
We have to start. “We have hardly started” is the
message that we are conveying. A register would be
useful. I think you probably have to make it
voluntary to start with, because I do not know what
this net is going to draw in. It would at least give the
nascent regulatory committee something to work
with, some real meat to start putting through the
regulatory machine. Ultimately, voluntary
procedures are not very satisfactory politically
because in Europe especially governments are
expected to look after their citizens and prevent
harm. My understanding is that in the US you can
sue the manufacturer. Corning was driven out of
business by suits over the silicone breast implants, for
example. But that procedure is much less easy to use
in this country, and in the face of blood contaminated
with CJD it was government ultimately who picked
up the bill.
Dr Falkner: I think a register is needed for two
reasons: one, it is in the nature of a globalised food
chain that a lot of new food ingredients, food
materials, are being traded that we as a society but
also the regulators do not know about. For that
reason we need to move in the direction of greater
transparency in global food chains. The question is
then, of course: Is a register, whether voluntary or
mandatory, the best tool for that? I thinkwe have had
some experiments with voluntary measures. Defra
has run a two-year pilot programme. The evidence, as
reported byDefra after the ﬁrst two years, shows that
only a third of the companies known to operate in the
UK and producing nanomaterials reported to Defra,
so two-thirds did not feel the need to follow voluntary
reporting requirements. In the United States, the
Environmental Protection Agency is running its own
two-year voluntary pilot project. While arguing in
the opening section that it was a great success,
towards the end of the report EPAnoted that only ten
per cent of all nanomaterials known in the US have
been reported under this scheme. For that reason, I
think both agencies are now considering very
carefully whether to move from a voluntary to a
mandatory system. In fact the Canadian
Government and the French Government have
already issued statements to the eVect that they are
now planning to introduce mandatory requirements
for companies to report nanomaterials. Whether this
will have a broader impact in Europe is hard to see
but the European Commission is likewise looking
into a mandatory system.
Q333 Chairman: Is one Member State allowed to
introduce a mandatory system without reference to
the European Commission?
Dr Falkner: I do not know the European law on that
speciﬁc matter, and it would depend under which
legal category it would fall, whether it is only about
food or whether it is about all materials, perhaps
under the chemicals regulation more generally. I
would have to look that up. This is only an intention,
as yet.We have not had any development in that area.
Chairman: Perhaps we could follow up whether that
is a European competence or a national competence.
Q334 Lord Methuen:Whatworriesme, coming back
to the food chain, is how far do you go, including
fertilisers, pesticides, animal feed stocks?
Dr Falkner: It is a diYcult question. As long as those
new novel materials end up in the human body,
whether it is through pesticide use or feed or, indeed,
the use in food products, I think there is a good
reason to require all such uses to be included. I think
what we are talking about at this stage is only a
register of materials in use. There is a more
demanding register that one could imagine, which is
to cover also environmental health and safety
dimensions, which is a much more diYcult one.
Professor Burke: But there is a network of committees
which have been working for many years alongside
the Novel Foods Committee. There is a committee—
which of course the Chairman was a member of, I
believe—on the release of genetic modiﬁcations into
the environment, which supervised all plant trials;
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there is a committee on toxicology; there are
committees that are concerned with the safety of
newborn children. The ministries and departments
run a network of committees with cross-
representation and often the transfer ofmaterial from
one committee to another. I found that worked very
well and the civil servants are very expert at guiding
it through the system, so I think that problem is
solvable.
Q335 Lord Cunningham of Felling: Can we learn any
lessons from our past regulatory experience on novel
foods and processes which would apply to
nanotechnology?
Professor Burke: There are some things which we did
which survived and some things which did not work.
The Novel Foods Committee had a consumer
representative on it very early who eVectively had a
veto. It had an ethical adviser who could say whether,
in his or her view, this raised ethical issues which
needed wider discussion. My successors as chairmen
have operated the Committee in public. Agendas are
now published beforehand, of course. All those have
come to stay under the general principle of
transparency. We were very ﬁerce about conﬂict of
interest in my time, and that has continued. A
number of potential problems were dealt with. What
we did not anticipate was a food that went into a very
large number of products—and I am thinking of
soya—produced by an American multinational, with
claims which needed investigation that it was toxic to
rats, coupled with a great sensitivity of the public to
food risks because of BSE and other problems, and
we got blown away. The Committee did do some
gazing, some horizon scanning in my time, and
since then—
Q336 Lord Cunningham of Felling: Excuse me
interrupting, but do you think we should do that in
respect of nanotechnology?
Professor Burke: Yes. I think scientists work very well
that way. You get a group of about this size in a room
and we ask ourselves, “What could go wrong?” Well,
we thought of lots of things that could go wrong but
not the one that did go wrong, but that is sometimes
the nature of the game. We had a whole research
programme looking at what happened to genes from
genetically modiﬁed plants in—
Q337 Lord Cunningham of Felling:Forgive me, but I
just want to get at who should organise the horizon
scanning?
Professor Burke: That can be done by the government
departments through their committees. I think all of
us who have been working scientists have
experienced horizon scanning, and in fact we do it
every time we write the research grant.We look at the
future and thinkwhat needs to be done. That is a style
which I think scientists take very readily to.
Particularly with the input from social sciences and
people like Robert here, those can be very productive
conversations. I do not think they have taken place.
Q338 Lord May of Oxford:You said in passing there
that you were very ﬁerce about conﬂicts of interest. I
wonder what you meant by that. Protocols for
science advice and policymaking, that the UK
Government has and has had from 1997, very clearly
state that conﬂicts of interest should be clearly
identiﬁed but should not be used as a reason for
excluding anybody. There are interesting examples
where, in seeking to avoid conﬂict of interest, you
exclude from the Committee anybody who knows
anything about what is going on. No representative
of the pharmaceutical industry may be on a
Department of Health committee, which is clearly
ludicrous. What did you mean by saying you were
ﬁerce about conﬂicts of interest?
Professor Burke: I can just say what our practice was.
We had people from commercial backgrounds on the
ACNFP in my time. We had one person I can think
of speciﬁcally who was an expert on large scale
fermentation whose input was unique and necessary.
The regulations were read out at the beginning of
each meeting, people were asked if they had any
possible conﬂict of interest, they were then asked to
explain what that possible conﬂict might be, and the
committee made a decision whether the person could
stay or not. It was a committee decision as to whether
they thought there was a conﬂict. There was a
consumer person there. I do not think we had a
problem, but meeting in public is of course a much
better way of dealing with this issue.
Q339 Lord May of Oxford: Clearly conﬂicts of
interest should be very transparent and exposed, but I
ﬁnd curious the idea that youmay exclude somebody,
because there are always vagaries in the deﬁnition of
conﬂict of interest. A commercial interest is a clear
conﬂict of interest, butmany of theNGOs or even the
academic interests of social scientists are in some
sense interests and they should be clearly identiﬁed
and welcomed.
Professor Burke: The playing ﬁeld is not quite level.
People from companies bring skills which are
essential for the regulatory process which are not
found in the academic world.
Q340 Lord Cunningham of Felling: I want to go
back, if I may, speciﬁcally on this point of conﬂicts of
interest and people with knowledge and
understanding of what is at stake. Do not people who
have widespread knowledge and experience, maybe
commercial, industrial, scientiﬁc or whatever, have
something to say about how these new nano products
would develop and how regulations for example are
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going to have to run very, very quickly to keep
abreast of them?
Professor Burke: I am ignorant. Do you know if there
has been any discussion in the scientiﬁc community?
Dr Falkner: I think there is a lot of discussion going
on in diVerent stakeholder groups. I do not think
there is an overall consensus on what needs to be
done. If you look, for example, at the various
industry interests, food producers are very diVerent
from food retailers. The food producers are very keen
to keep labelling requirements, any identiﬁcation of
content, at bay; food retailers are muchmore open to
such discussions. They have burnt their ﬁngers over
the GM issues. They put the labels on before legal
requirements for labelling came into force and they
feel this is the only way for them to remain neutral in
the debate and to retain their reputation for food
safety. In my research I have found that retailers tend
to be much more open to a stricter, more intrusive
and more comprehensive regulatory regime, because,
ultimately, it beefs up their claims of food safety. The
manufacturers, at least in Europe, where there are not
many nanomaterials in use, seem to be sitting on the
fence a little bit, watching the debate and trying to see
which way it goes. They can see clear potential. They
would like the science to continue to ﬁnd new
applications, but at the same time they know that if
they have a huge brand value, if you take Unilever,
for example, one of the big food manufactures, they
could be easily tarnished with just one nanotech
product that goeswrong. They aremuchmore careful
about those intrusive regulations. With regard to
scientists I am not too knowledgeable about those
things, but there is a lot of debate going on about
what needs to be done to shore up public conﬁdence.
Professor Burke: Scientists do not talk a lot about
regulation. It is something that you have to do but it
does not get you an FRS and it does not win any
grants, so it is a duty as a citizen rather than an
academic pursuit.
Dr Falkner:Could I respond to an earlier point about
the lessons of the GM controversy and add a social
science perspective to this?
Q341 Chairman: Yes.
Dr Falkner: I would make three points. I know it
sounds very academic, but let me do this nevertheless.
I think it will not do in the political area to insist that,
on a scientiﬁc risk-assessment basis, nanomaterials
are safe to eat. Even if we could reach that point—
and there are great questionmarks about this—it will
not do because food is part of a cultural system.
People perceive food not just as a safety issue but as
part of a broader system of engaging with nature.
Q342 Lord Cunningham of Felling: You are talking
about manufactured nanomaterials.
Dr Falkner: Manufactured nanomaterials. I think we
need to look at the ethical cultural dimensions. A
narrow focus on scientiﬁc risk assessment will not do.
Second, consumers demand transparency. Producers
themselves have learned the hard way in the GM
debate that if you even give the appearance of not
wanting to be transparent (that is, not disclose food
content) then you are suspected of devious practices.
Q343 Chairman: What you said about the voluntary
reporting was that in the UK less than one-third of
companies using nanotechnology report voluntarily
and in the United States around ten per cent. That
would imply that they have not necessarily learned
the lessons about transparency.
Dr Falkner: But there are competitive issues at work.
In a voluntary scheme you are at a disadvantage if
you are transparent but your competitors are not
required to be in the same way. That is why I would
argue for a mandatory regime to level the playing
ﬁeld and to let the industry, in a sense, come out and
declare what is in the food. The third point I want to
bring in is the international dimension. We approach
many of these issues from a national or European
perspective, but any regulatory system thatwe end up
with for nanotech food will have an impact on the
global food trade. As we have seen in the GM trade
debate, it caused huge furore in our transatlantic
relationship: it led to a very contentious negotiation
over the international biosafety treaty which the
United States has so far refused to ratify. I think we
also need to look at the international context in
which any of these rules are set, therefore. We should
seek internationalisation at an early stage.
Q344 Baroness O’Neill of Bengarve: You have led us
to the very topic that is the last in this session,
whether you think it is important to develop
international co-operation on standards and
regulation with the nanotechnologies and
nanomaterials in the food sector. How can it be done?
Dr Falkner: We are going to produce a 140-page
report on that very question, but it will not be until
September.
Q345 Chairman: That is a Readers Digest—
Dr Falkner: It is what I tell my students: keep it short,
brief, succinct. I would say that international
regulation and harmonisation is very important. We
have a couple of processes going on. The OECD is at
the moment the main forum for regulatory
interaction between the US and the EU. They are
looking mainly at what I would call the scientiﬁc
building blocks: the methodologies for assessing risk.
They are running a couple of pilot projects to focus
on the existing uses of nanomaterials; they are also
now looking into co-ordinating research eVorts; and
they have just set up a new register of international
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research projects that look at environmental health
and safety research. The ﬁrst steps have been made
but I would say that they are very slow and they are
not entirely transparent. The OECD does not have a
great reputation for fast, dramatic and transparent
action. It is a bit of a gentlemen’s club for
intergovernmental co-operation. It works well, in the
sense that it creates space for regulators to talk to
each other and to learn from each other, but it
certainly will not be themain platform for developing
internationally harmonised regulations. Whether we
need an international treaty on this, I do not know. I
have my doubts about that. We are not at the stage
where this could be done in any meaningful way.
There may well need to be such a treaty. If existing
national regulations in the US and in Europe—but
also think of the emerging economies (Brazil,
China)—go in diVerent directions, there will be a
need for harmonisation. We are not at that point yet.
I think much more needs to be done to, in a sense,
prevent regulatory divergence. We are at a historical
moment where we can do this without the heated
political debate getting in the way. I think regulators
on both sides of the Atlantic have that political space
there to co-ordinate, but of course without the
political pressure they do not feel the need to
harmonise their own approaches. They very much
focus on the national needs and that is what is
missing at the moment, that sense of urgency.
Q346 Baroness O’Neill of Bengarve: Do you have
speciﬁc concerns about the regulation of imported
food products containing nanotechnologies and
nanomaterials into the EU and into the UK?
Dr Falkner: In principle, all imported food products
should be covered in the same way as domestically
produced, so there is no legal distinction, as I
understand, between those categories. The question
for me seems to be one of detection and for that
reason I would say international co-ordination of
voluntary or mandatory reporting requirements is
needed to harmonise those reporting requirements to
make diVerent national registers compatible with
each other and to facilitate greater information
exchange. It is quite extraordinary to go to
internationalmeetings on this subject and to ﬁnd that
regulators are very keen just to ﬁnd out what the
other side is doing about these matters and what is in
their market. There seems to be a great deal of
uncertainty about the presence of nanomaterials in
food, and of course there are emerging producers,
China and others, which do not have a good track
record in that area.
Q347 Chairman: I would like to thank both of you
for an excellent session and for the time you have
taken to explain your views on the various questions
we have put to you. In closing, are there any
additional points you would like to make? I would
also oVer you the opportunity to write in with
additional points if you think there are things we have
not asked that we should have asked or where you
have not had the chance to expand as fully as you
would have liked to. If there are any brief comments
you would like to make now, this is the opportunity.
Professor Burke: Just a concern, as a UK national,
about the question I raised about complacency. I
really worry that wemay get caught by a repeat of the
GM soya scenario with some product coming in from
a wicked multinational based in North America
about which ETC makes statements which no-one
can refute and where we do not even have a protocol
working in this country to look at things. I think we
are in a weak defensive position politically and I am
hoping your Lordships will stir the pot a little,
because you are in the position to do it when maybe
others have their minds elsewhere at the moment, to
get something moving and to get the scientiﬁc
community involved in some way. I was quite
concerned when I looked at the ACNFP website to
ﬁnd that it was out of date and the interests of the
group were out of date. I was not impressed by the
urgency with which this topic was being tackled. A
report from the House of Lords is a wonderful lighter
of blue touch-paper.
Chairman: Thank you very much. That seems a very
positive note on which to end. You will be sent a
transcript of this session to make sure that it is
accurate from your perspective. Once again, I would
like to thank you both very much indeed for coming
in to join us in this morning’s session.
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Q348 Chairman: I would like to welcome both of
you to the sixth of our public hearings in the inquiry
into nanotechnologies and food and thank you both
very much for joining us for this evidence session.
I would remind you that the proceedings are being
webcast, so the great public out there can watch and
listen if they wish. I would like to draw to the
attention of members of the public that the
information note does list the Members’ declared
interests, so we will not be repeating those during
the questioning but they are there for you to see.
Before we start with the questioning, I would like
to invite the two witnesses, Mr Burall and Professor
Pidgeon, brieﬂy to introduce themselves. If you wish
to make any opening statement, this is an
opportunity to do so.
Mr Burall: Thank you very much for inviting us to
this inquiry. I am currently Director of Involve. We
are an organisation that is about three years old and
we are public participation specialists. We carry out
research and practice into how you engage the
public in challenging issues. In 2005—and Professor
Pidgeon was involved in this—we formed, along
with Cambridge University and the OYce of Science
and Innovation, the Nanotechnology Engagement
Group and we carried out some research into six
projects that tried to engage the public in
discussions about nanotechnology. I am here today
to talk a little bit about that and to draw on our
much wider experience in engaging the public in
challenging decisions.
Professor Pidgeon: Thank you again for the
invitation to come and speak. I am Professor of
Environmental Psychology at CardiV University. I
treat myself as an interdisciplinary researcher,
spanning psychology, sociology and geography. I
have had an interest for a number of years in
research on public attitudes and public engagement
with science and technology issues, including GM
foods which we may get on to a little later on. My
involvement in nanotechnology began in 2003 when
I was asked to be a member of the Royal Society &
Royal Academy inquiry. Since that time I have
served on the Responsible NanoCode Initiative.
Also, at a research level—sponsored independently,
I might add, by the Leverhulme Trust, a charity, and
also through collaboration with the USNSF Center
for Nanotechnology in Society at Santa Barbara
which is looking at risk perception and public
response to nanotechnology in both the USA and
the UK—as a collaborator and investigator, I have
been looking at a number of these issues. The one
opening remark I would make is that we are at a
very early stage in trying to understand public
understanding and perception on nanotechnology,
both as a general concept and as food. The inquiry
is timely, in the sense that if you had asked me to
come here three years ago I would have come with
very little evidence. There is a small amount of
evidence now. I hope we can cover that during the
session.
Q349 Chairman: Thank you very much. Perhaps I
could kick oV with a very general question. Both of
you in your diVerent investigations have looked into
the question of how the public perceive
nanotechnology in food at the moment. I wonder if
you could just give us a brief thumbnail sketch of
where you think we are in the question of public
understanding of public attitudes to the use of
nanotechnologies in foods.
Professor Pidgeon: If I may start. The ﬁrst point is to
make a distinction between public understanding
and attitudes towards nanotechnology as a general
category and public understanding and attitudes
towards nanotechnology in food. You need to make
a distinction between the two and I will just cover
the evidence on the former ﬁrst, which is just
nanotechnology in general. We have had about six
years of research on this in the US, in the UK and
in Europe and there are really two evidence
streams—there have been 12 or 13 surveys to date
which are nationally representative in various
nations and also more deliberative and qualitative
work that has been conducted by groups of
researchers in various locations. I will take the
surveys ﬁrst. What we know is that there are very
low levels of awareness of nanotechnology amongst
190 nanotechnologies and food: evidence
9 June 2009 Professor Nick Pidgeon and Mr Simon Burall
the general public as a category. When we asked this
question in 2004 of a British representative sample
for the Royal Society inquiry over 70 per cent had
not heard anything at all about nanotechnology.
That result is pretty well replicated over time, with
ups and downs in various locations, but there does
not seem to be a big shift to more or less knowledge.
There are therefore very low levels of awareness;
that is very important to bear in mind in all of this
discussion. But if you then go and ask the question
do you think the beneﬁts of nanotechnology will
outweigh the risks or the risks will outweigh the
beneﬁts, a majority will give you the answer we
think the beneﬁts of this new technology will
outweigh the risks. On ﬁrst sight, putting those two
together, that is a bit of a paradox; how can you
judge that the beneﬁts will outweigh the risks when
you have just said that you do not know anything
about it? But what is happening here is that people
are bringing in a judgment about general
technological progress, so when they are being asked
about nanotechnology in surveys they think it is a
new technology and we know from other surveys of
attitudes towards technology in general, not in
speciﬁc, the public remain very positive about
science and technology. So that is what is partly
basing that judgment. We also know that knowledge
has an impact in some surveys, trust has an impact,
gender also can be important in judgments about
nanotechnology, so those are the surveys and we
have to be very careful with these surveys because
of this very low level of awareness. Anything more
detailed asked in a survey makes it very diYcult to
interpret what the response really means from
somebody. The more deliberative work, which has
the advantage that you take a group of citizens,
either in a focus group or in a longer citizens’ jury,
through a series of discussions on nanotechnology
and maybe give them exposure to experts, has
slightly more nuanced ﬁndings. There are initial
diYculties engaging with the topic in a lot of these
exercises, but as people become engaged they do
start to understand and get going with it. The views
on risks and beneﬁts are more mixed. They are still
on balance positive despite several attempts of
research teams to raise the possible risks of
nanotechnologies or the governance questions here,
you still get on balance a positive response. But it
seems to be application-speciﬁc, that is one of the
emerging ﬁndings. In work that we did, in both
CardiV and Santa Barbara, we had groups looking
at energy in nanotechnology and health and
enhancement in nanotechnology and it was quite
clear that the energy groups were much more
positive about the energy applications, in fact they
did not really see that there were many large risks
with energy issues. That work is now published in
Nature Nanotechnology. Where concerns come in—
and this is not speciﬁc to nanotechnology, this
would be generic with most new, uncertain
technological issues that you put before a group of
the public—is you do get concerns for long term
unknowns, so what will the scientists do about
unknowns at this point in time, and also concerns
about the control of the new technology, so people
will ask who can be trusted to manage or control it.
That is nanotechnology in general. When we drop
down to food we have got far less data but just one
or two studies have come out in the last two or three
years. If we accept from the general work that
application matters you would expect—and I think
this is likely to be the case—that nanotechnology in
food will have a unique risk perception signature so
you cannot necessarily extrapolate easily from
responses to nanotechnology in aviation, let us say,
or nanotechnology in cosmetics to food. The very
few studies we have got—and I stress it is limited
evidence—suggest at this stage that food
applications, and I am quoting the International
Risk Governance Council here in their recent report
of 2009—
Q350 Chairman: Sorry, could we just collapse it a
little bit because we have got quite a few more
questions to get through.
Professor Pidgeon: Some Swiss studies suggest that
nano inside is less acceptable than nano outside; for
example, in the body versus packaging nano-
applications. Nano-food applications are also less
acceptable than energy and health and, to sum up,
I have argued in a number of publications that it is
diYcult to say whether or not nano will be like GM,
but in the food domain it looks very close to some
of the things that caused some of the public
controversy around GM in terms of its risk
perception signature. There is also this question of
lack of industry transparency currently, which was
also aVecting the GM controversy here, and also a
question of trust in the food industry or not. When
you take all those things together—going into the
body, trust in the food industry and transparency—
then nano in food looks closer to GM than many
of the other nano applications.
Q351 Chairman: Thank you. Is there anything very
brief that you would like to add to that?
Mr Burall: Three very brief points. The research in
the six studies that we looked at showed that people
are concerned about potential toxicity of nano
particles, and they are concerned about both the
risks and beneﬁts. I would echo this point about
trust as well, trust in the institutions both that
regulate but also are developing technologies, and
just the ﬁnal point that echoes this is that food
producers are very reluctant to participate in any of
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the public engagements that we studied. A lack of
trust kind of permeates this whole thing.
Q352 Chairman: We have heard from a number of
sources that the food companies are reluctant to
become the public face of nanotechnologies in food
because they are afraid of a negative reaction.Do you
think that is a reasonable position for them to adopt
or is it counterproductive?
Mr Burall: It is both counterproductive and
reasonable because the debate is contentious, the
technology is uncertain and the risks are uncertain.
The public is uncertain, the policymakers are
uncertain and the public debate about what we
should be using nanotechnology for, what the risks
are, what risks we are willing to bear and what
beneﬁts we are willing to accept on the back of that
risk are all uncertain. Industry is seen as pushing a
particular commercial line—industry cannot lead
this. In response to one of the questions you are going
to ask later I was musing on the fact that if you are
going to run an eVective engagement with the public
what you need to have is a neutral space where that
happens and it needs to be convened by a neutral
body. The industry cannot be that neutral body; even
if it wants to push itself forward it cannot be that
neutral body.
Chairman: That leads on neatly to a question from
Lord Mitchell.
Q353 Lord Mitchell: It does. Let me preface it all by
saying that in chats with my reasonably intelligent
friends when I talk about this whole subject,
particularly to do with food, number one they do not
seem to know much about it and then they recoil in
horror. I just wonder if there anything more we can
do about public engagement. You started on that
point but I will push it a little further forward because
it is key to much of what we have heard.
Mr Burall: As I said we looked at six diVerent
studies—they were very small-scale—and we
published a report two years ago, so Nick may have
some more recent evidence. What was clear was that
those that were more successful were those that spent
time up front educating the participants in what the
science was about, what the eVects of the science
might be and some of the boundaries of scientiﬁc
knowledge. That was an important precondition.
Secondly, having the public talk about it amongst
themselves was not enough, you needed both the
policymakers and the scientists in the room at the
same time as well, because what was important
coming out of these deliberations was not the policy
recommendations that could be read in Whitehall, it
was actually the discussions about the technologies
themselves, it was the process that was important.
Unless scientists and importantly policymakers are
involved in that conversation what comes out of it
has a much lower impact, so if you are going to go
down the route of engaging the public you do need to,
one, educate them so that they have got the level of
understanding but, two, then properly engage and
not have it as a conversation between a limited
number of participants.
Q354 Lord Mitchell: I was just going to add that the
Nanotechnology Engagement Group produced a
report in 2007 documenting the results of a series of
public engagement activities with the public about
the development and governance of
nanotechnologies. The report made a number of
recommendations to Government and I just
wondered how eVectively you think those
recommendations have been taken forward.
Mr Burall: I am not sure that I can answer that
question very eVectively. My sense is that things have
not really moved very far forward since that report
was written and that the ﬁeld of public engagement
has not really progressed much further. The clear
starting point for all public engagement, whether it is
about nanotechnology or anything else is that
whoever is commissioning it needs to be very clear
about why they are doing it.
Q355 Lord Mitchell: Do you sense it is diVerent in
other countries or the same?
Mr Burall: I certainly cannot answer that question, I
am sorry.
Q356 Chairman: Professor Pidgeon, have you got
any views about other countries?
Professor Pidgeon: I can partly answer that question.
In the US they are starting to do engagement but are
behind the UK and Europe. In Europe there are a
number of activities that have been going on. In
defence of the funding of public engagement in the
UK, the Royal Society recommended public
engagement around nanotechnology and, looking
back over the ﬁve to six year period since that report
and its recommendations have bedded in, there have
been a number of experiments in the UK, some
directly funded by government, others partly funded
by NGOs or the Research Councils. The one thing I
would say is that there has been a reluctance by
industry in the food domain to get involved. So if
there is a gap, looking back, then it is here and it is on
this topic, and I guess that is one of the reasons why
you are holding an inquiry into this. If I were to
evaluate the Government’s funding of this and the
work that has been done over the past six or seven
years, my colleagues and I would say that theUKhas
actually established a lead in public engagement
around nanotechnology compared to most other
countries.
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Q357 Lord Crickhowell: Can I ask a speciﬁc
question about this 159-page report of the
Nanotechnology Engagement Group? You have
already commented about the pluses andminuses for
industry of being involved in the public debate, but
what I found extraordinary reading this report is that
there is the participation of public groups ﬁnding out,
there are policymakers and there are academic
scientists, but nowhere in this report could I ﬁnd any
participation by representatives from industry who
are actually developing the technologies whichwe are
concerned with. It seemed to me an extraordinary
omission in a study of this; was it deliberate or why is
there no input? Surely if we are going to have a
serious discussion on this issue the people who are
actually moving on from the pure scientiﬁc research
to develop the kind of products are a vital input?
Mr Burall: I would agree with that, industry is clearly
a vital input.What the Nanotechnology Engagement
Group was doing was evaluating other people’s
studies and the studies that were evaluated were the
ones that were happening in the UK at the time, so it
kind of exposes what you are saying, that those
experiments in public participation were not
including industry. Clearly that is a huge gap and it
is a gap, I guess, particularly in the food areas as has
already been said, that it is very diYcult to ﬁll because
the food industry is struggling to give itself a public
face in this arena.
Professor Pidgeon: One example would be that
Unilever sponsored a very important public
engagement exercise at the back end of the 1990s on
GM food, crops and agriculture. It has been very
diYcult to get companies like that to dowhat they did
at that time with this issue. It is partly the GM saga
that has inﬂuenced opinions there—there is a
nervousness there.
Q358 Lord Crickhowell: Did they refuse to take part
in this exercise or were they not invited to participate?
Professor Pidgeon: Remember there was a whole
group of exercises convened by diVerent bodies and
parties and funded in diVerent ways.My guess would
be that industry was asked at various points and
where they were asked maybe they felt they could not
take part.Maybe it was easier just to do it at this stage
with academics and NGOs and other partners—the
Government had some input as well, as I have
indicated, to some of these exercises.
Q359 Earl of Selborne: I want to come to another
initiative, the Responsible NanoCode initiative,
which Professor Pidgeon reminded us that he
participated in and I remind the Committee that I
was also involved in it. I would just remind the
Committee that it was a voluntary eVort in the
absence of national and international regulation to
try and set out a code for how all participants might
address the issue of how you market and regulate
voluntarily nanoproducts and Unilever, Tesco,
banks, trade unions and others were involved, so it
was a good representative group. I would ask
Professor Pidgeon in particular, as he was involved in
this exercise, whether voluntary codes like this have
any real relevance in the face of commercial
imperatives and, furthermore, whether there is a role
for their proposal, which was that there should be a
permanent Nano Commission-style organisation to
continue to engage stakeholders and advise
government on issues, or is it all inevitably doomed
to failure until proper regulation is put in place.
Professor Pidgeon: The argument is of course that
voluntary codes are useful where there is an absence
of regulation or where the regulatory framework has
taken time to follow developments in industry and
elsewhere. So of voluntary codes for example the
Forestry Stewardship Council and others are held to
work well. The aim with theNanoCode is to ﬁll a gap
that was clearly there two or three years ago when the
parties were brought together. Whether or not a
voluntary code works well will depend upon who
signs up and the principles of the code. In fact there
are about four such codes that have been developed
independently and say not exactly the same thing but
a basic set of principles that are fairly similar, so in the
absence of a broader framework it is right that that
initiative went ahead and that the code is there. We
shall see in practice. The question of a Commission
we debated on the Royal Society inquiry fairly
extensively. I am personally somewhat ambivalent
about that: recommendation 21 of the Royal Society
inquiry was for a wider body because we felt at that
time that just to focus on nanotechnology might be
too narrow. There was, and remains, a case for
horizon scanning, looking at some of the ethical and
social issues and looking at some of the emerging risk
issues across the new technology domain. That is
actually a recommendation that government has not
fully taken up and in a sense it is a shame that it has
not. But for nanotechnology speciﬁcally, I am not
sure that the case could be made now that really was
not made then. What would tip the balance is if it
were clear that there really were serious potential
public sensitivities and serious risk issues that needed
to be coped with in the near future, and it may well
then be the case that there would be strong pressure
to have something like a Nano Council.
Q360 Chairman:MrBurall, do you have anything to
add to that?
Mr Burall: I guess codes alone, whether they are
voluntary or not, probably are not enough in this
area because of public trust. One of the key elements
of this has to be engaging the public in understanding
and perhaps even developing the codes to try and
build an element of trust into the system. That would
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be one point. On the question of the Commission
there is clearly a need to develop a better
infrastructure for engaging the public on much
broader issues than just nanotechnology, again
because of the trust issue. We are doing some work
with the Danish Board of Technology, which is part
of the Danish Parliament and has been going for 30
years. Their role is to facilitate discussion—I see
many heads nodding—between Parliament and the
public. They say it takes ﬁve years to train a
professional to do that sort of thing properly. One, we
do not have the capacity to do these things and, two,
setting up independent commissions on diVerent
issues probably is not good enough because there is a
range of technological issues. Secondly, building the
links between those commissions and the
infrastructure that is funding, that is regulating and
so on, these diVerent technologies is actually really
quite challenging, and unless there is a body that is
really properly institutionalised and is having a
dialogue both with the public and backwards into
these institutions that are trying to take on board the
recommendations, actually it is very diYcult to get
things to happen. I would say again that unless there
are some signiﬁcant terms that arise actually to have
a broader commission that can have a broader
dialogue about many of these diVerent types of issues
would be a much better idea.
Q361 Lord Haskel: You have told us an awful lot
about how important the process of engagement is,
but it all seems to be a bit ad hoc. Whose
responsibility is it to carry out or to run public
engagement? Is it the Government, is it industry, is it
academia, is it charities or is it some independent
neutral bodies? If this is going to be successful whose
responsibility is it to get it done?
Mr Burall: It is in everybody’s interest to get it done
and the question is where can the muscle come from
to have it happen and, secondly, how can you make
it happen in a way that makes it work eVectively as a
process of dialogue. Government has to make it
happen but whether government is the convenor and
facilitator of it I am less certain and it may well
depend in part on the issue, which may again speak
to why youmay need a broader commission than just
trying to do this on an ad hoc basis depending on the
issues. It needs signiﬁcant clarity in terms of money,
in terms of being able to communicate the results,
being able to communicate the process and so on, but
it needs neutrality. Perhaps government facilitating
this through Parliament may be one very good route
to do this.
Q362 Chairman: What about the issue of trust here
because earlier on one or the other of you said it is
diYcult for the industry to take a leadership role
because if they did people would be suspicious about
what it was they were trying to foist on the public or
cover up? Do you think that the issue of trust leads
you in a particular direction in response to Lord
Haskell’s question?
Mr Burall: Also to Lord Crickhowell’s point earlier,
why is industry not part of this? Probably one of the
reasons industry has not been part of the things that
we studied for the Nanotechnology Engagement
Group was precisely because they did not trust the
process. So trust is absolutely critical and it has to be
trust from all sides—the public, scientists,
stakeholder groups, Parliament, government. That
trust has to be across the board and how you create
that trust depends on the process you set up. It is not
an easy thing.
Q363 Chairman: Professor Pidgeon, do you want to
add anything?
Professor Pidgeon: Just brieﬂy. One convenes an
independent steering panel. That has been done with
a number of the exercises that have been conducted
so far. That would then include a number of the
interests involved: industry, NGOs, scientists,
government as well because of the link back into
regulation. That is the way to deal with this
irrespective of where the funding or the initial
sponsoring of the debate comes from. You avoid an
overemphasis on the interests of the sponsor if you
already have an independent steering panel.
Q364 Lord Haskel: How would you introduce the
ethical element, which is important?
Professor Pidgeon: The people who take part
introduce the ethical element because partly this is
about trying to understand the people’s values, and in
the previous evidence sessions on food andGM itwas
about cultural issues, so that comes very much from
the people who are deliberating. You are trying to
present a neutral space with some science, some
evidence and some positions that have been set out by
the NGOs, industry and others for people to then
debate and decide some of the ethical issues or at least
raise them for us.
Mr Burall: It is really important to be clear about
why you are setting it up. Are you setting it up in
order to inform policy and inform research or are you
setting it up in order to give some democratic
legitimacy to the policies that come out of it? Real
clarity about why you are setting it up will impact
totally on who you involve, on the process you use to
get there, so being absolutely clear and explicit about
what you are trying to achieve by establishing a body
is really absolutely vital, it will fail if you are not
certain about that, not clear about it.
Chairman: Thank you. That leads to the next
question. Lord May.
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Q365 Lord May of Oxford: The next question really
continues this.Myquestion iswhat doyou think is the
bestwayof going aboutmaking sure that public views
and concerns are integrated into themaking of policy
in ways that do help ensure that public opinion and
concerns inform the regulatory framework and also
inform the questions you want to be asking about
research topics thatare still insecure? I realiseyouhave
already said a lot of sensible things about this but I
wonder if in addressing that regulatory framework
and researchpriorities you couldpayabit of attention
to the fact that we use the word “public” when the
public is a very protean concept. Very often the
mechanisms which are most convenient for engaging
something that is called the public engage subsets of
them that are not necessarily representative.
Mr Burall: One of the things about the challenge you
are highlighting there is the diYculty of actually
getting a representative sample because if youwrite to
1000peopleperhapsonly tenwill turnuptosomething
that is about nanotechnology, so actually getting a
representative sample is a challenge in and of itself. If
youare looking forpublic engagement tobeoneof the
bits of evidence that informs the development of a
regulatory framework and the intervention of
research then holding not one-oV events but events
that happen on a number of diVerent occasions that
involve giving the public information ﬁrst of all and
then allowing them to deliberate, absolutely crucially
as I saidbefore,with scientists andpolicymakers, then
what you can get is some real insights from both the
public and from scientists about the direction of the
research. One of the fears we found in our research of
scientists going in was that the public would be ill-
informed, anti-scienceandanti-nanoandanumberof
thequotes in the reportmake it very clear that actually
thatwasnot the case.On theother side thepublicwere
really frightened that scientists would be aloof and
arrogant and, again, that misconception was broken
down. So it is possible to run these things in away that
breaks down misconceptions and has a dialogue that
then can inform research, and there are a number of
examples in that report of scientists who have gone
away and said “I am actually going to look at this
question now, it had not occurred tomebefore”, so by
running a proper, deliberative two-way process you
can inform research and therefore regulation.
ProfessorPidgeon:Anumberof thedialogues thathave
occurred in the UK already have ﬁndings which
regulatorsought to lookat.TheUKNanoJury said to
treat nano-materials, if there are any uncertainties, as
new materials for regulatory purposes. That is not
rocket science but it was a recommendation of the
public. Also there is some sensitivity about voluntary
reporting and other systems for health and safety, so
some of that evidence is already there. The diYculty is
linking it into the policy process; even if you have a
government sponsor for some kinds of deliberation it
is not transparently clear that a recommendation
would immediately then go to Defra or FSA or
wherever and would inﬂuence their policy. That has
always been the gap in this and it is always a great
diYculty.Whatoftenhappens though is that inﬂuence
occurs further downstream: so a deliberation will
occur, some ﬁndings will get into the public domain,
and then when something is being designed in
government eventually somebody takes notice of that
in amore indirect fashion—the evidence shows that it
is oftenmuchmore of an indirect impact. It is diYcult
to do, therefore, at a regulatory level. On the research
level this idea of bringing panels of citizens to debate
research priorities should not be the sole arbiter of
funding decisions either. I am sure we would all agree
that that is actually funded and sponsored but it is a
guide to what, potentially, the public would want to
see publicmoney spent on.
Q366 Lord May of Oxford: Speciﬁcally what do you
think is the role of consumer groups in this process
and, coming back to Lord Crickhowell’s question,
what do you think is the role of industry in being
engaged in this process? Against that background
what is your opinion of the recent EPSRC study of
engagement activities in nanotechnology and
healthcare in light of the discussion we have been
having?
Professor Pidgeon:Consumer groups are trusted by the
public, that is theﬁrst thing, soyouwouldhavetohave
them involved in the same way as the green
organisations are trusted in relation to environmental
issues, so if one is interested in the trust question they
have tobepartof the stakeholderswhoare involved in
these processes. I looked at the EPSRC process—
Simonprobablyhascommentsaswell—andIthought
the process was reasonable. There were some issues,
perhaps they wrote it up quite quickly and as a social
scientist I would have spent longer analysing the data
properly, but the ﬁndings resonated with some of the
ﬁndings from other research and deliberation
activities. Again, the question then is how does that
inﬂuence policy, howdoes that inﬂuence funding? It is
quite a diYcult thing to go from a list of priorities and
applications and then to say do we prioritise funding
or not? That is for the EPSRC and the Research
Councils to decide for themselves really.
Mr Burall: It comes back again towhat are you trying
to do and that will determine who should be in the
room. Clearly there are a number of processes where
youwouldnotwant to cut out the consumergroupsor
the industry, particularly where you are engaging in a
much more political discussion about what the
regulationsmightbe, but ifwhatyouare trying todo is
inform the regulations and you want to get an
understanding of what the public thinks about the
issue youmay notwant them in the roombecause you
are trying to do something diVerent.Again I amgoing
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to bang on about this: being very, very clear about
what you are trying to achieve is absolutely critical to
determiningwhowill be in the room.
Q367 Lord Haskel: If you say that what you are
trying to achieve is the acceptance of nanoproducts in
food and you do all of these things, at the end of the
day I imagine you will ﬁnd that some people will say
that nano products in food are going to poison you
andotherswill say they areﬁne.What doyoudo then?
Mr Burall: If you are trying to push in one direction
the acceptance of nanotechnology in foods then the
process will potentially immediately be distrusted, if
that is what your objective is and you are essentially
doing a PRor communication exercise.
Q368 Lord Haskel: What about the acceptance of
nanotechnology in food?
Mr Burall: If what you are trying to do is build an
understanding and a consensus about what the social
beneﬁts might be, what the risks might be and where
society stands on those, and that is leading to policy
decisions about regulation and the direction of
research, then that is a diVerent thing. If the public felt
we were pushing the acceptance of nanotechnology
they would hear “you want us to drink grey goo”. If
what they hear is “we are interested in understanding
whereyou think the risksandwhatyourattitude to the
risks is”, that is very, very diVerent and will lead to
acceptance of some things and not of others, so that is
why what you are trying to achieve is absolutely
critical.
Q369 Lord Crickhowell: Coming on to the question
of labelling, do you think that products using
nanotechnology or containing nanomaterials should
be labelled at point of sale and do you think that this
will be useful to consumers?
Professor Pidgeon: It is a very diYcult one because
again nanotechnologies have a multitude of
applications. If we are thinking about food, labelling
only works when a consumer also knows what to do,
so has some control over the risk management
individually and is able to adapt their behaviour in
someway, either bynot buying the foodorusing it in a
diVerent way. It is a very diYcult one and again, going
back to the Royal Society inquiry, I know there was a
small labelling recommendation but the consensus of
thediscussion fromeven the consumer group thatwas
represented there was that this is a very diYcult issue.
You have the diYculty that you might stigmatise a
whole setofproducts justbecauseonehasahealthand
safety issue associatedwith it.What dopeople dowith
this label anyway? You just end up with a packet that
is fullof labelsabout this, that and theotherand itmay
not provide useful information. The question
therefore is how do they provide a consumer with
useful information that would help them to actually
make a decision or behave in a diVerent way, and that
is the diYcult one.
Mr Burall: I would echo all of that and just go on to
reﬂect that we also do not want to get into a situation
where we have a profusion of labels, so if we are going
to go down the route of labelling it would seem
sensible to try and get to an understanding of what a
label can allow a consumer to do. Also the body that
labels—again trust is absolutely critical here—has to
be seen to be neutral, and industrywould appear to be
in a poor position to do the labelling from that
perspective, but it may or may not be to their beneﬁt
to label.
Q370 Chairman: Do you think there is any analogy
here with the labelling requirements for GM? The
argument therewas of course that people should have
the right to choose; it was not anything to do with
safety it was about consumer choice. Do you think
there is an analogy here?
Mr Burall: I suspect, given the level of debate and
understanding about nanotechnologies at the
moment, thereprobably is, and thequestion is canyou
get society to a state where it feels it understands the
risks and beneﬁts of the technology? Perhaps the
debate is not in that space, but at the moment it
probably is there I would say.
Q371 Lord Crickhowell: This is obviously the
problem that the Food Standards Agency has
identiﬁed and is exactly the problem that you have
been talking about. Those of us who look at labels are
worried about the quantity of information that is on
the label andwhether it has anymeaning, but there is a
sort of curious danger. I came across it in one of those
magazines that advertise travel products someone
calling it a nano product. I thought it was an entirely
meaninglessphrasebut there is adanger if people start
calling nano as being vaguely a selling point, and
therefore if we are going to label it from the point of
view of informing the public you have to be very clear
about what you are going to put on that label which is
meaningful, is that not right?
Mr Burall: The term nanotechnology itself, coming
back to objectives again, appears to cover a vast
swathe of products as you say, and if it is small it is
nano—we have got a car called Nano have we not?
There is clearly a huge issue about terminology here
that is obscuring the public debate or preventing a
meaningful public debate.
Q372 Lord Crickhowell: Until we get a deﬁnition of
some clarity about regulation really it is not a route
that we can seriously go down, is it?
Mr Burall: It is not something we are expert in but
personally it seems to be quite challenging.
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Q373 Lord O’Neill of Clackmannan: The
Government in its response to theRoyal Commission
of Environment Pollution report on Novel Materials
said that it would establish a pilot website that the
public can access to give a balanced source of
information on nanotechnologies including research,
products and regulation. Do you think that this is a
worthwhile initiative or is it window-dressing?
Professor Pidgeon: I know a little bit about the
development as well because it has grown partly out
of theNanoCode activities. It is a big task, it is part of
the process of making nanotechnology and the issues
around nanotechnology transparent to the public, so
anything that adds to that in a sensible way is a good
thing that we should support. But it will depend on a
number of things—in particular adequate funding
and commitment over a period of time. If the pilot is
seen to work then it requires a very long term
commitment. It will require, to come back to this
point, the involvement of trusted parties from the
public’s point of view, whether you are running it as
an independent process or with an independent
steering board. So there have been a number of things
put into place. Also one of the diYculties is that
because nano is very much upstream there are still a
lot of uncertainties—that is why we are talking about
the risks—there is a diYculty about what you put on
the website. That is not to say that it is not a useful
thing.
Q374 Lord O’Neill of Clackmannan: You are
damned if you do and damned if you do not.
Professor Pidgeon: You then have to come back to Sir
John Krebs and the Food Standards Agency
response to BSE and the Lords’ Science and Society
Report of 2000 where they were very clear—and they
were very successful in doing this—that where there
was an uncertainty they would say “Okay, we are not
going to just say nothing, we say there are
uncertainties here, this is what we are doing, there is
research being done and there are regulatory steps
being taken”, so you explain how in some sense these
issues are being dealt with. That was a very successful
strategy as far as I could see, both for the Agency and
for those who wanted to get information from the
Agency. Part of that process, if it can be done
properly, then looks to be welcomed, yes.
Mr Burall: Just two points, one to echo that is the
need for transparency, it cannot come across as being
a PR and communications exercise for the industry
or for government trying to push a particular line. It
has to be open about the risks and open about where
there are “known unknowns” to steal a phrase. That
is one thing, absolute transparency to build on trust.
The second is not to just launch into it but actually to
understand what the public might want from it and
what stakeholder groups or consumer groups might
want from it. The last thing you want is to, one,
produce information that people do not want or in a
way that people cannot access it and understand it or,
two, only provide partial information and you then
get another group that is putting up contradictory
information. If it is going to exist it has to be the
portal for this information.
Q375 Lord O’Neill of Clackmannan: There have
been identiﬁed research, products and regulation. Do
you think there is anything else required of the
website, or under these headings is it just as
important to keep updating it, which in itself might
be an expensive and diYcult operation? What are
your feelings on that?
Mr Burall: I would just say that what appears to be
missing is what the public’s understanding of the
technology is and the public’s views of it. That would
not just be about producing surveys and giving
survey results but actually saying that
communication of this sort cannot be the only
strategy, engaging the public on an ongoing basis and
then feeding that and the results of that onto the site
would seem to be absolutely critical.
Q376 Lord Cunningham of Felling: Should there be a
register of nano-derived food products and food
wrappings associated with this?
Professor Pidgeon: There is a simple answer to that; I
would say yes, it would be a good thing to have and
it comes back to the transparency question
immediately; it is very important. There was also the
subsidiary question of voluntary or mandatory and
again my advice would be that it should be
mandatory because there is always a suspicion in the
public mind about voluntary systems that they will
not work properly. In fact, in research that we
conducted last year in the US in a survey, refusal to
voluntarily report when presented to members of the
public was an extremely trust-destroying item. People
are very suspicious that industry will not voluntarily
report, so that would be the beneﬁt of a mandatory
system. Of course, there are all sorts of practical
diYculties with mandatory systems, IPR et cetera,
but surely it should be possible to overcome that in
the interests of transparency?
Q377 Lord Cunningham of Felling: Who should
operate it?
Professor Pidgeon:The Food Standards Agency could
operate it, I guess, as the regulator, with some kind of
independent board.
Q378 Lord Cunningham of Felling: Is there any point
in having such a mandatory register in a single
country?
Professor Pidgeon: Someone has got to start the
thing oV.
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Mr Burall: I guess if you feel it cannot be enforced
then probably not. I have just two reﬂections: one is
that a register seems to be a sensible idea because the
last thing you want is rumours about
nanotechnology in this or that food or this or that
product, so a register seems to be a good thing, but
reﬂecting also on the discussion that was being held
earlier about labelling, unless the public can actually
do something with that—
Q379 Lord Cunningham of Felling: When you say
nano products youmeanmanufactured ones because
there are nanomaterials occurring naturally.
Mr Burall: Indeed, absolutely. A register seems to be
a good thing as a way of countering rumours but it
runs into many of the same issues that labelling
would appear to run into.
Professor Pidgeon: There is a caveat on that though.
When you do focus groups with members of the
public about this very issue, about openness, whether
it is nuclear energy or GM, what you do ﬁnd is that
people want the information to be in the public
domain. If then you ask the question would you
yourself go and actually consult it most people
generally say “No, not necessarily, unless I have a
health issue or there is something speciﬁc in my
family that prompted it, but I want it in the public
domain because I know then that somebody else can
look at it, so that somebody can perform a watchdog
role.” That is the idea of having a public domain
register; you personally do not actually go to it but
you are aware that potentially somebody is looking at
it and scrutinising it. It is the opportunity for others
in civil society to look on your behalf.
Q380 Chairman: I wonder if I could just ask a
general question about public engagement, which is
this: can you point to examples of where the kind of
public engagement exercise that you have discussed
with us has been successful in the sense of changing
public attitudes, depending on what it was, maybe
from scepticism about a technology to acceptance of
it, or is there a cynical view, that this is a nice little
earner for academics and the public engagement
industry and is all very well, but actually public
attitudes and opinions are aVected by what is in the
Daily Mail as opposed to what is done by academic
researchers or public engagement? How would you
respond to this two-pronged question?
Mr Burall: I would respond by perhaps not drawing
on the ﬁeld of technology but by talking, brieﬂy,
about two case studies that are kind of outside that
area. One, British Columbia was struggling with the
voting system which was delivering very odd results;
a Liberal Government got in in 2001 or 2003 and
pulled together a citizens’ assembly to discuss voting
systems. Citizens engaged every second weekend for
six months on understanding this issue, discussing
this issue and coming up with a recommendation that
went to referendum. The referendum was expected to
fail because public understanding of the issue was
very low, but it just missed getting a double majority.
The follow-on story would suggest that in the end
that was a failure but what it was successful in doing
was demonstrating that the public is able to engage
with these issues and that they can make sensible
policy recommendations that can have an impact on
political debate.We also ran a process in Jersey where
there were issues of an aging population, of low tax
base and so on and, to cut a long story short, the State
of Jersey had very few policy options. At the end of
this process there were a series of policy options that
involved tax, immigration and so on that were not
open to them before, so it is possible to have these
debates about very, very contentious issues andwiden
policy choices and impact on the public debate, but
they have to be run properly.
Q381 Chairman: But neither example is to do with
novel technologies. Professor Pidgeon, are there any
examples that relate to novel technologies where
public engagement has “worked”?
Professor Pidgeon: It depends what it is for, because
you do not do public engagement to change attitudes
on a broad societal level, that is the ﬁrst thing to say.1
I am thinking of the one that did not work, whichwas
GMNation, because the people in the room in many
of the activities had prior positions and clearly did
not change. I go back to the UK Citizens’ Jury on
nanotechnology which was run in 2005 and the
recommendations there. It was a six-week process,
there were a number of evidence sessions with
witnesses. At the end the recommendations were
fairly ad hoc and fragmented at one level because
they did not have very clear direction at the start of
the process, but people had gone from “We know
nothing about this”—and it was actually quite a
deprived community that they drew people from for
that citizens’ jury, so it was not the chattering classes
doing this—to a series of balanced recommendations
which said we need to think about this but actually
nanotechnology could be a very good thing for
society. You did not get an ampliﬁcation of risk
around the engagement, you got quite a sensible
discussion at the end of that debate, so in a sense that
group of 12 or 16 people had their attitudes changed,
or better described as formed, as a result of the
engagement and that was a positive thing. I would
not say it was a failure.
1 “ A recent US National Research Council report “Public
Participation in Environmental Assessment and Decision
Making”, 2008 (ed. T. Dietz and P.C. Stern, Washington,
National Academies Press) is relevant. Chapter 7 in particular
reviews the evidence measuring the impacts of dialogue on
participants. The report concludes that ‘best practices in public
participation can advance decision quality, legitimacy and
capacity simultaneously’ (p 92).”
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Chairman:Thank you. One ﬁnal comment fromLord
Cunningham.
Q382 Lord Cunningham of Felling: Can you tell us,
what is a democratic technology?
Mr Burall: A democratic technology?
Q383 Lord Cunningham of Felling: As it says on the
front of this report.
Mr Burall: I am always slightly sceptical of scientiﬁc
metaphors coming into social sciences but what it is
attempting to say is that we have relied on
representative democracy for 100 year to take
democratic decisions but there are other ways of
doing it as well, there are many diVerent ways that
you can get the public to deliberate. They may be
around citizens’ juries, they may be around huge
citizens’ panels, the word technology refers to a
diVerent type of process, about getting people into a
place where they can discuss things.
Chairman: I would like to draw this session to a close
by thanking both Simon Burall and Professor Nick
Pidgeon for joining us and for answering our
questions so thoroughly. I would like to also invite
you if you have any additional points you would like
to make, that either we did not ask or we did not give
you time to expand on fully, please do write in. If you
make additional points they will be included in the
written evidence that we will take into account and
publish. I would also mention to you that the
transcript of this session will be sent to you to enable
you to check for any errors or misrepresentations of
what you said before we ﬁnally publish it. With that
I would like to thank you both very much indeed.
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Summary
Nanotechnologies oVer a broad range of potential applications in the food sector. For example:
— Food production and agricultural processes may be improved through the use of nanotechnologies
in the applications of pesticides, or in crop monitoring.
— Use of nanotechnologies in both packaging and edible ﬁlm coatings for food products may help to
extend product shelf life by reducing exposure to moisture or gases.
— Nanoencapsulation technologies for improved delivery of food functional ingredients and
manipulation of dietary nanoparticles to optimise absorption of nutrients oVer beneﬁts to human
health.
The Research Councils fund relatively little research relating directly to the applications of nanotechnologies
in the food sector, but support a much wider portfolio of nanotechnology research which underpins a variety
of potential application areas, including applications relating to food, in areas such as nanotoxicology,
nanometrology, characterisation and detection, nanotechnology-based sensor devices, food manufacturing
and processing, and food structure.
While the use of nanotechnologies and nanomaterials in the food sector oVers the prospect of signiﬁcant
beneﬁts, there are uncertainties about the potential risks of nanoparticles to human health (as well as potential
environmental impacts, though these are outside the scope of this inquiry).More evidence is required to inform
policy and regulation.
Regulatory considerations, economic viability and consumer acceptance will ultimately dictate the success of
nanoproducts and nanotechnologies in the food sector. It is therefore important that clear regulatory and risk
assessment frameworks are established as soon as possible, and that public engagement activities are initiated
at an early stage and are continued as the technologies and applications develop.
Introduction
1. Research Councils UK1 (RCUK) is a strategic partnership set up to enable the seven UK Research
Councils to work together more eVectively and enhance the overall impact and eVectiveness of their research,
training, innovation and public engagement activities.
2. The Research Councils welcome the opportunity to respond to this Inquiry. This evidence is submitted by
RCUK on behalf of the following Councils:
— Arts and Humanities Research Council (AHRC);
— Biotechnology and Biological Sciences Research Council (BBSRC);
— Economic and Social Research Council (ESRC);
— Engineering and Physical Sciences Research Council (EPSRC); and
— Medical Research Council (MRC).
1 Further details are available at www.rcuk.ac.uk
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3. It represents their independent views, and does not include or necessarily reﬂect the views of the
Department for Innovation, Universities and Skills (the sponsoringGovernment department for the Research
Councils).
4. This response focuses mainly on research, training and public engagement, in keeping with the Research
Councils’ missions and roles. Annex 1 provides summary information about relevant cross-Council research
programmes, and Annex 2 sets out some deﬁnitions.
5. The ﬁeld of nanotechnology is one in which the UK has considerable investment and an increasing
potential for exploitation in industrial applications to the beneﬁt of theUK economy and society. All Research
Councils have activities associated with this broad area of research. Examples of Research Council activities
are highlighted throughout this response.
6. All of the Research Councils, with the exception of AHRC, are members of the cross-agency
Nanotechnology Research Co-ordination Group (NRCG) and the Nanotechnology Issues Dialogue Group
(NIDG). The RCUK Nanotechnology Group, which has representatives from all Councils and the
Technology Strategy Board, co-ordinates Research Council activities in the area of nanotechnology, including
Research Council inputs to NRCG and NIDG. All of the Research Councils and the Technology Strategy
Board are partners in the EPSRC-led programme Nanoscience through Engineering to Application.2
State of the Science and its Current Use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
7. An overview of potential applications of nanotechnology in agriculture and food is available on the
Nanowerk internet portal at: http://www.nanowerk.com/spotlight/spotid%1846.php
Food Production and Agriculture
8. Nanotechnologies will play an important role in the food supply chain from “farm to fork”, where
improvements in food quality, eYciency of processing and supply, and reduced losses of food bring major
beneﬁts, including in terms of increased choice, higher quality and lower costs for consumers. Nanotechnology
promises new products and approaches to assist crop protection. For example, smart sensors and delivery
systemsmay help combat viruses and other crop pathogens through early detection of disease, andmonitoring
of soil conditions to improve application of water, fertilisers and pesticides. In addition, new products may
help plants’ ability to absorb nutrients.
Food Safety and Quality
9. The application of nanotechnologies and nanomaterials in food packaging may contribute to increased
food safety, eg nanoprinting for product authentication and identiﬁcation, or nanoscale in situ sensors for food
quality monitoring.
10. Nanotechnologies used in both packaging and edible ﬁlm coatings for food products may help to extend
product shelf life by reducing exposure to moisture or gases. For example, the MRC funds work into the
development of nanoparticulate surfaces that inhibit bacterial bioﬁlm formation, with potential applications
to food storage. Increased shelf life for foods subject to rapid spoilage such as fruit and vegetables not only
impacts on food quality, but could also contribute to reducing household waste, and so food demand. In the
UK, roughly a third of the food bought by consumers is thrown away.3
11. Nanotechnologies may also be used to improve the textural properties of food, or to enhance ﬂavours.
Health
12. Food based nanotechnologies have the potential to improve health. The range of potential beneﬁts is
large, and likely to be underestimated.
13. Absorption of nutrients may be optimised bymanipulating the properties of nanoparticles in the diet. For
example, current fortiﬁcation and supplemental forms of iron are poorly absorbed and potentially toxic in the
circulation and/or gastrointestinal tract. Scientists at MRC Human Nutrition Research (HNR), Cambridge,
are exploiting nanoparticle technology to synthesise novel ferric iron structures that mimic natural food iron,
allowing optimal bioavailability. These are currently being tested in human volunteers, and may lead to better
treatment of iron-deﬁciency anaemia. This nanotechnology is also being used to control levels of other key
2 http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/Intro.htm
3 WRAP, The food we waste, http://www.wrap.org.uk/retail/food waste/research/the food we waste.html
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molecules, including through sequestration to reduce harmful accumulation in disease. Further evidence on
this work will be given orally to the Select Committee byMRC scientists, although further written details can
be provided on request.
14. Improved delivery of food functional ingredients (eg vitamins, antimicrobials, ﬂavourings, colourings,
preservatives) through use of nanoscale carriers is another potential application. Nanoscale delivery systems
for micronutrients (essential for human growth and development eg vitamins and minerals), and
neutraceuticals (non essential but confer health beneﬁts and contribute to prevention of some diseases) are
intended to maximise delivery to, and release at, the desired site of action. Nanoencapsulation of functional
ingredients such as preservatives and ﬂavourings may improve functionality whilst minimising concentration
by protecting against degradation and allowing controlled release.
15. Nanoparticles may be used to protect people with food allergies by blocking the surface structures which
trigger the response.
16. Nanotechnologies and nanomaterials may be used to make food healthier (eg by increasing the nutrient
content, inclusion of antioxidants) without adversely aVecting the taste.
17. Nanotechnology also has the potential to improve food processes that use enzymes to confer nutrition and
health beneﬁts. For example, enzymes are often added to food to hydrolyze anti-nutritive components and
hence increase the bio-availability of essential nutrients such as minerals and vitamins. Tomake these enzymes
highly active, longlived and cost-eVective, nanomaterials can be used to provide superior enzyme-support
systems due to their large surface-to-volume ratios compared to traditional macroscale support materials.4
18. TheMRC funds a range of nanotechnology-based projects with therapeutic potential, although these are
mainly outside the scope of the present inquiry.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
Food Products
19. Publically available information on the use of nanomaterials in food products is limited. The Woodrow
Wilson International Centre for Scholars (TheWilsonCentre) has established an online inventory of consumer
products using nanotechnology,5 identiﬁed by the manufacturers. As of August 2008, this inventory
indicated that of 803 products or product lines using nanotechnologies, 80 products were in the food and
beverage category, none of which were produced by UK based companies. Of these 80 products, just three
involved use of nanoscale materials as ingredients in food products. However, this inventory relies on
information provided by companies about the scientiﬁc characterisation of their materials, and is therefore
unlikely to present an accurate reﬂection of the current state of the market.
Food Production Processes including Packaging
20. As part of the food supply chain, nanotechnology has already delivered improvements to pesticide
delivery through encapsulation and controlled release methods. Capsules can be inert until contact with leaves
or insect digestive tracts, at which point they release the pesticide.6 In combination with the use of
nanoemulsions (suspension of nanoparticles), pesticides can be applied more easily and safely.
21. Nanotechnology is used in packaging to improve the shelf life of foods, for example by the inclusion of
silicate nanoparticles that prevent oxidation and spoilage.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
22. Nanotechnologies and nanomaterials which will have particular relevance in the food sector7 include:
(a) Nanoscale encapsulation technologies, such as nanoemulsions (suspensions of nanoparticles) and
biopolymeric nanoparticles (nanometer sized particles derived from food grade biopolymers such as
proteins or polysaccharides), which can be used to encapsulate, deliver and release food functional
ingredients. These nanomaterials oVer better release eYciency, improved protection from
degradation, and controlled delivery systems for functional ingredients, compared with traditional
encapsulation technologies. The use of nanomaterials in food to sequester, and then enable the
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(b) Food-grade nanoscale coatings (comprising two or more layers of material with nanometer
dimensions) which can be used in the production of edible ﬁlms for foods such as fruits, vegetables,
meats and chocolate. These edible ﬁlms protect foods from (spoilage caused by) exposure to
moisture, lipids and gases, and can also be used to improve the textural properties of food, or serve
as carriers of colourings, ﬂavourings, antioxidants, nutrients and antimicrobials. Nanoparticulate
surfaces may also be used directly to inhibit bacterial growth.
(c) Nanoﬁbres and nanotubes derived from food biopolymers may have applications in the food
industry as elements of environmental friendly food packaging, as scaVolding for bacterial cultures
or to provide support systems for enzymes
(d) Sensor devices which use nanotechnology (eg lab-on-a-chip, cantilever devices) might be used to
monitor foods either for impurities/contaminants or for spoilage.
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
23. The Research Councils support a broad range of activities relating to nanotechnology, which includes
support for research which has or may have applications in the food sector. Some indicative ﬁgures on recent
Research Council investment in the area are provided in paragraphs 24–35 below.
24. TheMRC spent £3.8million on research into nanotechnology (including nanotoxicology) in 2007–08. The
MRC has a current commitment of £900k for two grants which have/may have an application within the food
sector. The MRC is also supporting a programme in one of its units with relevance to the area, with a spend
of £840k in 2007–08.
25. TheMRC’s mission is to improve human health through world-class medical research. Within this remit,
research into both the health beneﬁts and potential health risks of nanotechnology is supported. Research in
this area is funded in responsive-mode and as part of the MRC’s intramural programme. As the potential
therapeutic uses of nanotechnology in food begin to be realised, the MRC expects to receive increasing
applications from the scientiﬁc community in this area. In particular, nanotoxicology has been identiﬁed as a
topic for one of ﬁveMRC “highlight notices”, encouraging applications in nanotoxicology relevant to human
health. The highlight notice has recently been reﬁned, particularly to promote applications involving an in vivo
component. The aim of this highlight notice is to help inform policy development in this important area.
26. EPSRC leads the cross-Research Council Programme on “Nanoscience through Engineering to
Application”,8 which supports investigator-led research and training as well as infrastructure/equipment to
ensure the best use of resources. The programme has also identiﬁed a series of “grand challenges” in
nanoscience and nanoengineering, focused on the areas of energy, healthcare and the environment, spanning
basic research through to application. All of the Research Councils and the Technology Strategy Board are
involved in the programme.
27. In total EPSRC has committed over £220 million to nanotechnology research in the last ﬁve years. None
of this is directly related to food research although a signiﬁcant amount supports underpinning research in
areas such as nanometrology, characterisation and detection that might lead to new measurement or
processing techniques that would be of relevance to the sector.
28. BBSRC has an extensive portfolio of food research (covering the entire food supply chain, from
agricultural processes to dietary impacts), with an estimated spend of £185 million in 2007–08. BBSRC also
has an active nanotechnology portfolio (based on a speciﬁc deﬁnition of nanotechnology, set out at Annex 2),
with an estimated spend of £6.1million in 2007–08. The total BBSRC spending in 2007–08 on research relating
to nanotechnology (as deﬁned above) and food was £0.7 million. Other grants in the BBSRC nanotechnology
portfolio might also have downstream applicability to the food sector.
29. Some of the underpinning technologies developed in areas related to nanotechnology, such as drug
delivery, materials and sensors, could also potentially be applied to the food sector. Using a broader deﬁnition
of nanotechnology (encompassing related areas of drug delivery, materials, sensors, tissue engineering and
tools), the total BBSRC estimated spend in 2007–08 on research relating to nanotechnology and food was
£4.5 million.
8 http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/default.htm
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30. Many conventional foodmaterials contain structures at the nanoscale. BBSRC supports research on food
structure and processing within a broad category of “food manufacturing”. BBSRC’s estimated 2007–08
spend on food manufacturing research (a subset of the food research portfolio) was £5.3 million, a signiﬁcant
proportion of which was awarded as Core Strategic Grant funding to the Institute of Food Research. The
Institute of Food Research will be providing independent evidence to this inquiry.
31. ESRC has funded research on more cross-cutting issues which relate to food. Research questions include:
what are the key drivers of public and scientist perceptions of risks and opportunities of nanotechnologies in
this application?; what is the likely impact on industry and economies, including from the convergence of nano
with other technologies?; how will the global development of science and innovation and their multi level
regulation-aVect these technologies?; how, when and why will public engagement and social inﬂuences aVect
development of these technologies?
32. The ESRC has also carried out an authoritative review of the social, ethical and economic aspects of
development of nanosciences and nanotechnologies. The reports, published in 20039 and a follow-up in
2007,10 explain what nanotechnology is as well as its existing and potential consequences, and identify
important issues for research and society.
33. In January 2009 a workshop on “Nano: Regulation and Innovation: The role of the Social Sciences and
Humanities”, facilitated by a UK academic and supported by the Research Councils was held at the RCUK
Beijing OYce. The workshop, jointly presented by bothUK andChinese academics, covered aspects of ethical
challenges, and governance and regulation.
34. Cross-Research Councils programme and activities relating to nanotechnology are outlined at Annex 1.
35. Details of Research Council Units, Centres and sponsored Institutes that conduct research relevant to this
inquiry are at Annex 3.
What are the barriers to the development of new nano-products or processes in the food sector?
36. Regulatory considerations, economic viability and consumer acceptancewill ultimately dictate the success
of nanoproducts and nanotechnologies in the food sector.
37. Continued uncertainty over EU/UK regulations for the use of nanotechnologies and nanomaterials in the
food sector may stiﬂe research and development in the area. A clear regulatory and risk assessment framework
would serve to increase (public) conﬁdence in technologies, and stimulate investment in food-related
nanotechnology research.
38. Development of new nanoproducts or processes must be coupled to appropriate research into, and risk
assessments of, the potential eVects of those technologies. Adequate funding for research into the
environmental and health and safety implications of nanotechnologies will be essential to their application and
acceptance in the food sector.
39. Further underpinning research to develop understanding in areas such asmolecular self-assembly, surface
engineering and techniques such as electrospinning, will be vital for reliable production of nanoscale
structures. Further research is also needed on measurement and characterisations systems so that they can be
deployed on a widespread basis.
40. There are limited funding opportunities targeted directly at nanotechnology applications in the food
sector, compared with competing application areas (eg healthcare, energy). In the current economic climate,
where industrial/commercial sector funding for research may also be limited, there is a risk that the
development of new nanoproducts or nanoprocesses related to food will be restricted.
Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials in the food sector? In which areas does our understanding need to be developed?
41. Nanotechnologies have the potential to cause harm as well as beneﬁt, but their toxicology and
toxicokinetic properties are notwell understood. The same unique properties that confermany of their beneﬁts
may also cause damage to the body in unexpected ways. The MRC has made awards at a total level of £3
million for research projects in the area of nanotoxicology. This research aims to better understand the uptake
of nanoparticles into cells and the functional consequences including oxidative stress, inﬂammatory response,
cell death and genotoxicity. By linking this information to the physical and chemical characteristics of
9 http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/Images/Nanotechnology tcm6-5506.pdf
10 http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/Images/ESRC Nano07 tcm6-18918.pdf
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nanoparticles, predictive models for nanoparticle toxicity can be developed that will help risk assessment. A
lot of this work is currently focused on the lung and, although some of the principles may be transferable to
other organ systems, more evidence is needed to inform policy and regulation.
42. The MRC has a current commitment of £900k (see para 26 above) for two grants relevant to the health
and safety implications of the use of nanotechnologies in relation to food.
43. ESRC’s remit covers research into the health and safety implications of nanotechnologies and
nanomaterials in the food sector, however currently there are no projects being funded directly related to
this area.
44. EPSRC funds potentially relevant research in the area of developing new methods of measurement and
characterisation.
45. The Research Councils also support research into the environmental impacts of nanomaterials and the
potential eVects of environmental exposure on human health, for example through the Environmental
Nanoscience initiative and the Environment and Human Health initiative, both led by the Natural
Environment Research Council (NERC). However, this is largely outside the scope of the present inquiry.
Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the food sector
sufficient? Are current funding mechanisms fit for purpose?
46. The Research Councils have a variety of funding mechanisms through which research into the health and
safety implications of nanotechnologies and nanomaterials can be supported:
— Responsive mode—applications are accepted at any time and in any research areas which fall within
the Council’s remit. Highlight notices, signposting or identiﬁcation of priority areas may be used to
encourage submission of applications in particular areas.
— Research programmes at Research Council Units, Centres and sponsored Institutes (see Annex 3)
— Nanotechnology grand challenges11—the primary delivery mechanism for the cross-Council
programme “Nanoscience through Engineering to Application”, each Grand Challenge works
through a stage gate process, starting with the basic science but looking to the issues of scale up,
including reliability, reproducibility and safety considerations. The two Nanotechnology Grand
Challenges established so far do not relate directly to food sector applications, though safety issues
identiﬁed in other application areas (eg healthcare/nanomedicines) may be of relevance.
47. The current Research Council funding portfolio for research relating to the health and safety implications
of nanotechnologies and nanomaterials in the food sector is relatively small (see paragraphs 41–45 above). It
is likely that further research will be needed to inform policy and regulation, and the Research Councils will
continue to welcome applications for research in this area through the mechanisms described in paragraph
46 above.
Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to nanotechnologies
and nanomaterials for consumers? If not, what amendments are necessary?
48. The draft scientiﬁc opinion published by the European Food Safety Authority,12 highlights current
uncertainties for risk assessment of nanotechnologies (speciﬁcally engineered nanoparticles—ENMs) and
their possible applications in the food sector. The reports states that: “Current toxicity testing approaches used
for conventional materials are a suitable starting point for case-by-case risk assessment of ENMs. However,
the adequacy of currently existing toxicological tests to detect all aspects of potential toxicity of ENM has yet
to be established”, and recommends that “risk assessment of ENM in the food and feed area should consider
the speciﬁc properties of ENM in addition to those common to the equivalent non-nano form”. The report
recognises that formulation at the nanoscale changes the physico-chemical characteristics of materials as
compared to the dissolved and macroscale forms of the same substance, and that properties such as particle
size, surface-to-mass ratio and surface reactivity will be important for new applications, and in establishing
the associated potential health and environmental risks.
11 http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/RC/grandchallengesnanotech.htm
12 European Food Safety Agency, Draft opinion of the Scientiﬁc Committees on the Potential Risks Arising from Nanoscience and
Nanotechnologies on Food and Feed Safety, (October 2008) http://www.efsa.europa.eu/cs/BlobServer/DocumentSet/
sc opinion nano public consultation.pdf?ssbinary%true
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Are the risks associated with the presence of naturally occurring nanomaterials in food products any different to those
relating to manufactured nanomaterials? Should both types of nanomaterials be treated the same for regulatory purposes?
49. Many foods naturally contain nanoscale materials; these are not considered to require additional
regulation. For manufactured nanomaterials, even when derived from naturally-occurring nanomaterials,
appropriate assessments of risk and safety shouldbemade. Inmany cases, there is noprior reason to expect that
manufactured nanoparticles would be anymore hazardous than naturally-occurring ones. Regulations should
then be risk-based and proportionate.
RegulatoryFramework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food products
containing nanotechnologies and nanomaterials regulated?
50. here are currently no internationally accepted deﬁnitions of “nanotechnologies” or “nanomaterials”,
leading to problems both for industry and regulatory bodies in terms of labelling protocols, risk management
strategies andmethods for regulatory data capture.
51. Regulations should ideally cover the entirety of the process—from basic idea to product development and
commercialisation—in a consistentmanner. Internationalmutual recognition of standards should be a parallel
consideration.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
52. The UKVoluntary Reporting Scheme for engineered nanoscale materials, co-ordinated by Defra, was set
up for industry and research organisations to provideGovernmentwith information relevant to understanding
the potential risks posed by free engineered nanoscalematerials, though this was not speciﬁc to the food sector.
53. It may be beneﬁcial to compare the UK’s experience of voluntary reporting with the impacts of new
regulations elsewhere in the world, eg Canada’s proposed mandatory reporting requirement for nanoscale
materials.
54. Use of voluntary regulatory codes in other areas has often been directed more at public relations than at
standard setting. As such voluntary codes cannot be considered as adequate replacements for eVective
regulation.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
55. Regulatory and risk assessment frameworks should be informed by research into the environmental and
health and safety impacts of nanotechnologies and nanomaterials in the food sector. Regulations should be
reviewed regularly to ensure they remain ﬁt-for-purpose as new technologies andmaterials are developed.
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from regulatory
systems in other countries?
56. Intergovernmental co-operation should address the responsibility in research, and the need to share
knowledge of potential or emerging hazards between stakeholders in a reasonably openway.
57. Dependingon thedeﬁnitionof“standards”, ISO(InternationalStandardsOrganisation)TC229 (Technical
Committee) is deﬁningbasic standards suchas“nanotechnology”; theUKiswell connectedwith this and chairs
theCommittee (Defra leads in this activity) There is also a signiﬁcantOECDactivity in this area, where theUK
is playing a signiﬁcant role (Defra leads in his activity), though thismay be outside the scope of “food”.
PublicEngagement andConsumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
58. An initial point to note with reference to public awareness of nanotechnologies is that although terms such
as nanomaterial or nanotechnology have speciﬁcmeanings to scientists, their deﬁnitions are blurred in popular
language. This is indicative of the limits of the information available with which to engage the public. There is
little information about how commercial and public developers intend to use nanotechnology, few if any
commercially available products and no speciﬁc formal risk assessment and regulatory processes are in place.
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59. Further, it should be noted that the debate around nanotechnology and food is likely to be a “lightning
rod” for a range of other issues which will require careful handling, for example corporate control, use of
patents, relationship between government regulatory procedures and industry, and in particular the
precautionary principle and the safety of nanoparticles. This poses a risk that any possible issues speciﬁc to
nanotechnology and food become lost in wider debate. Framing of the engagement to avoid or minimise this
is therefore required, though it is also important to maintain an awareness of public engagement activities
undertaken in related areas (eg nanomedicines), where comparable issues may be raised.
60. The industrial, scientiﬁc and regulatory community should not take public acceptance for granted,
especially whilst potential safety risks are being openly acknowledged. Despite a deﬁcit of “hard facts”, the
public could and should be involved, even at an early stage, in identifying key concerns and laying down
benchmarks so that systems are in place to deal with issues as they arise when more evidence emerges. The
Research Councils have been involved in several public engagement activities (see paragraph 63 below).
61. In depth focus groups (conducted for the ESRC SCARR network by CardiV University School of
Journalism, Media and Cultural studies) found the following:
— few people who participated in the research knew anything at all about nanotechnology;
— if people “know”’ anything about nanotechnology they tend to associate it with medical treatments
(eg mini robots healing sick people) or minaturisation serving consumer convenience (eg “Ipod
Nano” brand);
— the current association of nanotechnolgy with medical science or consumer-senstive business gives
it a diVerent—more positive—proﬁle than GM crops (GM was most associated with food and
industry-out-for-proﬁt).
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
62. All of the Research Councils are committed to public dialogue and engagement around the research they
fund, and recognise the need to be as open and transparent as possible about the publically-funded research
they support. Details of funded research grants, including any industrial or other commercial co-funding, are
published on the relevant Research Council website.
63. The Research Councils have been involved in several public engagement activities used to examine public
perceptions of nanotechnology (see Annex 4), though these have not related speciﬁcally to the use of
nanotechnologies in the food sector, where public acceptance will be critical.
64. Initially, small scale deliberative dialogues may be an appropriate way to engage the public about
nanotech applications in the food sector. This would help to scope a wider public engagement, and could
follow a format similar to, and build on, those that have already taken place around other aspects of
nanotechnology. This would enable an understanding of likely public attitudes including nanotechnologies
speciﬁcally associated with foods, and reactions to some speciﬁc actual or possible applications. This will
inform as to how the technology and its potential might be discussed most constructively both to raise public
awareness and engender public participation in shaping research and policy development, and regulation
(including labelling).
65. Public engagement should be independently co-ordinated (eg not by Government or industry) and
overseen by a panel representing a wide range of stakeholder opinion.
66. It is important to ensure that industry are involved in public dialogue surrounding new technologies from
an early stage, to build trust between public authorities, industry and NGOs.
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
67. The timing of public engagement is important. In the past, engagement activities have been most
successful (eg stem cells) where they have been pre-emptive of signiﬁcant breakthroughs in the development
of new technologies, but where the underlying principles are widely available and disseminated. This has
allowed the public to help inﬂuence the direction that the technology takes and to ensure that it is regulated
to a level that they feel comfortable with. The Royal Society/Royal Academy of Engineering report
“Nanoscience and Nanotechnologies: Opportunities and Uncertainties”13 (2004) strongly recommended
“upstream” public engagement.
13 http://www.nanotec.org.uk/ﬁnalReport.htm
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68. Limited current awareness of nanotechnology and its breadth as a subject and range of potential
applications in food, will be challenges in public dialogue.Whilst the public will have many, probing questions
which they will rightly expect answers to, the information may simply not be available to answer those
questions. Engagement activities should handle this uncertainty openly and positively, so that it does not
trigger negative attitudes towards nanotechnology even before the beneﬁts of the technology are apparent.
69. Applications in food, as opposed say to medical uses, are likely to raise concerns about ownership,
consumer choice, and adulteration of natural processes, as seen in the GM debate.
70. Organisations such as AHRC/SCRIPT and Innogen have long-standing experience in related ﬁelds (eg
biotechnology, GM food etc) on which it would be prudent to draw.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
71. Previous experience with GM food has shown that the public values transparency and choice. This
suggests that it would be advisable to provide information or even labelling, about products that contain
nanotechnologies or nanomaterials. However, this might inadvertently imply hazards, or be completely
meaningless or confusing to consumers. Any information that is provided should be accurate, impartial and
balanced, and clearly distinguished from any advertising.
72. Public engagement should involve asking people what information they want. Information about why




CROSS-RESEARCH COUNCIL PROGRAMMES AND PARTNERSHIPS RELATED TO
NANOTECHNOLOGY
RCUK Nanotechnology Group
Across-council groupwhich co-ordinates Research Council activities in the area of nanotechnology, including
Research Councils’ inputs into the NRCG/NIDG. This group also includes representation from the
Technology Strategy Board.
Nanoscience Through Engineering to Application
http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/Intro.htm
A cross-Council programmewhich operates primarily through a series of Grand Challenges aimed at enabling
nanotechnology to make a unique contribution to areas of societal importance such as energy, healthcare or
the environment. Each Grand Challenge works through a stage gate process, starting with the basic science
but looking to the issues of scale up (reliability, reproducibility, safety etc). The programme has also supported,
through EPSRC, three centres for doctoral training and an equipment sharing scheme. The Programme is
managed by the RCUK Nanotechnology Group.
Annex 2
DEFINITIONS
RCUK has adopted the following deﬁnitions, provided by the Royal Society/Royal Academy of Engineering
report “Nanoscience and Nanotechnologies: Opportunities and Uncertainties”14 (2004):
Nanoscience is the study of phenomena and manipulation of materials at atomic, molecular and
macromolecular scales, where properties diVer signiﬁcantly from those at a larger scale.
Nanotechnologies are the design, characterisation, production and application of structures, devices and
systems by controlling shape and size at nanometer scale.
In conducting portfolio analyses, BBSRC used the following deﬁnitions:
Nanotechnology is the ﬁeld of science focused on the design, synthesis, characterisation and application of
materials and devices at the nanoscale. This involves the control and characterisation of properties at a
molecular level, rather than inferring (hence controlling) properties from macro-scale performance. More
14 http://www.nanotec.org.uk/ﬁnalReport.htm
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broadly, nanotechnology includes the many techniques used to create or manipulate structures at a size scale
below 100 nm.
Includes:
— fabrication of DNA nanowires, DNA tweezers or DNA based nano structures and machines;
— lithography techniques;
— molecular self-assembly techniques;
— molecular motors;
— molecular machines;
— studies involving scanning probe microscopy and arrays/microarrays;
— MEMS (microelectromechanical systems); and
— miniaturisation and single molecule studies.
Excludes:
— Research included in the broader deﬁnition of bionanotechnology, ie drug delivery, biomaterials,
sensors, tissue engineering, tools—unless included according to the deﬁnition above.
Annex 3




The BBSRC institutes conduct long-term, mission-oriented research using specialist facilities, some of which
are unique in the UK or internationally (such as animal disease containment facilities, long-term ﬁeld
experiments). They maintain strong interactions with industry, government departments and other end-users
of their research to provide advice and promote knowledge transfer, and are leading partners in numerous
overseas collaborations. BBSRC institute that conduct research of particular relevance to this inquiry are:
— Institute of Food Research (Norwich)—food structure, quality and safety, diet & health. The
Institute of Food Research will be providing independent evidence to this inquiry.
— John Innes Centre (Norwich)—plant and microbial science underpinning crop production.
— Rothamsted Research (Harpenden) and North Wyke Research (Devon)—arable and grassland
agricultural systems, including long-term ﬁeld experiments (some continuous since 1843).
ESRC Centres
CARR, the ESRC-funded Centre for Analysis for Risk and Regulation15 is an interdisciplinary research
Centre which focuses on the organisational and institutional settings for risk management and regulatory
practices. CARR has identiﬁed that there is a great deal of regulation and governance research which is at the
core of CARR’s work; for example: learning from the attempts to regulate previous novel materials; issues
around the framing, enforcement and impact of regulation; examination of how risk and uncertainty are
handled in regulation and governance situations Another aspect of CARR’s remit is analysing how diVerent
groups work together and regulate ie state regulators and regulators who are situated beyond the state eg
Professional groups (eg scientists), industry groups and other forms of self-regulation. Also relevant of course
is the potential for public engagement.
Cesagen (the ESRC Centre for Economic and Social Aspects of Genomics),16 a collaboration between the
Universities of CardiV and Lancaster, focuses on the social, policy, economic, ethical and legal aspects of
“genomics” and associated developments. This is focused primarily upon genomics-related sciences, and such
molecular-scale sciences and interventions encompass nano research and innovation. Issues such as whether
the development of nanotechnology requires the development of new ethical and/or regulatory approaches or
principles are being researched.
15 http://www.lse.ac.uk/collections/CARR/
16 http://www.genomicsnetwork.ac.uk/cesagen/
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Innogen (ESRC Centre for Social and Economic Research on Innovation in Genomics)17 is a collaboration
between the University of Edinburgh and the Open University. Research includes work on strategies to
facilitate interdisciplinary science (as in nanotechnology), company strategies for the development of socially
beneﬁcial innovations, and the eVective governance of life sciences; and key researchers are involved in the
development of a new approach to risk governance of nanotechnology, particularly to bring in more eVective
public engagement and a more sensitive approach by companies to public concerns.
SCARR (Social Contexts and Responses to Risk) is a recently completed research network which looked at
risk in everyday life and how the actual risk, or those risks identiﬁed as high priority by organisations such as
government or business, may diVer from people’s perceptions.18 This included work in the ﬁeld of
nanotechnology.
STEPS (Centre for Social, Technological and Environmental Pathways to Sustainability at the University of
Sussex) has investigated nanotechnology as one example of the eVects of new technologies on people and the
environment, in the context of developing countries.
BRASS (Centre for Business Relationships, Accountability, Sustainability and Society at the University of
CardiV), produced a policy brieﬁng entitled “Nanotechnologies: Gaps in the Regulatory Framework”.19 The
current regulatory framework was designed to regulate traditional technologies. The policy brief considers a
report produced by BRASS and asks whether the current regulatory framework is suYcient to regulate free
engineered nanoparticles (development, manufacture, supply, use and end of life).
MRC Units and Centres
http://www.mrc.ac.uk/Ourresearch/Unitscentresinstitutes/index.htm
The MRC funds a range of directly-supported units, several of which conduct work relevant to
nanotechnology and food:
— MRC Human Nutrition Research (Cambridge)—this “collaborative centre” exists to develop the
evidence underpinning public health nutrition strategies. It provides a national centre of excellence
for the measurement and interpretation of biochemical, functional and dietary indicators of
nutritional status and health. Work currently conducted in this Unit includes the use of
nanotechnology to regulate mineral uptake from foods, and the associated heath (and safety)
implications of this technology.
— MRC Toxicology Unit (Leicester)—this Unit aims to study and understand the fundamental
mechanisms of toxicity, particularly mechanisms of cellular and tissue response to injury caused by
drugs, chemicals and endogenous molecules. The study of nanotoxicology comes within this remit.
The MRC Toxicology Unit also manages the Integrative Toxicology Training Partnership (ITTP).
ITTP aims to build capacity in toxicology and related disciplines that is required to ensure the save
and eVective development of drugs, chemicals and consumer products through partnerships between
academia, industry and government. The initiative has a budget of x£3.5 million and so far 20
studentships and one career development fellowship have been awarded to UK Universities,
including projects to investigate the toxicity in nanoparticles.
Annex 4
RCUK INVOLVEMENT IN PUBLIC ENGAGEMENT ACTIVITIES RELATED TO
NANOTECHNOLOGY
EPSRC Consultation on Nanotechnology for Healthcare
As part of the nano Grand Challenge in Healthcare, developed through the cross-council theme Nanoscience
through Engineering to Application, EPSRC conducted a public dialogue exercise. Information on this activity
is available at: http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/RC/ConsultNanoHealthcare.htm
NanoJury UK
BBSRC provided ﬁnancial support to NanoJury UK, which took place in summer 2005.
This “citizen’s jury” brought together 20 people, chosen to represent a broad cross section of society but also
inclusive of a number of ethnicities and religions, to discuss issues surrounding nanotechnology.
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NanoJury UK was sponsored by Greenpeace UK, The Guardian, The IRC in Nanotechnology at the
University of Cambridge, and the Policy, Ethics and Life Sciences Research Centre at Newcastle University
Nanodialogues
The Nanodialogues project, led by Demos, was a series of four public engagement experiments about
nanotechnology, which ran from 2005–07.
BBSRC and EPSRC were involved in the second of the four experiments, which set out to answer two
questions:
— What are the sorts of questions that are likely to determine future public response to nanoscience and
nanotechnologies?
— What should public engagement with early technologies look like and how can Research Councils
build public value into their work?
The project report and evaluation are available at:
http://www.bbsrc.ac.uk/society/dialogue/activities/nanotechnology.html
BBSRC “What is Nano?” Exhibition and “Nanotechnology and You” Meeting
The Government’s 10 Year Investment Framework for Science and Innovation, and the think-tank Demos in
their leaﬂet “See-through Science”, called for public engagement early on in the development of technologies,
such as nanotechnology.
BBSRC’s ﬁrst “Nanotechnology and You” discussion meeting took place at Edinburgh International Science
Festival in April 2006, supported by BBSRC’sWhat is nano?Exhibition. A summary of the discussionmeeting
is at: http://www.bbsrc.ac.uk/society/meetings/archive/meeting nanotech.html




Witnesses: Dr John Wand, Engineering and Physical Sciences Research Council; Dr Declan Mulkeen,
Medical Research Council; Professor Peter Fryer, and Dr Amanda Collis, Biotechnology and Biological
Sciences Research Council, examined.
Q384 Chairman: I would like to welcome our four
witnesses to this, the seventh public hearing of our
inquiry into nanotechnologies and food. Just to
inform you that the proceedings are being web cast
and also to draw attention to the information note
which is available tomembers of the public which sets
out members’ declared interests, so we will not be
repeating those whilst asking questions. Before we
come on to the questions that we wish to put to you,
I would like to invite the four witnesses to introduce
themselves brieﬂy, starting with Dr Collis and
moving along the row, and also to put a request to
you that when answering our questions you keep
your answers as succinct as possible because we have
got quite a lot to get through in the hour or sowe have
ahead of us and that would be helpful to us. Perhaps
I could invite Dr Collis to lead oV, introduce yourself
and if there are any opening points you would like to
make, please do so.
Dr Collis: Thank you, my Lord Chairman. I am Dr
Amanda Collis from the Biotechnology and
Biological Sciences Research Council where I am
Head of Engineering, Data and Tools. Within that
remit nanotechnology, and speciﬁcally bio-
nanotechnology, falls. Thank you.
Dr Mulkeen: Good morning. My name is Declan
Mulkeen from the Medical Research Council. I am
the Director of Research and Training. I have overall
responsibility for the research programmes
supported through the MRC’s boards and special
calls.
Dr Wand: Good morning. My name is John Wand. I
am from the Engineering Physical Sciences Research
Council where I am head of that Council’s
Nanotechnology Programme and also leader of the
cross-Council Programme on Nanoscience through
Engineering to Application.
Professor Fryer: Good morning. I am Peter Fryer. I
am Professor of Chemical Engineering at the
University of Birmingham. I am on BBSRCCouncil.
My research interests are applications of engineering
principles to food processing, and Fryer is probably
an unfortunate name in that context, and I have
published on food nanotechnology and have
experience in that area.
Q385 Chairman: Thank you very much. Perhaps I
could kick oV with a rather general question to ask
you as representatives of theResearchCouncils.How
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are funding priorities in relation to research in
nanotechnologies determined? What mechanisms do
you have for that? How will you monitor progress in
funding and the implementation of any plans that
you have in relation to funding nanotechnologies?
Dr Wand: If I start from the cross-Council
perspective. We have an allocation for the cross-
Council programme from what was DIUS. We work
through that on a continuous basis through a cross-
Council group called the RCUK Nanotechnology
Group, which I chair, and part of what we do then
feeds into the cross-governmental exercise, in
particular through the Nanotechnology Research
Coordination Group.
Q386 Chairman: How large is this programme in
terms of annual fund?
Dr Wand:For the three year Spending Review period
it is £50 million.
Q387 Chairman: So £50 million over three years?
Dr Wand: Yes.
Q388 Chairman: Does anybody else wish to add
anything to that?
Dr Mulkeen: Could I come in from the MRC’s
perspective. The MRC’s investments divide into two
parts: one would be about medical applications of
nanotechnology and the other is related to safety. In
the earlier days of Research Council work on
nanotechnology we actively promoted
interdisciplinary work through Discipline Hoppers
and other grant schemes to try to link medical,
therapeutic and diagnostic science with the sort of
science that the EPSRC and other Councils were
supporting. That ﬁeld is now being managed mostly
through responsemode, so although there is a general
body of work across Councils to raise the proﬁle of
the area, there are not special calls out for it. We are
still in response to advice from CST, the Royal
Academy of Engineering and RCEP actively
promoting and calling for proposals in areas related
to nanotoxicology and safety. So we have reached the
stage within the MRC where part of our work is
managed in a more laissez faire way and part of it is
managed more proactively.
Dr Collis: If I may add from the BBSRC perspective,
when we look at our research portfolio in the broad
area of nanoscience, nanotechnology, there are three
categories. A lot of bioscience takes place at the nano
scale anyway, and has done for thousands of years
and, indeed, that is one class, and quite a large class,
of the work that we support. Then we have a class of
what I would term nanoscience which in the context
of food is perhaps using new analytical technologies
that provide better resolution, greater detail of food
structures to understand better the nature of those
structures. Then we have the bio nanotechnology
which has principally been in the area of
nanomedicine and also the development of new
analytical technologies. With regard to the process
through which we identify priorities, following on
fromDeclan’s comments, that is very much informed
by reports such as the Royal Academy of
Engineering/Royal Society report and the work of
groups such as the NRCG and the NIDG, but also
receiving input from our advisory boards, such as our
Tools and Resources Strategy Panel and also our
Strategy Advisory Board.
Q389 Chairman: Thank you. Just referring back to
the Royal Society/Royal Academy of Engineering
Report, one of the recommendations was that the
Research Councils should establish an
interdisciplinary centre to research the health and
safety implications of nanoparticles, to coordinate
research in this area and to liaise with regulators.
That has not happened but how do you justify the
alternative approach that you have taken?
Dr Mulkeen: The Safety Science community in the
UK is quite small but it is quite well networked. One
of the challenges that we have realised we face in the
UK is that toxicology in Safety Science was a
discipline that was shrinking rather than growing in
the academic base and over the last few years we have
had to take steps to strengthen that. The aim was
more to get the centres that had strength in
toxicology and Safety Science engaged with the
nanotechnology agenda rather than to try to
reorganise.
Q390 Chairman:Are there other comments to add to
that? Dr Wand?
Dr Wand: Yes, from a cross-Council perspective we
coordinate things through the RCUK
Nanotechnology Group and through the
Nanotechnology Research Coordination Group. As
a result of that we have done a number of things from
a multiple funders’ perspective, perhaps not in the
area of food safety speciﬁcally but if you take the
environmental area, for example, with the
Environmental Nanoscience Initiative which NERC
has led on, but that has had involvement in phase one
in a major way from Defra and the Environment
Agency and co-funding from BBSRC and EPSRC.
As we move into phase two we have had to involve
EPSRC again and also Defra and the Environment
Agency in a supporting role as well, and jointly with
the US Environmental Protection Agency in that
regard. In a lot of these areas the research spans more
than just the Research Councils’ areas of interests, so
how can we work together as a more coordinated
body in order to bring all these interests to bear in a
coordinated way?
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Q391 Chairman: Are any of you familiar with the
German initiative to establish a virtual laboratory
called NANOTOX?
Dr Collis: No.
Dr Mulkeen: No, sorry.
Q392 Chairman: I was going to ask whether you
thought this would be a useful initiative for the UK
to consider as a possible model.
Dr Mulkeen: My Lord Chairman, we are not familiar
with it but there is a very useful report coming out on
mapping the international eVorts in—
Q393 Chairman: Sorry, where is that coming out
from?
Dr Mulkeen: The EMERGNANO report in the last
day or so.
Dr Collis: The EMERGNANO report, which I
understand is commissioned by Defra reporting into
the NRCG and is being undertaken by one of the
projects funded through the Micro
Nanotechnologies Programme, will imminently
publish a worldwide assessment of the research that
is ongoing in the health and safety aspects of
nanotechnology and nanotoxicology. That, of
course, will be something which Research Councils
will consider when setting their priorities in this area
and it helps us to coordinate and not duplicate what
is happening within the UK but also more widely
within Europe, the US and the rest of the world.
Dr Mulkeen: I raised that because while not familiar
with the German initiative in its detail, we think we
are getting close to the stage in the UK where we will
need to take a more active approach to networking
across the various research groups. Our focus within
MRC over the last few years has been about
developing strands of toxicological and Safety
Science in one or twomore generations, andwemight
talk about that later. Over the next few years we need
to start looking at other areas of science that should
be connected with that core of nano safety science
and also to look at how that science as it starts to
create valuable knowledge is networked with the
various companies from engineering and materials
science and the various companies on the food
science side so they can start to factor in at an earlier
stage. I think it would have been premature to do that
a couple of years ago, but looking at the small
portfolio that we have got, looking at its quality and
its potential, we are getting to the point where we
need to start doing that.
Professor Fryer: Certainly in the States a lot of the
large companies are now driven very much by how
the FDA would respond to these sorts of issues and
the FDA are having some questions about how they
would regulate nanotechnologies, so the need is to
bring these together.
Q394 Lord Haskel: Just following on from this, we
have had a lot of evidence that there are major gaps
in the scientiﬁc knowledge base required for risk
assessment of nanotechnologies and nanomaterials
in food. We have also been told that there are
products nearing the market which have either been
processed with or contain this technology. What are
the Research Councils doing to ensure that these
knowledge gaps are ﬁlled before these products
actually reach the market and the public?
Dr Mulkeen: The problem of products emerging for
which there is not an adequate science base to assess
the safety is a real problem and it is one that is a
concern for the regulators as well as the Research
Councils. We see the Research Councils’ primary
responsibility as making sure that the fundamentals
of the generic science base that regulators need to
workwith that could be applied to whatever products
come out is well developed. That is what people
would look to the Research Councils to do ﬁrst and
foremost. Of course, there are other aspects that
Research Councils ought to be helping in in terms of
feeding that science quickly into the knowledge pool
of regulators and industry and also looking at the
safety aspects of, say, health or practical applications
of nanotechnology that are funded by Research
Councils themselves. You are absolutely right, there
are quite large gaps in our knowledge. At themoment
regulators have to take risk assessments based on
knowledge that is weaker than in other domains. We
would point in particular to the fact—you have
probably heard this already—that themode of action
of a nanoparticle that has a toxic eVect or health
hazard attached to it may be quite diVerent from the
toxicological action of a newmedicine and, therefore,
what we need to see is science emerging that is not
linked to a particular way of thinking that is in
classical toxicology. Some of the initial science that
came through when the MRC started promoting the
area was based around a few key hypotheses, that the
mode of action was the opposite of stress, and we are
now starting to see more hypothesis-free science
coming out using expression arrays, proteomics, to
look at the general state of health of cells without
having to go into the experiment with a presumption
about what precise eVect you would have, but with a
greater chance of picking up whatever eVect is there.
That is the sort of role the Research Councils should
be concentrating on ﬁrst and foremost to apply that
generic toolkit.
Professor Fryer:There is also a question about science
that is missing. We know really very little about
physically how material gets from the gut through
into the body. It is quite clear that materials must go
through a nano state—it starts as a yoghurt up here
and ends up in the bloodstream—but how that is
done physiologically is not known in detail, so the
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question of how any particle, be it a nanoparticle or
not, would behave under those circumstances is not
straightforward.
Q395 Lord Haskel: This is obviously a very
important gap in knowledge as regards
nanotechnology in food. What steps are you taking
to ﬁll this gap?
Dr Mulkeen:Could I say ﬁrst of all what we have been
doing since 2007 on nanotechnology generally and
then pass on to colleagues to talk about food.
Q396 Lord Haskel: The knowledge about
nanoparticles in the gut.
Dr Mulkeen: From the MRC’s points of view we are
happy generally with the progress we havemade since
we put out the highlight notice and started promoting
application of this in this areamore actively inMarch
2007, and we have updated that since. We are happy
with the response to that. A weakness that I would
concede is that the response has not included enough
gut work. It is a highlight notice that we think we will
be updating quite regularly over the next few years as
the science moves on. Right now we need to push out
a stronger message about gut physiology and also
some of the tissues, such as the nervous system.
Q397 Chairman: How many research groups in the
UK do you support who work on nanoparticle
toxicology from the point of view of the gut?
Dr Mulkeen: There is one group which has given
evidence to you, which is Jonathan Powell’s group,
which looks both at therapy and others. With the
proposals that are coming through now using Omics
approaches, they should be applicable to a number of
tissues but they are not looking exclusively on the gut.
Q398 Chairman: So is the answer one?
Dr Mulkeen: The answer is one exclusively, but even
there that group is working partly on using
nanotechnology to improve delivery of iron through
the gut as well addressing the safety concerns. The
portfolio that we have is very dominated by
respiratory exposures driven by the fear of carbon
nanotubes having asbestos-like characteristics.
Q399 Lord Haskel: Of course, the eVect of
nanoparticles in the gut will be both long-term and
short-term. Is there any work being done to look into
the long-term chronic eVects of nanoparticles?
Dr Mulkeen: As separate from the short-term eVects?
No. It is too early in the state of our knowledge to say
that you could pursue one particular experimental
line because there are some eVects we are looking at
chronically and some short-term. On areas such as
inﬂammation, as experiments progress they could be
unveiling either a short-term or long-term
inﬂammatory damage process. Not speciﬁcally
separate programmes on the chronic eVects.
Q400 Lord Haskel: Do you have any plans for that?
Dr Mulkeen: What we would like to see is more gut
work coming through the core generally of all sorts,
a broad spectrum.
Q401 Lord Crickhowell: Forgive me, I am not a
scientist and I know very little of the work of the
Research Councils, but I must say the answers that
we have received so far this morning leave me
bewildered. Here you are talking about structures
that coordinate and get research going in the right
direction and, as has already been said, we have had
evidence about very obvious gaps and urgent areas
that need research, yet I do not get a sense that
anything has been done or is being done to actually
get the work heading in this direction. I am worried
by the general air of, “Oh well, it’s very early, it’s all
very diYcult. We need to have more knowledge
before we set oV in a particular direction”. Am I
wrong in thinking that so far there is no real
coordinated eVort in this country—it appears to be
working slightly better in some other countries—to
get the research going in areas where there are
obvious gaps?
Dr Mulkeen: Could I comment from what the MRC
has done, which is not just about the gut, and then
pass over to Amanda.
Q402 Lord Crickhowell:The gut is one area but there
is a whole range of areas where there does not seem
to be an eVort to direct us into a ﬁeld which is clearly
going to be of crucial importance for regulatory eVort
and so on and where risk assessment at the moment
is very diYcult because we have not got the basic
knowledge. Surely this is an area where the Research
Councils ought to be able to coordinate and push
things rather further than I get the impression you are
able to do.
Dr Mulkeen: At the MRC we started promoting the
area inMarch 2007. Since thenwe have committed an
extra £3 million and at around the same time the
Department of Health committed slightly over half a
million. The ﬁrst few proposals that came in were tied
to a particular mechanism of action in the sense that
they were narrower proposals but good quality
science. We then took a look at what was coming
through and decided we needed to broaden it out,
encouraged a wider range of proposals and
encouraged people to come in with applications that
looked at nanoparticles in the context of the whole
body rather than cells in vivo. That second step was
successful as well and we have brought through some
very good high quality proposals. In the summer we
intend to put out a new statement to the community
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of what we now think the deﬁciencies are and what
the next step of gaps that wewant to see addressed are
and if the community is as responsive as it has been
over the last 18 months we think we will get in good
quality proposals there as well.
Q403 Lord Mitchell: Could I change the question
just a little to all of you. One of the areas where I have
been concerned is the area of alcohol and dangers to
the unborn child of mothers who drink alcohol and
the fact that alcohol ﬂows across the placenta and is
unable to be dealt with by the foetus. I am just
wondering as far as nanoproducts are concerned
whether this could be the same issue.
Dr Mulkeen: That it could pass into the foetus?
Q404 Lord Mitchell: Yes, because the foetus cannot
process it.
Professor Fryer: The simple answer is I do not know
but I suspect not because alcohol is a substantially
smaller molecule than anything that we would be
talking about in this context. If you are talking about
species that are at the 100/200 nanometre scale, this is
substantially bigger. My belief is that it is not
possible, but I will ﬁnd out.
Chairman: Perhaps you could let us have a follow-up
note on that particular point.
Q405 Baroness O’Neill of Bengarve:The BBSRChas
supported several public engagement projects in the
ﬁeld of nanotechnologies. How do Research
Councils coordinate their work with other
government agencies, including BIS and the Food
Standards Agency? How do they ensure that the
public engagement activities that they support are
built on and are useful to other government
departments that have an interest here?
Dr Collis: I would say that coordination operates
across several levels. As mentioned previously,
BBSRC and other Research Councils are members of
the Nanotechnology Issues Dialogue Group where
we sit alongside colleagues fromDefra, FSA andBIS,
and that provides a vehicle for exchanging
information and developing joint activities. We also,
within the RCUK arrangements, have a public
engagement with a research group and through that
group we work together to identify issues and
methods of engagement and to maintain awareness
we engage with key national players in the ﬁeld. We
have also worked speciﬁcally in collaboration with
other Research Councils, so BBSRC and EPSRC
worked in partnership in the Nanodialogues
experiment. In other areas outside of
nanotechnology we have worked with the MRC on
stem cells and also on ageing research.With regard to
those activities and activities in the nanotechnology
area, we also have our Bioscience for Society Strategy
Panel. Our thinking and our work is very much
informed by that and we receive advice from that
strategy panel. We also work with its counterpart in
EPSRC, the Societal Issues Panel.
Q406 Baroness O’Neill of Bengarve: That is a lot of
coordination. Do you have a sense of urgency about
this or do you feel that this is something that we need
to keep ticking over because the science is moving
fairly slowly and there is nothing that will surprise the
public or damage the adoption of new technologies
by the food industry?
Dr Collis: I think that BBSRC has been active, and I
will scope it out a bit to the broader nanotechnology
area, since 2003 with the discussion meeting Atom by
Atom, and that has moved through the provision of
ﬁnancial support for theNanoJuries project and then
Nanodialogues. There has been a series of activities
over the last few years which have been focused
around the early identiﬁcation of generic issues and
upstream engagement. Of course, with regard to
nanotechnology and food, through the
Nanotechnology Issues Dialogue Group we have a
forum where we can work with, say, the Food
Standards Agency. They may have issues that they
will take forward with consumer or citizens forums in
relation to perhaps labelling and regulation. Equally,
that will ﬂow from the Ministerial Group on
Nanotechnology with BIS. I would say that most of
our activities currently have been focused on that
upstream engagement, but it is important that those
activities sit alongside and are informed by the
activities that others may take forward perhaps more
around regulatory issues, labelling, et cetera. That
said, in other areas we have facilitated discussion
between regulators when we have considered it
appropriate as part of an upstream engagement
activity.
Q407 Chairman:Do you have any way of measuring
whether the work that you do in this area has any
impact? How do you measure that?
Dr Collis: I would say that Bioscience for Society
Strategy Panel, which is essentially a group that
oversees BBSRC’s public engagement work,
provides a forum through which we can receive
advice on how eVective those activities have been.
Q408 Chairman: What has the advice been?
Dr Collis: The membership of that group, which
spans food, environment and animal sciences as well
as learned societies and industry, has indeed received
reports from, say, theNanoJuries andNanodialogues
exercise and my understanding is they have
considered those activities to be appropriate and they
215nanotechnologies and food: evidence
16 June 2009 Dr John Wand, Dr Declan Mulkeen, Professor Peter Fryer
and Dr Amanda Collis
are able to view the area from the perspective and
knowledge of having seen developments in public
engagement over a period of time and able to look at
the issues around nanotechnology informed by the
experience around GM and also informed by
activities around stem cells, ageing and other areas.
Q409 Chairman: I must say I do not ﬁnd that a very
convincing answer that you knowwhether or not this
is making a diVerence, for example, to public
understanding or public attitudes. A report to a
committee that says, “Yes, it’s going okay”, does not
seem to me to be a very convincing answer.
Professor Fryer: When you physically do it and
explain to an audience the implications and we are
looking at once upon a time what would have been
called core science, so creating nanoparticles that are
not necessarily nanoemulsions, and you explain the
implications of that, which is essentially food grade
materials in food grade situations, my anecdotal
experience is this is not seen as a dangerous issue.
Whether that is simply the result of half a dozen
conversations with the public, I do not know. Quite
how you would gather that class of information,
again, I am not sure.
Dr Collis: Can I make an additional comment. In
looking at the NanoJuries, for example, one of the
recommendations from the NanoJuries project was
around greater openness in public funding and
development of nanotechnologies. Perhaps, John,
you could say something about theGrandChallenges
in nanotechnology and health activity that EPSRC
led on with regard to how advice has come in and
been implemented.
Dr Wand: Yes, if that is okay.
Q410 Chairman: Yes, but could you be brief, please.
Dr Wand: I will try and do so. The cross-Council
programme is working through a series of Grand
Challenges looking at where nanotechnology can
make a contribution to areas of societal importance.
Last year we were focusing on healthcare and
wanting to ﬁnd out where we should be focusing our
eVorts in nanotechnology for healthcare. We had a
series of advice streams feeding into that, naturally
enough from scientists, medics and so forth, but also
we carried out a public dialogue exercise where we
contracted an external professional organisation to
work with a series of focus groups to look at the
emerging conclusions from the scientiﬁc studies and
give us the public’s take on where we should be
focusing within nanotechnology for healthcare. That
was one stream of advice which fed into our decision-
making process and helped inform the actual areas
that we ended up focusing down on. That was a ﬁrst
for certainly the UK Research Councils in terms of
using a public dialogue process to then inform where
we should be focusing our research endeavours. We
have kept in contact with the members of the public
who participated in that exercise, which was 80 all-
told, so they are having updates as to what is going
on, and the feedback from them is they felt that was
a valuable exercise and they were actually inﬂuencing
how public money was being spent. Of course, it is
diYcult to generalise beyond that. The other thing we
have taken from the outputs from that public
engagement exercise is to feed it back to the scientists
who are generating research proposals and those
have been featured in some of the research proposals
we have funded as well.
Q411 Lord O’Neill of Clackmannan: Perhaps we
could look at one of the areas that came up in your
public engagement, namely the concerns about the
funding of health and safety research. In 2007 the
Council for Science and Technology expressed
concern about this and did so in the context of what
they regarded as the Government’s over-reliance on
the responsive mode funding. They felt that this was
perhaps not the best way to do it. What is the view of
the Research Councils on health and safety matters
and the availability of funds given the response mode
arrangement that you currently work in?
Dr Mulkeen: From March 2007 we moved beyond
response mode within the MRC, which leads on the
safety side. We put out a highlight notice, which
means we communicate with the community around
what we think is needed. We change that so that as
one wave of research proposals comes through and
gets funded we say what the next gap is. We have had
a good response to that. The Research Board that
assesses the proposals has also been very alert to the
importance of the area. The success rate of a typical
responsemode application to theResearchCouncil is
in the range of 20–23 per cent. In this area we have
funded nearly 40 per cent of the proposals that have
come through. The Board is being proactive.
Q412 Lord O’Neill of Clackmannan: That was in
nanotechnology?
Dr Mulkeen: No, that was in nanotoxicology, just on
the safety side.
Q413 Lord O’Neill of Clackmannan: It was only on
nanotoxicology. You say that the response rate has
been good and you have spoken in percentages, but
what does the percentage mean in real terms?
Dr Mulkeen: There are about six projects with about
£3 million in total from the MRC side, and the
Department of Health contributed a bit over half a
million, and another three or four smaller projects on
top of that.
216 nanotechnologies and food: evidence
16 June 2009 Dr John Wand, Dr Declan Mulkeen, Professor Peter Fryer
and Dr Amanda Collis
Q414 Lord O’Neill of Clackmannan: So we are
talking about nine projects in in vivo areas, is that
correct?
Dr Mulkeen: The new ones. There was some
preceding work in Edinburgh at the Centre for
Inﬂammation Research and some in the Human
Nutrition Centre in Cambridge, which you will have
heard about.
Q415 Lord O’Neill of Clackmannan: That is the
MRC’s one, but what about the other Research
Councils? Evidence from the EMERGNANO report
indicates that there are still major gaps in the research
into health eVects of nanomaterials. How are the
other Research Councils responding to these?
Dr Collis: From BBSRC’s perspective, we recognise
that with regard to human health theMRC leads and
with regard to environmental toxicology leadership
really comes from theNERC.That said, we recognise
the importance of ensuring that underpinning basic
biological science is integrated in the context of
human and environmental toxicology as
demonstrated through our co-funding through the
environment and human health activity that was led
by NERC and includes funding from the other
Councils here. As I mentioned earlier, with regard to
work on nanoscience of foods most of our work is
currently around the use of the very latest detection
technologies to understand better foodmaterials and
food processes.
Q416 Lord O’Neill of Clackmannan: You have told
us that you recognise there is a challenge, but I think
what we would like to know are speciﬁc examples of
the amount of response there has been to this
challenge. At the moment all you are telling us is you
know that there is an issue, but you do not seem to
know how big it is and you have not been able to tell
us so far how many institutions are engaged in this
area. Could you be a little more speciﬁc?
Dr Collis: In responding to that challenge we would
work in partnership withMRCon human health and
with NERC on environmental toxicology.
Q417 Lord O’Neill of Clackmannan: Do you think
the responsive mode is the best way of doing it or do
you think you should be more interventionist
yourselves?
Dr Collis: The responsive mode ensures that the very
best quality research is supported in this area. The
application of the strategic steer on responsive mode,
such as is operated by MRC, encourages the
submission of applications to the Research Councils.
In that respect, that strategic steer in increasing the
volume of applications coming and funding the very
best is a response to meet the research gaps here. Can
I just add, if I may, my Lord Chairman, that perhaps
one additional strategic intervention that we should
look to make as a group is around research
community networking and bringing together
researchers working in the safety area, and it is our
role to facilitate this, with those working in, say,
engineering departments on the actual free
nanoparticles themselves.
Q418 Chairman:Could I just pick up on this because
I am getting more worried as we go along. We have
heard from you and others that there are gaps in
knowledge, you have responsive mode or calls for
applications which yield pretty small numbers of
responses, to be quite frank—six or nine responses
from the whole scientiﬁc community seems to me to
be pretty small—but I am not convinced yet, echoing
perhaps what Lord Crickhowell said earlier, that you
are actually trying to plug the gaps, that you have got
a plan to plug the gaps in knowledge. Maybe you
would say it is not your job, but if it is not your job
be clear that it is not your job and, if you think it is
your job, tell us how you are planning to plug the
gaps.
Dr Mulkeen: On the numbers, as I said, the overall
Safety Science community in the UK is quite small, a
small number of centres of excellence.
Q419 Chairman: Can we just focus on the answer.
Are you intending to plug the gaps?
Dr Mulkeen: Yes, but it will not necessarily take the
form of a research programme with 200 small grants
scattered across the UK. I think a small number of
highly capable excellence centres is what we need and
the funding stream is oriented towards that. While
the numbers are small, a £3 million investment is
signiﬁcant and wewould rathermake a small number
of large highly capable awards than to scatter the
money thinly.
Q420 Lord Haskel: Will you be commissioning this
or, again, is it a matter of challenge?
Dr Mulkeen: There are two diVerent sorts of safety
challenges that the Research Councils face. One is to
strengthen the general fundamental science base. So
far the response we have had to the ﬁrst highlight
notice and then the changed highlight notice asking
for more in vivo, whole animal, whole organism,
science has been very good. That mechanism has
been adequate so far. If it started not to be adequate
we might have to take more active steps. To give one
example where we may need to take a more active
step, a very eminent neuroscientist in the UK who
was planning a substantial programme on the
movement of particles within the nervous system has
been poached recently by a German research
initiative, not related to toxicology, and we will need
to think about whether we can encourage some other
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people from the neurosciences background to step up
to themark. By and large, for the basic science we are
okay so far but we will take more active steps if
needed. The other area is the degree to which
particular lines of research that are oriented towards
a new product, treatment or class of products being
supported by the Research Councils engage with
Safety Science at an early stage. For example, in
many of the healthcare nanotechnology projects that
MRC, BBSRC and others have supported the people
leading those projects have a background in
pharmaceuticals, they understand the safety issues,
and while there may be gaps in everybody’s
knowledge about nanotoxicology worldwide they
know how to make sure the particular thing they are
developing gets state of the art treatment from a
safety point of view. What Amanda was pointing out
was that we are now reaching the stage in a wider area
of Research Council funded projects that have been
stepping up over the last few years where we need to
move beyond simply looking at the people who have
already got a strong healthcare nanotechnology
background and as the standard of Safety Science
steps up in the UK do much more active networking
to reach out and, for example, to draw in the
environmental toxicology work that NERC is
developing which provides some quite relevant
insights into the movement of particles out of the gut
in lower organisms and so on. It is the state of science
maturity that means we need to step up and take a
diVerent approach over the next few years compared
with what we have been doing over the last year.
Q421 Lord Cunningham of Felling: Is there any
overarching forum or dialogue in this area which
brings together the private sector with academia and
the Research Councils? If so, what is it?
Dr Wand: I suppose the most obvious forum is the
Nanotechnology Stakeholders Forum which is
chaired by Defra which has people able to come on
an open invitation basis from academia, government
departments, industry and non-governmental
organisations. Typically, that meets every quarter
and has 30-odd people round the table from 30-odd
diVerent organisations.
Q422 Lord Cunningham of Felling: Does it in any
way try to identify gaps where government funds
need to be directed, for example?
Dr Wand: It has not as yet, although there is nothing
to stop it doing so, but as one stream of evidence it
does feed into the Ministerial Group which, again,
meets on a quarterly basis.
Q423 Lord Cunningham of Felling: So what does it
do?
Dr Wand: At this stage it has been mainly taking
information and evidence from what Government in
particular and other organisations have been doing in
the area around public engagement and health and
safety issues.
Q424 Lord Cunningham of Felling:For example, say
someone believed we needed to be doing more work
in nanometrology characterisation or
nanotoxicology, would they be issues which would
emerge from this dialogue?
Dr Wand: There could well be issues which emerge
from that dialogue which would then feed either into
the Nanotechnology Research Coordination Group
to take that forward in more detail or through the
Ministerial Group depending on the nature of the
issue which was identiﬁed.
Dr Collis: Those issues would also arise from, say, the
EMERGNANO report which has been
commissioned via the NRCG because that would be
looking against the 18/19 research priorities to see
how well research activity on the global level has
delivered into those research priorities.
Q425 Lord Cunningham of Felling: Would this
quarterly meeting discuss issues relating to EU/UK
regulation of nanotechnologies?
Dr Wand: Again, in a broad sense, yes. We have
people from the EU Member States who attend and
make presentations to these meetings as well, so it
does take a European perspective.
Q426 Lord Cunningham of Felling: The Research
Councils have told us they believe that uncertainty
about regulation may already be stiﬂing research. Is
that your view collectively or individually?
Dr Wand: I think at the basic level not. It may be
stiﬂing more applied research perhaps in terms of
product development, but we do not see any evidence
of it stiﬂing very basic research.
Professor Fryer: There is a question about the
adoption of technologies, particularly in the
nanoemulsion, what is essentially an extension of
conventional emulsion science, in that the question is
what is the consequence of incorporating 100
nanometre emulsion droplets. To some extent, milk
has had them for millions of years but the industry is
nervous because the answers are not absolutely there.
The implication is that if you make food grade
materials with food grade equipment it will be food
grade, but the question of whether there is something
diVerent that happens at this scale in a food sense and
is eating an agglomerate of milk proteins the same as
eating milk proteins, essentially the belief is there is
not a problem but there is no certainty.
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Q427 Baroness O’Neill of Bengarve: Is there an
answer to the question whose responsibility is it to
identify gaps in knowledge at this stage?
Dr Mulkeen: On the safety side?
Q428 Baroness O’Neill of Bengarve: On the safety
side.
Dr Mulkeen: It needs a team approach. It needs
bodies like the Defra run Coordination Group to ﬁll
the gaps that are about how to synthesise
information to make good regulatory decisions, gaps
in individual companies’ abilities to make
preliminary assessments of safety and gaps in the
basic science that we are most responsible for. The
coordination process from where we sit seems to be
working well in terms of getting that dialogue going
in the main sectors that we have been dealing with.
Q429 Lord Crickhowell: I am puzzled, I must admit.
I was puzzled when I read the question that Lord
Cunningham put to you as to why uncertainty over
EU/UK regulation should stiﬂe research and
development in the area. I do not quite understand.
There are large areas where we have already got
established regulation—REACH on chemicals—
which may be the core to a lot of the regulation that
we are considering with nanomaterials and the
requirement to ensure its safety. That is already there
and up and running. Please explain to a simple-
minded non-scientist why some uncertainty about
the regulatory pattern should stiﬂe research. I do not
understand.
Dr Wand: I think it is a combination of regulation
and public acceptability, and we are back to the case
study of GMO. Does a company want to invest a lot
of money in developing a product which will then not
be acceptable in the marketplace either because of
public opinion or regulation which may still be in the
evolutionary stage? I do not know a lot about
REACH but I understand there are questions about
how far it will apply to nanomaterials and
nanoparticles. There is uncertainty in the regulatory
regime in detail and there is also uncertainty over the
public acceptability side of nanotechnology and
companies, therefore, want to take a cautious step
forward before investing potentially large sums of
money.
Lord Crickhowell: That may be a commercial
judgment, which I understand, as to whether they
take the research into the development phase and so
on, and a lot of them are doing the research, we know
they are, but I thought we were addressing here the
work of the Research Councils and I cannot see why
some doubts about the way the regulatory regime
may go should hamper research of the kind that you
are encouraging.
Q430 Baroness Neuberger: Can I just add to that
because I think this is key. I do not understand it
either. The thing that I would want to know is if there
is the worry about this might go the way that the GM
debate went, is there not all themore an obligation on
the Research Councils to take this very seriously,
either to do the research that reassures the public or
to do the research that makes the public think,
“Actually, it may be our suspicion was right”. I just
do not get the argument, that is the bit that is
worrying me.
Dr Mulkeen: I misunderstood the question, I thought
it was focused more on the industry uptake of what
Research Councils do. In our sector, leaving safety
aside and looking at nanotechnology applications in
healthcare, certainly there are some companies that
are more willing to take risks on innovative science
than others, but, as you say, that was not the
question. I cannot think of any area of MRC science
relating to safety which has been in any way inhibited
by uncertainty of the regulations.
Dr Collis: With regard to the research portfolio in the
broad bio nanotechnology area, equally I do not feel
that the uncertainty over regulation is stiﬂing that
basic research.
Q431 Chairman: You do not think it is?
Dr Collis: No. We are seeing our portfolio growing
year-on-year, but a lot of our portfolio is set in the
context of nanomedicine and new detection
technologies.
Professor Fryer: Industry is more worried about the
acceptability issue and whether these things will be
food grade materials. They must be in some form
nano when they are digested but the question is how
they are digested.
Q432 Lord Crickhowell: All the more reason for
research.
Professor Fryer: With my BBSRC Council hat, there
is an industry/university club that has been built that
the food industry are involved in and they are funding
the sort of work into digestion/gut behaviour that we
would hope for. It is not a very large programme. I
have to be slightly careful because we have applied to
it. It will be building this sort of understanding, I
hope. We know surprisingly little about what
happens between the mouth and the gut.
Q433 Lord Mitchell: I am always concerned about
duplication going on everywhere in the scientiﬁc
community and, therefore, the waste of resources
that could lead to. I just wanted to ask you how the
Research Councils within the UK coordinate with
the EU and other international bodies. How do you
coordinate research? How do you ensure that
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research in the UK complements rather than
competes with research abroad?
Dr Wand: I suppose one very signiﬁcant way of doing
that is through the OECDwhereDefra represents the
UK. I think you have already had evidence on this,
that there is this list of 14 nanoparticles that have
been identiﬁed and countries have agreed to take the
lead on looking at the health xenon and safety
implications of those nanoparticles. The UK is
leading on two of them—cerium oxide and zinc
oxide. As an example of a cross-agency funding
arrangement the work that is being funded is being
funded by a combination of Defra, EPSRC and the
Technology Strategy Board working in collaboration
with the Nanotechnology Industries Association. It
is trying to take a holistic view of the issue and feed
back through OECD channels into other
international partners looking at these particles and
other particles as well, so there is a coordinated eVort
occurring worldwide through that set of channels.
Q434 Lord Cunningham of Felling: It is hardly
worldwide because it would not include the People’s
Republic of China, would it?
Dr Wand: I think China is involved to some extent in
some of those activities. I think it sees itself as a
current player in the nanotechnology area.
Q435 Chairman: Could you perhaps follow that up
to conﬁrm whether China is involved in these
activities?
Dr Wand: I could do that20.
Q436 Earl of Selborne: On this subject of European
Union research funding, could we ask the opinion of
the Research Councils as to how eVective the present
framework programmes might be in this area and
what chances there are in the next round, in the eighth
round, of there being a contribution, particularly
plugging some of the gaps that we have identiﬁed
today.
Dr Mulkeen: I am not very familiar with the projects
that the EU has funded in the UK to date. The
number is small. Discussion on the next framework,
it is too early to say. Across Europe there is a good
level of information sharing. Whether the decisions
are taken in the framework programme to target
areas or whether it has the right level of speciﬁcity in
the targeting, I am not sure.
Professor Fryer: There has been a very large EU
programme on the molecular basis of allergenicity,
for example, which is about take-up of nanoparticles,
theymight bemolecules, and there is the beginning of
20 “ThePeople’s Republic ofChina is a participant in theWorking
Party on Nanotechnology of the Organisation for Economic
Cooperation and Development (OECD).”
a cross-European base in that area which I suspect
will be the sort of science that we are going to need.
Dr Collis: I understand there are four or ﬁve large
framework programme funded projects in the broad
nano health and safety arena and we can provide
details of those if that would be helpful.21
Q437 Chairman: How would you rate the UK’s
research eVort in the area of health and safety eVects
of nanotechnologies compared with other European
countries or, indeed, compared with other countries
outside Europe? Are we in the Premier Division, in
the Championship, whereabouts are we?
Dr Mulkeen: In Safety Science generally—
Q438 Chairman: Relating to nanotechnologies.
Dr Mulkeen: —the UK has got a strong base to build
on. The number of projects is probably lower than in
some other countries; the quality, I hope, is ﬁrst rate.
We should probably all take a look at the
EMERGNANO report when it comes out and use
that for some benchmarking over the next few
months. That will be a more comprehensive set of
information than we have had so far.
Q439 Chairman: At this particular stage you would
not care to oVer a view as to where we are in the
international league table?
Dr Collis: Simply to say with regard to the largest
number of studies in the broad health and safety area
the US would deﬁnitely be number one.
Q440 Chairman: I would like to go back, if I may,
before drawing this session to a close to ask you
about these gaps which we are obviously concerned
about. You did say earlier on in your collective
response that you would take more active steps if
needed to plug the gaps in knowledge. I wondered
how you would decide when it was needed and what
would trigger these more active steps.
Dr Mulkeen: On the safety side, I expect we will have
to review and restate the call for proposals in the light
of what is getting funded and work by the Defra/
NRCG Coordination Group on a six monthly basis.
Over the summer we will use EMERGNANO to add
to what we have already identiﬁed, which as I
mentioned earlier is that we are not getting in enough
proposals around gut, we have not had the proposals
in that we would like to see around movement of
nanoparticles in the nervous system, but it may be
that whenwe look at EMERGNANO there are other
21 “The EMERGNANO report, which was referred to in our
evidence, is now in the public domain on the Defra website at
http://randd.defra.gov.uk/
Document.aspx?Document%CB0409—7911—FRP.pdf . The
report covers 19 EU FP funded projects in the area of nano
health and safety and has the beneﬁt of placing these into a
worldwide context of some 293 projects.”
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areas that we would want to highlight as well. I think
we will be doing this every six months for the
foreseeable future because, as you say, even if the end
product of the research is to prove that there is a
much lower risk than people thought, it is still a very,
very worthwhile investment.
Q441 Lord O’Neill of Clackmannan: When does the
six month review period start? Has it started yet or is
it just an idea that you have got?
Dr Mulkeen: We reviewed it following discussions at
NRCG just after Christmas. We have already had
diVerent sorts of proposals coming in after that. We
will change it again this summer. Again, depending
on what we learn about what other countries are
ﬁnding and what we learn from the outcomes of the
science, it is going to be an exceptionally fast moving
ﬁeld, so six or nine months. We will just have to keep
our eyes and ears open and change the call to reﬂect
whatever gaps come up.
Q442 Lord O’Neill of Clackmannan: Six months has
become nine months, you did not know when it
started and you do not knowwhen the next one is.Do
Supplementary memorandum by the Biotechnology and Biological Sciences Research Council (BBSRC)
Foetal Risk from Nanoparticles.
This is a frequently-asked question in the community, with very limited data. There is some unpublished data
in rats showing that nanoparticles can cross from the mother to the foetus, and some data from smoke particle
studies that also suggests that transfer is possible. There are probably a variety of routes of access, as with gut
absorption, and diVerent particles may behave in diVerent ways.
The route to the foetus will probably be through the placenta. The placental membrane is designed to separate
the foetus and mother’s blood circulation whilst facilitating nutrient transport. The membrane is not a simple
size-selector; many of the mechanisms by which nutrients and other molecules are transferred involve activity
within the membrane. A recent review is Jones et al (2007). The involvement of the placenta in toxicology is
discussed in detail by Myllynen et al (2005). Blackburn (2007) reviews transport of molecules to the foetus:
— small molecules (less than molecular weight 100 if water-soluble, ie sub-nm in size) can cross the
membrane by simple diVusion; this is the mechanism by which alcohol can enter the foetus;
— larger molecules and structures enter through other mechanisms; for example, some very large
molecules (such as immunoglobulin G, molecular weight 150,000, which confers immunity) enter by
endo- and exo-cytosis; the molecule travels through the placental membrane in a vesicle; and
— some viruses can infect the foetus, but it is clear that the placenta provides a barrier; for example
maternal-infant transmission rate of HIV is only 25 per cent in mothers who do not receive
prophylaxis (Koi et al, 2006). Viruses obviously vary in size (10–300 nm).
It thus seems very unlikely that nanoparticles can enter the foetus through simple diVusion unless they are very
small and simple molecules. The mechanism of transport will be diVerent to that of alcohol. Much larger
molecules, such as nanoparticles can enter via other mechanism, but will have to stimulate the membrane in
the same way as immunoglobulin does. It seems unlikely that transport to the foetus can be completely
prevented, but the concentration of any nanoparticle will be substantially less than in the mother.
you not have a kind of diary, timetable or timeline
that you will operate along?
Dr Mulkeen: Absolutely. There is a regular series of
coordination meetings across the public sector. The
reason I have to be vague is I can say that we will
update it over the summer but I do not know when
the next update or next change in direction will be
necessary. I just know that given the sort of science we
are dealing with lots of new calls for statements will
be needed over the coming years. There is a very
regular timetable of meetings.
Chairman: Thank you very much. I would like to
draw this session to a close and thank all four of you
for helping us to explore the issues that are on our
minds. You will receive copies of the transcript for
correction before it is ﬁnalised and published. Also,
we have requested from you a couple of follow-up
points so I look forward to receiving some further
information from you. If you feel there are areas that
we have not covered that we should have asked you
about, we would also welcome any further comments
that you might wish to generate spontaneously.
Thank you very much indeed.
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Letter from Lloyd’s Corporation
Lloyd’s is the world’s leading specialist insurance market, trusted to shoulder the risks of the world. The
Corporation of Lloyd’s operates a performance framework for ﬁrms in the market to ensure that
underwriting, risk management and capital setting is robust. In this capacity we have established an Emerging
Risks Team which monitors for potential new threats and assesses the possible impact on the insurance
industry.
The rapid pace of development led us to publish a report, at the end of 2007, on the risks and opportunities
associated with nanotechnologies. This was launched at a co-hosted seminar assembling an expert panel of
insurers, academics and legal experts who presented their views to an audience of underwriters and risk
managers. There aremany interesting applications for nanotechnology andwe understand the societal beneﬁts
that will be gained through pursuing this ﬁeld. However, given the nature of our industry, we are also
concerned over the potential health and safety risks that couldmakemanufacturers of nano-enhance products
future targets for litigation. There is a compensation culture spreading within Europe and Asia1 which
heightens our concerns.
According to the Project on Emerging Nanotechnologies the use of nanotechnologies in the Food industry the
third largest sector to use nanotechnology enabled products, as ofAugust 2008. Therefore it is amajor industry
in this growing ﬁeld. Whilst far from clear whether insurance claims would arise, or if made whether they
would be upheld, we believe it is important to consider now the extent of insurability of these products. The
impact to insurers could manifest itself through several insurance products including:
— Product liability coverage that may pay out for having to recall a large number of products through
health risks, perceived or actual;
— general liability coverage may be triggered if manufacturers were negligent in their duty of care to
consumers, for example if the nano element of a product was shown to directly cause, or contribute
to, a disease;
— general and environmental liability policies may also become exposed with respect to environmental
disasters, for example if silver nano particles were to accumulate within the environment and either
travel up the food chain or by killing bacteria andmicrobes essential to local or national ecology; and
— employer’s liability policies, may cover employees who suVer disease or disability through their work
in the nanotechnology industry if it were to be shown that the risk management of health risks of
processes were to blame.
These risks predominantly relate to health risks that nanotechnology may pose when used in food containers,
within food products themselves, or in the exposure of workers when creating the products. There is also the
issue of full lifecycle management including how nano-materials behave after they have been disposed. For
example, the 27th report by the Royal Commission on Environmental Pollution stated that “to date, adverse
eVects on populations or communities of organisms in situ have not been investigated and potential eVects on
ecosystem structure and processes have not been addressed.”We understand that questions like this andmany
others cannot currently be answered. We are also aware of worrying research that suggests that some forms
of nanotechnology may have adverse health implications.
One of our key concerns relates to the length of time it takes to establish health impacts in humans. This is
important for insurers as, depending on policy terms, we can face the risk of claims for decades after the
premium is paid. When setting the premium we have to estimate the level of risk and, with respect to
nanotechnology, such estimates are inherently uncertain. The asbestosis cases of the 1990’s, led to massive
losses for the whole insurance industry. We believe that current spending on health impacts of
nanotechnologies is materially smaller than the amount spent on developing products.While we recognise that
1 “Directors in the dock”—Lloyd’s 360 project report,
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investment in developing new technologies is essential if the UK wishes to remain at the forefront of the
technological economy, we must also protect ourselves from the potential pitfalls of producing the next
product equivalent of asbestos insulation, leaded petrol or DDT pesticide.
As insurers it is our business tomanage risk.However the quantumof riskmust bewell understood and limited
in aggregate. Where this is not the case the risk can become uninsurable. We are aware of at least one US
company that has excluded all aspects of nanotechnology; others are actively avoiding providing direct cover
to this industry. There is a danger that some inherently safe nanotechnologies will be treated in the same way
as others, such as carbon nano-tubes, which are causing much concern. To combat this we need to identify
those speciﬁc nanotechnologies that could, or do, pose a signiﬁcant or long term risk. These could be excluded
from cover, or conversely cover could be restricted according to a published list of technologies understood
to be generally safe. This would help insurers calculate premium rates that better reﬂect the risk and ultimately
provide assurance against the societal cost of insurer insolvencies over the longer term.
We believe a clearer understanding can be achieved through coordinated research into the eVects of
nanotechnologies at a national or international level. The outcomes of such research should include standard,
ﬂexible and auditable risk frameworks that will protect employees and enable insurers to assess the robustness
of companies’ risk controls. There should be a requirement to demonstrate compliance with the framework
before products are used in food. There should be requirement for companies andResearch Councils to advise
immediately there is material research evidence to suggest adverse health impacts and the level of materiality
should be agreed by an independent body. To utilise a risk framework or perform a risk assessment, research
would also have to identify the level of hazard and exposure mechanisms that each type of nanotechnology
presents.
It is vital that products, especially food products, have adequate labelling when nano-technologies are used.
In this way the consumer can make an informed choice on whether to purchase the product and this, we hope,
will reduce liability costs in the future.
We believe the insurance industry is an important stakeholder in this debate and thank the House of Lords
Science and Technology Committee for giving Lloyd’s an opportunity to contribute.
Supporting information:
http://www.lloyds.com/emergingrisks/Lloyd’s report on Nanotechnology: Recent developments, risks
and opportunities.
http://www.safenano.org/NanoInsurancePerspective.aspx Nanotechnology: An insurer’s perspective.
http://www.lloyds.com/News Centre/360 risk project/Research and reports.htm Directors in the
dock: Is business facing a liability crisis?
http://www.nanotechproject.org/The Project on Emerging Nanotechnologies.
www.lighthillrisknetwork.org Website of Lighthill Risk Network sponsored by Lloyd’s, Catlin, Guy
Carpenter and Aon-Benﬁeld.
http://www.rcep.org.uk/novelmaterials.htm Royal Commission on Environmental Pollution—Novel
Materials in the Environment: The case of nanotechnology
13 March 2009
Memorandum by BSI British Standards
BSI British Standards welcomes this opportunity to respond to the Committee’s call for written evidence.
Internationally agreed standards, from the International Organization for Standardization (ISO), the Codex
Alimentarius Commission (CAC) and the Global Food Safety Initiative (GFSI) have become indispensible
to ensure food security and food safety. For example, the ISO 22000 “family” of standards addresses issues
such as the application of food safety, traceability in the feed and food chains, and audit and certiﬁcation:
ISO 22000:2005 Food safety management systems—Requirements for any organization in the food
chain;
ISO/TS 22003:2007 Food safety management systems—Requirements for bodies providing audit and
certiﬁcation of food safety management systems;
ISO 22005: 2007 Traceability in the feed and food chain—General principles and basic requirements for
system design and implementation; and the planned
ISO 22006, Quality management systems—Guidelines for the application of ISO 9001 in crop
production
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However, whilst these and some 700 other standards developed by ISO/TC 34 “Food products” have proven
extremely valuable in addressing many of the issues relevant to conventional food production, additional
measures will be needed to support the introduction of new technology, in particular, nanotechnologies, into
mainstream food manufacturing and packaging.
The recently published opinion on “Risk Assessment of Products of Nanotechnologies” by the Scientiﬁc
Committee on Emerging and Newly Identiﬁed Health Risks (SCENIHR) (see http://ec.europa.eu/health/
ph risk/committees/04 scenihr/docs/scenihr o 023.pdf) and the Scientiﬁc Opinion of the Scientiﬁc
Committee of the European Food Standards Agency on “The Potential Risks Arising from Nanoscience and
Nanotechnologies on Food and Feed Safety” (http://www.efsa.europa.eu/EFSA/efsa locale-
1178620753812 1211902361968.htm) highlight the need for validated measurement and characterization
methods, which standards can provide:
— “The methodology for both exposure estimations and hazard identiﬁcation needs to be further
developed, validated and standardized.”
— “There is a need to establish reliable and standardized measurement techniques, to develop
measurement strategies, and to implement screening/monitoring of nanoscale particles in sensitive
work areas.”
— “The main issues may be summarized as problems in replicating actual exposure conditions in
laboratory tests and the lack of general availability of robust and speciﬁc measurement methods.
Exposure assessment needs to consider each stage in the life-cycle.”
— “In relation to the physico-chemical characterization of ENM (Engineered NanoMaterials), stability
in FCM (Food Contact Materials), food and feed matrices, and analytical tools it is recommended
to develop and validate routine methods to detect, characterize and quantify ENMs in FCM, food
and feed matrices and in biological tissues”;
Satisfying other recommendations of both committees will rely upon the availability of suitable and validated
test and measurement methods developed through standardization:
— to determine the eVects of size of ENMs on physico-chemical properties, compared to those of the
dissolved chemical or micro/macroscale materials;
— to investigate the interaction and stability of ENMs in the presence of components in food and feed
matrices, in the GI tract and biological tissues;
— to generate information on the amount and form (dispersed or aggregated) of ENMs content in food
and feed, and the bioavailability of the nanoform following ingestion; and
— to determine migration of diVerent ENMs from FCM into food and feed.
When using nanomaterials, an extensive characterization is necessary, including the nanomaterial as produced
and the nanomaterials as used in test systems and the nanomaterial as present in ﬁnal products.
An issue of speciﬁc importance are the properties of the nanomaterial as it is actually used in products and to
which consumers may be exposed. For the risk assessment the latter characterization is of highest relevance.
Nanotechnology, deﬁned as “the application of scientiﬁc knowledge to control and utilize matter at the
nanoscale, where size related properties and phenomena can emerge” (deﬁnition by Committee ISO TC
229 “Nanotechnologies”, resolution 28/2008, November 2008), presents unique opportunities but also, as
highlighted above, unique challenges, and it is the latter that standardization typically addresses.
Where such challenges impact global markets, global consensus and harmonization are essential. Signiﬁcant
eVorts are being made to develop and approve international standards that will help address the diverse
challenges presented for the application of nanotechnology to food and food packaging. However,
international agreement in this area will require active participation and cooperation of the various members
of the international community, in particular the relevantNational Standards Bodies with activities in the area.
The UK committee for standardization for nanotechnologies, NTI/1, was established in 2004 to develop
voluntary, consensus based, anticipatory standards in this new and emerging ﬁeld. Through its early
establishment of NTI/1, the UK gained an “early mover” advantage by being able to propose and lead both
the international (ISO/TC 229) and European (CEN/TC 352) standards committees in the area, an advantage
it still holds. This has enabled the UK to exercise considerable inﬂuence over developments in these two
committees, where the ﬁrst published document in the ISO committee was the result of a UK proposal based
on a UK document (PAS 71, “Nanoparticles vocabulary”), sponsored by the then-DTI. The UK is currently
leading all of the approved, CEN led, work items in the CEN nanotechnologies committee and seven of some
30 approved work items in the ISO committee.
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It is widely recognized that, irrespective of the application area, the eVective and responsible development of
nanotechnologies requires the construction of a comprehensive and eVective foundation based on agreed ways
of naming, describing and specifying things, measuring and testing things, and agreed protocols for hazard
and risk assessment, risk mitigation, and risk communication. The UK national committee NTI/1 has already
taken a lead in these areas by the publication of seven sector-speciﬁc, terminology and deﬁnition documents,
and three guides: to safe handling and disposal of manufactured nanomaterials; to specifying nanomaterials;
and to labelling of manufactured nanoparticles and products containing manufactured nanoparticles. The
committee is also actively cooperating with its partners in the UK, Europe and internationally to identify how
best to support stakeholders in whatever sectors they operate.
The chairman of NTI/1, in his role as chair of ISO/TC 229 and CEN/TC 352, has participated in two DG
SANCO “safety for success dialogues” on the use of nanotechnologies in food and cosmetics, an International
Risk Governance workshop on “Risk Governance Of Nanotechnology Applications In Food And
Cosmetics” and participates in the OECD Working Party on Manufactured Nanomaterials. These various
activities help keep the committee at the forefront of this important area.
NTI/1 has active representation fromand close links to awide variety of stakeholders, including industry, trade
associations, research organizations, government departments and regulatory agencies, the Technology
Strategy Board (TSB), Knowledge Transfer Networks, universities, and societal stakeholders (http://
www.bsigroup.com/en/Standards-and-Publications/Industry-Sectors/Nanotechnologies/Introduction-to-
Committee/). The food and drinks industry is represented through the membership of the Food and Drinks
Federation, which plays an active role in the work of the committee. However, it has been diYcult to engage
with the Government’s own regulatory body in the area, the Food Standards Agency, despite its nominal
representation on the committee following a meeting with its chief executive at the beginning of 2007.
NTI/1 recommends a cautious approach to dealing with nanomaterials, and proposes that nanomaterials
should be treated as hazardous, unless adequate scientiﬁc evidence is available to the contrary or to enable
speciﬁc safety measures to be deﬁned. Whilst this recommendation was prepared principally for industrial
exposure scenarios, it is obvious that manufacturers should not allow their customers to be exposed to
unknown risks. Therefore NTI/1 recommends that the cautious approach proposed in BSI’s document PD
6699-2 “Guide to safe handling and disposal of manufactured nanomaterials” should be applied equally to all
products of nanotechnology that are placed on the market.
To help address this area, NTI/1 has prepared plans for the development of a comprehensive suite of standards
for hazard and risk assessment for nanotechnologies and nanomaterials, including exposure assessment in
both occupational and non-occupational settings relevant to nanotechnologies, whichwould include food and
food packaging. These documents would complement the guidance on safe handling and disposal of
manufactured nanomaterials and the guidance on labelling, both published with support from DTI/DIUS at
the end of 2007. However, at the moment there appears to be no appetite amongst government departments to
maintain theUK’s proactive leadership in the area, and the committee is concerned that its plans for a dynamic
programme of work, initiated with the development and publication of nine documents at the end of 2007,
will be thwarted, depriving UK industry and research of early guidance in this important area. In particular,
NTI/1 believes it should be working closely with the TSB on the development of the hazard and risk suite of
standards referred to above, and believes the TSB strategy for metrology and standardization in
nanotechnologies should be aligned with NTI/1’s objectives. Without such support the UK’s pre-eminent
position in standardization for nanotechnologies will be lost.
Technical standards, play a critical role in ensuring the safety, quality and reliability of products and processes,
eYcient production, and cost reduction through competition. They are equally valuable as a tool for
promoting innovation and commercialization by the dissemination of good practice, validation of new
measurement tools and methods, and veriﬁcation of new processes and procedures. Conventionally such
standardization activities would be supported by the industries beneﬁting from them. However, in new and
emerging areas, such as nanotechnologies, where the industry is still small and fragmented, there is an
unwillingness, or inability, to invest time, eVort and money in standards development. Thus without an active
commitment to standardization and metrology on behalf of the Government it is diYcult to see how the UK
can achieve its goal of creating wealth and a better quality of life, through high value products and processes
based on nanoscale technologies.
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About BSI British Standards
BSIBritish Standards is theUK’sNational Standards Body, recognized globally for its independence, integrity
and innovation in the production of standards and information products that promote and share best practice.
BSI works with businesses, consumers and government to represent UK interests and to make sure that
British, European and international standards are useful, relevant and authoritative. For further information
please visit www.bsigroup.com/britishstandards.
About BSI Group
BSI British Standards is part of BSI Group, a global independent business services organization that inspires
conﬁdence and delivers assurance to customers with standards-based solutions. Originating as the world’s ﬁrst
national standards body, the Group has over 2,300 staV operating in over 120 countries through more than
50 global oYces. The Group’s key oVerings are:
— The development and sale of private, national and international standards and supporting
information
— Second and third-party management systems assessment and certiﬁcation
— Product testing and certiﬁcation of services and products
— Performance management software solutions
— Training services in support of standards implementation and business best practice.
For further information please visit www.bsigroup.com.
About ISO
ISO is a network of the national standards institutes of 159 countries, one member per country, with a Central
Secretariat in Geneva, Switzerland, that coordinates the system.
ISO is a non-governmental organization that forms a bridge between the public and private sectors. On the
one hand, many of its member institutes are part of the governmental structure of their countries, or are
mandated by their government. On the other hand, other members have their roots uniquely in the private
sector, having been set up by national partnerships of industry associations.
Therefore, ISO enables a consensus to be reached on solutions that meet both the requirements of business
and the broader needs of society.
About CEN
The European Committee for Standardization (CEN) is a business facilitator in Europe, removing trade
barriers for European industry and consumers. Its mission is to foster the European economy in global
trading, the welfare of European citizens and the environment. Through its services it provides a platform for
the development of European Standards and other technical speciﬁcations.
CEN’s 30 National Members work together to develop voluntary European Standards (ENs).
These standards have a unique status, since they also are national standards in each of its 30 Member
countries. With one common standard in all these countries, and every conﬂicting national standard
withdrawn, a product can reach a far wider market with much lower development and testing costs. ENs help
build a European InternalMarket for goods and services and to position Europe in the global economy.More
than 60.000 technical experts as well as business federations, consumer and other societal interest
organizations are involved in the CEN network that reaches over 480 million people.
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Examination of Witnesses
Witnesses: Mr Trevor Maynard, Lloyd’s Corporation; Dr Peter Hatto, British Standards Institution; and
Professor Richard Owen, University of Westminster, examined.
Q443 Chairman: I would like to welcome our three
witnesses for this seventh public hearing of our
inquiry into Nanotechnologies and Food and just to
inform you that the proceedings are being webcast. I
would also to draw attention to the information note
available to members of the public which sets out the
declared interests of the members of this Select
Committee as they will not be repeated whilst we ask
questions. I would like to start oV by inviting our
three witnesses to introduce themselves for the record
and if you wish to make any brief introductory
statement this is also an opportunity to do that, so
perhaps I could kick oV with Mr Trevor Maynard.
Mr Maynard:Thank you to you and yourCommittee
on behalf of Lloyd’s for being given the opportunity
to take part in this evidence session. Lloyd’s is the
world’s leading specialist insurance market-place
covering some of the largest and most individual and
complex risks in the world. If I could just take a
moment to explain a little about Lloyd’s because it is
quite a complex place. It is not an insurance
company, it is an insurance market-place where 86
syndicates compete amongst one another to provide
insurance and reinsurance to companies and clients
around the world. Together they make one of the
largest insurance and reinsurance markets in the
world. Each syndicate is made up of one or more
members and historically they were individuals but
now there are fewer than 800 individual members of
Lloyd’s who are actively participating and they make
up only ﬁve per cent of the capital at Lloyd’s. The
remainder is provided by members backed by private
and public shareholders, investment funds and
specialist insurance investors. Each syndicate is
managed by a managing agent and it is the
responsibility of the managing agent to employ
underwriting staV and manage the syndicate on the
members’ behalf. The managing agents are regulated
by the Financial Services Authority. The
Corporation of Lloyd’s, where I work, oversees the
activities of the market, which includes admitting
new members, new managing agents, approving
business plans and ensuring solvency. The
Corporation itself does not carry out insurance
business but we supervise the market’s activities. We
are also regulated by the Financial Services
Authority. I am the Manager of Emerging Risks at
Lloyd’s Corporation.
Q444 Chairman: Thank you very much. Dr Peter
Hatto?
Dr Hatto: Certainly I would like to thank yourself
and the Committee for the opportunity to attend this
hearing. I would like to make a brief statement but
before I do that I would like to introduce myself as
the Chair of the UK, the European and the
International (that is the ISO) Standardization
Committees for Nanotechnologies. Standards are
not critical to life but they are critical to modern
living. Standards are one of the most important tools
used to take new technologies to the market-place.
Standards transfer research ﬁndings into guidance
documents thus providing a bridge that connects
research to industry. This connectivity is critical to
successful commercialisation. Standards are not part
of the regulatory framework but can and do support
regulation for example through the ‘New Approach’
Directives. They derive their legitimacy from the
voluntary consensus-based approach used for their
development and application. Standards are used
because they provide a reliable and validated basis
for best practice and to ensure inter-operability. Early
participation in standards-making allows countries
and organisations to help create and shape markets,
as with the Global System for Mobile
Communications (GSM) and can provide valuable
technical and business intelligence. Whilst it might
appear that standards will inhibit innovation, the
existence of relevant standards frees innovators to
concentrate on the essential essence of their
innovation rather than being diverted by issues that
are not core to the end product or service. Thus the
development of anticipatory standards in new and
emerging areas of technology provides a foundation
for innovation not a barrier to it. This was
highlighted in the Sainsbury Report Race to the Top
where metrology and standards were seen as critical
in the innovation ecosystem. In the area of
nanotechnologies the UK has established itself at the
forefront of standardisation activities and holds the
chair and secretariat of both the ISO and CEN, that
is the European committee for standardization
technical committees. It produced the ﬁrst
internationally reviewed standard in the area of
nanoparticle terminology and has developed
terminologies for another six sectors of
nanotechnologies together with guides to safe
handling and disposal of nanoparticles, labelling of
nanoparticles and specifying nanomaterials. It has
recently embarked on the development of a guide to
exposure assessment to nanomaterials and a guide
for small to medium-sized enterprises to regulation
and standards relevant to nanotechnology-based
business. By continuing its dynamic leadership of
standards-making for nanotechnologies the UK can
retain a position at the cutting edge of technical and
commercial developments in the area, despite a
signiﬁcantly lower national spend on
nanotechnologies than its principal competitors such
as the US, Germany and Japan. This leadership role
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will help secure critical opportunities to compete
eVectively in an increasingly aggressive global
market. The ﬁnal point is that failure to continue to
support this important activity will result in the UK
losing the leading position which it has established
over the last ﬁve years. Without having inﬂuence in
the standards arena technologywill be based on other
countries’ requirements and this will give them a
competitive advantage which will be to the detriment
of UK industry.
Professor Owen:Goodmorning everyone and likewise
thank you very much for having the opportunity to
talk with you all. I am a Professor of RiskAssessment
in the University of Westminster. I am physically
located at the Policy Studies Institute where I am a
fellow. Before Imoved back into academia Iwas head
of the Environment and Human Health Programme
at the Environment Agency where I led on
nanotechnologies and regulation. I was until quite
recently chair of the steering group for the OECD on
risk assessment in nanotechnologies and I am the co-
ordinator of the UK Environmental Nanoscience
Initiative which is a programme looking at the
environmental risks of nanomaterials. It is a science
programme between the Natural Environment
Research Council, Defra and the Environment
Agency which was set up with them in 2006. I am
particularly interested in risk governance of emerging
technologies, an area that I am now taking forward
at Westminster.
Q445 Chairman: Thank you very much. Perhaps I
could kick oV with a rather general question about
how you perceive the barriers to risk assessment in
relation to nanotechnologies and nanomaterials in
the food sector. In particular, I would like to draw
attention to one point that was made in the Lloyd’s
written submission calling for a ‘standard, ﬂexible
and auditable risk framework’. I wonder if you could
explain to us what that means and who would
produce it, and also perhaps at the same time to ask
all three of you, given that we have heard from a
number of witnesses that there is considerable
uncertainty in the underlying science, is it indeed
possible, even if you had a framework, to risk assess
products containing nanomaterials and, if not, what
should we be doing at the moment? That is an
envelope of questions that perhaps Mr Maynard
would like to kick oV with since I asked particularly
about the Lloyd’s submission.
Mr Maynard: Underwriting by its nature is a process
of risk assessment and in fact ﬁnancial quantiﬁcation
of the potential loss, so whenever our underwriters
take on a risk they are risk assessing. The premium
rates will depend ultimately on the risk
characteristics of the process or product. At present,
to my knowledge, there is no formal global list of
products, food or otherwise, that use
nanotechnology. There are informal databases such
as the Woodrow Wilson Center database but they
only include products which mention
nanotechnology in their marketing so they are likely
tomiss examples and we do not know howmany they
miss. We believe that a list of products that use
nanotechnologies should be set up andmaintained by
regulators or some independent third party that is
respected. Quite who that is, in a sense, is probably
for other people to decide but I think an organisation
that is respected is critical. We think that such a list
should include the companies involved in the full
supply chain including those outside the UK or EU.
It should have a precise deﬁnition of the
nanomaterial, including its size (because diVerent
sized versions of the same material can have diVerent
properties), how the material is used in the process or
product in detail, links to research on the properties
of the material, a list of health or environmental
concerns, and some sense of the uncertainty around
that, so you get research published, perhaps one
paper here or there that raises concerns, but the
questionwe are interested in is howwidespread is that
concern felt, what is the uncertainty. We think that
that sort of list would assist in the process of
underwriting and risk assessment and it is critical to
inﬂuence these emerging technologies before they
become embedded in our society, so now is the time
to inﬂuence this, I think.
Chairman: Are there other comments on this
including on the question about the uncertainties of
the science?
Q446 Lord Cunningham of Felling: Can I just ask a
question. I assume fromwhat you are saying that you
think that such a register should be compulsory and
legally binding?
Mr Maynard: Yes we do. I suppose I should come
back and answer your question about ‘ﬂexible,
standard and auditable’ just to give some points
around that. We would like it standardised where
possible if we can get global or as international as
possible agreement on these things, because Lloyd’s
operates obviously in a global framework. Flexibility
is just recognising that the pace of change with
nanotechnology is so fast that if you come up with
regulations that are hard-coded then you will not be
able to react to changes as they come along. Being
auditable really allows underwriters to diVerentiate
between risks and if they are audited in some sense
then you can get a sense of the rigour with which the
process has been followed, and even if you could give
a grading that would be even better, to be honest, to
give a risk assessment which would allow people to
diVerentiate better-managed companies from worse-
managed companies in the premium and then drive
responsible innovation.
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Professor Owen: I think that there are probably four
speciﬁc areas that come to mind straightaway of
which possibly the most pre-eminent is whether or
not current risk assessment methods are ﬁt for
purpose. It is a little like taking your car for a MOT
and the garage not quite knowing what to test.
There are technical guidance documents that ﬁt
within the regulation but we are not sure whether
they are ﬁt for purpose. In fact, the European Food
Safety Authority’s view at the moment, or rather I
should say the view of their Scientiﬁc Committee, is
that risk assessment processes are still under
development in respect to nanomaterials in food and
feed. There is a big question about whether the
current methods can demonstrate that these things
are safe in current form. The second area or barrier
is whether current regulations, for example for non-
foods legislation, trigger substances to be risk
assessed in nano form. Under REACH, with which
I am quite familiar, which is the more general
industrial chemicals regulation, the triggers are
tonnage so if you manufacture above a tonne of
material you have to provide a certain level of
information and more at ten tonnes and so on. The
question then—and this is something that the Royal
Commission on Environmental Pollution picked
up—is that the mass of a material is slightly
irrelevant in dealing with nanoparticles; it is the
surface area that is more important, so do these
triggers cover nanomaterials? This also links to
labelling which I will leave to Peter and others to
say whether or not you are actually going to pick
up a nanomaterial going through the regulatory
process if it has no way of identifying it as a
nanomaterial. The third area is whether or not there
is suYcient scientiﬁc evidence, to pick up your point
Lord Chairman, as to whether you can make a case
for nano regulation or whether there is a nano eVect,
so do nanomaterials in food or otherwise present
greater risks in terms of bio-availability, in terms of
their inherent toxicity, in terms of interaction with
other chemicals, natural or manmade, or biological
systems, or do they have novel eVects. At the
moment there is just insuYcient co-ordinated
research and, perhaps as importantly, inadequate
governance processes to ensure that that
information is presented in a timely way. I am really
picking up on what Trevor is saying as well, that we
need to speed that process up. Finally, we have not
to forget that risk assessment is not just a dry
process of understanding hazard exposure, it is
actually important to understand what we call the
social framing of that process, what the public views
are on that, and really more research needs to be
done about what people think about
nanotechnology in food, the risks and the beneﬁts,
because people do not think of risks in isolation,
they look at a risk/beneﬁt balance when they make
those sorts of appraisal.
Q447 Lord Haskel: You have told us about why
standards are important in innovation and in
insurance. Why are standards and deﬁnitions
important in the context of regulation and in the
context of risk assessment as well?
Dr Hatto: There is an old adage which says if you
cannot measure it you cannot make it. I think you
can extend that to regulation and say if you cannot
measure it and you cannot deﬁne it you certainly
cannot regulate it, and what we are missing is
universal agreement on deﬁnitions, and I will come
back to that in a moment, and of course universal
agreement and availability of protocols for
measuring. In terms of deﬁnitions, forgive me Lord
Chairman for making this statement but I think the
title of this investigation suVers from the problem of
deﬁnitions because it seems to me that although it
is about nanomaterials, you are probably thinking
more of what ISOTC229 (which is the technical
committee of which I am chair) calls “nano-
objects”. The Royal Society and Royal Academy of
Engineering study published in 2004 talked about
nanomaterials and gave a broad generalised
deﬁnition which includes both nano-objects, those
are the materials with one, two or three dimensions
in the nanoscale, but also nano structured materials.
I think the main concern here is probably with nano-
objects, with nanoparticles with three dimensions in
the nanoscale (and quite what that means is open to
question) with nano ﬁbres with at least two
dimensions in the nanoscale, probably not with
nanoplates because they are not of that much
interest in this particular area. It is clear that we
need international agreement on what we are talking
about when we use these terms. In terms of risk
assessment, risk assessment needs to somehow
consider hazards because without exposure (and risk
is a combination of hazard and exposure) there is
no risk, and we need to have some validated
protocols to determine hazard, and at the moment
we are somewhat lacking in that area. My own
committee in ISO is developing some documentary
standards for risk assessment based on some work
done over the last few years by DuPont and
Environmental Defense. We are developing some
work in the area of control banding which is a risk
assessment type of approach, but without these
tools at our ﬁngertips we are in a very diYcult
position. I think the biggest challenge is really on
measurement and characterisation, how you
measure things, what do those measurements mean.
It is very easy to say that these nanoparticles are 100
nanometres in diameter, but how did you measure
it, because the result you get is a function not only
of the particles but also of the measurement
technique, and there are enormous challenges in
determining the physical and chemical properties of
these materials. I am not sure if that is adequate.
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Q448 Lord Haskel: We are of course concerned with
nanoparticles in food and presumably the hazard
there is that people will get poisoned by it or they will
suVer chronic illness. How do you deal with that?
Dr Hatto: Presumably people will only get poisoned
(a) if they are exposed and (b) if they are poisonous,
and the question is whether they are poisonous.
Simply because they are nanomaterials does not
mean they are any more poisonous than the
macroscale forms of the material. As you are
probably aware, the OECD Working Party on
Manufactured Nanomaterials is about to undertake
a rather expensive, something like $45 million,
sponsorship study into 14 representative
nanomaterials. You will notice the deﬁnition has not
come out there and that is rather because the
Working Party on Manufactured Nanomaterials has
kept their working deﬁnition of manufactured
nanomaterials to themselves. There have been no
detailed studies into the impact of thesematerials and
there is a huge problem because a lot of the studies are
done using in vitro techniques where you are
exposing cells to nanomaterials and also in vivo
studies and there is a lot of disconnect between the
results from in vivo and in vitro studies, so which one
do you take? Do you take the one that kills the cells
or one that kills the organism? I think we would
prefer to take the one that kills the organism but a lot
of the chemical risk assessment and chemical
toxicology testing is based on in vitro studies and of
course the European Commission would like us to
use only in vitro, but there is a recognition that it
probably will not tell you what you want to know.
Q449 Lord Methuen: Is not one problem that you
have chosen a nice round number of 100 but it could
be 50 or it could be 250? Do you not have a problem
there in actually deﬁning what it is you want to
deﬁne?
Dr Hatto: That is a major challenge and the ISO
deﬁnition, if you like, is based on a deﬁnition of the
nanoscale. We use the nanoscale in all of our
deﬁnitions of nanomaterials. We have deﬁned the
nanoscale as the size range from approximately—and
it is important to say approximately—one to 100
nanometres. The ‘approximately’ can be ﬂexible but
it has been introduced simply because if you were to
stop at 100 then what about 101 and can you tell the
diVerence between 100 and 101? It is recognised there
might well be impacts of larger materials. In the area
of nanotechnology we want to put some sort of limit
otherwise we are going into the sunset almost. Why
did we choose a lower limit when the Scientiﬁc
Committee on Emerging and Newly Identiﬁed
Health Risks did not? The reason we chose a lower
limit was simply because if you do not have a lower
limit on the nanoscale then atoms are nanoparticles,
so clearly you want to think about materials that are
not atomic-sized or molecules or essentially
microscopic materials, and the way I think about
nanotechnology is not unique properties of materials
but unique challenges and anything in that size
range has—
Chairman: You have made your point. Lord
Selborne?
Q450 Earl of Selborne: My question is to Mr Hatto.
In your opening remarks you referred to the United
Kingdom being at the forefront of standardisation of
nanotechnology but in the written evidence the BSI
has told us that it has been diYcult to engage with the
Food Standards Agency and there is no appetite
amongst government departments to maintain the
United Kingdom’s leadership in the ﬁeld of
standardisation and risk assessment. First of all,
would it be correct to say from that that we have a
position of leadership in spite of theGovernment and
its agencies and what is it that you would like the
Government to do to reform its ways?
Dr Hatto: I would not say that we have leadership in
spite of theGovernment.We have leadership because
of the support we have received up to now, but that
support is dwindling, and I think the evidence did not
say there is no appetite, it said there appears to be no
appetite. I think that is an important diVerence
because it is not possible to engage with all aspects of
government. With regard to the Food Standards
Agency we are not currently involved in
standardisation in the area of nanotechnologies and
food and if we were that would not be the
responsibility of my committees. In ISO it would be
the responsibility of TC34 which is food, but we
would work closely with them to ensure that they
harmonised the terms and deﬁnitions with us. The
deputy chair andmyself had a meeting with the Chief
Executive OYcer at the Food Standards Agency
about two and a half years ago and we were given the
strong impression that they wished to engage in this
area, and in fact somebody was appointed to the
committee but that individual has attended I think
one meeting and has never to my knowledge
submitted any comments on any of the documents
that we have distributed for comment. Of course one
can understand that there are more pressing issues in
food than nanotechnology for that individual and for
the Food Standards Agency but these issues are
coming forward very rapidly. We believe that it is
important because we are at the stage of developing
the foundation of standardisation, the measurement
and characterisation and terminology and so on that
I think it would have been valuable to have had their
input on. A similar situation applies to the MHRA,
the Medicines and Healthcare Regulatory Agency,
who were engaged in the committee early on but then
they made a blanket decision to withdraw from all
standardisation activities as far as I am aware
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because there was a feeling that the regulatory
authority should not be engaged in these sorts of
activities, but without engaging with those parties, it
is diYcult to ensure that there is a complete connect
between industry and the regulator (it would not be
sensible to have a barrier between the two) and the
people involved in the development.
Q451 Earl of Selborne: Standardisation can only be
eVective in this technology at the international level
ultimately. OECD presumably would be the Holy
Grail of trying to get standardisation on that level,
not that you would not build by building blocks at
the national and European level ﬁrst, I assume?
Dr Hatto: I think it depends very much on what sort
of standardisation you are talking about. If you are
talking about toxicology testing I would certainly
agree but of course nanotechnology is not only
toxicology, it is a much broader area and a lot of our
work is involved in developing protocols for
measurement and characterisation of nanoparticles.
This is going to be critical for toxicology of course
because you need to understand the relationship
between the physical and chemical properties of the
materials that you are testing and the toxicological
impact simply because of the huge variety of
nanomaterials that we will have, unlike, let us say, a
chemical which you might dissolve and then expose
yourselves or your organisms to when you have an
insoluble nanomaterial then the presentation of that
material to the cells or to the organism—
Chairman: May we now move on to next question
please and Lord O’Neill.
Q452 Lord O’Neill of Clackmannan: Mr Maynard,
in your evidence you draw attention to the fact that
the precautionary principle has been recommended
in the EU but that the US and Japan prefer a lighter
regulatory touch. Do you think that the
precautionary principle should be applied to the use
of nanotechnologies and nanomaterials in food?
Mr Maynard: We would deﬁne the precautionary
principle to mean ‘if an action could cause harm to
the public or environment then in the presence of
uncertainty the burden of proof falls on those
proposing the action’. There are various deﬁnitions
of it around but that would be the deﬁnition we
would take. It is clear to us that consumers are
particularly sensitive to the use of nanotechnology in
food. Even from the submissions to this Committee
that I have read on your website that has become very
clear. It suggests to us that the public have an
expectation that particular care will be taken by
developers in this respect. There also appears to be a
low understanding of nanotechnology by consumers,
perhaps not surprisingly. They will therefore entrust
larger organisations such as retailers, manufacturers
and maybe even insurers to protect them from harm.
If appropriate care is not taken and harm arises we
have found that the views of society in general set the
backdrop for legal cases and awards for damages
certainly in the US with the jury system, and
therefore if particular care is not taken it might lead
to larger claims against insurance policies in due
course.We are verymuch aware that nanotechnology
might be transformative in the future and that there
are many important global trends that will require
innovative solutions to solve them, climate change
for example, population growth, food shortage,
water shortage, and we are not trying to stand in the
way of this innovation, but if I could give some
details on the cost of asbestos.
Q453 Chairman: Could you keep it succinct please.
Mr Maynard: Very succinct. The cost is estimated at
$200 billion globally of which insurers have paid $120
billion. The annual cost to us is still 2 to 3 billion per
annum and it is expected to last for another 15 years.
It led to a number of insurance company insolvencies
and it brought Lloyd’s very close to insolvency itself,
along with some other factors of which I am sure you
are aware. Asbestos had only one exposure
mechanism—inhalation—and was only one
material. Nanomaterial is many materials and many
possible exposure mechanisms, so I would say a
precautionary approach in this case seems very
sensible.
Q454 Lord O’Neill of Clackmannan: So you would
not really favour the lighter touch regulation that
perhaps—and I say perhaps because it is still in its
infancy—the American system seems to involve?
That may be because they are more litigious than we
are and therefore have a quicker and easier recourse
to the law. Given that you operate internationally,
how do you assess the diVerence between the
European approach and the American/Japanese
model?
Mr Maynard: Certainly in the US for example we
have suVered many lawsuits for many diVerent
liability claims and the culture there is diVerent. In
fact some of Lloyd’s research is showing that the
compensation culture is moving across from the US
to the EU. In terms of the standards, anything
around nanotechnology, the more deﬁnition you
have the easier it is for us to tighten our policies and
make sure we know what we are covering, so I would
say, yes, we do support the precautionary principle in
this case.
Q455 Chairman: Professor Owen, would you like to
add anything on this?
Professor Owen: First of all, it is probably worth
saying that you cannot generalise between the EU
and the US too much because it is not a consistent
invocation of the precautionary principle and the
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precautionary principle can be invoked in many
diVerent ways, as Trevor has said. I would take the
UN Rio Declaration which is “where there are
threats of serious or irreversible damage, lack of full
scientiﬁc certainty shall not be used as a reason for
postponing cost-eVective measures to prevent [in that
case] environmental degradation”, so the emphasis is
on serious or irreversible damage. The precautionary
principle is being implemented already for
nanotechnology in two contexts that youmay ormay
not be aware of. The ﬁrst is in the case of high aspect
ratio carbon nanotubes where some work published
in Edinburgh showed that they had “asbestos-like”
properties and since then the Environment Agency
took the view that they should be classed as
hazardous waste and the Health and Safety
Executive, if I recall correctly, described them as
substances of high concern. That was on the basis
that high aspect ratio carbon nanotubes may have
similar sorts of behaviour as asbestos and therefore
have serious implications to health. There was still a
lot of scientiﬁc uncertainty around that, the
experiments had not been done through inhalation
for example, but there was enough evidence there for
action. The second which perhaps you will be less
familiar with was theGovernment’s response in 2005,
which I was involved with to the Royal Society and
Royal Academy of Engineering report in which the
Royal Society and Royal Academy said that there
should be no deliberate introduction of
manufactured nanomaterials into the environment
until more was known about their risks. The
Government responded and agreed with that
recommendation and made a recommendation to
industry to minimise the introduction of
nanomaterials in waste streams and to take on a
voluntary stance of not introducing them deliberately
into the environment. There are two situations here
where there has already been the invocation of the
precautionary principle to set the context for your
work.
Q456 Lord Crickhowell: Can I probe a little about
the likely reaction of the insurance market and its
consequence. Lloyd’s has stated that there are
already certain insurance companies who have
refused to provide insurance for aspects of
nanotechnology. As you saidMrMaynard, Lloyd’s is
by far the largest specialist insurance market. More
than 30 years ago I was managing director for a
Lloyd’s insurance broking ﬁrm and I would certainly
have loved to have been able to place in front of
underwriters the neat, tidy, comprehensive
compulsory list that you described at the start of your
evidence. However, as we have also heard, there has
been insuYcient co-ordinated research, there is a lack
of agreement on deﬁnitions, and it is very unlikely,
even if we have a list, that it will be quite as
comprehensive and tidy as you say underwriters
would like it to be. Bearing in mind the realities, how
optimistic are you that an insurance market is likely
to develop which will provide companies cover for
the products as they introduce them, and,
presumably, if it is the companies themselves
introducing the products who are going to have to
provide as much evidence as likely to appear in the
lists, do you think a market is likely to emerge? If it
does not, howmuch do you think it is going to inhibit
the companies in developing and producing
products?
Mr Maynard: I understand that lack of availability of
insurance can be an impediment to innovation and in
terms of how big an impediment, I think that would
be for the companies themselves to comment on. In
terms of will a market be there, Lloyd’s and the
Financial Services Authority both require companies
to think about emerging risks when setting their
capital, so there is, if you like, an understanding that
these aggregations of risk have caused problems in
the past, like asbestos, and there is a requirement to
do scenario tests to think through how you might be
aVected in the future. The new Solvency II reserve
and capital requirements also require companies to
think about all possible emerging risks. The ﬁrst
point is that people do have to think about these
issues carefully. If the claims exceed the premium then
the capital is used to pay for the balance of the claim
andwe have a duty to protect the assets of our capital
providers. Our investors expect us to have a good
understanding of the risks we take on because if we
get that wrong it is their money that is being spent.
There are many unknowns with nanotechnology. We
also see that there is a predicted rapid increase in the
size of the market. In the absence of this list telling us
what products nanotechnology are used in, you have
an uncertainty of whether you are covering it or
whether you are not covering it, so that is a signiﬁcant
issue. The key point of course is that we are there to
provide insurance and so we wish to provide
insurance, that is our role, and, where possible, that
will be provided. However, there is always a danger
that cover will be withdrawn or limited if the risks are
too uncertain. The purpose of us submitting evidence
to this inquiry is to say that insurers do very much
care about this information. The more that is
available the better we can quantify the risk and keep
the market insurable for longer. As I have said, there
are companies who have said on a limited basis for
example, “We will not provide any employers’
liability cover. Any company involved in
nanotechnology, we are not going to cover them if
they have made a decision to do that.”
Q457 Lord Crickhowell: I suspect there is not much
point in asking you to speculate about what is still a
rather uncertain future, but there are already in the
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market certain nanomaterials in packaging, in the
coating of a refrigerator and so on, where the rules
may be changing. Do you know if cover is being
provided for those kinds of materials at present?
Mr Maynard: I would imagine it is. This is
something, as I tried to explain before, I work at the
Corporation, that it is very diYcult for me to know
but I would imagine it is.
Lord Crickhowell: I would say as a suVerer from the
asbestosis cover I hope we are not talking in terms of
nanotechnology in quite that sort of disaster area, but
I thank you. I do not think we can really discover
much more on what the markets will discover.
Q458 Baroness Neuberger: Pursuing that, Lloyd’s
has stated in its evidence that it is vital that products,
especially food products, have adequate labelling
when nanotechnologies are used. I would be very
interested in knowing why you think it is necessary. I
would like to add a supplementary straight away
because Professor Owen said earlier that he thought
it was essential that the products were labelled
because otherwise how would anybody know that
nanotechnology had been used in the production or
that nano products were there. If you could both
clarify that that would be helpful, if I understood you
rightly and I may not have done.
Mr Maynard: In our experience, if customers have
the opportunity tomake an informed choice then this
can cut down the risk of later litigation. Conversely,
misleading or silent marketing can lead to claims. As
I said before, consumer knowledge is low but they do
seem to be concerned when they are explained about
nanotechnology and they are resistant to it. Really
what we would fear is in the absence of labelling a
backlash from society that would then set up a
framework for claims which might be viewed
positively by certain juries for example in the US.We
think that labelling combined with an appropriate
explanation of these terms would reduce the risk.
Professor Owen: To give you an example, under the
REACH legislation, which is for general industrial
chemicals, the view is that if you are registering a
nanomaterial before you put it on the market you
need to provide the information on the properties of
that material and if you have information on the
hazard and exposure, but if you do not actually know
it is a nanomaterial then it is going to be quite hard to
do that. One might have a CAS number with a suYx
for example to say that it is deﬁned as a nanomaterial.
In the absence of that, there is actually some guidance
from BSI on the labelling of manufactured
nanomaterials which is really worth having a look at.
BSI have been very helpful in providing that sort of
support to the community. I think there is some work
going on in ISO in that area as well but it is
fundamentally important to know that you have the
material otherwise the Chemicals Agency in Helsinki
for example will not be able to do anything further
with that information.
Q459 Baroness Neuberger: I would agree and I also
think there is a public interest argument for it which
neither of you have made. I think, MrMaynard, you
have used the argument that actually it reduces the
risk of litigation. I am not clear that it is a
straightforward public interest argument you are
using, Professor Owen, so could you just clarify?
Professor Owen: If you want to ensure that your
nanomaterial does not fall through a regulatory gap,
fall between two stools, you have to be able to
identify it as a substance to be risk assessed in a
nano form.
Q460 Baroness Neuberger: And that in the end
comes to a public interest argument because of the
risk assessment?
Professor Owen: Yes it does.
Q461 Lord Mitchell: I just want to go on to the
subject of labelling. In another context in the alcohol
industry I have fought to ensure that labels are on
alcohol and it is a hard battle and they will obfuscate
youwith all sorts of things about voluntary codes and
ideas, and the bottom line is it does not get there. I am
sure the food industry is as well organised as the
alcohol industry is and I am sure they will resist every
single attempt to have compulsory labelling on their
products. That is just a statement.
Professor Owen: I suspect that there is an argument to
say is there a nano eVect and should a bulk form of
something be labelled in a diVerent way to a nano
form? The problem there is until we have got the
evidence to show that, that case has not been made.
There is a general issue here with emerging
technologies which I hope is coming to light here
which is it takes an order of decades for that
information to be assembled for the methodologies
to be proven to be ﬁt for purpose and in themeantime
you have got the diVusion of that technology into
society and the use of it and that comes down
fundamentally to issues of governance, about how
that information is assembled to ensure that it is at
the same pace as innovation, and that is where we
have a fundamental Achilles heel in terms of
procuring that evidence.
Q462 Baroness O’Neill of Bengarve: Mr Maynard,
you spoke a moment ago about reducing litigation
but also about the informed consent of consumers if
it was labelled. Would it really be informed consent?
Can you envisage a way of doing these labels so that
people know what the nanomaterials included in
their food are and what their signiﬁcance is? It seems
to me that this is rather far-fetched. Is it just that one
can make a claim that liability has been transferred if
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there is a label or do you really think there can be
informed consent?
MrMaynard: I suppose thealternative isworse, tonot
try and label is worse than to try, both from a societal
point of view, a public interest point of view, but also
froma litigation point of view. I think, as I saidbefore,
that people do expect great care to be takenwith these
things and using new technologies without fully
understanding the health impacts is a diYcult
practice. I think people should be given the chance to
know what is in their food. Yes, whether they can
really be expected to understand the consequence of
that is a verydiYcult questionbut I prefer to see us try.
Dr Hatto:Might I brieﬂy commenton that because, as
you are aware from Dr Owen’s comment, BSI has
produced a guidance document on labelling and that
was developed with the support of the Food and
Drinks Federation and a number of other
organisations. Of course it is a voluntary guide and
there is no obligation to use it. That guide has now
been introduced into the European Committee for
further development as a European guide, and the
InternationalCommitteehasalsoasked toparticipate
in that, so there will be an international document
coming out perhaps in the next one and a half to two
years. It will still be a voluntary guide but it was
developed following the Royal Society and Royal
Academy of Engineering recommendation that
labelling should be provided not only to inform but
fromtheup-streampublic engagement perspective, so
verymuch from a public interest direction.
Q463 Lord Cunningham: Can I ask Dr Hatto: do we
have at the industrial scale the ability to produce
complete uniformity of nanoparticles?
Dr Hatto:May I respondby askingwhat youmeanby
complete uniformity of nanoparticles?
Q464 Lord Cunningham of Felling:100per cent of the
material of exactly the same size?
Dr Hatto: Absolutely not, and in fact one of the
shortcomings or one of the problems at themoment is
that there are very, very few standard or certiﬁed
reference materials which can be used to calibrate
equipment, for example, and those that are available
tend to be at the top end rather than the bottom end. I
think the National Institution of Standards and
Technology in the States, NIST, has produced some
standard certiﬁed reference materials towards the
lower end of the order of 20 nanometres and this is
consistent and certiﬁed and so on, but, no, it is
absolutely impossible to produce.
Q465 Lord Cunningham of Felling: So this begs the
question then what is the label going to say about the
nanomaterials, how can it be speciﬁc?
Dr Hatto: It can be speciﬁc as to the nature of the
nanomaterials.
Q466 Lord Cunningham of Felling:But not about the
size or the properties, presumably?
Dr Hatto: It could give information about the size
range, of coursebecauseyoudonotget aﬁxed size you
get a size range. Unless of course the information
about any impact is known, then it clearly cannot say
that but it certainlywould enable people to know that
there are nanoparticles, let us use a generic term, in
there.
Q467 Chairman: It sounds a bit like the label “may
contain nuts”—“may contain nanos”.
Dr Hatto:May I just comment on that because in fact
one of the people involved in the development of the
guidance document appeared to have been
responsible for the “may contain nuts” and he was
adamant that it should not be “may contain nanos”.
Let us be clear that all foodwill contain nanoparticles
now—not in the future but now, not deliberately
introduced but they are there.
Q468 Lord Cunningham of Felling: When you say
that you mean manufactured nanoparticles or
naturally occurring ones or both?
Dr Hatto:Probably both.
Q469 Lord Crickhowell: Can I just ask Professor
Owen a question. You twice referred to REACH and
you, understandably, and I think rightly, suggested
that the present one tonne limit and so on would need
revision. In your experience within the Environment
Agency and so on, would you comment further about
the need for a fairly urgent review of REACH by the
EuropeanCommunityand thediYculty that any such
review, on past experience of the introduction of
REACH, is going to take a very long time. Are we
likely, do you think, to get changes in this very
important area of regulation soon enough?
Professor Owen:Theanswer to that is no,quite frankly.
Ofcourse a lotofour legislation in theUKcomes from
Brussels and legislation such as REACH is
fundamentally important and that bigger picture
always has to be borne inmine. The view onREACH
is that in principle the risk assessment framework is ﬁt
for purpose but the devil is in the detail in terms of
implementation. I come back to themethods. All that
sort of legislation is based on a risk assessment
methodology and if you are not surewhether that risk
assessment method is ﬁt for purpose it is very diYcult
formanufacturers and importers to be able to do their
job. In my view, it is for the OECD to expedite that
process and to focus its attentions on providing
guidance to be used in a harmonised way across the
globe, both under REACH and other forms of
legislation. Ifwe are going to try and reduce that time-
frame that might be one of the places that we might
look to do that job.
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Q470 Chairman: I would like to close by just going
back to two points that the three of you raised earlier
on and just try to clarify the points. One concerns the
precautionary principle and we heard two deﬁnitions
of the precautionary principle fromMrMaynard and
ProfessorOwen, one about theburden of proof on the
individuals or groups proposing the action, and the
other one about uncertainty being no excuse for
preventativemeasures if there is a serious threat. I just
wondered how you would apply the precautionary
principle in practice to the use of nanotechnologies in
the broadest sense in the food sector?
Professor Owen: The precautionary principle in all its
diVerent forms boils down to one simple thing, which
is that the absence of full scientiﬁc certainty is not an
excuse to donothing.What you do is not necessarily a
moratoriumor aban; all it is saying is that youhave to
dosomethingoryoushoulddosomething,youshould
not just sit there and do nothing. What that forms
takes can be various and it is worth saying that
nanotechnology is not one nano, it is a variety of
diVerent things—manufactured, some in diVerent
forms—and so it is very diYcult to generalise. I think
it is worth saying that from the outset. Where we had
carbon nanotubes there was a case in point there that
we knew that high aspect ratio carbon nanotubes
could have very dangerous and long-term damaging
eVects so by extrapolation one could say, yes high
aspect ratio nanomaterials may be like asbestos, so
you have to ask the question about whether or not
serious or irreversible damage is likely to occur from
that.
Mr Maynard: I have not got a great deal to add to that
other than precaution should as a minimum I think
include telling people what you are using, when and
how, so at least transparency.
Q471 Chairman:Thankyouandmyﬁnal, ﬁnalpoint,
which was touched on in the discussion on labelling,
we talked throughout this session on various
occasions about the deﬁnition of nanotechnologies or
nanoparticles and I just wondered if very succinctly
Dr Hatto could give us what he thinks are the key
aspects of the deﬁnition for the food sector in terms of
our report, just in a few sentences.
Dr Hatto:Letme just slightly side step that, if I may.
Q472 Chairman:No, please do not side step it!
Dr Hatto: Okay, it is critical that we have deﬁnitions
for all of these diVerent aspects of nanotechnologies
and there was a comment earlier about disagreement
or no agreement on nanotechnologies, but let me just
emphasise that the ISO committee of which I am a
chair,andwehadavery fullweekofmeetings lastweek
in Seattle, is currently working on developing
international agreement on nanotechnology
deﬁnitions, not a deﬁnition for nanotechnologies but
deﬁnitions relevant to nanotechnologies, and we are
working in sector speciﬁc areas.We have not yet dealt
with the food industry but we are addressing medical
health and personal care applications and the bio-
nano interface.
Q473 Chairman: Sorry, just to cut to the quick, this
means that your group does not yet have an agreed
deﬁnition as applied to the food industry?
Dr Hatto:An agreed deﬁnition for what?
Q474 Chairman: Nanotechnologies, nanomaterials,
nanoparticles?
Dr Hatto: We have agreed deﬁnitions for
nanoparticles. We have not yet ﬁnalised a deﬁnition
fornanomaterialbutnanomaterial is relativelyeasy to
deal with. The deﬁnition for nanoparticle will be
relevant to any industry not just to the food industry.
Q475 Chairman:Can you give in a sentence what the
deﬁnition of a nanoparticle is according to your
organisation?
Dr Hatto:Yes, it is based on this termnanoscale and a
nanoparticle is one of the nano-objects and it is a
nano-objectwith three external dimensionswithin the
nanoscale.
Q476 Chairman: But not a particular number,
because we have heard 100 nanometres?
Dr Hatto: No, because the deﬁnition comes back to
the nanoscale, so the nanoscale is the dimension
deﬁning terms from approximately one to 100 so if
something is within the nanoscale it is within that
range. A nanoparticle has three external dimensions
within the nanoscale.
Chairman: Thank you very much. I would like to
thank all three witnesses for sharing with us their
thoughts on the questions we have put to you during
this session. I would like to also remind you that the
transcript will be sent to you for correction before it is
published and also to invite you if you wish to send in
anyother additionalpointswhereyou feelwehavenot
given you a chance to clarify your thoughts, and of
course those would be published in the written
evidence alongside the transcript in due course. With
that I would like to thank you all verymuch indeed.
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Letter from the Royal Society of Chemistry
On behalf of the Royal Society of Chemistry [RSC] I am pleased to attach the formal submission to your
current inquiry on Nanotechnologies and Food.
This RSC evidence follows the questions outlined by Sub-Committee I in its Call for Evidence.
However you might ﬁnd helpful the following excerpts from our submission which seek to highlight the four
key areas covered by our evidence. These are:
Classification of Nanoparticles in Food
Novel nanoparticles in food can be divided into soft materials (these are largely consumed) and hard surfaces
(non-contact and contact applications such as processing equipment and packaging). Due to the nature of
their applications, the impact on human biology is less signiﬁcant for hard surface materials than soft
materials; therefore the risks to human health are likely to be lower for hard surface materials.
Regulatory Framework
In the absence of legislation and an appropriate risk assessment framework, the food industry will be liable
for any new hazard. Whilst small companies and academic institutions are researching the potential of this
emerging technology, commercial realisation of new products and ingredients is not being carried through
to market.
Potential Uses and Contributions
Nanotechnology has many potential contributions to make across the food supply chain. These include
noncontact sensors in food processing and packaging, new functional materials, food formulation and
improvements in diet, for example increasing the content and bioavailability of micronutrients of food. New
materials based on nanotechnology, with increased strength, oVer the potential to reduce packaging waste by
allowing down gauging of the packaging and improved thermal transfer.
Public Engagement and Consumer Information
People are often suspicious of new technologies because they are concerned that corporate proﬁts may come
before public safety. Thus, with the introduction of any new technologies, there must be an early dialogue
involving eVective communication of the beneﬁts as well as risks to the consumer and/or the environment.
There must be a balance of providing the relevant information necessary for consumer choice, and
bombarding the consumer with unnecessary detail. However, the balance must be in favour of information
being made available to consumers. This information should be presented in a standardised form.
If you need any further detailed information may I invite you to contact my colleague Dr Farrah Bhatti.
You may be aware that the Society launched a major report on food in the House of Commons on 21 January
2009 entitled The Vital Ingredient. This was co-authored by Dr Bhatti. Apart from emailing this evidence to
you I shall provide a hard copy together with a copy of the published report which I hope youmight ﬁnd useful
for your ﬁles.
If you need to get in touch with me by all means please do so.
I hope this is helpful.
Dr Stephen Benn
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The RSC welcomes the opportunity to contribute to the House of Lords Science and Technology Select
Committee call for evidence on “Nanotechnologies and Food”.
The RSC is the UK Professional Body for chemical scientists and an international Learned Society for
advancing the chemical sciences. Supported by a network of over 46,000 members worldwide and an
internationally acclaimed publishing business, our activities span education and training, conferences and
science policy, and the promotion of the chemical sciences to the public.
If you would like further information or need anything in this document clariﬁed, please do not hesitate to
contact me.
Farrah Bhatti
State of the Science and its Current use in the Food Sector
1. The RSC has recently published a comprehensive report identifying the science, engineering and
technological innovation that underpin food production. This report, The Vital Ingredient, covers the breadth
of the food supply chain: Primary Agriculture, Manufacturing, Processing, Distribution, Retail, Consumer,
and Waste. Nanotechnology is one of a number of existing and future opportunities for the chemical sciences
to improve food sustainability and food security.
2. Hard copies of the report are available on request, alternatively it can be accessed online (www.rsc.org/
thevitalingredient).
3. The RSC response will focus on the state of science, relating to nanotechnology, and its use in the food
sector.
4. It is important to clarify exactly what is meant by nanotechnology and nanoparticles in relation to food.
Nanomaterials have been broadly deﬁned by the Royal Society and the Royal Academy of Engineering as
having one dimension less than 100 nanometres. There are many examples of existing nanoparticles which are
not new, eg viruses which range in size from 10–300 nm across. Manufactured nanoparticles to be added to
food could involve manipulation of existing ingredients, or completely novel chemical structures.
Manipulation of food at the nano-level is also not new; homogenisation of milk to prevent the natural
separation of cream from the rest of the emulsion is a classic example of this.
5. Novel nanoparticles in food can be divided into soft materials (these are largely consumed) and hard
surfaces (non-contact and contact applications such as processing equipment and packaging). Due to the
nature of their applications, the impact on human biology is less signiﬁcant for hard surface materials than
soft materials; therefore the risks to human health are likely to be lower for hard surface materials.
6. In the absence of legislation and an appropriate risk assessment framework, the food industry will be liable
for any new hazard. Whilst small companies and academic institutions are researching the potential of this
emerging technology, commercial realisation of new products and ingredients is not being carried through
to market.
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
7. Nanotechnology has many potential contributions to make across the food supply chain. These include
noncontact sensors in food processing and packaging, new functional materials, food formulation and
improvements in diet, for example increasing the content and bioavailability of micronutrients of food. New
materials based on nanotechnology, with increased strength, oVer the potential to reduce packaging waste by
allowing down gauging of the packaging and improved thermal transfer.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
8. Nanotechnologies are currently being used in the treatment of aqueous eZuent from the food industry.
Microﬁltration, ultraﬁltration, nanoﬁltration and reverse osmosismembranes are all used forwater treatment,
depending on the size of the molecules to be removed or recovered. Some organisations are investigating the
potential to reduce beverage turbidity arising from the presence of insoluble components, particularly those
that might confer a functional beneﬁt.
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What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
9. Nanotechnology will provide the food industry withmore capability and precision, which will in turnmake
processes more eYcient and sustainable, both in manufacturing and in subsequent digestion. The need for
mechanisms to control the delivery of functional ingredients within the body has focused on the development
of nanostructures such as:
— the use of proteins to lower fat content in emulsion-based products with no detrimental end-product
organoleptic eVect;
— the use of acid-sensitive alginates that create a “full” sensation inside the stomach, slowing down gut
passage rates;
— engineering taste sensations into high fat products or nutritional beneﬁts;
— nano-ﬁltration, already applied to the ﬁltration of microorganisms from food;
— ﬁltering out components such as lactose frommilk and replacing it with another sugar, creating milk
suitable for lactose-intolerant individuals; and
— encapsulation systems used to provide protection against environmental factors, controlled release
and nutrient delivery.
10. The use of intelligent packaging systems and technologies for the improved control of food spoilage,
hygiene and food safety is a key area for further development, the emphasis being on control rather than
detection. For example, there has been considerable work on developing the use of time temperature
indicators, but their uptake has been limited, since detection without remedy, produces more waste.
11. Nanotechnology has potential beneﬁts by reducing deterioration. For example, packaging based on
nanotechnology that absorbs oxygenwill have signiﬁcant beneﬁts on the shelf-life and eating quality of certain
foods. However, such approaches cannot be applied without fully considering the microbiological impact of
reducing oxygen, which may include stimulation of growth or selection for wholly or facultative anaerobic
pathogens such as Clostridium botulinum.
12. Nanoscale ﬁlm on confectionery, based on oxides of silicon or titanium with antimicrobial properties
could increase the life of much manufactured food. Currently the application of such materials to food with
a short shelf-life is limited by the long contact time needed to achieve the desired antimicrobial eVects.
Additionally, the eVect of such ﬁlm may be limited to that part of the food that is in direct contact with it.
13. Nanolaminates for food packaging include edible ﬁlms for fruit, vegetables, meat, and chocolate baked
goods. Films that provide speciﬁc protection from moisture, lipids and gases can improve the textural
properties of food, and serve as carriers of colours, ﬂavours, antioxidants, nutrients, anti-browning agents,
enzymes and antimicrobials.
14. Nanoparticles could be used in printing ink, changing the colour of the label to indicate the remaining
shelf-life of a perishable food, possibly replacing (with regulatory agreement) the current “use-by date”
labelling system.
15. These developments require signiﬁcant technical, legal and consumer education issues to be considered
before any new products enter the market.
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
16. A suYcient supply of the omega-3 fatty acids is essential for a healthy diet. Since they cannot be
metabolically synthesised by humans, they can be considered comparable to vitamins. Omega-3 fatty acids,
or the triglycerides containing them, can be incorporated into food products; however they must be added
close to the end of the manufacturing process because high temperatures and heavy metal ions cause rapid
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oxidation. Another technique to protect these fats from oxidising in prepared foods is microencapsulation.
This technology is already available; however current research into the formation of nanoemulsions provides
further potential.1
17. Generally industrial research in nanomaterials is limited, although Leatherhead Food International and
the Nano Knowledge Transfer Network are working with industrial consortia. There is a risk that UK
developments in this area will lag behind other nations, due to fears of a repeat of the consumer resistance to
other new technologies such as GM and irradiation.
What are the barriers to the development of new nano-products or processes in the food sector?
18. Barriers to the development of new nano-products or processes in the food sector include uncertainty
surrounding issues of regulation, health and safety, the risks vs beneﬁts of the new technological developments,
and consumer acceptance.
Health and Safety
19. The RSC recommends looking at the following reports for information on issues of health and safety, risk
assessment, and regulation:
— Food Standards AgencyReport of FSA regulatory review of the use of nanotechnologies in relation to
food, 20082
— Royal Commission on Environmental Pollution report, Novel Materials in the Environment: The
case of Nanotechnology, 20083
— European Centre for Ecotoxicology and Toxicology of Chemicals workshop report “Workshop on
Testing Strategies to Establish the Safety of Nanomaterials”, 20064
— The European Food Safety Authority (EFSA) scientiﬁc opinion on “The Potential Risks Arising
from Nanoscience and Nanotechnologies on Food and Feed Safety”, 20095
20. Furthermore, the OECD Working Party on Manufactured Nanomaterials, established in September
2006, is looking at international co-operation in health and environmental safety related aspects of
manufactured nanomaterials.6
Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
21. This aspect is not well regulated owing to inadequate funding, the burden of import regulation falling on
some individual local authorities associated with major ports, lack of validated analytical methods, and gaps
on horizon scanning for risks associated with imported nanotechnologies and nanomaterials.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
22. No comment.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
23. This depends on any gross diVerences in the toxicity of nano materials. As always the ﬁrst step is to
determine the intrinsic toxicology of the “parent” material itself and then look to see if reducing the particle
size down to the nano scale changes the toxicological proﬁle.
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
24. EFSA is actively engaged in coordinating European risk assessment to feed into potential Commission
regulation of nanotechnologies and nanomaterials.7 The OECD is also working in this area.8





5 http://www.efsa.europa.eu/EFSA/efsa locale-1178620753812 1211902361968.htm
6 www.oecd.org/sti/nano
7 http://www.efsa.europa. eu/EFSA/efsa locale-1178620753812 1211902132298.htm
8 www.oecd.org/sti/nano
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Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
25. The last major study into public attitudes towards nanotechnologies in the UK was carried out in 2004
by the market research company BMRB International:9
— The results of the opinion poll, carried out by BMRB for the Royal Society and Royal Academy of
Engineering joint working group on nanotechnology, showed that 29 per cent of the public claim
they have heard of nanotechnology, while only 19 per cent are able to give some deﬁnition of it. Of
those who are able to oVer a deﬁnition of nanotechnology, 68 per cent said it would make things
better in the future.
— Participants drew a parallel with GM when considering the ethical implications of nanotechnology
because of the perception that both involve changes at themost fundamental level to form something
that does not occur in nature. BothGM and nanotechnology could be seen as “messing with nature”
in a speciﬁc way by “manipulating the building blocks of nature”. They expressed concerns about
whether scientists are trying to “play God”.
— Participants were very positive towards potential uses of nanotechnology in medicine, particularly
in terms of earlier diagnosis and treatments. However, they also had concerns about the long-term
potential side-eVects of nanotechnology, and about its reliability.
26. Public opinion may have changed in the last ﬁve years, and it would be worthwhile to repeat this study.
Indications from the USA are that the public are more accepting of nanotechnologies in the last two years.
Consumers are more likely to embrace technology when they can see a clear beneﬁt for them (as shown by the
more positive attitude towards nanotechnology in medicine). Public attitude in the UKmay have grown to be
more positive in recent years if the beneﬁts of nanotechnology in food (eg reduction of food waste, improved
nutritional content of food, and cost of food) have become clearer.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
27. Feeding emerging scientiﬁc areas, such as nanotechnology, into the communication and engagement
process should be done at an early stage, as exempliﬁed by the nanodialogues (experiments in upstream public
engagement), led by Demos, and part-funded by the government in 2005–07. As a result, EPSRC recently
included a public dialogue on nanotechnology to help develop its funding call in this area.10
28. Failure of consumer acceptance can also be guarded against by well informed and robust regulation
safeguarding consumers while promoting innovation. However, this will require funding for research into ﬁt
for purpose detection systems and deeper insights into the toxicology of engineered nano-products.
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
29. People are often suspicious of new technologies because they are concerned that corporate proﬁts may
come before public safety. Thus, with the introduction of any new technologies, theremust be an early dialogue
involving eVective communication of the beneﬁts as well as risks to the consumer and/or the environment.
30. This was done eVectively by Sainsbury and Safeway supermarkets when they started to sell Zeneca’s GM
processed tomatoes to their customers in 1996.11 12 The products were clearly labelled as GM and consumers
were given a free choice as to whether or not to buy the GM tomato product. Consequently, consumers tried
the new tinned tomato puree and sales started to grow.
31. The “climate” aroundGMchanged primarily due to concerns that theUSAwould not segregate their GM
soya and maize from their non-GM counterparts, thus removing choice from the consumer.13
32. One of the problems for companies promoting GM crops was that the consumer did not see the beneﬁts
and were not oVered choice. This is in contrast to the use of GM in the pharmaceutical industry, where beneﬁts
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Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
33. Consumers are often bombarded with large amounts of conﬂicting information about climate change, the
environment, and new technologies in food production and waste disposal; and it is very diYcult for them to
make balanced judgements. There must be a balance of providing the relevant information necessary for
consumer choice, and bombarding the consumer with unnecessary detail. However, the balance must be in
favour of information being made available to consumers. This information should be presented in a
standardised form. Emerging technologies will facilitate this, for example point of sale information in addition
to that available on a food label could be made available via mobile telephones, barcode scanners, wiﬁ devices
and similar innovative information rich streaming facilities. Websites can provide much more detailed
information particularly to shoppers using the internet.
13 March 2009
Memorandum by the Nanotechnology Industries Association
Background
TheNIA,Nanotechnology Industries Association (NIA), is themarket-independent, responsible voice for the
industrial nanotechnologies supply chains; it supports the ongoing innovation and commercialisation of the
next generation of technologies and promotes their safe and reliable advancement.
The NIA stands for science-and technology-based expertise in nanotechnologies, encompassing members
companies that have successfully developed and commercialised nanotechnologies for over 25 years.
Through proactive collaborations with regulators on the national, European and international level, as well
as engagement with other nanotechnology stakeholders, the NIA promotes a framework of shared principles
for the safe, sustainable and socially supportive development and use of nanotechnologies, by securing a
publically and regulatory supportive environment for the continuing advancement and establishment of
nanotechnology innovation.
On the 15 December 2009, the House of Lords Science and Technology Select Committee appointed a sub-
committee [Sub-Committee I], to investigate the use of nanotechnologies in the food sector.14
The Committee intends to focus on the following areas: food products, additives and supplements; food
contact packaging; food manufacturing processes; animal feed; pesticides and fertilisers; and products that
may come into contact with food, such as food containers and cooking utensils. The Committee will not be
considering what happens to nanotechnologies and nanomaterials when they become waste products, or their
potential impact on the environment.
On the 3 February 2009, the Sub-Committee launched an inquiry into the use of nanotechnologies and
nanomaterials in the food sector, inviting the submission of evidence to the questions below.
State of the Science and its Current Use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
— Nanotechnologies are enabling technologies, which help to improve existing products and enable the
development of entirely new applications and products; the (potential) applications of
nanotechnologies in the food sector include:
— Improved barrier material in food&drinks packaging (ie enabling better/longer safe storage and
transport of food & drink, preventing premature perishing of food & drink, enabling longer
retention of ﬂavours and gas content)
— Smart packaging materials, which enable real-time indication of potential perishing of a food/
drink (ie gas detector with colour indicators, etc.)
— Anti-fouling and anti-stick coating on food/drink processing surfaces (ie enabling a reduction of
water-and detergent-use in food/drink processing plants)
— Anti-microbial surfaces reducing food contamination
14 Follow this link to the House of Lords website, in order to ﬁnd out more about the members of Sub-Committee I: http://
www.parliament.uk/parliamentary committees/lords s t select/st1members.cfm.
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— Nanomaterials are one product of nanotechnologies; the (potential) applications of nanomaterials in
the food sector include:
— Increased solubility compared to macroscale particles of the same substance (ie enabling
increased ﬂavour with lower levels of ingredient, such as salt)
— Encapsulation of vitamins and other food additives (cf. nutraceuticals), preventing the
premature degradation of the additive upon ingestion
— Solubilitymodiﬁcation ofmacroscalematerials, enabling a change in bioavailability of beneﬁcial
substances
— Improved functionality of ingredients enabling lower levels of additives giving cleaner labelling
— Improved control of texture, taste and stability of processed foods
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
— A few sources of information on the current state of the market for nanotechnologies and
nanomaterials in food & drink:
— “Nanotechnology in Agriculture and Food” (Nanoforum report, 2006) 15
— “Nanotechnology in Agriculture and Food” (Project on EmergingNanotechnologies,Woodrow
Wilson International Center for Scholars, 2006) 16
— “Study: Nanotechnology in Food and Food Processing Industry Worldwide 2006–2010–2015”
(Helmut Kaiser Consultancy, 2006)17
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
— See above
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
— There are ongoing research and development activities conducted by University labs (part-funded by
public funding, and part-funded by industry), in enterprises focussed on nanotechnology, or on food/
drinks innovations, as well as in the labs of large multinational companies.
What are the barriers to the development of new nano-products or processes in the food sector?
— Public perception: Both large and small companies fear a consumer backlash, if the beneﬁts of using
nanotechnologies and nanomaterials in food, drinks and food processing cannot be communicated
adequately.
— Regulatory threats & lack of guidance on potential approval hurdles: Enterprises and small
companies, which are sometimes conducting contractual research for larger companies, fear that a
backlash on the use of nanotechnologies in the food sector, or, indeed the introduction of a
demanding and costly approval process will render their companies’ core technologies non-viable.
Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials in the food sector? In which areas does our understanding need to be developed?
— The use of nanotechnologies as an innovation to processing methodologies and tools, as well as the
use of nanotechnology-enables smart packaging and food-safety screening detector and sensors does
not create any new properties in the ﬁnal food/drink product; therefore, risk assessments apply as
before.
15 “Nanotechnology in Agriculture and Food” (Nanoforum report, 2006) http://www.nanoforum.org/dateien/temp/nanotechnology%
20in%20agriculture%20and%20food.pdf
16 “Nanotechnology in Agriculture and Food” (Project on Emerging Nanotechnologies,WoodrowWilson International Center for Scholars,
2006) http://www.nanotechproject.org/news/archive/new report on nanotechnology in/
17 “Study: Nanotechnology in Food and Food Processing IndustryWorldwide 2006-2010-2015” (Helmut Kaiser Consultancy, 2006): http://
www.hkc22.com/Nanofood.html
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— Nanomaterials are currently not used in food & drink in Europe (NOTE: this does not include
products available over the internet).
Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the food sector
sufficient? Are current funding mechanisms fit for purpose?
— “Nanotechnologies” should be excluded from this question (see above—ie “The use of
nanotechnologies as an innovation to processing methodologies and tools, as well as the use of
nanotechnology-enables smart packaging and food-safety screening detector and sensors does not
create any new properties in the ﬁnal food/drink product; therefore, risk assessments apply as before).
— For Nanomaterials:
— Research funding is needed, but needs to be aligned with other, ongoing programmes of research
into similar areas (cf. FP7 Programmes, other national initiatives, such as in Germany (see
Fraunhofer Institute))
— Research must be coordinated; test protocols must be agreed.
Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to nanotechnologies
and nanomaterials for consumers? If not, what amendments are necessary?
— “Nanotechnologies” should be excluded from this question (see above).
— For Nanomaterials:
Yes. The current RA methodologies have been reviewed; they have been found to be generally adequate to cover RA on






— Testing of (commercially) relevant nanomaterials
— Research, conducted in the absence of the above agreements, will only increase confusion, mixed
messages and will ultimately increase the possibility of a backlash.
Are the risks associated with the presence of naturally occurring nanomaterials in food products any different to those
relating to manufactured nanomaterials? Should both types of nanomaterials be treated the same for regulatory
purposes?
— The risks associatedwith engineered nanomaterials should not be diVerent from those associated
with naturally occurring nanomaterials (given that it is the transport mechanism of insoluble
material that causes the biggest uncertainties).
— HOWEVER, it needs to be clariﬁed, if (and when) a naturally occurring nanomaterial becomes
an engineered nanomaterial (ie do processing/manufacturing steps, such as harvesting/mining,
isolating, purifying, etc., turn a naturally occurring nanomaterial into an engineered/
manufactured materials).
Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
— On the 17 June 2009, the European Commission released a Review of the “Regulatory Aspects
of Nanomaterials”, which concluded that “current legislation covers to a large extent risks in
relation to nanomaterials and that risks can be dealt with under the current legislative
framework”. This conclusion is true for products of the food sector, which have to adhere to the
safety requirements laid out in the relevant directives (eg Novel Food Directive, Product Safety
Directive).
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— The European Commission highlighted that guidelines were needed, in order to clarify approval
processes of (food) products containing nanomaterials (ie if/and how additional data
requirements are triggered upon the use of nanomaterials in a product). The nanotechnology
industries agree that guidance for implementation is required.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
— The NIA worked very closely with DEFRA on the UK’s Voluntary Reporting Scheme; all
industry submissions have been made by NIA Members, most of them through the NIA as an
agent.
— DEFRAwas never able to say, how many submission were expected to be received in two years,
and the 10 submissions that had been received were openly called a “disappointment”. However,
DEFRA representatives have now repeatedly said that the low quantity of submissions seems to
be “commercial reality”.
— One major problem of voluntary reporting schemes is the high requirement of staV time to
complete the onerous questionnaires, without any visible beneﬁts.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
— The OECD is running two working parties on nanotechnologies:
— The Working Party of Manufactured Nanomaterials (WPMN) (established October 2005) is
concerned with the safety aspects of nanomaterials; this WP has recently started a multinational
Sponsorship Programme on the Safety Testing of Manufactured Nanomaterials:
14 internationally agreed, commercially relevant manufactured nanomaterials will be tested, and
testing protocols developed.
Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
— There is little understanding in the public domain of the use and beneﬁts of either
nanotechnologies or nanomaterials; the public is very vulnerable to science-ﬁction stories,
without realising that our daily food (ie milk, tea, etc.) is based on natural nanomaterials.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
— Governments and industries are adamant not to allow nanotechnologies and nanomaterials
become another “GMO” (ie public backlash against the technology), but the lessons learnt have
let to little action so far: industrial companies are still concerned to be the ﬁrst one to “stick the
neck out” by publically engaging in the debate, and Governments have done little to run
“generic” stakeholder engagement programmes, which do not highlight a particular company.
— The UK Government funded one of the most comprehensive reviews of public engagement in
nanotechnologies,18 without actually conducting public engagement itself. Now, that the review
has recommended, how it should done, Government should step up and run public engagement
programmes that are delivering balanced risk-beneﬁt communications.
18 The Nanotechnology Engagement Group (http://www.sciencewise-erc.org.uk/cms/nanotechnology-engagement-group-reports/)
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What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
— The public needs to be trusted to understand technical details, but they also need help to
understand the concepts of (a) very low risk potential, and (b) very low exposures.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
— Consumers should be given an opportunity to understand the beneﬁts of nanotechnologies and
nanomaterials.
— Consumers need to be provided with information, but labelling is not necessarily the best way
to provide balanced information—it often raises concern and causes confusion.
The NIA and its member companies thank you for the opportunity to provide these comments.
The Nanotechnology Industries Association
Formed in 2005 by a group of companies from a variety of industry sectors including healthcare, chemicals,
automotive and consumer products, the Nanotechnology Industries Association (NIA) creates a clear single
voice to represent the diverse industries in the multi-stakeholder debate on nanotechnologies.
The NIA provides a purely industry-led perspective, derived from the views of the collective membership and
forms an interface with government, acting as a source for consultation on regulation and standards,
communicating the beneﬁts of nanotechnologies and interacting with the media to ensure an ongoing
advancement and commercialization of nanotechnologies.
20 March 2009
Memorandum by Professor Richard A L Jones, University of Sheffield
1. The emerging debate about nanotechnology and food
The subject of applications of nanotechnologies in food is rising in media proﬁle. This is being driven, on the
one hand, by publications from promoters of nanotechnology pointing to substantial potential beneﬁts and
quoting very large projected future markets (see, for example, [1]), and on the other hand concern fromNGO’s
and consumer organisations (most recently, Friends of the Earth, who published a report on the subject last
year [2]). The debate is compromised, in my view, by a lack of clarity about the scope of the various
technologies that are being lumped together as nanotechnology.
2. What is nanotechnology?
Most people’s deﬁnitions are something along the lines of “the purposeful creation of structures with length
scales of 100 nm or less to achieve new eVects by virtue of those length-scales”. But when one attempts to apply
this deﬁnition in practise one runs into diYculties, particularly for food. It is this ambiguity that lies behind
the diVerence of opinion about how widespread the use of nanotechnology in foods is already. On the one
hand, Friends of the Earth says they knowof 104 nanofood products on themarket already (and some analysts
suggest the number may be more than 600). On the other hand, the CIAA (the Confederation of Food and
Drink Industries of the EU) maintains that, while active research in the area is going on, no actual nanofood
products are yet on the market. In fact, both parties are, in their diVerent ways, right; the problem is the
ambiguity of deﬁnition.
3. The naturally nanostructured nature of most food
The issue is that food is naturally nano-structured, so that too wide a deﬁnition ends up encompassing much
of modern food science, and indeed, if you stretch it further, some aspects of traditional food processing.
Consider the case of “nano-ice cream”: the FoE report [2] states that “Nestle´ and Unilever are reported to be
developing a nano-emulsion based ice cream with a lower fat content that retains a fatty texture and ﬂavour”.
Without knowing the details of this research, what one can be sure of is that it will involve essentially
conventional food processing technology in order to control fat globule structure and size on the nanoscale.
If the processing technology is conventional (and the economics of the food industry dictates that it must be),
what makes this nanotechnology, if anything does, is the fact that analytical tools are available to observe the
nanoscale structural changes that lead to the desirable properties. What makes this nanotechnology, then, is
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simply knowledge. In the light of the new knowledge that new techniques give us, we could even argue that
some traditional processes, which it now turns out involve manipulation of the structure on the nanoscale to
achieve some desirable eVects, would constitute nanotechnology if it was deﬁned this widely. For example,
traditional whey cheeses like ricotta are made by creating the conditions for the whey proteins to aggregate
into protein nanoparticles. These subsequently aggregate to form the particulate gels that give the cheese its
desirable texture. The distinction between “natural” food nanoparticles and structures and ones that have
been deliberately engineered is potentially very problematic. For example, the recent European Food
Standards Agency scientiﬁc opinion [3] concentrates on “engineered nanomaterials”, but goes on to add that
“‘Natural’ nanoscale materials (eg micelles) will be considered if they have been deliberately used eg to
encapsulate bioactive compounds or further engineered to retain their nanoscale properties. ‘Natural’ nanoscale
components present as emulsions (eg in homogenized milk, mayonnaise, etc.) will not be considered.” This places
the emphasis on whether the manipulation of the nanostructure has been done on purpose. Of course, in the
hypothetical case that a particular nanostructure developed during processing did have potentially harmful
eVects, then the potential danger it might pose would not be aVected by whether its introduction was
intentional or not.
4. Different types of nanotechnologies have quite different risk profiles
It should be clear, then, that there isn’t a single thing one can call “nanotechnology”—there are many diVerent
technologies, producing many diVerent kinds of nano-materials. One makes materials and structures at the
nanoscale in order to access new properties—and these new properties in principle could bring new risks. But
there are a number of quite diVerent classes of properties that going to the nanoscale unlocks, and it is this
variety of diVerent types of nanoscale behaviour that makes it impossible to precisely specify a size range that
constitutes the nanoscale. DiVerent properties are aVected by size in diVerent ways, and it is only a general
sense that many such properties start to be dramatically aVected below sizes of a few hundred nanometers that
underlies the adoption of deﬁnitions such as that which deﬁnes 100 nm as the upper limit of the nanoscale.
One class of properties is aVected by the simple issue of the larger surface to volume ratio of small particles;
this aVects issues such as solubility and catalytic eVectiveness. Another important class of properties arises
from the interaction of the physical dimensions of a nano-object with the wavelength of some kind of
radiation. This includes the well-known transparency of small dielectric particles such as nanoscale titanium
dioxide and the colour changes of gold colloids, and the quantum conﬁnement eVects that arise in
semiconductor nanoparticles (quantum dots). Finally there are a number of properties that arise due to the
importance of Brownian motion and strong surface forces at the nanoscale, in particular the phenomenon of
self-assembly, which underlies, for example, the formation of nanoscale surfactant micelles, and is of great
importance in biological processes at the nanoscale.
In the same way that the new properties that arise at the nanoscale can have their origin in quite diVerent
physical phenomenon, so the new potential risk proﬁles of such materials will be very diVerent, and it will be
impossible to generalise across these categories. To give a few examples, cadmium selenide quantum dots,
titanium dioxide nanoparticles, sheets of exfoliated clay, fullerenes like C60, casein micelles and phospholipid
nanosomes will all have quite distinct proﬁles of risk and uncertainty and it is likely to be very misleading to
generalise from any one of these to a wider class of nanomaterials.
5. Engineered nanoparticles versus self-assembled nanostructures
To begin to make sense of the diVerent types of nanomaterial that might be present in food, there is one very
useful distinction. This is between engineered nanoparticles and self-assembled nanostructures. Engineered
nanoparticles are covalently bonded, and thus are persistent and generally rather robust, though they may
have important surface properties such as catalysis, and they may be prone to aggregate. Examples of
engineered nanoparticles include titanium dioxide nanoparticles and fullerenes.
In self-assembled nanostructures, though,molecules are held together by weak forces, such as hydrogen bonds
and the hydrophobic interaction. The weakness of these forces renders them mutable and transient; examples
include soap micelles, protein aggregates (for example the casein micelles formed in milk), liposomes and
nanosomes and the microcapsules and nanocapsules made from biopolymers such as starch.
6. Varieties of food nanotechnology
Some potentially important areas of application of nanotechnology in food include the following:
— Food science at the nanoscale. This is about using a combination of fairly conventional food
processing techniques supported by the use of nanoscale analytical techniques to achieve desirable
properties. A major driver here will be the use of sophisticated food structuring to achieve palatable
products with low fat contents.
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— Encapsulating ingredients and additives. The encapsulation of ﬂavours and aromas at the microscale
to protect delicate molecules and enable their triggered or otherwise controlled release is already
widespread, and it is possible that decreasing the lengthscale of these systems to the nanoscale might
be advantageous in some cases. We are also likely to see a range of “nutriceutical” molecules come
into more general use.
— Water dispersible preparations of fat-soluble ingredients. Many food ingredients are fat-soluble; as a
way of incorporating these in food and drink without fat manufacturers have developed stable
colloidal dispersions of these materials in water, with particle sizes in the range of hundreds of
nanometers. For example, the substance lycopene, which is familiar as the molecule that makes
tomatoes red and which is believed to oVer substantial health beneﬁts, is marketed in this form by the
German company BASF.
7. Nanotechnology in packaging and food contact materials
Nanotechnology will also ﬁnd applications in packaging and food contact materials. Again, there are some
important distinctions.
— Essentially passive nanostructures. These will be typically used to control barrier properties (eg
controlling gas diVusion for plastic beer bottles), and examples will be the use of exfoliated clay
coatings and composites.
— Nanomaterials which release active ingredients. For example nanosilver may be incorporated in
packaging materials for anti-microbial properties.
— Active devices—from sensors to detect spoilage, through to “intelligent packaging”.
One issue is worth mentioning in this context. These ideas for incorporating nanotechnology in packaging all,
in diVerent ways, tend towards increased material complexity, which does go counter to some other trends,
particularly the drive to minimise waste and make things recyclable.
8. Clarity and shared understanding must underlie real dialogue
What is important in this discussion is clarity—deﬁnitions are important. There are large discrepancies
between estimates of howwidespread food nanotechnology is in the marketplace now, and these discrepancies
lead to unnecessarymisunderstanding and distrust. Clarity aboutwhat we are talking about, and a recognition
of the diversity of technologies we are talking about, can help remove this misunderstanding and give us a
sound basis for public dialogue.
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Examination of Witnesses
Witnesses: Dr JohnHoskins, Royal Society of Chemistry, Dr Steffi Friedrichs, Nanotechnology Industries
Association; and Professor Richard Jones, University of Shefﬁeld, examined.
Q477 Chairman: I would like to welcome the three
witnesses and apologise that you are so far away from
us. We are in rather a large room and we do not issue
free binoculars, so I do hope that you have got your
spectacles with you! I would like to welcome you to
this eighth public hearing of the inquiry into
nanotechnologies and food, to let you know that the
proceedings are being webcast, and I would like to
draw attention to the information note which is
available to members of the public which sets out the
declared interests of the members of this Sub-
Committee of the Science and Technology Select
Committee so we will not be repeating our declared
interests during the questioning. Before we start I
would like to invite each of the three witnesses in turn
to introduce themselves, and if you wish to make any
opening statement please feel free to do so. Professor
Jones, perhaps you could kick oV.
Professor Jones: I am Richard Jones. I am a physicist
from the University of SheYeld and my professional
interest is in the nanoscale properties of synthetic and
biological macromolecules. Relevant here, I have
done some work on food-related issues in
collaboration with some food companies. From 2007
to 2009, in fact to the beginning of this month, I was
the senior strategic adviser on nanotechnology to
EPSRC, which is the research council which leads on
the cross-council programme Nanoscience through
Engineering to Application. I have also had a very
strong interest in public engagement in the area of
nanotechnology over the last ﬁve years and I chaired
the Nanotechnology Engagement Group.
Dr Hoskins: I am John Hoskins and I am here as a
representative of the Royal Society of Chemistry.
Within that organisation I am a member of the
Environment, Health and Safety Committee who
have asked me to be here today and I am also a
member of Toxicology Group as well. My particular
expertise is in the toxicology of nanoparticulate
materials. I should add that the Royal Society of
Chemistry is particularly interested in this
Committee because of our launch in this House in
January of the paper The Vital Ingredient which
concerned our interest in food.
Q478 Chairman: Thank you very much.
Dr Friedrichs: I am SteY Friedrichs. I work for the
Nanotechnology Industries Association. The
industry association is globally the only one that is
focusing on nanotechnology and industry. That is
reﬂected in our membership in that we have members
from the US and from Australia as well and from
across Europe. There is still a large number of
industries from theUKbecause that is where we were
created in 2005, very much as an initiative by the
industry itself in saying that we need a voice at a time
when the UK was seen to be the most proactive
country in debating nanotechnology challenges and
opportunities in 2005. Last year, we moved over to
Brussels and we have now opened and incorporated
an oYce there but we retain our nanotechnology UK
base as well.
Q479 Chairman:Thank you very much indeed.May
I start oV the questioning by putting to you a
question that is very basic but has concerned us more
and more as the inquiry has progressed, namely
exactly how one deﬁnes what one means by
nanotechnologies or nanomaterials particularly in
the context of regulation. Professor Jones, I notice in
your excellent submission you have quite a long
discourse on diVerent kinds of nanotechnologies and
diVerent kinds of properties of nanoparticles and I
wonder if you could give us an introductory
comment, and then I would invite the others to
follow, on how you feel in the context of regulation
nanotechnologies and nanoparticles should be
deﬁned.
Professor Jones: As my written evidence suggested, I
think this is a very diYcult issue which is at the heart
of the problem that we face; the diVerence in
deﬁnitions that people are using is at the root of the
misunderstandings we see between diVerent groups
about to what extent nanotechnologies are already in
the market when it comes to food. The ﬁrst thing to
stress, which I am sure many people have said to you
already, is this issue of diversity. Nanoparticles,
nanoscale materials cover a very wide range of
diVerent materials that really do not have a lot in
common when it comes to toxicity, and certainly
there is no sense in which one can say there is a set of
common features that a particular set of
nanoparticles has. The important distinction that I
have tried to draw out in my evidence was the
distinction between engineered nanoparticles, hard
covalently bonded materials like titanium dioxide
and nanoscale silica, which have an essential
permanence about them (although they can actually
of course aggregate and become less nanoscale in that
way) from self-assembled nanostructures which
really are assembled due to weak non-covalent
bonds, things like nanosomes, liposomes, micelles
and such like where component molecules come
together in nanoscale assemblies through reversible
non-covalent bonding. These can be expected to be
much more mutable and in many cases will disperse
as soon as they are eaten if they are in a food product.
The other distinction that one can make is a
distinction between synthetic nanoparticles and
natural nanoparticles or natural nanostructures. It is
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a feature of interest as well as a problem from the
point of view of deﬁnition that food materials have a
lot of natural nanostructures in them already. Some
synthetic nanoparticlesmight bemade away from the
food processing location and put into food products
as ingredients, but some nanostructures will arise due
to the processing methods that are used in the
manufacture of food. The point to make is that, in
many cases, whether we can talk about food
nanotechnology or not is essentially an
epistemological issue, in the sense that many food
processingmethods produce nanoscale structures. To
some extent you could argue that it becomes
nanotechnologywhen you know that these structures
are on the nanoscale, when they are purposefully
introduced, and when you have analytical data to tell
you that these nanoscale structures are indeed being
created. One ﬁnal point—it would be very tempting
to think that we do not need to worry about those
nanostructures that arise from traditional food
processing methods or developments of those
because they have been around a long time. That is a
tempting conclusion that in many cases might be
right but I think one does need to bear in mind the
possibility that natural food processing will produce
nanostructures that may have harmful eVects. It is
not necessarily the case to say that because things are
natural that they are safe.
Q480 Chairman: Thank you very much. Would Dr
Hoskins or Dr Friedrichs like to add anything?
Dr Hoskins: Not really. I think that sums it up very
clearly.
Q481 Chairman: Dr Friedrichs?
Dr Friedrichs: I would like to comment very brieﬂy
and particularly thank you for mentioning that there
needs to be clariﬁcation of nanotechnology and
nanomaterials deﬁnition in the context of regulation,
because the problem that we have is that the purpose,
for which we are seeking a deﬁnition, is the one that
always needs to be mentioned, when a deﬁnition is
sought. Without that, deﬁnitions can be quite
detrimental or entirely misleading when it comes to
posting a deﬁnition without knowing what it is for. A
deﬁnition for risk assessment needs to be very
diVerent from a deﬁnition for technology and
innovation, for example. The problem that we have
at the moment is that we are dealing with a number
of diVerent deﬁnitions on a number of diVerent levels.
We have had the International Standards
Organisationworking on a deﬁnition for a number of
years now and they have come up with a working
speciﬁcation of nano objects and nanotechnology,
not even mentioning nanomaterials. Obviously that
is a technical deﬁnition, which is only going to go so
far when it comes to using it for the regulatory
context. Another aspect is that when we go into the
public domain and talk about the deﬁnition, more
and more things are coming into force. When you
look at the reports published by NGOs and by
consumer associations about the perceived presence
of nanotechnologies in consumer products, they are
quite often using diVerent deﬁnitions from those the
industry is using, and that is then seen as a very bad
eVect when industry is seen to say ‘we do not have any
nanotechnology in those products that you say
include nanotechnology’. They are both saying the
same thing; they are just not agreeing on the same
deﬁnitions. My appeal would be to always disclose
the deﬁnition that one is using for any discussion
upfront so that any misunderstanding, particularly
by the consumer and by the public, can then be
avoided from the ﬁrst moment on.
Q482 Chairman: Thank you. Perhaps I could just
follow-up with a couple of points. In the
Nanotechnologies Industries Association’s
submission you say: “The risks associated with
engineered nanomaterials should not be diVerent
from those associated with naturally occurring
nanomaterials.” So it seems as though in that
position you are disagreeing with the distinction that
Professor Jones drew between engineered particles
that are covalently bonded and naturally occurring
particles that may be held together by weaker
bondings and therefore are less stable. Is that a
genuine disagreement or is that something which
relates to the way it has been expressed?
Dr Friedrichs: I do not think it is a disagreement,
Chairman, particularly not regarding the example
you just gave because engineered nanomaterials and
naturally occurring nanomaterials are by no means
distinguished in the technical diVerences that you
have just recalled in covalent bonding or weak or
strong bonding. We have insoluble nanomaterials
occurring in nature. We are inhaling fumes from
combustion engines as anthropogenically created
nanomaterials daily and organisms have learned to
cope with those on a certain level, if not entirely. I do
not think it is a disagreement at all.
Q483 Chairman: So from a regulatory perspective
you would not want to consider naturally occurring
nanoparticles automatically being distinct from
engineered nanoparticles? You would want the
regulations to look at both?
Dr Friedrichs: Of course the distinction needs to be
made but what should then not be seen as an
assumption upfront is that the engineered ones, the
ones that are deliberately manufactured, as you quite
often ﬁnd, or intentionally manufactured as you
quite often ﬁnd in one of those deﬁnitions, that those
are seen inherently as more toxic than the ones that
we are inhaling daily either naturally occurring or
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anthropogenically produced by industrial
mechanisms.
Lord Crickhowell: I am not a scientist and every time
we have this discussion I become more confused. I
hear what you have been saying on what is a very
complicated issue. I have in front of me the report of
the Scientiﬁc Committee on Emerging and Newly
Identiﬁed Health Risks. They have a paragraph on
the same subject and when I ﬁnished reading it I was
even more confused than when I started. I suspect
that we as a Committee are not going to be able to
simply say it is all very diYcult and there are a lot of
diVerent factors to be taken into account. I think
people will probably expect us to suggest a workable
deﬁnition that people can at least discuss as a basis.
Are any of our witnesses going to be able to put
forward, are you going to be able to put forward a
basic deﬁnition which is likely to stand up to scrutiny
and examination and carry us forward? I think in the
days when I was a minister, having heard all these
expert views, I would have turned round to my
oYcials and said, “Sit down and produce a workable
draft, argue about it and let me know if that will stand
up.” Are we in a position to do that?
Q484 Chairman: Professor Jones, would you like to
come back on that?
Professor Jones: Yes, this is the point at which I am
rather glad I ama scientist and not a regulator. I think
it is very diYcult. You have heard the very simple idea
that people have that we can just say it is 100
nanometres and below that is a problem and above
that is not. That clearly will not wash. I think we need
to consider both the nature of the ingredients and the
degree to which nanoscale structure has been
introducedwith intentionality. I think you can clearly
distinguish engineered nanoparticles, which are
entities that you canmake a relatively clear deﬁnition
of. One should be looking at whether these have
substantially new properties by virtue of their size.
That is an important factor in determining whether it
was something one ought to consider. In a sense, I am
not volunteering to provide to youwith that cast-iron
deﬁnition, but I hope I have been able to illustrate
some of the issues that you would need to take into
account when one would make such a deﬁnition.
Q485 Chairman: Would any of the other witnesses
care to propose a cast-iron deﬁnition or do you follow
the lead of Professor Jones?
Dr Hoskins: I do not thinkwe can oVer cast-iron ones.
The nature of the beast is that we are going to have to
be fairly woolly about it. One of the important
factors is that the materials as manufactured should
maintain their nanoscale properties when in use. This
would of course be a rider to any deﬁnition rather
than a deﬁnition itself. If in use for example involves
dilution, then of course you can get a breakdown of a
number of covalently bonded nanostructures. I think
that is going to be the way. You are going to have to
keep to the very crude deﬁnition of compound or
structures or whatever—less than 100 nanometres—
and then add a number of riders depending upon
function.
Q486 Chairman: You have just disagreed with
Professor Jones who said the deﬁnition of below 100
nanometres will not wash.
Dr Hoskins: It will not as a deﬁnition in its own
right, no.
Q487 Chairman: Did you wish to add anything Dr
Friedrichs?
Dr Friedrichs: Just as a clariﬁcation in underlining
that Richard and John did not contradict each other.
Naming 100 nanometres as a really clear absolute
cast-iron cut-oV is clearly what is not going to wash.
If we look at what John mentioned about retaining
the nanoscale properties, when you look at
nanomaterials you will ﬁnd that most of them only
show true nanoscale properties—i.e. not just a linear
increase in surface area but really something
happening on the nanometre scale that the material
does not do at a larger scale; there is a step change of
property—we observe almost all of those below 50
nanometres and most of those below 20 nanometres.
Q488 Earl of Selborne: The Nanotechnology
Industries Association says in its submission to us
that the current regulatory framework is adequate
but that industry needs updated supportive
guidelines to address uncertainties in the toxicology
underpinning risk assessment. Could you give us
your thoughts as to what such guidance should
include and could you put that in the context of what
guidance is currently given to companies to tell them
whether a product falls under the Novel Foods
Directive?
Dr Friedrichs: The call for guidance is one that is
particularly necessary when you look at where
nanotechnology innovation is done. It is done to a
large extent where innovation is done in entirely new
emerging technologies: by small companies. It is in
particular the small companies that need guidance
when it comes to developing products for which they
need to know, when they are aiming for an exit
strategy, either selling the products to a client,
licensing the technology process, or in fact exiting by
being bought by larger companies, how much the
approval process of the ﬁnal product is going to cost.
Therefore you need guidance as to if there is any extra
data required when a consumer product contains
nanomaterials or is based on nanotechnology as
opposed to not having done so before. That is all the
guidance we are talking about. We need guidance
when it comes to approving such products for the
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market. For the food industries, we have in Europe,
as we have with all other products, the Product Safety
Directive which holds the manufacturer responsible
for making sure that the product is absolutely safe.
That is irrespective of the presence of nanomaterials
or the use of nanotechnologies. The guidance that
needs to be implemented and needs to be written at
some point, sooner rather than later, is if the
regulator thinks that they require additional data or
additional research in order tomaintain this approval
process as it is. For food products on the market,
particularly in Europe, that problem does not arise at
the moment.
Q489 Earl of Selborne: If I could come back to your
earlier observation that there should not be an
automatic assumption that nano-engineered
products are automatically likely to be more toxic. Is
not the underlying issue that the risk assessment has
to be determined because clearly nanoparticles have
been in our food supply which humans have evolved
to ingest whereas engineered nanoparticles may or
may not be equally benign; we just do not know? Is
there not therefore a precautionary element which
has to be taken into account in the risk assessment?
Dr Friedrichs: Yes, there is, but our regulation and
our risk assessments are fully capable of dealing with
uncertainties.
Q490 Chairman: Just to pick you up on that. I am
quoting from the EFSA opinion here which was
published in February this year which says: “The
adequacy of currently existing toxicological tests to
detect all aspects of potential toxicity of engineered
nanomaterials has yet to be established.” Then it goes
on to say: “Any individual risk assessment is likely to
be subject to a high degree of uncertainty.” That
seems to be a much less concrete and deﬁnite
assertion than the one you have just made, Dr
Friedrichs.
Dr Friedrichs: That goes hand-in-hand with EFSA’s
recommendation for a case-by-case approach to risk
assessment, so it is talking about the established risk
assessment, the established tests and approval
approaches. “Established” means that we have an
agreement which is the same for all nanomaterials
and for all nanotechnology when it comes to
approving them in food products. We are not there
yet.We do not even have any food products that have
any nanomaterials in them. The emphasis is very
much on the word “established” in that context. At
the moment all we can do and the best we can do is a
case-by-case approach. That is done to state-of-the-
art and on a European level with full recognition of
the precautionary principle.
Lord Mitchell: I would like to take a look at co-
ordination of research. I wondered what co-
ordination is going on between industry, academia
and government on risk assessment? Secondly, what
role should industry play in any national research
strategy?
Q491 Chairman: Professor Jones, you would
probably be best-placed to answer given that you
have been advising EPSRC on such matters.
Professor Jones: Indeed. As I am sure you have heard,
there are mechanisms for co-ordination of research
through the Nanotechnology Research Co-
ordination Group which is a forum for agencies like
the research councils and the Technology Strategy
Board.
Q492 Lord Mitchell: Is this UK or European?
Professor Jones: In the UK, yes. I think it is fair to
say—and I am talking about the UK picture at the
moment—that the research councils have various
priority areas for the application of nanotechnology,
so for example in the EPSRC programmes that have
been developed there has been an emphasis on
nanotechnology for medicine and nanotechnology
for things like clean energy and environmental
mediation, and so from the research councils’ point
of view their emphasis has been on making sure that
the research on potential adverse eVects as well as
public engagement has been aligned to what their
priorities are. It is not the case that the
nanotechnology applications in food are a priority
for the research councils, so there has not been a
particularly strong push from the research councils to
address speciﬁc issues arising from nanotechnology
in food. The Technology Strategy Board is the body
that is being tasked with co-ordinating research with
industry and for putting together industry consortia
to do research, both in bringing research to market
and in dealing with toxicological and eco-
toxicological issues. Their major instrument for
promoting research on the toxicological side has been
the Safe Nano Network which TSB has supported. I
know that the NIA has been active—and SteY can
speak to this—in identifying the research needs of
NIAmembers and feeding into TSB. I know that has
had an impact for example on some of the OECD
recommendations. The OECD is providing a kind of
transnational medium for people to identify research
priorities and the UK’s TSB and NIA have been
instrumental in making sure that the UK fulﬁls its
share of the OECD research programme.
Q493 Lord Mitchell: I wonder if Dr Friedrichs has
anything to add to that?
Dr Friedrichs: I believe you have already in your
records mentioned a number of times the OECD
eVort where 14 representative nanomaterials have
been agreed between industry and policy makers, ie
regulators, on the international forum that the
OECD represents. These are relevant and
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representative nanomaterials in that they are
commercially relevant, so we are not talking about
creating esoteric nanomaterials that might never be
used and never pose an exposure threat. These are
nanomaterials that are made by industry, they are
donated by industry into the co-ordinated research
programme at the OECD, the so-called OECD
sponsorship programme, and they have a large
potential and sometimes even current commercial
use. They are also representative in that once we have
the 59 end points that are currently set under the
sponsorship programme to be tested for all of these
nanomaterials and various diVerent forms thereof,
we will have a matrix of data points that will
hopefully, ultimately, give us an answer to the
question of whether there are such things as intrinsic
toxicological properties of nanomaterials or if there
is nothing that any nanomaterial has in commonwith
any other nanomaterial. It will also give us some
indication as to how many high aspect ratio or soft
and hard nanomaterials fall into this overall plot of
where the toxicology of nanomaterials needs to be
regarded.
Q494 Lord Mitchell: What eVorts are being made to
assess the risks from the introduction of
nanoparticles into the food chain from unintended
and accidental means? What should government be
doing about this?
Professor Jones: I think it is fair to say that the eVort
in nanotoxicology in the UK has really been focused
on the respiratory aspects of nanoparticles. This is a
function of the way the decision was made to rely on
responsive mode funding for nanotoxicology. That
means to some extent we have the research that
reﬂects what people in the UK are good at, which is
respiratory toxicology. I cannot say that there has
been a huge amount of research supported in the area
of understanding the eVects of direct ingestion of
nanoparticles.
Q495 Baroness Neuberger: Dr Friedrichs, you have
already said that almost all the development here is
being done by small companies and theRoyal Society
of Chemistry has said that whilst it is small
companies and academic institutions that are
researching the potential of the emerging
technologies, the commercial realisation of new
products and ingredients is not being carried through
to market. I think what we would be very interested
in knowing probably ﬁrst from Dr Hoskins and Dr
Friedrichs but also from Professor Jones is what you
think the main barriers are to the commercialisation
of nanotech products in food, food packaging and
agriculture.
Dr Hoskins: The big problem for large companies is
probably fear: fear of the unknown and fear of
litigation, unfortunately. Another problem which
underpins this is the fact that legislation such as the
European legislation REACH on the transfer of
chemicals, and indeed the assessment of the safety of
chemicals such as we get with IARC, the
international agency in Lyons, will not accept that the
nanostate is in fact any diVerent from the bulk state,
and therefore in spite of the fact that they continue to
discuss the risk properties and hazard properties of a
number of nanoparticulate materials they will not
diVerentiate them from the bulk materials. A good
example is titanium dioxide which we see of course in
paints and everybody is comfortable with. People are
less comfortable when they come to the
nanoparticulate material because of the fact that,
probably not in use but possibly in manufacture,
there is a chance of people respiring thismaterial, and
work has shown (interestingly for a pharmaceutical
company but not for a food company) that the
particles are taken up by the nerves in the nose and
transported directly into the brain through the blood/
brain barrier which has a very substantial eVect on
the brain, at least in so far as one can interrogate
mice. This may well be happening in people as well
and it is this sort of scientiﬁc fact that is holding back
the big companies because through the various Food
Safety Acts and amendments to these they have a
requirement to produce safe food, and if there is
going to be a problem in its manufacture (and it is
probably more likely in its manufacture than in its
consumption) then they have to be extremely careful
as to how they approach things because the penalties
for them making a mistake and, if you like,
unleashing a particular health problem are just too
great for them to bear at the present time, so
conservatism and fear is holding back the companies.
Q496 Baroness Neuberger: You are talking about
reputational concern there because if the small
companies are doing it they are presumably bearing
the same degree of risk?
Dr Hoskins: The bottom line is that it is a question of
share prices that are aVected. There is another
problem in that there is little doubt that the vox pop
part of the media is in places trying to demonise the
preﬁx ‘nano’. “What have we got going into our
foods?” It only wants a handful of journalists to start
saying, “We have another GM problem,” and then
the big companies will rush away from the situation
very quickly indeed.
Baroness Neuberger: We have had a sense of some of
that from people that we have talked to and we
certainly had a sense of that from people we were
talking to in theUS last week. I suppose what you are
really saying is some of the small companies are
keeping going because they are not as worried, it is
not share price and reputation, but the big ones are
fearful in a whole variety of ways.What is the barrier,
253nanotechnologies and food: evidence
30 June 2009 Dr John Hoskins, Dr Stefﬁ Friedrichs and Professor Richard Jones
what is stopping the smaller companies anyway from
realising it and bringing it to market?
Q497 Chairman: Dr Friedrichs, perhaps you would
like to add a comment on that.
Dr Friedrichs: There is a necessity to consider the
value chain here. No small company is going to
produce a product and take it through the full value-
adding steps of putting it into an existing product
and taking it all the way to market. What the small
companies do at the moment is contract research or
they might have identiﬁed a particular new
mechanism by which to improve a material by going
on to the nanometre scale with production
mechanisms. They need a business-to-business client
in order to bring that to market, so when we are
talking about the small companies you will not ﬁnd
them as the brand owners selling into the ﬁnal
market.
Q498 Baroness Neuberger: Just one very quick
thing on this from all three of you perhaps is about
the R&D in the UK both on the innovation and on
the translation. Is that keeping pace with other
countries? We had a slight sense when we were in
the States that perhaps it is not but we do not know.
Professor Jones: Can I just add something about the
barriers because I think there is something obvious
but important to state. A big barrier to the uptake
of nanotechnology in food is simply the fact that
food is a ruthlessly low-margin business with very
strong competitive pressures, so very sophisticated
bits of science need to be justiﬁed. They will add
production costs and they need to be justiﬁed by
very tangible new beneﬁts, so I think it is easy to
see barriers in terms of fear of public reaction, but
the pure commercial realities of producing the
product may be just as important.
Q499 Lord Mitchell: If I can come back on that.
Food may be low margin but it is very high volume.
Professor Jones: Absolutely.
Q500 Lord Mitchell: And research and
development does not go by unit cost; it goes over
the complete amount.
Professor Jones: But I am not talking about the
research and development costs. I absolutely
appreciate, yes, you can spread the research and
development costs over a very big volume of
products, but it is the additional costs in processing,
rather than research, that I am talking about here.
Very small additional costs in processing will make
food companies rather reluctant to introduce new
technologies unless they have a really tangible
beneﬁt that is going to come out from it.
Q501 Lord Cunningham of Felling: To take an
obvious example in the food business—salt—
presumably (and some people have argued this) salt
on a nanoscale would mean that far less salt would
need to be added in food processing and food
products, presumably with a consequent saving on
cost, and at the same time at the nanoscale we are
told that the food would appear to taste exactly as
before with much less quantity of salt in it. What is
holding up that kind of development?
Dr Friedrichs: It is in combination with what
Richard just explained, it is the scale-up as well. You
will quite often ﬁnd that for the small research and
development lab, the small company that has
developed a desk-top approach or maybe a
prototyping approach, the scale-up is still one of the
highest barriers to making very high volume
nanomaterials. In combination with what was said
it is the scale-up that one needs in order to
commercialise these materials. That is exactly the
answer to that.
Q502 Baroness Neuberger: Can I pick up that point
about how we are doing in comparison with other
countries because that would be quite useful to
know.
Professor Jones: Do you mean in food speciﬁcally or
in nanotechnology as a whole?
Q503 Baroness Neuberger: In food speciﬁcally and
the innovation and translation bit
Professor Jones: My guess—and this is really just my
impression—is that I would not have thought that
we were particularly far behind. The food sector is
a strong sector in the UK and it is supported by
strong R&D. If one is thinking about the big multi-
nationals, Unilever, Nestle´, Kraft, Danone, one of
the biggest of those is based in the UK, and I think
that drives a very substantial science base.
Q504 Lord Crickhowell: Dr Hoskins, reference to
REACH takes one rather conveniently to my next
question. The problem about REACH at the
moment is that it deals with the bulk materials and
clearly it is going to need revision if it is going to
provide cover for what we are talking about. All our
witnesses agree that it is likely that the revision of
REACH is going to take a very long time; these
things do. Its introduction took a pretty long time.
The Royal Society of Chemistry state that imported
food products containing nanotechnologies and
nanomaterials are not well-regulated owing to
inadequate funding, the burden of import regulation
falling on local authorities with major ports, lack of
validated analytical methods and gaps in horizon
scanning for risks. Can you elaborate on this? Do
you have evidence that this is happening? What
basically that is saying is that if nanotechnology
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products are being developed elsewhere in the world
we are not very likely to know about it when they
arrive in this country or Europe.
Dr Hoskins: This is a major problem. Since about
half of our food is imported and there are major
exporters in, shall we say, China or India, if they
were to produce a material containing nanp-
particulates we would not know about it, and since
our food comes in through a relatively small number
of places, the major ports, it is down to the local
authorities in those ports to check the imports that
are coming in. I discussed this with the Government
Chemist, who are liable to be involved in validation,
and the trouble is that while at some considerable
expense one can analyse and determine the presence
of nanoparticulate material, let us take an example
and say something like nanoparticulate silver in
food packaging, it is an expensive exercise and
probably there is not the funding or the laboratories
to whom the local authorities will have to go and
these will not have a validated method to work to.
In fact, only a few of them will have the equipment
to do the sort of electron microscopy and plasma
spectroscopy that is needed to determine both the
presence and the nanostate of a material that
comes in.
Q505 Chairman: Do you suspect that there is in
imported food coming into this country containing
engineered nanomaterial that is just not being
detached? Is that your suspicion?
Dr Hoskins: I think we have to regard it as a distinct
possibility but I do not know.
Q506 Chairman: I wonder whether Dr Friedrichs
has anything to add to that.
Dr Friedrichs: I do not think I can add anything. I
would very much doubt considering what we said
before that a company would put expensive
nanomaterials into a food product without wanting
to cash in on the beneﬁts claimed.
Q507 Lord O’Neill of Clackmannan: The FSA is
considering a register of nano-derived foods and
food contact materials. What would be your view
on such a register? Do you think it should be
voluntary or mandatory?
Dr Friedrichs: I was surprised to hear that because
we are struggling with the very ﬁrst topic you
mentioned when we opened this hearing in that they
would have to deﬁne what nanomaterials are and, in
particular, when it is a mandatory requirement you
would then have to set very strong strict cast-iron
(as you called it before) rules of “you are in if you
are under a certain threshold and you are out if you
are not”. Because of that, the current understanding
and the verdict of all expert committees and the fact
that we only have limited cases at the moment, I
would strongly recommend that such a register
ought to be a voluntary approach in which industry
is worked with in order to be inclusive rather than
exclusive because I think that would bring
everybody a lot further. I would like to see a lot
more on how that would be structured and what it
would be based upon, in particular with regard to
deﬁnition if it goes forward.
Q508 Lord O’Neill of Clackmannan: We do have an
example already of Defra’s voluntary scheme which
is signiﬁcant only in the low participation rates. Are
these low participation rates by your members
because of the diYculties of deﬁnition or are they
reluctant to put their heads above the parapet?
Dr Friedrichs: The Defra voluntary reporting
scheme is one of my pet topics. Defra launched it
when I was new in the job and had appointed
somebody to see it through who was as new to
dealing with that sort of issue as I was. We worked
together on that to the extent that we the NIA
actually went to our member companies, sat down
with them and completed the reporting form with
them. I can tell you it is 12 pages of detailed
questions. For a company that makes a living from
having developed a new process of making
nanomaterials for example, they might have a
drawer of 27 diVerent samples of nanomaterials,
and since no weight threshold was given in the VRS
reporting template,they were expected to ﬁll in 12
pages of detailed questions for every one of those
27 nanomaterials. Naturally with one of those
submissions taking of the order of three to ﬁve
hours when you are a company of six people, you
can close the shop if that is required of you. We went
out and did it with the companies and helped them
to do it. We actually had to rewrite the reporting
format because it had been lost somewhere in the
ﬁles. That was all ﬁne. All of the industry
submissions to the reporting scheme that Defra
received have come from NIA members, as far as I
know, some of them through us, some of them
external to us. I know that Defra is now saying after
having commissioned the Nanotechnology
Knowledge Transfer Network, that it is bringing in
another 1,100 companies in the UK and asking
them to participate in the reporting scheme. From
interviews with over 1000 companies, the KTN has
received one more submission, so Defra is now
oYcially saying in a number of fora that this is the
commercial reality in the UK. I do not think
claiming that this has been disappointing has any
grounds. This is the commercial reality of those
companies that are actually making nanomaterials
in this country within the remit of allowing that they
might have gram scales of proof of principle
materials for which you cannot ask them to
complete all of it. If Defra wants a speciﬁc
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completion for a speciﬁc nanomaterial, they are
welcome to come and ﬁnd out more about it.
Q509 Lord O’Neill of Clackmannan: Am I right in
thinking that you came into this process once the
survey had been set up and you merely helped in the
ﬁlling in of the forms? Is that right?
Dr Friedrichs: We commented on the survey itself. It
underwent a six-month public consultation and some
changes were made to it. One of our very strong
recommendations based on how Australia and
Germany had done reporting schemes before was to
make it a tiered approach. Do not send out 12 pages
of detailed questions, which is going to have a scary
eVect on everybodywho opens the letter, but send out
a simple letter saying what are companies making,
how much of that, and what is done with it when it
leaves your premises. Then, if Defra is interested in
any of those submissions that come in, with an
answer that you can make within ﬁve minutes, they
could then go back and ask for more detail on those
nanomaterials they are really interested in. Australia
has been more successful in doing that tiered
approach and asking very few very simple questions
in the ﬁrst place. That is what we recommended.
Q510 Lord O’Neill of Clackmannan: Just one last
point, do I take it then that the diYculty with
deﬁnition and the problems involved in completing
the forms would make it such that to have
nanomaterials included in food labelling information
would be almost worthless because of the complexity
and inability to have a consensual form of deﬁnition?
Dr Friedrichs:Labelling is an entirely diVerent aspect.
I would not want to answer the question on the basis
of what we have said so far in a diVerent context.
Q511 Chairman: That is surprising because if you
started oV by saying a register would be diYcult to
assemble because of the deﬁnition, it is surprising
that you would not make the same comment about
labelling.
Dr Friedrichs: The comment about deﬁnition stands,
but everything else that we have said regarding the
voluntary reporting scheme being voluntary or not
and having a threshold is not something that is of
foremost priority when you consider labelling.
Chairman: I understand. Lord Selborne?
Q512 Earl of Selborne:There have been a number of
voluntary codes for the nanotechnology sector
around the world, including one in this country in
which I declare an involvement. Do these voluntary
codes serve a purpose? Do they impart public
conﬁdence or do they help the nanotechnology
industry?
Dr Friedrichs: Yes, I guess we were involved in that.
What you have to appreciate is that the code that in
particular Lord Selborne chaired and that we helped
to set up was called in by the ﬁnancial community in
collaboration with the Royal Society. We worked on
it to bring industry to the table. It does not only, and
certainly not in the way that it is put, serve the
industries. What it does is it cuts across the
international market and it cuts across the supply
chains, bearing in mind that current regulation and
agreements are always done on products and on
applications and there is no cut across between the
regulations that apply to products and applications.
This comes verymuchwith the spirit of codes inmind
that a code needs to be implemented in diVerent areas
of the market no matter if they are regionally
restricted or supply chain restricted. To ourmembers,
who are working with the code, it deﬁnitely helped
them to have an internal audit. It deﬁnitely helped to
raise the proﬁle. The ﬁrst principle of this code is that
it needs to be signed oV by a board or by
management, it has to be taken into consideration by
all of them and they can all vouch for the fact that it
has helped multinational companies to raise the
proﬁle of what they are doing in nanotechnology
safety.
Q513 Earl of Selborne: Do you see voluntary codes
as a step towards regulation or a substitute?
Dr Friedrichs: It is neither a substitute nor is it the ﬁrst
necessary step. It will always have a role alongside
regulation, where it can grip, in particular between
one regulatory region to another one where it can
hold everybody to the same level of safety, if a
company has plant and is commercialising products
in more than one legislative area. It always has a role
in parallel to regulation and it always should be kept
within regulation where it is seen to.
Q514 Lord Cunningham of Felling: In view of what
you have been saying, what new role, if any, do you
think government should adopt in respect of the
development of nanotechnologies, particularly in the
area of food? Should the government be looking for
a new regulatory framework? Should it take the view
that existing regulatory arrangements are adequate
or should it do something diVerent?
Dr Friedrichs: I think what government should do in
this particular context, particularly when we are
looking at food—and let us just focus for a moment on
food—is that we should learn from what went wrong
on the GMO debate and step up when it comes to
communication, working hand-in-hand with the
people who can actually deliver the data and the sound
science and technology-based facts and take the public
away from speculation and from scare stories.
Chairman: That leads us neatly to a point which I
think Baroness Neuberger would like to make.
256 nanotechnologies and food: evidence
30 June 2009 Dr John Hoskins, Dr Stefﬁ Friedrichs and Professor Richard Jones
Baroness Neuberger: You have absolutely made the
point. What public engagement activities do you
think industry should use? You have said they should
step up to the plate and actually do it but what should
the industry be doing and indeed, to follow Lord
Cunningham’s point, what also should government
be doing in informing the public and communicating
with the public on nanotechnologies and food? Do
you think there is something that industry should do
that is separate from what government should do?
Should government should take some kind of lead?
Q515 Chairman:Perhaps, Professor Jones, since you
have been involved in the EPSRC dialogue?
Professor Jones: I think this is hugely important. This
comes down to trust. The public does not necessarily
have trust in the food industry. It does not necessarily
have trust in government either. So I think the role of
government needs to be to provide a space where
government, industry, NGOs, academia and other
people with an interest can meet and discuss things in
a way that makes them feel a little bit safe from the
pitfalls of when public engagement goes wrong. For
example, I think we have seen the problem so far of
people in industry where nobody particularly wants
to be the person to step forward ﬁrst. So we need to
make a place where industry can feel they are
presenting a collective voice, and no individual
company is going to be picked oV. We need a place
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Q517 Chairman: Thank you very much for joining
us for this session. I should remind you that the
session is a public session. It is the eighth hearing of
our inquiry into nanotechnologies and food. The
proceedings are webcast so it is available to the public
at large. I also mentioned to the members of the
audience who you cannot see but who are sitting here
with us that the interests of the Committee members
that have been declared are on the information slip
available. Perhaps Dr Carlander, before we come to
the ﬁrst question I could ask you brieﬂy to introduce
yourself for the record.
Dr Carlander: My name is Dr David Carlander and I
have been with EFSA for the last three years.
Previous to my position in EFSA I was working for
the SwedishMinistry of Agriculture as well as for the
National Food Administration in Sweden. In EFSA
I initiated my work here working for the GMO unit
aiding in the risk assessment of genetically modiﬁed
organisms. For the last two years I have been
working with the Scientiﬁc Committee and Advisory
Unit where I am co-ordinating EFSA’s work on
animal cloning and also on nanotechnology, the
reason why we are having this conversation.
where scientists can contribute without thinking that
the media is about to tear them apart in all the ways
that the media does. Government’s role is not
necessarily to do this job itself but it is to facilitate a
mechanism for doing it at one remove.
Q516 Baroness Neuberger: A sort of safe space kind
of thing. The Royal Society was very complimentary
about the EPSRC dialogue so that is presumably the
kind of structure you are talking about?
Professor Jones: Exactly, yes, I think it is important
that it is seen to be run not directly out of government
but at one remove from that. One needs to worry
about where funding for such an activity comes from
so that people feel conﬁdent that the organisation
that is doing this is above the fray.
Chairman: Thank you very much. I think I need to
draw this session to a close now but I would like to
thank all three of our witnesses for their answers to
our questions as well as their written submissions. If
there are any points on which you have not felt able to
express the full richness of your views or if there are
any points that we have not raised with you that you
would like to draw to our attention, please do write in
with further evidence and that material will, as with
the written evidence, be published alongside the
transcript of this session in due course. You will of
course receive a copy of the transcript for correction
before it becomes the ﬁnal public version. Thank you
very much indeed.
Q518 Chairman: Thank you very much. May I start
oV by referring to the EFSA scientiﬁc opinion on
potential risks arising from nanoscience and
nanotechnologies that was adopted on 10 February
2009. In the report you identify various research gaps
and knowledge gaps in relation to risk assessment
and I wondered what you see the priorities are for
research and whether or not EFSA inﬂuences the
Commission in its allocation of funds for ﬁlling
these gaps?
Dr Carlander: As for the research priorities, as
indicated in our opinion, they are not prioritised as
such and for the time being EFSA has not made any
ﬁrm priorities on the research needs. These were
research gaps which we identiﬁed during the work on
the opinion. As for co-operation with EFSA andDG
Research, EFSA is regularly asked to provide our
input into the future programmes on DG Research.
That is a procedure we have in place already.
Q519 Chairman: So does that mean that if you were
to identify priority areas through this scientiﬁc
opinion those might well be taken up by the
Commission in calls for research proposals?
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Dr Carlander: Yes, I assume that would be the case.
Coming back to the opinion, obviously it was asked
for by DG Sanco at the European Commission but it
has also been submitted to theEuropeanCommission
as such. It also involvedDGResearch so they already
should be aware of the recommendations that we
provide in this opinion.
Chairman: Thank you. I would like to turn to Lord
Selborne.
Q520 Earl of Selborne: Good morning, Dr
Carlander. We were told by the UK Food Standards
Agency that Silver Hydrosol was recently evaluated
by EFSA in the context of establishing an EU list of
authorised sources of vitamins andminerals for use in
food supplements and that as there was insuYcient
informationtocomplete theassessment thisproduct is
unlikely tobe included intheeventual list. Is itpossible
therefore to risk assess products when there is such a
high level of uncertainty about their toxicity and
exposure and does this not make a product inherently
a high risk one?
Dr Carlander: Thank you for the question. Silver
Hydrosol is in a sense both a good and a bad example.
In away it is a good example in that it showed that the
risk assessors, the EFSA experts, were not able to
conclude on the data provided in the dossier. The risk
assessors need the full data otherwise we cannot
conclude on the risk assessment. Silver Hydrosol is a
bad example because there were not enough data and
wedidnotmake anassessment and therefore, because
we could not make an assessment of that product,
there is in a sense a safety for the consumer that unsafe
products should not be on the market. As for the
uncertainties that exist, they were so clear in this case
of Silver Hydrosol that some additional information
would have been needed to perform the risk
assessment. So already now in the system, the risk
assessors,when they identiﬁed that there isnot enough
data to perform a risk assessment, they (as is usually
the case for other products we assess) ask for more
data or we may come to a statement that we cannot
conclude on the safety. In a sense, you are absolutely
right that if there is no data we cannot perform a risk
assessment but in a sense such products would then
not be risk assessed and therefore in the future would
likely not be on themarket.
Q521 Earl of Selborne: So were you not able to get
any further data?Was it just not available?
Dr Carlander: For this product the data was just not
available yet. It is possible in the future that the
applicant will come back with a more complete
dossier.
Q522 Lord Crickhowell: The trouble is that we keep
gettingevidence that there isageneral lackofexposure
data for humans and particularly a lack of research
into the eVects on the gut and therefore transmission
through the blood system into the brain. We are told
that really there is very little known about it. In that
situation how is it possible that in the immediate
future you are going to be able to obtain data or carry
out a risk assessment on almost any product that is
going into the human gut?
Dr Carlander:This would fall a little bit under the last
response.We cannot do a risk assessment if we do not
have the data and this may be very much resource
demanding for companies that would like to place
products on the market. To conform to the
information there may be a need for substantial
studies being done at this stage until we get more
informationavailableonhowthesenanomaterials are
distributed throughout the body, where the toxicity is
and their classiﬁcation. We are coming back to the
issue that without the information we cannot do the
risk assessment.
Q523 Chairman: At the moment your approach is a
case-by-case approach, as I understand it. Do you
think that that is sustainable in the long run?
Dr Carlander: I am sorry, your voice did not come
through. Could you just repeat that question?
Q524 Chairman: Yes. As I understand it, you would
at the moment take a case-by-case approach to risk
assessment. In the long run would you envisage
carrying on with that or would you like to switch to
somemore systematic framework?
Dr Carlander: Well, as information develops and we
can learn from experience how pathways would work
andhow thesematerialswouldwork, I am sure that in
the future we will be able to make a more facilitated
risk assessment. The case-by-case approach is in a
sense not very diVerent from the current case-by-case
assessment we have onmost products and substances
that we assess, so in a sense I would not say it is very
much diVerent but obviously the more that is being
published and the more research is being performed,
themorewewill learn andwewill eventually probably
end upwith a simpliﬁed risk assessment.
Q525 LordO’Neill ofClackmannan:Onthisquestion
of the risk assessment of products, what guidance do
you think the Commission should be giving to
companies in this area?
Dr Carlander: To start with, the EFSA being the risk
assessor and the Commission being the risk manager,
I would prefer to avoid speculating whether the
Commission would provide some guidance, but I can
mention that the Scientiﬁc Committee of EFSA in
May last month endorsed a self-tasking facility, so we
will set up a newworking group onnanotechnologies.
One of the tasks thatwe can ask thisworking group to
address is to lookmore speciﬁcally into guidance and
for guidance to be provided to companies. As a ﬁrst
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response Iwould like to say that in theopinion thatwe
have producedwehave a generic section on providing
guidance for risk assessment that we provide as
guidance for our risk assessors so our risk assessors
should know what to look for speciﬁcally. Just from
that guidance document it could also be deduced by
companies what information would be needed. The
opinion we produced was admittedly, as asked for by
EuropeanCommission, an initial opinion, andwewill
go on working in this area and we may also provide
more detailed guidance for companies, as we have
done in other areas such as inGMO for example.
Q526 Lord O’Neill of Clackmannan: I am just not
quite clear here. Are you telling us that the work that
you undertake is independent of the Commission but
were the Commission to give guidance they would
have to refer to you as the source of information if not
the source of opinion, would that be correct?
Dr Carlander: Yes, that would be correct. As an
example I can just mention what is written in the
proposal for the novel food regulation where there is
also a proposed deﬁnition of nanomaterials. There is
an article asking that the Commission should provide
guidance to industry and to do so they should co-
operate with the European Food SafetyAuthority, so
obviously there is already in the regulations that we
will provide speciﬁc advice to the European
Commission.
Q527 Lord O’Neill of Clackmannan: But you have
yet to be asked for it and until you are asked for it you
are not prepared to tell us what kind of information
or advice you would give them, is that correct?
Dr Carlander: Yes, in a way, because this new
working group will starts its work when we have the
new scientiﬁc committee. You may be aware that we
have just changed our committees and the panels,
and so they will start their work in July when they
have the ﬁrst plenary meeting. I do hope that this
working group will initiate its work in August/
September and then go on. They have a mandate for
the next two years and then after that we will see
where we will take it further.
Chairman: Perhaps I could now turn to Baroness
Neuberger.
Q528 Baroness Neuberger: It is rather following on
on some of the same lines. How would you deﬁne
nanoparticles within legislation such as the Novel
Food Directive; is that something you can tell us at
the moment?
Dr Carlander: If I could tell you the answer to that I
would be very much appreciated by the whole
international world.
Q529 Baroness Neuberger: This is the impression we
are beginning to get, yes.
Dr Carlander: It is very diYcult to put it into
perspective or put it in the correct context, and it is
outside the remit of EFSA as being risk assessors. In
our opinion we did not provide a deﬁnition, which
you might have read, and it is up to the risk manager.
There are diVerent approaches that can be taken and
I would not like to speculate too much where this
would lead us, unfortunately.
Q530 Baroness Neuberger: Can I probe a little bit
further, and I realise that there are some things you
may not want to say, but in your opinion you state
that “natural” nanoscale materials such as micelles
will be considered as engineered nanomaterials if they
have been deliberately used, such as to encapsulate
bioactive compounds, or further engineered to retain
their nanoscale properties. Would you suggest that
that might be used within a deﬁnition?
Dr Carlander: Possibly. I would not know, but
possibly.
Baroness Neuberger: Okay, that is as far as you can
go. Thank you very much.
Q531 Earl of Selborne: EFSA has recommended
that the Commission should gain an overview of the
current products on the market containing
nanoparticles. How would you suggest that the
Commission sets about this and monitors their
current and future use?
Dr Carlander: There are many ways that the
Commission could do this but again being the risk
assessment body of the European Commission that
may be touching a little bit on how to manage
potential risk, but it could involve Member States,
surveillance teams, the various measures that the
Commission can take together with the Member
States. Also at the European Food Safety Authority
we do not have a remit ourselves to sort of scan or
have the competence to ask for this speciﬁc data
which would be on the European market. It is more
related to the risk manager, the Commission in this
case.
Q532 Earl of Selborne: You are the risk assessor
whereas the Commission are the risk manager. What
as risk assessor would you require in order to ensure
that the monitoring is eVective for your purposes?
Dr Carlander: We would like to get a good
understanding, and if we could use such information,
especially for the exposure assessment, which is a
diYcult area. If the quality of this information could
be so good that we could use it for our exposure
assessment, that would be very appropriate, but I do
not have a very detailed answer to this question
unfortunately.
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Q533 Chairman: Thank you. Could I ask you one
very speciﬁc question and then a couple more general
ones? The very speciﬁc question is whether in your
risk assessment you deal with all kinds of food
contact materials such as food packaging or
chopping boards that have been impregnated with
nano silver particles, or refrigerators that have a nano
silver particle in their lining. Do you deal with all of
these in terms of risk assessment?
Dr Carlander: We would deal with all the food
contact materials that would fall under the European
food contact materials legislation, and we would do
the risk assessment based on a request or a mandate
that we would receive from the European
Commission. In that sense, yes, if we were to receive
such a request we would do this risk assessment.
Q534 Chairman: My second point was about risk
assessment itself. We were recently in the United
States and we heard that the National Research
Council there has published a report suggesting a new
approach to risk assessment in relation particularly
to nanotechnologies. Is this something that EFSA is
aware of?
Dr Carlander: I am not fully aware what speciﬁc
report you are referring to.Would it be on the toxicity
pathways? I would be very happy to receive
information about this report obviously.
Q535 Chairman: Yes. Maybe it is something we
could follow up in writing afterwards, if you do not
mind.
Dr Carlander: That would be very much
appreciated19.
Q536 Chairman: Then ﬁnally, just to clarify, could
you brieﬂy recount the relationship between the risk
assessment that EFSA does and the research that is
required to underpin that, and the work done by the
national bodies within the Member States—bodies
like AFSSA in France or the Food Safety Authority
of Ireland or the Food Standards Agency in the UK?
Dr Carlander: Maybe just a broad reply to that. We
have in EFSA our Advisory Forum where we have
regular contacts with the Member States and the risk
assessment bodies of the Member States, so that is
one forum that we are using to share and discuss
information speciﬁcally for nanotechnologies. The
network is there, it exists, and it is being used.
19 “This is refers toNationalResearchCouncil’sReview of Federal
Strategy for Nanotechnology-Related Environmental, Health
(ISBN-10: 0-309-11699-6, ISBN-13: 978-0-309-11699-2). The
report is well structured and highlights important
considerations for the development of a research strategy and
indicates issues relevant to be developed to for a risk assessment
of nanomaterials. The report is an assessment of the strategy
applied in the US, which may not be fully relevant in a
European context.”
Q537 Chairman:What about the sharing of research
information, is that also through the same network?
Dr Carlander: Obviously it will depend on what stage
the research is at. For scientiﬁc publications we
would collect the information from everywhere we
can; for information that has not yet been made
publicly available the networks that we have built up
within EFSA could also be used to share this
information.
Chairman: Thank you. Lord Cunningham would
like to ask a follow-up question.
Q538 Lord Cunningham of Felling: It is a fairly
simple question I hope. Are you able to tell us what
percentage of the total eVort of the European Food
Safety Authority at the moment is being directed
towards nanotechnologies and food? Is it one per
cent, ﬁve per cent, ten per cent or less than that?
Dr Carlander: It is a good question but unfortunately
I am not aware. StaV-wise we have an internal
taskforce on nanotechnologies with experts or staV in
the various units that are involved in potential
applications of nanotechnology such as in feed, food
contact materials, nutrients and food additives. We
have about ten to 15 people in this taskforce butwhen
it comes to the budget unfortunately I do not know.
I can of course provide the information20.
Lord Cunningham of Felling: You can provide the
information. Thank you.
Q539 Chairman: Thank you very much indeed, Dr
Carlander, for answering our questions. I wish to
draw this session to a close now and I would invite
you, if there are any further points on which you
would like to comment in writing, please feel free to
do so. We have asked you about two speciﬁc points,
one was the allocation of resources to
nanotechnology within EFSA which you said you
could supply us some information on.
Dr Carlander: Yes.
Q540 Chairman: Secondly, if we give you the
information about this American report from the
National Research Council you could let us know
whether it is inﬂuencing the approach to risk
assessment taken by EFSA. Those would be very
helpful comments for us to receive. You will in due
course receive the transcript of this session which will
be available for you to correct before we make it
public, and any written evidence you provide is also
of coursemade public. I would like to close and thank
you very much indeed for your time and for
answering our questions.
Dr Carlander: Thank you very much.
20 “Depending on how the calculations are performed diVerent
estimates can be made. For the development of the Scientiﬁc
Committee March 2009 opinion we had 15 types of meetings
with 2–10 experts over the period 2007–09”
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Q541 Chairman: WelcomeMinister and Mr Dalton,
we are delighted that you have been able to join us.
This is our ninth public hearing of our inquiry into
nanotechnologies and food. May I just remind those
present that we are being webcast? There is an
information note available to the public and we
welcome the members of the public who have joined
us. This sets out the declared interests of members.
May I therefore now invite you Minister for the
record to introduce yourself andMr Dalton and then
perhaps, if you would like to make an introductory
statement, please do so?
Lord Drayson: Thank you. I am Minister for Science
and Innovationwithin theGovernment. In that role I
also chair theMinisterial Group for Nanotechnology
and therefore have responsibility for this matter
within the Government.
Mr Dalton: I am Ian Dalton. I am Head of the
International Chemicals and Nanotechnologies
Team within Defra. Just to give my apologies, John
Roberts, who gave evidence last time to the
Committee actually had an appointment he could not
get out of, so I have taken over for today.
Q542 Chairman: So you can help us with the Defra
side of aVairs in so far as they do not come under
Lord Drayson’s sphere.
Mr Dalton: Yes.
Q543 Chairman: Would you like to make any
opening statement or shall we go straight into the
questions?
Lord Drayson: May I just very brieﬂy say how, as
Minister for Science and Innovation,
nanotechnologies are high on my agenda. I recognise
this is an issue of some concern and is a matter which
we take very seriously. The main mechanism for the
way inwhichwe aremanaging the issue is through the
Ministerial Group for Nanotechnology.
Q544 Chairman: When do the Government plan to
publish their national strategy for nanotechnologies?
In an earlier session in March we were told that the
ministerial group would meet towards the end of
April when they would agree the way ahead for the
next steps of the strategy, potentially including a
consultative process. How will the Government
coordinate this national strategy across Government
and indeed to what extent will they be leading the
strategy?
Lord Drayson: Our plan has now been agreed across
the Government and the various departments which
have an interest in this matter and it has been agreed
that we will work towards a consultation process this
year, leading to publication of the strategy early next
year. The process by which we do that is by means of
consultation with all of the various stakeholders both
from scientiﬁc communities, from industry and from
those interested parties, for example consumer
groups, to provide us with the information to be able
to put together a coordinated strategy encompassing
matters of concern and publish that early next year.
Q545 Chairman: So that would be some time in
2010?
Lord Drayson: That is correct.
Q546 Chairman: So far as there is coordination of
the research, would that be led by your Department
or by the research councils?
Lord Drayson: There are several groups which feed
into the overall responsibility for this issue, the
ministerial group chaired by myself. For example,
there is a coordination group for oYcials, there is a
research coordination group and, in a growing
example of the way in which the research councils
work together, there is a coordination group for
research from the research councils, all of which feed
into this process to enable us to form the strategy. It
requires us to do a thorough analysis of the issues, the
state of play of those issues today, the view relating to
the potential concerns that there may be with regard
to consumer products using nanotechnology and to
give a clear sense of the coordination of the
implementation plans across Government. Therefore
RCUK, Research Councils UK, is an important
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group for the coordination of that research from the
research councils.
Q547 Lord Haskel: In 2006 the Centre for Business
Relationships, Accountability, Sustainability &
Society at CardiV University published a review of
the regulations on nanotechnology. Have the
Government now responded to this?
Lord Drayson: We have not responded speciﬁcally to
the BRASS report because we believed that our
response to those issues was satisfactorily
encompassed within the response to and our view on
REACH, the overarching review of regulation
relating to chemicals as a whole. Our conclusion on
that is that there is a strong case for the science of
nanomaterials to be regarded as needing further
work within the overall regulations for chemicals.We
believe that our response, through the European
Commission, through arguing the case for the
development of further regulation, is best done under
REACH.We believe that the response to the BRASS
report had been covered in that overall response
relating to REACH.
Q548 Lord Haskel: As I understand it, there were
some special concerns about nanotechnology in this
report.Will you be addressing those special concerns?
Lord Drayson: Yes, we will. We recognise that the
science of nanotechnology is moving quickly. The
particular challenge of understanding, for example,
the nature of the body’s immune response to particles
of size 100 down to one nanometre requires
signiﬁcant research. We regard the current REACH
regulations, for example, which set out a framework
based upon the one-tonne threshold for regulation,
as not being adequate in the case of nanomaterials.
We believe that the case has been made for there to be
development of legislation and regulation in this area
and that is what we are pursuing through European
channels.
Q549 Lord Haskel: Do you expect the European
Parliament to make special amendments to REACH
to treat nanomaterials diVerently to the bulk forms of
REACH?
Lord Drayson: Yes, we do. That is the drive of our
argument. We feel that the one-tonne limit is not
satisfactory for these materials. This is a loophole
which needs to be closed.
Q550 Lord Haskel:Do you have a timescale for this?
When do you think that this will happen?
Lord Drayson: Given the nature of the European
process, it would be unwise for me to commit myself
to a timescale but I can tell you that this is something
which we regard as being important. We regard the
scientiﬁc understanding to be such that this one-
tonne limit is no longer eVective, given the way in
which the science has moved on.
Q551 Lord Crickhowell:You have been very positive
about the two main issues I was going to raise. I once
had to chair a Committee in an earlier incarnation on
an inquiry into REACH and perhaps the one lesson
we learned there was that it all took a very long time.
The trouble about the timescale is that it seems to me
likely that it will be several years before anything is
likely to emerge from Europe to cover this point. Is
that not cause for anxiety?
Lord Drayson: It is a track record in this area and the
speed of regulation which leads us to have a strong
sense of the importance of establishing a regulatory
framework which keeps up with the movement of the
technology and the science. This is a challenge in
many areas of science and technology but it is
particularly of concern in this area where I believe
that in this country we have learned some important
lessons from GM foods. There are some parallels in
the way in which this is an underlying technology
where the potential beneﬁts and risks of the
technology are just emerging. Therefore, where we do
identify loopholes in the regulation because of the
way in which this technology does not eVectively get
covered under the one-tonne limit, we need to move
quickly and this is the argument we will be taking
within Europe, but I accept your concerns.
Q552 Lord Cunningham of Felling: How are the
Government ensuring that health and safety research
into nanotechnologies is coordinated across
Government and within the research councils and, as
importantly, that the research into the scientiﬁc
knowledge base required by regulators for risk
assessment is funded?
Lord Drayson: This is an area which requires us to
have a light touch but where, as Science Minister, I
should be grateful for feedback and guidance from
this Committee. The reason I say that is because the
principles under which we carry out scientiﬁc
research in this country, the peer review process under
Haldane, where it is not for ministers to direct where
research takes place or which speciﬁc research
projects should be funded, is a process which I think
we all recognise works extremely eVectively. Where
there are areas for directed research to take place, we
have used a light touch, through the encouragement
of research coordination groups, where again it is the
scientiﬁc community itself, through the NRCG,
making decisions, making recommendations about
cross-cutting research, but where we are not as a
government directing that research. As I am sure the
Committee is aware, there have as yet been no clear
safety concerns which have been raised through the
application of nanotechnology, of nanomaterials, but
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we must not be complacent. We do believe the nature
of research being directed to explore speciﬁc issues
needs to come from the research community. The
research community itself is best placed to raise those
concerns, the best place to identify those research
projects, for example in areas of immunology.
Although the Royal Commission argued for a more
coordinated approach to the direction of research,
this is not something we are pursuing at present.
Q553 Lord Cunningham of Felling: We will come
back to concerns in a little while. Can we safely
assume that, as the person who chairs theMinisterial
Group for Nanotechnology, it is actually your
responsibility ultimately to see that all these things
are carried forward?
Lord Drayson: Absolutely; it certainly is.
Q554 Lord Cunningham of Felling: In that case, how
will you ensure that the knowledge base we have just
been talking about is ready and robust enough to be
eVective by the time products start appearing on the
market, say in a three- or ﬁve-year timescale? How
will you make sure that happens?
Lord Drayson: As part of the process we are going
through at the moment, in the run-up to the
publication of our strategy, we are reviewingwhat has
gone on. We have not been standing still; a lot of
work has gone on over the last two years and one
example of that is the way in which we will be
reviewing the voluntary reporting by companies in
the use of nanotechnologies and asking ourselves
whether or not voluntary reporting is working well
enough, whether we need to move to a more assertive
requirement on companies to do so. The point of the
strategy is to make sure that we get the balance right
between not putting regulatory barriers in the way of
the development of this technology, which potentially
has very signiﬁcant beneﬁts, for example in health,
but being suYciently on top of any potential
indications of risk that require us to do the
underpinning research to understand how the body
deals with these nanoparticles in a diVerent way to
the way it deals with more conventional particles and
the whole area of toxicity for example.
Q555 Lord Cunningham of Felling: The Committee
understands that the nanotechnology research
coordinating group has been preparing a new
research strategy for nanotechnologies. Is that
correct?
Lord Drayson: That is correct.
Q556 Lord Cunningham of Felling: Is this group
eVective?
Lord Drayson:Yes. I would say that we are seeing that
cross-cutting research coordination across the
research councils is of growing eVectiveness and this
is a good example of that, because we can see how, in
a number of important areas, and nanotechnology is
one of those areas, it is an interdisciplinary approach,
both in terms of research proposals but also in terms
of understanding how research that may be taking
place in physical science can be coordinated with
research in medical science. I do not have any sense
that this is not working well: quite the opposite.
Q557 Lord Cunningham of Felling: Who is
responsible within Government for ensuring that the
gaps in scientiﬁc knowledge, identiﬁed in this strategy
I have just referred to, will be ﬁlled? Where it appears
from the strategy that work that should be done is not
being done, who will take responsibility for ensuring
that it will in future be done?
Lord Drayson: The responsibility ﬂows from the
individual research councils, coordinated through
RCUK, the coordination group is providing advice
to me as the Science Minister and therefore it is my
responsibility as Science Minister to ensure, based
upon the advice from this group, that the knowledge
base and any potential gaps are ﬁlled.
Q558 Lord Cunningham of Felling: Is the Food
Standards Agency responsible in any way for taking
initiatives on commissioning relevant research
needed for their regulatory role?
Lord Drayson: Yes. In terms of the more applied
research responsibility of Defra, in terms of leading
that research and the Food Standards Agency
providing input to that, perhaps Mr Dalton would
like to comment.
Mr Dalton:TheFSAobviously have their regulations
in place which govern—
Q559 Lord Cunningham of Felling: Yes, but if I
might put the question another way, if the FSA sees
that it does not have relevant research needed to
underpin its regulatory role, will it take the initiative
in commissioning such research?
Mr Dalton: Yes. Sandy Lawrie from the FSA is here
and, speaking on his behalf, I think that is the case,
yes.
Q560 Lord Cunningham of Felling: In all of this,
where gaps may appear or the need for new work
arises or becomes apparent, who can make
authoritative, budgetary allocations or changes in
budgetary allocations to ensure that the work is
properly funded?
Lord Drayson: There are two aspects to this research.
In terms of the underpinning research, the decision is
taken by the research councils through the peer
review process but based upon their cross-cutting
coordination group. If the FSA, for example, felt that
there was a gap in fundamental research which
needed to be ﬁlled to enable them to develop an
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eVective regulatory framework, then that is
something which would be taken into account by
research councils and therefore the responsibility for
the allocation of their funding made by the research
councils and based upon that input.
Q561 Lord Crickhowell: I understand very well what
you are saying about light touch andHaldane. I think
you are anticipating a future inquiry of the main
Committee on this very subject. I hope you will
forgive me if I repeat a question which I put at what
we thought was a very unsatisfactorymeeting that we
had with representatives of the research councils. I
said “ . . . I must say the answers that we have
received so far this morning leave me bewildered.
Here you are talking about structures that coordinate
and get research going in the right direction and, as
has already been said, we have had evidence about
very obvious gaps and urgent areas that need
research, yet I do not get a sense that anything has
been done or is being done to actually get the work
heading in this direction. I am worried by the general
air of, ‘Oh well, it’s very early, it’s all very diYcult.We
need to have more knowledge before we set oV in a
particular direction’”. Am I wrong in thinking that so
far there is no real coordinated eVort in this country?
It appears to be working slightly better in some other
countries. It may be that the evidence we received
from the research councils was at fault in coming to
that conclusion but that was the conclusion of the
Committee when we concluded our meeting with
them a long time later.
Lord Drayson: I will take the Committee’s views on
this very seriously andwill take up the points that you
make. I recognise that this area of technology is
moving at a speed which is leading to people’s
concerns. Thankfully there have been no safety issues
raised at present but there is a sense that the
technology is being used in products and that there
are gaps in our knowledge. It is therefore very
important that underpinning research is done and if
the Committee feels that the coordination which is
taking place within the research councils is not
suYciently eVective, that is something which I will
address.
Lord Crickhowell: The one area which at virtually
every session we have had has come up as an urgent
area which needs research is the eVect of prolonged
presence of artiﬁcially manufactured
nanotechnologies in the gut and eVectively nothing
has been done in that ﬁeld. Some work has been done
on the lung. There does appear to be an urgent need
to go into certain areas like that and all the evidence
we have received is that nothing has happened so far.
Q562 Chairman: We were taking evidence in
WashingtonDC a couple of weeks ago and, although
Lord Crickhowell said just then that some countries
appear to be doing better, quite frankly I do not think
we felt the United States was one of them because
they had the same problemwhichwe feel the FSAwill
be facing soon. In order to perform their regulatory
role they will need some fundamental science which
appears to have been commissioned neither here in
the UK, nor possibly at the EU level, nor in North
America. I do feel, as you will feel from the tenor of
our questioning, that the technologists, the food
industry, are moving faster than the fundamental
research, which often happens in emerging
technologies. Perhaps it is something the research
councils, who did not appear to have a very
coordinated approach to this to our mind, although
we perhaps should reserve judgment for the moment,
would need to give some strong leadership on in
determining these priorities for fundamental
research.
Lord Drayson: We accept that concern as being valid.
We recognise that this science of the interaction of
nanomaterials with the body, and in particular with
the gut, is not well understood and more research
needs to be done. The way in which we can most
eVectively ensure that we establish a sound scientiﬁc
basis for that research does depend upon the
academic community coming forward with
appropriate research proposals which are then judged
through the normal process for funding. We are also
aware that existing regulation and legislation do put
an absolute requirement onto food companies to
ensure that the food products that they develop and
market are safe whatever the materials that are used
within them. Nonetheless, the long-term
toxicological eVects of nanomaterials, for example
on the gut, need to be better understood and it is
themes like this which I expect to become clear
through this work which is taking place now and
which is to be incorporated in the strategy document
alongside the work which is being done on public
engagement around this issue. It is important for us
not only to be actively working on the underpinning
science of understanding nanomaterials, but it is also
very important to be engagingwith the general public
and consumer groups in particular relating to the
perceived risks and potential beneﬁts of those
technologies such that the technology and its
adoption does not get ahead of the public’s
conﬁdence in it.
Q563 Lord Mitchell: One of the things which
became apparent to us both in the UK and in the
United States was that leading food companies and
also other companies involved in cosmetics and
sunscreen and the like seemed to be in some degree of
denial or certainly secrecy regarding what they were
doing. We found them very unwilling to share their
thoughts with us as to what was happening in this
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direction. I just wondered whether this climate of
secrecy is helpful to what we are trying to explore.
Lord Drayson: I do not believe that it is helpful. We
have put in place a voluntary reporting system. If I
am right, I believe we have had 12 responses to that.
I have to say that the response from industry has been
disappointing and unless industry ismore open about
this issue then we will have to look at more assertive
means to encourage industry to be so. The industry in
this case needs to learn some of the lessons which
were learned relating toGM foods. ThisGovernment
have absolutely learned those lessons. The way in
which this House, for example, has worked very hard
to establish an eVective regulatory framework
around stem cell research has been because there has
been a really eVective public engagement, openness,
debate of the issues. That cannot take place if
companies are not providing clarity about the work
that is being done and potential applications and we
take this very seriously indeed.
Q564 Chairman: One of the problems perhaps with
research councils, I know they do not use it
exclusively, is that they are used to the responsive
mode of funding but, if a gap is developing, would
direct funding be used as the more appropriate
model?
Lord Drayson: It may be. Because of the sensitivity
around this issue of directed funding from
Government, the danger of the scientiﬁc community
being seen to be told what to research by the
Government, we really do need to move carefully in
this area with feedback from this Committee as to the
right balance, what the Committee would feel, in
terms of a light touch but an eVective approach in
more directed funding. To be eVective, funding really
does need this direction, it needs to get down to the
level of speciﬁc areas of research and it would not be
eVective for the Government to be talking in general
terms; we are identifying the speciﬁc gaps in
understanding. The Committee has already
mentioned issues relating to interaction with the gut
for example, which therefore raises the question as to
how we can most eVectively encourage the research
community to focus those areas of research where
there are identiﬁed gaps without it being seen as being
directed by ministers.
Q565 Lord Methuen: How is work on health and
safety issues coordinated with similar research being
undertaken in the EU and in the wider international
community?
Lord Drayson: The responsibility for health and
safety issues was brought into the coordination of
these areas through, for example, ministerial
responsibility at the ministerial group, then, in terms
of the nanotech issues discussion group including
oYcials with responsibility for health and safety
making their contribution within that, down into the
coordination through research councils. So the
health and safety issues are brought through these
mechanisms into the work and will be incorporated
into the review which is taking place, leading to the
publication of the strategy document next year.
Q566 Lord Methuen: What about the international
aspects?
Lord Drayson: All aspects of getting a ﬁrm grip of the
state of play are the responsibility of the
stakeholders, for example the Department of Health,
Defra and so forth putting their recommendations
and their views into the international context. I
believe that there is a fair argument to say that the
United Kingdom is a leader in both consideration of
these issues and putting these issues into a wider
context of maintaining and developing public
conﬁdence in a new technology. I believe that the UK
has learned some important lessons in dealing with
some of the challenging ethical issues which have
come out of science and I think that we are pretty
eVective now in doing that within the UK but it is the
responsibility of those stakeholder groups, when
making that contribution, to do so in the context of
views from other countries, particularly the United
States and Europe.
Q567 Lord Methuen: The EFSA, the European
Food Standards Agency, is obviously concerned.
Lord Drayson: Yes.
Q568 Baroness O’Neill of Bengarve: I want to ask a
question about capacity. We were told by Dr Andrew
Wadge, the Chief Scientist from the FSA, of concerns
about the capacity of toxicologists to cope with this
research, namely numbers and an ageing cohort. Are
you seeking to address this issue?
Lord Drayson: Yes. Capacity of scientists and
engineers in research is a broad issue of concern. One
of the key themes which I have within my areas of
responsibility is developing the concept of skills
activism within the research base. By that I mean
getting a clear audit of where there are gaps in
particular skills and expertise needed for national
priorities. You mentioned toxicologists. In a review
which we are carrying out at the moment for the life
sciences industry we have noted the lack of clinical
pharmacologists, for example. We have had a model
within higher education of the Government having a
very hands-oV approach to decisions taken by
universities and colleges relating to the provision of
courses in particular areas; eVectively the market is
determined through the interest of students as to
whether or not those courses are provided. We are
now carrying out this audit andwe are looking at this.
What is clear from this is that this is leading to a
mismatch in terms of both the types of skills and
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expertise which are required for industry—in this
particular case toxicologists—and the provision of
courses. We are looking actively now at how we can
most eVectively inﬂuence students to participate in
those courses for which there are skills gaps, where
there are clear needs, therefore career paths within
industry, which are needed for national priorities and
research. I hope that we are able to come forward
with some new policies addressing this issue over
this year.
Q569 Baroness O’Neill of Bengarve: When you say
“inﬂuence”, is it envisaged as a way of raising
students’ consciousness and inviting them to change
their choices or is it a move away from a demand-led
competition for research studentships and for
master’s level courses?
Lord Drayson: This is an area where we are at a very
early stage in thinking about this. I do believe that
this summer in particular, in part because of the
global economic downturn, a greater shift is now
taking place in the relative attractiveness of diVerent
career options than we have seen for some time. We
have certainly seen, for example, a huge positive
inﬂux of science graduates going into teaching. We
have said for a long time that we need science teachers
having qualiﬁcations in the particular sciences they
teach and we are seeing that a number of people are
coming back to teaching. We believe that there are
opportunities tomake a shift here in research towards
encouraging people who are qualiﬁed in these areas,
who have maybe left the research sphere, to come
back to it. However, what we need to do is to think
about how we are allocating our national resources
and directing those resources most eVectively to
aVect the motivations of the people.We need to think
about all aspects, whether that is the knowledge and
increasing the visibility of these courses or increasing
the understanding of the gaps and therefore the
career opportunity, but also other factors, for
example issues relating to student loans, looking at
the whole package of what aVects the motivations of
people to choose courses.
Q570 Lord Crickhowell: The Government’s 2009
Budget announced that £106 million of savings
would be delivered by the research councils within the
science and research budget to be re-invested within
that budget to support key areas of economic
potential. Will this reallocation into resources have
any impact on the budget for health and safety
research into nanotechnologies?Will any work be cut
back or postponed in this area?
Lord Drayson: It is very important for it to be clearly
understood that this is not about cuts; this is about an
expectation from the Government of all
departments, and within those departments, my
department and therefore the research councils, to
improve eYciency in what they do. Very positively, I
believe, the eYciency which can be achieved has been
ring-fenced within the research budget and will be
spent on research. So these eYciencies which I do
believe can be achieved—I have seen for myself the
way in which we are moving to shared services across
the research councils, co-location of those shared
services in Swindon—are leading to cost savings and
those cost savings are being re-invested in research
rather than administrative support. I believe, again
not ministers but research councils should decide
where those research monies, the £106 million you
mentioned, are invested in research, through the peer
review process, through the independence of
Haldane. The way in which they are doing that is to
identify cross-cutting research themes and that is for
them to decide and that is wholly appropriate. I do
not see this leading to any cuts in funding for health
research in this area as you describe.
Q571 Lord Crickhowell: I am sure when I was a
minister I used to give answers like that and say we
are going to get it all out of savings and there will be
no cuts. Forgive my slight scepticism based on the
experience of successive governments. It is surely
going to produce pressures and I come back: are you
quite conﬁdent that, in this area where we have
already identiﬁed shortcomings in knowledge which
makes risk assessment extremely diYcult, we are not
going to see such failings as damage the programme
that we identify as important?
Lord Drayson: One of the really pleasant aspects of
being ScienceMinister in thisGovernment is that this
Government have shown by the decisions they have
taken now for 11 years that they believe in the
absolute importance and value of scientiﬁc research.
We have more than doubled the science research
budget and we have maintained the science ring-
fence. What could be a stronger sign that we are
serious than that the Prime Minister, Lord
Mandelson and I have all made clear that we are
maintaining investment in science despite the
downturn, we are maintaining the science ring-fence
but I do believe, having been a practitioner in science
myself in industry, that scientiﬁc research and the
management of scientiﬁc research can achieve
eYciencies in the way in which it is organised and
managed like anything else. It is right, for example,
for the MRC to think about whether or not all of its
staV should be located in central London in a very
expensive building or whether it could be more
eVectively done if a number of those staV were to be
moved and relocated in Swindon. The savings which
are generated being freed up and re-invested in the
research is a very positive aspect of our policy and it is
one which I believe the research community supports
provided they understand that is exactly what we
are doing.
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Q572 Lord Methuen: To what extent are the
Government looking into the potential of
nanotechnologies to help with wider societal issues
such as obesity? Are there any plans to support
research into the potential beneﬁts of
nanotechnologies in food in this area?
Lord Drayson: The understanding of the use of
nanotechnologies, so, for example, nano-
encapsulation of foods to modify the way in which
they are taken up by the body and therefore it having
a role in eVect inmanaging such challenges as obesity,
is at a very early stage. This is an area where
signiﬁcant research is being undertaken by the food
companies themselves. The important role for
research in this area is to address the underpinning
understanding of theway in which the body processes
nanomaterials and whether or not there are diVerent
mechanisms for the processing of those materials
when presented to the body in the nanosize. I believe
it is too early to say whether or not there is a realistic
prospect in the medium term of this technology being
applied to address obesity.
Q573 Lord Methuen: This comes back to targeted
delivery by micro-encapsulation.
Lord Drayson: Targeted delivery both of functional
foods and medicines is a well-established ﬁeld but it
is understood how, for example, the presentation of
particles has an adjuvant eVect on the skin. That
adjuvant eVect is better understood in terms of the
interaction with the immune system in the epidermis
than it is understood in the gut. Therefore, before
getting to the point where we can realistically
understand the potential beneﬁts of nanotechnology
to be used to address obesity—a very important
health challenge—we have to get a better
understanding of the underlying mechanisms and the
way the body processes nanomaterials through the
gut and whether or not that leads to any speciﬁc
immune response. That should be the right focus now
for our research, to get a handle on that in parallel
with the work which is taking place within the food
companies, the development of these technologies to
see their potential in novel foods.
Q574 Lord Methuen: It worried me that you implied
in one of your earlier answers that you were waiting
for the universities to come forward to propose
research. I think you should be more proactive in
encouraging this research.
Lord Drayson: We see a real role for the FSA here. If
the FSA have a concern and they do not feel that
there is enough understanding of this research to
enable them to provide eVective regulatory
framework, this is something which provides us with
the opportunity to put that into the assessments,
decisions which are made by the research councils in
judging the research projects. Research into this area
is taking place at the moment funded by the research
councils. If it would be helpful to the Committee, I
can ask our research councils to provide a summary
of the research projects which are being undertaken
at the moment, but I do think the Committee has
identiﬁed a very important area of the need for
further research relating to interaction with the gut.
Q575 Chairman: If the FSA do have these concerns
to which you refer, it is quite probable, given the
international nature of the food industry, that these
concerns will be shared with other health and safety
agencies in Europe—France, Germany and the like.
To what extent are Government conﬁdent that we are
able to coordinate the research programmes not just
of the European Food Safety Authority, which after
all is not really a regulatory body, but of its other like-
minded agencies in Europe, which clearly would be
the right way to approach these issues?
Lord Drayson: As I am sure the Committee is aware,
a signiﬁcant proportion of research which is funded
by the research communities is of proposals which are
international collaborations or research groups
across both Europe and with the United States. That
is something which we encourage. We have certainly
seen the eVectiveness of that, for example in stem cell
research and development of the memorandum of
research understanding with the State of California.
However, it is not perfect and I do believe that
ensuring there is better coordination internationally
of the understanding of research priorities is an area
where more work needs to be done. We need to put
more eVort into this because, as we have already
discussed, the science is moving quickly in this area,
the possibility of application of the science to
products needing to be marketed requires us to move
more quickly, hence the need for this strategy which
we will be publishing early next year.
Q576 Lord Haskel: While this work is going on, and
in the expectation that there might be some
signiﬁcant beneﬁts to health from nanotechnology,
have the Government given any thought to
supporting the commercialisation of these
technologies?
Lord Drayson: The Government are very active in the
general sphere of encouraging a culture within our
universities which supports the transfer of
technology from the laboratory into
commercialisation and we have made huge progress
on this over the last 10 or 11 years. For me, working
as a science entrepreneur 10 or 15 years ago, the
attitude now is extremely supportive. I believe that
the role of the Technology Strategy Board has been
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very eVective; again independent of ministers, private
sector input to the decisions relating to which
technology platforms are supported. The feedback
which I have had recently in doing the review of the
commercialisation of science has led to the
conclusion that the UK has a stronger set of early-
stage science-based enterprises and projects now than
it has ever had, that the quality of management that
we now see is stronger than it has ever been. We now
have a number of serial science entrepreneurs who are
re-investing their talent and expertise. The problem
which has been identiﬁed has been the lack of money;
there has been a lack particularly of venture capital
which is dogging the ability of these projects to be
developed in the current economic environment. We
have addressed that. The Government have recently
announced a new £1 billion venture capital fund
speciﬁcally targeting areas of growth such as
technology such as this, where the Government are
acting as a cornerstone investor, providing £150
million, investing pari passu on the same terms as the
private sector and we anticipate that fund will be able
to start investing in companies working in these high
growth areas at the end of this year.
Q577 Lord Haskel: I am not aware that any of the
Technology Strategy Board platforms actually
incorporate nanotechnology. Hopefully they may
well do in the future. Of course technology transfer
plays an important role but are the Government
going to do anything about translation research or
oVer any incentives to food companies to use these
products?
Lord Drayson: You are correct that there is not a
speciﬁc nanotechnology-related technology
platform. In part the nature of this technology is so
broad in its scope that it is actually quite diYcult to
identify an all-encompassing technology platform.
What is likely to happen is that certain themes within
the application of nanotechnology into particular
industrial sectors—youmentioned food—will in time
identify the underpinning technologies. Remember
that the Technology Strategy Board’s role is, once it
is understood what the underpinning technologies
are likely to be, to do a review to assess whether or not
it is likely that the United Kingdom is well placed to
commercialise and exploit that and then to put
targeted investment into those areas. It does not seem
at present that we are at the stage to be able to
identify those areas. Nanotechnology is moving fast
but it is not clear what are likely to be those
underlying platforms. This is something which the
Technology Strategy Board monitors carefully.
Q578 Lord Haskel: So it is really too early for
Government to deﬁne some sort of commercial
strategy to commercialise these technologies.
Lord Drayson: That is one of the answers which I
expect to come out of this process which will be
reporting with the strategy document at the
beginning of next year. If that is identiﬁed, then that
gives the Technology Strategy Board something very
clear to latch onto.
Q579 Lord Crickhowell: May I ask a question which
goes rather wider than just nanotechnology? I was
very interested when you said we were doing better
than we have done in the past about getting the link-
up between the university world and industry. I
worked extremely hard when I was Secretary of State
for Wales, based on what I learned in California and
my old college, Trinity Cambridge, which was
probably more successful at that stage than anyone,
to try to get the same kind of development going in
CardiV and in Wales. You said that there was a lack
of venture capital. The one thing that one found in
California almost without fail was that the venture
capitalists sat themselves down next to the
universities because they realised that the
opportunities were swinging out of them because of
the ability of people in the university world in
California to move in and out of the university
industry, backwards and forwards, and make a lot of
money out of it. I am sorry this does go wider than
technology. Why is it that venture capitalists are not
actually involving themselves in this world and what
are you trying to do to make them realise that. Based
on your own experience, you are a man who is
perhaps better qualiﬁed than almost anyone to tell
them.
Lord Drayson: The single biggest problem that we
have had in the United Kingdom, that Europe has
had, is the diVerence between the United States
venture capital industry and in particular the West
Coast, the Sand-Hill-Road-type investors, people
like Kleiner Perkins and so forth, is that because of
the success of the waves of technology investments
which took place which led to the building of Silicon
Valley, the West Coast investments funds have been
able to achieve scale typically of $1 billion or more
per fund. It has not been possible hitherto for the
United Kingdom or European funds to match that
size. What that has meant has been that where an
investor is making an investment of $1 billion, where
a rule of thumb is that youwould invest nomore than
let us say 10 per cent of that fund in an individual
company, a $1 billion fund enables you to make
follow-on investments as the company develops of
suYcient size to create a real world leader. On the
other hand, in Europe, where we have had funds of
the order of £50 to £100 million or so maximum size,
10 per cent of those funds is a much smaller amount
of money, which has meant that in the United
Kingdom and in Europe venture capitalists have only
been able to go so far with their investment in a
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company and they have then come up against that
barrier and the company has had to be sold or has
had to ﬁnd alternative forms of ﬁnance. Our analysis,
as the Government has determined, is not only to
address short-term problems relating to venture
capital at the moment in the UK, where venture
capital funds are limiting their investments to
companies in which they are already an investor, but
to address this for the long term too and that we need
to create a fund of equal size. This is why this is a real
ﬁrst for the UK, this innovation investment fund
which we launched last Monday of £150 million
cornerstone investment by the Government which
will then be followed on with investment from the
European Investment Bank and then pension funds
to create a £1 billion venture capital fund, a ten-year
fund which will have suYcient size to address this
long-term equity gap issue. The feedback which I
have had both from investors in the United States as
well as investors here in Europe is that the
Government has, in addressing this fundamental
issue, removed themajor barrier. This is an important
step forward which consolidates the progress which
we have already made in this country relating to the
science, the commercialisation of science and the
management expertise. If I might just ﬁnish this very
long answer to your question, one of the things that
venture capitalists in the United States in Silicon
Valley have been telling me is that they have been
coming to the United Kingdom to identify managers
and scientists to take back to California because they
recognise the science and the expertise is here. I hope
that this new fund addresses that brain drain and we
can attract people from the United States and people
to stay here and be funded.
Lord Crickhowell: It was a very interesting answer.
Chairman:We are verging on another very interesting
report we should do. Indeed the main Select
Committee is looking at its priorities; perhaps it
should take due note of that. Can we get back to
nanomaterials now?
Q580 Baroness O’Neill of Bengarve: You have
already referred a couple of times to Defra’s
voluntary reporting scheme and this question may be
for both you andMr Dalton. Why do you think that
the voluntary reporting scheme for nanomaterials
has not been taken up at a very high level?Why is the
take-up low?
Lord Drayson: I will ask Mr Dalton to comment on
this from the Defra point of view because this is a
joint project.
Mr Dalton: It is worth just putting the voluntary
reporting scheme into the context in which it was
launched. The ﬁrst principle at the launch was not to
get complete coverage of all industry which was
dealing with nanomaterials but instead it was to get
some information back around what diYculties
companies were experiencing, what research
prioritiesmight need to be addressed, things like that.
The intention was never to get 100 per cent coverage.
With that in mind, we actually asked for information
that was quite technical; there was quite a lot of work
involved, if you wanted to report to the scheme. That
hampered take-up quite a lot but the intention was
not to get 100 per cent take-up.
Q581 Baroness O’Neill of Bengarve: Would Defra
see the scheme developing? Would it want to
encourage participation? Might it even make the
scheme into a mandatory one?
Mr Dalton: This has already been touched on by the
Minister. We are now reviewing the options around
howwe take the reporting scheme forward. There are
some decisions to be made around the level of
information you might want to ask for again in any
revised reporting scheme. If you were to simplify it
then you would get a much larger uptake and
working in partnership with industry you might get
nearer to 100 per cent coverage simply through a
voluntary scheme, if you revised the kind of data you
wanted to ask for. The option of course does lie to
make a mandatory reporting scheme something we
could take forward. As we develop the options, then
ministers will take the ﬁnal decision on that.
Q582 Baroness O’Neill of Bengarve: What do you
want the scheme to achieve?
Lord Drayson: A perfect scheme would be one which
had full support and engagement of industry on a
voluntary basis and provided us with suYcient
information on what the individual companies were
doing to enable us to feel we had a ﬁrm handle on the
development and potential application of these
technologies in future products. The response to date
has been disappointing, that we have only received 13
responses from a request to something like 40
companies. The request to the companies, as Mr
Dalton says, was detailed and I can understand why
companies may have felt there was a considerable
burden on them. However, I would argue very
strongly to the industry association that it is very
important and in the interests of the company
concerned for public conﬁdence to be maintained.
These are issues of some complexity and therefore
require quite considerable information from the
companies concerned and we do need to see a better
response in future. OYcials are reviewing the
information which has come back to us. We will take
into account the feedback from the industry
association and listen to the industry association and
the companies as to whether or not moving to a
simpler request for data makes sense. I have to say
really quite clearly that I do expect industry to
respond eVectively. It is not good enough to see this
level of response.
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Q583 Baroness O’Neill of Bengarve: Do you
envisage the scheme developing in a way that might
be relevant to creating a register of nano-derived
foods and nanofood contact materials?
Lord Drayson: Possibly. We need to maintain an open
mind as to whether or not we move to some form of
mandatory reporting. Given that this is an areawhich
is moving quickly, in those circumstances it is best if
you have a voluntary relationship of real eVectiveness
between Government and industry where you have
good communication from industry as to the area of
development and research that they are undertaking
rather than moving to a mandatory scheme or some
form of regulation. I want to stress that we do need
to see a better response in future.
Q584 Baroness O’Neill of Bengarve: I note that it
would be ideal to have a voluntary and eVective
scheme, but in a context where evidence we have been
given is that industry is often quite coy about work
that it is undertaking in this area because they have
not taken on board lessons which Government have
taken on board about being open about these things,
do you think that the likelihood is that a voluntary
scheme can be made to achieve what you wish to
achieve?
Lord Drayson: No. I have to be direct with the
Committee; I do not think that it is likely based on the
evidence to date. I am open-minded. I hope I can be
surprised, but I am determined, as Science and
Innovation Minister, to ensure that the diVerent
industries that we have and we rely upon to be
successful in the country learn from each other. There
are huge lessons to learn from the way in which these
diVerent issues raised by science have been taken on
board by industry and there are some common
themes which we have learned. The most important
one is that the more open an industry and science is
with the general public, the greater the conﬁdence of
the general public because the general public is able
to assess for itself the relative risks and beneﬁts and
Parliament is able to put in place light-touch eVective
regulation which maintains the public’s conﬁdence.
We are determined to ensure those lessons are
learned.
Q585 Lord Crickhowell: Staying in the same broad
area, the Government’s response to the RCEP’s
report on Novel Materials states that the
Government will review their existing structures and
mechanisms for sharing information and for
stakeholder engagement with a view to ﬁnding light-
touch ways of encouraging researchers and
companies to provide early evidence of developments
without compromising their commercial advantage.
What are the existing structures in place to do this?
Do the Government have early ideas on how they
might be improved?
Lord Drayson: The discussion that we have just had
really focuses on this. It is around getting a clear sense
from our review which is taking place this year as to
whether or not we are going to be able to generate
suYcient conﬁdence from our existing regime, say for
example the voluntary reporting regime. If we are not
going to have suYcient conﬁdence, then to put in
place such mechanisms as will provide us with the
conﬁdence to move to the next stage in terms of clear
regulatory framework and public engagement and
conﬁdence in this issue. We are very clearly focused
this year on gathering the information from the
various stakeholders to come to a conclusion which
would then be part of the recommendations coming
out of the strategy document early next year.
Q586 Lord Crickhowell: Is there a central database
for health and safety data on nanotechnologies in the
UK, where companies and academic institutions can
deposit their work and share information on health
and safety issues?
Lord Drayson: I am not aware of a central database.
I will write to the Committee, but I am not aware of
such a database being in place.
Q587 Lord Cunningham of Felling: In thisministerial
commitment to openness and dialogue, the
Government committed themselves in January of
this year to developing a programme of dialogue
around nanotechnology developments. Can you
bring us up to date with how that programme is
coming along?
Lord Drayson: Yes, that dialogue is part of the wider
initiative that we have, Science and Society, and a
number of programmeswhich we have put in place to
improve both the understanding and engagement of
science with the general public and to ensure that
there is a clear understanding within the science
community eVectively of the duty of the science
community as we see it, particularly where funded by
the taxpayer, to engage with the general public. For
example, a practical example of how we are doing
this, ministers have written to HEFCE asking
HEFCE, in the development of the new research
assessment framework, to take into account the
eVectiveness of individual scientiﬁc researchers and
university departments in the public engagement that
they carry out as part of the overall assessment of the
excellence of their research. What we want to see is
the development of a new generation of scientists in
this country who welcome engagement,
communication of the work that they do as scientists,
issues such as this. This is a themewhichwe have been
very actively developing this year. In the general sense
the Science: [So what? So everything] campaign,
which was launched by the Prime Minister and
myself earlier this year, was speciﬁcally aimed at not
targeting the scientiﬁc community but targeting the
270 nanotechnologies and food: evidence
7 July 2009 Rt Hon Lord Drayson and Mr Ian Dalton
general public. We are clear that the scientists have
huge support from the general public, but science has
been seen toomuch as something which is done apart
from the general public, done by a scientiﬁc elite. We
need to develop further scientiﬁc literacy within this
country and, whether it is nanotechnology or stem
cell research or GM foods, these are underpinning
strengths which we need to develop. I believe the
activities which we are undertaking in Science and
Society are delivering that. We are seeing real
progress in this.
Q588 Lord Cunningham of Felling: Is it intended that
there will be upstream widespread dialogue with the
public about nanotechnologies and food? Has that
already begun or is it planned?
Lord Drayson: It is expected. It is what I expect from
the input, the work that has been taking place, the
consultation that is going on. We have taken on
board, for example, the comments which were made
at the end of last year in theWhich report relating to
nanomaterials. We have learned how eVective public
engagement on issues in other areas of science has
enabled positive assessment in the minds of the
general public in terms of the risks and beneﬁts and
disengagement, particularly with the community of
scientiﬁc journalists in this country, is also important
to ensure that the lessons that were learned the hard
way from GM foods are applied here in the case of
nanotechnology.
Q589 Lord Cunningham of Felling: Is it right to
conclude that in your role as chairman of the
ministerial group you are also responsible for taking
this project forward?
Lord Drayson: Yes; I am responsible for the whole
area of science communication with a seat in the
Cabinet and as chairman also of the Cabinet
Committee for Science and Innovation which was
established in October last year to ensure that there is
a cross-departmental coordination of science, science
underpinning good government policy. That
committee has been eVective in ensuring that we
develop clear use of policy based around well-
founded science, for example the way in which
independent scientiﬁc expertise is used by
departments, used by ministers to inform public
debate and develop it into good policy.
Q590 Lord Cunningham of Felling: When the
Government responded to the Royal Commission on
Environmental Pollution report on novel materials,
they said they were commissioning a pilot initiative,
I am quoting here, “to provide public access to a
balanced source of information on
nanotechnologies”. Can you tell us about that? Is
there a website? How is it being taken forward?
Lord Drayson: Yes, we are developing a website
exactly for the purposes of developing the
engagement of the general public. I do believe that
development of websites, although helpful, is not
suYcient. We need to stimulate open discussion and
debate about issues relating to developments in
science, for example nanotechnology, and the way in
which the development of that debate that has
happened relating to stem cell research, for example,
which took place whilst the regulatory framework
was being debated within Parliament, showed the
importance of that debate having taken place ahead
of the development of the framework. We can expect
that there will be a developing regulatory framework
for nanotechnology as the research comes into place,
as we can see from this review which is taking place
this year, which is going to lead to the provision of the
strategy document next year. We are putting in place
therefore consideration of mechanisms for
stimulating that public dialogue in parallel with that.
What the Committee can expect, what comes out of
that strategy document, is not just recommendations
relating to regulation, relating to research, but also a
plan for public engagement in those issues in parallel
with it.
Q591 Lord Cunningham of Felling: Is it the case that
all government departments, across Government are
totally committed to this strategy?
Lord Drayson: The departments which are most
relevant to this strategy, my Department, Business,
Innovation and Skills, Defra, Department of Health
and the DWP with its responsibility for health and
safety, absolutely are. I have seen good engagement
from ministers in this. In terms of the wider
engagement in science, both frommy own position as
Minister for Science and Innovation but also the way
in which science has been increasingly discussed over
recent months in the context of a vision for this
country’s future, it gives me conﬁdence that there is
an understanding and buy-in to this across
Government. That is the sense I have.
Q592 Lord Cunningham of Felling: We have heard
from several witnesses, indeed you have referred to it
yourself on a couple of occasions this morning, about
the paucity of information, the lack of information
and announcements coming to the public about
nanotechnologies in the food sector. You also made
some comments about what you said was the
unsatisfactory response to the voluntary reporting
project. What more can the Government do? What
thought have you given to this, other than making it
compulsory to encourage the better ﬂow of
information to the public from the private sector?
Lord Drayson: One important role that the
Government can fulﬁl is to explain how lessonswhich
have been learned in one industrial sector give a sense
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for other industrial sectors and the development of a
body of corporate knowledge around the most
eVective way to handle emerging scientiﬁc issues and
the ethical considerations which come out of them.
There is a real role for the Government in doing that.
The way in which that can be most eVectively done is
ﬁrstly tomake sure within the Government that there
is good coordination between ministers and between
civil servants of good practice. We have established
the Science and InnovationCabinet Committee to do
that. In the case of nanotechnology we have the
research coordination groups; we have the nanotech
issues discussion groups. I do feel we have the
mechanisms to do that. Then it is about us having an
open but pretty robust dialogue frankly with the
various industry groups and encouraging them to be
as open as possible within the constraints of
commercial conﬁdentiality. I believe that we are
making some progress on that. I do not think we have
made enough progress in the area of nanotechnology
and we will be pressing industry to respond more and
to go further.
Q593 Chairman: We would all recognise that in
previous exercises in public engagement on emerging
technologies the absolutely essential requirement is,
and there will be uncertainties, uncertainties both as
to the beneﬁts and the risks, that there has to be
openness, there has to be transparency, there has to be
accountability. One thing which is clearly not
happening at the moment, for reasons which are
perhaps understandable, is that those food
companies who are most likely to run with this
particular emerging technology are not at all keen to
Supplementary letter from the Minister for Science and Innovation, Department for Business
Innovation & Skills
In follow up to the evidence that I gave to the House of Lords Science and Technology Sub-Committee on
7 July 2009 you asked me to investigate the existence of a central database for health and safety information.
Having consulted with colleagues from the Health and Safety Executive I can now conﬁrm that whilst there
is no central UK database as described, the OECD’s Working Party on Manufactured Nanomaterials has
developed a database of global research conducted into the safety of manufactured nanomaterials. The
recently-launched database provides a comprehensive inventory of information on international research
projects and aims to support the evidence base, highlight knowledge gaps and facilitate a joined-up approach
to further research. Additionally, the monitoring and safety of nanotechnology products is something that we
are considering as part of our evidence gathering to inform the UK Strategy for Nanotechnologies.
I hope that this information is useful in your inquiries.
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put their head above the parapet. This, on the face of
it, appears to be a recipe for disaster in terms of public
engagement and conﬁdence.
Lord Drayson: Absolutely right. I have mentioned
GM foods at length; animal rights extremism is
another example of where initially CEOs of
pharmaceutical and biotechnology companies did
not wish to put their heads above the parapet and
discuss the issue. That was a mistake and it took a
recognition that it was only by chief executives of
those companies being prepared to explain and
discuss openly why it was regrettably necessary to
undertake animal research to ensure that medicines
were safe and it was also a legal requirement to do so,
that we started to have the environment which
enabled politics to work eVectively. These are
important lessons which have been hard won in
science in this country. I am determined, as Science
Minister, to ensure that those lessons are applied to
emerging issues such as this one.
Chairman: Thank you very much. Minister, we have
come to the end of our questions. You have been very
generous with your time with us and the session has
been most helpful. May I thank you and your
colleagueMrDalton for helping the Committee. You
will of course see the transcript and have an
opportunity for corrections and if there are any other
points or supplementary data, for example you said
to Lord Crickhowell that you might just check on the
central database for health and safety data, if any
such information could be made available to the
Committee, we should be most grateful. Thank you
again very much for your help today. We are most
grateful.
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Q594 Chairman: Good afternoon, welcome and
thank you very much for giving evidence to this
House of Lords Select Committee on Science and
Technology. As you know, we are conducting an
inquiry, and have been for some weeks now, on
nanotechnologies and food. We do have members of
the public here also who are sitting in on our evidence
session but you will probably not be able to see them.
May I start by asking whether you could tell us what
role DG Research plays in funding health and safety
research in the ﬁeld of nanotechnologies in
comparison with national research councils and
government agencies? How much of the research
budget for nanotechnologies is devoted to health and
safety research?
Dr Deliyanakis:The European Commission as well as
the national funding bodies, for example in the UK
the Health and Safety Executive, do fund research
into the safety of nanomaterials in general. The
Commission, through its framework programmes for
research, has so far dedicated around ƒ40 million to
this research in the last two years alone with a further
ƒ10 million this year. Before that, in previous
framework programmes, we invested something like
ƒ28 million in this research. Other international
bodies also carry out a great deal of research into the
safety of nanomaterials. Compared with the overall
budget for nanotechnology research, in the case of
the framework programmes, of the order of ﬁve per
cent is spent on safety research, but I hasten to add
that a comparison would not be appropriate. It
would not be appropriate, because of course safety
considerations are of current concern, whereas the
rest of the research into nanotechnology focuses
inevitably on the future, on things like applications in
health, energy and the environment. So we are
looking at diVerent timescales. Moreover, the generic
research into nanotechnology does include safety and
that component is not included in the ﬁgures.
Q595 Chairman: Could you just perhaps tell us a bit
about your own role within DG Research?
Dr Deliyanakis: I am a member of the unit for
nanotechnology inDGResearch andmy role is as the
Secretary of the Commission’s inter-service group for
nanotechnology. In the Commission we have a so-
called action plan for nanotechnology, which covers
all the issues from research to safety to ethics and of
course it is implemented with the help of Member
States, other bodies and the many diVerent DGs in
the Commission. My role is to help coordinate this,
as well as to follow some of the research projects.
Q596 Lord Mitchell: Good afternoon, as it will be in
Brussels. We want to talk about coordination in
research. How is research within the EU on
nanotechnologies coordinated between the Member
States? Secondly, what coordination takes place
between the EU and other countries outside the EU
with international organisations such as OECD?
Dr Deliyanakis: It is coordinated in many diVerent
ways. Let me ﬁrst say something about coordination
of research in general. The research that the
Commission funds is coordinated formally through
the so-called programme committees, whereMember
States are represented. Moreover, within the
Commission it is coordinated through the so-called
inter-service consultation. Both interested DGs and
interested Member States can bring their opinions
and they are part of the decision-making process.
Turning to the research on the safety of
nanotechnology, that is coordinated in additional
ways, additional to these two mechanisms I
mentioned. One of them is, as you say, the OECD,
which has a working party on manufactured
nanomaterials and, very brieﬂy, this deﬁnes goals in
several areas of safety from toxicity to exposure and
so on. The delegations to the OECD then sponsor
this work, in other words they undertake part of the
work. The Commission participates very actively in
that working party, so in practice we have in the
shape of that working party a good coordination
mechanism for the research into safety.Moreover it is
one of the mechanisms which allow us to take the
results of research projects and bring them to bear on
regulation1. There is international cooperation. The
Commission does engage very actively in that also. I
have already mentioned the work within OECD and
that of course is international, as it includes not only
European Member States; we also collaborate on
research projects, for example with the US, and we
have had so-called coordinated calls, whereby a
1 “That is, the technical implementation of regulation, through
the development and validation of test methods for instance.”
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number of projects are selected with joint funding
from the two sides, the European and US sides for
example. This is an additional international
cooperation mechanism in the ﬁeld of research on
safety. Finally, we also cooperate in terms of
regulation through a regulatory dialogue. For
example, we have funded a project which concluded
this year and which looked at the diVerences between
the approaches to the regulation of nanomaterials in
the US and the EU.
Q597 Lord Methuen: How are funding priorities for
nanotechnologies research determined within the
EU? What input do European Community
organisations such as DG Sanco and EFSA and
national bodies such as the UK research councils,
have into this process?
Dr Deliyanakis: I have already mentioned two formal
mechanisms, one within the Commission and one
involving the Member States through programme
committees. Now there are also many informal but
very important mechanisms for such input. In the
case of nanotechnology research, as well as research
into the safety of nanotechnology, we work very
closely with the so-called European technology
platforms. They bring together representatives from
industry and academia and they come up in each
case, in each area of research, with a so-called
strategic research agenda. Many of these platforms
address safety, so we take their input when we
develop the topics for the research on safety. Within
the Commission we have the inter-service group for
nanotechnology, of which I am the Secretary, and
what we do within that group is to assess the needs
with regard to regulation, that is the technical needs
with regard to the implementation of regulation, and
then address them with appropriate research topics
that come up in the successive work programmes of
the framework programme. Once that is done, we get
proposals and in the fullness of time fund them and
get the results from the projects. There is an internal
mechanism for taking the interests of regulators like
DG SANCO and EFSA into account and there is
also a number of external mechanisms, both formal
and informal, which again cooperate very actively in
the case of the research into the safety of
nanotechnology.
Q598 Lord Methuen: How does the Director
General Research ensure that the regulatory needs of
the Commission and the national bodies are taken
into account in this process?
Dr Deliyanakis: Our colleagues in the “regulatory”
DGs, that is DG Sanco2 and DG Enterprise and
Industry interact with national regulators. I am not
an expert in the regulatory side so I cannot go into the
details, but what I can say is that through the
2 “The Directorate General for Health and Consumers.”
mechanisms I described it is fair to say that the needs
of all regulators are taken into account. That does not
mean that we have covered all the uncertainties by
funding research projects; there are still gaps and the
current research projects have not answered all the
questions. However, we do have the mechanisms in
place, and of course in principle the funding as well,
to pursue whichever questions remain open on the
technical front. That is my personal role in the whole
ediﬁce of European nanotechnology.
Q599 Lord Crickhowell: A major regulatory
measure is REACH for the control of chemicals. We
have received a lot of evidence that there is an urgent
need to revise REACH in order to cover the
nanotechnology possibilities and problems
eVectively. Are you involved in linking up with
REACH to ensure that job is done eVectively?
Dr Deliyanakis:Yes, we are very closely involved both
with the national regulators and with ECHA, which
is the agency which implements REACH, and this is
done primarily with the help of our colleagues who
work on regulation. The current position of the
Commission, as you probably know, is that in
principle regulations like REACH, but not only
REACH, are suYcient in principle to cover risks of
nanomaterials. Incidentally, let me say that REACH
does not cover chemicals as such, it covers
substances, therefore it is partly for this reason that
we say that REACH covers it. A normal, very
frequent objection is: yes, you cover chemicals in the
bulk form but you have nothing to say about
chemicals in the nano form and that is not entirely
correct because of course there is scope, even under
the present provisions, to deal with nanomaterials
separately from their corresponding bulk forms. That
said, we do not rule out changes or adaptations in the
existing regulations. Here I speak very much as a
non-expert, but I mention it only for completeness
and I think you will hear more about that from my
colleagues in the Commission. SuYce to say that we
do have plans both to monitor the implementation of
REACH as regards the regulation at the level of
nanomaterials, and to present the results in 2011 and
if necessary to revise it3 as well. Partly the reason why
we are funding the research into the safety of
nanomaterials is to be in a position technically to
supplement the regulations we have or support
regulatory changes. Here I must say once again that
I speak very much as a non-expert in my capacity as
the Secretary of the Commission’s inter-service
group. It is my job to have an overview and I am
trying to present this overview now. I hope you will
hear more about that from my colleagues who are
experts on the regulatory side.
3 “That is, not only REACH, but the regulatory framework in
general.”
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Q600 Lord Haskel: You have told us all about the
workwhichhasbeendoneabouthealthandsafetyand
about the technology platforms and indeed you
mentioned some gaps. When we talk to the industry
and when we talk to researchers here, we are
repeatedly told that there are major gaps in the
scientiﬁc knowledge required for the risk assessment
of nanotechnologies in the food sector to satisfy the
requirement that food is safe. What are you doing to
ensure that it is these knowledge gaps, these gaps in
knowledge which are being ﬁlled before EFSA is
required to risk assess new products?
Dr Deliyanakis: What we are trying to do is to focus
our research on the gaps. As I explained, we talk to all
the stakeholders within the Commission and outside
to identify thegapsand thenwhatwedo is to focusour
research topics on the safety of nanotechnology on
these gaps. I have to admit that so far theCommission
has not funded any projects which look speciﬁcally at
the safety of nanotechnology in food4. Of course it
goeswithout saying that this is oneof theareas thatwe
will lookat.However a lotof the research thatwehave
already funded is relevantbecauseofcoursewe looked
at the toxicity of certain common nanomaterials and
to some extent the route of introduction is immaterial.
I am not saying that we do not need research
speciﬁcally on the safety of nanofoods. What I am
saying is that some of the research results we already
have are relevant. The general answer is that we look
very carefully at where the gaps are, and for that we
have a number of scientiﬁc committees outside the
Commission; and then we focus our research funding
speciﬁcally to address the gaps. The other thing I can
say is that we are encouraging our diVerent projects,
the diVerent research teams in the projects that we
fund, to cooperate not only within their own projects
but within what we call a cluster, in other words to
compare results and to see where the gaps are, to see
how eVorts can be consolidated. For this eVort we
have funded a so-called coordination action called
NanoImpactNet with more than 20 partners,
including several in the United Kingdom, which tries
to bring together all the work, both the EC-funded
work and the national work on the safety of
nanotechnology.
Q601 Lord Haskel: All I can say is that from the
people that we have seen and the food companies that
wehave seentheydonotseemtobeawareof theeVorts
youaremakingand it is obviouslyvery important that
they are aware, otherwise they are not going to make
much progress.
Dr Deliyanakis: This is a very good point. It is also an
aspect of the approach to nanotechnology that the
Commission is trying toaddress, albeitpartially,and it
4 “Although such research may well have been a part of some
funded projects in the theme of FP7 dealing with food and
biotechnology.”
is a general questionofoutreachand engagementwith
society. I do take thepoint that not all of our activities,
be that in research or eVorts to ensure the safety of
nanotechnology, are presented in the best possible
way; that is certainly oneof the challenges. SuYce it to
say, as I explained earlier, thatwe are verymuchaware
of what has to be done in the area of research into
safety and we are doing all we can, using the
framework programme as a tool, to address the gaps,
and engage both with the technical stakeholders and
with what we might call the societal stakeholders. Of
course it is very much work in progress. I think it
would be fair to say that we have achieved a lot in the
diVerent aspects of the nanotechnology policy but in
each one of these areas, safety, outreach, regulation,
more remains to be done. Speaking personally as a
Commission oYcial engaged primarily in research, all
I can say is that we are doing our bestwith the funding
available tous toaddress thisneed.Thereareof course
questions that only the legislators can address, with
regard towhat should ultimately be allowed andwhat
the overall policy should be, but what we are trying to
do as Commission staV is to ensure that we have an
integrated policy and that we implement it as
eVectively as possible.
Q602 Lord Cunningham of Felling: Does the
Directorate-General have a wide-ranging dialogue
with the private sector and the academic world on
these issues?
Dr Deliyanakis: I did not quite understand the
question. Is there dialogue with the private sector?
Q603 Lord Cunningham of Felling:Correct.
Dr Deliyanakis:Yes, there is a lot of dialogue with the
private sector now. I have already mentioned the
European technology platforms. This is one of the
many mechanisms we have to engage in dialogue, in
this case with industry. In this dialogue and in the
context of nanotechnology,whatweare trying todo is
todevelopnanotechnologybotheVectivelyandsafely.
Inotherwordswewant to take apragmatic approach,
we want to develop nanotechnology, come up with
new ideas and make sure that these ideas are
implemented in the shape of projects. On the other
hand we want to do so safely, hence the funding into
safety research.Wedonotwant todoonlyonethingor
only the other. As far as I am concerned, our
interlocutors in industry are very much behind the
research programme and, incidentally, in our safety
projects we often have research partners from
industry. Now, looking at private partners more
generally, again there aremany other dialogues, other
mechanisms that we use. For example, in the context
of ethicsandsafetywe talk toNGOsand inthecontext
of international cooperation we talk both to
governmentalandprivatepartners.This isall I cansay
about that.
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Q604 Lord Cunningham of Felling: Can the
Committee conclude that you have a similar dialogue
with universities and research institutes on
nanotechnology?
Dr Deliyanakis:Absolutely; that is absolutely correct.
We have a strong dialogue with academia as well as
industry. I mentioned a number of advisory
mechanisms: one of them is an expert advisory group
which advises the Commission on nanotechnology
issues. There, both industry and academia are
represented. Then of course we have a very eVective
and formal mechanism in the shape of the projects
that we fund and that we follow. That is, incidentally,
the added value of having the Commission spending
considerable human resources in following projects
directly, instead of just deﬁning some research policy
and then allowing projects to be funded without any
follow-up. People like me talk directly to the
researchers, both academic and industrial, who are
engaged in a project; and in addition to the formal
mechanisms, we very much try to follow their
concerns and their ideas in formulating both our
generic policy and our speciﬁc priorities for research.
The other thing of course is that we are trying to bring
academia closer to industry in REACH and in many
other ways.
Q605 Lord Cunningham of Felling: That leads me to
my ﬁnal question, which you have just touched on
brieﬂy. When these dialogues with industry, the
private sector and the academic world show gaps in
funding in the nanotechnology area, maybe for
detection or nanotoxicology or nanometrology, what
role does the Directorate have in ensuring that those
funding gaps are addressed?
Dr Deliyanakis: That is done primarily in the case of
nanotechnology safety through the inter-service
group for nanotechnology which I mentioned. Every
research topic is discussed for roughly a year up to the
time of publication. So every year there are many
opportunities both formal and informal for the
regulators, for example, to bring their needs together
for the choice of topics. In research on safety as well
as research in general, it is inevitable that one has to
make hard choices because of course in general the
framework programme funding accounts for
something like ﬁve per cent of the national public
funding, so we have to prioritise in safety as well as in
research in nanotechnology and research in general.
That said, we do have an impressive and growing
portfolio of projects on safety research, even before
we begin to look at the research on safety which is
done within larger and more generic nanotechnology
projects. Of course it is very important to bear in
mind that the national funding bodies have to play a
large role, not only in research funding in general, but
research in the safety of nanomaterials. I mentioned
the coordinationmechanism. I would alsomention in
passing that there is a project on food safety which is
funded in the UK, I believe by the Health and Safety
Executive and possibly another body but certainly
funded at the UK national level. Of course we try to
coordinate all this work, as we are doing in other
areas of research.
Q606 Chairman: Thank you. That brings us to the
end of questions that we would like to put to you. Is
there anything else that you would like to add?
Anything that youwould like to put on the record but
we have not given you an opportunity to do so?
Dr Deliyanakis: Thank you for this opportunity. I do
not have any factual information to add. What I
would say is that the nanotechnology policy is very
diverse. It includes innovation, research, training,
infrastructure, regulation and safety. What we try to
do is approach it in what I call an integrated
responsible and safe way. In my evidence I have not
been able of course to give you a precise picture of our
whole approach, but I think I have been able to make
it clear that we are all working together between the
Commission and the Member States, to ensure that
on the one hand nanotechnology applications are
realised, and on the other hand that it is done safely.
Thank you.
Chairman: Thank you Dr Deliyanakis. You have
given us a lot of assistance this morning.We are most
grateful to you for having joined us in this videolink.
Thank you.
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Q607 Chairman: Minister, thank you very much for
coming to see us this morning and also thank you
very much for indicating that you might be willing
to stay on a little bit longer than the planned time
of ﬁnish at 11.40 up to about noon if we need to
continue with a few questions. I would like to
welcome you and Dr Baynton and Dr Lawrie from
the Food Standards Agency. As you will be aware,
the proceedings are being webcast and for the
members of the audience sitting behind you I would
like to refer to the information note which sets out
the declared interests of the members of the Select
Committee so we will not be repeating those during
the questioning. Before we come to the questions, I
would like to invite the Minister, and the others
indeed, to say a few words of introduction that you
might wish to say and to introduce yourselves for
the record. I would like to hand over to the Minister.
Gillian Merron: Thank very much, Chairman, and
perhaps if you will allow me as well as introducing
my colleagues to make a very brief statement which
sets out how I see this very important issue. Can I
start by saying thank you for inviting me. I am very
happy to help the Committee and if there are any
matters that we perhaps do not deal with as well as
you might like then I am very happy to ensure that
we provide further information. I understand that I
am your ﬁnal witness so I will do my best to wind
up proceedings well for you. Of course, as the
Committee is aware, I am the Health Minister
responsible for the Food Standards Agency which
is why I am before you. As many of the members
of the Committee are also aware, I am not a scientist
so I am delighted to be joined by Dr Baynton and
Dr Lawrie who are scientists, which will assist me
greatly. I am also very aware that around the table
we have many experts in all ﬁelds, including of
course the Food Standards Agency. Perhaps if I can
just make a few points which for myself as a
relatively new minister I have realised on this issue.
We have a very fascinating new area of technology
before us and it also strikes me that it is very much
work in progress. I think it is probably diYcult for
the average consumer, in which I put myself as well,
to grasp the range of possibilities, not least of all
because there are very few practical examples on the
market. From my point of view we are keeping very
much an open mind about the future beneﬁts of the
use of nanotechnologies and nanoparticles in
relation to food. I also feel that we are very much
at a development stage. It is diYcult to assess how
much of this will come to fruition. When I ask
myself what do we need to do, it strikes me that we
need to ensure that beneﬁts are not lost if there is
not an appropriate and proportionate regulatory
system. That is what we need and it will allow those
products to come on to the market in a way that
gives the consumer full conﬁdence that the new
products are safe as well as of beneﬁt to them. So
obviously a robust approach to safety assessment is
crucial. There are gaps in the underlying science that
need to be ﬁlled if the risk assessors are to do a
proper job and ask the right questions and draw
very valid conclusions from the data. I feel there is
a lot of work still to do. In conclusion, I am very
keen that we explore the possibilities in respect of
food but there are two things that are uppermost in
my mind. One is safety and second of course is the
interests of the consumer, and I hope that will help
the Committee to understand where I hope we will
go in respect of nanotechnology and food.
Q608 Chairman: Thank you very much indeed. I do
not know whether Dr Baynton or Dr Lawrie would
like to add anything or simply to introduce
themselves for the record.
Dr Baynton: I am Clair Baynton from the Food
Standards Agency. I head the Novel Foods,
Additives and Supplements Division. My division
has a co-ordinating role for nanotechnology across
the Food Standards Agency.
Dr Lawrie: I am Sandy Lawrie and I also work in
the Food Standards Agency and I head the part that
deals speciﬁcally with novel foods, which of course
includes this general area of nanotechnology.
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Q609 Chairman: Thank you very much. Perhaps I
could kick oV. One of the things that we have spent
quite a lot of time discussing and hearing evidence
about is a very basic question and that is what is the
deﬁnition of a nanomaterial as applied to food. We
are aware that the European Commission has been
revising the Novel Foods Regulation and has come
upwith a deﬁnition of nanomaterials which therefore
under their deﬁnition thosematerials should undergo
pre-market safety assessment. However, the Food
Standards Agency told us that it has reservations
about the proposed deﬁnition. We would be
interested to hear what are the concerns and what
should be included in the deﬁnition of
nanotechnology. Obviously this is fundamental to
any discussion about safety assessment, about
regulation, or consumer information.
Gillian Merron: It is crucial indeed and the main
problem is workability. First of all, what we look for
in a deﬁnition obviously is clarity and enforceability.
I think it is on those two that it falls down. My view
is that the deﬁnition is better on cosmetics than it is
on food and an interesting one to look at. If we are
asking food operators to comply then we have to give
them something to comply with that they understand
and where they do not ﬁnd themselves accidentally
falling foul of compliance. So scientiﬁcally the view
of the European Parliament was useful but not so in
workability. Perhaps to quote very speciﬁcally, the
deﬁnition includes criteria such as the “of the order of
100 nanometres”. Well, for operators and for
enforcement I think that will create some blurring.
Similarly with materials with larger dimensions, of
the order of 100 nanometres, are to be included “if
they retain properties characteristic of the
nanoscale”. The truth is that in the debate we do not
know enough to say what is characteristic. So that is
why the UK did abstain and we feel that to move
forward what we need is much greater consultation
and deliberation by stakeholders because it has not
only got to be relevant but it has also got to be
testable, it has got to be enforceable. Those are the
reasons for our concerns.
Q610 Chairman: Would in fact the UK position go
as far as the position we heard from the Food and
Drug Administration in the States that they would
rather not have a precise deﬁnition at all because I
think, in their view, any deﬁnition that you try to
come up with would leave loopholes or possibly
provide ambiguities?
Gillian Merron: I am a bit of an optimist so I would
hope that that we could ﬁnd the right deﬁnition. For
me the important thing is that we must test it with
stakeholders. I think that perhaps not enough of that
was considered. If we did not have a deﬁnition my
question would be how do we enforce that? How do
we work with that? Perhaps I could ask Dr Lawrie to
comment.
Dr Lawrie: I think in this debate it is important to
recognise that we do not rely on this new deﬁnition in
order to say that new nanomaterials fall within the
scope of the novel foods regulation and therefore
need to go through the whole requirements of pre-
market application, evaluation and then formal
authorisation. You will see from our previous
regulatory review we felt that there was very good
coverage of nanomaterials that might be introduced
for food use through existing regulation, none of
which mentioned nanotechnology or nanomaterials
already, so the inclusion of a new deﬁnition in the
novel foods regulation provides welcome clarity in
saying yes, clearly these materials fall within the
scope, but I would argue that even if you do not have
a deﬁnition in that legislation you are still covering
virtually all the cases you can imagine.
Q611 Chairman: So how do you decide thenwhether
to include it for pre-market approval or not?
Dr Lawrie: The scope of the regulation on novel
foods talks about whether it is a newmaterial. Taking
as a crazy example adding carbon nanotubes as an
ingredient, plainly that is a new ingredient that has
not been used in food before and it is a novel
ingredient falling within the scope. At the other end
you have a familiar material which is engineered in a
way to make it nanoscale and that is covered under
our existing regulation as an example of a novel
process applied to an existing ingredient but which
changes its properties. So we have a deﬁnition based
(a) on novelty and (b) on changes in properties,
particularly biological properties, which seems to
cover all the areas of concern. A regulatory deﬁnition
would be useful to provide clarity for people who say
yes, but there might be a loophole, but it is not the
only reason why nanomaterials added to food would
have to undergo a pre-market assessment.
Chairman: Thank you. May I turn to Baroness
Neuberger.
Q612 Baroness Neuberger: It is really a follow-on in
a way. The BSI told us that it had been very diYcult
to engage with the FSA on issues of standardisation
for nanotechnologies—part of what we have been
talking about—and then I quote: “There appears to
be no appetite amongst government departments to
maintain the UK’s proactive leadership in this area”.
I think what we would like to know is what the FSA
is actually doing about that, how it is working with
other organisations and whether it wants and, if so,
how to ensure that international deﬁnitions and
standards are appropriate to its role as regulator?
Gillian Merron: It may be helpful if I were to clarify
this. It is a diYculty because the BSI Committee does
not focus on food, it is not speciﬁc, and so the role of
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the FSA is more of a watching brief. I hope that gives
a bit of context. Also in terms of theGovernment and
the BSI ourmain interface is throughDefra and there
is a representative from Defra who routinely does
attend the BSI Committee and the chair of the BSI
Committee contributes to the work of one of a
number of cross-government groups that we have in
nanotechnology, the Research Co-ordinationGroup,
in respect of measurement and also standardisation
of nanomaterials. What I would say is that the work
of the various standardisation bodies nationally, at
EU and at international level, is useful in providing a
baseline. As is rightly said, that follows on from the
previous discussion that we have just had. I do not
know that I would share the view there is no appetite
amongst government departments.
Q613 Baroness Neuberger: I am not wholly
surprised to hear you say that.
Gillian Merron:No, Iwould not share that view. I ﬁnd
it diYcult to take that because that Committee does
not speciﬁcally deal with food. Perhaps if the
Committee were to bear that in mind that would be
of use to us. I am sure we will go on to this but there
are a number of cross-government committees and
actually of course one of them that I will certainly be
involved with is the Ministerial Group. We have a
whole range of cross-government groups so it is not
just the FSA.
Q614 Lord Methuen:Do you think the EFSAwill be
able to keep pace with the demands for safety testing
of all new nanotechnologies that enter the market in
food, food supplements, food additives, packaging
and perhaps agricultural products?
Gillian Merron: The ﬁrst point is that it is very
diYcult to predict what the ﬂow will be and what the
number of new nanomaterials in industry will be
coming forward. What I can say is the more general
issue of the EFSA matching its resources to the
demands upon it is not speciﬁc to nanotechnology.
What they do do, and I would expect them to do, is
extend their resources by extending capacity by using
external contracts, for example for technical support
with Member States, and I would expect them to do
the same.
Q615 Lord Methuen: Is the FSA concerned with
that? Do they provide additional support?
Gillian Merron: Would you like to comment, Dr
Baynton.
Dr Baynton: Yes, the FSA has a number of scientiﬁc
experts that are members of the various scientiﬁc
panels in EFSA. One of the oYcials of the Food
Standards Agency was involved in the discussions on
the EFSA opinion that was published earlier this
year, so we do play a very key role within the EFSA
scientiﬁc panels.
Q616 Lord Methuen: Does the FSA have enough
resources or would it need additional resources if a lot
of these things come forward?
Dr Baynton: I think that is something that—
Gillian Merron: That will be a question for the
Minister, will it not!
Dr Baynton: Sorry.
Gillian Merron: I was not taking it away from you. I
think the main thing is it is diYcult to predict what
demands it will put on the EFSA and of course we are
not the only Member State.
Q617 Chairman: Just as a follow-up to that, one of
the things that we have heard from a number of
sources is that the products on the market at the
moment using nanotechnology are largely food
supplements. There are quite a signiﬁcant number of
food supplements that are on the market that use
nanotechnology to encapsulate for example vitamins
or minerals. I know there are now new regulations
that cover food supplements but I wonder if you
could explain to us whether the nano-engineered
food supplements have been through some approval
process before they are put on the market.
Gillian Merron: That question is for you.
Dr Baynton:We are aware obviously of the nano Q10
that I think we have referred to before and a colloidal
silver product. I know that EFSA has been looking at
colloidal silver and has recently given an opinion on
that, but I am not aware that EFSA has given an
opinion on the nano Q10 product, so I am not aware
that that speciﬁc product has undergone a safety
assessment in relation to use of nanomaterials.
Q618 Lord May of Oxford: I particularly worry
about this area because I start with the possibly
incorrect prejudice that much of the food supplement
market is a hark back to the quackery of the 19th
century, not to say the 13th century, so I do not have
much conﬁdence in the kind of science they are likely
to apply in thinking about it. Do you think that is
unfair?
Gillian Merron: I think it is radical. I think it is
plainly spoken!
Dr Lawrie: If I could just comment particularly on
the nano Q10 product. This is a new formulation of
an existing product. Co-enzymeQ10 has been around
for a while and is used indeed in supplements. It is a
type of material which is not well-absorbed in the
body so it is a class of compound which the
pharmaceutical industry is very familiar with in
dealing with these problems. So there is constant
striving to get more reliable absorption of these types
of compound and some vitamins are like that as well.
This nano formulation, using the technical term, is a
kind of micelle formulation. Micelles themselves are
not new and they have been used in formulating both
food ingredients and pharmaceuticals for many
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decades, and I think the co-enzyme Q10 product has
been researched in quite some detail by the company.
In fact, I know that the German authorities have
looked at it and consider that because it is simply an
extension of old technology it does not actually hit
the criteria for the novel foods requirements but they
have also concluded that Q10 has not behaved
diVerently, so I think we can be relatively conﬁdent in
that particular case that the product has been looked
at in some detail.
Q619 Chairman:But if we go from the speciﬁc to the
general for us my question was under the regulation
of food supplements is there any speciﬁc reference to
nanotechnology?
Dr Baynton: No, there is not.
Q620 Chairman: What we have been told by some
witnesses is that food supplements, whether or not
they do any good, may be harmless in a normal form
but because in a nano- encapsulated form the
exposure may be increased because of the vastly
increased surface area they could indeed become
toxic. That is a possible risk and I guess you would
acknowledge that too. Should not the regulations
then speciﬁcally ask the question: are these food
supplements manufactured with nanoparticles or
nanotechnologies which could alter their potential
risk to human health?
Dr Lawrie: I think that is an example of a more
general question about the reformulation of any kind
of biologically active material. In the case of vitamins
and minerals, we now have a positive list which will
come into force in a few months’ time across Europe
in terms of what substances can be added. Unlike
pharmaceuticals though we do not regulate
individual formulations of those substances and the
argument that you quite rightly make that bymaking
a nano formulation you could alter the
bioavailability or the fate of the substance within the
gut or whatever is certainly true, and you can make
exactly the same argument for any other
reformulation also. The question then would be
whether nano is so diVerent in terms of the diVerences
it might be introduce that we need to have special
control for nano formulations but we can leave the
industry to self-regulate for other kinds of
reformulation. We would be interested to hear
whether the Committee has a view on this.
Q621 Chairman: Just to try and bottom this out, the
current position of the regulations and the list that
you mentioned of minerals and vitamins is that there
would be no speciﬁc reference to whether or not they
are nano-engineered?
Gillian Merron: Correct, yes.
Q622 Chairman: So whose judgment is it to decide
whether or not they need to be looked at in a
particular way because you have acknowledged that
the nano engineering of them could alter their
properties? Are they covered by novel foods?
Dr Lawrie: I was going to answer in those terms. In
fact we looked at the formulation of co-enzyme Q10
as a food supplement potentially under the novel
foods regulation before concluding that in fact in that
particular case it did not hit the deﬁnition of a change
which changed the biological properties of the
material, but certainly other formulations could be
looked at and if it is a new process or if it is a new type
of formulation it could fall within the scope of
novel foods.
Q623 Baroness Neuberger: I am ﬁnding this a little
bit confusing so let me give you a non-scientist’s
version of what I am hearing and you will be able to
correctme if I have got it wrong. On the one hand, the
fact that there are nano-sized manufactured
ingredients in food does not, because the deﬁnition
does not require it, trigger any special attention. On
the other hand, the fact that there are such elements
in food as an ingredientmay produce novel reactivity.
So how can it be grandfathered in on the basis of the
other larger particles being known to be safe if there
is a diVerent reactivity?
Dr Lawrie: The whole point of the novel foods
regulation is to catch new ways that foods have been
processed that change their properties, and if there
was a formulation of a supplement which did change
its properties in a remarkable way, as you have
suggested, it seems to me that would clearly fall
within the scope of the novel foods regulation and
therefore require the product to the assessed and
authorised before it could be used.
Q624 Baroness Neuberger: So you would get
evidence of a form in this product, we are not using
any novel ingredient but we are using it at a novel
size, and it does or does not have diVerent reactivity?
Dr Lawrie:That is right because the regulation covers
novel processes as well as novel ingredients.
Q625 Chairman: And the same argument would




Q626 Chairman: There is of course a ﬂaw in that
argument because we have heard on numerous
occasions that the science that is required to assess
the risks associated with re-engineering things at the
nanoscale is incomplete, so it is all very well to say we
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simply look and see if the properties have changed
and the potential toxicity has changed as a result of
nano engineering but if the science is not there to
answer that question how does the regulator
implement the regulations?
Dr Lawrie: A very good point. This leads on to the
question about the gaps in our understanding and
how we could be ﬁlling those.
Q627 Baroness O’Neill of Bengarve: We received
evidence from BIS (only they were DIUS then) in
Annex 4 of their submission, that the Science and
Innovation Network in Germany refers to the
potential risks associatedwith the use of synthetically
amorphous silica as a food additive in nano form if
new gel-based production processes are used, and
notes that they may require new safety assessment.
Preliminary results from a German group at the
University of Du¨sseldorf have shown that there is the
potential for amorphous silica to be toxic to gut
epithelial cells once it is nanosized (the tests were
actually done on 14 nanometre sized particles). Is this
a matter of concern for the FSA? Is it considering
new safety assessments?
Gillian Merron: I think it would be fair to say that it
is certainly of interest and the document that was
provided by DIUS, as it was, does correctly say that
the new manufacturing process would require a new
safety assessment, and I would certainly agree with
that. It is a bit early to say is the honest answer to the
question because it is not clear whether the product
that we are talking about is commercially available
and whether it is the type of silica that will be used in
the food industry. I do know that EFSA is doing a
review of all existing food additives so questions in
this area will obviously be addressed when the silica
is re-evaluated. Just one ﬁnal point. It is possible to
speed up the review of silica if necessary if new
information says that there is a potential risk from an
existing product, but, in truth, it is just a bit early to
give much more of a comment than that.
Q628 Chairman: We were informed in the United
States that amorphous silica is widely used as an anti-
caking agent in food manufacture. I wondered if that
is the case in Europe as well.
Dr Lawrie:Certainly silica as a food additive is widely
used in general. There is a type of silica called fumed
silica which typically contains these very small
particles which I think is diVerent to the process that
theGermans are talking about, but again it is another
type of silica manufacture that does result
undoubtedly in nanoparticles. The extent of the use
of fumed silica is something which the industry has
not yet been able to conﬁrmwith us. There are people
saying it is used and others saying that we do not use
it, it is an historical quirk. Certainly the substance has
existed for many decades. As I say, that is diVerent to
the process that the Germans are talking about.
Q629 Chairman: Do we know that it has properties
that are diVerent from the properties of this one that
could have adverse aVects on the gut?
Dr Lawrie: I do not know the answer to that.
Q630 Chairman: You do not know?
Gillian Merron: We would be very happy to write to
the Committee on that point.
Chairman: Could we follow that up? Thank you.
Q631 Baroness O’Neill of Bengarve: Another
example given in evidence by Dr Jonathan Powell at
the MRC Centre for Human Nutrition Research
stated that titanium dioxide particles with an average
diameter of 200 nanometres were added to food as a
whitening agent. That of course is outside the 100
nanometre limit but it is within the range at which
titanium dioxide particles show novel properties
associated with the nanoscale. How is the FSA to
ensure that examples like this where there is
confusion over whether a product might contain
nanomaterials that the regulations can apply?
Dr Lawrie: It always strikes me as rather odd that
people talk about nanoscale titanium dioxide being
used as a food colour because the whole point of
nanoscale titanium dioxide, as used in sunscreens, is
that it is transparent. Titanium dioxide is used as a
food colour to give an intense whiteness to foods. For
example some candies, if you suck the colour oV a
Smartie you are left with a white colour underneath
which is essentially titanium dioxide. The idea of
using nanoscale titanium dioxide for its colouring
purposes seems to me to be perverse. Having said
that, any material which is used in particulate form
will contain a range of particle sizes, so you may ﬁnd
a substance with an average particle size of 2,000
nanometres, say, but if you look at the spread of
particle size there could be some particles which are
very small and some that are much larger as well. So
that could be a source I guess of a small proportion
of the titanium oxide being in nanoform, but
certainly the addition of nano titanium dioxide as a
food colour itself would seem to be
counterproductive.
Q632 Baroness O’Neill of Bengarve: So does that
lead you to think that any deﬁnition should be very
cautious in looking at everything below a size
considerably greater than 100 nanometres or does it
lead you to think that a deﬁnition in terms of particle
size may be a dead end?
Dr Lawrie: It is one of the complications. Everybody
talks very clearly about this 100 nanometre boundary
and plainly it is not as simple as that. If you are going
to have a regulatory deﬁnition which is based on that
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size you would have to say what proportion of
particles would have to fall above or below that
threshold in order for clarity to be there. We were
talking about the deﬁnition in the legislation earlier,
if I could just add that it is recognised that this is, as
we have said on a number of occasions, an emerging
area and the deﬁnition perhaps will need to be
updated as we ﬁnd out more about what should or
should not be included. Within the proposal which is
going forward for novel foods that will be possible
using a very easy committee-based procedure to
change that particular aspect of the deﬁnition so that
it is recognised as a moving target at the moment.
Q633 Chairman: Could I just be clear on this. So the
view of the FSA would be that although each of us in
this room on average is eating, according to Dr
Powell, ﬁvemilligrammes per day of these engineered
titanium dioxide particles, you could say with
conﬁdence that that poses no safety risk, and part of
your argument is that many of the particles (not all)
are larger than 100 nanometres?
Dr Lawrie: I do not know that we can be sure what
the source of this titanium dioxide is. As I understand
it, this is not based on the analysis of food, it is based
on what ends up in the gut, so the titanium dioxide
could be coming from other environmental sources
other than food. In terms of the risk assessment, I
know that titanium dioxide in the form it is used as a
food colour has been assessed for safety, albeit some
years ago, but as we mentioned earlier these safety
assessments are currently being updated and colours
are at the top of the list, and titanium dioxide would
be covered there. Titanium dioxide in the form that is
used as a colourant is regarded as safe based on a
whole range of data at the time and that may include
any small proportion of the material which is in
nanoscale.
Q634 Baroness Neuberger: I want to go back to the
reply that you gave, Dr Lawrie, on this question
about silica and that fact that you cannot get a
straight reply, it seemed to me from what you were
saying, from the food industry as to whether or not
this particular form of silica, not the amorphous
silica but the fumed silica, is actually being used and,
if so, towhat extent and atwhat scale. I think it would
be quite interesting to press you a little further on that
and ﬁnd out what you really think is happening
because one of the things that we found both in the
States and in a visit that we made in this country is
that there is some reluctance on the part of the food
industry to be really clear about what is happening
and what the size is of what they are using. We
certainly heard an example in the States of a cosmetic
company that started talking about using nano-sized
material and then changed its advertising.
Gillian Merron: Just to make a general point, I know
we are likely to discuss this point but for me the issue
of transparency is crucial and I think without it
consumers will rightly wonder what is being hidden
and therefore it will come back to bite the industry. A
lot of the FSA’s work is to try and press that point
home. Perhaps on the science I could refer to Dr
Lawrie.
Dr Lawrie: I think you are right. If it would help the
Committee we can redouble our eVorts in trying to
ﬁnd out from the industry more about the nature of
the silica that is used.
Baroness Neuberger: That would be very helpful.
Q635 Lord May of Oxford: As a preamble to my
question I would just like to say that when I wasChief
Scientist I found myself many, many times saying
that government handles very well, with very
competent people, things which are well within the
domain of known science. Regulating that you have
conscientious people and generally people of science
are all you need. The problems of public perception
and sometimes the problems of actual, real worries—
which are two diVerent things but they are both
real—come when you are at or beyond the frontiers
of things that you conﬁdently know and where you
really need to be getting the very best people. You
need to be freely admitting what you do not
understand. I already ﬁnd a little disconcerting the
preliminary discussion we had about exactly getting
a deﬁnition. I think you have to have a deﬁnition and
that deﬁnition has to include an acknowledgement of
the diYculty in having a deﬁnition and recognition
that it is not precise. That brings me to my question,
which is Lord Drayson told us that it is the
responsibility of the FSA to commission relevant
research for its regulatory role with respect to
nanotechnologies. Other people have told us that
there is quite a lot of uncertainty that cannot be
qualiﬁed just in size because what you are really
interested in is the way surface-to-volume ratio can
change the properties, and that cannot necessarily be
given one clear size, and it can change properties so
that things get out of the gut into other places where
they are not meant to be. Finally to come to my
question, what steps is the FSA taking to ﬁll the
knowledge gaps or to clearly deﬁne the areas of
uncertainty that are required for them to make a
meaningful risk assessment of nanotechnologies in
the food sector?
Gillian Merron: There are two speciﬁc areas of work
being commissioned by the FSA. Then I will go back
to the more general point about the role of the FSA.
The ﬁrst one is on the fate of nanomaterials in the gut,
whichobviously relates back toour earlier discussion.
That will be a two-year plan for a piece of research.
The proposals have been received and they are
currently being assessed and the intention is that will
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start at the beginning of next year. The second area is
that the FSA is looking into contributing to a newEU
project which will be three years beginning next year,
January 2010, which will examine the methods of
measuring nanomaterials in food, again the kind of
thing we have just been speaking about. It does strike
me that this is an area where we do need that research
to support the risk assessment and toworkaround the
points that were correctly made by Lord May about
people’s sensitivities in the absence of information. In
general terms perhaps I can say to theCommittee that
the FSA is of course part of the Nanotechnology
Research Co-ordination Group co-ordinated by
Defraand thatgrouphasdeﬁnedanumberof research
requirements and they are very much based on the
gaps relevant to risk assessment. I know that the
Committee has heard from other witnesses that the
mainmechanism for commissioning relevant research
has beenvia the research councils and Ialsoknowthat
the Committee is aware that there are some projects
which have been commissioned already in respect of
nanoparticles in the gut either by the UK research
councils or at EU level. LordDrayson is right to point
out government departments such as the FSA which
do have a role in funding that relevant research.
Q636 Lord May of Oxford: To what extent do you
very deliberately go out not just to solicit expert
opinion but to take account of dissident opinion and
mavericks and so on to make sure that you engage in
the full spectrum of possible concerns? What is your
mechanism for doing that?
Gillian Merron: Could I just clarify, is that more in
respect of people’s general concerns or scientiﬁc?
Q637 LordMayofOxford: It is spelt out fairly clearly
in the Protocols for Science Advice and Policy-
Making actually. My personal experience has been
that too often it is a cosy group of people.
Dr Baynton:TheAgencyat themoment is considering
its science and evidence strategy from 2010 to 2015
whichwill underpin our newStrategic Planwhichwill
cover that ﬁve-year period. We have been working in
consultation with stakeholders looking at the type of
research that we should fund over the next ﬁve years.
Our Strategic Plan at the moment refers to new and
emerging technologies and obviously that would
include nanotechnology. Clearly this is a particular
area of research where we would want to consider
funding more work. Obviously we have to consider
that against competing priorities for FSA resources
and other research areas within the Agency. We are
certainly at the moment working with stakeholders
andworking within theAgency andwith ourGeneral
Advisory Committee on Science and considering
where our future research funding should be focused.
Q638 Lord May of Oxford:And how is this folded in
with the European Commission and the regulatory
agencies in the other European countries?
Dr Baynton: I do not have a very detailed knowledge
of how the funding works, certainly with the
European Commission, but we are looking to fund a
speciﬁc piece of work, as the Minister described,
looking at detection methods in relation to
nanomaterials. Obviously, we are aware of diVerent
research requirements for diVerent areas that the
EuropeanCommission is focusing on andwould look
to contribute to funding some of those initiatives.
There is this one project that we are hoping to fund
whichwill be on the detection of nanomaterials.
Gillian Merron: If it would be helpful we can provide
further details to the Committee.
Chairman: That would be helpful, thank you very
much.
Q639 Lord Crickhowell: I am ﬁnding these answers
interestingbecauseupuntil nowwehavebeen leftwith
something of a black hole. When we saw the research
councils they were extremely vague about what was
happening andof coursewehave the general diYculty
that scientists like pure research andmaynot like tobe
directed into particular areas of research and so on, a
subject which I think the wider Science and
TechnologyCommitteemay be looking at quite soon.
For the ﬁrst time I have really been hearing about
speciﬁc research projects being selected and ﬁnanced
byanorganisation.What is the scale? Ihaveno ideaof
the scale of the FSA research budget. How big a part
do you play in actually getting speciﬁc research where
it is needed? Can you really fund the research
yourselves, for example in this great hole about the
gut?
Dr Baynton: The Agency has a budget of about £22
million per year that we spend on research. I did not
quite understand your question about the project on
the gut.
Q640 Lord Crickhowell: We have been identiﬁed
again and again, and indeed I think the Minister
referred to it right at the start, that there is a great hole
at the moment because there has not been any real
research into the gut issue. I am really probing as to
whether this is something where you can perhaps get
speciﬁc research projects underway out of your own
research budget and through your own push?
Gillian Merron:Thatwas theﬁrst researchproject that
I referred to where we have already indicated an
intention by the FSA to commission, all being well,
starting at the beginning of next year and that is very
much about nanomaterials in the gut.
Q641 Chairman:Onequestionthat is relatedtothat is
that we have been concerned about is the capacity to
carry out that research in the UK. We have become
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aware of one research group in Cambridge that does
work on nanoparticles in the gut. How many
applications did you receive when you sent out your
call for this work?
Dr Lawrie: I am not sure that we are at liberty for
conﬁdentiality reasons to say but we have had more
than one.We had a number of applications to look at
from diVerent groups and what we have to do
obviously is assess the quality of those applications.
Wehave stressedthat this is thekindofworkwhichnot
just one man and his dog could carry out, it needed
input from various diVerent specialisms, and we were
looking particularly for collaborative approaches
which would allow the measurement and toxicology
and so on all to be dealt with as part of a larger
consortium. We are in the process of evaluating
research proposals at the moment and we should be
able tomakeadecision inthenextcoupleofmonthson
which one of thosemight be successful.
Gillian Merron: Again anything we can legitimately
and helpfully provide to theCommitteewewill do. So
we can perhaps take that away and see what we can
oVer.
Q642 LordMayofOxford:What is the secret element
of thenumberofproposals? I thoughtyou saidyouare
not at liberty to say the number of proposals.
Dr Lawrie: I am not sure.
Q643 Lord May of Oxford: Why not? I ﬁnd that
bizarre.
Gillian Merron: Please do not ﬁnd that bizarre. I was
just enquiring of oYcials about what we could say.
That is why I suggested perhaps you will let me take
that away.Whatever I can freely give to you of course
I will.
Chairman: Normally the research councils for
instance would not be secretive about how many
proposals there have been.
Q644 Lord May of Oxford: And it is frankly in
contradiction with the guidelines in the Protocols on
ScienceAdvice and Policy-Making.
Gillian Merron: We can come back to you on that
point.
Dr Lawrie: I did not want to speak out of turn.
Q645 Lord May of Oxford: It resonates with all my
worries.
Gillian Merron: Dr Lawrie was approaching it
through the best of intentions but whatever we can
helpfully provide youwill have.
Dr Baynton: I am not sure about the timetable for
commissioning thatpiece ofworkbut certainlyonce it
has been commissionedwe canupdate theCommittee
on the successful applicant and the project in more
detail. We normally place that sort of information on
our website once the project has been commissioned.
Q646 Lord O’Neill of Clackmannan: How do you
advertise for this research? Does it go in theEuropean
Bulletin or is it something where self-starters come
along and say, “We want some money?” How is it
done?
Dr Baynton: The Agency publishes what are called
research requirement documents that outline the
research that we are considering funding, but we also
invite expressions of interest. If people feel that they
have a particular interest and they feel it is something
that the Agency might be interested in then certainly
we very much welcome that as well as part of our
horizon scanning for future research.
Q647 Lord Crickhowell: Minister, have any further
developments been made on proposals for an EC
register for nanotechnologies and would this register
cover all instances of nanotechnologies or just those
related to food?
GillianMerron: I canonly respondin termsof foodbut
we are not aware that there are plans from the
Commission to do this. Our view is that it would be
useful to have an inventory.We need to clarify what is
or is not on the market and so if it is not going to
happenat anEUlevel thenwedowant todo it at aUK
level. The FSA is going to be working on this in the
next fewmonths and talking with stakeholders about
it,but I think it is important thatwedohave thisbefore
others who have more vested interests do so, so I am
keen that we get onwith this area of work.
Q648 Lord Crickhowell: The ﬁrst question I want to
ask iswhat is the role of sucha register? Is it a source of
public information about marketed products or is it
principally an aid to regulation giving the FSA
advance information about what is coming on to the
market? It seems rather important that we know
exactly what the register should be for.
Dr Baynton: I think it is something that we would like
to discuss with stakeholders about how useful that
particular register would be. I think really we will
decide after we have had those types of discussions
with stakeholders whether it is meaningful to have a
list ofproducts for consumers andwhether consumers
would ﬁnd that helpful. I think it is important we talk
to stakeholders about this before we make any ﬁnal
decisions.
Q649 Lord Crickhowell: The stakeholders may have
very diVerent views and consumers may take a very
diVerentviewfromthe industry,which takesmeneatly
to my second question. Lord Drayson last week with
reference to a voluntary reporting scheme run by
Defra said that unless industry participation
improved there was a case for making the reporting
scheme mandatory and that he did not believe that
voluntary schemes would necessarily be eVective.
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What is your view about that issue as it refers to the
register that we are talking about here?
Gillian Merron: My preference is to start with
voluntary. I verymuch recognise the problemwith the
Defra scheme. Some of the feedback I have had on
that was that it was onerous in terms of what was
required, so I do think that if we are to have a
voluntary scheme we do have to make it possible to
participate. Again relating back to an earlier
conversation, industry was, I understand, rather
reluctant to take part, they did not want to share
information, so I think alsowemust not rely solely on
industry to provide that information. Going back to
our earlier discussion, we have to work with industry
tomake themrealise that it is in their interests.Thirdly,
itmustnot be tooonerous. Iwouldhope thatwe could
learn from the fact that theDefra schemedidnotwork
and perhaps ﬁnd a better way to do it. I think our
general preference is always to start with voluntary
before deciding to go intomandatory.
Q650 Lord Crickhowell: So the third question is how
doyouget themtosharehealthandsafety testingdata,
inorderobviously toavoidduplicationofeVortand to
help develop standard testingmethods?We detected a
considerable reluctance by companies to share their
data, for obvious commercial reasons, but if you are
going to have a register are they not going to have to
share some data with you?
Dr Lawrie: These are exactly the sort of questions
which mean we should not rush into designing
something oV the top of our heads.We need to talk to
people and say would it be possible and what would
the diYculties be with this approach or that approach
and also to be clear at the outset about what the
purpose of the register is. The purpose of the Defra
scheme was to try and assemble detailed information
on a number of nanomaterials, recognising perhaps
that they would not get them all because not
everybody would participate, but to give a body of
knowledge about the safety testing that had been
carried out on these nanomaterials. The purpose of
the register for food might be quite diVerent. I sense
that it is the lack of public information that is one of
the major drivers for it. Perhaps once we have got a
clearer idea of the range of so-called nanomaterials,
bearing inmind thatwe thenhave to godown the road
of what we deﬁne as a nanomaterial—are we
concernedaboutwaterandoil emulsionasmuchaswe
are about silver nanoparticles for example—and once
we have a clear idea of the size and scope of it and
purpose thenwe can design themechanism for it.
Q651 Lord O’Neill of Clackmannan: You have
already spokenabout involvement inEFSAbut if you
are going to secure the harmonisation of regulation,
who would you consider to be the most appropriate
international bodies or large national bodies for this
and who would you envisage working with to secure
harmonisation of regulation?
Gillian Merron: I think Lord O’Neill’s question raises
an interesting question which I thought of when I was
preparing for the Committee which is the question of
EUversus broader, andwhere themost eVective route
is. Iamsure that theCommitteewillwishtotakeaview
on that and I will be very interested in their view. To
relate to the speciﬁcquestion, in termsof international
harmonisation it would be through Codex
Alimentarius a body which, as the Committee will
know, is between the Food and Agriculture
Organization and the World Health Organization.
They have recently convened an expert consultation
onthe issueof the impactofnanotechnologieson food
and we are awaiting the report which should be
published shortly.There is alsoworkbeing carriedout
throughtheOrganisationforEconomicCo-operation
andDevelopment. It is not directly related to foodbut
it will help the safety experts to develop risk
assessments that perhaps we can apply to a range of
products. It is probably worth saying also that there
have not beenmoves really at an international level to
harmonise regulations for nanotechnologies and
nanomaterials although there isworkunderway to try
and secure a common understanding before making
judgments about harmonisation. I think again that is
abit like thediscussionaboutan inventory.Wehave to
think very carefully about what we want to achieve
and through what means because if there is to be
harmonisation I want it to have some value.
Q652 Lord Crickhowell: I am just interested in the
answer and so far virtually nothing has been said
about the European Community. I would be
interested to know how the regulatory eVorts of the
FSA ﬁt into the European Community regulatory
systemand of courseREACHhas an impact on this. I
am not quite clear how that relates to novel foods and
so onbut surely ifwe are actually getting co-ordinated
eVort, the European Community must play a fairly
big part?
Gillian Merron: I think that was my point right at the
very beginning. We spoke earlier in the Committee
about the role of the EuropeanUnion and I knowDr
Lawriecanaddsomethingtothesecomments.There is
a question about harmonisation of regulation and at
which level it should be and what is its eVectiveness.
The reality is we probably can achieve things quicker
through the EU than we can wider and what matters
is, as I say, what eVect we want to achieve. I knowDr
Lawrie would like to add to that.
Dr Lawrie: It is perhaps because in the food area we
automatically assume when we are talking about
regulation that we are talking about European
regulation.98pluspercentof foodlawapplying in this
country is European legislation so it is essentially a
European activity.Whenwe think of international we
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think of going to the next stage beyond what we have
through Brussels. The Commission itself has drawn
upitsownplans for takingnanotechnologyforward in
food and in other areas. I think as part of our initial
written evidence from the Agency to the Committee
we provided you with a copy of the top ten actions
which the Commission was keen to take forward, so
there is activity there, both within novel foods, as we
havementioned, with the regulation of food additives
and food contact materials and so on. Everything in
Europe is moving to take better care of
nanotechnology and nanomaterials already. I do not
know if that helps to answer the question.
Q653 Chairman:The last part of Lord Crickhowell’s
question concerned REACH. We are interested to
know how important the REACH regulations are in
relation to food safety.
Dr Lawrie: Typically they do not apply at all. We can
give you chapter and verse on that but the materials
used for food production are excluded from the scope
of REACH and so for example if you have a food
additive, and that is the only reason a substance is
produced itmaynot cropupunderREACHat all, as I
understand it.We can check back on that.
Q654 Chairman: Can you please provide us with a
follow-up note?
Dr Lawrie: I will do that. Obviously many substances
will be multi-purpose and will be included under
REACHaswell as under food legislation.
Q655 Lord Cunningham of Felling:Can we now turn
tohowinformationaboutengineerednanoparticles in
foodmightbe conveyed to thepublic,with labellingas
an example. We understand that the Novel Foods
Regulation is proposed to be changed in respect of a
requirement to label food that contains engineered
nanoparticles. Is that correct?
Gillian Merron: The suggestion was not taken up as a
commonposition in respect of blanket labelling if that
is the reference.
Q656 Lord Cunningham of Felling: We understand
that there are proposed changes to the Regulation to
include the addition of a requirement to label foods
that contain engineered nanomaterials. Is that
correct?
GillianMerron:Doyouwant tocommentﬁrst ofallon
the European thing andwe can go on to the detail.
Dr Lawrie:Under the novel foods regulation there is a
requirement to consider the labelling of each product
that comes throughcase-by-caseandsince that iswhat
the regulation allows, and in fact requires, we think
there should not be a blanket requirement for a
particular category of ingredient to be labelled in a
particularwayunder that regulation.That takes away
any ﬂexibility theremight be for perhaps tailoring the
wayaparticular ingredient is labelled. Itprovidesonly
one aspect of control when there might be other
nanomaterials which for one reason or another are
regulated elsewhere and do not fall under the novel
food regulation and these provisions here would not
apply to them. If there is a requirement for labelling
nanomaterials in food, it should be across the whole
board not just for those which happen to come
through the novel foods regulation.
Q657 Lord Cunningham of Felling: It should be
across the board?
Dr Lawrie: If there were to be one, it would be better.
Q658 Lord Cunningham of Felling: Is there to be one
or not? I am afraid you have lostmewith all of that.
Gillian Merron: The simple answer is that there was a
proposal from the Parliament for blanket labelling
and, as I say, this was not accepted as the common
position for reasons that I am sure you will now want
to ask us about.
Q659 Lord Cunningham of Felling: Why is this not
desirable?
Gillian Merron: The issue is blanket labelling. The
regulation already requires that labelling is on a case-
by-case basis. Perhaps I can use the opportunity to
makeageneral point aboutconsumers. I think thatwe
have to be sensitive to consumers. We need to keep
away from the worries of something is not natural;
something isbeingdone tous;wedonotunderstand it.
For me if blanket labelling of what something
contains does not tell me something that is going to
assist me to make a sensible decision then it may
simply mislead me. That is why I think blanket
labelling is not helpful and that iswhy I think it should
be case-by-case.What Iwould say to theCommittee is
the FSA has a programme of citizens forums where it
is consulting directly consumers and it is going to
include nanotechnologies, in other words asking
people what is it that they would like to know, what
wouldbehelpful,whatwouldgive themthat insight to
make a proper choice. Rather than go for blanket
labelling we should be sayingwhat do we need so that
people know what is in their food so that they can
make a right decision, and blanket labelling for me
misses that point.
Q660 Lord Cunningham of Felling: I think what you
are saying to us, Minister, is that some engineered
nanoparticles in foodmay require information on the
label and somemay not.
Gillian Merron: It may ormay not, absolutely.
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Q661 Lord Cunningham of Felling: How will the
public have any conﬁdence in a system which tells
them that some foods have engineered nanoparticles
in themwhereas in other cases the public are not told?
Gillian Merron: First of all, I am not approaching it
from a position of not telling people. I think my
position is that we do not know what is going to be
helpful. All I am interested in is establishing what is
going to be helpful. If it is helpful that for whatever
reason everybody is told everything then there will be
a way of doing that, but I do not think we are at that
stage at the moment.
Q662 Lord Cunningham of Felling: It is a fairly
simple question though is it not: does this material
contain engineered nanomaterial or not?
Gillian Merron: Let me put it this way: you could
indeed put that on every label but will it serve the
purpose?
Q663 Lord Cunningham of Felling: When this
consultation, which I think we are all reassured to
hear is already in process, concludes, and if the
overwhelming conclusion and the dialogue with the
public is that the public believe that in every case the
presence of engineered nanoparticulate material in
foodstuVs should be conveyed to them through
labelling, will that be the outcome? Will the
Government accept that?
Gillian Merron: The words that I am about to use are
we need to get it to be balanced, we need it to be
proportionate and we need it to be informative. I
think we have got to make a decision on any special
labelling. I know that the FSA has already provided
in written evidence to this Committee the report that
was issued in March of this year which was an
evidence review about public attitudes to emerging
food technologies, but what I would like to convey to
this Committee is my understanding—and I know
only too well as a Member of Parliament—of the
sensitivities that are around emerging food
technologies, but I do think that we have to ﬁnd a
way of making that known in a way that is
understood and sensible and, as I said in my opening
statement, so that people get the beneﬁts. I think
there is a lot of interest in getting the beneﬁt of
nanotechnology and food without frightening
people. I am sure you are with me.
Q664 Lord Cunningham of Felling: Having spent 40
years of my political life supporting the civil nuclear
industry I am certainly not in favour of frightening
people, and having dealt with BSE and variant CJD
and for that matter GM foods, I am certainly not in
favour of frightening people.
Gillian Merron: You have got the scars!
Q665 Lord Cunningham of Felling: So I absolutely
accept that no-one sensible in this Committee or
anywhere else wants to scare people. I know there are
some people outside of this Committee who adopt
those tactics but that is not what we are here for. A
few questions earlier, Minister, you said to the
Committee that you thought transparency was
absolutely essential in all of this. If that is the
underlying principle in approaching engineered nano
particulate matter in food then the case for ensuring
that in every case the public are told seems pretty
conclusive.
Gillian Merron: I am just thinking back to what the
fundamental principle about food labelling is. It is
that consumers have suYcient information to make
informed choices about what they eat. Information
must by law be clear and not misleading and there is
a limit to how much information can go on a food
label. I think we have got quite a solid basis. Perhaps
I should say what I am not doing. I am not seeking to
withhold information; I am seeking to ensure that we
have the right amount of information in the right
form that consumers want and will be able to use. I
am not trying to circumvent the provision of
information. Perhaps I can give that assurance. I just
ﬁnd myself in a position where it is a bit early to give
greater detail on that without seeing evidence.
Chairman: It also refers back to the very start of our
discussion about what the deﬁnition of
nanotechnologies is. If you are going to have blanket
labelling, do you include things that are traditionally
used ingredients that have been re-engineered on a
nanoscale? Dr Lawrie told us those would not
necessarily come under the novel foods regulation.
They may or may not depending on whether the
properties change, so it does open up a very broad
question about the deﬁnition. Rather than dwelling
on that perhaps I could move on to Baroness
Neuberger.
Q666 Baroness Neuberger: You have already
referred,Minister, to the report showing that the FSA
has been looking at some of the public views about all
of that. Could you tell us whether the FSA has
mechanisms through which the public’s ethical and
social views on new technologies in the food
technology sector can actually be taken into account
in policy-making? That is very much following up
what Lord Cunningham said that if the public has a
strong view about this how do we translate that into
policy?
Gillian Merron:Bearing inmind the scars on the back
of Lord Cunningham and many others, as has
already been referred to, I am very keen that we do
take account of any ethical and social factors, indeed
any factors, whether that is misinformation or fear. It
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would be stupid not to, I think, is the simple way to
put it. Just to reiterate to the Committee, we are
running citizens forums through the Agency with ten
to 12 participants reﬂecting the make-up of the local
area, which are scheduled to meet up to three times a
year, to give the kind of evidence through that
nationwide programme that we will need. I am going
to be very interested in what they are saying because,
as I say, I am keen that we do not lose the beneﬁts but
that we get the beneﬁts in a way that people will
value. There are a lot of people who would welcome
the reduction of fat, sugar and salt without loss of
taste, to put it simply, and they want to be reassured
that it is safe. That, as well as protecting consumer
interests, is uppermost in my mind. Yes, there is a
measure and it is through the citizens forums, and as
a Minister I will be particularly interested in what
those citizens forums come up with.
Q667 Baroness Neuberger: That will be in some way
translated into policy? You may not take everything
they say but there will a policy element in that?
Gillian Merron: Yes, and we are working with the
British Market Research Bureau to put this work
together.
Chairman: We have talked quite a lot about
transparency, I do not know whether Lord
Cunningham would like to pick that up again brieﬂy.
Q668 Lord Cunningham of Felling: Yes, if I may,
Chairman. What is the Government going to do or
what does the Government have in mind to secure
transparency among companies in the food sector
with regard to their activities and work with
engineered nanomaterials?
Gillian Merron: Following on from our earlier
discussions, I do think that if we establish an
inventory, that will help us. We have had the
discussion about the diYculties of the previous
Defra-led inventory, so I am well aware of that. I
think it is a mechanism that does allow companies to
give factual information. The truth is that consumers’
fear is often about lack of information. I know that
very well. I think one way of encouraging
transparency—and it may be the Committee’s
deliberations might invite me to consider others—
would be through that inventory. We also note that
this is a very sensitive area for food companies. They
are reluctant, and the Committee will have seen that
for itself, and they are worried about all sorts of
things, including damaging their commercial
position, but the reality is with their consumers that
openness will reap them some rewards. I feel that we
have to continue through theAgency to not just stress
the value but actually explain and cajole and
persuade them of what the value of openness is. In
fact in emerging food technologies, in my view, there
is no other way because if they withhold they will be
in battle with the consumers and I do not think
companies would welcome that, so more work is
necessary, but I do completely accept that this is a
tough one.
Q669 Lord Cunningham of Felling: Is it safe for us to
conclude then that the Government will exert
pressure on food companies to be transparent and
open in their activities?
Gillian Merron: Lord Cunningham, we will act
always in the most appropriate way to get the result
that we wish to have. Voluntary is always better. I
always like it when people see the light more. It is my
preference. I am new to the area so I will be seeing
how far we are getting in getting them to see the light.
As I say, perhaps this Committee’s investigation may
be able to produce some ideas also for me. I think the
thing that the Committee needs to hear fromme ismy
wish to see greater transparency from the companies.
Q670 Lord May of Oxford: I think it is fair to say
that some of our conversations with the industry
have been along the lines of, “Well, they have not
noticed yet and let’s hope they do not notice as long
as we keep quiet about it.” It poses a challenge for the
lightly-lightly way of doing things.
Gillian Merron: If I might say this is the value of an
investigation by committees such as this because it
does highlight the need for that work.
Q671 Lord O’Neill of Clackmannan: If we could
maybe take things back a wee bit. We are assuming
that the foods are on the market, but before they get
to the market we have had concerns expressed by
witnesses about the lack of clarity in terms of the
requirements of data which need to be provided in
order to secure the permission under, for example,
registering of products with nanomaterials as novel.
What are you doing about that, if anything?
Gillian Merron: I will invite Dr Baynton and Dr
Lawrie to comment, but I understand that we have
not had enquiries yet of the FSA on data. There are
regular meetings between the FSA and companies.
Companies should be referring themselves to the
EFSA, which sets out the questions that they need to
answer. It is also the case that the European
Commission, as the Committee probably knows, has
acknowledged the need for more formal guidance
and the EFSA will be producing this. Perhaps on a
further point, companies should be aware that, in
introducing any new substance or a substance which
has been produced by a novel process, it is very likely
to require clearance under the novel foods
regulations, and if those regulations are to be revised
in future to include a special category in respect of
nanomaterials, then of course the FSA would be
publicising that in its formal guidance. Certainly I
would be interested if there were evidence of a lack of
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industry guidance because of course that would not
be appropriate. Perhaps I could ask Dr Lawrie or Dr
Baynton to add to that.
Dr Baynton: Just to reiterate what the Minister has
said, we already work very closely with the industry
in relation to the novel food regulation.Weworkwith
companies when they are producing their dossiers for
assessment under the novel food regulation.
Obviously there will be guidance at a European level
from EFSA and we are aware that the Commission is
very keen for EFSA to produce that guidance.
Equally, we would be happy to continue our
discussions with companies and advise them
accordingly on applications for the use of
nanomaterials or nanoparticles in food. We would
want to maintain the current good dialogue that we
have under the novel food regulation for future
applications in this area.
Q672 Lord Crickhowell: The Committee has heard
concerns over the diYculties surrounding the
detection and regulation of nanomaterials in
imported food. Who is responsible for ensuring that
there are appropriate techniques for monitoring
imported food products?
Gillian Merron: The ﬁrst point of course is that local
authorities and port health authorities are the ones
with the powers to check on the importation of food,
and that includes taking samples for laboratory
analysis. They may seek advice from the FSA about
what laboratory tests are appropriate for each
situation and the FSA has that general role to ensure
that the enforcement bodies have all the tools that are
necessary at their disposal. That includes the
development and validation of appropriate test
methods. The Nanotechnology Research Co-
ordination Group is working at looking on how they
can even better support this area and the FSA is also
looking at contributing funds to a new EU project
which will investigate the methods for measuring
nanomaterials in food. Perhaps the overall point is
that we do have to look to the future to ensure that
we have the right technology available in order that
we can properly detect and regulate as is required in
imported foods.
Q673 Chairman: Could I follow up and ask would a
typical trading standards oYcer or port health
authority inspector have at his or her disposal the
techniques to detect whether or not there are
nanomaterials in imported food as we speak today?
Gillian Merron: Not at present but they will do.
Q674 Chairman: So there could be food coming in at
the moment which is not being analysed because the
techniques are not there?
Dr Baynton: Possibly, yes. We are not aware
obviously of many products on theUKmarket but—
Q675 Chairman: There could be.
Dr Baynton: —coming from outside, yes.
Q676 Lord Crickhowell: It is obviously very early
days, but are the trading standards oYcers and port
health authority oYcers being told that this is an area
that they are going to have to look at and should be
looking at perhaps even now to some extent? I was
once a director of a large port company and I would
be a little sceptical that many port health authority
oYcials actually have nanotechnologies high on their
agenda about food coming in from, say, China or
Brazil or some other part of the world.
Gillian Merron: I would agree, that is true, and that is
the result of being at a very early stage. I can assure
the Committee that we will have in process the
necessary alert to those said authorities. I think this
is a function of the stage at which we are.
Q677 Lord Methuen: The Food and Drink
Federation has commented on the need for
transparency along the food chain so that
manufacturers are informed by their ingredient and
packaging suppliers about the use of nanotechnology
in any products that they are purchasing. What are
the current requirements for reporting along the
food chain?
Gillian Merron: Well, business-to-business sales are
not covered by the same food labelling legislation, as
I am sure the Committee is aware, that applies to
consumer sales. However, businesses are required to
pass on information that will make sure that the ﬁnal
food that is presented to consumers is in full
compliance with the law. It is of course open to
businesses to enter into a contract which is over and
above what is required to make sure they get the
disclosure of information in theway that theywant it.
For me the real issue is ultimately with the consumer.
Does the consumer have all the information
required? The law does require that whatever the
supply chain that will have to be the ultimate
provision, but, as I say, it is not absolutely required
along the way as long as the outcome is correct. That
may be amatter for example that the Food andDrink
Federationmay wish to work on with its members, as
well as others if that is an area of concern to them.
Q678 Lord Methuen: Does it not concern you? It
strikes me as slightly vague that the supplier could be
not really informing the producers.
Gillian Merron: It would concern me if the consumer
product at the end was not in compliance with the
law, yes, and it may be that by deﬁnition one has to
do that but, yes, of course compliance with the law is
absolute. That compliance is not required business-
to-business but, as I say, businesses may require that,
and going back to our discussion on transparency, as
the technology develops I think there will be
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movement. It is probably not something they are
considering at present.
Q679 Lord May of Oxford: This is possibly a step
too far but how is the Government thinking about
the possible inadvertent contamination of foods with
nanoparticles in ways which were not intended?
Gillian Merron: The most likely source of
contamination of food is from their use with food
contact materials. We are not aware that we have got
any food packaging materials in the UK containing
nanoparticles at this stage and it is diYcult to
generalise on the likelihood.
Q680 Lord May of Oxford: I am thinking of food
processing places where other uses of nanoparticles
are being made. In the nature of some of them they
are going to get out into the atmosphere, as it were.
Gillian Merron: My point was it is diYcult to
generalise on the likelihood that nanoparticles can
migrate from packaging to food. It depends on the
type and composition of the materials used.
Q681 Lord May of Oxford: I just wondered if it was
something that was being considered?
Gillian Merron: It is something of interest and I am
going turn to my scientist colleagues.
Dr Baynton: The Food Standards Agency is very
aware of the potential for incidents to occur along the
food chain. We have horizon-scanning activities to
try and identify where there might be potential
problems in the future. This is perhaps something
that we do need to consider.
Q682 Lord Methuen: Could this not be fungicides
and pesticides which are used in warehouses and
other food storage places?
Dr Baynton: That could be one mechanism. I think
that is something that we need to consider as part of
thinking about incident prevention and prevention of
Letter from the Minister of State for Public Health, Department of Health
Thank you for inviting me to appear in front of your Committee today, which I found very valuable. I hope
the Committee also found it useful.
At the hearing, I promised to write to the Committee on the following points:
(a) the current use of fumed silica as a food additive and its relationship to the type of silica that was used
in the German research;
(b) the number of research proposals that the FSA has received in relation to the fate of nanomaterials
in the gut;
(c) how Food SA’s food research relates to EU research programmes in similar areas; and
(d) the applicability of REACH to substances that are used in food.
contamination of food supplies with those types of
chemicals.
Q683 Chairman: My recollection from my time at
the FSA is that contamination is normally picked up
by local authority inspectors. This goes back to the
earlier question of whether the local authority
inspectors have the techniques in their current tool
kit to detect contamination if contamination were
occurring. I think the information we heard earlier is
that they probably do not at the moment, but you are
working with them to build up the armoury of
techniques, so if something happened at the moment
in theway that LordMay referred to, and inadvertent
contamination of a foodstuVwith a nanomaterial did
occur, am I right in believing that the trading
standards oYcers would not have the technical
armoury to ﬁnd that out so it could be happening and
we would not know?
Gillian Merron: That is true.
Q684 Chairman:Wehave used upmore time thanwe
were originally intending to, but I do appreciate very
much, Minister, that you have been willing to answer
our questions so fully and frankly and to engage with
us, and also your colleagues from the Food
Standards Agency. There have been a number of
points on which you have agreed to follow-up in
writing so we very much appreciate that and look
forward to receiving those comments. Of course there
will be a written transcript of this session which will
be sent to you for checking before it becomes the
published record. Any subsidiary evidence that you
give us will also be part of the public record of our
inquiry. As you said, this is our last oral evidence
session, so thank you very much for rounding oV our
sessions with witnesses and we now set to work to
complete the draft report which we hope to ﬁnalise
during the autumn.
Gillian Merron: Thank you very much and I look
forward to seeing the report. I think it will be of great
assistance to us. Thank you.
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I will send you this information by summer recess, with the exception of point “a” above which my oYcials
tell me requires further investigation and liaison with industry. I have instructed the Food Standards Agency
to respond to you directly on this point by the end of July 2009.
I hope that this is acceptable.
14 July 2009
Supplementary Letter from the Minister of State for Public Health, Department of Health
In my letter of 14 July I promised to provide the Sub-Committee with additional information on four points.
My responses on three of these are set out below. I have asked the Food Standards Agency (FSA) to respond
by the end of July on the remaining point, concerning nanoscale silica.
1. The Number of Research Proposals that the FSA has Received in Relation to the Fate of
Nanomaterials in the Gut
The FSA has advised me that they are currently in the process of evaluating the proposals that have been
submitted in response to its published requirement for research into the fate of nanomaterials in the gut.
Considering the stage the FSA are at, revealing the number of proposals submitted at this stage could
jeopardise any negotiations with applicants prior to placing of the research contract. However, the Agency
will, of course, be happy to provide the Committee with this information once the commissioning process is
complete.
2. How the FSA’s Food Research Relates to EU Research Programmes in Similar Areas
The Food Standards Agency engages actively with the EU research programmes to help ensure that FSA and
UK priorities are reﬂected in the EU programmes, and to ensure we are able to identify and beneﬁt from
opportunities for collaborative approaches.
The FSA is joint UK lead, with Defra, on the Management Committee responsible for the theme “Food,
Agriculture & Fisheries, and Biotechnology” in the current EU research programme, FP7, which has the
greatest overlap with Agency research priorities—one of its three sub-themes, on food health and well-being,
has very close parallels with the Agency’s principal objectives of food safety and healthy eating. The Agency
also takes part in the UK’s cross-government EU research networks with other Departments and Research
Councils, to ensure it is informed on and can inﬂuence other themes which have elements of interest to the
Agency, including the themes on: Environment; Health; Nanosciences, nanotechnologies, materials & new
production technologies; and Social Sciences & Humanities.
The Agency’s own research programmes take account of relevant research in Europe and the wider
international context, and we can provide co-funding for European projects where these align with our
priorities. The FSA co-funded ﬁve projects in FP6 (which ran from2002–06) and to date has agreed co-funding
for two projects in FP7—with co-funding under discussion for a number of further FP7 projects, including
one on detection of nanomaterials in food. The Agency also collaborates in other ways with EU projects of
interest, for example by participating in stakeholder, expert or advisory groups set up by EU projects to
provide forums to exchange information and expertise between projects and interested parties. The Agency is
also a partner in the FP6 “ERANET” project SAFEFOODERA, which aims to co-ordinate national research
in food safety across some 19 European countries, and which has issued two successful jointly-funded research
calls. Progress in co-funding in Agency research is reported annually in the FSA Chief Scientist’s Annual
reports.
The Agency also takes part in theUKprogramme of support to UKorganisations to engage with EU research
programmes, through promoting and facilitating opportunities to participate and to beneﬁt from the results.
3. The Applicability of REACH to Substances that are used in Food
FSA oYcials have consulted with Defra on the application of REACH (Regulation (EC) 1907/2006, which
governs the registration, evaluation, authorisation and restriction of chemicals) to nanomaterials used in food.
Article 2 of the Regulation sets out a number of exemptions and, according to Article 2(5)(b), substances are
excluded from the requirements for registration, evaluation and authorisation “to the extent that they are
used … in food and feedingstuVs”. In this context “food” refers to ingredients, ﬂavourings, additives etc, as
well as food consumed as such.
The REACH legislation could, in theory, be used to place restrictions on substances used in food. However,
this seems unlikely in practice as the exemption mentioned above means that no information on relevant uses
will have been collected and assessed.
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The exemption for substances used in food does not extend to substances used in food packaging.
I hope this is helpful. Please let me know if you would like any further information.
21 July 2009
Further supplementary memorandum from the Minister of State for Public Health,
Department of Health
Your letter also invited further information on ﬁve points. Points 3 and 5 were answered in Gillian Merron’s
letter of 21 July, which also addressed point 2 but from the broader perspective of the relationship between
FSA and EU funded research (Q638 in the transcript). The speciﬁc work that is being considered for funding
by the FSA is part of a 4 million euro project (Nanolyse) that is being led by the RIKILT Institute of Food
Safety (TheNetherlands), and is aimed at developing analytical methods for detection and characterisation of
nanoparticles in food. The project aims to fulﬁl a major current need for validated detection/characterisation
technologies that will enable quality control and safety assurance of the food products that are developed using
nanotechnology-derived materials. The project is being undertaken by a consortium of research centres that
includes the Food and Environment Research Agency in York. FSA has been asked to provide “top-up”
funding for FERA’s part of the work.
In relation to point 1, FSA oYcials have not yet been able to ﬁnd any more information about the
characteristics of silica that is used as a food additive and it is therefore not possible to comment on the
relevance of theGermanwork on amorphous silica. FSAOYcials will continue to search formore information
and report back shortly on progress. Point 4 concerns the European Commission’s plans for an EU inventory.
This was originally included in the list of “top ten actions” that the Commission drew up at the end of 2008.
However, they have taken no action to date and oYcials understand from their Commission contacts that
nothing is currently planned, at least in the food area. I hope this resolves the apparent inconsistency.
5 August 2009
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Written Evidence
Memorandum by Campden BRI
1. Our Organisation
1.1 Campden BRI is the world’s largest, independent, membership-based, research and technology
organisation serving the food and drinks sectors. The organisation has over 1,700 member companies in more
than 60 countries. Over the last three years, we have received funding from defra and EPSRC to identify
applications and potential barriers to the uptake of nanotechnologies in the food sector. This has been, and
continues to be achieved, through a series of meetings with industry and through email alerts to industry on
developments in nanotechnologies that may have relevance to food applications. The mailing list for emails
consists of 1,100 industry contacts.
1.2 The meetings have been composed of presentations from companies providing nanotechnology-based
products such as coatings, manufacturers of foods, ingredients and agro-chemicals, academics carrying out
research on nano-science or consumer attitudes, and representatives of Government departments. Our
response to the call from the House of Lords is based on those presentations and information and enquiries
from our members in response to those meetings and the email alerts.
1.3 Our response begins by looking at “Other Issues” not speciﬁcally identiﬁed in the call as we believe these
set the scene for our response.
2. “Other Issues”
2.1 Questions from industry indicate a diYculty in understanding the meaning of the term
“nanotechnologies”. Some companies know that they experience equipment wear and that this leads to
particles, at the nanoscale of 1-100 nm, in the product. Some processes used in the manufacture of foods
produce particles that exist at the nanoscale for only short time periods and do not exist at that scale in the
ﬁnal product. Other processes, such as vapour deposition used in the manufacture of packaging, may create
particles that are short-lived at the nano-scale or create ﬁlms that are at the nano-scale in the ﬁnal package.
Conventional food processing operations, such as emulsiﬁcation, may also create nano-structures. There is
confusion as to whether these products are to be considered as “nano-products”. There is also concern that
sales of such products, which have been produced by methods available for many years, would be damaged
if legislation were introduced that required them to be labelled as “containing manufactured nanoparticles”.
2.2 DiYculties arise because nanotechnology has been given a speciﬁc size category but novel properties may
be achieved outside this range and conventional processes, used for many years, may produce particles within
that range.
2.3 Existing legalisation requires food to be safe irrespective of the method of manufacture or size of particles
that it contains.
2.4 Deﬁning nanotechnologies as producing materials with novel properties restricts some of the diYculties
in understanding what the term means but it does not altogether eliminate the problem. For example, a beer
bottle has been available that includes a layer containing clay particles at the nanoscale. The bottle extends
the shelf life of the beer by restricting oxygen ingress. This would appear to be a novel property of the bottle
material but not necessarily of the individual particles. Our comments below relate to nanotechnologies as
procedures or equipment that create particles that have novel properties.
3. State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits?
3.1 Applications for which the industry would like to see nanotechnology deliver solutions include: extended
shelf life to reduce waste; improved quality such as ﬂavour; alternative utilisation of food waste such as energy
generation; sensing of contaminants (microorganisms, allergens); improved packaging to increase shelf life
and reduce waste; alternative methods of creating desired mouth feel and taste of products with reduced fat,
sugar, and salt composition. Nanotechnologies are believed to have the potential to oVer solutions.
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What is the current state of the market?
3.2 There have been at least eight reports written about the applications of nanotechnologies in the agri-food
sector and at least one computer-based inventory of consumer products containing nanoparticles is available
(WoodrowWilson Inventory). Whether all of the applications or products are created using nanotechnologies
is often unclear.
3.3 Silver is a known anti-microbial and applications to food supplements, food containers and food cutting
boards are cited in the Woodrow Wilson inventory. None of these materials have been identiﬁed in the UK
market although some clothing containing silver has been available. The inventory also cites canola oil and a
tea as food products containing particles. The canola oil claims to use micelles to restrict the transfer of
cholesterol into the blood stream. The tea is promoted as releasing increased selenium due to a ball milling
operation reducing the size of the tea during manufacture. Micellation and ball milling have been known for
many years.
3.4 Probably the most widely cited application of nanotechnology in the drinks sector is the beer bottle
incorporating a layer of nano-clay, although other bottles based on vapour deposition of silicon oxides have
also been reported.
3.5 Despite our eVorts, we have not identiﬁed any food products or food packaging materials on the UK
market that contain particles that have been deliberately engineered at the nano-scale using new and novel
technologies. Understanding of food structure is developing through measurements and modelling at the
nano-scale.
What are the barriers to the development of new nano-products or processes in the food sector?
3.6 Discussions at our meetings have indicated that the greatest barriers are cost (some barrier materials for
packaging could be created for greater shelf life but the increased cost would not be justiﬁed); technical
diYculty (nanoparticles can be diYcult to manufacture and control); and health and safety concerns. A
signiﬁcant barrier is consumer attitude and the industry concern over that attitude. There is considerable
worry that nanotechnology could suVer from adverse public opinion in a similar way to developments in
biotechnology and that conventional food processing methods, which involve control of nano-structures in
foods, would be associated with the newer developments in nanotechnology.
4. Summarising Comments
4.1 Despite there being deﬁnitions of “nanotechnologies” from many recognised sources, there is still
uncertainty about the meaning of the word. It is unclear whether any process that produces particles at the
nano-scale should be considered as “nanotechnology”. Even if the meaning is extended to include a reference
to novel properties, there could still be concern that nano-scale particles, irrespective of how they were created,
could have an adverse eVect on health. There are many developments in food and packagingmanufacture that
could provide beneﬁts to consumers and nanotechnologies oVer one of the routes to achieving those goals.
March 2009
Memorandum by Cargill
Cargill is an international producer and marketer of food, agricultural, ﬁnancial and industrial products and
services. Founded in 1865, the privately held company employs 160,000 people in 67 countries. Cargill helps
customers succeed through collaboration and innovation, and is committed to applying its global knowledge
and experience to help meet economic, environmental and social challenges wherever it does business. For
more information, visit www.cargill.co.
Nanotechnology in Cargill
Materials of nano dimension have been present in the food chain for a long time. Our comments to this inquiry
will be focussed on the deliberate fabrication of “nanoscale” materials, potentially of value because of their
novel physico-chemical properties, or the novel processes by which these are fabricated and incorporated into
products. It is of vital importance to Cargill that the regulatory deﬁnitions of nanotechnology only encompass
new, deliberately fabricatedmaterials. Any broader scope could inadvertently and signiﬁcantly impact existing
global food and feed supply chains.
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The recent developments inmaterial science that havemade possible the study and control of matter at atomic
andmolecular scale, nano-technology, have resulted in the introduction of over 300 newproducts intentionally
derived from this technology in non-food areas (eg cosmetics, coatings) and in some cases in the food and
agricultural sectors. A recent review (see Woodrow Wilson Int Center) has identiﬁed that in the food sector,
these products cover:
— Forms: nanoparticles, nano-emulsions, nano-catalyst, liquid crystals, nano-ﬂuids, nano-crystals.
— Functions: inc. solubility/uptake, stability, ﬂavor release/enhancement, colour release, packaging-
antimicrobials.
— Needs: nutrition, improved immune system, ﬂavor, fun, individualization, stability, safety.
— Products: oils, supplement, chocolate, beverages, gum, ice cream, dressing, ﬁllings.
Cargill is well aware of these opportunities and believes that nanotechnology-based materials may oVer
valuable beneﬁts to the food chain such as measurement sensors to enhance safety and quality.
However, after spending considerable time analysing the subject within the company, we have concluded that
the potential safety risks, the emerging regulatory environment and the level of consumer acceptance of
products incorporating nanotechnology are not generally well understood. In particular the investigation of
the health, safety, and environmental aspects of these novel substances has not matched investment in
nanotechnology research and development.
Consequently there are many gaps in understanding the eVects of nanotechnology-enabled products on health
and on the environment and particularly how their use in the food chainmay expose our employees, customers
and consumers to these materials. It is our understanding from the peer-reviewed science that the extremely
small size of nano-particles permits possible transfer, after inhalation or ingestion, into and through human
tissue by new and unknown routes. This potential toxicological hazard is diYcult to measure and assess, and
represents a signiﬁcant risk until detailed studies have been carried out. This uncertainty about toxicological
risk is a signiﬁcant gap in determining safety legislation on which proper controls should be based.We support
investigation into these issues.
Furthermore consumer surveys on nanotechnology, including speciﬁc applications in foods, indicate that the
public has a low level of understanding of nanotechnology.
Experience has shown that the successful introduction of a new technology, especially one with potential
health, safety and environmental impacts, requires a clear science-based regulatory regime, overseen by
credible governmental authorities, and that the technology providers engage the public and other stakeholders
to convince them of the advantages of the technology. None of these steps has been taken for nanotechnology
As a result, Cargill will not incorporate intentionally-engineered nano-materials into its products for the
foreseeable future until these shortcomings are remedied.
This position does not mean that we will not maintain our interest in nanotechnology, especially where
materials can be fabricated into devices and wholly enclosing nano-materials and where no human exposures
need result. We will continue to assess these “non contact” uses in terms of their beneﬁt to process control and
product quality.
14 August 2009
Memorandum by the ESRC Centre for Business Relationships, Accountability,
Sustainability and Society (BRASS)
Respondent Profile
The ESRC funded Centre for Business Relationships, Accountability, Sustainability and Society (BRASS) at
CardiV University is a major research centre dedicated to providing a critical view on all aspects of business
relationships that aVect issues surrounding sustainability, accountability and their interaction with diVerent
components of society. The comments provided in the response are based on the report “An Overview of the
Framework of Current Regulation AVecting the Development andMarketing of Nanomaterials”, written by
the respondents for the OYce of Science and Innovation in December 2006. The report is located at: http://
www.berr.gov.uk/ﬁles/ﬁle36167.pdf.
Currently, BRASS is conducting research for the Department for the Environment, Food and Rural AVairs
on the application of corporate social responsibility by the nanotechnologies industries in the context of
safeguarding the environment and human health.
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Introduction
BRASS welcomes this opportunity to contribute to the invitation to submit written evidence on the use of
nanotechnologies in the food sector. In view of our previous work, and given our role as social science
researchers, we have restricted our responses to the questions relating to the regulatory framework and to
public engagement.
Regulatory Framework
Q. 1 Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
In principle, current uses of nanotechnologies and nanomaterials will fall within the scope of a range of
existing regulatory provisions. There is no nano-speciﬁc legislation, either in the UK or EU. The regulation
of nanomaterials is therefore question of whether, and to what extent, legislative provisions designed to
manage risks from bulk-scale materials also cover potential risks from materials at nano-scale. Given that
current uses of nanotechnologies tend to involve the nano-scale versions of materials already subject to
regulatory control, there are usually obvious regulatory regimes into which nanomaterials will fall.
Nanomaterials may be caught within the remit of a wide range of existing legislative provisions, in areas such
as consumer protection, occupational health and safety, and environmental protection.
There are instances, however, in which regulatory gaps can arise (see BRASS, 2006). First, nanomaterials may
fall outside the remit of existing provisions because, even at bulk-scale, those materials are unregulated.
Secondly, the content of existing legislation may, in some instance, be ill-suited to nanomaterials. Thirdly, the
particular implementation of those provisions may fail to account for the properties or behaviour of
nanomaterials. Existing legislative provisions were never designed with nanomaterials in mind (RCEP, 2007).
It is unsurprising, therefore, that their capacity to aVord adequate protection may be limited.
The limitations of current legislation are brought into sharp focus by considering their application to food
products. The greatest potential diYculty arises in relation to the Novel Foods Regulation (EC) No. 258/97.
Pre-market approval is required for novel foods and novel food ingredients, but not for those that are deemed
by a national food assessment body (FSA) to be substantially equivalent to comparable traditional foods.
Substantial equivalence between new and existing foods is determined by a range of factors, such as their
composition, nutritional value and intended use; although there is no explicit provision in the Regulation that
particle size or the unique properties of novel foods should be taken into account. This creates the possibility
that novel foods or food ingredients containing nanomaterials will be deemed to be substantially equivalent
to their existing bulk-scale counterparts, and thereby escape the need for pre-market approval, even though
they may pose a greater risk to human health.
The European Commission has recently presented proposals for a new, amended Regulation on Novel Foods
(COM (2007) 872). One of the proposed Recitals seeks to clarify whether foods comprising nanomaterials are
“novel” and therefore subject tomarket entry control. “Novel food”, theCommission suggests, should include
“foods modiﬁed by new production processes, such as nanotechnology and nanoscience”. The fact that
amendments such as this are under consideration is encouraging. Some caution, however, should be expressed
in respect of its technology-based approach to regulation. A product-based approach—in which the novelty
of nano-foods is determined on a case-by-case basis according to their individual properties, functions and
hazards—remains preferable, not least because process distinctions are not well recognised in the world trade
treaties such as GATT.
Generally, food additives legislation (adopted under the framework of the food additives Directive 89/107/
EEC, eg Directives 94/35/EC on sweeteners for use in foodstuVs, 94/36/EC on colours for use in foodstuVs,
95/2/EC on food additives other than colours and sweeteners, and 96/77/EC laying down speciﬁc purity
criteria on food additives other than colours and sweeteners) is suYciently broad to encompass the use of
nanomaterials. Some aspects of that legislation, however, may be problematic.Directive 95/2/EC, for example,
prohibits the use of certain additives in quantities above prescribed maximum levels. Although these
maximum levels might be suitable for additives composed of bulk-scale materials, they are not necessarily so
for materials at nano-scale. Legislation in this area tends to overlook particle size as a determining factor in
the toxicity of substances. The new food additives Regulation (EC) No. 1333/2008 addresses this issue (see
Article 12). We welcome this initiative as it presents an obvious solution to track developments in the use of
nanomaterials as food additives.
Although the food additives Directive (89/107/EEC) does not set out speciﬁc criteria for the assessment of
nanomaterials, it contains a number of “safety net” provisions which require that foods are continually
observed and re-evaluated in light of changing conditions of use or new scientiﬁc information.Umbrella safety
legislation (such as the General Food Regulation (EC) No. 178/2002 and the (UK) General Product Safety
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Regulations 2005) provide an additional layer of regulation, prohibiting the placing of unsafe foods or
products on the market. The capacity of these provisions to aVord adequate protection against potential harm
from nanomaterials, however, will ultimately depend on whether there are suitable procedures for the
identiﬁcation, characterisation and assessment of risks. These procedures are still lacking. Moreover there are
questions about how far a general food safety law might actually deter risk taking conduct.
Q.3 Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
The capacity of current regulations adequately to control the present, let alone the next, generation of
nanotechnologies and nanomaterials is limited. As applications of nanotechnologies and nanomaterials
develop, and become increasingly dissimilar to conventional (regulated) technologies and materials, gaps in
current legislation will only grow to be more pronounced. Before the capacity of regulations to address future
applications of nanotechnologies can be properly examined, it is necessary to gain a clear idea of what those
future applications actually entail. Whilst we do not consider it necessary to impose overarching nano-speciﬁc
legislation (giving eVect to a moratorium, for example), current regulations will, in our opinion, need to be
amended to account for more sophisticated nano-based products and processes. Moreover these will need to
be adapted to cover not merely foodstuVs but also packaging and materials used in food preparation.
Public Engagement
Q.1 What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of
nanotechnologies and nanomaterials in the food sector? What is the public perception of the use of such technologies and
materials?
Broadly speaking, the available evidence on public awareness in countries such as the USA and UK shows
that awareness of the existence of nanotechnology in general has changed little from a low level a few years
ago (Currall, King et al. 2006; Kahan, Slovic et al. 2007; Scheufele, Corley et al. 2007). For example, in 2006,
42 per cent of Americans surveyed had not heard of nanotechnology (Peter D. Hart Research Associates
2006), with this actually increasing to 49 per cent in 2008 (Peter D. Hart Research Associates 2008). However,
research on attitudes towards speciﬁc potential applications of nanotechnologies demonstrates that there may
be signiﬁcant concern about food applications, particularly where nanoingredients are actually present within
foods rather than simply used within packaging materials. A survey for the Woodrow Wilson Institute
indicates that only 7 per cent of Americans would buy nanofood now, with 29 per cent not wanting to buy it
at all, and 62 per cent wanting more information on risks and beneﬁts, vs 12 per cent, 73 per cent and 13 per
cent for food containers (Peter D. Hart Research Associates 2007). Evidence from research in Switzerland
suggests that people may be hesitant to buy foods which either contain nano-additives or use packaging which
contains nanomaterials or nanostructures (Siegrist, Cousin et al. 2007). This research also indicates that trust
in institutions is a key factor in determining perceptions of such technologies. Survey data fromGermany also
indicates that mistrust of regulators and industry could be particularly signiﬁcant with respect to nanofoods,
as low trust of these groups is correlated with high rates of rejection of the use of nanoadditives in food
(Halliday 2007). Further, research from recent public engagement events in the UK indicates that, in general,
the public are perhaps more concerned about the extent of scientiﬁc uncertainty surrounding risk, rather than
about the nature of risks that have to date been identiﬁed (Gavelin, Wilson et al. 2007, 39).
Q.2 How effective have the Government, industry and other stakeholders been in engaging and informing the public on
these issues? How can the public best be engaged in future?
Other evidence indicates that whether the public trusts or mistrusts the ability of regulators and industry to
handle risks and uncertainties is based on experiences of previous technology controversies (eg Macoubrie
2006, 235–6; (Pidgeon, Harthorn et al. 2009), and on whether these controversies have been ampliﬁed by a
lack of transparency from industry and regulators, both about risk and about scientiﬁc uncertainty. Although
the assumptions behind public engagement activities have shifted in large part away from “deﬁcit” models of
public information about science, some commentators have observed that these models risk being replaced by
a “trust deﬁcit” model. For these commentators, unless the purpose and practice of engagement is altered, its
purpose risks becoming merely about convincing the public, envisaged as “end-user consumers”, of the
potential future beneﬁts of a technology (eg Kearnes and Wynne 2007). To counter these eVects, the aim of
future public engagement exercises on nanotechnology must focus on transparent discussion of scientiﬁc
uncertainty over both beneﬁts and risks. Unfortunately, to date the food industry has manifested a low degree
of transparency regarding the presence of nanomaterials in food and food packaging (Schelke 2006). In certain
areas such as ﬂavourings, competitive forces may militate against greater openness.
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Q.3 What lessons can be learned from public engagement activities that have taken place during the development of
other new technologies?
There is evidence from research done on public attitudes to GM foods to suggest that demonstration of
technological beneﬁts alone is not enough to persuade people to consume modiﬁed food (Cox, Koster et al.
2004). There is reason to suspect that similar attitudes may be evident in relation to “nanofoods”. Trying to
win public trust by stressing potential beneﬁts may therefore be ineVective, as well as reproducing “deﬁcit”
models of engagement in new forms. It has also been argued that new technologies (with GM as a prime
example) act as condensation points for the expression of broader public concerns, about eg the wider social
responsibilities of industry (Kearnes, Grove-White et al. 2006, 300–301). Given thatmistrust, in aUK context,
is strongly correlated with experiences of controversies over BSE and GM, the importance in the future of the
relationship between factors like mistrust and how both risks and uncertainties are communicated is diYcult
to overemphasise.
Q.4 Should consumers be provided with information on the use of nanotechnologies and nano-materials in food
products?
Concerns which are sometimes expressed over exposure to risk turn out, on further investigation, to be about
the imposition of risk, ie about the social context through which risk is distributed. Recent research shows that,
as well as demanding information about the state of scientiﬁc uncertainty, publics are concerned with the
management of consent to bear risk, and the moral issues which underlie issues of consent (Shrader-Frechette
2007). How marketing is used as a conduit for product information features again and again in recent
consumer research as an object of concern (eg Federal Institute for Risk Assessment (Germany) 2006,Which?
2008, 10). Labelling and other marketing information provides a vital means of allowing people to make
decisions about consenting to bear risk and uncertainty, and thus may be a key factor (amongst others) to
establishing the social legitimacy of some uses of nanotechnologies.
Conclusion
In general terms we would stress that the Regulatory framework is not water-tight. It is capable of adaptive
management since food is generally well regulated and those engaged in food production have strong
incentives to ensure that food is safe. While work is already underway at a European level as a beginning of
this process, progress to date has been slow. In part this is because of the diYculty of regulating in the absence
of agreed deﬁnitions, metrics, processes of characterisation etc. However, this should not be used as an excuse
to delay regulatory reform.
As for public engagement, this is not easy as a formal exercise amidst a low level of recognition of
nanomaterials. However, there are strong messages demonstrating the importance of a continuing form of
dialogue with the public and processes of transparent dealings.Without this, distrust of nanotechnologies and
their regulation might quickly develop.
March 2009
Memorandum by the European Commission Directorate-General for Health and
Consumers (DG SANCO)
Nanotechnologies and Food
1. Could you provide the Committee with a brief update on the activities to update legislation relevant to the use of
nanotechnologies in food, additives and food packaging, and the timetable for future activities?
Brief update on the novel foods, food additives and food contact materials:
Novel foods: Under current novel food legislation (Regulation (EC) 258/97) all foodstuVs obtained through
new production processes giving rise to signiﬁcant changes, need an EU authorisation before getting market
access. In the draft EU Regulation revision this legislation, it is explicitly proposed that food ingredients,
which contain or consist of engineered nanomaterial will require an EU authorisation preceded by an
evaluation by the European Food Safety Authority (EFSA) before getting market access. As regards the
legislative process, the Council reached a “political agreement” on 22 May 2009 and the second reading will
start under the Swedish Presidency in view of the ﬁnal adoption of the text.
Food additives: The Community legislation on food additives requires a safety evaluation and pre-market
approval of each new additive which is to be placed on the market and used in the Community. The new
Regulation 1333/2008 on food additives, which was adopted in December 2008, clariﬁes that when for a food
additive there is a change in particle size, for example through nanotechnology, a new evaluation would be
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required from EFSA. Under such circumstances, the food additives in the nanoscale is considered a new
additive and therefore needs a new entry into the Community list before it can be placed on the market
(Article 12).
Food contact materials: General safety requirements for food contact materials are set out in a Framework
Regulation which also empowers the Commission to adopt material speciﬁc requirements. For plastics,
cellophane and active intelligent packaging harmonised Community requirements exist. These requirements
foresee a pre-market approval of substances used in their manufacture. Current authorisations cover
substances in bulk form but not in nano-form. In case a business operator using authorised substances has
new scientiﬁc or technical information, which might aVect the safety assessment of the authorised substance
in relation to human health he has to immediately inform the Commission, who shall ask EFSA to review the
assessment. The use of an authorised substance in nano-form is regarded as an information which would
trigger a review by EFSA. All other materials which are not covered by speciﬁc Community requirements are
subject to speciﬁc national provisions.
2. How does the Commission intend to define “nanotechnologies” and “nanomaterials” in the context of regulating their
use in the food sector?
The discussion on how to deﬁne “nanotechnologies” and “nanomaterials” is an on-going process in the
Commission where also discussions at international level are taken into account. The Commission agrees on
the need to develop a deﬁnition, preferably at global level, to serve as a basis also for EU regulation and
implementing measures and instruments.
In the draft novel food Regulation, currently in the co-decision procedure, a draft deﬁnition of “engineered
nanomaterials” has been introduced at the request of the EP. It has been supported both by the EP and the
Council. According to this proposal, the proposed deﬁnition can be adapted, if necessary, taking into account
new scientiﬁc and technical developments. Once such deﬁnition is adopted, it may be applied in other ﬁelds
of food legislation, if necessary.
3. What efforts are being made to harmonize the use of definitions for nanotechnology across food, food additives and
food packaging legislation?
Concerning food additives legislation, a deﬁnition of nanomaterials is not included in the newRegulation (EC)
No 1333/2008. Independently from a nanomaterial deﬁnition, any signiﬁcant change in particle size, including
in the nanoscale, compared to the conventional food additive, would mean that the “new” food additive is
not covered by the previous safety evaluation and would need a new authorisation preceded by a new EFSA
evaluation. Similar provisions exist for food packaging legislation.
If and when deﬁnitions on “nanotechnologies” or “nanomaterials” are agreed in the Community, these could
be also used in the area of food additives and food packaging.
4. What advice does the Commission give to the industry on whether or not new products come under the novel food or
other relevant regulations, and what guidance is provided specifically on the risk assessment of foods containing
nanotechnologies?
In the ﬁrst instance the Member States should give advice to industry on whether a given product falls under
the novel food or other relevant regulation. In addition, in the area of novel food and food additives, the
Commission may decide under comitology on the legal status of a substance.
The Commission has requested EFSA to provide guidance on how the risk assessment of foods containing
engineered nanomaterials should be carried out and what data is required for such an assessment. EFSA’s
Scientiﬁc Committee adopted the ﬁrst opinion on nanotechnologies in food and feed on 11 February 2009
which was a general opinion on the approach to be taken when assessing nanomaterials.
In July 2009, the Commission has asked the EFSA to produce a detailed guidance document that addresses
the practical needs of the safety assessment of applications of nanoscience and nanotechnologies to food (food
additives, enzymes, ﬂavourings, food contact materials, novel foods), feed and pesticides.
The Commission has requested that the guidance document should spell out requirements directly usable in
the elaboration of applications. These requirements should specify the data and the information that the
applicant should provide to describe the relevant mechanisms of action and demonstrate the safety of these
food and feed applications. Furthermore this guidance should cover both the case when engineered
nanomaterials are added by themanufacturer andwhen the nanomaterials result from the production process.
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5. How does the Commission co-ordinate its work on nanotechnologies, both within the Commission and with Member
States? How is health and safety research co-ordinated, and what input does DG Sanco have into this process?
In order to ensure internal co-ordination on nanotechnology policy and action, the Commission has
established a permanent Inter-serviceGroupwhere all theGeneral-Directorates which have research or policy/
regulatory responsibilities for nanotechnology are represented. The Group meets regularly in order to review
developments and on-going activities, co-ordinate positions and decide how to organise collaboration onmore
speciﬁc initiatives. Meetings at Director-level take place when necessary in order to take policy decisions.
Commission services activities are framed by a Nanotechnology Action Plan adopted by the Commission
(Colle`ge) itself.
Co-ordinationwith theMember States takes place, as far as necessary, in a sectoral manner, within the existing
committees and working groups established within the framework of the various regulatory instruments. In
addition, ad-hoc meetings are organised to discuss horizontal issues of common interest. An example is the
meeting organised by Directorate General Health and Consumers on 17 March 2008 in order to discuss
collaboration on risk assessment with the experts of the Member States.
Health and Safety research on nanotechnology is co-ordinated both through the Inter-service Group
mentioned above, which may discuss research priorities, and via the usual inter-service consultation
procedures which apply to all steps of deﬁnition and execution of research programmes, including in particular
the establishment of themes for speciﬁc calls and the choice of projects. The diVerent General Directorates,
including DG Health and Consumers, provide their input at the occasion of the relevant inter-service
consultations.
6. How does DG Sanco ensure that health and safety research supports the regulatory needs of the Commission and
Member States?
As said above, the diVerent DGs, including DG Health and Consumers, provide their input at the occasion
of the relevant inter-service consultations. As a rule, discussions are initiated before the launch of the formal
inter-service consultation in the context of the Inter-service Group. This ensures that the regulatory needs of
DGs, including DG Health and Consumers, are taken into account when calls for proposals for research
projects are launched.
7. There have been several research gaps which have been identified in relation to health and safety testing of nanofoods
for example work on the gut, the behaviour of nanoparticles within a food matrix, or the long-term health effects of
nanoparticles in food. What work has been done across the European Union to close these gaps?
EFSA adopted its scientiﬁc opinion on “The Potential RisksArising fromNanoscience andNanotechnologies
on Food and Feed Safety” on 10 February 2009 and published it on 5 March 2009, which documents such
gaps and identiﬁes research priorities. One project presently under negotiation under the Framework
Programme for Research and Technological Development managed byDirectorate General Research and the
NanoGenoTox Joint Action recently approved under the Health and Consumers Programme managed by
SANCO should respectively address some aspects of the issue. More research on understanding the
interactions between nanomaterials and living organisms–and of nanoparticles in the gut, in particular–is
clearly needed and is being ﬂagged as a priority for funding at EU level, in EU Member States, and
internationally (please also see below).
8. How will the recommendations from the EFSA’s Scientific Opinion on the Potential Risks Arising from Nanoscience
and Nanotechnologies on Food and Feed Safety be taken forward?
EFSA concluded that the use of nanomaterials in food will be assessed on a case-by-case basis. This approach
is already in place for the authorisation of food additives, novel foods and plastic food contact materials.
Guidance documents on risk assessment are being reviewed for food additives and for food contact materials
and will also address nanotechnology aspects.
As mentioned earlier, the Commission will be asking for further advice from EFSA on data to be submitted
for case-by-case risk assessment also in other sectors.
EFSA has made on research recommendations especially as regards shortcomings of risk assessment in
relation to toxicokinetics, toxicity, exposure assessment and analytical methods. DG Health and Consumers
supports that these recommendations will be addressed in new calls for research proposals managed by DG
Research. Already in the end of 2008DGResearch launched a call relating to analytical methods. The decision
on which projects will be supported is on-going.
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9. What contribution might nanotechnologies make to wider food policy issues, such as sustainable farming and healthy
eating? Does the Commission have any initiatives to encourage such developments in nanotechnologies?
Analysts expect nanoscience and the nanotechnologies to make a number of valuable contributions to “wider
food policy issues, such as sustainable farming and healthy eating.” First, nanoscience empowered by
observational and analytical tools such as Atomic Force Microscopes (AFMs) and Transmission Electron
Microscopes (TEMs) and nanotechnology-enabled labs-on-a-chip advances our understanding of the
behaviour of food as it is manufactured and in storage, of the assimilation and digestion of food in the body,
of food intolerances, of individual dietary needs, etc. Addressing these issues, nanoscience and the
nanotechnologies oVer means to extract better essential nutrients, to monitor the production of food more
accurately, to increase the safety of the food chain–in particular thanks to sensors, to make foods more
digestible, to reduce or eliminate their allergenicity, to cater to individual dietary needs, etc.
Nanoscience and the nanotechnologies also exhibit great potential regarding ﬁltration and water puriﬁcation.
10. The EFSA opinion recommended that the Commission should monitor the current and potential future uses of
nanotechnologies in food—what measures are currently in place to allow the Commission to monitor the use of
nanotechnologies in the food sector?
In the area of Community competence pre-market approval is required before a new product is place on the
market. Food business operators have the responsibility to comply with the law. For example, if a food
additive is produced in the nanoscale it is considered as a new food additive which needs a new EFSA
evaluation and authorisation. The enforcement of the Community legislation and the control are the
competence of the Member States. In non-harmonised areas the Commission is investigating with food
business operators and Member States the use of nanotechnologies in the food sector. However, as there are
currently no validated and internationally recognised methods to detect nanomaterials in food, the possibility
for the Member States to control imported foods or foods sold on the internal market is limited. Research
programmes are underway to address analysis of nanomaterials in food.
11. The Food Standards Agency informed us that the commission will begin work on an EU inventory of nanomaterials
in 2009. Can you tell us what progress has been made with the inventory, and how “nano” will be defined? Will it be
a voluntary or mandatory register?
In the light of the debate in the EP on the Commission’s Communication on regulatory aspects of
nanomaterials, the Commission announced that it will present a report in 2011 providing general information
on the types and uses of nanomaterials, including safety aspects. The forthcoming report will be based on
results from diVerent sources, including research projects, regulatory reporting (eg REACH, Regulation on
Classiﬁcation, Labelling and Packaging) and scientiﬁc literature.
12. The Draft Report on Regulatory Aspects of Nanomaterials by the European Parliament Committee on the
Environment, Public Health and Food Safety calls for a clear regulatory framework on nanomaterials that fully
addresses the nature of potential safety problems relating to nanomaterials. Do you think that this is necessary?
In its response to the EP resolution of 24 April 2009 on regulatory aspects of nanomaterials, the Commission
indicated its intention to review relevant legislation and instruments of implementation, and report on this in
2011; regulatory change will be proposed where necessary.
13. Does the Commission feel that the control of imported foods containing nanoparticles is adequate across Member
States? How are imported foods assessed and monitored by the Commission?
In application of the subsidiarity principle, the enforcement and control of foods is the responsibility of the
Member States. Through the Rapid Alert System on Food and Feed, ﬁndings can be communicated to all
Member States. For example the Finnish border control oYcers stopped on diVerent occasions, a product that
contained vitamin C in nanoform and a product that contained nanosilver, both on the basis of the non-
compliance with the novel foods legislation. DG Health and Consumers has started a dialogue with the
Member States at technical level on how Member States control nanomaterials in food.
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14. Does the Commission have any plans to engage with the public on this issue, or to conduct research on public
perceptions of the use of nanotechnologies in the food sector? Is there any co-ordination of activities in this area between
Member States?
Involvement of citizens remains a priority for the Commission. It will pay particular attention to this aspect
in the follow-up to the Commission’s ﬁrst Nanotechnology Action Plan, and look into mechanisms to bring
the outcome of national initiatives to the European level, where issues require a follow-up at the European
level.
22 October 2009
Memorandum by the Food Additive and Ingredient Association
Introduction
The Food Additive and Ingredient Association (FAIA) represents the UK suppliers of Food Additives and
Ingredients—details of our association are appended to this Submission as an Annex.
We have been monitoring the development of nanotechnology for several years and as an innovative industry
we support its use. We believe that, as for all new technologies, there should be a robust safety assessment
covering both human health and environmental issues. It is our understanding that the existing regulatory
system can be used to ensure this.
The use of nanotechnology in the food additive area is extremely limited at the present time and is mainly in
the research phase. Consumer acceptance is essential if it is to develop further and this will only be achieved
if there is an open debate between all parties.
State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
For food additives and ingredients the technology oVers beneﬁts in the method of delivery. It will enable
improved coatings and encapsulating techniques.
In the area of packaging it can control gases and moisture thus reducing spoilage. This will enable higher
quality products to be produced and reduce wastage.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
We are not aware of any food ingredient or additive deliberately produced using this technology on the UK
market at the present time. There are a small number of ingredients which contain some nano size particles as
a result of the standard productionmethod, these have been on sale formany years andwe have not considered
them here.
We are aware of developments in the specialist supplement area where by the technology can be used to aid
absorption and to deliver products without adverse taste eVects.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
Like all scientiﬁc developments—nanotechnology will evolve over the years. The research is however often
company based and when at an early stage subject to conﬁdentiality and that FAIA would not have access to
theses details.
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What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
As in the previous question FAIA would not have access to this type of information.
What are the barriers to the development of new nano-products or processes in the food sector?
As stated in the introduction Consumer acceptance and hence use of the technology by the retailers and food
manufacturers is essential. In the past beneﬁcial technologies have been lost to industry due to their rejection
by the consumer. The consumer needs to understand the technology and appreciate the advantages it can bring
to them.
In addition the burdens placed on industry in bringing products to market need to be taken into account.
Whilst it has to be a prerequisite of sale that the safety of these products be demonstrated, a lengthy and
complex approval system will prevent all but the large manufacturers from entering the market.
Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials in the food sector? In which areas does our understanding need to be developed?
In recentmonths there have been a number of reports published on this issue including those of the SCENIHR
(Scientiﬁc Committee on Emerging and Newly identiﬁed Health Risks ) and the IRGC (International Risk
Governance Council). These set out the areas of potential uncertainty but do not always provide guidance or
oVer solutions.
Very recently the European Food Safety Authority (EFSA) has a published its opinion, which recognises that
the established international approach to risk assessment can be used but that there are many uncertainties
which require additional research and may require case by case considerations.
One area which has to be satisfactorily addressed is the Health and Safety aspects for workers handling
nanoparticles.
Is research funding into the health and safety implications of nanotechnologies and nanomaterials in the food sector
sufficient? Are current funding mechanisms fit for purpose?
Can current risk assessment frameworks within the food sector adequately assess the risks of exposure to nanotechnologies
and nanomaterials for consumers? If not, what amendments are necessary?
The aforementioned reports do make some recommendations in this area but further work is required.
Are the risks associated with the presence of naturally occurring nanomaterials in food products any different to those
relating to manufactured nanomaterials? Should both types of nanomaterials be treated the same for regulatory
purposes?
Where naturally occurring nanoparticles are used in additive preparations they have already been assessed as
part of the standard approval procedure. These are not considered by industry to be the products of
nanotechnology and should be treated in a diVerent manner.
Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
As new legislation is enacted Nanotechnology is one of the factors considered and the EU regulatory program
is extremely comprehensive.
Imported products also have to meet the EU requirements irrespective of their country of origin however we
are unable to comment on the enforcement of this legislation with respect to imports.
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How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
The Food Additive and Ingredients business takes its responsibilities in this area extremely seriously. In
addition the General Food Law ( EU Regulation 178/2002) requires Food Business operators to ensure that
all food products placed on the market are safe.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
FAIA is of the opinion that the EU Regulatory framework is able to adapt to encompass new developments.
In addition the existing Novel foods and packaging regulations are believed to already cover these products.
Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
We understand that there is an ongoing dialogue between the major players in this area.
Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
We believe public awareness to be very low, even in non food areas where there are products on the market
that confer consumer beneﬁts such as sun screens.
There are a number of initiatives in this area, such as that undertaken by the Responsible Nano Forum but
this is an important issue which requires greater emphasis.
How effective have the Government, industry and other stakeholders been in engaging and informing the public on these
issues? How can the public best be engaged in future?
FAIA is not aware of any speciﬁc Government Initiative in this area. Any public debate has been driven by
NGO’s. A more comprehensive program is needed but this can only take place when products are available—
see comments below.
The Association believes it is essential for Government to take the lead on a proactive public communication
programme. The application of new scientiﬁc developments to public beneﬁt has on previous occasions (such
as Genetic Modiﬁcation) been misrepresented by, or been the subject of biased reporting in, certain segments
of the popular press and broadcast media. We strongly believe that clear messages from Government must be
delivered to prevent such a hijacking of the popular press by the anti-science lobby on this occasion.
What lessons can be learned from public engagement activities that have taken place during the development of other
new technologies?
The Consumer needs to relate the technology to products which confer a direct beneﬁt to them and until such
foodstuVs are available on the market it will be diYcult to engage in a productive dialogue.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
Consumers should be provided with information about a product which is clear and factual. It should add to
their understanding of the product to be purchased and should not be misleading.
11 March 2009
Memorandum by Dr Chris Groves, ESRC Centre for Business Relationships, Accountability,
Sustainability and Society
1. What is the public perception of nanotechnologies and food?
It should be noted, ﬁrst of all, that available evidence tends to suggest that awareness of the existence of
nanotechnology in general has changed little from a low level a few years ago. For example, in 2006, 42 per
cent of Americans surveyed had not heard of nanotechnology (Peter D. Hart Research Associates 2006), with
this actually increasing to 49 per cent in 2008 (Peter D. Hart Research Associates 2008). As a result, evidence
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of public concerns about diVerent applications of nanotechnologies has generally only been available from
deliberative exercises which include extensive brieﬁng sessions to get participants “up to speed” with current
and potential future developments. As a result of such exercises, there is evidence that participants often
express signiﬁcant concern about food applications, particularly where nanomaterials are actually present
within foods rather than simply used within packaging materials. A survey for the WoodrowWilson Institute
indicates that only 7 per cent of Americans would buy nanofood now, with 29 per cent not wanting to buy it
at all, and 62 per cent wanting more information on risks and beneﬁts, vs 12 per cent, 73 per cent and 13 per
cent for food containers (Peter D. Hart Research Associates 2007). Evidence from research in Switzerland
suggests that people may be hesitant to buy foods which either contain nano-additives or use packaging which
contains nanomaterials or nanostructures (Siegrist, Cousin et al. 2007). But research has also indicated that
it is not so much “technologies” that are the subject of trust or mistrust, as the institutions whose are seen as
having the responsibility to ensure that technologies are applied in ways which produce beneﬁts and avoid
risks. Survey data from Germany also indicates that mistrust of regulators and industry could be particularly
signiﬁcant with respect to nanofoods, as low trust of these groups is correlated with high rates of rejection of
the use of nano-additives in food (Halliday 2007).
2. What do you think should be the aim of public engagement? Is the aim of public engagement activities to encourage the
dissemination of information and inform debate on the issue, or to help guide research agendas, and inform public policy?
While dissemination of information is a vital need, in relation to emerging technologies it is vital to avoid
projecting propositions about either risks or beneﬁts of prospective technological applications as surrounded
with certainty. The extent of uncertainties around both the EHS implications of speciﬁc applications and their
social implications should also form a central theme of public engagement. Whatever forms public
engagement activities take, they should, as far as possible, avoid positioning the public as merely a passive
recipient of information (whether said information concerns actual/potential hazards or beneﬁts). Research
suggests that the often ambivalent responses of publics in deliberative exercises circle aroundwhat they suspect
that scientists, business and regulators do not know and perhaps cannot know about the applications of
nanotechnology.With this inmind, engagement needs to focus on how to build consensus around the purposes
for which technologies can and should be used, and how much uncertainty (including, but not limited to,
known and determinate risks) society is collectively prepared to bear in pursuit of these ends. This implies that
engagement needs to have some degree of input into shaping research agendas and regulatory policy, even
extending to passing judgement on the social legitimacy or otherwise of a given application.
3. Submissions from Which? and others note the need for more government research on what the public think about the
issues surrounding nanotechnologies and food, and for more effective consumer engagement specifically focused on food.
Is the Government doing enough to understand public attitudes to food and engage the public on the issues surrounding
nanotechnologies and food?
In the UK, the issues surrounding nanotechnologies and food have to date been the subject of one of the
“Nanodialogue” events (funded mainly through OSI’s Sciencewise scheme, organised by Demos and the
University of Lancaster), which produced a report in 2007.More research is undoubtedly needed, but this also
needs to be framed within a more systematic and long-term vision for the purpose of public engagement (see
responses to Qs 4 and 6 below).
4. The Responsible Nanocode initiative has suggested the establishment of a permanent ‘‘Nano Commission’‘ style
organisation to engage stakeholders and advise government on issues. Do you support this suggestion?
No. First of all, there are questions to be asked about such an organisation’s remit, and whether it makes sense
to, once again, attribute a specious unity to “nano”. In operating, such a body would have to respect the vast
degree of diVerentiation between diVerent nanotechnologies and their applications. This is reﬂected in the
diVerent issues which aVect businesses who operate within distinct industry sectors. There will be diVerent
potential beneﬁts, risks and social concerns to consider for diVerent sectors. Consequently, it would at least
be necessary to organise diVerent working groups under the aegis of such a Commission. Further, research has
suggested issues of trust, risk and uncertainty, and social purposes are key to understanding how publics assess
technological applications—these are not unique to nanotechnologies. With synthetic biology already been
touted as “the next nanotechnology”, it would make more sense to talk of an organisation whose remit was
identiﬁed as eg “Emerging Technologies” or “Responsible Innovation, which would seek to situate broader
processes of technological development in the context of multi-stakeholder debates over social priorities.
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5. Is it primarily the responsibility of Government to run public engagement activities? What public engagement work
do you think industry should be undertaking, given that the BRASS Centre has noted that the industry have been
criticised over the lack of transparency regarding the presence of nanomaterials in food and food packaging?
While the Government will inevitably have an important coordinating, and to some extent, ﬁnancing role to
play, it is necessary for industry to assist in organising engagement programmes and events in conjunctionwith
public and academic partners. There is no reason to expect that individual businesses that are not already
involved in systematic proactive public engagement (mostly in the pharma sector, but also in some cases in the
chemical industry, eg BASF) to undertake extensive activities. For smaller companies, costs are prohibitive
and expertise lacking; for larger consumer-facing companies, such activities are often located “downstream”
in the product development process. Instead, the setting up of sector-speciﬁc collaborative bodies should be
undertaken (Leatherhead Food is, for example, already involved in such eVorts for the food sector). Such
eVorts may assist with overcoming the barriers to communication which have been evident in the food sector,
but also elsewhere. Such bodies would have an important role to play in eg engaging business in considering
the beneﬁts of wider stakeholder engagement.
6. What are the ways, practices or mechanisms to integrate public views into research strategies to allow public opinion
and concerns to inform future research priorities and directions? The EPSRC recently conducted some engagement
activities concerning nanotechnologies and healthcare. Do you think that this is an example of good practice?
In terms of its methodology and approach the EPSRC exercise appears to have beneﬁted from some of the
lessons presented in the NEG’s report from 2007 (with the extent of uncertainty about beneﬁts and risks being
at the forefront of the debates. However, it is not clear from the report available from the EPSRC website
(http://www.epsrc.ac.uk/ResearchFunding/Programmes/Nano/RC/ReportPublicDialogueNanotechHealthcare.htm)
how far participants were informed about the purpose of the engagement exercise and what inﬂuence their
participation might have on future research. Nonetheless, the speciﬁc application and case-study based
approach used here provides a useful example of how such studies may be undertaken. More broadly, while
individual exercises may represent examples of bad or good practice, it is arguably necessary to support
whatever deliberative exercises are undertaken with a clear vision and commitment to systematic and iterative
dialogue, with the possibility of allowing its focus to evolve as potential applications become more concrete.
If planned and undertaken under (for example) the aegis of something like a “Commission for Responsible
Innovation”, such a longer term process might look to move from providing input on research priorities (with
EHS and socio-economic research included alongside physical/life science work), to assessing the design of
individual applications, to providing guidance on what (if any) limits should be drawn around technological
development based on speciﬁc concerns (eg over the limits to privacy).
7. What are the best ways/practices mechanisms to integrate public views and concerns into policymaking (upstream
dialogue) to ensure that public opinion and concerns inform the regulatory framework?
See response to (6) above.
8. Do you think that products made using nanotechnologies or containing nanomaterials should be labelled at the point
of sale, and do you think that this will be useful to consumers?
Labelling may have a role in allowing customers to make informed choices about the products they purchase,
and may be seen as part of a response to moral issues which surround the marketing of products where
uncertainties surround the possibility of harmful eVects. However, reliance on labelling alone as a means of
providing information to consumers is highly problematic, as it shifts questions about the social acceptability
or legitimacy of a product very far downstream. Current public awareness of nanotechnologies is at low
enough a level that such a measure would arguably not give consumers much useful information. It is far more
important that industry and regulators should pursue openness and transparency through other avenues. If
such a strategy is pursued, it should be undertaken only with coordinated information support, eg a website
(funded perhaps by the EU) which outlines the state of the art with respect to EHS assessments of given
ingredients, with transparency about the current limits to knowledge (with the URL provided prominently on
the label). The objections made by cosmetics companies to the usefulness of labelling are in this respect quite
valid. There is, for example, a distinction to be made between eg products which contain fullerenes and ones
which contain nanoscale TiO2, but simply requiring all such products to carry a “nano” label would go against
the need to reﬂect the variousness of nanomaterials. Labelling has a vital role in setting the conditions for
informed consent, but it must be located carefully within an overall strategy which has better upstream
engagement for its basis.
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9. The Government has stated in its response to the Royal Commission of Environment Pollution’s report on Novel
Materials that it has now commissioned a pilot initiative “to provide public access to a balanced source of information
on nanotechnologies, including research, products and regulation”. The pilot will be based around an interactive website.
Do you think this would be useful? What additional information should be provided to consumers this way?
Yes (see response to Q.8 above). Part of the “balance” any such resource should manifest would have to
include, as mentioned previously, discussion of the current limits to knowledge. This would mean that the
website would have to be viewed as an aid to reﬂection about nanotechnologies (and technologies) more
widely, rather than simply being about “what nanotechnologies are”, what they “will” do to shape the future,
and “what risks there are”. It would have to be viewed as a resource for opening up and supporting critical
reﬂection, rather than a sort of nano FAQ. For example, to support such an approach, it would also arguably
be necessary to provide resources to illustrate how far, in other areas of our lives, we deal with diYcult-to-
assess risks and open uncertainties (to encourage people to think about why, for example, they are happy to
own and use a mobile phone despite continuing EHS uncertainties).
10. The FSA is currently considering developing a register of nano-derived foods and food contact materials. Do you
think such a register would be justifiable and helpful? Do you think it should be voluntary or mandatory?
Such a register would be useful, but only if (i) due consideration is given to how it can best be developed as
part of an integrated approach from government both to the dissemination of information and consultation,
and (ii) thought is given to how such a register can be supported to ensure wide compliance. In other words,
neither asking for submissions, nor requiring them, can by itself be a solution. It would arguably be necessary,
for example, to accompany such an initiativewith new institutional arrangements of the kindmentioned above
in response toQs 4, 5 and 6 above, in order to secure both public and industry assent. The nature of the register
itself would also need careful consideration: would it simply be a database of products and manufacturers, or
would it also provide information on characterisation of materials, the extent of relevant toxicology, and so
on? The more information that is required, the more costly compliance would be, which would of course
disincentivise both larger and smaller companies from pursuing food nanotechnologies. Any new regulatory
measures therefore need to be accompanied by reﬂection on how best compliance can be supported (with eg
incentives of access to expert advice, or even grants to aid compliance activities or seedmoney for collaborative
research between companies or between companies and academia). Should an adequately supported scheme
be made possible, then incentivised voluntary compliance followed by mandatory compliance after a suitable
period (eg two years) might be appropriate.
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Memorandum by the Dr Hadwen Trust for Humane Research
Introduction
The following comments on nanotechnologies and food are submitted by the Dr Hadwen Trust for Humane
Research.
The Dr Hadwen Trust is the UK’s leading medical research charity that funds and promotes exclusively non-
animal techniques to replace animal experiments. Our vital work beneﬁts humans with the development of
more relevant and reliable science whilst also beneﬁting laboratory animals. We believe that excellence in
medical research and testing can and should be pursued without animal experiments. Our organisation has
38 years’ experience of funding high-quality, peer-reviewed and innovative research aimed both at advancing
medical progress and replacing procedures on animals.
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Weverymuch appreciate the opportunity to comment on this paper, and believe that as a research organisation
dedicated to replacing animal tests (as well as the use of animals for other experimental purposes), our speciﬁc
scientiﬁc expertise in the ﬁelds of toxicology and human health are relevant to this topic.
We hope that our comments will be considered useful and constructive.
Dr Hadwen Trust Comments
1. The current uncertainties for risk assessment of nanotechnologies and their possible applications in the
food and feed area, as well as in other areas of use, arise due to the presently limiting information in
characterisation, detection and toxicology data. This view was also echoed in the recent scientiﬁc opinion
produced by the European Food Safety Authority on the potential risks arising from nanoscience and
nanotechnologies on food and feed safety.1 We are also aware of the lack of knowledge surrounding the
current usage of engineered nanomaterials (ENM) and therefore exposure to such products is an area requiring
immediate attention.
2. Whilst recognising that the currently used risk-assessment paradigm is applicable for ENM our concerns
regarding proposed guidance for risk assessment of ENM in food and feed area centre around the acceptance
of conventional toxicity testing methods to be used in identiﬁcation of ENM hazards. We are of the opinion
that additional issues speciﬁc to ENM need to be addressed due to the diVerent properties displayed by ENM
when compared to the bulk-form material,2 as well as the diVerences likely to arise when storage and
production methods are diVerent, and this will require use of new test methods as well as new criteria by which
the validity of such methods should be assessed. We also believe that assessment of ENM should be based on
a case-by-case approach and that current testing strategies are not adequate for ENM and do not represent
the most scientiﬁcally robust methods to employ. As with the cosmetics sector, it will be extremely diYcult in
the food and feed industry to characterise ENMand current guidelines do not speciﬁcally address ENM.Until
methods are in place to properly determine the behaviour of ENM in living organisms and make careful and
informed risk assessments, it is hard to see how regulators or companies are in a position to assert that ENM
in food or feed products are safe.
3. We feel that it is more appropriate in the case of nanomaterials for companies to take a precautionary
approach by avoiding exposing workers, consumers or the environment to these forms of substances. We do
not believe clear commercial and societal drives to produce and market the many new and exciting nano-
containing applications should overtake the fundamental requisite to protect human and environmental
health and safety.
4. In a recent scientiﬁc opinion produced by the European Food Safety Authority on the potential risks
arising from nanoscience and nanotechnologies on food and feed safety they concluded that engineered
nanomaterials should be assessed on a case-by-case basis. It was also concluded that current toxicological
methods may need methodological modiﬁcations which may include observing additional toxic eVects and
endpoints as well as developing, improving and validating in silico and in vitro test methodologies.3 We
wholly agree with the recommendations into furthering the currently limited knowledge and understanding of
ENM behaviour and toxicokinetics through in silico and in vitro methodologies, as suggested by EFSA.
However, we do not support the assumption that in vivo studies can bemodiﬁed so that they accurately predict
eVects of EMN on human health or the environment for reasons set out below.
For these reasons the Dr Hadwen Trust recommends that for non-essential, non-medical applications
(including cosmetic and household products, sporting equipment, textiles, food, feed and paints), ENM
manufacture and use is prohibited immediately until relevant non-animal and nano-speciﬁc safety testing and
risk assessment protocols are in place.
5. In a recent publication by the Royal Commission on Environmental Pollution it was acknowledged that
“…the scientiﬁc basis to fully understand all properties and risks of nanomaterials is not suYciently available
at this point in time”.4 In accordance with this the Dr Hadwen Trust further believes that animal testing of
nanomaterials is scientiﬁcally highly questionable. We would prefer to see an acknowledgement that, in
concordance with the mention that some speciﬁed in vitromethods are not yet validated, existing animal tests
are also not validated for this application (indeed, in some cases, existing animal tests have not been formally
validated to modern standards for any application), and greater emphasis to be placed on the development,
validation and use of non-animal test methods.
1 EFSA (2009) The potential risks arising from Nanoscience and Nanotechnologies on Food and Feed Safety. Scientiﬁc opinion of the
Scientiﬁc Committee.
2 SCENIHR (June 2007) The appropriateness of the risk assessment methodology in accordance with technical guidance documents
for new and existing substances for assessing the risks of nanomaterials.
3 EFSA (2009) The potential risks arising from Nanoscience and Nanotechnologies on Food and Feed Safety. Scientiﬁc opinion of the
Scientiﬁc Committee.
4 Royal Commission on Environmental Pollution (2008) Novel materials in the environment: the case of nanotechnology.
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6. Animal tests have limited value because of their inherent uncertainties.5 These include the diYculties of
extrapolating test data between species, genders and breeds of animals including humans (due to anatomical,
physiological, biochemical, metabolic and pharmacological diVerences). There are major uncertainties in
interpreting information from high-dose animal tests with single chemicals in ways that are relevant to low-
dose human exposures to chemical cocktails. There are also problems with mimicking human routes of
exposure in animal tests, and with scaling up from small animals with a short lifespan to larger humans who
may be exposed to chemicals over decades. Even for data-rich chemicals, these uncertainties often delay rather
than facilitiate regulatory decision-making, prolonging risks of damage to human health and the environment.
7. With a new ﬁeld such as nanomaterials, the full range of potential toxicities is not known. Using standard
animal toxicity tests, which are little more than “black box” methods, would risk overlooking novel unwanted
eVects. Human cell-based assays, in contrast, would allow the study and elucidation of a range of molecular
and cellular mechanisms of toxicity. For example, human cell culture assays can be used to monitor the
oxidative stress responses of cells exposed to nanoparticles.
8. There are a number of non-animal techniques currently being developed that represent a potential for
nanomaterial safety testing. For example, perfusable 3D cell-matrix chambers for testing nanoparticle
permeability and transport through tissues;6 and the HµREL device,7 which allows the toxicity of
nanomaterials to be tested on several cell types in a multi-chambered microchip with a microﬂuidic channel,
represent promising in vitro methods.
9. Human cell culture techniques have provided useful information on speciﬁc cellular responses to
nanomaterials by measuring chemical responses8 or responses at the DNA level using biomarkers and
genomic techniques.9 The feasibility of analysing in vitro nanomaterial activity in a general, systemic fashion
has also been demonstrated using a multidimensional proﬁling approach with multiple cell types and assays
reﬂecting diVerent aspects of cellular physiology.10 The data are then clustered using computational methods
to identify nanomaterials with similar patterns of biological activity across a broad sampling of cellular
contexts, as opposed to sampling from a single assay. This approach yields robust and detailed structure-
activity relationships. Additionally, interesting alternative tests are already being developed by EU-funded
Joint Research Centre projects such as Nanotox, which involves human cell culture techniques.
We hope that theHouse of Lords Select Committee will recommend that funding bemade available for further
research intended to result in creation of nano-speciﬁc non-animal test methods that have a clear regulatory
applicability. Sadly, it appears to be the case that some potentially useful research in this ﬁeld is not suYciently
targeted to meet genuine regulatory needs, and we would suggest that regulators or researchers with
knowledge of the regulatory environment are required partners in any publicly funded research intended to
produce new test methods.
10. In summary, human-relevant non-animal assays oVer several advantages: using human cells or sub-
cellular components they avoid species diVerences, and high-throughput systems allow the very rapid and cost-
eVective testing of multiple chemicals and multiple toxic endpoints, including novel ones. A moratorium
should be introduced on all non-essential uses of ENM. This will ensure the protection both of human health
and environmental safety, as well as fulﬁlling citizens’ wishes to maintain high animal welfare standards11 and
prohibit unnecessary laboratory animal use, especially with inhumane and misleading methods.
March 2009
Memorandum by Professor Geoffrey Hunt, St Mary’s University College, London
Certiﬁcant of the Institute of Risk Management, Professional Fellow of the Institute of Nanotechnology.
Currently engaged in two FP7 (EU) nanotechnology projects, and in BSI/CEN nanotechnology
standardisation initiatives. Co-author of book: Nanotechnology: Risk, Ethics & Law, Earthscan, London,
2006, 2008.
5 Langley, G (2004) Chemical Safety and Animal Testing: A Regulatory Smokescreen? BUAV report, 35pp. Report available from the
Dr Hadwen Trust.
6 Ng, C and Pun, SH (2007) A perfusable 3D cell-matrix tissue culture chamber for in situ evaluation of nanoparticle vehicle penetration
and transport. Biotechnology and Bioengineering 99:1490–1501.
7 www.hurelcorp.com
8 Lin W, Huang Y, Zhou X, Ma Y (2006) In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicology and Applied
Pharmacology 3, 252–259.
9 Papis E, Gornati R, Ponti J et al (2007) Gene expression in nanotoxicology: A search for biomarkers of exposure to cobalt particles
and ions. Nanotoxicology 1, 198–203.
10 Shaw SY, Westly EC, Pittet MJ et al (2008) Perturbational proﬁling of nanomaterial biologic activity. PNAS 105, 7387–7392.
11 http://ec.europa.eu/environment/chemicals/lab animals/pdf/results citizens.pd
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Submitted on an Individual Basis
As a specialist in risk and ethics I would simply like to point out the following:
At the nanoscale, technological innovation for applications faces unprecedented complexity and uncertainties
which impinge on all aspects of the nanotechnological research and development. This set of technologies has
the power to transform our industry, play a part in overcoming our severe environmental issues and create new
opportunities for recession-busting investment. It must be supported.
However, the real opportunities are in strong lightweight materials, industrial catalysts, energy, insulation,
electronics and the like. There are gains to be had in nanomaterials for storage of food, but nanotechnology
for food and drinks additives are a very low priority and too risky at our current state of knowledge. These
should be the last to develop once we have gained understanding of nanoscale interactivity in other areas of
theory and applications development.
To give some examples. It is not clear ….
(1) that nanoscale ceramics in PET (plastic) bottles, now widely in use, do not leach into the drink and
if they do what the long term consequences would be for consumer health;
(2) whether nanoscale additives such as Silver, useful as anti-pathogenic agents, are not cumulatively
toxic to humans; and
(3) whether the ability of some nanoparticles to pass through the protective biological barriers such as
the blood-brain barrier, the retinal barrier and the fetal (placental) barrier does not pose cumulative
risks for human health.
There are countless other questions that currently have no clear answer, but many “nano” food-related
products are already on the market without the innovative risk assessment which is appropriate for a new
technology with unknown risks, and without any requirement for the labelling which the public would expect.
In this situation it is incumbent on theUKgovernment to ensure that the food industry acts in accordance with
the Precautionary Principle, which it has signed up to (Commission of the European Communities, Brussels,
2.2.2000, COM [2000] 1 ﬁnal Communication from the Commission on the precautionary principle. Attached
[not printed].) It is not impossible that any future mass tort may rebound on the UK government.
12 May 2009
Memorandum by the Institute of Food Science and Technology
Introduction
1. IFST, the professional qualifying body of food scientists and technologists, has concerned itself with
nanotechnology for many years and has produced a comprehensive Information Statement.12
2. IFST supports the use of nanotechnology where it is/will be beneﬁcial to consumers in terms of product
safety, quality and economics; these beneﬁts may derive directly from food products themselves or from
indirect food applications such as those indicated in more detail below.
3. Where application of nanotechnologies results in changes to existing products or processes, and it may be
anticipated that new risks to human health or the environment may arise, IFST believes there will be a need
for an adequate safety assessment, on a case-by-case basis.
4. IFST believes that it is possible to adapt the existing regulatory system to deal with new scientiﬁc evidence
on engineered nanoparticles as necessary.
5. Nanoscience and nanotechnology are about understanding and engineering materials at the molecular or
atomic level, and generally concernmaterials with one ormore dimensions that are 10–100 nanometres or less.
In this size range, the behaviour of materials begins to change. Some foods already contain natural
nanoparticles but this submission will focus on engineered nanomaterials (ENMs).
6. Making materials smaller does not just lead to an increase in compactness, preciseness, or reﬁnement of
their structure and properties; it may lead to signiﬁcant changes in properties. Due to its small size, high
surface-to-mass ratio and surface reactivity, an ENM may have changed physico-chemical characteristics as
compared to the dissolved and micro/macroscale forms of the same substance. These changed characteristics
may have an important bearing both for potential beneﬁcial food-related uses by permitting applications that
might not otherwise be possible but, conversely, may also pose potential health and environmental risks.
12 Nanotechnology (2006): http://www.ifst.org/uploadedﬁles/cms/store/ATTACHMENTS/Nanotechnology.pdf
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7. Any new technology has risks. Policy should go beyond just beneﬁt/risk analysis. Where the potential
beneﬁts are signiﬁcant, it should identify the hazards and encourage research and measures to eliminate
unacceptable risks.
State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
8. Many traditional methods of processing or cooking foods work through modifying naturally-occurring
nanostructures within foods, or generating new nanostructures through tried and tested processes. Studies of
nanoscience of food materials will lead to better understanding of such processes, better selection of raw
materials and rational improvement in the processing of food materials.
9. The potential use of ENMs in food-related applications include: direct use of ENM ingredients and food
additives; nano-encapsulation of ﬂavours or other ingredients to give improved quality; improved emulsions
and emulsion delivery systems; new, highly-selective ﬁltration and separation techniques; use of packaging
materials containing ENMs to provide improved product protection from external degradation factors and
enable signiﬁcant weight reduction; ENM cleaning materials: ENM food contact surfaces: development of
new sensors for diagnostic use and to provide consumers with “real time” information about individual food
products. These uses could potentially lead to the design of foods to address obesity, target chronic diseases,
provide improved bioavailability of nutrients in foods, better food stability, reduced waste and improved food
hygiene and food safety.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
10. In the absence of a universal deﬁnition of “nanomaterials”, it is not possible to give a deﬁnitive answer to
this question. Not only is the deﬁnition related to particle size but it must also be considered in relation to the
proportion of a product’s size distribution that has to fall below, say, 100nm in order for the product to be
considered as “nano-containing”. We will restrict our comments to those techniques and applications where
the particle size has been deliberately engineered to possess properties and functional behaviour that diVer
from its conventional counterpart. We will not consider, therefore, the natural occurrence of nano-sized
particles such as in protein, fat or sugar molecules/micelles, or the presence of a very small tail of nano-sized
particles in the size distribution derived during conventional processing techniques such as emulsifying and
milling.
11. IFST is not directly involved in the manufacturing or sale of food products but we believe that there are
only a very limited number of food products currently on the market that contain ENM. We understand that
the use of packaging such as plastic bottles is increasing, as is the use of nano-separation/nano-ﬁltration.
Although there are several databases claiming to list products that contain nanoparticles, we would urge
caution over the use and interpretation of these. There are also products where the “marketing platform”
claims “nano” in various forms but, when examined more closely, many of these claims do not withstand
scientiﬁc scrutiny.
12. Amongst the small number of products on the UK/EU market that can be regarded as “genuine nano”
are a laminated plastic bottle which incorporates clay nanoparticles as a gas barrier; a food supplement using
a nano-encapsulated ingredient; a number of calcium/magnesium mineral ingredients and a form of silicon
dioxide in which a proportion falls into the nanoscale and which has long been used as an “anti-caking agent”
to facilitate the handling of powder mixes. We are aware of developments in oil-in-water and water-in-oil
emulsions comprising micelles, into which ingredients such as ﬁsh oils can be encapsulated (to avoid
unpleasant taste/smell); we understand a “light” oil (water in nano-emulsiﬁed droplets of oil) is also available,
but not as yet in the UK.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
13. IFST is not aware of near-commercial developments other than those covered by the principles of the
applications outlined above. Potentially, nano-sensors can be envisaged that would permit improved
monitoring and quality control throughout the supply chain, eg temperature control and other external
adverse inﬂuences. Targeted delivery of fertilisers, crop pesticides and veterinary medicines will also be
increasingly feasible.
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What is the current state of nanotechnologies research and development in the UK and how does it compare to research
being carried out in other countries?
14. Whilstmuch nanoscience and nanotechnology research is not speciﬁcally food-related, it may nevertheless
result in applications relevant to food. In the UK, the Institute of Food Research (IFR) is in the forefront,
together with the Universities of Leeds and Nottingham.
15. Many major food companies are monitoring or researching the potential beneﬁts of nanoscience in food.
Much of their work is covered by commercial conﬁdentiality; some are more willing to discuss this aspect of
their research than others, so it is diYcult to assess their precise level of interest and activity. Kraft Foods
started the ﬁrst nanotechnology laboratory in 1999 and its “Nanotek” consortium, involving 15 universities
worldwide and national research laboratories was established in 2000. Both Unilever and Nestle are known
to have research topics involving potential uses of nanotechnology. The food department at Rutgers
University inNewYork appointed what is believed to be the ﬁrst professor of food nanotechnology. However,
it is generally recognised that leaders in the ﬁeld are USA followed by Japan and China. The USA’s 21st
Century Nanotechnology Research and Development Act, passed in 2003, allocated approximately $3.7
billion from 2005–08, compared to an expenditure of $750 million in 2003. In Europe, current funding for
R&D in nanotechnology is believed to be around ƒ1 billion, much of which is funded through national and
regional programmes.
16. In the UK, following the joint Royal Society and Royal Academy of Engineering Report13 a Research
Co-ordinationGroupwas set up to focus research on regulatory gaps and needs, and to promote dialogue with
international organisations. Funding for research was to come from current allocation to government
departments and research councils. The reports of the group would be peer reviewed and placed in the public
domain. In March, 2008, a UK government statement by the Group was published14 and Periodic Reports
of this Group have appeared on the Defra website.15
17. Defra’s Government initiative on Micro—and Nano-Technology Manufacturing oVered £45 million in
support of commercial applications between 2003–09. FSA is funding two research projects to assess safety
implications of ENMs used in food packaging and as food ingredients or additives.
What are the barriers to the development of new nano-products or processes in the food sector?
18. This question falls more to those responsible for commercialisation of any developments but IFST can
identify a number of key issues. Consumer acceptability of nanotechnology products will be essential. There
is a long history of distrust by consumers when new technologies are applied to food and food processing (well
before BSE and GM, c.f. objections to pasteurisation and irradiation). This distrust is increased when the
technology is diYcult to understand and/or the beneﬁts to them, as consumers, are not immediately apparent.
It is further magniﬁed when the science and technology is the subject of alarmist and unbalanced media
coverage.
19. Conversely, IFST would highlight the “hype” promulgated by certain sectors that makes it diYcult to
distinguish between genuine nanotechnology applications and over-the-top advertising and which,
understandably, therefore breeds a degree of cynicism among consumers (see para 11). IFST strongly
advocates greater transparency and openness between all stakeholders so that all parties are better informed
about the technologies, their applications and, most importantly, their beneﬁts and potential risks. In the case
of the latter, it will be essential to be fully open and transparent.
20. We are aware of the regulatory hurdles faced by a business in bringing any genuinely novel product to the
EU market, the immense direct costs involved to develop and progress a submission and the indirect
commercial costs incurred by the lengthy timescales involved. Notwithstanding (and fully recognising) the
paramount need to establish consumer safety, these hurdles must be addressed if nanoscience and
nanotechnology are to play their part in a competitive economy.
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Health and Safety
What is the current state of scientific knowledge about the risks posed to consumers by the use of nanotechnologies and
nanomaterials? In which areas does understanding need to be developed?
21. We should always be alert to the potential risks associated with the applications of technologies, especially
new ones, and balance these against tangible beneﬁts that the technology will bring. However, any target of
zero risk is a false goal; there is no such thing in any aspect of life.
22. It cannot be generically assumed that a given ENM is safe based on previous risk assessments carried out
on the corresponding macro—or micro—substance. Individual ENMs need to be risk assessed, on a case-by-
case basis, as if they were novel substances. This will require more knowledge to characterise the ENM, more
toxicological data and knowledge of usage levels and likely exposure from possible applications and products.
While current toxicity-testing approaches used for conventional materials are a suitable starting point, their
adequacy to detect all aspects of potential toxicity of ENMs has yet to be established. Toxicity-testingmethods
may need methodological modiﬁcations.
23. SCENIHR16 and EFSA17 both describe the uncertainties regarding toxicology and potential new risks
associated with nanoscale materials. In view of the recently-revised framework of EU legislation on additives,
ﬂavourings etc and the ongoing review of the Novel Foods Regulation, it will be essential for clear guidance
to be available to all parties on how these uncertainties are to be addressed if/when innovative products are to
be evaluated prior to launch.
Can current risk assessment frameworks adequately assess the risks of exposure to nanotechnologies and nanomaterials
for consumers? If not, what amendments are necessary?
24. The recently-published SCENIHR Report and EFSA Opinion address this question.
Are risks associated with the presence of naturally-occurring nanomaterials any different to those relating to
manufactured nanomaterials? Should both be treated the same for regulatory purposes?
25. IFST has restricted this commentary to techniques and applications where the particle size has been
deliberately engineered to possess properties and functional behaviour that diVer from its conventional
counterpart. We do not consider as “nanotechnology”, therefore, natural occurrence of nano-sized particles
such as in protein, fat or sugar molecules/micelles, or the presence of a small tail of nano-sized particles in the
size distribution derived from conventional processing techniques.
26. We suggest that there are 3 types of nanomaterials: (i) naturally-occurring, (ii) adventitiously present in
conventional materials and (iii) deliberately engineered to confer novel properties (and, hence, might pose different
risks). We consider it is impossible to regulate/legislate for naturally-occurring materials such as are present in milk
and very difficult to legislate where the nanoscale material is adventitious; we question how such presence would be
defined/identified/quantified or legal constraints be enforced?
Regulatory Framework
Is the regulatory framework for nanotechnologies and nanomaterials fit for purpose? How well are imported food
products containing nanotechnologies and nanomaterials regulated?
27. The regulatory framework for nanotechnology was fully evaluated by both FSA18 (food applications)
and the European Commission19,20 (all applications). Both concluded that there were no major gaps but
identiﬁed shortfalls in the toxicological knowledge on which risk assessments would be based.
28. We generally concur with the ﬁndings of both FSA and the Commission, but have a number of additional
points which we describe below.
16 SCENIHR: Risk assessment of products of nanotechnologies, 19 January 2009: http://ec.europa.eu/health/ph risk/committees/
04 scenihr/docs/scenihr o 023.pdf
17 EFSA: Scientiﬁc Opinion on the Potential Risks Arising from Nanoscience and Nanotechnologies on Food and Feed Safety. The
EFSA Journal (2009) 958, 1-39. Available at: http://www.efsa.europa.eu/cs/BlobServer/Scientiﬁc Opinion/sc op ej958 nano en,
0.pdf?ssbinary%true
18 FSA Review of Potential Implications of Nanotechnologies for Regulations and Risk Assessment in relation to Food (2008): http://
www.food.gov.uk/multimedia/pdfs/nanoregreviewreport.pdf
19 COM(2008) 366: Commission Communication: Regulatory Aspects of Nanomaterials: http://eur-lex.europa.eu/LexUriServ/LexUri
Serv.do?uri%COM:2008:0366:FIN:EN:PDF
20 SEC(2008) 2036: Regulatory Aspects of Nanomaterials: Summary of legislation in relation to health, safety and environment aspects
of nanomaterials, regulatory research needs and related measures: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri%SEC:
2008:2036:FIN:EN:PDF
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29. It is currently very diYcult, if not impossible, to detect, measure or quantify ENMs in food matrices but
we are aware of work at NPL in this area. Although most agree that the existing regulatory structure is
applicable, without an appropriate enforcement regime underpinned with sampling and robust quantitative
analysis, written regulations are of limited value per se. It remains an open question how legal constraints on
the use of individual ENMs would be enforced (eg against imports) and, in particular, whether any such
enforcement regime that would, in all probability, have to be based on paper traceability would satisfy
consumers as to its rigour (c.f. GMO legislation).
30. Numerous Regulations and Directives provide a comprehensive regulatory framework but, in view of the
identiﬁed deﬁciencies in the toxicological science on which they depend, need to be supported by appropriate
guidance on their application to nanotechnologies and ENMs if they are to remain ﬁt for purpose. Although
most potential food-related uses of nanotechnologies are covered by some form of prior-approval process, the
legislation is potentially deﬁcient in apparently failing to distinguish ENMs of food-approved materials and
permitting their use, based on safety guidelines and evaluations produced for macroparticles. In the absence
of speciﬁc requirements for ENMs to be formally cleared as novel ingredients, food additives or food contact
materials, or to indicate their presence on food labels, replacement of already-permittedmacroscopicmaterials
with ENMs of the same chemical composition (albeit limited to date) appears to have been considered as a
simple formulation change.
31. The safety of novel foods and food ingredients is currently regulated by the EU Novel Foods Regulation
258/97.However, currentmechanismsmay not bewholly appropriate for ENMs, particularlywhere the parent
material already has an established history of food use. However, Regulation 258/97 is being revised and the
ongoing trialogue between the EC, EP and COREPER is seeking mutually-acceptable wording to bring
ENMs speciﬁcally into the revisedRegulation. It will then be essential to updateRecommendation 97/618/EC,
which provides the framework under which the scientiﬁc safety assessment is performed, to provide suitable
guidance to the risk assessors to take into account the extent of prior knowledge of the individual materials
and any uncertainties around their toxicology at the nanoscale.
32. ENMs intended for direct food additive use should be considered under the framework of Regulations
(EC) No 1331/2008 and 1333/2008 and be assessed either as novel additives or, where the macro-material is
already approved, through amendments to appropriate purity criteria. Under the general provisions of the
Regulations, safety of any new additive must be assessed by EFSA. However, it is not obligatory for the
Commission to seek EFSA’s opinion if amendments to the purity criteria or speciﬁcation of an existing
approved material are sought and the changes are not liable to have an eVect on human health. Recognised
deﬁciencies in current knowledge on the toxicology of nanomaterials may expose this as a potential loophole.
33. Where ENMs are being used in packaging and other food contact materials (FCM), this appears to rely on
clearance given to the use of the macroscopic material. The potential risk involved in the use of such materials
will be negligible if it can be shown that minimal leaching of ENMs into relevant foods will occur. Although
appropriate migration tests will have been done for FCM containingmacroscopic additives within the existing
regulatory framework, it is not clear whether additional tests have been carried out, related speciﬁcally to the
use of ENMs.
34. The use of ENMs in food contact materials should be assessed within Regulation 1935/2004. This applies
to all materials which are intended to come into contact with foodstuVs such as all types of packaging, bottles
(plastic and glass), cutlery, domestic appliances and even adhesives and inks for printing labels. It provides for
the establishment of a positive list of authorised substances, within speciﬁc legislation for each type of food
contact material, and requires that new substances for food contact use must be authorised, following
consideration by EFSA in respect of their potential toxicity. This Regulation will be of particular importance
if/when nanotechnology food processing surfaces are introduced more widely. Furthermore, this Regulation
also establishes requirements relating to the traceability of food contact materials from production to sale.
How effective is voluntary self-regulation either in the UK or EU or at an international level? What is the take up by
companies working in the food sector?
35. Defra has operated a voluntary notiﬁcation scheme but we understand uptake was limited.
Will current regulations be able adequately to control the next generation of nanotechnologies and nanomaterials?
36. Subject to the comments above, IFST considers the regulatory framework to be adequate but needing
updated supportive guidelines to address uncertain toxicology underpinning risk assessment.
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Is there any inter-governmental co-operation on regulations and standards? What lessons can be learned from
regulatory systems in other countries?
37. The European Commission Seventh Framework Programme has adopted the “Nanosciences and
Nanotechnologies: An Action Plan for Europe”. This deﬁnes a series of interconnected actions for the
immediate implementation of a safe, integrated and responsible strategy. Whilst not inter-governmental, BSI
developed several Publicly Available Speciﬁcations and Guidance Documents which we understand to be
under consideration for wider, international adoption by CEN.
Public Engagement and Consumer Information
What is the current level of public awareness of nanotechnologies, and the issues surrounding the use of nanotechnologies
and nanomaterials in the food sector? What is the public perception of the use of such technologies and materials?
38. The Royal Society and RAE Report commented that the general public had begun to voice concerns
about possible long-term side eVects associated with nanotechnology and stated the importance that, before
nanoparticles are used in foods and food-related materials, the relevant safety information is available within
the public domain. The report further commented that without a considered approach, there is a risk that
potential beneﬁts of nanotechnology might be lost if, as with genetic engineering, consumers feel the
technology is being imposed without warning, adequate perceived need or understanding of potential risks
and beneﬁts, and appropriate mechanisms for its control.
39. The Department of Innovation, Universities and Skills (DIUS) funded two “public engagement”
activities, Nanodialogues and Nanotechnology Engagement Group21,22 The Second UK Government
Research Report23 “Characterising the Potential Risk posed by Engineered Nanoparticles” (December, 2007)
claimed that “The UK is ahead of other countries in engaging the public in nanoscience. Few such initiatives
have taken place elsewhere”.
40. In 2008, the German Federal Institute for Risk Assessment24 stated: “As conﬁrmed by BfR surveys,
consumers expect nanotechnologies to simplify their daily lives. They mostly think of cleaning products,
impregnating agents and functional textiles. By contrast, they are more sceptical about nanoparticles in food.”
41. We note that the same lobby groups which stirred up unwarranted public concerns about the safety of
foods and ingredients derived from GM crops are attempting to do the same for nanotechnology.
Should consumers be provided with information on the use of nanotechnologies and nanomaterials in food products?
42. IFST strongly advocates greater transparency and openness between all stakeholders so that all parties
are better informed about the technologies, their applications and, most importantly, their beneﬁts and
potential risks. In the latter case, it will be essential to be fully open and transparent.
43. Current food labelling legislation speciﬁcally requires the names of ingredients to indicate details of their
physical condition or any treatment which they have undergone, where omission of such information could
mislead a purchaser. Whilst interpretation of this requirement is necessarily subjective, it could be argued that
the name of an ingredient used in ENM form should be qualiﬁed accordingly. The key legal counter-argument
would be whether the absence of such information could mislead a purchaser; IFST recognises that views on
this will be highly polarised.
44. Similarly, legislation requires food additives to be identiﬁed either by name or designated E-number. In
some cases, the E-number is sub-divided according to the origin and ﬁnal form of the additive. This scheme
has the potential, if required for consumer information, to be extended to encompass nanoscale additives.
Additional References not Quoted Above
Council for Science and Technology (2007); Nanosciences andNanotechnologies: A Review of Government’s
Progress on its Policy Commitments: http://www2.cst.gov.uk/cst/news/Files/nano review.pdf
EuropeanCommission(2005).Nanosciences andNanotechnologies: An action plan for Europe 2005–09. ftp://
ftp.cordis.lu/pub/nanotechnology/docs/nano action plan2005 en.pdf





24 German Federal Institute for Risk Assessment (2008): Nanotechnology in the focus of consumer health protection. http://
www.bfr.bund.de/cd/27077
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UK Government (2007); Second Research Report “Characterising the Potential Risks posed by Engineered
Nanoparticles” www.dius.gov.uk/policy/documents/statement-nanotechnologies.pdf
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Please see also the attached report from the observatoryNANO project, written by IoN staV. [Not printed]
State of the Science and its Current use in the Food Sector
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
Includes processes to encapsulate chemical compounds within foodstuVs (such as vitamins, minerals, ﬂavours,
aromas) and protect them from degradation before consumption (eg moisture, oxygen) or allow them to be
absorbed better by the gastro-intestinal tract. Such processes include nano emulsions, liposomes, solid lipid
nanoparticles. This has the beneﬁt of adding nutritional value to processed foods. Other advances are in
packaging where nanocomposite materials can increase gas barrier properties thus helping maintain the
desired environment of the packaged foodstuV (eg prevent ﬁzzy drinks going ﬂat, reduce the rate of food
spoilage). For food production, coatings of nanostructured materials can help prevent microbial build-up and
fouling of machinery.
What is the current state of the market for, and the use of, food products and food production processes involving
nanotechnologies or nanomaterials, either abroad or in the UK?
Packaging materials containing nanoclays are being used by a number of companies, including Miller
Brewing, for bottles, coatings on paperboard, and ﬁlms. Such materials are manufactured by companies such
as Bayer (Durethan), Honeywell (Aegis), and Nanocor (Imperm). There are a number of companies
manufacturing delivery systems for nutrients such as Aquanova (based in Germany—most of the others are
outside the EU). Several companies within the EU manufacture nanostructured coatings and ﬁltration
systems that could have applications in the food processing industry, including ItN Nanovation, SuSoS AG,
Few Chemicals GmbH, Sarastro GmbH, NanoGate and Aquamarijn Micro Filtration bv.
What might the “next-generation” of nanotechnologies and nanomaterials look like? How might they be applied in the
food sector, and when might they enter the market?
There is much research into next generation biodegradable polymers for packaging purposes. The rationale
is to usematerials that would normally be regarded as waste (eg stalks from cereal plants), process the cellulose
into nanostructured material and combine with other materials such as nanoclays to provide a robust
composite that can be composted at the end of its useful life. For foodstuVs we will see evermore ingenious
emulsion technologies, allowing multiple nutrients/minerals to be stably incorporated in diVerent foodstuVs
according to their solubility, and we will see lower fat, lower salt and lower sugar processed foods, that from
the consumer’s perspective will still taste the same. These could be expected on the market within the next
10–15 years.
What is the current state of research and development in the UK regarding nanotechnologies and nanomaterials which
have or may have an application within the food sector? How does it compare to research and development in other
countries?
With the exception of Unilever and Leatherhead Food International, most industrial research on
nanotechnology applications in agrifood takes place outside theUK, egGermany (Bayer, BASF, Evonik). The
hubs of academic research are Netherlands (Wageningen, NIZO) and US (Uni Mass, Rutgers, Rensselaer,
Georgia Tech). In the UK we’ve have excellent polymer (eg University of SheYeld) and sensor research (eg
University of Strathclyde) for food applications.
What are the barriers to the development of new nano-products or processes in the food sector?
For food additives, the main barrier is consumer acceptance. The reality is that we all rely (at least partly) on
processed foodstuVs. Nanotechnology applications can help increase shelf-life of these (while reducing the use
of preservatives) and increase nutritional value.
March 2009
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Memorandum by the London Centre for Nanotechnology
REPORT WRITTEN BY DR THIERRY BONTOUX
Introduction
This white paper is the response of the London Centre for Nanotechnology (LCN) to the Call for Evidence
sent by the sub-committee chaired by Lord Krebs and appointed by the House of Lords Science and
Technology Committee on Nanotechnology and Food. The purpose of this paper is to demonstrate that
nanotechnology is not new in food processing. It will also list new products used in food production and
describe some of the major applications of nanotechnology in packaging.
General Background
The London Centre for Nanotechnology is a UK-based, multidisciplinary research centre bridging the
physical and biomedical sciences. It has a management structure that allows for a clear focus on exploitation
and commercialisation. It brings together two world-leading institutions in nanotechnology, namely
University College London and Imperial College London, in a unique operating model that accesses the
combined skills of multiple departments, including medicine, chemistry, physics, electrical and electronic
engineering, biochemical engineering, materials and earth sciences, and two leading business centres.
The LCN building in Bloomsbury, opened oYcially in November 2006, is the only nanotechnology focussed
building at the heart of a major metropolis. The facility comprises investments of £14 million for the building
and £7 million for equipment and provides a complete range of interdisciplinary tools for bio—and non-bio
nanotechnology, including senior staV with clinical expertise. A £2.4 million grant from EPSRC enabled the
procurement of a scanning transmission electron microscope—the ﬁrst of its kind in the UK and one of few
in the world—now installed on the Imperial College site in South Kensington.
Operating funds come from a range of private and public sector sources, including the UK research councils,
the EU, private companies such as STS/Sumitomo, and charities such as the Wolfson and Gatsby trusts.
Nonetheless, UK government remains the most important funding source, and the LCN has been able to win
large numbers of contracts, with values ranging between several thousand and several million pounds. For
example, the LCNwon a Science and Innovation award (£5.6M) to develop newnanometrology capabilities—
key for the engineering and quality assurance needed for nanotechnology to achieve its commercial promise—
on behalf of the UK.
LCN is organised around three application themes:
— Information Technology: The computing and communications needs of society continue to grow and
have become increasingly complex. Approaches based on current technology are limited and a variety
of new methods are being sought by LCN staV to circumvent these limitations, applying
nanotechnology-driven paradigms such as quantum computing and spintronics.
— Healthcare: Society’s need for healthcare continues to grow. Expenditure on healthcare in Europe is
typically the largest item on a nation’s balance sheet. LCN is uniquely placed; it has access to a vast
bio-medical expertise, enabling new paradigms in healthcare. Under development are specialised
sensors and novel cancer-diagnosis systems, as well as new insights into cellular biophysics and novel
research techniques.
— Planet Care: Climate change is probably the single largest threat to society in the 21st century. The
LCN uses its expertise ranging from biology to chemistry and materials science to conduct research
in novel photovoltaics, new approaches to exploring current energy supplies, new materials for the
nuclear industry and to store eYcient hydrogen storage at room temperature.
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What is Nanotechnology
Figure 1





































There is often a misunderstanding about what nanotechnology is. The general idea is that nanotechnology
refers to novel engineered “nano” structures that never existed before in nature. Because it has only recently
been branded as a science of its own, it generates both fear and fascination. We should consider how
commercial IT brands use the term “nano” as a synonym of positive progress and how, on the opposite side,
the cosmetic and the food industries often fear to speak about it. The commercial fascination is easily
symbolized by the “IPod Nano”, and a simple search on Internet will show many products using “nano” to
brand high-tech electronics. The fear of nanotechnology can hardly be better described thanwith respect to the
food industry. The public has lost trust in the regulatory authorities in general as well as in the food industry. It
is fortiﬁed in its opinion by rare but dramatic events such as the baby powdermilk poisoning last year inChina.
Even if these two diVerent perceptions of nanotechnology seem widely divergent, they have one thing in
common: they see nanotechnology as a new science providing completely new products to the market, and it
is human nature to consider that what is new is frightening. Activists try to mobilise public opinion against
novel technology while the food industry conceals its use of nanotechnology to avoid alarming its clients. A
rational approach that goes beyond stereotypical perceptions is needed to deal with the real meaning of nano-
science and technology. In particular, nanotechnology does not necessarily imply nano-engineered particles.
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Figure 2
MOLECULAR ATPASE TURBINES VISUALISED AT THE NANSCALE
COURTESY STAHLBERG, H. ET AL.
We start by considering what “Small” is. Figure 1 compares the diVerent scales of usual objects and links them
to the nano-scale. There is a clear borderline betweenmacro/micro scale and “nano” objects. This demarcation
is the wavelength of visible light. Until the 1980s, scientists used either optical or electron microscopes to
obtain direct images of the small-scale world. The latter microscopes could only produce images of small
structures, usually in vacuum and generally destroying them in the process. The optical microscope however
could lead to “in vivo” studies but could not “see” structures smaller than the wavelength of the light used to
illuminate the samples. This is the origin of the 1µmboundary between traditional and nanoscale science. This
limit was only overcome with the invention of the Scanning Tunnelling Microscope (STM) in the 1980s. The
STM gave scientists and engineers the means to observe conductive surfaces at the atomic scale. They started
to manipulate atoms one by one and develop “micro” electronics that soon became “nano” electronics.
However, the main disadvantage of the STM is that it uses an induced current between the scanned surface
and its “optics”. The later invention of the Atomic Force Microscope (AFM) really made the diVerence and
launched nanotechnology in the form we know it today. It allows us to “see” objects smaller than a micron
without damage. It uses a pin to probe the surface of samples in a similar way as a blind person can “see” or
read using his hands. The AFM found many applications in electronics and in biology. It gave birth to the
modern understanding of biological nanostructures, enabling us to see cells and sub-cellular structures with
unprecedented resolution (Figure 2).
Figure 3
HOME-BUILT AFM AT THE LCN
COURTESY BART HOOGENBOOM
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Today, there are many other types of equipment used to study nano structures, but none has had an impact
comparable to that of the AFM. They all have in common that they are used across disciplines, in
nanoelectronics, in chemistry and biology. Nanotechnology is not one branch of science, but a platform
technology that gathers tools enabling scientists to study and manipulate objects below the 1µm optical limit.
There is thus not one nanotechnology but a full range of nanotechnologies, comparable to the extremely broad
meaning of the concept “engineering”.
It has been rather common to associate electronics, genetics, and cell biology with nanotechnology, because
during the last few years it has led to incredible developments in those ﬁelds. However, well before the word
nanotechnologywas even invented, there were other disciplines such as Chemistry, Biochemistry, Virology and
CondensedMatter Physics (physics of solids and liquids) that had already dealt with nanoscale structures but
were not capable of directly and easily seeing the objects they studied. In other words the concept of
nanotechnology is new in everyone’s minds but the studies and its applications are as old as modern science.
Figure 4
A CHOCOLATE MELANGER—PROBABLY ONE OF THE OLDEST NANOTOOL IN FOOD
PROCESSING.
COURTESY SANJAY ACHARYA
One illustration can be found in what most of us consider as basic and very traditional food: chocolate. The
recipe to achieve the transformation of cocoa seeds into chocolate is certainly one of the oldest processes based
on nanotechnology. It aims to create small crystals of cocoa of only one speciﬁc type andwhose building blocks
measure approximately 6.5 nanometres across. The online encyclopaedia Wikipedia describes the process in
the following wayi:
“Making chocolate considered ‘good’ is about forming as many type V crystals as possible. This provides
the best appearance and texture and creates the most stable crystals so the texture and appearance will not
degrade over time. To accomplish this, the temperature is carefully manipulated during the crystallization.
Generally, the chocolate is ﬁrst heated to 45 )C(115 )F) tomelt all six forms of crystals. Next, the chocolate
is cooled to about 27 )C (80 )F), which will allow crystal types IV and V to form. At this temperature, the
chocolate is agitated to create many small crystal ‘seeds’ which will serve as nuclei to create small crystals
in the chocolate. The chocolate is then heated to about 31 )C (88 )F) to eliminate any type IV crystals,
leaving just type V. After this point, any excessive heating of the chocolate will destroy the temper and this
process will have to be repeated. However, there are other methods of chocolate tempering used. The most
common variant is introducing already tempered, solid ‘seed’ chocolate.
Two classic ways of manually tempering chocolate are:
— Working the molten chocolate on a heat-absorbing surface, such as a stone slab, until thickening
indicates the presence of suYcient crystal ‘seeds’; the chocolate is then gently warmed to working
temperature.
— Stirring solid chocolate into molten chocolate to ‘inoculate’ the liquid chocolate with crystals (this
method uses the already formed crystal of the solid chocolate to ‘seed’ the molten chocolate).”
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We chose to give this example only to demonstrate that nanotechnology is not novel as such and that
nanostructures are not necessarily as dangerous or frightening as some members of the public believe. On the
other hand, not all food engineering based on nanotechnology is necessarily as safe as manufacturing
chocolate. The next chapter will look into the actual use of nanotechnology in food production.
Nanotechnology in our foods today
To underline that nanotechnology does not refer to only one speciﬁc type of technology, we shall use
“nanotechnologies” from now on instead of “nanotechnology”. Nanotechnologies can be found in the food
manufacturing processes at diVerent levels:
— Nanotechnologies can be incorporated into the food itself to create speciﬁc properties.
— Nanotechnologies can be used in packaging: several examples of such products are already available
on the market.
— Nanotechnologies can be used to develop new materials and methods to manipulate and process
foods, but this will not be treated in this report.
Nanotechnologies in foods
Figure 5
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The ﬁrst important point is that nanotechnologies have been used in food manufacturing for a long time
without being named as such. One example is the addition of emulsiﬁer to traditional manufacturing
processes. For instance, to cut costs and meet consumer requirements, the food industry needs to reduce the
quantity of fat and cream in the manufacturing processes of dairy product. Ice-creams need to be made with
less cream, and since water is much less expensive than cream, the simple idea is to replace cream by water.
However, ice creams made from water alone have never been considered as “delicatessen”; even sorbets need
cream for unctuousness. This is where nanotechnologies come into action, even though ice-creams are not
identiﬁed as nanofoods. Emulsiﬁers, such as lecithin, are used to mix products that previously needed cream
to thicken.
Ice-cream is a complex nanostructure. It is at the same time a foam and an emulsion: it can be simpliﬁed as
an emulsion of frozen water and air meshed into a foam of fat. The introduction of emulsiﬁers has had many
positive eVects on the structure and the conservation of the frozen dairy product. Emulsiﬁers are added to ice
creams to replace the milk proteins found in cream, to actually reduce the stability of the fat emulsion, by
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placing proteins on the fat globules surface, leading to thinner membranes more prone to coalescence during
whipping. When the mix is subjected to the whipping action of the barrel freezer, the fat emulsion begins to
partially break down and the fat globules begin to ﬂocculate or destabiliseii. The air bubbles which are being
beaten into the mix are stabilised by this partially coalesced fat. If emulsiﬁers were not added, the fat globules
would resist this coalescing, the air bubbles would not be properly stabilized and the ice creamwould not have
the same smooth texture.
Beside the bulk introduction of chemical in the manufacturing process, there is intense research on the
nanostructures of traditional food, to understand and optimise the stability of the product while further
reducing their costs. Today’s ice-creams are barely made with cream but nearly exclusively with water, thanks
to chemical/nano-engineering. The same principle applies wherever emulsiﬁers are used. In general, nanoscale
studies can contribute to the creation of better and cheaper food. Think of chocolate mousses that remain
stable in time, even after days opened or kept outside of a refrigerator.We should alsomention a famous brand
of chocolate sweets which “do not melt in the hand but only in the mouth”, and tomato ketchup sauces that,
although being made only from natural ingredients, can stay fresh for up to 8 weeks once opened, and for
several months if unopened. Any normal tomato pure´e would encounter phase dissociation only hours after
processing. The only way to preserve those sauces for such a long time is by engineering their inner structures
at a molecular level (ie nanoscale). Here again, the understanding of what happens at the nanometre scale is
key to conservation and enhancement of gustative properties. Although being simple and basic foods, they all
are the result of chemical and molecular engineering and, therefore could all be considered as “nanofoods”.
Nanotechnologies can also be used to protect and deliver essential nutrients. Food processing relies on
techniques that potentially degrade nutrients such as vitamins. They need to be protected from heat and
acidity. Encapsulation is a reliable way to do so, also enabling faster absorption by the organism. It is used
in two types of manufacturing: food enrichmentiii and food supplements. Encapsulation concerns vitamins,
preservatives and enzymes, but there are many new candidates for encapsulation, sometimes thousands of
times smaller than living cells. For instance, Omega-3 additives are enclosed in nano-capsules of 30–40 nm
to enhance their absorption by the organism and thus their eVectiveness. TheWoodrowWilson International
Centeriv for Scholars maintains a list of products available to the general public and openly advertised as
containing nanostructure or issued from nanotechnology. It shows that while food manufacturers have a
certain reluctance to speak about nanotechnology, the sport food supplement industry is much more open
about it.
In both cases, encapsulation presents many beneﬁts for the industry and possibly for the general public.
Nanocapsules can be incorporated in food to deliver nutrients while being rapidly assimilated by the body
because of their size. The nutrient properties of food are better preserved because they are undamaged by the
digestive process. The NovaSOL technology from the German ingredients ﬁrm Aquanovav is used to
encapsulate vitamins A, D, E, K, ß-carotene, ascorbic acid, Omega3 fatty acid, lipoic acid, and lutein. The
NovaSOL technology involves encapsulation of the ingredients in artiﬁcial micellae whichmeasure just 30 nm,
imitating the absorption process of nutrients by the human organism. Using the same technology, Aquanova
has also found a way to extend the use of the preservatives sorbic and benzoic acid in foods with a high pH
using its NovaSOL nanotechnology. Sorbic and benzoic acid are commonly used as preservatives, but until
now their usefulness has been limited to themore acidic end of the pH scale, since performance decreases above
pH4 and above pH6 they are almost totally ineVective. In the case of sorbic and benzoic acid, encapsulation
enables pH-independent performance through the whole acidity scale. Thus, whereas in the past the
preservatives were only suitable for use in sour-tasting products, they can now be used to protect against
microbial spoilage in milder tasting products as well.




Another example of an encapsulated supplement is DriphormEvi, a dry powder form of ﬁsh oil produced by
Nu-Mega. This Australian-based company advertises numerous other potential applications for their
patented encapsulation technology:
— Infant nutrition—infant formulas and moist solid preparations.
— Bread and bakery products.
— Cereals—muesli bars, breakfast products.
— Dairy—frozen confection, yoghurts, fromage frais, milk.
— Supplements—capsules, dietary products.
— Beverages and juices.
— Animal Feeds.
— Fruit.
Nu-Mega recommends encapsulation because nano-size dispersions, emulsions and ﬁlled micellae are not
subject to sedimentation, resulting in better product life span and storage. As their size is much smaller than
the wavelength of light, they can be incorporated in clear and transparent foods without causing clouding.
Aquanova and Nu-Mega are no exceptions. The European industry is very active in this ﬁeld. Groups like
Nestle´, DANONE, Kraft, BASF, Bayer, Associated British Foods invest millions in research linked to
nanotechnologyvii. It is likely that the result of such research and investment will be used throughout the food
production chain. In fact, there is already evidence of such practices in the usage of Transglutaminase (TGase).
TGase is an enzyme that acts as a catalyst to promote cross-linking between proteins. It has a signiﬁcant
impact on properties of proteins such as: ability to gel, thermal stability and water holding capacity; thereby
improving the functional characteristics of foods such as elasticity, binding ability, mouth feel, ﬂavour, texture,
and so on. This enzyme is very often used in non-dairy products and mousses, foams and jellies in association
with Na-caseinate.
The number of examples of nanotechnologies used for food processing could be extended over several pages.
Most of them would concern modiﬁcations of molecular and protein properties, and some are obviously
linked to nanoengineering, like Nanocapsules. It is not the purpose of this report to give an exhaustive list of
the application of nanotechnologies. However, we have demonstrated that nanotechnology in food is not
science-ﬁction but a reality, and that there is not one type of nanotechnology applicable to the food industry,
but several diVerent approaches derived from traditional physics, molecular chemistry and biology.
Nanotechnology & Packaging
Food packaging has three aims:
— To contain.
— To protect.
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— To inform—this will not be treated here because it is not directly linked with foods and toxicology.
There is no such thing as simple packaging today. Traditional materials such as paper and wood disappeared
long ago to be replaced by more convenient materials such as plastics. The same is happening again now, but
less visibly due to the similarity in appearance of the new materials with plain plastics.
Contain & Protect
The primary purpose of packaging has always been to contain raw or processed food. This has not changed
today, but the search for proﬁtability and mass production has led to the development of increasingly
sophisticated technology. This involves lighter, stronger, and smarter materials that are cheaper to produce.
For instance, new materials can now provide longer shelf life by improving the barrier function of food
packaging, reducing gas and moisture exchange and limiting exposure to UV light. Although those new
materials look like many of their predecessors, most of them are the direct consequence of “nanotechnology”









The ﬁrst evidence we shall give is used by everyone and is considered as a must-have in any kitchen: the Cling
Films. Although the original ﬁlm was invented by accident in 1953, long before the term “nanotechnology”
existed, what makes them so popular is a direct consequence of a nanoscale phenomenon.
Cling ﬁlms are made of polyvinylidene chloride (PVC). It forms a remarkable barrier against water, oxygen
and aromas. It has superior chemical resistance to alkalis and acids, and is insoluble in oil and organic solvents.
It has very low moisture retention and is impervious to mould, bacteria, and insects. Therefore, it has been
widely used in all food industries for packaging and is most commonly employed in wrapping ﬁlms of 100µm
thickness. Non-PVC alternatives are now being sold, because of the risk transfer of plasticisers from PVC into
food. It is indeed problematic for PVC to achieve full polymerization of the material, which could contain
remnants of the vinyl chloride monomer. To achieve the full polymerisation and to develop new and better
materials, engineers need to understand the dynamic of polymerisation, which involves studies at a molecular
scale. In July, 2004 the composition of Cling ﬁlms was changed to Low Density Polyethylene (LDPE). SC
JohnsonE claimed that this change was the result of an initiative to look for more sustainable and
environmentally acceptable plastic. The new ﬁlm does not contain chlorine. However, LDPE does not possess
the same qualities as barrier to oxygen, aroma, and ﬂavour molecules that vinylidene chloride copolymers do,
making the new product a lower quality plastic wrap, as it is not as useful in protecting from spoilage or
ﬂavour loss.
In daily household practice, the ﬁlms are interesting for their physical properties that originate from nanoscale
behaviours, although most people never realise it. The “clinging” property is not due to any coating or glue
sprayed onto the ﬁlm, but to the molecular attraction between two layers of ﬁlms. The chains of polymers try
to bind together between layers when wrapped one against the other. The second interesting property of such
ﬁlms is their ability to block oxygen from reaching the foods. The chains of polymers form a mesh within the
material, tight enough to block the way to molecules of gas. Hence, when optimising the manufacturing and
changing the composition of the ﬁlms, engineers have studied the nanoscale properties and structures of the
chains of polymers, using the nanotechnology platform, although being recognised as chemistry by the public.
DurethanE ﬁlms are another example of amaterial using nanotechnology and openly advertised as such. These
ﬁlms are manufactured by Bayer and have nano silicate platelets incorporated into a polyamide (PA) matrix.
Contrary to the PVC ﬁlms, the PA ﬁlms are not as impervious to oxygen but are less hazardous to human
health than PVCs. They tend to be preferred for industrial applications for this reason. Silicates are simple
nanoscale clay structures, the same particles used in toothpaste or gum and gel manufacturing. The
Nanoparticles of clay interact in various ways with the plastic ﬁlm. They act as nuclei for crystallisation of the
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polymer and improve the microstructure of the ﬁlm. They also form a labyrinth of nano layers that O2
molecules have to go through before reaching the foods packed inside. The molecules are forced to make long
detours and their penetration is thus slowed down.
Similar usage of clay nanoparticles has been developed byNanocor to create plastic bottles that do not interact
with alcohol stored in beer. This new plastic development resulted in extending the shelf life of the packed beers
up to six months by minimising the loss of carbon dioxide and impeding the penetration of oxygen into the
beverage.
Mitsubishi Gas Chemical (MGC) and Honeywell Specialty Polymers both are using Nanocor’s nanoclays in
nylons as barrier layers in multi-layer PET bottles and ﬁlms for food packaging. MGC’s MXD6 nylon
nanocomposite, called Imperm N, is commercially used in Europe in multi-layer PET bottles for beer and
other alcoholic beveragesviii. It is also being used for small carbonated soft-drink bottles, such as for PerrierE
carbonated water.
Honeywell aimed its Aegis nylon 6 nanocomposites initially at PET beer bottles. In late 2003, a version
containing an oxygen scavenger made a commercial splash with the introduction of the 1.6-liter Hite Pitcher
beer bottle fromHite Brewery Co. in SouthKorea. Aegis is the barrier layer in this three-layer structure, which
is said to provide a 26-week shelf lifeix.
Honeywell aims at using other Aegis nano-composites grades (without oxygen scavenger) as replacements for
EVOH25 in ﬁlms and pouches. Such grades are reportedly lower in cost than EVOH, provide a better barrier,
and also have better puncture resistance and good clarity. (Because of their size, nano-particles do not interfere
with light transmission.)
To conclude this list of actual application of nano-composites designed for food packaging, we mention
DuPontDeNemours, which has released a new additive to plastic ﬁlms “DuPont Light Stabilizer 210” aiming
to reduce damaged by UV radiation in transparent packagingx. It contains titanium dioxide with better
properties than benzophenone and benzotriazole. In addition titanium dioxide is not prone to migration
according to the manufacturer.
25 Ethylene Vinyl Alcohol, commonly abbreviated EVOH, is a formal copolymer of ethylene and vinyl alcohol.
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Nano-based materials have also been introduced for antimicrobial purposes. There are several products on
the market nano-engineered to prevent bacteria to develop. They range from refrigerators sold by LG,
Daewoo and Samsung, to kitchenware (made for example by Nano Care Technology Ltd), but also including
containers like CamelbakE or baby cupsmade by BabyDreamE. This is only a short list and the nomenclature
could be extended far beyond the few brands we have listed here. They all incorporate nanocrystals speciﬁcally
identiﬁed for their antibacterial properties. There are four main diVerent type of substances used:
— Silver: Silver ions and silver compounds show a toxic eVect on some bacteria, viruses, algae and fungi,
this eVect is shared with heavy metals like lead or mercury, but without the high toxicity to humans
that are normally associated with these other materials. Silver has been used since antiquity in
medicine to cure wounds without any side eVects; silver compounds were used to prevent infections
during World War I, before the advent of antibiotics. Silver nitrate solution was a standard of care
but was largely replaced by silver sulfadiazine cream (SSD Cream)xi. SSD creams became the
“standard” of care for the antibacterial and antibiotic treatment of serious burns until the late
1990sxii. Silver can be found today in the form of nanocrystals with sizes ranging from 15nm to
100nm, with no evidence of toxicity for human being. Silver Nanoparticles are heavily used in food
packaging and storage containers today.
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— Silicon Dioxide: it is most commonly known as sand or quartz. In its nano form, fumed silica has a
very strong thickening eVect. Its primary particle size is 5—50 nm. The particles are non-porous and
have a surface of 50—600 m2/g. Density 2.2 g/cm3. Inhaling ﬁnely divided crystalline silica dust (or
fumed silica) in very small quantities over time can lead to silicosis, bronchitis or (much more rarely)
cancer, as the dust becomes lodged in the lungs and continuously irritates them, reducing lung
capacities (silica does not dissolve over time). However this is more a side eVect of inhaling dust into
the lungs rather than a direct eVect of silicate dioxide chemical and physical properties. Such particle
sizes are naturally present in the environment and if not inhaled, pure silicon dioxide is inert and
harmless. Pure silicon dioxide produces no fumes and is insoluble in vivo. It is indigestible, with zero
nutritional value and zero toxicity. When silica is ingested orally, it passes unchanged through the
gastrointestinal tract, exiting in the faeces, leaving no trace behind.
— Titanium Dioxide: has widely been used as a white pigment for paint, but recently found new
applications in nanoengineering. Titanium Dioxide is being used for its antibacterial properties and
as aUV protector in cosmetics and in food packaging. Generally considered non-toxic, nanoparticles
have sizes ranging from 20 nm to 200 nm. However, several researchers reported evidence that it led
to deterioration of health in some animalsxiii. The European Chemistry Industry Council and the
America Chemistry Council (groups funded by the chemical industry) initiated toxicology studies.
The studies exposed rats, mice and hamsters to pigment-grade TiO2 (PG-TiO2, 0, 10, 50 and 250 mg
m-3) or ultraﬁne TiO2 (UF-TiO2, 0, 0.5, 2 and 10 mg m-3) for 90 days and the lung burdens and tissue
responseswere evaluated at the end of the exposure period and for up to one year after exposure. They
show very diVerent results between species, always linked to exposure of high doses of TiO2 absorbed
either by inhalation or absorption through food, but never in a way that could lead to a conclusion
regarding usage of TiO2 in food processingxiv.
— Zinc andZincOxide: Zinc is a nutrient that is critical to human health, but it is also an active chemical
component that needs to be correctly dosed. Excessive absorption of Zinc can lead to poisoning and
death, but this is also the case with many other types of nutrients. Furthermore, in the case of Zinc
and Zinc Oxide, it is not the size of the particles that will inﬂuence the toxicity of the Zinc when
absorbed. Zinc dissolves easily into the gastric acid and becomes Zinc chloride.
Conclusion
In this report we have provided evidence that nanotechnologies have traditionally been used in the preparation
of food, albeit under diVerent names such as “colloid chemistry” and “materials science”, Nanotechnology
does not necessarilymean nano-engineering, andmany of the chemical modiﬁcations made to proteins in food
should also be considered as nanotechnology. At the same time, it is true that nano-engineering approaches
are introducing novel food additives and adding functionality to food packaging. Regulatory and legislative
bodies should be aware of the full range of these applications when debating the use of nanotechnology in
food.
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Memorandum by nanoTox Inc.
Testimony of Christopher J Gintz on Behalf of nanoTox Inc. before the Select Committee on
Science and Technology—The United Kingdom’s House of Lords—Nanotechnologies and Food
Subcommittee on 24 June 2009
By invitation from the British Government—British Embassy, Washington, DC
Biography of Mr Christopher J Gintz
Christopher JGintz is a lifelong inventor involved in the formation of companies in the computer, information
processing and science technology business. In 2003 he co-founded NanoHoldings LLC, a Company that
raised $30 million for investment in the commercialization of nanotechnology from leading nanotech research
centers such as Rice and Cambridge Universities. From 2005–09 years he helped form and served as Chief
Technology OYcer for 14 nano-speciﬁc technology companies spanning a wide range of civilian and military
uses. Innovative technologies under development include materials with improved mechanical strengthening
properties and replacements for earth metals that are increasingly depleted. InMarch 2009 he joined nanoTox
Inc. as a strategic advisor for the advocacy of a private company- government partnership to study the
toxicological properties of nanomaterials. He is the co-inventor of the notebook computer and has been
responsible for the development of many electronics and energy technologies requiring complex
understanding of the interaction between users and the environment. He holds a Bachelor of Arts degree in
Sociology and Bachelor of Science Degree in Computer Science with advanced studies in statistics, chemistry
and technology commercialization.
Introduction
The global economic crisis has signiﬁcantly altered American national investment priorities. Science
investment leading to accelerated technology commercialization is now a signiﬁcant national priority. The size
of this ﬁnancial investment in American science is unprecedented. The country has not seen an equivalent
commitment to the mobilization of scientiﬁc eVort since the creation of the space program in the 1960’s.
Foremost on the administration’s priority list dovetailing with its economic plans is the creation of an
alternative energy policy that simultaneously reduces America’s carbon footprint and increases its
commitment to technology by creating high paying nanotech jobs. This agenda cannot advance without the
successful commercialization of nanotech. The Economic Recovery Act is comprised of both a commitment
to an investment in fundamental science and a renewed commitment to responsible regulation of technology
making environmental, health and safety a national priority. Scientiﬁc investment and discovery in this area
is global in scope with the American investment dwarfed by the ﬁnancial commitments of America’s trading
partners in the United Kingdom, the European Community, Russia, China, Korea, Japan and Singapore.
This commitment is shownby the scope of the eVort that is underway to study the complex interaction between
these new technologies, people and the environment. Never before in mankind’s history have we had the
opportunity to study the potential health consequences of a material as it is being developed. Regulatory
eVorts heretofore have been reactive and usually after some debilitating health, safety or environmental
problem emerged. This is not true for drug development however, where clinical trials assessing the potential
health consequences are a major element of the regulatory environment. Stakeholders’ interests in the
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nanotech debate are meant to be inclusive. There is a general agreement by all concerned stakeholders that the
speciﬁc studies of nano/biological interactions are important.
The following list of American governmental agencies involved in this process is not meant to be exhaustive
but is indicative of the range of scientiﬁc and regulatory frameworks in which American business operates.
However, a host of Federal agencies including the National Science Foundation, the Department of Energy,
the National Institute of Health, the Food and Drug Administration, the Environmental Protection Agency
and the National Institute of Occupational Safety and Health all have a stake in the development of
nanotechnology. They have convened working groups consisting of domain experts covering the spectrum of
interested stake holders including science experts, academic researchers, industrial partners, consumers and
regulators to study the complex interaction of these materials and their interface with macro systems.
For example, in May 2009 the United States Food and Drug Administration convened its Second National
Workshop at the Greentech/Nanotech Conference in Houston, Texas to deﬁne and access reference nanoscale
particulates by their chemical composition, surface characteristics, size, and electrical characteristics to
determine their behavior when interacting with biological systems. Future health and safety studies
contemplated include but are not limited to an evaluation of their potential toxicity when handled and
processed by workers and their subsequent disposal at the end of their life cycle.
nanoTox Inc. business and technical personnel are involved in participating from the inception in these
workshops acting as an advocate for the safe and responsible handling of materials through the entire
scientiﬁc, business development and materials production supply chain. In addition, nanoTox scientists are
engaged with the emergence of food nanotechnology and during the last three years have published chapters
in the most recent textbooks in the specialized area of gastrointestinal toxicology. Although it is funded by
private investors it seeks to act in the role as a coordinating body bridging private industry concerns for factual
scientiﬁc inquiry with the government’s regulatory information requirements. It is formed out of the belief that
all stakeholders are interested in veriﬁable scientiﬁc proof as a basis for responsible and balanced
governmental regulation. nanoTox Inc. believes that periodic, on-going assessments are needed and that
continuous monitoring of industrial processes is necessary to protect workers, consumers, and the
environment. These assessments will help jump start the nanotech industry by creating a scientiﬁcally proven
data base on which insurers can depend so that nanotech companies can accelerate product development in
the marketplace thereby stimulating the economy.
nanoTox’s initial deliverables include using both in vivo strategies (acute and subchronic toxicity studies
focused on diVerent exposure routes) and in vitro strategies (development of in vitro engineered human tissues,
epidermis, bronchial and intestinal epitheliums.) These studies are intended to identify the potential impact of
manufactured nano scale particles on human health.
Food Safety
Insuring the safety of the food supply is a global concern. People’s concerns are well founded. During the past
ﬁve years there have been signiﬁcant health concerns about global pandemics with health scares involving the
meat supply (mad cow’s disease, swine ﬂu, bird ﬂu), bacterial outbreaks caused by improper inspection and
handling of vegetables and peanuts, and deliberately tainted food stuVs such as themelanomin contamination
in baby formula and milk supplies in China. Each health scare has been created by its own unique
circumstances costing the world economy billions of dollars and created a general uneasiness among the
populace about the safety of its food supply. As a result, the American agricultural industry has called for
additional inspection and regulation to govern food safety. TheWall Street Journal reported on 18 June 2009
that the Congress has drafted legislation speciﬁcally for this purpose.
Since it is the Select Committee of the Science and Technology Committee of the House of Lords speciﬁc
interest to investigate the speciﬁc use of nanotechnology in food, my comments will now speciﬁcally address
the use of nanotechnologies and nanomaterials in food products, dietary supplements and food packaging. I
will separate my comments between the food chain and the cosmetics chain.
Nano stakeholders have formed several mechanisms for the orderly dissemination of factual information
about nanotechnology and both its interaction in the food chain and cosmetics. Two qualiﬁed sources of
information are www.goodnanoguide.org/tiki-index.php and the International Risk Governance Council:
“The Appropriate risk governance strategies for nanotechnology applications in food and cosmetics” see
www.irgc.org/img/pdf/irgc Pbnanofood web.pdf.
Most experts agree that the negative implications for nanoscale materials in the food chain and cosmetics are
unlikely but cannot be excluded, especially particles smaller than 20 nanometers.
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According to the IRGC:
“. . . There are problems at all phases of risk governance in nanotechnology. These include accepted and
approved deﬁnition of what does and does not constitute a nanomaterial. Almost no hard data regarding
nanoparticles in the contents of materials in speciﬁc products and very little scientiﬁc knowledge of the
risks associated with nano scale ingredients or the products that contain them. As a result, the general
public with a limited knowledge of nanotechnology is being inﬂuenced by alarmists writing
communications, which are based on societal culture rather than any scientiﬁc basis. Consequently
concerns about health issues and risks are growing even though there is no substantive evidence to justify
these concerns.”
State of the Science
As proof of this assertion, a literature search on the Internet ﬁnds only three references to food products and
nanoscale particles. Science News reported on 27 May 2007 that the number of consumer products including
food and food packaging using nanotechnology has doubled from 212 to 475 since the Project on Emerging
Nanotechnologies launched the world’s ﬁrst online inventory of manufacturer-identiﬁed nanotech goods in
March 2006. Clothing and cosmetics top the inventory . . .” See http://www.nanotechproject.org/
consumerprodcuts. One can conclude from this search that given the billions of dollars spent on groceries, the
size of the market for nanoparticle foodstuVs at this point in time is nearly non-existent.
Active research agendas on nanotechnology food and food packaging are also limited. There is no coordinated
research eVort on the study or use of nanotechnologies in food and food packaging. Only two scientists have
a published research agenda in the ﬁeld of nanotechnology and food. Dr Frans Kampers, a Dutch scientist at
theWageningen University and Research Center and Dr RodHill at the University of Idaho were symposium
presenters on the subject (See Science News, 18 February 2009 “Could Nanotechnology Make an Average
Donut into Health Food?” www.ScienceDaily.com/releases/2009/02/090214162746.htm) at the American
Association for the Advancement of Science annual meeting entitled “From Donuts to Drugs: Nano-
Biotechnology Evolution or Revolution.” Dr Kampers alleged “. . . that European food companies already
use nanotechnology in consumer products but few volunteer the information to consumers.” Dr Kampers
research agenda focuses on applications, products, processes, and sensors useful in food safety, food quality
monitoring and in packaging.”
Dr Kampers stated “European food scientists use nanotechnology to create structures in food that can deliver
nutrients to speciﬁc locations in the body for the most beneﬁcial eVects.” What are the nutrients and where is
the scientiﬁc proof to back up these allegations? This is one investigator speculating in a symposium about
what may happen not what is factually happening at this time. The main barriers to developing nanoscale
nutrients are the cost and beneﬁts associated with their development. We believe that those are anticipated
developments are and not currently actively under development.
The nanotech packaging industry is in its infancy. There are nine references regarding nanoparticles and food
storage in the Products on Emerging Nanotechnologies database. This is hardly an unmanageable group of
products to access. They span the gamut from devices for actual food storage (plastic storage bags containing
silver particles), beer bottles containing nanoparticles to keep gas from dissipating (nanoclays), plastic wrap
(containing zinc oxide acting as an ultraviolet catalyst), baby bottles and salad bowls (silver nano particles to
ﬁght bacteria), aluminum foil (nanoscale carbon linings for better heat adsorption) and nano starch (improved
adhesion in sealing bags) and refrigeration solutions including (nanoparticles in insulation) and odor
adsorption. If there were a gap in the nanotechnology regulatory environment, it would involve the packaging
industry. This application area represents a potential regulatory gap and perhaps merits further scrutiny
because the food stored in somemethods comes in direct contact with nanoparticles that subsequently contact
biological systems.
Speciﬁc examples of the debate about cosmetics usually encompass a discussion of TiO2 (titanium dioxide)
base sunscreens. These sunscreens contain engineered nanoparticles but there is no current mechanism to
distinguish “nano forms” from “other forms” of titanium dioxide. Here is a case where TiO2 sunscreens are
considered existingmaterials not “new or novel”materials. This application area, like food packaging perhaps
merits further scrutiny because nanoparticles are directly coming in contact directly with biological systems.
Answers to Specific Inquiries
(1) Most of the speciﬁc research in America on food and packaging is conducted at leading academic
research universities in the form of non-Good Laboratory Practices (GLP) studies with poor
documentation/reproducibility. These researchers have problems getting the necessary funding.
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(2) The main barriers to developing these technologies are: (a) fear of consumer rejection of nano
products and (b) the regulation of technology.
Health and Safety
The health and safety risks associated with nanoparticles in food and food packaging in the United States are
unknown at this time. The two issues must be handled separately. The ﬁeld is wide open since there has been
no risk assessment performed in either area. Speciﬁc to the food supply we believe strongly that the United
States Food and Drug Administration has the primary responsibility for monitoring all developments in food
safety including food additives and nanotechnology. This is equivalent in Europe to the European Food Safety
Authority (EFSA) and in the United Kingdom, the Food Safety Board. We would encourage the FDA’s
participation in international rule making with its regulatory counterparts.
Nanotechnology is not genetically modiﬁed food. Risk management regarding the food supply should be
approached from the perspective of balance and proportionality between the costs and beneﬁts of regulation.
The regulatory impact of mandatory versus “indirect” approaches versus an absence of regulation should be
considered. “Food” is diVerent from “dietary supplements.”
See ScienceDaily 10 February 2009 “Nanoparticles in Dietary Supplements Cause Health Concerns,
Regulatory Challenges;” http://www.sciencedaily.com/releases/2009/02/090909075633.htm. In the United
States there is limited regulatory control over the dietary supplements business. They have limited distribution
and are perceived to be a niche between the food business and the pharmaceutical business. Most products
come with a disclaimer that these products are outside of the review of the Food and Drug Administration.
Admittedly this is a regulatory gray area. Further assessment of the use of nanoscale nutrients that are used
to boost nutrient adsorption and other alleged health beneﬁts needs further study and assessment.
Answers to Specific Inquiries
(1) The health and safety risks that present the highest risks in food and packaging are leachables from
packaging. Testing has not been conducted at the nano scale but may have been tested in some form
at the macro scale.
(2) nanoTox assists companies in analyses, stability of the nanoformulation and toxicology testing.
Additional research needs to be conducted comprehensively.
(3) We cannot speak for the government. Industry plans to risk assess new food products through
CFSAN on a case-by-case basis and nanotechnology will need to be retested. The food industry
follows basic toxicology testing guidelines as set forth in the FDA Redbook (guidelines for testing
Food Additives . . . Direct and Indirect)
Regulation
We believe that there are six key regulatory governance principles we wish to propose for consideration by all
domestic and international nanotechnology regulators without regard to select topics. These are:
(1) The regulatory response should be coordinated; coordination with international entities between
states as well as inter-departmental and interagency levels.
(2) Regulatory approaches to nanotech should be adaptive and ﬂexible as we learn more factually about
the technology.
(3) Information gathering initiatives, a key ﬁrst step in an additive regulatory system, should be designed
with end points in mind, should oVer incentives for participation and should involve industry and
academic researchers.
(4) Risk management approaches should strive to be comprehensive, by incorporating a lifecycle
approach to govern the potential risks of nanotechnology and should be designed with the
importance of scope and timing horizons in mind.
(5) Risk management approaches should strive for balance and proportionality.
(6) An understanding of the proﬁle of the beneﬁciaries of nanotechnology and the risk bearers in concert
with who is accountable ensuring the appropriate deployment of both technology and regulatory
oversight. Stakeholders should be engaged appropriately and regulatory systems should be
transparent.
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The US Government through the Food and Drug Administration believes that it has the necessary expertise
and scientiﬁc depth to coordinate the involvement of stakeholders in the process for deﬁning nanomaterials
and nanotechnologies as they apply to its regulatory area, which includes the topic area. The primary statute
applicable to the regulation of nanoproducts falling under the FDA’s authority is the Food, Drug and
Cosmetic Act (FDCA). For products subject to pre-market approval which includes pharmaceuticals, high
risk medical devices, and biological products, existing regulatory requirements are expected to be a suYciently
stringent and ﬂexible to accommodate the regulation of nanotechnology—however, the FDA does recognize
that current data requirements, reporting and notiﬁcation mechanisms do not contain speciﬁc information to
allow for the assessment of nanomaterial safety.
Some products are subject to post-market surveillance requirements including cosmetics and food. This is
perhaps an area that stakeholders may agree that there is a need for increased regulatory scrutiny of products
containing nanomaterials. This is not a trivial matter since many standard scientiﬁc tests do not apply to nano
and is most cases measurement techniques and instrumentation is not yet developed. This situation is further
complicated by the lack of deﬁnition with associated materials being tested. For example, “is a ﬂat platelet of
nanometer dimensions equivalent to a round particle of the same material?”
A regulatory approach to developing policy options for nanotechnology including food and food packaging
should include:
(1) A formal statement of policy or preparation of a jurisdictional strategy.
(2) An attempt to gain more knowledge of nanotechnology’s risks especially in the context of its
interaction with biological systems.
(3) Commission a regulatory gap analysis.
(4) Make use of existing current regulations to indirectly regulate nanotechnology.
Answers to Specific Inquiries
(1) The US Government today has no single deﬁnition of “nanomaterials” and “nanoparticles” but
eVort is underway by industry, government, academic researchers and consumer stakeholders to
deﬁne them according to their composition, size, surface area, dimensions, and properties such as
their electronic conductivity.
(2) The US Government does not yet have a reporting mechanism for reporting nano-sized materials to
the Food and Drug Administration.
(3) The USGovernment intends through the eVorts of the Environmental Protection Agency to monitor
and regulate the use of pesticides and fertilizers that contain nanotech materials.
(4) In terms of where nano will be used, CFSAN has no nano notiﬁcations as of this time.
(5) The US Government coordinates its work on nanotechnologies through voluntary participation by
interested stakeholders. Forums for the purpose have been held at Rice University (Houston, Texas),
the Alliance for Nanohealth, Conferences, Workshops, and Conference Calls organized by agencies
and Symposia.
Public information and consumer engagement
The American public obviously has a major stake in the acceptance of products that contain nanoparticles
and avenues of debate about nanomaterials in food and food packaging must be developed. There are public
and private groups that are instrumental in the conduct of this debate. For example, the US Government’s
Consumer Products Safety Commission has the primary responsibility for organizing stakeholder opinions on
product safety. We believe that the Government and its regulating bodies have the following responsibilities
when talking about nanotechnology:
(1) The Government should be positive stating its intention to support nanotechnology research and
development with the intent to capture future beneﬁts.
(2) Beneﬁts of nanotechnology need to be balanced with statements about potential risks, the extent to
which we do not yet fully understand from a scientiﬁc perspective.
(3) Jurisdictions need to stress that until such time more information is available, existing regulatory
frameworks are suYcient to ensure health and safety of stakeholders including consumers and the
environment.
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(4) Jurisdictions need to note the current lack of data pertaining to new materials novel properties, the
lack of measurement instruments, standards, and methods to deal with hazards, exposure evaluation
and overall risk assessment.
(5) Jurisdictions note the need to review the need for nanotechnology speciﬁc regulatory frameworks in
the future and update existing regulatory frameworks as required.
(6) Jurisdictions should aggressively work with a Company like nanoTox and research universities to
speed the process for building and evaluating a fact track model of proposed nanotechnology
regulations. It would greatly reduce business uncertainty, foster investment leading to jobs creation
needed in the world economy today.
Answers to Specific Inquiries
(1) We cannot ascertain any existing public perception in the United States about food nanotech and
therefore we have seen little written or discussed about it in either the scientiﬁc or popular media. The
United States tends to be much less formal about the regulation of new technology and the strategy
is to have the competition in the marketplace deﬁne the features and beneﬁts by the producers.
(2) We have yet to see any diVerence in nano; it is uncertain whether it will have any impact since few
products exist. We do not see the need to label something as diVerent if there is no proven diVerence.
24 June 2009
Memorandum by the Project on Emerging Nanotechnologies, Woodrow Wilson International Center for
Scholars
1. There is little doubt that nanotechnologies have an important role to play in the food sector. They have
the potential to raise nutritional value, increase shelf life, decrease manufacturing costs, and prevent harm to
consumers. These advances will beneﬁt producers and consumers alike. But they do not come without raising
the possibility of new potential risks to human health and the environment. As our abilities to construct and
manipulate sophisticated materials at ever-smaller scales increase, the challenges of understanding and
managing the full implications of these abilities multiply. Without a careful evaluation of emerging risks, and
strategies for managing these risks, it is unlikely that the full beneﬁts of nanotechnologies will be realized—
whether in the food sector or the many other areas where the technologies are being developed and used. In
this context, I am encouraged that the House of Lords Science and Technology Select Committee are
investigating the use of nanotechnologies in the food sector, and am pleased to be able to provide evidence
frommy perspective as an expert in nanotechnology risk research and policy, and as the Chief Science Advisor
to the Project on Emerging Nanotechnologies.
2. By way of background, the Project on Emerging Nanotechnologies is an initiative launched by the
Washington DC-basedWoodrowWilson International Center for Scholars and The Pew Charitable Trusts in
2005. It is dedicated to helping business, government and the public anticipate andmanage the possible health
and environmental implications of nanotechnology.As part of theWilsonCenter, the Project is a non-partisan,
non-advocacy organization that collaborates with researchers, government, industry, non-governmental
organizations (NGOs), and others concerned with the safe applications and utilization of nanotechnology.
Our goal is to take a long-term look at nanotechnologies; to identify gaps in the nanotechnology information,
data, and oversight processes; and to develop practical strategies and approaches for closing those gaps and
ensuring that the beneﬁts of nanotechnologies will be realized. We aim to provide independent, objective
information and analysis that can help inform critical decisions aVecting the development, use and
commercialization of responsible nanotechnologies around the globe.
3. My own interest and involvement in nanomaterials stems from research I conducted at the University of
Cambridge in the early 1990’s, where I explored applying advanced electron microscopy to the
characterization of atmospheric nanoparticles. Since then I have worked, published and lectured extensively
on the potential beneﬁts and risks of nanotechnologies, as well as broader issues relating to emerging
technology and science policy. I was previously co-chair of the US government working group coordinating
interagency activities related to nanotechnology risk research and currently serve on a number of
nanotechnology-related boards and committees, including the World Economic Forum Global Agenda
Council on the Challenges of Nanotechnology and the Executive Committee of the International Council on
Nanotechnology.
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4. Since its inception in 2005, the Project on Emerging Nanotechnologies (PEN) has undertaken a number of
activities relevant to this call for evidence, and I would like to summarize the pertinent points arising from
these activities. I will also provide brief answers to some of the speciﬁc questions posed by the subcommittee,
where they coincide with my particular areas of expertise and knowledge. Where relevant, I have provided
links to further resources. However, given the brevity of this submission, I would ask that the subcommittee
feel free to contact me directly on any points requiring further clariﬁcation. While this submission is written
from a US perspective, much of it will hold relevance for the safe use of nanotechnologies in food in the UK.
5. Regulatory Framework. In 2006, PEN published a report by Michael R. Taylor—former Deputy
Commissioner for Policy at the US Food and Drug Administration (FDA)—on regulating the products of
nanotechnology from a FDA perspective.26 Taylor’s top-line recommendation for all FDA-regulated
products—including food additives, food ingredients and food packaging—was that criteria need to be
established for determining when substances are “new for legal and regulatory purposes,” and “new for safety
evaluation purposes.” He expressed concern that, without such criteria (which still do not exist in the US),
FDA and industry lack the means to identify and regulate nanoscale forms of materials that may present new
risks due to novel nanostructure-dependent functionality. In particular, he was concerned over the
(continuing) lack of clarity concerning how nanoscale versions of substances “Generally Regarded As Safe”
should be regulated. The issues surrounding the regulation of nanotechnology-enabled food products by the
US FDA have been articulated repeatedly by Taylor.27,28,29
6. Use of nanomaterials in food packaging. It is currently unclear how the use of engineered nanomaterials in
food packagingmight impact on consumer safety, either through the release of material for packaging to food,
through additional protection aVorded by advanced packaging, or through feedback on the safety of food
contained within packaging embedded with nanotechnology-enable sensors. In 2008, PEN published the
ﬁndings of a study focused on assuring the safety of nanomaterials in food packaging—the result of a
collaboration between PEN and the Grocery Manufacturers Association (GMA).30 Using hypothetical
scenarios, the study was based on a series of dialogues among experts and stakeholders from the US
government, industry and the public interest community exploring the legal and policy issues, as well as
scientiﬁc and technical issues that might arise in ensuring the safe use of nanomaterials in food packaging. The
study concluded that, while current regulatory approaches in the US provide a high level of consumer
protection, the current state of scientiﬁc knowledge and need for case-by-case evaluation of emerging products
requires greater scientiﬁc investment and innovation in order to satisfy established regulatory standards.
7. Tracking consumer products (including food products) allegedly based on nanotechnology. PENmaintains a
publicly available on-line database of over 800 consumer products allegedly using nanotechnology in some
form.31 Entries are based on manufacturer claims, which are not validated independently, and are
international in scope. As of 6 March 2009, there were 84 food-related items listed in the database. Nine of
these are listed as used in cooking, and range from nanoscale silver particle-infused cutting boards and
nanotechnology-enabled non-stick surfaces, to nano-silver sprays for disinfecting surfaces. 20 products are
used for food storage—many of them using nanoscale silver particles as an antimicrobial agent. 44 listed
products are categorized as dietary supplements, where the use of nanotechnology ranges from silver (and
other metal) nanoparticles, to the use of nanoscale ingredients in enhancing uptake and eVectiveness, to uses
that are somewhat hard to fathom from the manufacturer-supplied information. Only three products listed
are entered as “foods,” and include oil that contains nanoencapsulated ingredients, a milkshake that uses a
nanoscale silica-based compound to enhance the taste, and a tea that claims to use a non-disclosed form of
nanotechnology to deliver beneﬁcial components of the drink to consumers.
8. It is currently unknown how many nanotechnology-enabled food products are on the market that are not
clearly identiﬁed. It is known that the food industry is carrying out research into using nanotechnology to
improve manufacturing processes, increase food security and shelf life, and improve nutritional value and
consumer satisfaction. And nanoscalematerials such as fumed silica have been used in food products formany
years. Yet the food industry is reticent to discuss its use of the technology in public, and is currently under no
obligation to reveal how nanotechnology is being used in products already on the market.
26 Taylor, M. (2006). Regulating the products of nanotechnology: Does FDA have the tools it needs?, PEN 5Washington DC, Woodrow
Wilson International Center for Scholars, Project on Emerging Nanotechnologies.
27 See footnote 26
28 Public meeting on Nanotechnology Materials in FDA –Regulated Products Available at: http://www.nanotechproject.org/
publications/archive/statement michael taylor at fda/
29 Taylor,M. R. (2008). Assuring the safety of nanomaterials in food packaging: The regulatory process and key issues.WashingtonDC,
Project on Emerging Nanotechnologies.
30 see footnote 29
31 An inventory of nanotechnology-based consumer products currently on the market. http://www.nanotechproject.org/inventories/
consumer/
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9. Public perceptions. Since 2006, PEN has commissioned annual phone surveys of public attitudes towards
nanotechnology from Peter D. Hart Research Associates, Inc. The 2007 study, which included
1,014 participants, incorporated questions about attitudes towards the use of nanotechnology in food
products.32 Considering food in general, two thirds of the participants felt the food supply has become less
safe in recent years. When asked about the speciﬁc use of nanotechnology in food related products and food,
a large majority said they needed more information about the health risks and beneﬁts associated with using
the technology to enhance these products before they would use them. 13 per cent of respondents said they
would not use food storage products enhanced with nanotechnology and 73 per cent said they would need
more information before deciding to use them. In regards to food, 29 per cent of adults claimed they would
not purchase foods enhanced with nanotechnology, while another 62 per cent said they would need more
information before doing so. Adults who initially weremore aware of nanotechnologywere considerablymore
likely to report they would use both food storage products and foods enhanced with nanotechnology.
Additionally, adults who had heard a signiﬁcant amount about nanotechnology were nearly three times more
likely than adults who had heard nothing to say they would use food storage products enhanced with
nanotechnology, and were two and half times more likely to use foods enhanced with nanotechnology.
10. Providing information on the use of engineered nanomaterials in foods. There has been considerable
discussion over the pros and cons of labeling nano-enabled products, although many of the discussions have
been somewhat unclear on the purpose behind labeling or the information to be conveyed. Putting the
contentious issue of “labeling” aside, information availability and communication is important for eVective
regulation and informed consumer choice. Regulators need clear information on ingredients and materials
that may raise health and environmental concerns if not used appropriately. Manufacturers need clear
information on the materials they handle and incorporate into their products, if they are to manage product
safety eVectively. And consumers need information on biologically relevant ingredients in the food products,
if they are to be empowered to make informed choices on what they purchase and eat. The current state of
science suggests that there are no underlying mechanisms of action that would justify blanket labeling of food
items as containing engineered nanomaterials. Due to the diversity of engineered nanomaterials and their
physical, chemical and biological behavior, such labeling would obfuscate evidence-based decision-making.
However, current knowledge suggests that some engineered nanomaterials may have an eVect on consumers
that is associated with physical form as well as chemical make-up, and in these cases it would be helpful to
identify the physical, as well as the chemical, form of ingredients. Such identiﬁcation, whether available on the
ingredients list or as supplemental publicly accessible information, would aid regulators and business as well
as consumers.
11. Next generation nanomaterials. Many engineered nanomaterials currently being used in applications are
nanoscale forms of materials that have been in use for some time. For instance, nanosilver consists of
nanometer scale particles of metallic silver, and nano-titanium dioxide is a nanometer-scale form of a material
used widely as a whitener in foods and other products. However, scientiﬁc and technological advances are
enabling the formation of nanoscale materials with increasingly sophisticated forms and functions. These
more sophisticated materials are often referred to as next generation nanomaterials. While no formal
deﬁnitions exist for these nanomaterials, they can be typiﬁed by materials that are built up of complex
arrangements of chemicals at the nanoscale, materials that change their behavior in the presence of diVerent
external stimuli (such as heat, light, pH, magnetic ﬁelds), materials that are designed to exhibit multiple
functions (such as particles that can both deliver a drug to a predetermined site, then release it on demand),
and materials that are designed to interact together—essentially to communicate—in complex ways. Such
nanomaterials have more in common with complex products than simple chemicals, and raise questions over
how their potential health and environmental impact should be evaluated and managed.
12. A number of “next generation” nanomaterials are under investigation for use in food products in the
laboratory, although it is unclear whether any have been used in commercial products. Examples include
materials designed to self-assemble into ingredient-carrying nanoscale capsules which can disassemble once in
the body, and nanoscale sensors which are designed to be placed on or in food, where they can respond to their
local environment and signal the presence of contaminants. Although the building blocks of these materials
are invisible to the naked eye and may be transitory, they behave very diVerently from well-deﬁned chemicals
upon which many food regulations are based.
32 Hart, Peter D. (2007) “Awareness of and Attitudes Toward Nanotechnology and Federal Regulatory Agencies” Peter D. Hart
Research Associated, Washington DC, conducted on behalf of: Project on Emerging Nanotechnologies and The Woodrow Wilson
International Center for Scholars Available at: http://www.nanotechproject.org/process/assets/ﬁles/5888/hart presentation 2007
analysis.pdf
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13. Current state of scientiﬁc knowledge. Although the state of scientiﬁc knowledge on engineered
nanomaterials in food products is increasing, it is still low. In 2006 I published an assessment of the current
state of knowledge, and a plan to ﬁll in the knowledge gaps33 (this was followed up later that year with a
commentary in Nature laying out the greatest challenges to ensuring the safe use of nanotechnology across
multiple areas of use).34 At the time, I could not identify any research on the behavior of engineered
nanomaterials in the gastrointestinal tract. While there is now a small amount of relevant research being
conducted in this area, it remains at a low level. More generally, there are a number of current or recently
completed research projects around the world that are concerned with the potential health impacts of
engineered nanomaterials in food products. PENmaintains a public database of nanotechnology risk-related
research, and searching this using the keyword “food” returns 23 projects.35
14. Over the past few years, there have been numerous expert reviews on the state of science regarding
potential impacts of engineered nanomaterials.36 In broad terms, these indicate that many nanomaterials
demonstrate functionality that depends on their form as well as their chemical makeup; that diVerent types of
nanomaterials behave very diVerently; that some nanomaterials have the potential to cause harm by getting
to normally inaccessible places, and/or demonstrating a biological activity that is associated with their form as
well as their chemistry; that conventional toxicology assaysmay not provide a clear indication of nanomaterial
toxicity; and that the potential harmfulness of nanomaterials may change with time and environment. There
have been no known cases of health eVects directly linked to exposure to engineered nanomaterials. However,
there remain many knowledge gaps to understanding how newmaterials might cause harm, and how to avoid
this harm.
15. Regarding food products, questions still requiring answers include: Can engineered nanomaterials in
packaging migrate to food products and how can migration, and the resulting consequences, be evaluated?
How is the potential toxicity of engineered nanomaterials best tested? How are engineered nanomaterials most
appropriately measured and characterized? How do physical form and substance chemistry at the nanoscale
inﬂuence biologically relevant behavior? How do changes in the physical structure and size of particles aVect
their absorption, dispersion, metabolism and excretion? Are increased dose rates resulting from decreased
particle size and substance encapsulation important? Are people likely to be exposed to substances that can
assemble into nanoscale materials in the body, and what might the health consequences be?
16. Natural versus engineered nanomaterial risks. Regarding food product safety, the important question is
“how might something cause harm, and how can that be avoided”, rather than “is this an engineered or a
natural material”—the latter question having no direct bearing on safety. Natural nanoscale materials are
present in food products, and there are no known cases of these being directly linked to health problems.
Indeed, it can be argued that our bodies have evolved to manage and even take advantage of naturally
occurring nanoscale substances. It is more relevant therefore to ask whether a new material—whether
nanoscale or not—demonstrates properties that could lead to unconventional risks. From the current state of
the science, there is a greater likelihood that materials speciﬁcally engineered to have nanoscale features will
exhibit such novel properties. These include nanometer scale particles that are able to penetrate to regions of
the body inaccessible to larger particles, increased dose rates associated with nanoscale materials, and
mechanisms of action that are linked to the chemistry and physical form of speciﬁc engineered nanomaterials.
Not all nanomaterials will be harmful. But there is a chance that some engineered nanomaterials will be more
harmful than a conventional understanding indicates.
17. Research funding. Unanswered questions over the safe use of nanomaterials in food products currently far
outstrip strategic investment in relevant research. In the US, investment in research projects speciﬁcally
directed to understanding the health and environmental impacts of engineered nanomaterials is on the order of
$20 million per year, although signiﬁcantly more is being spent on research having some relevance to potential
impacts. It is diYcult to estimate the fraction of this investment dedicated to food-related research, but records
in the PENNanotechnology Environment, Health and Safety Research Database suggest that it is something
less than $1 million per year.37
33 Maynard, A. D. (2006). Nanotechnology: A research strategy for addressing risk, PEN 03 Washington DC, Woodrow Wilson
International Center for Scholars, Project on Emerging Nanotechnologies.
34 Maynard, A. D., R. J. Aitken, T. Butz, V. Colvin, K. Donaldson, G. Oberdo¨rster, M. A. Philbert, J. Ryan, A. Seaton, V. Stone, S. S.
Tinkle, L. Tran, N. J. Walker and D. B. Warheit (2006). “Safe handling of nanotechnology.” Nature 444(16): 267–269.
35 An inventory of current research involving nanotechnology health and environmental implications Available at: http://
www.nanotechproject.org/inventories/ehs/
36 Eg Maynard, A., D. (2007). “Nanotechnology: The next big thing, or much ado about nothing?” Ann. Occup. Hyg. 51: 1-12.
Oberdo¨rster, G., V. Stone and K. Donaldson (2007). “Toxicology of nanoparticles: A historical perspective.” Nanotoxicology 1(1):
2–25.
37 See footnote 35
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18. Recently, the US National Academies of Science criticized the US government for not having a robust
research strategy in place to address the safe use of nanotechnologies, and recommended the development of a
national research strategy.38 European funding for risk-relevant research appears to be outstripping the US39,
although it is unclear whether current research will lead to answers that will support evidence-based decision-
making on the safe use of nanotechnology in food products. My published assessments40 indicate there
remains a signiﬁcant chasm between the research needed to support the safe use nanotechnologies, and
research currently being funded.
10 March 2009
Letter from Dr Anthony Robson, Swansea University
I submit the information below on the recommendation of Professor David Tolfree, Vice President—Africa/
Europe of the Micro and Nanotechnology Commercialization Education Foundation (MANCEF) http://
www.mancef.org/
My general interest is how better nutrition can help prevent the modern diet induced “diseases of civilization”
and includes the potential of nanotechnology food products. I am currently a post-doc researcher at the
Institute of Environmental Sustainability, Biological Sciences, Swansea University, UK and likely to move
soon to do post-doc research elsewhere.
On behalf of Swansea University, UK, I spoke about preventing diet induced disease on BBC Radio 4 on 29
May 2008. I was paid as a consultant to talk to Kellogg’s@ (cereal company) nutritionists about preventing
diet induced disease in December 2007 (cereals are truly humanity’s double-edged sword).
The information I provide is based onmy latest (2009) review of peer reviewed scientiﬁc research publications,
including my own. For example:
Robson A (2006) Shellﬁsh view of omega-3 and sustainable ﬁsheries. Nature 444 (7122),
1002 http://www.nature.com/
Robson A (2008) Preventing Diet Induced Disease. Proceedings from the 13th International Conference of
the Commercialization of Micro and Nano Systems, held 27–31 August 2008 in Puerto Vallarta, Mexico
http://mancef-coms2008.org/
Robson AA (in review) Preventing Diet Induced Disease. Nutrition Research Reviews http://journals.cam
bridge.org/action/displayJournal?jid%NRR
Please do not hesitate to contact myself if the committee requires any further information. I would be
honoured to give oral evidence at Westminster that has the potential to help prevent the modern diet induced
disease epidemic. To help prevent the diet induced diseases of civilization policy makers, nanotechnologists,
food producers and consumers need to be made aware of the causal mechanisms of disease by understanding
how people die. The fact thatmodern diet induced inﬂammatory eicosanoids are major mediators of mortality
is not widely known in the public domain, even though the extensively used drug Aspirin is a cox-enzyme
blocker that prevents the formation of inﬂammatory eicosanoids.
State of the Science and its Current Use in the Food Sector
The answer to the question below is referenced using superscript Arabic numerals in parentheses. Please refer
to the Appendix on page 12 for further information. Acting on the information in the appendix would be a
great service to public health.
What are the main potential applications and benefits of nanotechnologies and nanomaterials in the food sector, either
in products or in the food production process?
1. What theWorld needs is a joined up and sustainable food policy that makes the best, andmost appropriate
use of the technologies at our disposal. You might be surprised, or not, of how few experts there are in this
area—a lot of hype, misinformation and biased views, often based on the distortion of scientiﬁc facts and of
course deliberate intentions to mislead for political and commercial reasons.
38 Committee for Review of the Federal Strategy to Address Environmental, Health, and Safety Research Needs for Engineered
NanoscaleMaterials, Committee on Toxicology, National Research Council. (2008). Review of Federal Strategy forNanotechnology-
Related Environmental, Health, and Safety Research. The National Academies Press, Washington, D.C.
39 http://www.nanotechproject.org/news/archive/ehs-update/
40 Eg Maynard, A. D. (2008). United States House of Representatives Committee on Science & Technology Hearing on: The National
Nanotechnology Initiative Amendments Act of 2008. Testimony of: Andrew D. Maynard, Ph.D. Chief Science Advisor, Project on
Emerging Nanotechnologies, WoodrowWilson International Center for Scholars, Washington, DC. April 16 2008., Washington DC,
Project on Emerging Nanotechnologies.
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2. Nanotechnology food products have great potential to help prevent unnecessary human suVering and
premature death, especially in future generations. Fundamental changes in the human diet, beginning with the
introduction of agriculture and animal husbandry x10,000 years ago, account for the largest burden of
chronic illnesses and health problems Worldwide. In modern societies diet induced diseases typically aZict
50–65 per cent of the adult population. Cardiovascular diseases are the number one cause of death globally
(30 per cent of all deaths) and cardiovascular diseases are predicted to continue increasing(1). In the Europe
Union, brain disorders have now overtaken all other burdens of ill health at an estimated cost of „386 billion
(„829 a year for each European citizen) in 2004(2) and mental ill health is predicted by the Global Forum of
Health (www.globalforumhealth.org) to be in the top three burdens of ill health Worldwide by 2020. Heart
disease and mental ill health can start in the foetus in the womb.
3. Primary prevention of cardiovascular disease andmental ill health starts, crucially, with maternal nutrition
before the inception of pregnancy and continues throughout life of the new born and includes consumingmore
DHA, EPA and ALA (alpha-linolenic acid) omega-3 fats and bio-available brain minerals and less LA
(linoleic acid) omega-6 fat (eg seed and nut oils) to enhance DHA and EPA synthesis from ALA, so tissues
have less intense inﬂammatory eicosanoid action (eg x0.35–3.5 g DHA! EPA day"1based on a 2,000-kcal
diet dependant on LA intake). The fats and oils from aquatic based-foods contain high contents of these
beneﬁcial omega-3 fatty acids but increased consumer demand has also increased strain on the ability of the
World’s ﬁsheries tomeet demand fromwild capture.Molecular biology now allows the engineering of oilseeds
for the production of DHA! EPA omega-3 HUFAs in a seed oil with an omega-3:6 ratio 1.5:1 (a ratio close
to that of many ﬁsh oils). Food nanotechnology may also be able engineer currently pro-inﬂammatory food
products to reduce the formation of inﬂammatory mediators—eicosanoids, cytokines, and reactive oxygen
species and increase the formation of anti-inﬂammatory mediators termed resolvins (Figure 1). Uncontrolled
excessive production of inﬂammatory eicosanoids over prolonged periods of time is associated with heart
attacks, thrombotic stroke, arrhythmia, arthritis, asthma, headaches, dysmenorrhea (menstrual cramps),
inﬂammation, cancer (such as colon, breast, kidney and prostate) and osteoporosis(3, 4). It is important to note
that if DHA andEPA oils undergo oxidation it may attenuate their beneﬁcial eVects and food nanotechnology
may be able to help prevent oxidation. Further, the excessive consumption of anything may cause disease or
premature death, even omega-3(eg 5, 6, 7).
Excess Fats +
Food Energy






Example of Diet Induced Disease       
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Figure 1. Low DHA and EPA dietary intake and excess food energy link diet to disease and premature
death(modiﬁed from 8). Three types of medication, Aspirin, Nitroglycerin, and Statins used widely to diminish the
processes set in motion by the two nutritional factors shown in the upper left of Figure 1 are noted, to show
the step in the process at which these familiar drugs intervene. It should be noted that the hydrophilic statin
Pravastatin may promote the development of cancer (inﬂammation) by causing an increase in mevalonate
synthesis in extrahepatic tissues(9–11).
4. Globally in 2005, at least 20 million children under the age of ﬁve years were overweight, approximately
1.6 billion adults (age 15!) were overweight and at least 400 million adults were obese(12). The World Health
Organization further projects that by 2015, approximately 2.3 billion adults will be overweight and more than
700 million will be obese. Within the past 20 years, substantial evidence has accumulated showing that long
term consumption of high glycemic load carbohydrates can adversely aVect metabolism and health(13–15). A
healthy diet-plus-exercise is most eVective for preventing diabetes mellitus(16). Nanotechnology may be able
to engineer the novel Neolithic and Industrial Era foods that dominate the typical modern diet (generally
energy dense, nutrient poor, processed foods such as breakfast cereals, bread, cake, cookies, crackers, cheese,
fried food, pizza, pasta, kebabs, sandwiches, soft drinks, alcoholic drinks, sweets, chocolate bars, ice cream,
condiments and salad dressings) to maintain low glycemic loads (diet low in reﬁned sugars with moderate
levels of carbohydrates and not as low in fat and protein as a low fat diets(see 17)) and reduce any insulinotropic
properties with potential positive eVects on metabolism and health.
5. Protein has more than three times the thermic eVect of either fat or carbohydrate(18) and because it has a
greater satiety (feeling of fullness) value than fat or carbohydrate(18, 19), increased dietary proteinmay represent
an eVective weight-loss strategy for the overweight or obese. Studies have indicated that ﬁsh protein may have
a greater eVect on satiety compared to other protein sources of animal origin(see 20). Clinical trials have shown
that calorie-restricted, high-protein diets are more eVective than are calorie-restricted, high-carbohydrate diets
in promoting(21–23)andmaintaining(24)weight loss in overweight subjects while producing less hunger andmore
satisfaction(25). Furthermore, high protein diets have been shown to improvemetabolic control in patients with
type two diabetes(26–28). In obese women, hypocaloric, high-protein diets improved insulin sensitivity and
prevented muscle loss, whereas hypocaloric, high-carbohydrate diets worsened insulin sensitivity and caused
reductions in fat free mass(29). In numerous population studies, summarized by Obarzanek et al(30), higher
blood pressure has been associatedwith lower intakes of protein. An increasing body of evidence indicates that
high-protein diets (approximately one third of total food energy intake at the expense of lowered
carbohydrate) may improve blood lipid proﬁles(27, 28, 31–33) and thereby lessen the risk of diet induced disease.
Improvements in the nutritional value of crop plants, in particular the protein composition has been a major
long-term goal of plant breeding programs. The future of bio-nanotechnology/molecular biology looks
promising to increase protein consumption at the expense of carbohydrate in the human diet, with potential
health beneﬁts.
6. Endemic clinical and sub-clinical iodine deﬁciency is present in about 20 per cent of humans Worldwide.
Two billion people, over 30 per cent of the World’s population are anaemic, many due to lack of iron(34). Iron
and other key minerals needed for brain development and function (zinc, copper, selenium) are more bio-
available from shellﬁsh and ﬁsh than from plant-based diets where their absorption is impaired by phytates
and other anti-nutrients. Plant based diets rich in staples like cassava or soy (the basis of many vegan and
vegetarian food products) are not only a very poor source of iodine but they also contain goiterogens which
inhibit iodine absorption(35). Bio-fortiﬁcation of novel foods throughmodernmethods of nanotechnology and
biotechnology has the potential to help oVset essential nutrient deﬁciencies and improve human health
through elevated levels of essential nutrients, reduced levels of toxic factors and anti-nutrients that impact
bioavailability and utilization of nutrients, and increased levels of factors that enhance bioavailability of
nutrients(36, 37).
7. Diets low in dietary ﬁbre may underlie or exacerbate constipation, appendicitis, hemorrhoids, deep vein
thrombosis, varicose veins, diverticulitis, hiatal hernia, and gastroesophageal reﬂux(38). Fibre type and
quantity are undoubtedly under genetic control, although this topic has received little attention. The
technology to modify ﬁbre content and type by nano-engineering would be a great beneﬁt in persuading the
many individuals who, for taste or other reasons, do not include adequate amounts of ﬁbre in their daily diet.
For example, ﬁbre content could be added to more preferred foods (eg milk, cheese, ice cream, reﬁned cereals
and white bread—but these are all novel foods that can promote the diet induced diseases of civilization) or
the more common sources of dietary ﬁbre could be altered for greater health beneﬁts.
8. In conclusion, to promote health and help prevent disease the future direction of food production should
be towards greater production of anti-inﬂammatory (DHA, EPA, ALA, LA and ARA proﬁle similar to
aquatic foods eg musselsMytilus spp), higher protein (x one third of total food energy intake at the expense
of lowered carbohydrate), low glycemic load, high ﬁbre (25–30 g day"1), bio-available nutrient rich, high
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potassium—low sodium, brain foods (foods rich in preformed DHA, EPA, Iodine, Iron, Copper, Zinc and
Selenium). Advances in food bio-nanotechnology that focus on these diet issues will in the long-term help
prevent unnecessary suVering and premature death.
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What is the current level of public awareness of the issues surrounding the use of nanotechnologies in the food sector?
1. Almost non-existent. When informing the public on any matter, great care must be taken because most of
the population is scientiﬁcally illiterate. I often read, see and hear the over-simpliﬁcation and
miscommunication of rigorously peer reviewed and well established health science by health agencies and
health charities in the press, on the radio and TV (eg the Food Standards Agency advert about eating excess
saturated fat is misleading. It is eating too much food energy per meal that is the problem—see Figure 1). It
is very easy to make a convincing argument to the majority of consumers by adding two bits of (im)plausible
science together and then coming to an implausible conclusion. See Science communication on page 346 in the
appendix for further information.
2. In my experience, even when aware of the diet induced diseases of civilization, most people still want to
have their cake (modern diet) and eat it. We can make the consumer aware of several options:
1. eat wild ancestral (eg shore-based) foods, which is almost impossible for the vast majority of the
population in countries surrounded by novel and domesticated human foods and polluted coastal
waters. Further, there are more humans on Earth, than can be sustained by the natural World.
2. continue eating the modern diet and thus, continue the diet induced disease epidemic (unnecessary
suVering and premature death).
3. modify the novel foods in the modern diet (while still looking and tasting the same as before
modiﬁcation), so they cannot induce the diseases of civilization.
What are the risks posed to consumers by the use of nanotechnologies and nanomaterials in the food sector?
1. The risks of well regulated and rigorously tested food nanotechnology products that help prevent disease
are likely to be insigniﬁcant when compared with the magnitude of the current problem of the diet induced
disease epidemic. Using bio-nanotechnology (or molecular biology) to engineer novel foods so they cannot
promote the diet induced diseases of civilization is likely to be of great beneﬁt to mankind. In reality there are
already more humans on Earth, than can be sustained by the natural World.
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2. The World spent US$4.4 trillion on health in 2005(30). Chronic illnesses and health problems either wholly
or partially attributable to diet account for the largest burden of chronic illnesses and health problems
Worldwide. The modern diet (the replacement of ancestral foods (eg aquatic-based foods) by the excessive
consumption of reﬁned seed and nut oils, cereals, dairy products, reﬁned sugars, fatty meats, salt, and
combinations of these foods) adversely aVects the following dietary indicators (1) fatty acid composition, (2)
glycemic load, (3) macronutrient composition, (4) micronutrient density, (5) acid-base balance, (6) sodium-
potassium ratio and (7) ﬁbre content.(39)
APPENDIX
PREVENTING DIET INDUCED DISEASE BIO-AVAILABLE NUTRIENT RICH, LOW-ENERGY-
DENSE DIETS
Anthony A Robson
Key Words: nanotechnology, diet, disease, cardiovascular disease, diabetes, cancer, prevention, DHA, EPA,
brain, mental, ill, health, obesity, food, pregnancy, salt, energy, nutrition
Abstract
What the World needs is an integrated and sustainable food policy that makes the best, and most appropriate
use of the technologies at our disposal to promote health and help prevent disease. Diet induced diseases
account for the largest burden of chronic illnesses and health problems Worldwide. Historically a lack of
knowledge about the human nutritional requirements (including for the brain) helped promote diet induced
disease. The scientiﬁc knowledge exists to help prevent many of the current deﬁciencies and imbalances in
human diet. Primary prevention of cardiovascular disease and mental ill health starts, crucially, with maternal
nutrition before the inception of pregnancy and continues throughout life of the new born and includes
consuming more DHA, EPA and ALA (alpha-linolenic acid) omega-3 fats (and their co-factors) and bio-
available brain minerals and less high-energy-dense foods (eg reﬁned sugars and land-based fats and oils), so
tissues synthesize less inﬂammatory mediators and lower transient short-lived meal-induced oxidative stress,
inﬂammation, proliferation and impaired nitric oxide (eg x0.35–3.5 g DHA ! EPA day"1 dependant on
energy intake and availability of co-factors). Micro- and nanotechnologies are already engineering foods for
human (and livestock) consumption that may eventually (without excessive consumption) prevent the current
diet induced disease epidemic, especially in future generations, by preventing the causalmechanisms of disease.
Greater knowledge about the causal mechanisms of disease awaits to be discovered, which could further
enhance the human desire to increase longevity in optimum health (creating more problems and challenges
for society).
Introduction
Diet (oral ingestion) has always been a major mediator of disease and mortality in humans eg malnutrition,
typhoid fever and polio. Currently many of the chronic diseases epidemic in human populations are diet
induced diseases. This paper attempts to provide an understanding of the magnitude of the problem of diet
induced disease. The primary objective is to provide information on how to help prevent diet induced disease,
including the use of food nanotechnology. Nanotechnology promises to transform medicine from being
therapeutic to being preventative. It is estimated that within the next two decades human life expectancy for
healthy people will approach 100 years(1). This means that many people reading this paper could see the 22nd
century. Meeting people’s aspirations to increase life expectancy, with all the problems it will bring to society,
should be coupled with living as long as possible in good health (disease free). To achieve that future potential,
it is necessary to look beyond the status quo eg medical eVorts focusing more on treatments for older people
than on preventing primary causes of diet induced disease before they occur—starting with appropriate
maternal nutrition before the inception of pregnancy and continuing throughout the life of future generations.
To understand our dietary needs it is necessary to look at human diets in relation to the causal mechanisms
of disease. The review begins with the importance of diet as a fuel supply for the brain.
Nutrition for the Brain
The brain evolved containing DHA (omega-3) in the sea 500–600 million years ago(2). DHA has been used in
neural signalling systems over a 500–600 million year stretch of evolution. DHA is involved in neural receptor
domains, gene expression with derivatives providing protection from oxidative stress in the brain and
resolution of injury(3). Shellﬁsh, ﬁsh and shore-based animals and plants are the richest dietary sources of the
key nutrients needed by the brain; the preformed dietary omega-3 fatty acids—DHA, EPA, iodine (I), iron
(Fe), copper (Cu), zinc (Zn) and selenium (Se)(4, 5). The omega-6 fatty acid arachidonic acid (AA) is also
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important for brain development and present in shellﬁsh and other aquatic-based foods (Table 1). DHA and
AA are transferred across the placenta and accumulated in the brain and other organs during fetal
development andmaternal diet impacts fetal DHA and AA accretion(6, 7). Postnatal nutrition is also a priority
to ensure good maternal health and nutrition for the mother and her breast milk(8). Increasing dietary alpha-
linolenic acid (ALA) intake has little eVect on increasing maternal transfer of DHA to the foetus, or on
increasing DHA secretion in breast milk(9, 10). Similarly, increasing the intake of ALA in infants, as in adults,
has little eVect on increasing circulating levels of DHA(eg 11, 12).
Historically a lack of knowledge about the human nutritional requirements (including for the brain) helped
promote diet induced disease. There is growing awareness that the profound environmental changes (eg in diet
and other lifestyle conditions) that began with the introduction of agriculture and animal husbandryx10,000
years ago occurred too recently on an evolutionary time scale for the human genome to adapt(13–16). In
conjunction with this discordance between our ancient, genetically determined biology and the nutritional,
cultural and activity patterns in modern societies, many of the so-called diseases of civilization have
emerged(13–23).
Chronic Disease Epidemic
The World spent US$4.4 trillion on health in 2005(24). Chronic illnesses and health problems either wholly or
partially attributable to diet account for the largest burden of chronic illnesses and health problems
Worldwide. Cardiovascular diseases are the number one cause of death globally (30 per cent of all deaths) and
cardiovascular diseases are predicted to continue increasing(25). An estimated 17.5 million people died from
cardiovascular diseases in 2005(25). Cancer is a leading cause of deathWorldwide and accounted for 7.9 million
deaths (around 13 per cent of all deaths) in 2007 and deaths attributable to cancer are projected to continue
rising(26). An estimated one-third of all cancer deaths are due to nutritional and life style factors(27, 28). Taking
into account deaths in which diabetes was a contributory condition (heart disease or kidney failure)
approximately 2.9 million deaths in 2005 were attributable to diabetes(29). Type 2 diabetes is rapidly becoming
a disease of children and adolescents. In 2000, it was estimated that 30 per cent of boys and 40 per cent of girls
born in the USA are at risk for being diagnosed with type 2 diabetes at some point in their lives(30). Globally
in 2005, at least 20 million children under the age of ﬁve years were overweight, approximately 1.6 billion
adults (age 15!) were overweight and at least 400 million adults were obese(31). The World Health
Organization further projects that by 2015, approximately 2.3 billion adults will be overweight and more than
700 million will be obese. In the Europe Union, brain disorders have now overtaken all other burdens of ill
health at an estimated cost of „386 billion („829 a year for each European citizen) in 2004(32) and mental ill
health is predicted by theGlobal ForumofHealth (www.globalforumhealth.org) to be in the top three burdens
of ill health Worldwide by 2020.
Human Diet
There are universal characteristics of pre-agricultural hominin diets that are useful in understanding how the
modern diet may predispose humans to chronic disease. Increasingly, clinical trials and interventions that use
dietary treatments with nutritional characteristics similar to those found in pre-industrial and pre-agricultural
diets have conﬁrmed the beneﬁcial health consequences predicted by the template of evolutionary discordance
theory.(15, 16, 33)
Before the development of agriculture and animal husbandry hominin dietary choices would have been
necessarily limited to minimally processed, wild foods. Agriculture, introduced novel foods as staples for
which the hominin genome had little evolutionary experience. More importantly, food-processing procedures
were developed, particularly following the Industrial Revolution, which allowed for quantitative and
qualitative food and nutrient combinations that had not previously been encountered over the course of
hominin evolution. Although reﬁned seed (vegetable oils) and nut oils, dairy products, cereals, reﬁned sugars,
and alcohol make up 72.1 per cent of the total daily energy consumed by all people in the USA, these types
of foods would have contributed little or none of the energy in the typical pre-agricultural hominin diet.(34)
Additionally,mixtures of these foodsmake up the ubiquitous, generally energy-dense, nutrient poor, processed
foods (eg breakfast cereals, bread, cake, cookies, crackers, cheese, fried food, pizza, pasta, kebabs, sandwiches,
soft drinks, alcoholic drinks, sweets, chocolate bars, ice cream, condiments and salad dressings) that dominate
the typical modern diet.
The novel foods (reﬁned seed and nut oils, cereals, dairy products, reﬁned sugars, fatty meats, salt, and
combinations of these foods) introduced as staples during the Neolithic and Industrial Eras fundamentally
altered several key nutritional characteristics of ancestral hominin diets and ultimately had far-reaching eVects
on health and well-being. As these foods gradually displaced the minimally processed wild foods in human
diets, they adversely aVected the following dietary indicators (1) fatty acid composition, (2) glycemic load, (3)
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macronutrient composition, (4) micronutrient density, (5) acid-base balance, (6) sodium-potassium ratio and
(7) ﬁbre content(33).
Using cereals (eg wheat, rice andmaize) as an example, cereal grain consumptionmay appear to be historically
remote but it is biologically recent; consequently the human immune, digestive and endocrine systems have
not yet fully adapted to a food group which provides 56 per cent of humanity’s food energy and 50 per cent
of its protein(21). Cereal grains are truly humanity’s double-edged sword(21). For without them, our species
would likely have never evolved the complex cultural and technological innovations which allowed our
departure from the hunter-gatherer niche. However, because of the dissonance between human evolutionary
nutritional requirements and the nutrient content of these domesticated grasses, many of the World’s people
suVer disease and dysfunction directly attributable to the consumption of cereals.(21)
Dietary Fat, Essential Brain Nutrients and Health
Substantial evidence now indicates that to prevent the risk of chronic disease, the absolute amount of dietary
fat is less important than is the type of fat.(35) Fatty acids fall into one of three major categories: (1) saturated
fatty acids, (2) mono-unsaturated fatty acids and (3) polyunsaturated fatty acids (PUFAs). Essential PUFAs
required by all mammals are not produced within the body, and must come from the diet and occur in two
biologically important families, omega-3 and omega-6 (Table 1). The most prominent omega-6 fatty acids in
the human diet are the highly unsaturated fatty acid (HUFA) ARA found in aquatic foods and animal meat
and the PUFA linoleic acid (LA) found in foods including seeds, nuts and their oils (Table 1) which can be
converted into the HUFA ARA by enzymes. Existing USA and UK recommendations to increase the
consumption of EPA/DHA to 1 g day"1 and 0.5 g day"1 for those with and without existing cardiovascular
disease respectively(36, 37) include consumption of shore-based foods eg shellﬁsh and not just mainly pelagic oily
ﬁsh eg mackerel and salmon(38) and high strength DHA! EPA oils. Much of the evidence upon which these
guidelines are based, however, comes from supplemented intakes of preformed EPA/DHA at levels in excess
of 1 g day"1and x3.5 g DHA/ EPA day-1has been recommended by some for current USA diets(39). The high
requirement for DHA/EPA can likely be reduced to one-tenth of that amount by consuming less energy per
meal and less energy per day (ie low-energy-dense food and drinks—see Table 2) (compare (39)with (40)). Major
dietary sources of the omega-3 PUFA ALA include seed oils (Table 1), which can be converted to EPA and
then DHA by enzymes. However, the conversion of ALA through to the EPA and DHA is ineYcient and may
be an evolutionary consequence resulting from the ubiquitous presence of DHA! EPA HUFA containing
foods in the food chain of our human ancestors, thus reducing the importance of the de novo synthesis
pathway(41).
The cardio-protective eVects of DHA/EPA have been recognized for over 50 years with the low incidence of
mortality rate from CHD (coronary heart disease) in Greenland Eskimos, a population consuming a high fat
diet, but rich in DHA/EPA(42). In Greenland, coronary heart disease is almost undetectable(43, 44), while
globally cardiovascular diseases account for 30 per cent of all deaths(25). The totality of evidence for the
positive eVects of DHA and EPA from aquatic food and ﬁsh oil products on various outcomes of
cardiovascular disease is almost incontrovertible, according to the review by GriYn(45). However, others state
that DHA, EPA and ALA do not have a clear eVect on total mortality, combined cardiovascular events, or
cancer(eg 46). The section of the Cochrane study(46) regarding cardiovascular disease has been formally rejected
by the Society for the Study of Fatty Acids and Lipids(47). A more recent review highlights the important
cardio-protective eVect ofDHA/EPA in the secondary prevention of sudden cardiac death due to arrhythmias,
but suggests caution to recommend dietary supplementation of PUFAs to the general population, without
considering, at the individual level, the intake of total energy and fats(40). The current review suggests that the
real value ofDHAandEPA in the primary prevention of cardiovascular disease starts, crucially, with adequate
maternal consumption of DHA and EPA (dependant on energy intake and availability of co-factors) before
the inception of pregnancy and continues with adequate intake of DHA and EPA during pregnancy and
lactation and throughout the life of the new born child. The slow progressive injury to human tissues that
eventually becomes cardiovascular disease and premature death becomes irreversible overtime(48, 49). Thus,
secondary prevention of cardiovascular disease using DHA/EPA dietary interventions may not repair all the
damage already done to human tissues by the lack of DHA and EPA and other factors in the diet earlier in
life. It is important to note that if DHA and EPA ﬁsh oils undergo oxidation it may attenuate their beneﬁcial
eVects(50); bioactive-packaging made from nanomaterials can help to control the oxidation of food stuVs(51).
Further, the excessive consumption of anythingmay cause disease or premature death, even omega-3(eg 52, 53, 54).
In the United States, during the 90 year period from 1909 to 1999, a striking increase in the use of seed oils
occurred. Speciﬁcally, per capita consumption of salad and cooking oils increased 130 per cent, shortening
consumption increased 136 per cent and margarine consumption increased 410 per cent(55), which directly
increased daily energy intake due to their high energy-density (Table 2). These trends occurred elsewhere in
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the World and were made possible by the industrialization and mechanization of the oil-seed industry(56). The
trend towards an increase in daily energy intake was exacerbated by the excessive human consumption of
energy-dense cereals, seeds and nuts, and as meat from grain fed cattle, poultry and other livestock became
the norm in the Western diet over the past 100 years(23, 57).
The top predicted causes of death and disability Worldwide for 2020 (ischemic heart disease and unipolar
major depression) and three top causes in developed regions (ischemic heart disease, cerebrovascular disease
and unipolar major depression)(58) all seem linked to a lack of preformed DHA and EPA in the diet and excess
food energy (imbalance between the expenditure/intake of energy). The close interaction between omega-3
(including DHA/EPA) and omega-6 (including GLA, DGLA and AA) fatty acids on the ability to modify
inﬂammatory markers, production of PGI2, PGE1, PGI3, LXs, resolvins(59), neuroprotectins, NO (nitric
oxide), nitrolipids, and the action of statins (HMG-CoA reductase inhibitors) and glitazones (PPARs
agonists) on essential fatty acid metabolism and NO explains the relationship between various fatty acids and
CHD and stroke(60). Uncontrolled excessive production of pro-inﬂammatory mediators over prolonged
periods of time is associated with heart attacks, thrombotic stroke, arrhythmia, arthritis, asthma, headaches,
dysmenorrhea (menstrual cramps), inﬂammation, cancer and osteoporosis(61, 62) and the American Heart
Association urged putting more omega-3 HUFAs into daily diets(63). However, most epidemiologic cohort
studies found no association between DHA and EPA intake and cancer risk(64–66). But, inverse associations
with breast cancer have been reported in Chinese and Japanese women having omega-3 HUFA intakes up to
40 times greater than Western intakes(67–69). A large cohort study on breast cancer suggested that women with
the lowest DHA and EPA intake but highest omega-6 PUFA intake (highest energy intake/excess food
energy?—20–30 per cent of dietary fatty acids undergo betaoxidation to acetyl-CoA to enter the Kreb’s cycle
generating ATP(40)) could beneﬁt from increasing their omega-3 HUFA intake(70). Another study(67) found a
direct association between omega-6 PUFA intakes (energy intake/excess food energy?) and breast cancer risk
conﬁned to women having the lowest intakes of omega-3 HUFAs. Such observations are consistent with the
eVect of the absolute amount of omega-3 fatty acids on the biosynthesis of anti-inﬂammatory 3-series
eicosanoids(45); AA derived 2-series tumor promoting eicosanoids and/or decreased synthesis of anti-
inﬂammatory and beneﬁcial eicosanoidsmost likely being an underlyingmechanism for cancers such as colon,
breast, kidney and prostate cancer(71–73). Tumor cells undergo apoptosis on exposure to certain fatty acids
(especially in response to DHA, EPA and GLA) due to an increase in intracellular free radical generation and
the formation of lipid peroxides(60). Further studies are required to better explain the Worldwide variations in
the incidence of cancer which may be linked to diVerences in diet and lifestyle.
Additional evidence showed important actions of omega-3HUFAs in brain function(74). DHA is an important
component of human retinal and brain membranes and has been shown to play a role in the cognitive
development of infants(75–77). Poor maternal health and nutrition before and during pregnancy disadvantages
fetal development with permanent mental and cognitive deﬁcits(78) and behavioural dysfunction(79, 80)with a
risk of heart disease, diabetes and stroke in later life—prenatal programming(81, 82). Maternal nutrition before
and during pregnancy is an independent risk factor for low birth weight and poor pregnancy outcome(83–87). A
diet high in omega-6 PUFAs is generally thought to be associatedwith an increased risk of preterm delivery(88).
Increasing evidence suggests that depression, bipolar disorder, behavioral disorders and cognitive impairment
in later life (dementia) also relate to a lack of DHA and EPA in the human diet (reviewed by 89). Supplementation
with a combination of both DHA and EPA (or consumption of aquatic-based foods) is likely to be more
eVective than use of either alone(90). There is increasing evidence that the reasons for brain disorders are related
to the replacement of aquatic-based foods by land-based foods(80, 91, 92). Thus, it is especially important to eat
a diet rich in essential brain nutrients DHA, EPA, I, Fe, Cu, Zn and Se (aquatic foods) before the inception
of pregnancy, during pregnancy and breastfeeding and to give it to young infants (eg in baby food) to ensure
optimal brain development and help prevent mental ill-health. The regular consumption of essential brain
nutrients should continue throughout life because although the brain recycles its constituents rather than
relying on imports, the process is not 100 per cent eYcient and the continual loss needs to be replaced by
some import.
The growing awareness of the importance of DHA and EPA omega-3 fats is evident from the single major
personal health change recommended by the health and nutrition division members of the American Oil
Chemists’ Society: to eat more ﬁsh and take an omega-3 supplement(93). The fats and oils from aquatic based-
foods contain high contents of these beneﬁcial omega-3 fatty acids but increased consumer demand has also
increased strain on the ability of the World’s ﬁsheries to meet demand from wild capture. Many consumers
are choosing ﬁsh oil supplements or are eating foods that have been complemented with ﬁsh oils instead of
consuming aquatic foods directly. However, removing undesirable odours, ﬂavours and contaminants is
expensive. In contrast, oils derived from land plants such as soybean are inexpensive and contaminant free.
Given the potential beneﬁts to the environment with regards to over-ﬁshing and the health prospects of
increased consumption of these healthy fatty acids, producing these fatty acids in oilseeds is a desirable and
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worthy goal (except for the high-energy density of oils (and fats) which may be reduced using
nanotechnology(94)).Molecular biology now allows the engineering of oilseeds for the production ofDHAand
EPA omega-3 HUFAs in a seed oil with an omega-3:6 ratio 1.5:1 (a ratio close to that of many ﬁsh oils)(41). A
bread containing nanocapules of DHA/EPA omega-3 fatty acids is being sold in Australia as Tip-Top
Bread(94).
Increasing human consumption of DHA, EPA and ALA omega-3 fats and by humans eating less food energy
per meal (eg a 2,000-kcal daily diet consumed in six smaller energy portions—breakfast, brunch, lunch,
afternoon tea, dinner and supper, rather than three large portions) to lower transient short-livedmeal-induced
oxidative stress(95–97), inﬂammation, proliferation and impaired nitric oxide(98–102), ultimately could have far-
reaching eVects on health and well-being. However, appreciating the nutrients essential for brain
development(4, 5), the addition of I, Fe, Cu, Zn and Se to daily diets including DHA and EPA rich engineered
seed oils with reduced levels of toxic factors and anti-nutrients (eg phytic acid) that impact bioavailability and
utilization of nutrients and increased levels of factors that enhance bioavailability of essential nutrients(103, 104),
would have even greater positive implications for human mental health in addition to helping prevent diet
mediated inﬂammatory diseases. Further, for their physiological/beneﬁcial action(s) PUFAs need many co-
factors such as folic acid, vitamin B12, vitamin B6, vitamin C, tetrahydrobiopterin (H4B), zinc, magnesium,
calcium, L-arginine, and small amounts of selenium and vitamin E(105). Hence, it is essential that these co-
factors should also be provided in adequate amounts to bring about the beneﬁcial action of omega-3 and
omega-6 fatty acids. Although principally a lack of DHA and EPA and excess food energy link diet to
cardiovascular disease and premature death, evidence gleaned over the past three decades now indicates that
virtually all so-called diseases of civilization arise from a complex interaction of multiple nutritional factors
directly linked to the replacement of ancestral foods by the excessive consumption of novel Neolithic and
Industrial era foods, along with other environmental agents and genetic susceptibility (c.f. 33).
Energy-density
Reﬁned grain and sugar products nearly alwaysmaintainmuch higher energy densities than unprocessed fruits
and vegetables. In the typical USA diet, sugars with a high energy density (HFCS 42, HFCS 55, sucrose,
glucose, honey, and syrups) now supply 18.6 per cent of total energy, whereas reﬁned cereal grains with a high
energy density supplies 20.4 per cent of energy(33). Soybean oil 8.8 kcal g"1 (data calculated from USDA
National Nutrient Database for Standard Reference), appears to deliver 20 per cent of all calories in the
median USA diet, with x9 per cent of all calories from LA alone(55). Within the past 20 years, substantial
evidence has accumulated showing that long term consumption of high-energy-dense ( 2 kcal g-1(106)) foods
can adversely aVect metabolism and health(107–109). Hence, 39 per cent of the total energy in the typical USA
diet is supplied by foods that may promote the causes of insulin resistance(110–115). In addition to high-energy-
dense carbohydrates, other elements of Neolithic and Industrial Era foods may contribute to the insulin
resistance underlying metabolic syndrome diseases. Milk, yogurt and ice cream are highly insulinotropic, with
insulin indexes comparable with white bread(116). It is known that omega-3 PUFAs are of beneﬁt in type 2
diabetes by decreasing insulin resistance(117). Diseases of insulin resistance include obesity, type 2 diabetes and
hypertension.
The global epidemic of obesity-associated diabetes is a symptomof themodern diet and lifestyle, in which food
is plentiful and exercise is optional. Type 2 diabetes accounts for 90 per cent of all diabetes cases around the
World(29). Obesity and sedentary lifestyles closely linked with this type of diabetes(29) are both modiﬁable and
even preventable risk factors. A healthy diet-plus-exercise is most eVective for preventing diabetes mellitus(118).
Unfortunately, in modern societies, it is often easier to persuade people to take a pill, than to persuade them to
change their diet and lifestyle for the long-term.Diet inducedmetabolic syndromemay extend to other chronic
illnesses and conditions that are widely prevalent in Westernized societies, including: myopia(119), acne(120),
gout(121), polycystic ovary syndrome, epithelial cell cancers (breast, colon, and prostate), male vertex balding,
skin tags and acanthosis nigricans(109). Although sugars and grains with a high-energy-density now represent
a dominant element of the modern urban diet, these foods were rarely or never consumed by average citizens
as recently as two hundred years ago(33). Diseases of insulin resistance are rare or absent in hunter-gatherer
and other less westernized societies living and eating in their traditional manner(14, 122, 123).
The ﬁnding that persons with a low-energy-dense ('1.6 kcal g-1) diet had the lowest total intakes of energy,
even though they consumed the greatest amount of food has important implications for promoting
compliance with prescribed dietary regimens(106). A reduction in liquid calorie intake has been found to have
a stronger eVect than has a reduction in solid calorie intake on weight loss(124). Of the individual beverages,
only intake of sugar-sweetened beverages (SSBs) was signiﬁcantly associated with weight change(124). A diet
plan that severely restricts the amount of food a patient consumes will likely lead to feelings of hunger and
have unfavourable inﬂuences on the patient’s satisfactionwith the diet and long-term compliance. Overweight
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and obese patients may develop paradoxical nutritional deﬁciency from eating high-energy foods with a poor
nutrient content. The impact of sedentary lifestyles and availability of energy-dense food in modern societies
is undeniable, but substantial individual diVerences in bodyweight persist, suggesting that individuals respond
diVerently to the “obesogenic” environment(125). Psychometric measures of child appetite and child weight
suggest that appetitive trait proﬁles may not only promote obesity but also protect against it and will include
both genetic and environmental inﬂuences(125)which require further investigation.
High energy density (c.f. Table 2) and low nutrient density (Table 3) which characterise diet in developed
countries are major targets that must be overcome. 2,000 kcal day-1% 334g of chocolate (70–85 per cent
cocoa), 353g peanuts, 496g cheddar cheese, 554gKellogg’s@Corn Flakes, 1,681g chocolatemilkshake, 2,325g
mussels, 2,439g cod, 4,444g fresh orange juice or 8,695g spinach (data calculated from USDA National
Nutrient Database for Standard Reference). Nanotechnology or molecular biology may be able to engineer
high-energy-dense foods abundant in the modern diet to maintain lower energy densities ('1.6 kcal g-1) while
looking and tasting the same as before modiﬁcation to aid public acceptance and reduce any insulinotropic
properties with potential positive eVects on metabolism and health.
Macronutrient Composition
In the present USA diet, the percentage of total food energy derived from the three major macronutrients is
as follows: carbohydrate (51.8 per cent), fat (32.8 per cent), and protein (15.4 per cent)(33). Advice for reducing
the risk of cardiovascular disease and other chronic diseases has been to limit fat intake to 30 per cent of total
energy, to maintain protein at 15 per cent of total energy and to increase complex carbohydrates to 55–60 per
cent of total energy (eg 126). Both the current USA macronutrient intakes and suggested healthful levels diVer
considerably from average levels obtained from ethnographic(34) and quantitative(127) studies of hunter
gatherers in which dietary protein is characteristically elevated (19–35 per cent of energy) at the expense of
carbohydrate (22–40 per cent of energy)(34, 127). Because protein has( three times the thermic eVect of either
fat or carbohydrate(128)and because it has a greater satiety value than do fat or carbohydrate(128, 129), increased
dietary protein may represent an eVective weight-loss strategy for the overweight or obese. Studies have
indicated that ﬁsh protein may have a greater eVect on satiety compared to other protein sources of animal
origin (see 130). Clinical trials have shown that calorie-restricted, high-protein diets are more eVective than are
calorie-restricted, high-carbohydrate diets in promoting(131–133) and maintaining(134)weight loss in overweight
subjects while producing less hunger and more satisfaction(135). Furthermore, high protein diets have been
shown to improve metabolic control in patients with type 2 diabetes(136–138). In obese women, hypocaloric,
high-protein diets improved insulin sensitivity and prevented muscle loss, whereas hypocaloric, high-
carbohydrate diets worsened insulin sensitivity and caused reductions in fat free mass(139). In numerous
population studies, summarized by Obarzanek et al(140), higher blood pressure has been associated with lower
intakes of protein. An increasing body of evidence indicates that high-protein diets may improve blood lipid
proﬁles(137, 138, 141–143) and thereby lessen the risk of diet induced disease.
Improvements in the nutritional value of crop plants, in particular the protein composition has been a major
long-term goal of plant breeding programs. Molecular biology has produced transgenic potatoes with about
33 per cent more protein and substantial amounts of essential amino acids including lysine(144), which is
deﬁcient in many developing countries where diets are heavily based on cereals(21, 103). Strains of protein-
enriched maize have also been created(145). Some protein based nanotubes are considered food-grade
materials(146), which should make their introduction into the human food chain relatively easy and might
further facilitate increases in protein composition of currently high carbohydrate foods. The future looks
promising to increase protein consumption at the expense of carbohydrate in the human diet, with numerous
potential health beneﬁts.
Micornutrient Density
Reﬁned sugars are essentially devoid of any vitamin or mineral (Table 2). Accordingly, the consumption of
reﬁned sugar or foods containing reﬁned sugar reduces the total vitamin and mineral (micronutrient) density
of the diet by displacing more nutrient dense foods (Table 2). A similar situation exists for reﬁned seed and
nut oils (Table 2), except that they contain two fat-soluble vitamins (vitamin E and vitamin K)(147). Because
seed and nut oils and reﬁned sugars contribute(36.2% of the energy in a typical USA diet, the widespread
consumption of these substances, or foods made with them, has considerable potential to inﬂuence the risk of
vitamin and mineral deﬁciencies(33). At least half the USA population fails to meet the recommended dietary
allowance (RDA) for vitamin B-6, vitamin A, magnesium, calcium, and zinc, and 33% of the population does
not meet the RDA for folate(33). Wild foods known to be consumed by hunter-gatherers generally maintain
higher micronutrient concentrations than do their domesticated counterparts(13, 148), as does the muscle meat
of wild animals(147).
347nanotechnologies and food: evidence
Endemic clinical and sub-clinical iodine deﬁciency is present in about 20 per cent of humans Worldwide. The
global problem of iodine deﬁciency primarily aVects people not regularly consuming shellﬁsh, ﬁsh or iodized
table salt, without which clinical hypothyroidism, subnormal cognitive development and cretinism would still
be the public health dilemma they were prior to iodization of table salt(149). The scale and impact of endemic
iodine deﬁciency is rivalled only by iron deﬁciency. Two billion people, over 30 per cent of the World’s
population are anaemic, many due to lack of iron(150). Unlike iodine, iron is not yet legislated into the food
supply but great eVorts are beingmade to ﬁnd a simple, cheap, reliable way to provide iron supplements where
they are needed. Iron and other key minerals needed for brain development and function (zinc, copper,
selenium) are more bio-available from shellﬁsh and ﬁsh than from plant-based diets where their absorption is
impaired by phytates and other anti-nutrients. Plant based diets rich in staples like cassava or soy (the basis
of many vegan and vegetarian food products) are not only a very poor source of iodine but they also contain
goiterogens which inhibit iodine absorption(149).
The displacement of more nutrient-dense foods (eg aquatic-based foods) by less nutrient-dense novel foods
(reﬁned sugars, cereals, seed and nut oils and dairy products) and the subsequent decline in dietary vitamin
andmineral density has far reaching health implications, consequences that not only promote the development
of vitamin-deﬁciency diseases but also numerous infectious and chronic diseases(21).
Bio-fortiﬁcation of novel foods through modern methods of biotechnology/nanotechnology has the potential
to help oVset essential nutrient deﬁciencies and improve human health through elevated levels of essential
nutrients (including their co-factors(105)), reduced levels of toxic factors and anti-nutrients that impact
bioavailability and utilization of nutrients, and increased levels of factors that enhance bioavailability of
nutrients(103, 104). A number of crops, developed with a focus on improving nutritional quality are advancing
through regulatory processes towards commercialization(103). Some examples of nutritionally enhanced crops
include cyanogen-free cassava(151); nutritionally enhanced rice with an elevated level of beta-carotene(152),
increased levels of iron and zinc(153), an elevated level of cysteine residues to enhance iron bioavailability and
a decreased level of phytates to improve iron and zinc bioavailability(154); and tomatoes and soybeans with
increased antioxidant contents(155). Food and nutrition products that contain nanoscale additives are already
being sold, such as iron in nutritional drink mixes, micelles that carry vitamins, minerals and phytochemicals
in oil and zinc oxide in breakfast cereals(51). Other food nanotechnology products are cooking oils that contain
nutraceuticals within nanocapsules and nanoparticles that have the ability to selectively bind and remove
chemicals from food (“Nanotechnology in agriculture and food”, available at http://www.nanoforum.org).
Delivery of fragile micronutrients including their co-factors can be improved through nanoencapsulation(156).
By reducing particle size, nanotechnology can contribute to improve the properties of bioactive compounds
(eg DHA and EPA), such as delivery properties, solubility, prolonged residence time in the gastrointestinal
tract and eYcient absorption through cells(157). Bioactive compounds that are encapsulated into the packaging
itself are a promising approach because this would allow the release of the active compounds in a controllable
manner(51).
Acid-base Balance
After digestion, absorption, andmetabolism, nearly all foods release either acid or bicarbonate (base) into the
systemic circulation(158, 159). Virtually all pre-agricultural diets were net base yielding because of the absence of
cereals and energy-dense, nutrient poor foods, foods that were introduced during the Neolithic and Industrial
Eras and that displaced base-yielding fruit and vegetables(159). Consequently, a net base-producing diet was
probably the norm throughout most of hominin evolution(159). The known health beneﬁts of a net base-
yielding diet include preventing and treating osteoporosis(160, 161), age-related muscle wasting(162), calcium
kidney stones(163, 164), hypertension(165, 166), and exercise-induced asthma(167) and slow the progression of age
and disease-related chronic renal insuYciency(168). Research is required to determine if micro- and
nanotechnologies can modify novel net acid producing cereals to become net base yielding foods.
Salt
The average sodium content (3,436mg day"1) of the typicalUSAdiet is substantially higher than its potassium
content (2,617 mg day"1)(169). The addition of manufactured salt to the food supply and the displacement of
traditional potassium-rich foods by foods introduced during the Neolithic and Industrial periods (Tables 3
and 4) caused a 400 per cent decline in the potassium intake while simultaneously initiating a 400 per cent
increase in sodium ingestion(13, 22, 170). The potassium concentrations in vegetables are four and 12 times those
in milk and whole grains, respectively, whereas in fruit the potassium concentration is two and ﬁve times that
in milk and whole grains(147). The inversion of potassium and sodium concentrations in hominin diets had no
evolutionary precedent and now plays an integral role in eliciting and contributing to numerous diseases of
civilization(33). Diets low in potassium and high in sodium may partially or directly underlie or exacerbate a
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variety of maladies and chronic illnesses, including hypertension, stroke, kidney stones, osteoporosis,
gastrointestinal tract cancers, asthma, exercise-induced asthma, insomnia, air sickness, high-altitude sickness
and Meniere’s Syndrome (ear ringing)(171–181). The removal of sodium salt from processed foods and bio-
fortiﬁcation of cereals and dairy products with potassium may help alleviate the current sodium-potassium
imbalance in the human diet.
Fibre Content
The ﬁbre content (15.1 g day"1)(169) of the typical USA diet is considerably lower than some recommended
values (25–30 g)(126). Reﬁned sugars, seed and nut oils, dairy products, and alcohol are devoid of ﬁbre and
constitute an average of 48.2 per cent of the energy in the typical USA diet(33). Furthermore, ﬁbre-depleted,
reﬁned grains represent 85 per cent of the grains consumed in the USA and because reﬁned grains contain 400
per cent less ﬁbre than do whole grains (by energy), they further dilute the total dietary ﬁbre intake(33). Fresh
fruit typically contains twice the amount of ﬁbre in whole grains, and non starchy vegetables contain almost
eight times the amount of ﬁbre in whole grains on an energy basis(147). Fruit and vegetables known to be
consumed by hunter-gatherers also maintain considerably more ﬁbre than do their domestic counterparts(148).
Diets low in dietary ﬁbre may underlie or exacerbate constipation, appendicitis, hemorrhoids, deep vein
thrombosis, varicose veins, diverticulitis, hiatal hernia, and gastroesophageal reﬂux(182).
Fibre type and quantity are undoubtedly under genetic control, although this topic has received little attention.
The technology to modify ﬁbre content and type by micro- and nano-engineering would be a great beneﬁt in
persuading the many individuals who, for taste or other reasons, do not include adequate amounts of ﬁbre in
their daily diet. For example, ﬁbre content could be added to more preferred foods (eg milk, cheese, ice cream,
reﬁned cereals and white bread—but these are all novel foods that can currently (without modiﬁcation)
promote the diet induced diseases of civilization) or the more common sources of dietary ﬁbre could be altered
for greater health beneﬁts.
Science Communication to the Public
The risks of well regulated and rigorously tested food micro- and nanotechnology products that help prevent
disease are likely to be insigniﬁcant when compared with the magnitude of the current problem of the diet
induced disease epidemic. Using bio-nanotechnology (or molecular biology) to engineer foods so they cannot
(without excessive consumption) promote diet induced diseases is likely to be of great beneﬁt to mankind. In
reality there are already more humans on Earth, than can be sustained by the natural World. However, the
consumption of (wild) aquatic-based foods in a sustainable manner should not be discouraged and
nanotechnology will probably enhance the production, utilization and food safety of this nutritious resource.
Bio-nanotechnology will change society beyond anything that has gone before. This should, but not with any
certainty, eventually slow down the spiraling diet induced healthcare costs. Further, today’s controversial
areas such as nanotechnologies in foods, stem cell research, cloning, gene therapy, human enhancement and
biochip implants will become acceptable practice before 2050.(1)
Conclusion
Chronic illnesses and health problems either wholly or partially attributable to diet account for the largest
burden of chronic illnesses and health problems Worldwide. These diseases (eg cardiovascular disease) are
epidemic in modern societies and typically aZict 50–65 per cent of the adult population, yet they are rare or
non-existent in hunter-gatherers and other lessWesternized people.What theWorld needs is an integrated and
sustainable food policy that makes the best, and most appropriate use of the technologies at our disposal. To
promote health and help prevent disease the future direction of food production should be towards greater
production of anti-inﬂammatory (DHA, EPA, ALA, LA and AA proﬁle similar to aquatic foods eg mussels
Mytilus spp), higher protein (x one third of total food energy intake at the expense of lowered carbohydrate),
low-energy-dense, high ﬁbre (25–30g day"1), bio-available nutrient rich (including co-factors), high
potassium—low sodium, brain foods (foods rich in preformed DHA, EPA, I, Fe, Cu, Zn and Se—aquatic
foods). Micro- and nanotechnologies are already engineering foods for human (and livestock) consumption
that may eventually (without excessive consumption) prevent the current diet induced disease epidemic,
especially in future generations, by preventing the causal mechanisms of disease. Nanoscience and
nanotechnology are new frontiers and their potential cannot be underestimated. There is still an ocean of
knowledge about the causal mechanisms of disease that awaits to be discovered, which could further enhance
the human desire to increase longevity in optimum health (creatingmore problems and challenges for society).
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Table 2
AMOUNT (G) OF A SELECTION OF FOODS EQUIVALENT TO THE 119 KCAL OF ENERGY IN
ONE TABLESPOON (13.5 G) OF OLIVE OIL (04053)
Food g
Chocolate bar, 70–85% cocoa (19904) 20
Peanuts (16087) 21
Chocolate cookies (18159) 25
Masterfoods@, Snickers Bar (19155) 25
MuYn, blueberry (18274) 30
Cheese, cheddar (01009) 30
Oats (20038) 30
Sugars, granulated (19335) 31
Kellogg’s@, Corn Flakes (08020) 33
Distilled alcoholic drink, 50% abv (14533) 41
Beef, brisket (13803) 47
Bread, whole-wheat (18075) 48
Chicken, with skin (05006) 55
Ice cream, vanilla (19095) 58
Pork, loin (10020) 60
Salmon, Atlantic (15076) 84
Anchovy, European (15001) 91
Chocolate milkshake (01110) 100
Shrimp, mixed species (15149) 112
Bananas (09040) 134
Crab, Dungeness (15143) 138
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Food g
Mussel, blue (15164) 138
Red wine (14096) 140
Cod, Atlantic (15015) 145
Oyster, Paciﬁc (15171) 147
Clam, mixed species (15157) 161
Potatoes (11354) 172
Apples (09003) 229
Seaweed, wakame (11669) 264
Orange juice, freshly squeezed (09206) 264
Carrots (11124) 290
Budweiser@, beer (14004) 290
Cola, soft drink (14148) 290
Spinach (11457) 517
Tomatoes, red (11529) 661
Lettuce (11251) 700
Drinking water, tap (14411) N/A
1 Entries retrieved from the US Department of Agriculture,
Agricultural Research Service, 2007, USDA National Nutrient
Database for Standard Reference, Release 21, http://
www.ars.usda.gov/ba/bhnrc/ndl are followed by a 5-digit
nutrient database number in parentheses. Data were not
adjusted for country and seasonal speciﬁc diVerences in





































ESTIMATED FATTY ACID COMPOSITION OF A RANGE OF AQUATIC
AND LAND BASED FOODS
Food Omeag-3 Fatty acids Omega-6 Fatty acids
ALA (18:3w"3) EPA (20:5w"3) DPA2 (22:5w"3) DHA (22:6w"3) LA (18:2w"6) AA (20:4w-6)
Aquatic g/100g g/100g
Mussel, blue (15164)1 0.020 0.188 0.022 0.253 0.018 0.070
Oyster, Paciﬁc (15171) 0.032 0.438 0.020 0.250 0.032 0.038
Shrimp, mixed species (15149) 0.014 0.258 0.046 0.222 0.028 0.087
Crab, blue (15139) 0.000 0.170 0.000 0.150 0.012 0.055
Salmon, Atlantic (15076) 0.295 0.321 0.287 1.115 0.172 0.267
Mackerel, Atlantic (15046) 0.159 0.898 0.212 1.401 0.219 0.183
Catﬁsh, channel (15010) 0.071 0.130 0.100 0.234 0.101 0.149
Seaweed, wakame (11669) 0.002 0.186 0.000 0.000 0.010 0.021
Salmon oil (04593) 1.061 13.023 2.991 13.232 1.543 0.675
Land
Spinach (11457) 0.138 0.000 0.000 0.000 0.026 0.000
Kale (11233) 0.180 0.000 0.000 0.000 0.138 0.002
Carrots (11124) 0.002 0.000 0.000 0.000 0.115 0.000
Potatoes, white (11354) 0.010 0.000 0.000 0.000 0.032 0.000
Chickpeas, cooked (16057) 0.043 0.000 0.000 0.000 1.113 0.000
Mung beans, cooked (16081) 0.009 0.000 0.000 0.000 0.119 0.000
Milk, 3.7% fat (01078) 0.053 0.000 0.000 0.000 0.083 0.000
Cheese, cheddar (01009) 0.365 0.000 0.000 0.000 0.577 0.000
Butter, unsalted (01145) 0.315 0.000 0.000 0.000 2.728 0.000
Egg, whole (01123) 0.033 0.004 0.000 0.037 1.148 0.142
Chicken, with skin (05006) 0.140 0.010 0.010 0.030 2.880 0.080
Chicken, no skin (05011) 0.020 0.010 0.020 0.030 0.550 0.080
Pork, shoulder (10070) 0.130 0.000 0.000 0.000 1.600 0.100
Beef, sirloin (13954) 0.052 0.000 0.000 0.000 0.303 0.039
Lamb, domestic (17011) 0.320 0.000 0.000 0.000 1.090 0.070
Wheat ﬂour, whole grain (20080) 0.038 0.000 0.000 0.000 0.783 0.002
Cornmeal, whole grain (20320) 0.049 0.000 0.000 0.000 1.589 0.000
Rice ﬂour, brown (20090) 0.042 0.000 0.000 0.000 0.954 0.000




































Food Omeag-3 Fatty acids Omega-6 Fatty acids
ALA (18:3w"3) EPA (20:5w"3) DPA2 (22:5w"3) DHA (22:6w"3) LA (18:2w"6) AA (20:4w-6)
Kellogg’s,@ All-Bran (08001) 0.150 0.000 0.000 0.000 1.960 0.000
Kellogg’s,@ Corn Flakes (08020) 0.020 0.000 0.000 0.000 0.300 0.000
Kellogg’s,@ Special K (08067) 0.096 0.000 0.000 0.000 0.705 0.000
Masterfoods,@ Snickers Bar (19155) 0.048 0.000 0.000 0.000 2.966 0.000
MuYns, blueberry (18274) 1.234 0.000 0.000 0.000 8.469 0.000
Bread, whole wheat (18075) 0.025 0.000 0.000 0.000 0.574 0.001
Tortillas, corn (18363) 0.034 0.000 0.000 0.000 1.385 0.000
Walnuts, english (12155) 9.080 0.000 0.000 0.000 38.093 0.000
Peanuts (16087) 0.003 0.000 0.000 0.000 15.555 0.000
Pecan nuts (12142) 0.986 0.000 0.000 0.000 20.628 0.000
Brazilnuts (12078) 0.035 0.000 0.000 0.000 20.543 0.000
Almonds (12061) 0.006 0.000 0.000 0.000 12.061 0.000
Sunﬂower seeds (12036) 0.060 0.014 0.000 0.000 23.050 0.000
Sesame seeds (12024) 0.363 0.000 0.000 0.000 20.654 0.000
Flaxseed (12220) 22.813 0.000 0.000 0.000 5.903 0.000
Apples, with skin (09003) 0.009 0.000 0.000 0.000 0.043 0.000
Bananas (09040) 0.027 0.000 0.000 0.000 0.046 0.000
Oranges, Florida (09203) 0.011 0.000 0.000 0.000 0.031 0.000
Olive oil (04053) 0.761 0.000 0.000 0.000 9.762 0.000
Cottonseed oil (04502) 0.200 0.000 0.000 0.000 51.500 0.100
Groundnut oil (04042) 0.000 0.000 0.000 0.000 32.000 0.000
Corn oil (04518) 1.161 0.000 0.000 0.000 53.515 0.000
Soybean oil (04044) 6.789 0.000 0.000 0.000 50.952 0.000
Sesame oil (04058) 0.300 0.000 0.000 0.000 41.300 0.000
Sunﬂower vegetable oil (04060) 0.200 0.000 0.000 0.000 39.800 0.000
Palm oil (04055) 0.200 0.000 0.000 0.000 9.100 0.000
Flaxseed oil (42231) 53.300 0.000 0.000 0.000 12.700 0.000
Margarine, 80% fat (04628) 2.040 0.000 0.006 0.000 22.252 0.000
Benecol@ , light spread (04687) 2.187 0.000 0.000 0.000 9.724 0.000
Peanut butter (16097) 0.083 0.000 0.000 0.000 14.715 0.000
1 Entries retrieved from the US Department of Agriculture, Agricultural Research Service, 2007, USDA National Nutrient Database for Standard Reference,
Release 20, http://www.ars.usda.gov/ba/bhnrc/ndl are followed by a 5-digit nutrient database number in parentheses. Data were not adjusted for country and





































EXAMPLES OF THE ESTIMATED VITAMIN AND MINERAL CONTENT OF REFINED AND UNREFINED SUGAR, A SEED OIL, SHELLFISH,
LAND-BASED MEAT, A VEGETABLE AND A FRUIT
Units Food
/100g
Sucrose1, 2 Molasses3 Sunflower oil Mussel, blue Oyster, Pacific Beef, grass fed Broccoli Apples, with skin
(19335) (19304) (04060) (15164) (15171) (13047) (11090) (09003)
Vitamin C mg 0 0 0 8.0 8.0 0 89.2 4.6
Vitamin B-12 µg 0 0 0 12.00 16.00 1.97 0 0
Niacin mg 0 0.930 0 1.6 2.010 4.818 0.639 0.091
Riboﬂavin mg 0.019 0.002 0 0.210 0.233 0.154 0.117 0.026
Thiamine mg 0 0.041 0 0.160 0.067 0.049 0.071 0.017
Folate µg 0 0 0 42 10 6 63 3
Vitamin B-6 mg 0 0.670 0 0.050 0.050 0.355 0.175 0.041
Vitamin A µg4 0 0 0 48 81 0 31 3
Calcium mg 1 205 0 26 8 12 47 6
Iron mg 0.01 4.72 0.03 3.95 5.11 1.99 0.73 0.12
Magnesium mg 0 242 0 34 22 19 21 5
Phosphorous mg 0 31 0 197 162 175 66 11
Potassium mg 2 1464 0 320 168 289 316 107
Sodium mg 0 37 0 286 106 68 33 1
Zinc mg 0 0.29 0 1.60 16.62 4.55 0.41 0.04
Copper mg 0 0.487 NA 0.094 1.576 0.063 0.049 0.027
Manganese mg 0 1.530 NA 3.400 0.634 0.010 0.210 0.035
Selenium µg 0.6 17.8 NA 44.8 77.0 14.2 2.5 0.0
1 Entries retrieved from the US Department of Agriculture, Agricultural Research Service, 2007, USDA National Nutrient Database for Standard Reference,
Release 20, http://www.ars.usda.gov/ba/bhnrc/ndl are followed by a 5-digit nutrient database number in parentheses. Data were not adjusted for country and
seasonal speciﬁc differences in nutrient compositions of foods. 2 Sucrose is a reﬁned sugar. 3 Molasses is unreﬁned sugar. 4 Vitamin A units in retinol activity
equivalents (RAE).
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Table 4
ESTIMATED SODIUM AND POTASSIUM COMPOSITION OF A RANGE OF FOODS
AVAILABLE IN MOST DEVELOPED COUNTRIES
Food Sodium Potassium
mg/100g mg/100g
Salt, table (02047)1 38,758 8
Shrimp, mixed species (15149) 148 185
Salmon, chinook (15078) 47 394
Salmon, chinook smoked (15179)* 2,000 175
Spinach (11457) 79 558
Bananas (09040) 1 358
Wheat ﬂour, whole-grain (20080) 5 405
Bread, whole-wheat (18075)* 472 248
Milk, 3.7% fat (01078) 49 151
Cheese, cheddar (01009)* 621 98
Butter, unsalted (01145) 11 24
Butter, salted (01001)* 576 24
Pork, shoulder (10070) 65 302
Pork, salami (07071)* 2,260 378
Kellogg’s@ , Corn Flakes (08020)* 723 79
Kellogg’s@ , Special K (08067)* 721 196
Masterfoods@ , Milky Way Bar (19135)* 167 124
Margarine, 80% Fat (04628)* 654 18
Benecol@ , light spread (04687)* 670 4
Soy sauce (16123)* 5,637 217
Peanuts, dry roasted (16390) 6 658
Peanuts, dry roasted (16090)* 813 658
1 Entries retrieved from the US Department of Agriculture, Agricultural Research Service, 2007,
USDANational Nutrient Database for Standard Reference, Release 20, http://www.ars.usda.gov/ba/
bhnrc/ndl are followed by a 5-digit nutrient database number in parentheses. Data were not adjusted
for country and seasonal speciﬁc diVerences in nutrient compositions of foods. * indicates the
addition of sodium salt to the food.
3 March 2009
Memorandum by the Royal Academy of Engineering
Introduction
The Royal Academy of Engineering is pleased to submit evidence to the House of Lords Science and
Technology Committee call for evidence on “Nanotechnologies and Food”.
In 2004, the Royal Academy of Engineering and Royal Society were commissioned by Government jointly to
produce a study on “Nanoscience and nanotechnologies: opportunities and uncertainties”41. The study did
not focus particularly on the food industry; however most of the recommendations are relevant.
This response is based on contributions from Fellows of the Academy. The Academy is content for its input
into this call for evidence to be made public and would be pleased to provide supplementary evidence if
required. We have chosen to respond to the broad subject areas outlined in the call for evidence rather than
the speciﬁc questions.
41 www.raeng.org.uk/policy/reports/nanoscience.htm
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1. State of the science and its current use in the food sector
1.1 Nanoparticles occur naturally and have always been created as the products of combustion and food
cooking. Naturally occurring nanotechnology is present in many foods. For example, milk contains casein
micelles which consist of nanostructures and deliver calcium phosphate to the body.
1.2 New nanotechnologies for food tend to be based on existing systems rather than being completely novel.
Producing processing food can involve the creation of micro or nano structures, and understanding how those
created structures can be broken down in the digestive system. For example, understanding of how butter
emulsions are structured and broken down can be used to build new structures, producing butter with lower
fat content yet similar taste and “mouth-feel”.
1.3 Nutrition and pharmaceuticals
1.4 Nanoemulsions and particles in food can be used to deliver ﬂavours and nutrients. Examples include bio-
nanomaterials that allow metabolic inclusion and controlled release systems that help regulate diet and
nutrition. Coupled with a stronger understanding of how foods and nutrients are digested, these applications
could result in strong health beneﬁts. It is likely that bio-nanomaterials will increasingly be used for food
therapeutics (nutriceuticals).
1.5 Pharmaceutical drug products could also be delivered to the body using similar methods. “Smarter” bio-
molecules can be synthesised with tailored release and absorbency characteristics. Nanotechnology will
contribute to the low cost manufacture of these bio molecules.
1.6 Some nutritional and pharmaceutical applications (including those mentioned above) could be made
commercially available fairly easily, but the food industry tend to be more risk averse than most. The risks of
consumer rejection and reputation damage may outweigh any potential beneﬁts of a new food technology.
1.7 Food packaging
1.8 In developed countries, nanotechnology tends to be used to create sophisticated food products and
packaging to attract consumers. There is signiﬁcant research eVort in areas such as antimicrobial surfaces and
in reactive packaging (eg indicators that change colour when food is unsafe to eat). These packaging
technologies have obvious crossover withmedicinal applications such as “smart” bandages and anti-microbial
hospital surfaces.
1.9 Improving manufacturing
1.10 The food industry is keen to increase manufacturing eYciency and reduce waste. Nonstick surfaces that
enable a production plant to be cleaned and re-usedmore rapidly would reduce water usage and therefore cost.
It currently requires several litres of water to produce one litre of mineral water, because of cleaning
requirements. A range of products is now being tested in the market, using either nano patterning or
structuring methods. However, they are currently too expensive to be widely used, or need further
development.
2. Public engagement and consumer information
2.1 One of the most important issues to address is the requirement for continued dialogue with the public on
nanotechnology. Good public engagement is a two-way process that increases understanding of public
attitudes and why barriers in consumer acceptance of new technologies may exist.
2.2 In the US the widespread cultivation of genetically modiﬁed (GM) corn is generally accepted, whereas in
the UK there has been a backlash against all use of GMmaterials, including food. UK public attitudes to GM
and the reasons for the initial backlash are multi-faceted. The GM example illustrates the need for genuine
public dialogue around emerging technologies at an early enough stage to understand people’s expectations
and concerns, and the reasons underlying these. This indicates the need for public engagement to include those
who are not involved in the commercial aspects of the food supply chain.
3. Health and safety and regulations
3.1 Regulatory frameworks are currently adequate although there remains uncertainty over the relative
toxicity and therapeutic/nutritional beneﬁts of many nanomaterials. Research is occurring that will produce
data on the beneﬁts and risks; this should help inform regulation.
3.2 There are no speciﬁc provisions for nanomaterials within the Registration, Evaluation and Authorisation
of Chemicals (REACH) regulations.
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4. Other comments
4.1 Food production is a complex system involving many inputs such as water and energy. It is worth noting
that nanotechnologies can make an indirect contribution to improving food production by helping produce
clean water and energy more eYciently.
March 2009
Memorandum by the Royal Society
1. The Royal Society welcomes this opportunity to respond to the Select Committee’s call for evidence on
nanotechnologies and food. This submission has been prepared from previous policy work, and takes account
of recent developments in nanotechnologies and food. Our submission focuses on aspects of the call under
“health and safety”, “regulatory frameworks” and “public engagement and consumer information”.
Introduction
2. The Society agrees with the Select Committee that the use of nanotechnologies and nanomaterials in the
food sector requires investigation.We ﬁrst reported on the opportunities and uncertainties of nanoscience and
nanotechnologies in 2004 (Royal Society and Royal Academy of Engineering 2004). At that time, we noted
that nanoparticles and nanomaterials would ﬁnd future applications in the food sector; we recognise that
applications are now with us including food ingredients, food additives and food contact materials (eg
Chaudry et al 2008).
3. Nanoscience is likely to bring beneﬁt to manufacturers and consumers of foodstuVs and related products.
We note however that technical, social and ethical uncertainties, that we documented in 2004 and which have
not been wholly addressed, relate to nanotechnologies and food just as they do for other uses of nanoscience.
Yet use in food brings new concerns in the areas of health and safety, regulation, public and stakeholder
engagement, and consumer information.
4. There is need for openness and clarity in this area. There is a paucity of information on the current state
of commercial development of nanotechnologies applied to food, not helped by industry reticence and by a
general diYculty of determining genuine uses of nanoscience and nanomaterials in the commercial ﬁeld. We
would welcome a survey from the Select Committee of the extent of research, development and use of
nanoparticles related to foodstuVs, to add to other organisation’s inventories (see for example
www.nanotechproject.org/inventories/). It would seem reasonable to say that commercial activity is in its early
stages (Chaudry et al 2008). Therefore there remains a window of opportunity to address uncertainties, but it
will close fast.
Health and Safety
5. When we published our major report on the risks and opportunities associated with nanotechnologies in
2004, we concluded that most nanotechnologies posed no new risks. However, we highlighted at that time, and
have done repeatedly since, that there is a lack of evidence about the risks posed by manufactured
nanoparticles, particularly those that are free rather than ﬁxed. Our concern has been updated and reinforced
by the Royal Commission on Environmental Pollution (RCEP) report Novel materials in the environment
which concluded that we remain ignorant about many aspects of the toxicology of nanomaterials (RCEP
2008:30).
6. TheFood StandardsAgency (FSA) has undertaken a review of current procedures for identifying, assessing
and controlling any potential risks arising from the use of nanotechnologies or the presence of manufactured
nanomaterials in food (FSA 2008). We note that the FSA concluded that whilst current approaches to risk
assessment would be appropriate for nanomaterials, there are limited toxicological data on nanomaterials
available at present (p15). The European Food Safety Authority (EFSA) came to a similar conclusion but
went further, stating that the adequacy of current toxicological tests for nanomaterials has yet to be established
(EFSA 2009).We have to improve our fundamental understanding of these substances and high priority must
be given to ensuring that the underpinning research is undertaken to allow the assessment of risks associated
with manufactured nanoparticles. The balance must be found between the amounts of funding allocated to
the development of new applications compared with that being spent on the research needed to underpin the
responsible development of these technologies.
7. In March 2007, the Council for Science and Technology said that Government had not made suYcient
progress on its commitments to research, pointing in particular to research on toxicology and health and
environmental impacts (CST 2007). We acknowledge that Government has directed or contributed to a range
of research projects on risk and other aspects of nanotechnologies (eg DIUS 2008, Defra 2007). Previously we
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have argued for an alternative approach, suggesting that an interdisciplinary research centre with a directed
research programme would be the best mechanism for addressing knowledge gaps (RS/RAEng 2004, 2006a,
2007). The House of Lords might consider if a fragmented approach can grow capability in the UK and lead
to outcomes comparable with that which might be expected from a interdisciplinary research centre (physical
or virtual).
8. The import of nanomaterials into the food chain through unintended or accidental means must not be
overlooked. Previously we noted that organisms such as bacteria and protozoa may take in nanoparticles
through their cell membranes, allowing the particles to enter a biological food chain and introducing a possible
exposure route (RS/RAEng 2004:36). We note that the RCEP similarly considers incidental mechanisms by
which nanomaterials may enter the food chain, and highlight that the issue of bioaccumulation and entry of
nanoparticles and tubes into the food web has yet to be seriously addressed (RCEP 2008:38)
Regulatory Framework
9. Mechanisms must be explored that support the commercial development of nanotechnologies and which
take into account business interests whilst at the same time addressing uncertainties over the potential
environmental, health and safety risks of some nanomaterials. The Society has had success in raising and
discussing areas of uncertainty with business and industry, and we acknowledge that it does not only fall to
Government to fund research into the potential implications of products. With Insight Investment and
Nanotechnology Industries Association, the Royal Society held a workshop in November 2006 to explore
strategic responses to technical, social and commercial uncertainties of nanotechnology. The workshop
brought together 17 European companies with commercial interests in nanotechnologies from food and
chemicals manufacturers to retailers of healthcare and fashion (Royal Society/Insight Investment/
Nanotechnology Industries Association 2007).
10. Participants felt that business should be fully involved in the processes of agreeing common deﬁnitions,
standards and regulatory approaches so that their needs could be taken into account. One of the main
outcomes of the workshop was unanimous agreement on the requirements for a voluntary Code of Conduct
for businesses engaged in nanotechnology. To date Seven principles of the code and a series ofExamples of good
practice have been published (www.responsiblenanocode.org/). Some organisations represented on the Code
Working Group have interests in the food sector. These representatives could be used to develop links with
business and industry to explore the speciﬁc area of nanotechnologies and food.
11. The early initiation of discussions with businesses in the food sector may avert diYculties that have come
to light in the cosmetics sector where environmental, health and safety research has lagged behind commercial
exploitation. Lessons need to be learnt from the cosmetics experience. A particular concern concerns methods
of risk assessment. The European Commission’s Scientiﬁc Committee on Consumer Products (SCCP) has
indicated that we cannot ensure the adequacy of risk assessment methods for cosmetic products containing
nanomaterials, including products already on themarket (SCCP 2007).We understand that attempts to assess
methods have been hampered by industry reluctance to provide SCCP with information on the use of
nanoparticles and methods employed for their risk assessment. We recognise that proprietary and other issues
may limit the free and open exchange of information. Yet early discussion with representatives in the food
industry may begin to address barriers to business and industry working cooperatively with Government and
regulators.
12. Reluctance to participate is a pattern repeated in the Defra Voluntary Reporting Scheme for engineered
nanoscale materials (VRS). We have previously said that if participation in the VRS was poor, then Defra
should be prepared to take steps to make the schememandatory (RS/RAEng 2006b).With eleven submissions
in the two years that the voluntary scheme was operational, take-up was not encouraging. We have no reason
to change our opinion and recommendDefra look to put in place amandatory reporting scheme.We note that
the RCEP (2008) also recommended mandatory reporting of nanomaterials, and that the Canadian
Government recently moved to introduce the world’s ﬁrst mandatory scheme (Sanderson 2009), although we
understand that this will be a one-oV request for information on material used in 2008 (see eg
www.nanotechproject.org/news/archive/7061/).
13. We acknowledge that progress is being made towards understanding the fate and toxicity of particular
nanomaterials (eg the work of the OECD, to which the UK Government is contributing; DIUS 2008; Defra
2007). The programme of work however must continually evolve, not only to address sector developments
(such as the emergence of nanotechnologies applied to food) but also to assess, and if necessary control,
coming generations of nanotechnologies and nanomaterials.
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Public Engagement and Consumer Information
14. Public perception is broadly well disposed towards nanotechnologies and public thinking on
nanotechnology has previously been explored through engagement projects initiated by Government and
others. This should not be considered a ﬁnished project. First, public perception is dynamic and may change
due to myriad factors. Second, public dialogue on nanotechnologies needs to be more closely linked with
policy making processes than has been the case so far. Third, public dialogue needs to be a long term
commitment that follows and intersects with the evolution of the ﬁeld, and considers signiﬁcant developments
as they arise. We suggest that nanotechnologies and food is an area that now needs focused public dialogue
work and opportunities should be sought for the ﬁndings to feed into policy and innovation processes. A
leading example from which lessons can be drawn is the recently completed public engagement work by the
Engineering and Physical Sciences Research Council (EPSRC) on potential applications of nanotechnology
to healthcare. Public thinking was integrated into EPSRC’s subsequent prioritisation process.
15. In 2004 we anticipated the use of free nanoparticles in consumer products including food, yet have been
surprised at the speedwith which products have reached themarket. If food products containing nanoparticles
reach the market whilst there are uncertainties over their possible health eVects &/or methodologies used in
their risk assessment (as has happened in the case of cosmetics), then those products should identify the fact
that manufactured nanoparticulate material has been added (cf. RS/RAEng 2006a). But we stress that
labelling is no substitute for prioritising research that reduces those uncertainties.
16. The issue of food labelling may be a good candidate for focused public and stakeholder engagement.
Nanotechnologies have the potential to bring beneﬁt to manufacturers and consumers, and open dialogue
between the science, policy, commercial and public communities will be an important part of realising this.
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Memorandum by Hilary Sutcliffe, Responsible Nano Forum
This is the response of Hilary SutcliVe, Director of the Responsible Nano Forum, to the House of Lords
Science and Technology Select Committee Call for Evidence on Nanotechnologies and Food.
Personal Perspective Only
It is a personal perspective only and does not represent the views of the Steering Group or Trustees of the
Responsible Nano Forum who have not been consulted and have not contributed to the crafting of this
submission.
View informed by . . .
These views are formed in part from my recent involvement in the area of nanotechnology and governance
through the development of the Responsible Nano Code for which I ran the secretariat and also through the
work of the Responsible Nano Forum, a multi-stakeholder, not-for-proﬁt organisation which was set up in
August 2008. It’s purpose is: to serve the public good, we aim to inspire and motivate all stakeholders—
business, government, scientists, ngos, the public, the media and others—to play their part responsibly in
realising the beneﬁts of nanotechnology, minimising risks and involving the public in deliberation about the
social, ethical, health and environmental issues it raises. (See Appendix 1 for further information).
The research for and attendance at a recent Nano &Foodmeeting held by the Responsible Nano Forum. This
brought together key stakeholders across business, government, ngos, research and academia to discuss the
issues which arise in this area. This is part of the RNF remit to provide a “Forum for Reﬂection” for diVerent
stakeholders in the area of nanotechnology and also fulﬁlls its commitment to helping all stakeholders play
their part in the responsible development of the nanotechnologies.
State of the Science and its Current use in the Food Sector
Response—the urgent need for a shared understanding of the spectrum of nanotechnologies in all food related
applications (and in other products)
It is unlikely that anyone can adequately answer most of these questions posed and the lack of transparency
and understanding in this area may be a signiﬁcant barrier to the eVective current or future use of
nanotechnologies in food. One of the most important issues getting in the way of a comprehensive response
is the lack of a shared understanding of what actually constitutes nanotechnology and where areas of concern
really lie.
The lack of a publicly available, agreed, clear description of the diVerent ways in which the various
nanotechnologies can be used in food (and many other applications)—from naturally occurring particles in,
say, milk, to novel and newmaterials or processes. This has led to confusion among diVerent stakeholders and
perceptions of companies “keeping quiet” about their use of the technology and ngos “inﬂaming the debate”
unnecessarily.
This debate has often got stuck on the discussion about the size of the particles which constitute
nanotechnology in many fora, (eg under 100nm, up to 300nm etc), which has not been helpful as the question
is richer than simply a size issue. The discussion about safety and usage of nanotechnologies needs to be
broader than just a size issue.
In addition to the “what is nano” issue some information is required on where there are potentially real areas
of concern and where the technology is an extension of existing processes and the risks are minimal.
Some work is being done on that at OECD, EU and UK government level, but the communication is often
so heavily caveated that it is diYcult to see, not where the risks lie, but actually where the lack of risk lies.
Informal dialogues with experts in the area indicates that this is certainly possible, but concerns about, among
other things, legal and perception issues prevent it from happening.
This will allow for the focus of the discussion to be around these areas of uncertainty and potential concern
rather than a general catch all discussion about nano in general.
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It will give all stakeholders the ability to focus their attention, whether it be testing, legal issues, campaigning
positions etc where it is most needed.
The Responsible Nano Forum, as an independent, multi-stakeholder body would be pleased to assist in the




Response—The effectiveness of voluntary self-regulation
Whilst I am fundamentally opposed to voluntary codes of conduct which are designed to subvert or delay the
development of eVective legislation, and some are transparently designed for this purpose, I believe that there
may be a useful role for the right scheme in the area of nanotechnologies in which food and packaging
companies can usefully participate.
Current voluntary schemes
The UKVoluntary Reporting Scheme has been considered ineVective in that it had poor uptake among those
groups to whom it was targeted. However this does not mean that a reﬁned version may not achieve its aims,
whether a voluntary scheme in this area is appropriate is not certain.
Again the lack of clarity about the spectrum of nanotechnologies is not helpful in assessing which materials
and processes are appropriate for such a scheme and which are not and whether a voluntary approach is in
itself appropriate. It may be that a more targeted mandatory approach may be more eVective where there is
agreed concern about risks-as occurs with carbon nanotubes, or a precautionary approach appropriate where
expert advice concurs—but not in other areas.
The European Commission’s recommendation for a Code of Conduct for Responsible Research exists, but
drafting issues and lack of clarity about its monitoring and policing framework adds to the confusion about
its role and eVectiveness.
In addition the food industry (through the CIAA Code of Conduct) and the chemical industry (through
Responsible Care) are looking to demonstrate responsible behaviour through these initiatives. It is not clear
how the all important monitoring and evaluation process will work for these, detailed guidance is lacking and
industry support unclear.
For these reasons they cannot be considered “eVective” in that the behaviours required, the companies
involved and the monitoring process has not been fully developed to my current knowledge and so the success
of their stated aims is not known. Certainly they have not resulted in increased transparency about safety and
testing which is paramount, and therefore have probably not been successful so far.
Other commercial certiﬁcation schemes exist such as AssuredNano in the UK, forumnano in Germany and
CENARIOS in Europe. The level of support for these is unclear, though such schemes can make a useful
contribution to raising standards.
The Responsible Nano Code
Another scheme for the monitoring and assessment of companies involved in nanotechnologies is the
Responsible Nano Code (developed by a multi-stakeholder working group and sponsored by the Royal
Society, Insight Investment and the Nano KTN) has the potential to be eVective in its stated aims through a
process of benchmarking and comply or explain adoption, with transparent governance and reporting
schemes. Though it is a principles-based code and necessarily “high level” the Responsible Nano Code could
be eVective in:
(a) Promoting the issues of responsible nanotechnology to the range of organisations in all parts of the
supply chain frommaterials manufacturers to retailers and those involved in disposal and recycling.
(b) Allowing companies to demonstrate compliance with good practice in a transparent and easily
understood way for the consumer. Some aspects of the good practice outlined in the code are
enshrined in law, others are not. A voluntary initiative like this allows that information to be made
clear in a way that simple adherence to regulation does not.
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(c) Some feel that regulation in this area is not clear and ﬁt for purpose, if this is the case a voluntary
initiative such as this may help bridge that gap and provide information in the public domain to allay
concerns.
There are a number of such principles-based codes in operation in a number of ﬁelds, somemore eVective than
others. However where they are not monitored eVectively, Codes of Conduct like this can provide a sort of “ﬁg
leaf” which is counter productive to the responsible development of the sector and the perception of
responsibility with critical stakeholders. This aspect must be eVective in order for a voluntary initiative like
this to make a useful contribution.
The Responsible Nano Code is designed for use by companies across the world and has support and
champions in the US, Asia and Europe. The Responsible Nano Code working group has partnered with
Cranﬁeld University for the delivery of the benchmark and adoption process. However its usefulness is
dependent on signiﬁcant funding to enable the secretariat at Cranﬁeld to ﬁnalise the appropriate
benchmarking and compliance mechanisms to make the code eVective.
It is not appropriate that this comes from business alone and the government should consider how the
Responsible Nano Code can assist with the responsible development of nanotechnologies and how the UK
can take a lead through the support of such an initiative whilst also assisting in the development of a “level
playing ﬁeld” for UK companies operating across the globe.
Public Engagement and Consumer Information
Response—ongoing engagement required—not forgetting social and ethical issues
We believe that it is important that consumer are given information on nanotechnologies because it likely to
have a huge impact on all our lives. Not just because of the new and sometimes life changing products it may
help create or even the potential risks whichmay arise from the use of some nanomaterials or applications, but
the ways it, in combination with other technologies, may alter our societies, our attitudes and our approach to
our world.
This is central to the core purpose of the Responsible Nano Forum.
Information about the use of the various nanotechnologies in food should be part of that communication and
engagement programme. The description of the spectrum of the technology will be helpful in assessing when
and what is appropriate. For example labelling may be important in some areas where there is a hazard or an
uncertainty, but not in others where this is not the case.
Where there is uncertainty about the uncertainty it may also be appropriate to make this known in some way!
(See Nano&me below).
Clarity about the beneﬁts will also assist in building conﬁdence in the technology. At the moment it appears,
according to a submission to our Nano&Food meeting “there is no ‘killer app’ in the food area which makes
it worth the potential downside”. Also companies are too nervous to put their head above the parapet in this
area to promote a beneﬁt in case it gets shot oV, and the reputational hit aVects their other products.
Previous initiatives—basically effective in their context
There isn’t any particular reason why the public should currently know much about nanotechnologies, so
naturally the awareness is low. Neither is there any stakeholder to whom it is particularly important that they
know—ditto.
That being said, theUK is considered to be a leader in the area of public engagement with nanotechnologies—
there have been a number of engagement initiatives sponsored by the government, the Research Councils, the
consumer group Which?, various social science departments of universities, Phd students and even the East
MidlandsDevelopmentAgency. This is more thanmost/any other country has done and should be applauded.
The general attitude of the public may be summarised as—supportive, as long as the technology provides real
beneﬁts and is made safe for people to use and not destructive of the environment. Not an unreasonable
approach to a new technology!
These initiatives were considered eVective in achieving their goals in the context in which they took place.
However we now believe, as did the recent Royal Commission on Environmental Pollution, that it is now
appropriate to develop a more sustained approach to public communication and engagement on
nanotechnologies. This is central to the work of the Responsible Nano Forum.
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Nano&me—permanent, ongoing information for the public
The Responsible Nano Forum has developed the concept of a website, called nanoandme.org through which
we hope to contribute to this sustained approach. (See attached www.responsiblenanoforum.org for brief
outline of the site’s aims and style and “stills” of its proposed style—the pilot site will diVer, but not in overall
design “feel”.)
It aims to provide balanced information to the public and engage them in the debate about the issues—in
particular the potential social and ethical issues which may arise from the development of the technology.
We have had signiﬁcant co-operation from all stakeholders in the development of the content of this site,
including a government group convened to help communicate about regulation, ngo involvement in content
development and review, and business support and assistance in the development of product sectors and
overall review. This is hugely encouraging and will help achieve our aim of providing balanced information,
developed through an inclusive mechanism, in an easy to understand format.
DIUS have agreed to fund a pilot of this site for consultation with the participants of the previous public
engagement initiatives and opinion formers. The outcome of this consultation and the appetite and scope of
a ﬁnal site should be available in August 2009.
The site will incorporate a “Nano Debate” section which will not only feature the Forum’s own direct and on-
line engagement initiatives, but will also act as a showcase for others programmes.
For example sponsored initiatives by government or research councils on speciﬁc applications, online versions
of the relevant DEMOCS engagement projects, “Nano Cafe’s” (done successfully in the US), Meet the
Scientist events or business engagement projects.
We believe that this is an important contribution to the ongoing dialogue and involvement with the public. It
will require signiﬁcant ongoing funding, which we hope to achieve though multi-stakeholder funding streams
from government, business and charitable foundations.
Benefits of nanotechnologies
Our research has indicated that the focus of public debate was very much on the risks of nanotechnologies and
that the beneﬁts of the technology and linkages to some of societies pressing problems has not been adequately
explored, particularly in relation to the important challenges facing the UK—eg obesity, poverty, energy,
ageing etc.
We are aware of ad hoc initiatives looking at the beneﬁts of the technology in speciﬁc areas (eg environment,
nanomedicine) but that a cohesive strategy had not been developed which makes these connections and links
nano development with the UK research strategy, the commercialisation incentives for the technology and the
UK development strategy. This maybe particularly interesting in relation to nano in food and the obesity
debate.
We believe that the government’s ministerial committee has indicated that a public and stakeholder debate
about the UK’s nanotechnology strategymay be appropriate, but that this is not currently envisaged as linked
to some of the UK’s challenges. We support that move, but think that it is essential to join up the discussion
about nano and other technologies with the pressing issues we face as a society.
The potential for a permanent “Nano Commission” style organisation?
Would it be useful to have a permanent, independent organisation with the authority to engage stakeholders
and advise government on these issues—in the style of Human Genetics Commission or the Sustainable
Development Commission—with multi-stakeholder governance and an independent remit?
The stakeholder engagement we undertook as part of the development process for the Responsible Nano
Forum and our subsequent work has led us to consider that this maybe a useful step in promoting the
responsible development of the technology in a way which maximises its potential for the UK and engages the
public appropriately in the process of its development. This is as necessary in the area of nano and food as it
is in any other.
The Responsible Nano Forum as it is currently conﬁgured is funded a charitable foundation (the Esme
Fairbairn Foundation) and by money raised for projects. We are more of an “ngo” or “think tank” than a
formally constitute organisation. No detailed planning has been undertaken to assess the usefulness of such
an organisation, its governance or its remit and if or how the Responsible Nano Forum could contribute to
or evolve into such an organisation, neither has our our Steering Group had chance to discuss this thinking.
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But we raise it here to contribute to take further the question raised in the original Royal Society report of
2004 andmentioned by the Royal Commission for Environmental Pollution of what institutions may be most
appropriate to help ensure the responsible development of the technology, in food and any other area sector.
APPENDIX 1
THE RESPONSIBLE NANO FORUM
Our Purpose
To serve the public good, we aim to inspire and motivate all stakeholders—business, government, scientists,
ngos, the public, the media and others—to play their part responsibly in realising the beneﬁts of
nanotechnology, minimising risks and involving the public in deliberation about the social, ethical, health and
environmental issues it raises.
Why this is Important
Nanotechnology is likely to have a huge impact on all our lives. Not just because of the new and sometimes
life changing products it may help create or even the potential risks which may arise from the use of some nano
materials or applications, but the ways it, in combination with other technologies, may alter our societies, our
attitudes and our approach to our world.
Because of this, we believe it is essential that everyone, particularly the general public, is aware of the
nanotechnology, has access to information about its uses and has the opportunity to help shape the way the
technology develops. We believe there is a need for an impartial voice in the debates around nano and we will
strive to avoid creating concern or conﬁdence where it is not appropriate.
Our Strategy is:
— To ensure easy access to clear and balanced information on nanotechnologies and the products it
enables.
— To act as a catalyst for the involvement of the general public in shaping and contributing to the
debate about nanotechnologies and the direction of current and future research.
— To stimulate others to play their part in the responsible development of nanotechnologies and nano-
enabled applications.
— To be a trusted forum for reﬂection about some of the social, ethical, health and environmental
issues, in which all stakeholders can and do participate.
— To stimulate and promote the development of “socially beneﬁcial” applications of nanotechnology.
Our Plan of Action
Our plan of action will evolve as we continue our process of research, engagement and involvement with
opinion formers and the general public. However, an opinion former consultation sponsored by the UK
government (DIUS) inspired our plan for a number of important areas of work with which to begin:
— www.nanoandme.org—a website for consumers.
— The hub of public engagement and communication for the general public.
— Comprising easy to understand, impartial information on nano, including the range of
stakeholder perspectives and current and future social, ethical health and environmental
aspects.
— Highlighting ways people can get involved and contribute to the debate and shape its
development.
— Including database of current UK consumer products using nano, the classiﬁcation and
deﬁnitions used in the diVerent sectors and the beneﬁts and any potential risks.
— Public engagement programmes
— The UK is considered a world leader in public engagement with nanotechnologies.
— We would like to take this engagement to its next stage as the facilitator and catalyst for deeper
and more speciﬁc engagement, in particular around the social, ethical and environmental
aspects of current and future applications and the direction of research.
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— We would work with opinion formers and the public to prioritise the key issues and design a
dynamic engagement programme. This may include direct groups such as citizen’s juries, or
through media partners, You Tube debates, polling and website interaction through
Nanoandme.org. We would also hope to work with existing initiatives (eg East Midlands
NanoWhat project), to include social and ethical issues in their programmes and where
appropriate publicise these initiatives.
— We would articulate the “business case” for public engagement to help businesses and
universities understand why public engagement is important and how to do it.
— A trusted forum for reﬂection—Debates and events on social and ethical issues
— Wewould undertake deliberative researchwith opinion formers to prioritise the areas for debate
around the wider social and ethical impacts of nanotechnologies and help shape the information
available on the consumer website.
— We propose holding a series of debates, both “live” and internet run which explore these issues
with opinion formers and the general public.
— We may also facilitate dialogues for others—eg nano labelling—where our independence
adds value.
— Stimulate others to play their part in the responsible development of the technology
— Our approach to this area is still under discussion. However we see some valuable contributions
through:
— Ongoing involvement with the Responsible Nano Code through Steering Group members
participation in oversight group and support of its aims.
— Through the Responsible Nano Forum website providing information and interaction with
opinion formers on “what is responsible nanotechnology” and what organisations can do to
discharge their responsibilities.
— Initiatives to eVectively promote and support responsible nano—eg The Responsible Nano
Awards, to highlight responsible behaviours, initiatives and partnerships.
— Stimulate and promote the development of “socially beneﬁcial” applications using nano.
— Our most appropriate contribution to this area is also still under discussion. However we feel
that not enough is done to stimulate the socially beneﬁcial aspects and are seeking ways to do
that. Eg
— Research to articulate UK priorities for beneﬁcial applications (eg like the Foresight
Challenges), including opinion former and public engagement.
— Engage with business leaders, government and scientists to promote these priorities (eg CEO
dinners with the Centre for Tomorrow’s Company, initiatives with KTN’s etc).
— Partnership broking—with ngos, business and government to support highly practical ventures
to support the priorities. (Eg arsenic measurement tech in Nepal with Practical Action ngo)
The Way we Work—We are:
Inclusive—this is demonstrated by the multi-stakeholder governance of the organisation, our commitment to
balanced debate and bringing stakeholders together to develop solutions.
Trustworthy—this is demonstrated by the importance we give to the integrity of our information and
communication; our commitment to transparency and disclosure and the direct and clear style of our
communication.
We aremindful of the responsibility which comes with a focus on the public good—ensuring scientiﬁc integrity,
avoiding bias or sensation, avoiding creating either concern or conﬁdence where it is not appropriate and
avoiding “favour” in terms of stakeholders or points of view.
Challenging—these other values do not prevent us from also being challengingwithout favour or bias. Amulti-
stakeholder approach can result in watered-down perspectives, stagnancy and bureaucracy. We aim to create
an organisation that can retain its dynamism and energy despite these potential constraints, which is actually
more enlivened because of our structure and the way we work.
Enthusiastic—we love what we do and we think it is important. This enthusiasm for our work shows—you
will ﬁnd it in our humour, our honesty, a “can do” attitude and a dedication to solving problems, clearing
blockages and smoothing feathers to get the best outcomes we can.
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1. Who is Involved?
The Director of the Forum, Hilary SutcliVe, has signiﬁcant expertise running small and “virtual” companies
over a 12-year period, both as an executive director of Addition, Shared View and Responsible Futures and as
a non-executive director of the Ethical Investment Research Service. She also has experience in working in
communication, public engagement and in corporate responsibility over a period of 27 years, in the UK and
USA, working in the ﬁeld of nanotechnologies since 2006. She previously ran the secretariat for the
Responsible NanoCode and is author of the paper “An uncertain business: the technical, social and commercial
challenges presented by nanotechnology”, sponsored by the Royal Society, Insight Investment and the NIA.
The Managing Director of the Forum—Graham Broadbelt has extensive experience in management and
operations for organisations similar in many ways to the Forum, being previously managing director of the
think tank Demos and the community involvement charity Common Purpose.
Trustees and The Steering Group
The direction of work for the Responsible Nano Forum is set by a multi-stakeholder Steering Group and
delivered by a small executive group and strategic partnerships, while the formal Board of Trustees of the
charity will oversee its governance and organisational competence. The Board of Trustees is currently being
appointed, but it will be multi-stakeholder in its make up. The Steering Group is comprised as follows: (shown
here in alphabetical order):
Mr Frank Barry, Unite Union
Mr David Baxter, Lead Ms Karen Folkes, Head of Public Arved Luth, forumnano (A group
Researcher, Emerging Risks, Engagement with Science and of German SMEs seeking to build
Lloyds (Insurance) Technology, DIUS their reputation for responsible
nanotechnologies
Mr Stuart Challenor, Trading Law Professor Richard Jones, FRS, Gene Matthews, Leigh Day
& Technical Manager—Tesco EPSRC Senior Strategic Advisor Solicitors
for Nanotechnology, Professor of
Physics, University of SheYeld
Ms Rachel Crossley, Director, Dr David Grimshaw, Head of Dr David Santillo, Senior
Investor Responsibility, Insight Prog: New Technologies, Practical Scientist, Greenpeace International
Investment Action
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